https://biospectrumindia.com/rssfeed/bio-med/medtech medtech https://biospectrumindia.com/news/93/28649/bpl-medical-technologies-advances-global-growth-strategy-with-acquisition-of-medec.html https://biospectrumindia.com/news/93/28649/bpl-medical-technologies-advances-global-growth-strategy-with-acquisition-of-medec.html Wed, 14 Oct 2026 13:40:33 +0530 BPL Medical Technologies has acquired a majority shareholding in Medec, a European medical technology company, in a strategic technology acquisition that strengthens the company’s growth trajectory and advances its ambition to build a globally competitive medical technology organisation. The acquisition marks an important step in BPL Medical Technologies’ strategy to strengthen its ownership of technology and product development capabilities while expanding its global presence. Medec brings advanced anaesthesia workstations and ventilators, along with three patents and a product development pipeline that includes an electronic vaporiser and a value engineered version of the Caelus anaesthesia workstation. The transaction goes beyond expanding BPL Medtech’s product portfolio. It provides the company with greater control over product quality, functionality, technology and margins, while reducing its dependence on external suppliers for anaesthesia workstations and ventilators. The acquisition also brings specialised intellectual property and engineering capabilities into BPL Medical Technologies, creating further opportunities for technology development within its own ecosystem. Medec also brings an established international commercial network, with an active distributor presence across more than 30 countries in Europe, MENA, Southeast Asia and Latin America. This gives BPL Medtech an expanded platform through which it can take Medec’s CE certified technologies to additional markets, supporting the company’s broader objective of developing a more globally connected medical technology business. The acquisition also aligns with BPL Medical Technologies’ efforts to build capabilities across technology, innovation and digital health. As part of its medium term technology roadmap, BPL Medtech is exploring the integration of Medec’s technologies with its Cortex AI platform, potentially bringing together Medec’s anaesthesia capabilities with BPL Medical Technologies’ existing digital technology ecosystem. ]]> https://biospectrumindia.com/news/93/28630/centre-for-3d-cancer-omics-launches-at-indian-institute-of-technology-madras.html https://biospectrumindia.com/news/93/28630/centre-for-3d-cancer-omics-launches-at-indian-institute-of-technology-madras.html Sun, 11 Oct 2026 14:47:10 +0530 The Centre for 3D Cancer Omics has been launched at Indian Institute of Technology, Madras, supported by the Gogri family, IIT Madras, and India's Translational Research Initiative (ITRI)Housed at the Sudha Gopalakrishnan Brain Centre (SGBC), the Centre will build on its advanced 3D tissue imaging capabilities to develop a comprehensive 3D tumour atlas at single-cell resolution. By bringing together 3D tissue structure with molecular and liquid biopsy data, the Centre aims to build a deeper understanding of how tumours develop, evolve and respond to treatment.Over the next five years, the programme will focus initially on breast cancer, with the ambition to translate this rich dataset into clinically actionable biomarkers, AI-enabled diagnostic tools, digital pathology applications and new avenues for targeted therapies. The Centre is expanding its team and has the following full-time, onsite openings at the IIT Madras campus in Chennai: Principal Project ScientistProject Scientist, Cancer BiologyProject Scientist, Computational BiologyResearch Associate, Histopathology & GenomicsResearch Associate, Computational BiologyProject ManagerLab Technician ]]> https://biospectrumindia.com/news/93/28613/zeiss-india-signs-multi-year-strategic-partnership-with-dr-agarwals-eye-hospital-and-narayana-nethralaya.html https://biospectrumindia.com/news/93/28613/zeiss-india-signs-multi-year-strategic-partnership-with-dr-agarwals-eye-hospital-and-narayana-nethralaya.html Wed, 07 Oct 2026 19:21:42 +0530 ZEISS India has signed a Memorandum of Understanding (MoU) with Dr. Agarwal’s Eye Hospital and Narayana Nethralaya during the 44th Congress of the ESCRS Annual Congress hosted at the ExCeL exhibition centre in London.  The collaboration will focus on advancing clinical excellence and expand the adoption of ZEISS intraocular lens technologies, while continuing joint work through ZEISS VISUMAX 800 and SMILE pro® platforms for refractive surgery. It will also include educational programmes, training and knowledge exchange in cataract and refractive surgery. The partnership will promote best practices in intraocular lens (IOL) selection, cataract procedures and laser vision correction. It will further support participation in clinical studies, scientific evaluations and evidence-generation initiatives, along with the sharing of clinical experience and research findings at national and international ophthalmology conferences. Dipu Bose, Head - Medical Technology, ZEISS India and Neighbouring Markets, said, “As a foundation-owned company, we take a thoughtful approach to partnership led by shared values, trust and sustainable impact. Our collaboration with Dr Agarwal’s Eye Hospital and Narayana Nethralaya reflects our common commitment to patient-centred eye care and clinical excellence. Their extensive network and reach will help us make our advanced technologies accessible to more patients, while providing valuable insights into evolving clinical practices and patient needs. Through this MoU, we look forward to deepening our collaboration and contributing to the continued advancement of eyecare segment in India.” Dr Ashvin Agarwal, Chief Clinical Officer, Dr. Agarwal’s Eye Hospital, said, “Our partnership with ZEISS brings together advanced technology and clinical expertise to address the changing needs of patients. By strengthening access to innovative cataract and refractive solutions, we aim to make eye care more precise, personalised and accessible, while continuing to uphold the highest standards of patient care.” Dr Naren Shetty, Vice Chairman and Head of Cataract and Refractive Lens Services, Narayana Nethralaya, said, “Our association with ZEISS is an opportunity to contribute to the future of ophthalmology through evidence-based practice, professional education and collaborative research. By combining our clinical experience with ZEISS’s technological capabilities, we seek to advance standards of care, strengthen clinical outcomes and support the wider adoption of high-quality ophthalmic solutions across India.”     ]]> https://biospectrumindia.com/features/93/28610/building-more-connected-healthcare-infrastructure-from-emergency-response-to-laboratory-safety.html https://biospectrumindia.com/features/93/28610/building-more-connected-healthcare-infrastructure-from-emergency-response-to-laboratory-safety.html Tue, 06 Oct 2026 21:39:47 +0530 Healthcare infrastructure is often discussed in terms of hospital capacity, clinical staffing and access to care. Yet the equipment and physical systems that support diagnosis, treatment, emergency response and laboratory work are equally important. As healthcare delivery becomes more distributed across hospitals, diagnostic centres, community programmes and mobile units, procurement decisions increasingly need to be viewed as part of a wider care pathway. Five areas illustrate this broader view particularly well: ambulance systems, dialysis equipment, portable X-ray imaging, laboratory fume hoods and laboratory storage systems. Together, they show how mobility, continuity of care, diagnostic access and laboratory safety are becoming interconnected parts of modern healthcare infrastructure. Ambulances Are Part of the Care Pathway, Not Just Transportation The terminology used in commercial procurement can vary. Patient Transport Vehicle, or PTV, is the term used in the government data above; some suppliers and buyers may use terms such as Patient Transport Ambulance or PTA. For procurement, the important issue is not the label alone but the intended use, equipment configuration, patient-handling requirements and operational environment. For organisations evaluating ambulance solutions, the same principle applies: define the clinical and transport requirement first, then specify the vehicle and onboard equipment around that requirement. Dialysis Equipment Requires a Systems Approach Dialysis is another example where the equipment cannot be considered in isolation. In haemodialysis, blood is circulated outside the body through a dialyzer, where wastes and excess fluid are removed before the filtered blood is returned to the patient. The dialysis machine controls and monitors important parts of this process. Organisations researching dialysis machines should assess the equipment against the clinical model and infrastructure available at the facility rather than comparing specifications in isolation. Portable X-Ray Is Expanding the Reach of Diagnostic Imaging This is increasingly relevant to emergency care, intensive care, remote healthcare and mobile medical programmes. BioSpectrum India has previously reported on initiatives using portable X-ray equipment in mobile healthcare delivery, including Fujifilm India's Care on Wheels programme in Himachal Pradesh, where a mobile van combined portable X-ray and clinical chemistry testing with tele-radiology and tele-health services. Radiation safety remains essential with mobile and portable radiography. Appropriate justification of examinations, controlled working areas, beam direction, distance, shielding where required and adherence to applicable radiation-safety requirements should form part of the deployment plan. For facilities assessing portable X-ray systems, the product itself is only one part of the decision. The clinical use case, operating environment and radiation-safety workflow should be evaluated alongside the equipment. Laboratory Fume Hoods Are Engineering Controls Laboratory safety depends heavily on engineering controls that reduce exposure at the point where hazardous work is performed. A laboratory fume hood is one example. The US Occupational Safety and Health Administration defines a laboratory-type hood as an enclosure designed to draw air from the laboratory and prevent or minimise the escape of airborne contaminants into the laboratory. Facilities planning or upgrading laboratory infrastructure can review laboratory fume hoods as one component of a wider laboratory design that also considers utilities, work surfaces, storage, workflow and safety procedures. Laboratory Cabinets Support Safer Storage and Better Workflow Storage is another infrastructure decision that can have a direct impact on laboratory safety and workflow. Chemicals, reagents, instruments, samples and consumables all require storage arrangements appropriate to their properties and intended use. When comparing laboratory cabinets, procurement teams should begin with the storage requirement and chemical or equipment profile, then evaluate construction, configuration and safety features against that use case. What Connects These Five Infrastructure Categories? At first glance, an ambulance, dialysis machine, portable X-ray system and laboratory cabinet appear to belong to very different procurement categories. The common thread is that each has to operate reliably within a larger healthcare environment. The Procurement Conversation Is Moving Beyond the Product Catalogue Healthcare organisations increasingly need procurement processes that connect clinical requirements with infrastructure planning. For a new hospital, diagnostic centre, dialysis unit, laboratory or mobile healthcare programme, this can mean evaluating several equipment categories together rather than making disconnected purchases. A More Connected View of Healthcare Infrastructure Ambulances, dialysis machines, portable X-ray systems and laboratory infrastructure serve different clinical and operational purposes, but they are connected by the same underlying requirement: dependable healthcare systems need equipment that fits the environment in which it will be used.   Authored by- Shelves Tech Private Limited, a healthcare infrastructure and medical solutions company ]]> https://biospectrumindia.com/news/93/28594/stryker-launches-mako-4-smartrobotics-in-india-for-robotic-assisted-joint-replacement.html https://biospectrumindia.com/news/93/28594/stryker-launches-mako-4-smartrobotics-in-india-for-robotic-assisted-joint-replacement.html Mon, 05 Oct 2026 16:18:33 +0530 Stryker, a global leader in medical technologies, has announced the launch of Mako 4 SmartRobotics™, the fourth generation of Mako, bringing its latest robotic-arm assisted technology to India. Designed to support a more integrated clinical and operational experience, Mako 4 combines patient-specific planning, robotic technology and haptic guidance in a single system across three applications: Mako Total Knee, Mako Partial Knee and Mako Total Hip with Advanced Primary and revision. Building on more than two decades of innovation, Mako 4 pairs 3D CT-based planning with AccuStop™ haptic technology to support surgeons in planning and executing procedures according to each patient’s individual anatomy. The platform provides real-time intraoperative guidance, helping deliver greater precision and control during joint replacement procedures. The launch builds on the global Mako platform, which has supported more than 2.5 million procedures across 47 countries, demonstrating its growing role in robotic-assisted orthopaedic surgery. ]]> https://biospectrumindia.com/news/93/28583/govt-sanctions-rs-1600-cr-for-41-pharma-and-medtech-innovation-projects-under-first-round-of-prip.html https://biospectrumindia.com/news/93/28583/govt-sanctions-rs-1600-cr-for-41-pharma-and-medtech-innovation-projects-under-first-round-of-prip.html Wed, 30 Sep 2026 23:25:30 +0530 Under the first phase of Promotion of Research and Innovation in Pharma MedTech Sector (PRIP), 41 projects with financial assistance of about Rs 1,600 crore have been approved. These sanctioned projects are expected to bring in additional private investment of Rs 3,020 crore, taking the total R&D investment in these projects to about Rs 4,620 crore. The approved portfolio encompasses the innovation value chain, which includes new drug discovery, clinical development, and innovative medical technologies. Out of the 41 projects sanctioned so far, 12 are in the initial stage and 29 are in the later stage. 19 projects are being done by startups and MSMEs, while 22 projects are being done by big companies. As per the priority areas, 27 projects are under New Drugs, five projects are under Complex Generics and Biosimilars and nine projects are under New Medical Devices. These projects primarily reflect the shift from the volume-based pharmaceutical model to the innovation-based, technology-intensive model, bringing together pharmaceutical companies, biotechnology enterprises, and MedTech innovators. The portfolio includes projects from companies and innovators such as Biocon, Bharat Biotech, Sun Pharma, Wockhardt, Zydus, Mankind Pharma, Pandorum Technologies, Celogen Therapeutics, Origin Oncology and Bugworks Research. These projects showcase a wide range of innovation supported under PRIP, including first-class innovations, emerging technologies, innovations with potential for global markets, and strategic priority innovations involving areas critical to public health. The projects supported under these categories include antibacterial drugs targeting multidrug-resistant Gram-negative infections, exosome-based regenerative therapy for corneal disease, in-vivo CAR-T platform, patient-derived breast cancer organoids, programmable RNA-targeting antiviral technology, portable plasmonic-PCR for point-of-care infection diagnosis, and microfluidic platform for TB detection. Under the strategic prioritization framework, more support is available for innovations focusing on areas such as unaddressed tropical diseases, rare diseases, AMR (antimicrobial resistance) for India's priority pathogens (pathogens), pathogens with epidemic or mass transmission potential, and vaccines for vaccine-preventable diseases. So far, six projects have been approved under this framework, which include projects related to bacterial pneumonia/meningitis, dengue, influenza and next-generation TB vaccines. The remaining applications under the first round are under evaluation and the results will be announced in the coming months. ]]> https://biospectrumindia.com/news/93/28531/syrma-johari-medtech-expands-manufacturing-footprint-with-new-medical-plastics-and-precision-molding-facility-in-jodhpur.html https://biospectrumindia.com/news/93/28531/syrma-johari-medtech-expands-manufacturing-footprint-with-new-medical-plastics-and-precision-molding-facility-in-jodhpur.html Wed, 23 Sep 2026 17:40:03 +0530 Syrma Johari MedTech Limited (SJML), a medical-device manufacturing company, has expanded its manufacturing footprint with the launch of a new medical plastics and precision molding facility in Jodhpur, strengthening its capabilities to support the evolving requirements of medical device, diagnostic and healthcare applications. Spread across 1.29 lakh sq. ft., with 0.98 lakh sq. ft. currently developed and 0.31 lakh sq. ft. reserved for future expansion, the facility adds dedicated capabilities in injection molding, plastics extrusion and stretch blow molding to SJML’s manufacturing platform. The expansion enables the company to address a broader range of polymer-based components and consumables across varying geometries, material systems and production volumes. The facility has been developed to respond to the increasing role of engineered plastics in medical and diagnostic products. The facility also incorporates ISO Class 7 and ISO Class 8 cleanroom environments, enabling controlled manufacturing conditions for applications where particulate control, cleanliness and contamination management are critical. Its material-processing capabilities cover thermoplastics, elastomers and engineering polymers, including PP, PE, PS, PC, TPEs, PA6, PA66 and glass-fibre-reinforced polymer systems, allowing material selection to be aligned with the functional and manufacturing requirements of individual applications. The new facility is supported by SJML’s established quality and regulatory framework for medical-device manufacturing. The company operates under an ISO 13485 Quality Management System, with manufacturing systems designed around US FDA regulatory requirements, processes aligned with MDSAP requirements and compliance with applicable CDSCO regulations. As medical-device and diagnostic architectures become increasingly sophisticated, the ability to develop and manufacture polymer components with greater control over material selection, precision, cleanliness and repeatability becomes an important part of the product development and manufacturing journey. SJML’s expanded capabilities are designed to support this transition from component development to repeatable and scalable production.   ]]> https://biospectrumindia.com/news/93/28533/indian-medical-parliamentarians-forum-organises-national-policy-summit-on-swasth-bharat-se-saksham-bharat-to-reimagine-medtech-access-in-india.html https://biospectrumindia.com/news/93/28533/indian-medical-parliamentarians-forum-organises-national-policy-summit-on-swasth-bharat-se-saksham-bharat-to-reimagine-medtech-access-in-india.html Wed, 23 Sep 2026 21:09:58 +0530 The Indian Medical Parliamentarians’ Forum (IMPF) convened the National Policy Summit on MedTech Access on September 22 at Meril Academy, Vapi, under the theme “Swasth Bharat Se Saksham Bharat | Reimagining MedTech Access in India.” The summit brought together Members of Parliament, senior government officials, healthcare institutions, clinical experts and industry stakeholders to deliberate on strengthening India’s medical technology ecosystem and expanding access to quality, advanced and affordable healthcare technologies. The summit was chaired by Dr Anil Sukhdeorao Bonde, Member of Parliament, Rajya Sabha and Chairperson, IMPF. Senior representatives from the Department of Pharmaceuticals, Department of Health Research, Indian Council of Medical Research (ICMR), Ministry of Health and Family Welfare, National Health Authority (NHA), AIIMS Nagpur and the National Health Systems Resource Centre (NHSRC) participated in the discussions. The summit featured two panel discussions that brought together policymakers, healthcare experts, academic leaders and industry representatives to advance reform-oriented discussions on India’s medical technology ecosystem and pathways to wider patient access. The first panel, “Building a Sustainable and Globally Competitive MedTech Ecosystem,”examined the enabling ecosystem required to support indigenous medical technology development and global competitiveness. The discussion covered areas including research and innovation, regulatory and quality frameworks, industry-academia collaboration, domestic manufacturing capabilities, supply-chain resilience, clinical requirements and the creation of an ecosystem that could support Indian MedTech companies in addressing both domestic and global healthcare needs. The panel was chaired by Dr Shivaji Bandappa Kalge, with Manoj Joshi serving as Co-Chair. Dr Vibhav Garg, Moderator, Meril, moderated the discussion, which also featured Prof. (Dr) Prashant P. Joshi and Dr Neha Dumka as panellists. The second panel, “Expanding Access to Quality Care through MedTech Innovation,” focused on the factors that determine whether medical technology can translate from innovation into meaningful patient access. The discussion examined clinical evidence, health technology assessment, financing and reimbursement, technology adoption, healthcare workforce capabilities and the challenges of extending advanced technologies across different levels of the health system. The panel was chaired by Dr Jashvantsinh Parmar and moderated by Dr Sharmila Sarkar, with Dr Gaurav Shanker Pradhan, Dr Shailesh Kumar Yadav and Dr Suchita Markan participating as panellists. Speaking at the summit, Dr Anil Sukhdeorao Bonde, Member of Parliament, Rajya Sabha and Chairperson, IMPF, said, “Innovation without access has limited impact, and access without evidence cannot be sustained. For India to build a globally competitive medical technology ecosystem, we need stronger indigenous research and development, credible clinical evidence, appropriate health technology assessment and sustainable reimbursement mechanisms. Manufacturing must be supported by the right clinical skills, infrastructure and technical ecosystem, particularly as advanced technologies such as robotics become more accessible. Our ultimate objective must be Indian innovation, global-quality technology and affordable access for every patient who needs it.” Manoj Kumar Joshi, Co-Chair and Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, said, “For India to become self-reliant in medical devices, we need a strong ecosystem built around quality, evidence and credibility. Our regulatory system must evolve to ensure that products developed in India meet globally credible standards. At the same time, we need to strengthen domestic supply chains, engineering capabilities and component manufacturing. Building this ecosystem will not only support healthcare access but also contribute to employment and the country’s overall prosperity.” Addressing the role of healthcare institutions in advancing medical technology, Dr Prashant P. Joshi said, “Medical institutions should not be limited to validating technologies developed elsewhere; they should help identify unmet clinical needs and work with engineers, researchers and innovators to develop solutions around those needs. We need stronger collaboration between medical and engineering institutions through joint research, academic programmes, fellowships and training. At AIIMS Nagpur, we are exploring such collaborations with institutions such as IIT Bombay. Building this interdisciplinary ecosystem can significantly strengthen India’s medical technology innovation and ultimately improve patient care.” Highlighting the importance of clinical adoption and capacity building, Dr Gaurav Shanker Pradhan said, “Access to medical technology is not simply about making a device available. A device can create meaningful impact only when healthcare professionals are able to use it safely, confidently and effectively. We need to move from an equipment-centric approach to a technology adoption model, with competency-based training for clinicians, technicians and other healthcare professionals. Digital learning and remote training can also help extend this capacity to underserved and rural areas.” Dr Shailesh Kumar Yadav, IAS, Joint Director, National Health Authority, highlighted the importance of linking innovation with sustainable financing and reimbursement. He said, “For a medical technology to reach the patient, clinical effectiveness must be supported by appropriate financing and reimbursement pathways. Under Ayushman Bharat, newer interventions require credible clinical and economic evidence before they can be incorporated into health benefit packages. We also need to look beyond the upfront cost of a device and consider the total cost of care, including treatment, hospitalisation, personnel and follow-up. This will help us build a healthcare system that is both affordable and sustainable.” Emphasising the need to evaluate technologies within the realities of the health system, Dr Neha Dumka said, “Technology has an important role to play in strengthening primary healthcare, particularly as our disease burden continues to evolve. However, innovation must be assessed not only for its technical capabilities, but also for ease of use, cost-effectiveness, scalability and sustainability within the health system. We need to ensure that technologies can be effectively adopted at different levels of care and ultimately reach the beneficiaries who need them. Strengthening this pathway will be essential for equitable access to quality healthcare.” Speaking on strengthening healthcare delivery at the grassroots, Dr Jashvantsinh Parmar said, “To take medical technology from innovation to meaningful patient access, we first need to identify the bottlenecks in the existing system. We must strengthen the capabilities of healthcare professionals at the grassroots, particularly those working at CHCs and sub-district centres. Technologies should be introduced systematically and evaluated through comparative, data-based studies. Most importantly, their acceptability among healthcare professionals and patients must be considered if we want innovations to achieve meaningful adoption.” Highlighting the potential of Indian medical device manufacturers, Dr Shivaji Kalge said, “Indian medical device companies are increasingly capable of developing technologies that meet international standards while remaining affordable for Indian patients. We are already seeing Indian companies compete with international products in areas such as ophthalmology and other medical specialties. If we continue to strengthen research, quality and innovation, these technologies can become more widely accepted globally. This can help improve access to quality healthcare for Indian patients at more affordable prices.”   ]]> https://biospectrumindia.com/news/93/28517/brainlab-and-amrita-hospital-to-build-north-indias-first-brain-spine-centre-of-excellence-in-faridabad.html https://biospectrumindia.com/news/93/28517/brainlab-and-amrita-hospital-to-build-north-indias-first-brain-spine-centre-of-excellence-in-faridabad.html Mon, 21 Sep 2026 19:31:05 +0530 Brainlab and Amrita Hospital, Faridabad have inked a Memorandum of Understanding (MoU) to set up North India’s first Centre of Excellence for Brain & Spine powered by Brainlab’s Loop-X® Mobile Imaging Robot, strengthening access to cutting-edge technology-enabled neurosurgical and spine care in the region. The dedicated centre will bring together Amrita Hospital’s clinical expertise in neurology and Brainlab’s intraoperative imaging and surgical navigation technologies. It will be used for complex operations on the brain and spine, as well as a platform for clinical training, technology demonstrations and the sharing of knowledge between surgeons and health care professionals. The centre will be based on Loop-X®, a robotic mobile imaging system providing 2D and 3D cone-beam computed tomography (CBCT) images inside the operating room. This gives surgical teams detailed images during surgery that can be integrated with navigation technology to guide surgery and confirm results before the patient leaves the operating room. Intraoperative imaging allows the surgeon to visualise the anatomy, verify the placement of any implants and acquire new images as necessary. This is particularly important in complex brain and spine surgery where accuracy is paramount. Loop-X® also offers patient-specific imaging, by concentrating the scan on the area to be treated, helping to optimise radiation exposure. As a part of the Centre of Excellence, Brainlab and Amrita Hospital seek to establish a dedicated hub for advanced brain and spine surgery, clinical learning and technology-enabled surgical innovation, while increasing access to specialised care in neuro and spine for patients across North India. ]]> https://biospectrumindia.com/news/93/28507/robotic-assisted-surgery-in-india-enters-next-phase-as-intuitive-introduces-da-vinci-5.html https://biospectrumindia.com/news/93/28507/robotic-assisted-surgery-in-india-enters-next-phase-as-intuitive-introduces-da-vinci-5.html Fri, 18 Sep 2026 17:08:42 +0530 Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, has announced the introduction of da Vinci 5, its latest-generation robotic-assisted surgical system, in India. Da Vinci 5 builds on the highly functional design of da Vinci Xi and features more than 150 enhancements. It is the latest addition to the Intuitive portfolio of da Vinci systems that surgeons across India have already used in more than 200,000 procedures to date. The focused introduction of da Vinci 5 in India will enable selected hospitals and programs to build experience with the platform — supporting responsible adoption across the country's growing robotic-assisted surgery community. Da Vinci 5 is designed to deliver enhanced surgical senses to support better patient outcomes, including first-of-its-kind Force Feedback technology, designed to enhance intra-operative awareness of the force exerted on tissue during surgery, by enabling surgeons to feel push and pull forces through their da Vinci 5 console hand controls; the most realistic 3D da Vinci vision system to date; and an ergonomic, immersive surgeon console to support career longevity. Rohitt Mahajan, Vice President and General Manager, India, Intuitive, said, “The introduction of da Vinci 5 marks an important milestone in the evolution of robotic-assisted surgery in India. As the ecosystem matures, the focus is shifting from technology adoption alone to how innovation can consistently deliver better patient outcomes, support surgical excellence, and strengthen healthcare delivery. With advanced capabilities such as Force Feedback, enhanced computing power, integrated workflows, and connected learning, da Vinci 5 is designed to help surgeons and care teams continuously improve performance and patient care." Iman Jeddi, Ph.D., Senior Vice President and General Manager, da Vinci Platforms & Product Operations, Intuitive, said, "da Vinci 5 represents the next generation of robotic-assisted surgery, combining advanced sensing and vision technologies, intelligent software, and integrated workflows in a single platform." Da Vinci 5 has been used by more than 15,000 surgeons globally, providing meaningful insights into how surgeons work with the platform. This experience adds to a wider body of clinical evidence that includes more than 50,000 peer-reviewed publications related to Intuitive technologies. Da Vinci 5 is cleared for use in surgical procedures, including urologic, gynaecologic and general surgery, cardiac and thoracoscopic surgical procedures in India.   Image caption- From left: Jason Hart, Senior Vice President, Global Marketing, Communication and Enablement, Intuitive; and Rohitt Mahajan, Vice President and General Manager, India, Intuitive, at the launch of da Vinci 5 in India. ]]> https://biospectrumindia.com/news/93/28498/wadhwani-innovation-centre-for-life-sciences-and-medical-technologies-opens-at-iit-kanpur.html https://biospectrumindia.com/news/93/28498/wadhwani-innovation-centre-for-life-sciences-and-medical-technologies-opens-at-iit-kanpur.html Thu, 17 Sep 2026 16:13:10 +0530 The Wadhwani Innovation Centre for Life Sciences and Medical Technologies - a Centre of Excellence (CoE), has been established at the Indian Institute of Technology (IIT) Kanpur to strengthen the translation of research into products and solutions for healthcare. The Centre will receive $5 million in funding over five years to support the development, validation and commercialisation of promising innovations across life sciences, biotechnology, medical technologies, and AI-enabled healthcare services. The new Centre will support high-potential research from areas like therapeutics, regenerative medicine and drug delivery to vaccines, medical devices and diagnostics. It will also focus on emerging fields like neurodegenerative diseases, mental health, antimicrobial resistance and AI-enabled healthcare. Building on IIT Kanpur’s research strengths, the Centre will help promising ideas move from the lab to real-world healthcare applications. It will support researchers through validation, IP and regulatory processes, while helping connect them with industry for technology transfer and commercialisation. The Wadhwani–IIT Kanpur Innovation Centre is part of the Wadhwani Innovation Network (WIN), the Wadhwani Foundation’s flagship innovation initiative in India, which is building a national network of Innovation Centres to strengthen research translation and commercialisation. ]]> https://biospectrumindia.com/news/93/28494/sahajanand-medical-technologies-secures-regulatory-approval-in-egypt-for-supraflex-cruz-coronary-stent.html https://biospectrumindia.com/news/93/28494/sahajanand-medical-technologies-secures-regulatory-approval-in-egypt-for-supraflex-cruz-coronary-stent.html Wed, 16 Sep 2026 17:43:35 +0530 Surat-based Sahajanand Medical Technologies (SMT) has received regulatory approval from the Egyptian Drug Authority (EDA), Central Administration of Medical Devices, for its Supraflex Cruz Sirolimus Eluting Stent System, marking the company’s entry into a new market in Africa. This EDA approval gives physicians in Egypt access to the Supraflex Cruz platform and strengthens SMT’s broader expansion strategy in new markets. According to World Health Organization data, ischaemic heart disease was the leading cause of death in Egypt in 2021, underscoring the country’s substantial cardiovascular disease burden. By making SupraFlex Cruz available to Egyptian interventional cardiologists, SMT is expanding access to its clinically evaluated, coronary stent platform. This milestone also advances SMT’s commitment to improving access to cardiovascular care and saving lives. “Egypt is an important addition to SMT’s international footprint and strengthens our presence in Africa. Expanding access to our coronary technologies in this market advances our commitment to supporting physicians, improving cardiovascular care and saving more lives around the world,” said Anil Suri, Chief Commercial Officer, at Sahajanand Medical Technologies. ]]> https://biospectrumindia.com/news/93/28480/amtz-to-drive-brics-biodesign-programme-for-healthcare-innovation.html https://biospectrumindia.com/news/93/28480/amtz-to-drive-brics-biodesign-programme-for-healthcare-innovation.html Mon, 14 Sep 2026 21:45:37 +0530 The Andhra Pradesh MedTech Zone (AMTZ) is spearheading the BRICS BioDesign Programme to advance healthcare innovation and medical technology across BRICS member nations. The initiative was recently launched in New Delhi by Principal Scientific Adviser to the Government of India, Ajay Kumar Sood. The launch included the exchange of a Memorandum of Agreement among participating institutions and the unveiling of the official programme website. The programme operates through a collaborative framework involving AMTZ, the Office of the Principal Scientific Adviser, FICCI, and the Science & Technology Cluster. It aims to connect researchers, healthcare professionals, academic institutions, and commercial stakeholders to accelerate the deployment of affordable and accessible medical technologies. As part of the launch, Prof. Sood delivered an address highlighting the significance of BRICS+ cooperation in advancing medtech innovation. He underscored India’s leadership role in the BRICS framework and highlighted the AMTZ-Vizag S&T Cluster, which serves as the Secretariat, as a unique example of bringing together clinical expertise, engineering, prototyping, manufacturing and regulatory capabilities on a single collaborative platform. Prof. Sood also mentioned the integrated approach of BRICS+ Biodesign Program, which aims to establish a structured, multi-country platform for medical technology innovation across BRICS+ member states. ]]> https://biospectrumindia.com/news/93/28477/kims-hospitals-in-association-with-boston-scientific-launches-illumina-3d-technology.html https://biospectrumindia.com/news/93/28477/kims-hospitals-in-association-with-boston-scientific-launches-illumina-3d-technology.html Sat, 12 Sep 2026 21:19:04 +0530 KIMS Hospitals, Mahadevapura, Bengaluru in association with Boston Scientific, has launched Illumina 3D™ technology, an image-guided programming platform for Deep Brain Stimulation (DBS), making the hospital the first in India to introduce the technology. Designed to support greater precision and personalised DBS programming for patients with movement disorders such as Parkinson’s disease, the technology uses advanced imaging and intelligent algorithms to help develop customised stimulation programmes.The launch was graced by key leadership from KIMS Hospitals, including Dr Guruprasad Hosurkar, Director & Lead Consultant in Neurology and Head of Parkinson’s Disease and Movement Disorder Programme; and Dr Raghuram Gopalakrishnan, Director & Senior Consultant and Head of Stereotactic and Functional Neurosurgery. The introduction of Illumina 3D™ marks an important milestone in KIMS Hospitals’ efforts to bring advanced neurological technologies to India and strengthen access to personalised care for patients with complex movement disorders. ]]> https://biospectrumindia.com/news/93/28449/government-supports-commercialisation-of-3-d-printed-patient-specific-bone-graft.html https://biospectrumindia.com/news/93/28449/government-supports-commercialisation-of-3-d-printed-patient-specific-bone-graft.html Wed, 09 Sep 2026 22:19:50 +0530 The Technology Development Board (TDB) under the Department of Science and Technology (DST), Government of India, has provided financial assistance to Ceramat, in Palghar, Maharashtra, for a project titled 'Calcium Phosphate-based Standard and Customised Patient-Specific Grafts by 3D Printing through Digital Light Processing Technology and Extrusion-Based Device'.  The project aims to commercialise advanced, patient-specific bone grafts using indigenously manufactured bioceramic materials and 3D printing technologies.  The use of indigenous calcium phosphate-based materials combined with advanced additive manufacturing is expected to expand Ceramet's current biomaterial capabilities, allowing it to expand beyond traditional graft products to more sophisticated, digitally designed, and patient-specific solutions. This initiative will also help the company offer a wide range of bioceramic and orthobiological products through an integrated domestic manufacturing system. The company's product portfolio includes technologically advanced biomaterials such as hydroxyapatite, beta-tricalcium phosphate, biphasic calcium phosphate, and bioactive glass, which are used in orthopedics, oral care, cosmetics, and industrial sectors. ]]> https://biospectrumindia.com/news/93/28431/cyrix-healthcare-acquires-blue-star-ees-medtech-solutions-business.html https://biospectrumindia.com/news/93/28431/cyrix-healthcare-acquires-blue-star-ees-medtech-solutions-business.html Fri, 04 Sep 2026 19:39:29 +0530 Kochi-based Cyrix Healthcare has completed the acquisition of the MedTech Solutions business of Delhi-based Blue Star Engineering & Electronics (Blue Star E&E), effective September 1, 2026. The acquisition strengthens Cyrix’s capabilities in medical imaging, equipment sales, installation, maintenance, repairs, refurbishment and lifecycle management. The acquisition brings together Blue Star E&E’s established MedTech Solutions business, experienced professionals, customer relationships and deep expertise in multi-brand CT and MRI with Cyrix Healthcare’s growing Total MedTech Management platform. Blue Star E&E’s refurbishment capabilities will further strengthen AURUM, Cyrix’s refurbished medical equipment business, particularly in refurbished CT and MRI systems. The combined platform will also provide stronger access to refurbished equipment, spare parts and accessories, supported by Cyrix’s warehouse and service network across India. The combination of Blue Star E&E’s specialist imaging expertise and Cyrix’s broader MedTech capabilities creates a stronger platform to serve the evolving needs of healthcare providers and advances Cyrix’s vision of building a comprehensive Total MedTech Management ecosystem across India, the Middle East and Africa.   Image caption- Ajith Kumar S, Co-Founder & Executive Director, Cyrix Healthcare (L) and Joy K John, Co-Founder & Executive Director, Cyrix Healthcare (R) ]]> https://biospectrumindia.com/news/93/28409/stryker-advances-clinical-excellence-in-fluorescence-guided-surgery-in-gynaecology-in-india.html https://biospectrumindia.com/news/93/28409/stryker-advances-clinical-excellence-in-fluorescence-guided-surgery-in-gynaecology-in-india.html Wed, 02 Sep 2026 15:42:50 +0530 Stryker, a global leader in medical technologies, has announced a strategic partnership with the Indian Association of Gynaecological Endoscopists (IAGE) to strengthen surgeon education and capabilities in fluorescence-guided surgery (FGS) in gynaecology. This strategic partnership was signed during the Pelvic Organ Prolapse Conference 2026 in Chennai, in the presence of 350 gynaecological surgeons and healthcare professionals from across India. Fluorescence-guided surgery (FGS) is emerging as an important advancement in gynaecology, enabling enhanced intraoperative visualisation that can support surgical precision, informed clinical decision-making and improved patient care. Through this partnership, Stryker and IAGE aim to expand access to high-quality educational opportunities in FGS. Over the next two years, the collaboration will deliver pan-India clinical educational initiatives. Participating surgeons will also gain exposure to leading Indian and international experts, fostering knowledge exchange and encouraging the adoption of global best practices in gynaecological surgery. ]]> https://biospectrumindia.com/news/93/28400/india-health-2026-showcases-medtech-manufacturing-and-healthcare-innovation-landscape-expansion.html https://biospectrumindia.com/news/93/28400/india-health-2026-showcases-medtech-manufacturing-and-healthcare-innovation-landscape-expansion.html Tue, 01 Sep 2026 20:59:34 +0530 India Health 2026, organised by Informa Markets in India, recently concluded at Bharat Mandapam, New Delhi. The third edition brought together 300+ domestic and international brands and more than 8,000 healthcare professionals, creating a comprehensive platform for healthcare providers, manufacturers, clinicians, procurement leaders, policymakers, distributors, innovators and international stakeholders to engage across the healthcare value chain. The event witnessed a 38% increase in unique visitors compared with the previous edition. The event showcased the breadth of the healthcare sector, including medical-device manufacturing, diagnostics, medical imaging, surgical technologies, digital health, artificial intelligence, hospital infrastructure, and wellness. The exhibition connected technology providers with healthcare institutions and decision-makers, while providing opportunities to discover new solutions, explore sourcing requirements and build commercial and strategic relationships. A defining moment of the edition was Time Medical’s unveiling of its first-ever Made-in-India CT scanner, highlighting the growing emphasis on domestic medical-device manufacturing and the development of capabilities across the value chain. The focus was further reinforced through the Medical Manufacturing Pavilion, where companies showcased their manufacturing capabilities and innovations. With India’s medical-devices market projected to reach approximately $30 billion by 2030, the growing attention to local production and technology development comes at a significant point in the evolution of the sector. The exhibition also showcased the convergence of healthcare and emerging technology. Exhibitors including DKS Ortho, DRGEM Healthcare, FaceEcho.AI and Hamdard presented solutions across orthopaedics, medical imaging, AI-enabled healthcare and wellness. Advanced surgical technology was also represented through the Euler Advanced Bipolar and Ultrasonic Energy Generator, listed on the Government e-Marketplace (GeM). International engagement formed another important dimension of the exhibition. The participation of the Dubai Health Authority strengthened dialogue around healthcare collaboration between India, the UAE and the wider international community.  While the exhibition demonstrated what is changing in healthcare today, the conference programme examined what comes next. Themed ‘Driving Innovation to Shape the Future of Clinical Care’, the conference brought together healthcare leaders, clinicians, technology experts and industry stakeholders for discussions on how innovation can translate into better clinical outcomes, more efficient delivery and wider access to care. ]]> https://biospectrumindia.com/news/93/28395/prip-scheme-opens-up-new-opportunities-for-startups-msmes-and-industry-in-pharma-and-medtech-sectors.html https://biospectrumindia.com/news/93/28395/prip-scheme-opens-up-new-opportunities-for-startups-msmes-and-industry-in-pharma-and-medtech-sectors.html Fri, 28 Aug 2026 21:43:35 +0530 The Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, government of India, has announced the second date for inviting applications under the Research and Innovation Promotion in Pharma and MedTech (PRIP) Scheme. With a financial outlay of Rs 5,000 crore, the scheme aims to strengthen the country's pharma and MedTech R&D ecosystem by supporting startups, MSMEs, and large companies to move faster in the innovation value chain. Applications are invited for two categories: Preparatory Phase: Projects of startups and MSMEs with the objective of scaling up products or technologies at TRL (Technology Readiness Level) 1, 2 or 3 in priority areas to a higher TRL not exceeding TRL 5 will be eligible. A two-stage process will be followed for these projects, starting with a brief concept note. This will be followed by a detailed application for the selected applicants. The concept notes can be submitted by eligible MSMEs and startups directly or by ecosystem enablers on behalf of promising projects that exist in their network. Financial assistance up to Rs 5 crore per project will be provided under this scheme. Subsequent Phases: Projects in industry, startups, and MSMEs that aspire to scale up the products or technologies present on TRL 4, 5, or 6 in priority sectors to a higher level are eligible. Projects in further stages can apply directly through a detailed application form. Under the scheme, a maximum financial assistance of Rs. 100 crore per project will be provided, subject to a maximum of 35% of the total project cost sanctioned, and the balance amount will have to be co-financed by the applicant. ]]> https://biospectrumindia.com/news/93/28392/worlds-first-pinhole-pupilloplasty-centre-opens-at-dr-agarwals-eye-hospital.html https://biospectrumindia.com/news/93/28392/worlds-first-pinhole-pupilloplasty-centre-opens-at-dr-agarwals-eye-hospital.html Thu, 27 Aug 2026 19:15:51 +0530 The World’s First Pinhole Pupilloplasty Centre was inaugurated at Dr Agarwals Eye Hospital, in the presence of Dr Amar Agarwal, Dr Manoj Khatri and many other important dignitaries, marking an important step in advancing access to innovative, tissue-preserving solutions for selected patients affected by complex corneal conditions.   The initiative also complements the ongoing 41st National Eye Donation Fortnight, reinforcing the importance of exploring innovative approaches to restoring vision while preserving precious donor tissue.   The dedicated centre will focus on Pinhole Pupilloplasty (PPP), a microsurgical technique, developed by Dr Amar Agarwal, designed to improve the quality of vision in appropriately selected patients with conditions such as corneal scars, irregular corneas, high corneal aberrations and certain post-surgical optical distortions.   The inauguration places renewed focus on an important challenge in ophthalmology, restoring useful vision to patients with complex corneal optics while preserving the natural cornea whenever clinically possible.   Instead of replacing the cornea, PPP modifies the eye's optical system by creating a small, precisely centred pupillary aperture. The smaller aperture helps block scattered and distorted light rays and allows better-focused rays to reach the retina. This pinhole effect can reduce the impact of higher-order optical aberrations and thereby improve functional vision and visual quality.   Importantly, the procedure does not require donor corneal tissue, making it particularly relevant in the context of the global shortage of donor corneas.   A landmark international survey on corneal transplantation and eye banking estimated that approximately 12.7 million people worldwide were awaiting corneal transplantation, while only one donor cornea was available for every 70 people in need. The survey further reported that approximately 185,000 corneal transplants were performed annually across 116 countries, highlighting the significant gap between global demand and donor tissue availability.     ]]> https://biospectrumindia.com/news/93/28371/depuy-synthes-announces-collaboration-with-cmc-vellore-to-establish-orthopaedic-skill-lab.html https://biospectrumindia.com/news/93/28371/depuy-synthes-announces-collaboration-with-cmc-vellore-to-establish-orthopaedic-skill-lab.html Tue, 25 Aug 2026 15:25:34 +0530 DePuy Synthes, a global leader in orthopaedic technologies and solutions, has announced a new initiative with the Department of Orthopedics at Christian Medical College (CMC), Vellore to create a specialised Orthopaedic Skill Lab at the college. The strategic partnership was extended with the aim of facilitating procedural simulation, instrumentation training, and increasing awareness of technology-assisted surgery for orthopaedic residents, fellows, and faculty. The lab provides residents and fellows with a structured introduction to modern orthopaedic tools, implant management, and surgical processes through saw-bone practice, faculty-led case discussions, and a gradual introduction to technology-assisted techniques, developing essential skills prior to or alongside live surgeries. Tamil Nadu hosts 78 medical colleges, making it one of India's largest hubs for medical training. As orthopaedic care advances towards greater specialisation and incorporates new technologies, South India's high concentration of institutions positions it to excel in practical, hands-on surgical education. The planned skill lab at CMC Vellore aims to establish a lasting, practice-focused training infrastructure for the region.   Photo Caption (L-R): Vishnu Kalra, International President, DePuy Synthes and Dr Anil Thomas Oommen, Professor & Head of the Department, Christian Medical College, Vellore    ]]> https://biospectrumindia.com/news/93/28375/remidio-receives-us-patent-for-wearable-eye-imaging-technology.html https://biospectrumindia.com/news/93/28375/remidio-receives-us-patent-for-wearable-eye-imaging-technology.html Tue, 25 Aug 2026 18:26:43 +0530 Bengaluru-based Remidio Innovative Solutions has been granted US Patent for a 3D eye imaging technology built around a wearable form factor, smart glasses or a VR-style headset in place of a bulky slit lamp or ophthalmoscope. The device folds more than five separate exams into one. Slit lamp imaging, fundus imaging, and diffused anterior segment imaging, among others, are normally done on separate instruments, this design does all of them, and it can capture images of the eye without pupil dilation, using infrared illumination in place of the bright visible light conventional instruments rely on for a clear view of the back of the eye. That combination - no dilation, wearable rather than desk-mounted, is what makes the patent relevant to Remidio's broader Oculomics push. The retina is one of the few places in the body where blood vessels can be seen directly, non-invasively, and without radiation. This is why retinal imaging is backed by growing research and clinical validation as the best way to screen for conditions well beyond the eye, cardiovascular disease, diabetes, kidney disease, and neurodegenerative conditions among them – in a fast evolving field of research called Oculomics. A lighter, dilation-free imaging device is a step toward taking that kind of screening out of the specialist's chair and closer to the patient, and eventually, the consumer. ]]> https://biospectrumindia.com/news/93/28362/health-ministry-proposes-amendments-to-medical-devices-rules-2017-to-promote-ease-of-doing-business.html https://biospectrumindia.com/news/93/28362/health-ministry-proposes-amendments-to-medical-devices-rules-2017-to-promote-ease-of-doing-business.html Mon, 24 Aug 2026 18:59:12 +0530 The government has introduced major regulatory reforms in the medical devices sector with an aim to promote ease of doing business (EoDB), simplify regulatory processes, enhance transparency, and facilitate timely access to advanced medical technologies in the country. Towards this objective, the Medical Devices Regulations, 2017 have recently been amended to simplify the regulatory framework governing outsourced sterilisation of medical devices and to expand the list of stringent regulatory jurisdictions recognised to remove diagnostic requirements. The amendment to Rule 44 of the Medical Devices Regulations, 2017 has been finalised after extensive stakeholder consultations aimed at simplifying regulatory compliances for medical device manufacturers availing outsourced sterilisation facilities. Under the amended provisions, manufacturers outsourcing sterilisation of products to any other facility having a valid license under the Medical Devices Rules, 2017 will no longer be required to obtain a separate loan license for outsourced sterilisation activity. The amendment eliminates the need for a separate loan licensing process in such cases, reducing duplication, administrative burden, compliance costs, and associated timelines, especially for manufacturers who do not have in-house sterilisation facilities. The amended provision also provides for a transition period of six months for implementation of the new labelling requirement. Further, Rule 63 of the Medical Devices Regulations 2017 has been amended to include the European Union (EU) in the stringent regulatory jurisdictions recognised for relaxation of diagnostic testing requirements for medical devices without prescribing devices. ]]> https://biospectrumindia.com/news/93/28353/medicover-hospitals-launches-new-transcranial-magnetic-stimulation-lab-in-mumbai.html https://biospectrumindia.com/news/93/28353/medicover-hospitals-launches-new-transcranial-magnetic-stimulation-lab-in-mumbai.html Fri, 21 Aug 2026 17:45:50 +0530 Medicover Hospitals, Navi Mumbai, has launched its Advanced Transcranial Magnetic Stimulation (TMS) Laboratory, expanding access to non-invasive brain stimulation therapy for patients with selected psychiatric and neurological conditions. The facility will offer evidence-based TMS protocols for conditions including treatment-resistant depression, obsessive-compulsive disorder (OCD), anxious depression, post-traumatic stress disorder (PTSD), smoking cessation, and migraine, along with selected neurological applications where scientific evidence is evolving. These include stroke rehabilitation, post-stroke speech and language disorders, neuropathic pain, fibromyalgia, Parkinson’s disease, cerebellar ataxia, Alzheimer’s disease, and tinnitus. TMS uses controlled magnetic pulses to stimulate specific areas of the brain. The treatment is non-invasive and does not require surgery or general anaesthesia. Depending on the condition and protocol, TMS may be used to influence brain circuits involved in mood regulation, cognition, movement, pain processing, and other neurological functions. Patients undergo a detailed clinical assessment before treatment, and the protocol is selected according to the individual's condition and treatment goals. The new facility will provide TMS for Major Depressive Disorder, Treatment-Resistant Depression, Obsessive-Compulsive Disorder, Anxious Depression, Post-Traumatic Stress Disorder, smoking cessation, and migraine, along with selected neurological applications such as stroke rehabilitation and post-stroke speech and language difficulties. Other neurological conditions, including neuropathic pain, fibromyalgia, Parkinson’s disease, cerebellar ataxia, Alzheimer’s disease and tinnitus, may be considered for appropriate patients based on clinical assessment and available evidence. ]]> https://biospectrumindia.com/news/93/28355/rs-70000-cr-medtech-ecosystem-takes-centre-stage-at-india-health-2026.html https://biospectrumindia.com/news/93/28355/rs-70000-cr-medtech-ecosystem-takes-centre-stage-at-india-health-2026.html Fri, 21 Aug 2026 23:28:19 +0530 India Health 2026, organised by Informa Markets in India, opened on 21 August at Hall 6, Bharat Mandapam, New Delhi, bringing together healthcare providers, manufacturers, policymakers, innovators, procurement leaders, distributors and global stakeholders. The three-day exhibition, being held from August 21 to 23, features more than 300 domestic and international brands and is expected to welcome over 8,000 healthcare and medtech professionals. Dr Jitender Sharma, MD, Founder and CEO, AMTZ said, “As an association partner for India Health 2026, we are proud to support a platform that brings the complete healthcare and MedTech ecosystem together. AMTZ has grown into one of the world’s largest MedTech clusters, with 187 manufacturers and 212 startups generating a collective annual business of nearly Rs 70,000 crore. Through the exhibition, we want to demonstrate that India can move beyond manufacturing individual devices to operating entire hospitals with safe, high-quality, Made-in-India medical technologies. Our Made in India Hospitals initiative will establish 100 hospitals in tier-2 and tier-3 cities, adding 10,000 beds and creating a powerful proof point for Indian healthcare innovation.” Highlighting the broader growth trajectory of India's healthcare sector, Yogesh Mudras, Managing Director, Informa Markets in India, said, "India's healthcare sector is entering a new phase of growth, driven by expanding manufacturing capabilities, increasing investment, digital transformation, and a strong focus on innovation. With healthcare expenditure expected to contribute 5% of India's GDP by 2030, the sector is poised to play an even greater role in the country's economic and social development." Nital Patel, Secretary, ADMI, further highlighting the digital transformation, added, “At India Health 2026, technology must be viewed not simply as an innovation showcase, but as a means to solve real healthcare challenges. From diagnostics and digital transformation to scalable manufacturing, the focus must remain on solutions designed around patients and the realities of care delivery—from major hospitals and laboratories to small towns and remote rural communities. The true measure of progress will be the partnerships, stronger capabilities, better products and wider access to dependable healthcare that follow these conversations.” The exhibition floor featured the latest products and technology-led solutions aimed at strengthening clinical efficiency, diagnosis and patient care. DKS Ortho presented its latest orthopaedic products, while DRGEM Healthcare showcased medical imaging technologies. Faceecho.AI highlighted AI-enabled tools for clinical workflows and patient engagement, while Hamdard displayed its healthcare and wellness range. Together, the exhibits reflected the growing convergence of medical devices, diagnostics and artificial intelligence. The conferences will address issues related to women’s health, fertility, cancer, neurosciences and oral-health integration, reflecting the need for more coordinated, specialised care pathways. Workforce development will remain in focus, covering digital competencies, nursing leadership, simulation-based training and continuous professional learning. Across the remaining sessions, the emphasis will remain on balancing clinical preparedness, patient safety, operational efficiency and financial sustainability.   ]]> https://biospectrumindia.com/news/93/28345/insight-tribe-and-vpro-join-forces-to-address-indias-cardiac-imaging-expertise-gap-.html https://biospectrumindia.com/news/93/28345/insight-tribe-and-vpro-join-forces-to-address-indias-cardiac-imaging-expertise-gap-.html Thu, 20 Aug 2026 12:06:35 +0530 The Insight Tribe, a boutique healthcare strategy and market intelligence firm, has partnered with VPRO Cardiac Imaging Solutions, a specialist group cardiothoracic imaging service. The partnership extends RadioActiv, Insight Tribe's growth strategy practice for diagnostic centres, beyond the strategy table and into delivery — pairing the roadmap for entering or scaling a cardiac imaging service with the specialist expertise required to run one. The move addresses a pattern playing out across India's diagnostic sector. Centres have been investing in cardiac MRI and CT platforms with confidence in the equipment and the market opportunity, only to find that the harder problem was never the hardware. It has been finding someone who can read a complex cardiac study to a sub-specialist standard, defend that reading in a multidisciplinary heart team discussion, and do so consistently enough to build a referring physician's trust. For most centres outside the metros, that gap has been the real barrier to entering cardiac imaging at all. Diagnostic centres evaluating cardiac imaging as their next growth category, or looking to strengthen an existing service, can now access both the strategic roadmap and the clinical expertise behind it through Insight Tribe and VPRO. RadioActiv is Insight Tribe's growth strategy practice for diagnostic centres, built to identify where the next opportunity lies and to build the plan to capture it. VPRO brings the specialist clinical delivery behind that plan — sub-specialist reporting on cardiac MRI, cardiac CT, and vascular imaging, planning support for TAVI and TMVR cases, and the protocols and training needed to get a unit running properly. ]]> https://biospectrumindia.com/news/93/28341/orthograft-to-commercialise-advanced-tissue-derived-biological-dressings-for-wound-care.html https://biospectrumindia.com/news/93/28341/orthograft-to-commercialise-advanced-tissue-derived-biological-dressings-for-wound-care.html Wed, 19 Aug 2026 18:24:18 +0530 With an aim to translate advances in tissue engineering into useful solutions for the therapeutic treatment of chronic wounds, the Technology Development Board (TDB) of the Department of Science and Technology (DST), Government of India has provided financial assistance to Gujarat-based Orthograft for a project titled "Production Setup of Advanced Tissue Derived Biological Dressings". In collaboration with TDB, the company will establish the capability to manufacture indigenous organic dressings for clinical wound treatment applications, including chronic wounds, diabetic foot ulcers and burns. Orthograft is a DPIIT accredited medical device startup engaged in developing tissue alternatives for diagnostic reconstruction and functional repair. The company is developing its own specialised technology to process viable human tissue into long-term safe tissue alternatives. At the same time, it also maintains the key biological and structural characteristics of the parent tissue relevant to the wound healing process. With the support of TDB, Orthograft will strengthen its production infrastructure at the Gujarat government's Savli Technology Business Incubator in Vadodara, where the company has rented a bio-incubation facility. The company has also obtained necessary licenses from CDSCO for manufacturing of medical devices for testing purposes. At the same time, it is exploring the possibilities of collaboration with tertiary care hospitals and medical institutions for further development and clinical use of the technology. The company has developed multifaceted expertise in tissue processing and tissue replacement and currently holds two approved US patents.  ]]> https://biospectrumindia.com/news/93/28333/kerala-angel-network-partners-with-sree-chitra-tirunal-institute-for-medical-sciences-and-technology.html https://biospectrumindia.com/news/93/28333/kerala-angel-network-partners-with-sree-chitra-tirunal-institute-for-medical-sciences-and-technology.html Tue, 18 Aug 2026 15:59:05 +0530 Kerala Angel Network (KAN) has announced the signing of a Memorandum of Understanding (MoU) with SCTIMST TIMed – the MedTech Incubator of Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) Thiruvananthapuram. The collaboration marks an important step towards strengthening the support system for MedTech and healthcare startups emerging from Kerala. TiMed, with its strong focus on medical technology innovation and healthcare entrepreneurship, has been instrumental in nurturing startups working on solutions addressing critical healthcare challenges. KAN aims to work closely with TiMed to identify and support the next generation of MedTech innovators and healthcare entrepreneurs, and to contribute towards building globally scalable healthcare companies from Kerala. ]]> https://biospectrumindia.com/news/93/28328/aiims-new-delhi-introduces-customised-retina-training-modules.html https://biospectrumindia.com/news/93/28328/aiims-new-delhi-introduces-customised-retina-training-modules.html Mon, 17 Aug 2026 17:46:52 +0530 In a significant step towards strengthening India’s retinal healthcare ecosystem, Dr. Rajendra Prasad Centre for Ophthalmic Sciences (RPC), AIIMS New Delhi, has launched the Modulated Retina Training Programme at the National Retina Skill Development Centre, a first of its kind facility aimed at strengthening clinical capabilities in retinal care across India.   Developed in partnership with the Roche India Healthcare Institute (RIHI), the platform created brings together the clinical and academic expertise available at AIIMS with RIHI’s commitment to health-system strengthening to create a scalable model for hands-on training, research and innovation in retinal diseases.   At the core of the Programme is a state-of-the-art Retina Skill Lab CORE (Comprehensive Retinal Education), equipped with high-resolution OCTs, fundus cameras and specialised microscopes to enable modular retina training programmes.   The National Retina Skill Development Centre will aim to train over a hundred ophthalmologists from public health ecosystems over the next three years. Ophthalmologists will experience a structured training programme packaged in eight modules. The system is designed to provide training to enable efficient early detection, diagnosis and management of retinal diseases.   Retinal disorders are among the leading causes of irreversible vision loss in India. The growing burden of these conditions, coupled with gaps in availability of retina specialists and  infrastructure, underscores the need for greater capacity building in retinal care. ]]> https://biospectrumindia.com/news/93/28304/motorica-becomes-exclusive-representative-of-tehlin-in-india-expanding-access-to-lower-limb-prosthetic-technologies.html https://biospectrumindia.com/news/93/28304/motorica-becomes-exclusive-representative-of-tehlin-in-india-expanding-access-to-lower-limb-prosthetic-technologies.html Fri, 14 Aug 2026 13:31:57 +0530 Motorica, a MedTech company focused on assistive technologies and medical cybernetics, has become an exclusive representative of Tehlin in India. Under the partnership, Motorica will be responsible for the promotion, availability, service and support of Tehlin’s lower-limb prosthetic solutions in the Indian market. Tehlin Prosthetics is a Taiwan-based manufacturer with more than 60 years of experience in developing and producing prosthetic and orthotic solutions, with a portfolio of lower-limb components. The partnership brings together Motorica’s expertise in upper-limb prosthetics and its growing network of clinical partners in India with Tehlin’s experience in lower-limb prosthetic technologies, including knee joints, carbon feet and gel liners. For Tehlin, Motorica provides a partner with a strong understanding of the Indian market, established relationships with clinics and the local infrastructure needed to support the brand and its products. For Motorica, the cooperation expands its portfolio beyond upper-limb prosthetics and enables the company to offer lower-limb solutions from Tehlin as part of a broader range of prosthetic technologies. Both companies see the cooperation as a long-term strategic alliance aimed at strengthening their presence and capabilities in the Indian market. The cooperation goes beyond product distribution: from August 12 to 14, the Tehlin team was working in India with Motorica’s partners and specialists through product presentations, professional training and hands-on sessions, complemented by clinical activities in Delhi. ]]> https://biospectrumindia.com/news/93/28306/heartnet-india-signs-mou-with-iit-jodhpur-technology-park-to-advance-healthcare-and-medtech-innovation.html https://biospectrumindia.com/news/93/28306/heartnet-india-signs-mou-with-iit-jodhpur-technology-park-to-advance-healthcare-and-medtech-innovation.html Fri, 14 Aug 2026 14:05:39 +0530 Heartnet India, an IoT-based high-quality cardiac care solution company, has signed a Memorandum of Understanding (MoU) with IIT Jodhpur Technology Park to promote collaboration between academics and industry and to aid innovation in the healthcare & MedTech ecosystem. The partnership will focus on leveraging the strengths of both organisations in the fields of AI-powered healthcare solutions, Medical devices and diagnostics, Point-of-care technologies, and Next-generation MedTech innovations. The partnership is designed to build bridges between academia, research, and industry from IIT Jodhpur with Heartnet India, thus accelerating the research and ideas from the lab into practical applications. This partnership comes at a time when the future of healthcare delivery is becoming more and more driven by artificial intelligence, connected technology, medical devices, and data-based decision-making. The partnership will serve as a platform to develop research outcomes that address healthcare challenges from both a technology and implementation angle, emphasising real-world solutions. Arindam Sen, Founder, Heartnet India, said, “Healthcare innovation becomes meaningful when research and technology can move beyond the laboratory and address problems that patients and healthcare professionals actually face. Our collaboration with IIT Jodhpur Technology Park allows us to work closely with an academic and research ecosystem while bringing our understanding of healthcare delivery to the table. We look forward to exploring practical applications across AI, diagnostics, medical devices and MedTech that can create measurable value for healthcare.” The MoU between IIT Jodhpur Technology Park and Heartnet India marks a step towards creating a stronger interface between healthcare, technology and academic research. Through continued collaboration, both organisations will explore opportunities to develop innovations that can move from ideas and research towards practical healthcare applications. ]]> https://biospectrumindia.com/news/93/28293/c-camp-onboards-two-dutch-medtech-startups-focusing-on-neurological-disorders-and-cardiac-health.html https://biospectrumindia.com/news/93/28293/c-camp-onboards-two-dutch-medtech-startups-focusing-on-neurological-disorders-and-cardiac-health.html Wed, 12 Aug 2026 13:13:05 +0530 Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) has onboarded two Medtech startups from the Netherlands, positioning itself as a globally reckoning bio innovation destination. The startups are in the domains of neurological disorders and cardiac health. The move is catalysed by the Embassy of the Netherlands as a part of its commitment towards bilateral innovation bridge between the Netherlands and India that aims to promote exchange of innovators from mutual ecosystems. The agreements with the two startups were announced at C-CAMP premises in the presence of Dr Taslimarif Saiyed, C-CAMP Director-CEO and Anne Cremers, Acting Consul General of the Kingdom of the Netherlands in South India. Aikon Health, represented by founder Thiru Kanagasabapathi, has developed a modular, skin‑patch wearable for heart failure and an accompanying digital platform to capture longitudinal vital-sign and hemodynamic data that is interoperable with hospital/RPM systems. The technology can monitor clinically validated digital biomarkers and send out predictive alerts to support medication titration and reduce hospital readmissions. On the other hand, Alpha Brain Technologies, represented by Co-CEO & Tech lead, Mehrdad Seirafi, has developed a non-invasive, easy-to-wear medical device that predicts seizures before they happen, alerting the patient and caregiver ahead of time. ]]> https://biospectrumindia.com/news/93/28295/aig-hospitals-collaborates-with-johnson-johnson-to-implement-polyphonic-surgery.html https://biospectrumindia.com/news/93/28295/aig-hospitals-collaborates-with-johnson-johnson-to-implement-polyphonic-surgery.html Wed, 12 Aug 2026 16:02:36 +0530 Hyderabad-based AIG Hospitals has announced a collaboration with Johnson & Johnson to implement Polyphonic™ Surgery, the flagship solution within the Polyphonic digital ecosystem for surgery, designed to support secure surgical video recording, review, collaboration, learning, and knowledge-sharing across surgical teams. AIG Hospitals will be among the early centres in not just in India but entire Asia-Pacific to implement such a digital ecosystem for surgical procedures, marking an important step towards the future of surgical intelligence. The platform is designed to bring surgical video, case-based review, team collaboration, learning resources, and structured feedback into one centralized environment. Through hands-on use and ongoing collaboration with surgeons, operating room teams, residents, information technology professionals and hospital leadership, AIG Hospitals will help evaluate how connected digital technologies can support clinical excellence and operational effectiveness. The collaboration also aligns with AIG Hospitals’ larger vision of integrating clinical excellence with academics, research, digital innovation and AI-enabled healthcare solutions. As part of the programme, participating users at AIG Hospitals will provide feedback on usability, workflow integration and clinical connectivity, helping inform future applications across surgical specialties and hospital systems. ]]> https://biospectrumindia.com/news/93/28270/health-minister-releases-knowledge-paper-on-ai-in-medtech.html https://biospectrumindia.com/news/93/28270/health-minister-releases-knowledge-paper-on-ai-in-medtech.html Sat, 08 Aug 2026 19:27:24 +0530 Union Minister of Chemicals & Fertilizers and Health & Family Welfare J. P. Nadda released a knowledge paper on "AI in MedTech: Revolutionising Healthcare Through Artificial Intelligence" at the 9th Edition of India Medical Device 2026, organised by the Department of Pharmaceuticals in association with FICCI, at Vigyan Bhawan, New Delhi, on 8 August. The report highlights the growing role of Artificial Intelligence (AI) in the healthcare sector, from creating new opportunities to addressing emerging challenges. Jointly developed by Praxis Global Alliance, in association with FICCI, the knowledge paper examines India's evolving AI-enabled MedTech landscape and outlines the strategic actions needed to accelerate responsible AI adoption across healthcare. It explores AI's role in diagnostics, clinical decision support, operational efficiency and medical device innovation, while identifying the regulatory, policy and ecosystem interventions required to enable large scale adoption. The report while noting that India has already built important foundations through the Ayushman Bharat Digital Mission (ABDM), the IndiaAI Mission, SAHI, BODH and the National Medical Devices Policy, 2023, observes that moving AI solutions from successful pilots to large-scale clinical adoption is a major challenge. The report notes that this transition requires addressing fragmented health data and limited evidence, developing predictable lifecycle-based regulation for adaptive AI, and creating supportive reimbursement and procurement mechanisms. The report highlights five priorities for accelerating AI-enabled MedTech adoption in India: •MedTech represents India's most immediate and scalable AI opportunity, •India has the foundations for AI leadership, but not yet the ecosystem for scale, •India must move beyond successful pilots to routine clinical adoption by addressing three ecosystem gaps: AI-ready data and evidence, lifecycle-based regulation, and procurement and reimbursement mechanisms that recognise AI-enabled value' •AI-enabled diagnostics are expected to be the first large-scale application, •Coordinated action across government, regulators, healthcare providers, payers, industry and academia will be essential to position India as a global leader in responsible AI-enabled MedTech. ]]> https://biospectrumindia.com/news/93/28259/indias-medical-devices-industry-to-reach-250-b-by-2047-ficci-dua-associates-consulting-report.html https://biospectrumindia.com/news/93/28259/indias-medical-devices-industry-to-reach-250-b-by-2047-ficci-dua-associates-consulting-report.html Fri, 07 Aug 2026 20:30:16 +0530 According to the whitepaper titled 'Service and Maintenance of Medical Devices in Indian Healthcare – Towards a Safe, Reliable, and Sustainable Medical Device Maintenance Ecosystem' released by FICI-Dua Associates Consulting, India's medical devices industry is expected to emerge as a global force by 2047 with an estimated market size of $250 billion. The white paper released during the inaugural session of the 9th 'India Medical Device 2026' organised by the Department of Pharmaceuticals in association with FICCI (FICCI) states that India's medical devices sector, which is currently valued at around $14 billion, is projected to reach $30-50 billion within this decade and is likely to reach $250 billion by 2047. Increasing demand for healthcare, increased adoption of advanced medical technologies, government support for indigenous manufacturing, and the country's ambition to become a global MedTech hub will drive this rapid growth, it said. According to the white paper, India has made significant progress through initiatives such as the Production-Linked Incentive (PLI) scheme and the Medical Devices Industry Strengthening Scheme, which has enhanced domestic manufacturing capabilities and improved India's global competitiveness. However, the report emphasises that the sustained growth of this sector will depend not only on manufacturing but also on building a world-class ecosystem for servicing, maintenance, calibration, and lifecycle management of medical devices. According to the report, proper maintenance improves patient safety, increases diagnostic effectiveness, reduces the unusability of equipment, extends their lifespan, and maximizes the benefits of investments made in healthcare. To address these problems, the White Paper proposes a risk-level hybrid maintenance framework based on the Equipment Classification System of the Central Drugs Standard Control Organisation (CDSCO). It includes recommendations such as maintenance protocols based on equipment risk categories, creation of a national certification framework for service engineers, strengthening technical training, encouraging commercial model innovation and rationalizing the fiscal framework to promote compliant maintenance systems. The report also advocates for the widespread adoption of digital technologies, including predictive maintenance, digital monitoring, and lifecycle management systems, to improve equipment reliability and reduce downtime. ]]> https://biospectrumindia.com/news/93/28260/9th-india-medical-device-2026-opens-in-new-delhi-to-focus-on-developing-india-as-global-medtech-hub.html https://biospectrumindia.com/news/93/28260/9th-india-medical-device-2026-opens-in-new-delhi-to-focus-on-developing-india-as-global-medtech-hub.html Fri, 07 Aug 2026 20:37:11 +0530 The 9th edition of the two-day India Medical Device 2026 began on 7th August at Vigyan Bhawan, New Delhi. The conference is bringing together policymakers, regulators, industrialists, innovators, and other stakeholders to advance the country's medical devices sector and strengthen its position as a global hub for quality medical devices. The conference is being organised by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India in collaboration with the Federation of Indian Chambers of Commerce and Industry (FICC) on the theme "Towards Viksit Bharat: India's Progress as a Global Hub for Quality Medical Devices". Manoj Joshi, Secretary, Department of Pharmaceuticals, while addressing the inaugural session, emphasised that the medical devices sector should be viewed from both the healthcare and industry perspectives. The Secretary said that we have to create an export-oriented industry that can cater to the needs of global markets. The Indian medical devices market is valued at around $16 billion, while the global market is valued at over $600 billion, offering immense opportunities for Indian manufacturers.  Dr Rajiv Singh Raghuvanshi, Drug Controller General of India (DCGI), said that India's medical devices sector is undergoing a fundamental transition from an import-based market to a domestic manufacturing-based ecosystem. He stressed on the need to strengthen indigenous capabilities in high-end Class C and Class D medical devices and in vitro diagnostics, while ensuring prompt, transparent and predictive regulatory approvals. The next phase of growth is to foster India's innovation, strengthen R&D, build resilient supply chains, develop advanced manufacturing capabilities, promote globally harmonised quality standards, said Jyoti Vij, Director General, FICCI. ]]> https://biospectrumindia.com/news/93/28247/mtai-calls-for-regulatory-reforms-to-maximise-healthcare-gains-from-ftas.html https://biospectrumindia.com/news/93/28247/mtai-calls-for-regulatory-reforms-to-maximise-healthcare-gains-from-ftas.html Mon, 03 Aug 2026 17:01:41 +0530 The Medical Technology Association of India (MTaI) has called for closer alignment between India’s Free Trade Agreement (FTA) framework and domestic policies governing regulation, procurement, investment and workforce mobility to ensure that expanding trade partnerships translate into stronger healthcare outcomes and faster patient access to advanced medical technologies. The call was made at MTaI's closed-door roundtable on 31 July, held as part of its 10th anniversary celebrations, "FTA Frameworks in an Evolving Global Order: Shaping the Healthcare Roadmap" which brought together policymakers, diplomatic representatives from Embassies of Germany, Netherlands, Sweden, Saudi Arabia, Denmark, Luxembourg, Sri-Lanka, trade experts and MedTech industry leaders. Opening the roundtable, Pavan Choudary, Chairman, MTaI, said, "Geopolitics increasingly shapes commerce today. Trade corridors and supply chains are as important to understand as business itself. The world is not deglobalising; it is moving towards minilateralism, with regional pacts and FTAs increasingly influencing how companies will source, manufacture and invest. The roundtable deliberated on the practical measures required to translate India's expanding FTA network into stronger healthcare outcomes and a globally competitive MedTech ecosystem. Discussions focused on ensuring that trade liberalisation is complemented by timely customs notifications, consistent product classification, simpler rules of origin, greater regulatory cooperation and more predictable implementation of trade commitments. Deliberations also examined the alignment of trade commitments with public procurement frameworks, including the Global Tender Enquiry (GTE) mechanism, while emphasising that tariff reduction alone cannot deliver meaningful market access unless supported by clear regulatory pathways, faster product approvals and stronger coordination between regulatory authorities. Speaking at the roundtable, Dr Gyanendra Nath Singh, Advisor to the Chief Minister of Uttar Pradesh and Former Drugs Controller General of India (DCGI), emphasised the importance of a science-driven regulatory ecosystem that accelerates innovation while safeguarding patient interests. He said, "India has already put in place provisions for the fast-track approval of innovative medical technologies. Going forward, industry proposals must remain ethical, science-led and evidence-based. Our objective is to build an ecosystem that reduces costs, improves quality and simplifies regulatory processes, enabling India to emerge as a global hub for medical-device manufacturing and supply." The roundtable also focused on strengthening India’s component supply chain and supporting Indian manufacturers seeking access to international markets. The discussion also highlighted the importance of greater mobility of specialised professionals, including engineers, technicians and healthcare professionals involved in the installation, servicing and clinical use of medical technologies. Participants also underscored the need for stronger cooperation on qualifications, training standards and credentialing, while noting that MTaI member companies collectively train nearly 250,000 healthcare professionals every year. The roundtable further highlighted the need for FTAs to remain active through joint monitoring mechanisms, regulator-to-regulator engagement and dedicated platforms to resolve implementation challenges.   ]]> https://biospectrumindia.com/views/93/28205/structural-challenges-have-slowed-the-growth-of-the-indian-medtech-ecosystem.html https://biospectrumindia.com/views/93/28205/structural-challenges-have-slowed-the-growth-of-the-indian-medtech-ecosystem.html Sat, 01 Aug 2026 00:00:00 +0530 Can you share how the partnership with CfHE at IIT Hyderabad will support the development and commercialisation of next-generation healthcare technologies?  Silicon Labs has entered into a strategic collaboration with CfHE at IIT-H to accelerate the development and deployment of next-generation smart medical devices designed and manufactured in India.  Through a Memorandum of Understanding (MoU), the two organisations will work together to nurture healthcare entrepreneurship by enabling startups and innovators to leverage advanced embedded systems, low-power wireless technologies, edge computing, secure IoT platforms, and AI-driven healthcare solutions. As part of the collaboration, startups incubated at CfHE will gain access to Silicon Labs' energy-efficient wireless MCU chips with edge-ML capabilities, along with technical guidance and hands-on workshops. The partnership also includes support for pilot deployments in hospitals and healthcare centres, helping startups validate and scale their innovations in real-world settings.  What key challenges in India's MedTech ecosystem is this partnership aiming to address? The Indian MedTech ecosystem has tremendous potential, but structural challenges have slowed its growth. The partnership is focused on addressing key challenges, such as access to advanced technologies at the design stage, technical expertise, product validation opportunities, the gap between prototype and real-world deployment, and support for translating research into commercially viable healthcare solutions. By combining CfHE's healthcare entrepreneurship ecosystem with Silicon Labs' semiconductor technologies and technical expertise, the collaboration aims to help startups accelerate product development, improve device reliability and performance, and gain access to real-world deployment opportunities. The initiative also seeks to support the development of affordable, secure, and regulatory-compliant medical devices that can serve both Indian and global markets, ultimately strengthening India's deep-tech medtech ecosystem. How will this collaboration help MedTech and deep-tech startups move from innovation to commercialisation? Through CfHE, startups will gain access to Silicon Labs' advanced wireless and edge-AI technologies, technical expertise, and hands-on workshops, helping them accelerate product development and build globally competitive medical devices. Beyond access to technology, the collaboration provides startups with real-world validation opportunities through pilot deployments in hospitals and healthcare centres. By combining access to advanced technology with mentorship, industry collaboration, and deployment support, the initiative aims to accelerate innovation, strengthen commercialisation pathways, and help build globally competitive healthcare solutions from India and strengthen India's medtech and deep-tech startup ecosystem. Which MedTech technologies and innovation areas will be the focus of this partnership, and why? Through our collaboration with CfHE, we are focused on technology areas that address India's healthcare needs while enhancing the global competitiveness of Indian medical device startups, such as advanced embedded systems, edge computing architectures, low-power wireless health monitoring technologies, secure IoT-enabled medical platforms, and AI-driven diagnostic and remote healthcare solutions. These are key areas where advanced semiconductor technologies can help accelerate the development of smart, secure, and scalable medical devices.  How will this partnership enable clinical validation and hospital deployment for MedTech startups? Hospital deployment is, in fact, a core component of this partnership, not an afterthought. Through Silicon Labs' CSR initiative, we are providing financial and technical support for the rollout of pilot projects in hospitals and healthcare centres across India, giving CfHE-incubated startups a structured pathway to early-stage clinical deployment of devices built on Silicon Labs chipsets.  This is important because real-world validation is critical to turning a promising prototype into a deployable medical device. Our deployment focus spans primary healthcare centres, rural health systems, and urban hospitals, ensuring that solutions are validated across diverse healthcare environments.  What outcomes do you expect from this partnership over the next three to five years? CfHE is a preeminent incubator in the healthcare area located within IIT-H that is supported by the government and other funding agencies. It offers an annual fellowship programme for people interested in healthcare entrepreneurship. It is supported by academic research from IIT-H, clinical partners to provide an immersive experience to participants, and many other partners helping in manufacturing, prototyping, and fund raising.  The first step would therefore be to enable entrepreneurs in the programme to get started on technology products, build prototypes, carry out a pilot manufacturing run and conduct trials with a clinical partner. We would expect a few successful prototype products every year. In three to five years, some of these would go to mass production and find success in the marketplace in India and beyond.  Do you plan to expand similar partnerships to further strengthen India's MedTech and deep-tech ecosystem? We have been establishing ‘Centres of Innovation in IoT’ at universities – over a dozen such labs created so far. The focus here is on connected and intelligent products in general with med tech also featuring prominently. We provide workshops, training, support and mentorship to student innovators paving the way to building a talent pool in this area. We have recently launched a global IoT Challenge with the theme of ‘Smart Healthcare with Edge AI’ where competing teams would create and demonstrate edge-AI enabled healthcare innovations using Silicon Labs Chips. We saw over 200 entries from India with eight out of the global top 20 teams being from here. The challenge will have its finale in September this year.  How can India build a future-ready workforce to support the growth of its MedTech industry? Taking a medtech solution to market is an intensely multi-disciplinary effort. On the clinical side, a good understanding of the medical aspects of the chosen area is required, in addition to learning clinical workflows and regulatory compliance. On the technology side, knowledge of electronic circuits and sensors, materials, electromechanical systems, embedded system architecture, firmware development, analytical and AI software, and UI/UX design, among others, would be required. Fundamentally then, we need to leverage the existing core engineering education. In addition, we would need skills related to product thinking, business analysis, building partnerships and engaging with government and other agencies. All this is best done through structured programmes putting people from different areas of expertise together. CfHE is an example of such an effort.  Looking at the evolving global MedTech ecosystem, what opportunities do you believe India is best positioned to capture, and what challenges must it overcome to realise its potential?  Global trends include a big focus on AI for dramatic improvements in many areas like diagnostics, remote monitoring, insights, and automated healthcare workflows. There is also an emphasis on preventive care. Devices like Continuous Glucose Monitors (CGM) are being used by the healthy as much as by those with a medical condition. New age sensors along with AI processing provide unprecedented non-invasive diagnostics. AI-enabled electromechanical systems such as surgical robots and exoskeletons are increasingly complex, capable, and pervasive. Most of these and other innovations would be adopted in India with positive results. They would help satisfy the growing requirements of remote healthcare, preventive medicine and the growing demands of elder care. The Ayushman Bharat Health Account (ABHA) identifier allows full and secure integration of health records and makes technology adoption easier and more effective.   Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/93/28235/invest-india-and-apacmed-sign-mou-to-strengthen-indias-medtech-ecosystem.html https://biospectrumindia.com/news/93/28235/invest-india-and-apacmed-sign-mou-to-strengthen-indias-medtech-ecosystem.html Thu, 30 Jul 2026 20:42:19 +0530 Invest India, the National Investment Promotion and Facilitation Agency of the Government of India, has signed a Memorandum of Understanding (MoU) with the Asia Pacific Medical Technology Association (APACMED) at Bharat Mandapam in New Delhi. The MoU aims to strengthen cooperation between the government and the global MedTech industry to promote investment, innovation, and sustainable growth in India's Medical Technology Sector (MedTech). The MoU was exchanged in the presence of Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers and Dr M. Srinivas, Member, NITI Aayog. The partnership provides a framework for cooperation in areas such as investment facilitation, regulatory and policy engagement, research and innovation, technology transfer, and digital health. It will foster greater engagement with APACMED member companies and facilitate investment and expansion in India. This collaboration is expected to strengthen domestic manufacturing, promote local value addition, enhance ease of doing business, and strengthen India's integration with global MedTech value chains. The signing of the MoU was followed by a CEO Roundtable on the theme "MedTech as a Catalyst for Viksit Bharat@2047" chaired by Manoj Joshi. The conference saw senior government officials, industry leaders, and key stakeholders deliberate on strategic priorities to strengthen India's MedTech sector and enhance its global competitiveness. The discussions discussed key policy issues, including procurement from local sources and strengthening of supply chains, R&D, the role of Global Competence Centres (GCCs), talent and workforce development, and opportunities to increase India's participation in global medtech markets. Regulatory and investment priorities were focussed. ]]> https://biospectrumindia.com/news/93/28210/cdsco-releases-guidance-document-on-medical-device-software.html https://biospectrumindia.com/news/93/28210/cdsco-releases-guidance-document-on-medical-device-software.html Mon, 27 Jul 2026 12:56:56 +0530 Software role in healthcare is becoming increasingly critical, as a diverse array of products serves various medical and administrative functions across clinical and private settings. Any software, whether alone or in combination, intended by the manufacturer for medical purposes and attracts the definition of medical device under the Drugs and Cosmetics Act, 1940 and Medical Devices Rules, 2017 (MDR-2017) is regulated as ‘medical device.’ The Central Drugs Standard Control Organisation (CDSCO) has released a document to provide guidance to stakeholders (manufacturers, importers and innovators/researchers, etc.) for the submission of application to the Licensing Authority (LA) for obtaining regulatory approvals for Medical Device Software (Medical Device Software) (including In-vitro Diagnostic (IVD) Medical Device Software) under the MDR-2017. This Guidance Document reflects current practices under the MDR-2017 and should not be misconstrued as a new regulatory control on MDSW (including In vitro Diagnostic (IVD) MDSW). Manufacturers of AI-enabled MDSW intended for use in India should demonstrate that device performance has been evaluated in at risk populations, healthcare settings, and operational environments representative of the intended use. As per the document, manufacturers should design MDSW to maintain safe operation during cybersecurity incidents, including partial loss of connectivity, denial of-service conditions, or integrity compromise. In-vitro diagnostic systems, digital pathology solutions, radiology AI systems, and diagnostic decision-support software deployed within healthcare facilities should be designed such that they support ABDM compliant health record generation and exchange, maintain patient consent controls, and enable traceability of diagnostic outputs to registered facilities and authorized healthcare professionals. ]]> https://biospectrumindia.com/news/93/28211/sctimst-and-tata-elxsi-partner-to-accelerate-healthcare-innovation-and-medtech-development.html https://biospectrumindia.com/news/93/28211/sctimst-and-tata-elxsi-partner-to-accelerate-healthcare-innovation-and-medtech-development.html Mon, 27 Jul 2026 14:01:25 +0530 Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Thiruvananthapuram, an Institution of National Importance under the Department of Science and Technology (DST), Government of India, has signed a Memorandum of Understanding (MoU) with Tata Elxsi, a global leader in design and technology services, to collaborate on the development of next-generation healthcare solutions. The MoU was signed at SCTIMST, Thiruvananthapuram, in the presence of senior leaders from both organisations, including Dr Sanjay Behari, Director, SCTIMST, and Manoj Raghavan, CEO & Managing Director, Tata Elxsi, along with members of the healthcare, research, and technology leadership teams from both institutions. The collaboration combines SCTIMST's strengths in cardiovascular sciences, neurosciences, biotechnology, and clinical sciences with Tata Elxsi's expertise in product engineering, design, AI, and digital technologies. Together, the organisations will address opportunities across diagnostics, medical imaging, digital health, biomedical engineering, medical devices, and related healthcare technologies for India and global markets. Unlike traditional industry-academia engagements, the partnership creates an extended innovation and engineering environment for Tata Elxsi, its customers, and healthcare partners. It brings together clinicians, specialist researchers, advanced laboratories, prototyping infrastructure, and product engineering capabilities within a single collaborative ecosystem. This will enable MedTech companies to develop, validate, and scale new products more efficiently. The partnership also strengthens capabilities in biocompatibility, toxicology, and other areas. The MoU establishes a framework for joint research, academic engagement, technology development initiatives, and intellectual property creation through project-specific collaborations. Initial efforts are expected to focus on identifying a select set of high-potential opportunities for collaborative development. ]]> https://biospectrumindia.com/news/93/28222/india-advances-medical-robotics-ecosystem-through-strategic-collaboration.html https://biospectrumindia.com/news/93/28222/india-advances-medical-robotics-ecosystem-through-strategic-collaboration.html Mon, 27 Jul 2026 20:39:57 +0530 A strategic collaboration has been announced between I-Hub Foundation for Cobotics, the Technology Innovation Hub of IIT Delhi, Andhra Pradesh MedTech Zone (AMTZ) MediValley, NITI Aayog, and RoboMed Innovations, to accelerate innovation, entrepreneurship and commercialisation in Medical Robotics Technologies. The MoU was signed in the presence of Principal Scientific Advisor to the Prime Minister, Prof. Ajay Kumar Sood. This partnership marks a significant step toward building a robust ecosystem that bridges research, innovation, clinical validation, manufacturing, and commercialization of indigenous medical robotic technologies. Key highlights of the collaboration include- To establish a collaborative ecosystem to nurture Medical Robotics startups; Launch innovation challenges, hackathons and accelerator programmes; Facilitate access to incubation, testing, mentoring and manufacturing infrastructure; Strengthen technology translation from laboratory to market; Promote indigenous robotic surgical systems and advanced healthcare technologies aligned with the Make in India vision One of the ambitious goals of this collaboration is to facilitate the establishment of at least 12 medical robotics manufacturing companies at AMTZ over the next three years, creating a strong innovation pipeline for India's MedTech sector. The partners aim to enable the next generation of entrepreneurs, researchers, clinicians and industry partners to shape the future of Medical Robotics and strengthen India's position as a global hub for advanced and affordable healthcare technologies. ]]> https://biospectrumindia.com/news/93/28194/manav-rachna-launches-centres-for-futuristic-dentistry.html https://biospectrumindia.com/news/93/28194/manav-rachna-launches-centres-for-futuristic-dentistry.html Fri, 24 Jul 2026 22:18:09 +0530 Manav Rachna Dental College (MRDC), Faridabad, has inaugurated the Centre for Digital Dentistry and the Centre for Advanced Oral Implantology under its Department of Futuristic Dentistry, along with the Temporomandibular Disorders (TMD) Centre under the Department of Prosthodontics. The new facilities combine digital diagnosis, smile design, implant planning and computer-guided treatment in one integrated ecosystem, enabling students to train using contemporary technologies while making advanced dental care more accessible to the public. Lt. Gen. Dr Vimal Arora, Chief Clinical Officer, Clove Dental, inaugurated the three centres as the Chief Guest. The Centre for Digital Dentistry introduces digital workflows for diagnosis, treatment planning and the in-house fabrication of dental restorations using intraoral 3D scanning and computer-aided design (CAD) and computer-aided manufacturing (CAM) technology.  The Centre for Advanced Oral Implantology strengthens the institution's implant dentistry capabilities through Cone Beam Computed Tomography (CBCT), digital implant planning and guided implant surgery. By integrating three-dimensional imaging with computer-guided workflows, the centre supports accurate diagnosis and treatment planning while enabling comprehensive implant care within the institution. The Temporomandibular Disorders (TMD) Centre provides specialised diagnosis and management for disorders affecting the temporomandibular joint and associated structures. Equipped with advanced diagnostic technologies, including surface electromyography (EMG), Joint Vibration Analysis (JVA) and digital occlusal analysis systems, the centre offers evidence-based evaluation and treatment for patients experiencing jaw pain, joint dysfunction and related conditions. ]]> https://biospectrumindia.com/news/93/28174/medtech-firm-bioscan-research-raises-1-m-in-seed-round-for-market-expansion-.html https://biospectrumindia.com/news/93/28174/medtech-firm-bioscan-research-raises-1-m-in-seed-round-for-market-expansion-.html Wed, 22 Jul 2026 15:22:39 +0530 Bengaluru-based MedTech firm Bioscan Research, which is leveraging deeptech in optics, electronics, mechanics and software to develop, test, manufacture and commercialise affordable medical devices for early detection of brain injuries non-invasively, has raised $1 million in a seed round led by Unicorn India Ventures. The funds raised will be strategically deployed for market expansion, additional regulatory approvals, product upgradation and new IP creation. Incorporated in 2017, by Anupam Lavania and Shilpa Malik, Bioscan Research aims to improve traumatic brain injury patient outcomes via an objective assessment for early detection at a pre-symptomatic phase with the help of machine learning powered NIRS device - CEREBO. The flagship product CEREBO, is an advanced intra-cranial injury detector designed to assist in managing trauma patients, even in the absence of visible symptoms, ensuring timely intervention within the golden period. In the last 12 months the company has witnessed 5x growth and is redefining how critical conditions are identified—enabling faster clinical decisions, improved outcomes, and more accessible care worldwide. Over the next 12 months the company’s goal is to grow 3x and plans to expand in India and overseas markets. ]]> https://biospectrumindia.com/news/93/28135/medtronic-and-apollo-hospitals-to-establish-state-of-the-art-advanced-icu-in-hyderabad.html https://biospectrumindia.com/news/93/28135/medtronic-and-apollo-hospitals-to-establish-state-of-the-art-advanced-icu-in-hyderabad.html Thu, 16 Jul 2026 16:53:07 +0530 Medtronic, a global leader in healthcare technology, and Apollo Hospitals have announced the inauguration of “ICU of the Future” an 11-bed, state-of-the-art Intensive Care Unit (ICU) at Apollo Hospitals, Jubilee Hills. The new facility will be fully integrated with Medtronic’s advanced Acute Care & Monitoring (ACM) technologies and solutions, marking a significant milestone in collaborative healthcare innovation. The MoU was officially signed by Dr Sangita Reddy, Joint Managing Director, Apollo Hospitals Group; Manpreet Singh, Chief Executive Officer, Apollo HealthAxis and Mandeep Singh Kumar, Managing Director & Vice President – India Subcontinent Countries, Medtronic during a formal inauguration ceremony held at the Jubilee Hills campus. Developed in collaboration with Medtronic’s ACM team, the initiative represents a step forward in strengthening critical care infrastructure and advancing collaborative healthcare innovation. The integrated ICU is designed to support evolving clinical needs while fostering closer collaboration between clinicians and technology leaders. By bringing together clinical expertise and advanced technologies, the collaboration aims to help enable more informed care delivery and contribute to improved patient outcomes. Mandeep Singh Kumar, Vice President – India Subcontinent Countries, Medtronic said, “This advanced ICU at Apollo Hospitals reflects a shared commitment to patient care and clinical excellence. Through this collaboration, we aim to gain valuable insights from real-world clinical environment that can help inform the development of technologies designed to support clinicians and improve patient care in India and around the world.” Dr Sangita Reddy, Joint Managing Director, Apollo Hospitals Group said, “Critical care is where every decision, every minute and every intervention can make the difference between life and loss. As medicine becomes increasingly data-driven, our responsibility is not only to bring the best technologies to India but to ensure they meaningfully improve clinical decisions and patient outcomes."   ]]> https://biospectrumindia.com/news/93/28103/intuitive-signs-mou-with-fortis-hospital-to-support-development-of-sustainable-robotic-assisted-surgery-programmes.html https://biospectrumindia.com/news/93/28103/intuitive-signs-mou-with-fortis-hospital-to-support-development-of-sustainable-robotic-assisted-surgery-programmes.html Sat, 11 Jul 2026 13:34:32 +0530 Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), and Fortis Mohali, have announced the signing of a Memorandum of Understanding (MoU) to establish India’s first Total Programme Observation (TPO) site in a non-metro city.  The collaboration reflects a shared vision to support the next phase of robotic-assisted surgery in India, with a focus on programme maturity, structured training, patient safety and multidisciplinary readiness. The TPO site at Fortis Hospital Mohali will create a peer-to-peer learning platform for healthcare professionals to observe how an established robotic programme is built, governed and sustained in a real-world Indian healthcare setting. Fortis Hospital Mohali has developed a multidisciplinary robotic-assisted surgery programme across specialties including gynaecology, gastrointestinal oncology, urology and head and neck surgery. The hospital has completed more than 3,600 robotic-assisted procedures, supported by 18 robotic surgeons and two da Vinci surgical systems. Serving patients across Punjab, Haryana, Himachal Pradesh, Chandigarh and neighbouring regions, Fortis Hospital Mohali offers a valuable non-metro reference point for institutions looking to strengthen robotic-assisted surgery programmes in similar healthcare settings. Through the TPO site, visiting surgeons, care teams, hospital administrators and executive leaders will have the opportunity to engage in structured peer-to-peer learning with an established robotic-assisted surgery programme. Beyond clinical observation, participants will gain exposure to the broader elements that support programme maturity, including surgeon training pathways, multidisciplinary team coordination, operating room workflows, patient safety processes, programme governance, executive alignment, financial planning and long-term service development. This collaboration is expected to strengthen India’s robotic-assisted surgery ecosystem by creating a practical learning platform for hospitals seeking to build or enhance their own programmes, particularly beyond major metropolitan centres. ]]> https://biospectrumindia.com/news/93/28100/fibroheal-raises-rs-14-cr-to-expand-advanced-wound-care-technology.html https://biospectrumindia.com/news/93/28100/fibroheal-raises-rs-14-cr-to-expand-advanced-wound-care-technology.html Thu, 09 Jul 2026 22:19:05 +0530 Bengaluru-based Fibroheal Woundcare has successfully raised Rs 14 crore in fresh capital to accelerate its next phase of growth and expand into developed global markets. Founded with a vision to transform wound care through silk protein-based biomaterial innovations, Fibroheal has emerged as one of India's promising MedTech companies. The fresh investment will enable the company to strengthen its commercial capabilities, expand internationally, and accelerate the development of breakthrough biomaterial-based healthcare solutions. This milestone reflects not only the confidence of its investors but also the strength of India's innovation ecosystem in creating globally competitive healthcare technologies. With plans to enter developed markets and launch next-generation biomaterial products, Fibroheal is well positioned to make a significant global impact in the MedTech sector. The company is working towards bringing two game changing products – Fibroplug ORC – a bioresorbable material to arrest internal bleeding post surgeries; and a bone regenerative solution for infected bone injuries and other complex orthopaedic recoveries and is expected to launch in FY 2027. ]]> https://biospectrumindia.com/news/93/28101/new-strategic-partnership-to-strengthen-telanganas-medtech-innovation-ecosystem.html https://biospectrumindia.com/news/93/28101/new-strategic-partnership-to-strengthen-telanganas-medtech-innovation-ecosystem.html Thu, 09 Jul 2026 22:29:52 +0530 A Memorandum of Understanding (MoU) has been signed between Research and Innovation Circle of Hyderabad (RICH) and the Medical Devices Park Industrial Welfare Association (MDPIWA), Telangana at T-Hub, for establishing a strategic partnership to further strengthen Telangana’s MedTech innovation ecosystem. This collaboration creates a structured framework for advancing key areas of ecosystem development, including international market access and strategic global partnerships, industry–research linkages, startup engagement and innovation support, joint MedTech conclaves and knowledge‑exchange platforms, and accelerated pathways for technology commercialisation. Through this MoU, RICH and MDPIWA will jointly enable deeper integration between the Medical Devices Park, home to more than 70 medical device companies, and the broader innovation landscape comprising researchers, clinicians, healthcare institutions, and international collaborators. The partnership aims to catalyse innovation, support the development of high‑impact medical technologies, and enhance the global competitiveness of Telangana’s MedTech sector. Together, RICH and MDPIWA look forward to building a stronger, innovation‑driven, and globally connected MedTech ecosystem, creating meaningful opportunities for collaboration, growth, and technological advancement in Telangana and beyond. ]]> https://biospectrumindia.com/news/93/28086/low-rd-spending-constrains-medtech-innovation-in-india-exim-bank-study.html https://biospectrumindia.com/news/93/28086/low-rd-spending-constrains-medtech-innovation-in-india-exim-bank-study.html Wed, 08 Jul 2026 23:05:54 +0530 India’s medical devices industry stands at a critical juncture. While the country has made significant strides in manufacturing and exports, achieving technological self-reliance will require a shift from low-value production to innovation-led growth. Key findings from the Exim Bank Study, “Building Technological Capabilities in India’s Medical Devices Industry,” are as follows: Domestic manufacturing is gaining momentum- Production of medical and dental instruments more than doubled from Rs 162.6 billion in 2019–20 to Rs 348.7 billion in 2023–24 (21.0% CAGR), while production of irradiation, electromedical, and electrotherapeutic equipment rose from Rs 70.8 billion to Rs 113.9 billion (12.6% CAGR). Exports are growing but not reducing import dependence- Medical device exports increased from $4.7 billion in 2019 to $6.9 billion in 2024 (8.1% CAGR), outpacing global growth (7.7%). However, the trade deficit widened from $2.9 billion to $4.9 billion, reflecting continued reliance on imports. Technology gap remains the core challenge- Exports are concentrated in low- and medium-technology segments such as consumables (37.2%) and PPE (29.8%), while imports are dominated by medium-tech instruments and high-tech equipment. Low R&D spending further constrains innovation. Global market presence remains limited- India accounts for only ~1% of high-technology exports, 1.3% in low-tech, and 0.7% in medium-tech segments, indicating significant untapped potential. High-potential product opportunities identified- The study highlights 11 Product Champions ($1.4 billion India exports vs. $45 billion global market) where India has export competitiveness and exhibits strong global demand and 68 Underachievers ($3.7 billion vs. $576 billion globally), indicating substantial scope to expand exports in high-demand segments. Strategic roadmap aligned with National Medical Policy 2023- In line with the National Medical Devices Policy 2023 target of achieving a 10–12% global market share by 2047, the study outlines measures to build a technology-driven, high-value manufacturing ecosystem. Key policy recommendations include strengthening domestic production of critical components; improving MSME access to finance; scaling public–private R&D partnerships; upgrading testing and certification infrastructure; developing specialized medical devices clusters and med-tech parks; deepening industry–academia collaboration. Market expansion opportunities exist in high-growth markets such as Mexico, Brazil, Canada, Russia, Vietnam, Hong Kong, Saudi Arabia, and Singapore,  leveraging recently signed FTAs with Australia, UK, EU, EFTA, New Zealand, UAE, Oman among others, alongside digital and AI-driven innovation in product and services. ]]> https://biospectrumindia.com/news/93/28078/garware-fulflex-completes-acquisition-of-medical-products-manufacturing-facility-in-us.html https://biospectrumindia.com/news/93/28078/garware-fulflex-completes-acquisition-of-medical-products-manufacturing-facility-in-us.html Mon, 06 Jul 2026 19:16:01 +0530 Pune-based Garware Fulflex has announced the successful completion of its acquisition of a 300,000-square-foot, fully automated medical products manufacturing facility in Jacksonville, Texas, marking a major milestone in the company’s global healthcare growth strategy and significantly expanding its manufacturing footprint in North America.   Situated on a 30-acre campus, the Jacksonville facility employs more than 250 people and manufactures a broad range of critical medical products used by healthcare providers and patients across North America and around the world.   The highly automated facility features advanced injection molding, blow molding, thermoforming, extrusion, assembly, and quality systems, further strengthening Garware Fulflex’s ability to serve leading global healthcare companies with world-class manufacturing capabilities.   The acquisition significantly enhances the company’s manufacturing presence in the United States and reinforces its long-term strategy of building a leading global healthcare manufacturing platform. ]]> https://biospectrumindia.com/news/93/28079/iit-d-launches-national-translational-platform-for-advancing-medical-device-and-diagnostics-innovation.html https://biospectrumindia.com/news/93/28079/iit-d-launches-national-translational-platform-for-advancing-medical-device-and-diagnostics-innovation.html Mon, 06 Jul 2026 19:20:20 +0530 The Indian Institute of Technology (IIT) Delhi has announced the inauguration of a state-of-the-art CNC and Sterilisation & Packaging lab at mPragati, IIT Delhi, a national translational platform dedicated to advancing medical device and diagnostics innovation. Dr Rajiv Bahl, Secretary to Government of India, Department of Health Research and Director General, Indian Council of Medical Research, inaugurated the facilities. The CNC facility provides state-of-the-art precision machining for medical implants, surgical instruments, dental devices, and diagnostic components — enabling indigenous manufacturing with certified biocompatible materials. With advanced multi-axis machining, Swiss-type turning, and high-speed milling, the CNC facility supports both patient-specific and standardised components. It bridges a critical gap in India’s MedTech value chain by reducing reliance on imports and accelerating translation of prototypes into clinically deployable products. The Sterilization & Packaging Facility provides an end-to-end infrastructure for the development, validation, sterilisation, and packaging of medical devices, diagnostics, and biomedical products. The facility is equipped with advanced sterilisation systems, including Ethylene Oxide (EtO) and steam autoclaves, precision device assembly workstations, automated reagent dispensing systems, stability chambers for reagent and product shelf-life validation, a high-precision laser welding system, laser marking, and secure vacuum packaging integrated with batch coding and product traceability. Complementing these capabilities is a comprehensive biological and molecular testing infrastructure comprising thermal cyclers, real-time PCR systems, Trans-Blot systems, gel electrophoresis and gel documentation systems, high-speed ultracentrifuges, HPLC, CO₂ incubators, fluorescence microscopy, biosafety cabinets for mammalian cell culture, and ultra-low temperature storage. ]]> https://biospectrumindia.com/news/93/28038/government-proposes-amendment-to-medical-devices-rules-2017.html https://biospectrumindia.com/news/93/28038/government-proposes-amendment-to-medical-devices-rules-2017.html Mon, 29 Jun 2026 15:36:54 +0530 The Ministry of Health and Family Welfare, Government of India, has published a draft gazette notification proposing amendments to the Medical Devices Rules, 2017. It aims to simplify and expedite the licensing process of medical devices while ensuring full compliance with the prescribed standards related to quality, safety and performance. The proposed amendments are aimed at rationalising the timelines for licensing of medical devices of various risk categories. The objective of this initiative is to promote ease of doing business, improve regulatory efficiency and ensure timely availability of high-quality medical devices in the country. Under the Medical Devices Rules, 2017, medical devices have been classified into four categories — Class A, Class B, Class C and Class D — based on risk. These include the highest-risk medical devices in Class D. These rules prescribe statutory timelines for disposal of applications received for grant of licenses of each category of medical devices. The proposed amendments seek to reduce these timelines so that regulatory approvals can be granted more expeditiously without compromising on the established standards of quality, safety and performance. The time limit for licensing of Class B medical devices, including low to medium risk devices such as blood pressure monitors, hypodermic needles and pulse oximeters, has been proposed to be reduced from 140 days to 115 days. Similarly, the time limit for licensing of Class C and Class D medical devices, including high-risk devices such as heart stents, hip and knee implants and implants related to other orthopaedic diseases, is proposed to be reduced from 105 days to 90 days. The amendments to the proposed draft also prescribe clear timelines for each stage of the licensing process. This includes scrutiny of applications, audit by notified bodies, verification of compliance and process for issuance of licenses. This is expected to bring in greater transparency, predictability and efficiency in the regulatory regime. This will benefit the medical devices industry as well as the patients as they will have faster access to quality medical devices. The draft notification has been placed in the public domain inviting suggestions and comments from all stakeholders. ]]> https://biospectrumindia.com/news/93/28013/fortis-institute-of-robotic-surgery-opens-in-faridabad.html https://biospectrumindia.com/news/93/28013/fortis-institute-of-robotic-surgery-opens-in-faridabad.html Wed, 24 Jun 2026 22:27:44 +0530 Committed to advancing surgical excellence through world-class clinical infrastructure, advanced technology, and patient-centric care, Fortis Escorts Hospital, Faridabad has launched the Fortis Institute of Robotic Surgery - a dedicated Centre of Excellence under its ‘Future of Surgery’ initiative. The Institute represents a significant investment in next-generation surgical infrastructure, integrating advanced robotic platforms, specialised operating environments, and multidisciplinary clinical expertise to deliver highly precise, minimally invasive interventions across multiple specialties. The Institute brings together highly experienced surgeons across Oncology, General & Gastrointestinal surgery, Urology, Orthopaedics, CTVS, ENT and Gynaecology under a unified, multidisciplinary platform supported by advanced imaging technologies, sophisticated diagnostics, and comprehensive peri-operative care. A First-of-its-Kind Integrated robotic surgery Programme in the Faridabad Region, the Institute is committed to elevating advanced tertiary care standards for patients across Faridabad and beyond. Its scope extends well beyond clinical delivery. It is designed to serve as a hub for innovation, surgical skill development, and the adoption of emerging technologies, reinforcing Fortis Healthcare's broader vision of advancing the future of surgery through excellence, research, and patient-focused care.   ]]> https://biospectrumindia.com/news/93/28002/mick-digital-enters-medical-devices-distribution-through-amtz-partnership.html https://biospectrumindia.com/news/93/28002/mick-digital-enters-medical-devices-distribution-through-amtz-partnership.html Mon, 22 Jun 2026 16:21:03 +0530 MICK Digital India, a wholly-owned subsidiary of Hyderabad-based MIC Electronics, has been empanelled as an authorised Channel Partner of Andhra Pradesh MedTech Zone (AMTZ), strengthening its healthcare technology portfolio and expanding access to indigenously manufactured medical devices across India. The empanelment authorises MICK Digital to market, distribute, and support AMTZ-manufactured medical devices and healthcare equipment across hospitals, healthcare institutions, and government healthcare programmes nationwide. As an authorised channel partner, the company will also be eligible to participate in government procurement opportunities through platforms and initiatives such as GeM, National Health Mission (NHM), and various State Health Missions. Through this partnership, MICK Digital will distribute a broad portfolio of healthcare technologies, including critical care equipment such as ventilators, patient monitors, and ICU systems; dialysis and renal care equipment; surgical and operation theatre solutions; diagnostic imaging and laboratory equipment; hospital infrastructure products; and medical consumables. The partnership marks a significant step in MICK Digital's expansion into India's fast-growing healthcare technology sector and aligns with the Government of India's vision of strengthening domestic medical device manufacturing under the Make in India and Atmanirbhar Bharat initiatives. Incorporated in 2024, MICK Digital was established as the Group's dedicated commercial and solutions subsidiary, operating across Indian Railways, Electronics Manufacturing Services (EMS/SMT), Medical Electronics Distribution, and LED Lighting Solutions. By extending the reach of indigenous medical technologies into Tier 2 and Tier 3 markets and supporting the adoption of Make-in-India medical devices, the partnership is expected to contribute to improved healthcare accessibility, stronger domestic supply chains, and reduced dependence on imported medical equipment. ]]> https://biospectrumindia.com/news/93/27992/lubrizol-and-polyhose-inaugurate-advanced-medical-tubing-facility-in-chennai.html https://biospectrumindia.com/news/93/27992/lubrizol-and-polyhose-inaugurate-advanced-medical-tubing-facility-in-chennai.html Fri, 19 Jun 2026 19:44:52 +0530 Lubrizol, a global specialty chemicals leader, and Polyhose, a leading manufacturer in fluid conveyance systems, have inaugurated a new medical manufacturing site in Chennai, Tamil Nadu. The facility will manufacture precision extruded medical tubing for minimally invasive devices, supporting India’s rapidly growing medical technology and healthcare sectors. Designed as a world-class operation, the ISO13485 facility provides customers with a reliable source of high-quality medical tubing, backed by dedicated quality control and the same rigorous standards applied across Lubrizol’s global manufacturing network. This investment strengthens Lubrizol’s ability to serve customers in India and across global markets. Operations focus on delivering precision extruded tubing from a wide range of high-performance materials, including polyamides, nylon, Pebax®, polypropylene, polyethylene, and Lubrizol’s medical grade thermoplastic polyurethane (TPU). Abhishek Shrivastava, Managing Director, Lubrizol IMEA said, "India is a strategic growth market for Lubrizol and a key hub for our investments in manufacturing, R&D and technical services. This medical manufacturing site in Chennai is another step in building a stronger local ecosystem for high-value, technology-driven products. By working closely with Polyhose and regional stakeholders, we aim to support innovation, create high-skilled jobs and enable India to become a more significant contributor to the global medical device supply chain." The new site is set to expand India’s capacity for precision extruded medical tubing, contributing to the country’s focus on building domestic medical device manufacturing capabilities, reducing reliance on imports, and enhancing patient access to high-quality, safe product. ]]> https://biospectrumindia.com/views/93/27973/injectable-aesthetics-and-regulatory-certainty-what-cdscos-clarification-means-for-medtech.html https://biospectrumindia.com/views/93/27973/injectable-aesthetics-and-regulatory-certainty-what-cdscos-clarification-means-for-medtech.html Mon, 15 Jun 2026 22:32:13 +0530 India's aesthetics market has expanded in a regulatory grey zone for years. Injectable products that altered physiological functions often occupied an uncertain position between cosmetics and drugs. This allowed businesses to leverage differing regulatory pathways depending on how products were positioned in the market. The ambiguity is beginning to disappear with the Central Drugs Standard Control Organisation  (CDSCO) clarifying that injectable cosmetic products fall within the drug regulatory framework. While much of the discussion has focused on consumer safety, the development carries broader implications for India's MedTech and healthcare innovation ecosystem. The clarification is less about restricting market growth and more about establishing regulatory certainty in a segment where product classification has remained inconsistent. Classification is one of the most important foundations of any regulatory system. It determines evidence requirements, approval pathways, manufacturing standards, post-market obligations and ultimately the level of accountability attached to a product. When products with drug-like mechanisms and physiological effects are regulated under cosmetic frameworks, the resulting mismatch creates uncertainty for regulators, manufacturers and investors alike. Injectable aesthetic products differ fundamentally from traditional cosmetics. Cosmetics are intended for external application and are generally designed to cleanse, beautify or alter appearance without affecting the body's structure or functions. Injectable products, by contrast, interact directly with biological systems. Whether influencing muscle activity, stimulating collagen production, or modifying tissue structure, their effects extend beyond the scope traditionally associated with cosmetic products. Globally, regulators have largely addressed this distinction. In the United States, botulinum toxin products are regulated as prescription drugs, while European regulations limit cosmetic products to external applications. India's clarification signals greater alignment with these international principles and reflects a broader trend toward risk-based regulation. The immediate impact will be felt through increased compliance expectations for manufacturers. Product development strategies, clinical evidence generation, manufacturing controls, import approvals, quality systems, pharmacovigilance mechanisms and post-market surveillance frameworks will require greater attention. Companies that have historically operated within drug-regulated environments are likely to adapt relatively smoothly. However, businesses that entered the market through cosmetic pathways may face significant adjustments in both timelines and compliance costs. The clarification also highlights the growing importance of regulatory preparedness. As healthcare technologies become increasingly sophisticated, the line between consumer wellness products and regulated medical interventions continues to blur. Companies that integrate regulatory strategy into product development are likely to be better positioned than those that treat compliance as a downstream activity. The move may ultimately improve market confidence for innovators and investors. Regulatory uncertainty often discourages long-term investment because future compliance obligations remain unclear. A more predictable classification framework creates clearer expectations regarding evidence generation, commercialisation pathways and market access requirements. The broader lesson extends beyond injectable aesthetics. Emerging healthcare technologies, digital therapeutics, AI-enabled diagnostics, combination products and advanced wellness interventions are creating new classification challenges across the healthcare ecosystem. Regulators globally are increasingly focusing on intended use and risk profile rather than marketing labels alone. The CDSCO clarification therefore represents more than a sector-specific intervention. It signals a regulatory philosophy that prioritises product function over product positioning. For the MedTech industry, this serves as a reminder that regulatory classification is a strategic consideration that influences innovation and long-term market success. As India's healthcare innovation ecosystem matures, regulatory certainty will become as important as technological advancement. The aesthetics market may be the immediate focus but the implications extend much further into the future of healthcare innovation and regulation.   Rishi Agrawal, CEO, TeamLease RegTech ]]> https://biospectrumindia.com/news/93/27923/biorad-medisys-unveils-quantino-20w-laser-system-for-kidney-stones-management.html https://biospectrumindia.com/news/93/27923/biorad-medisys-unveils-quantino-20w-laser-system-for-kidney-stones-management.html Tue, 09 Jun 2026 10:58:06 +0530 Pune-based medtech firm Biorad Medisys announced the launch of Quantino 20W Thulium Fiber Laser for kidney stone management at UROLITHOCON 2026, the annual conference of the Urolithiasis Section of the Urological Society of India (USI), recently held in Bengaluru. The launch comes at a time when kidney stone disease is emerging as a growing health concern across India. Studies suggest that nearly 12% of the Indian population is likely to develop kidney stones during their lifetime. The Quantino 20W Thulium Fiber Laser has been developed to support these evolving clinical needs. The compact system is designed for stone fragmentation procedures and expands Biorad Medisys' existing Quantino portfolio, which includes 40W and 75W platforms. Integrated with the company's Smart OR (Operation Room) ecosystem, the solution combines laser technology with visualisation, irrigation, suction and workflow management capabilities, helping clinicians perform stone procedures more efficiently while optimising operating room resources. Its compact footprint and lower power requirements make it particularly relevant for hospitals and urology centres looking to strengthen their stone management capabilities without significant infrastructure additions. ]]> https://biospectrumindia.com/news/93/27968/ss-innovations-announces-worlds-longest-robot-assisted-cardiac-telesurgery-.html https://biospectrumindia.com/news/93/27968/ss-innovations-announces-worlds-longest-robot-assisted-cardiac-telesurgery-.html Mon, 15 Jun 2026 17:05:56 +0530 In a landmark achievement that could redefine the future of surgery worldwide, a world record in medical history was established with the successful completion of a robot-assisted cardiac procedure across nearly 20,000 kilometres of fibre network distance between Guyana and India, making it the world's longest-distance robotic cardiac telesurgery ever conducted. Prior to this historic event, the longest robotic cardiac telesurgery done was from Strasbourg, France to Indore, India with a communication distance of 10,000 kilometers utilising the Made in India SSI Mantra Surgical Robotic System.  To date, 22 cardiac telesurgeries have been successfully performed using the SSI Mantra system, the only robotic surgery system globally that has been used for cardiac telesurgery. The historic procedure connected Georgetown Public Hospital Corporation (GPHC), Guyana with IRCAD India, Indore, where renowned robotic cardiac surgeon Dr Sudhir Srivastava, Founder, SS Innovations International, Inc., remotely performed a Left Internal Mammary Artery (LIMA) takedown using the India-developed SSI Mantra Surgical Robotic System.     As part of the launch of Guyana’s National Robotic Surgery Programme, three robotic procedures were successfully performed on the inaugural day. The achievement also coincided with Guyana’s Diamond Jubilee celebrations commemorating the country’s 60th Independence anniversary, adding symbolic significance to what healthcare experts are calling the beginning of a new era in borderless surgical care. The SSI Mantra’s tele-surgical architecture has been specifically designed to maintain procedural precision across high-latency, long-haul network environments. To date, more than 173 telesurgeries have been successfully performed globally using the SSI Mantra surgical robotic platform. Additionally, the SSI Mantra system is the only system globally that has been used for robotic cardiac telesurgery.  The company recently received regulatory approval for the SSI Mantra Surgical Robotic System from Guyana’s Government Analyst-Food and Drug Department (GA-FDD) in May 2026. ]]> https://biospectrumindia.com/news/93/27903/johnson-johnson-introduces-pulsed-field-ablation-technology-in-india.html https://biospectrumindia.com/news/93/27903/johnson-johnson-introduces-pulsed-field-ablation-technology-in-india.html Wed, 03 Jun 2026 15:14:06 +0530 Johnson & Johnson has announced the approval of the VARIPULSE™ Platform, India’s first Pulsed Field Ablation (PFA) technology that has been used to perform catheter ablation procedures for atrial fibrillation (AFib) in more than 80,000 procedures globally.  AFib is an irregular and often rapid heartbeat caused by extra, uncoordinated electrical signals in the atria and is associated with structural changes in the heart due to underlying conditions and lifestyle factors. It significantly increases the risk of stroke, heart failure, and mortality. Atrial Fibrillation affects 50 million people worldwide, representing a burden comparable to heart failure, which impacts over 64 million people globally.  In India, AFib prevalence is estimated at 0.1% to 1.6% of the population, with approximately 5 million people currently living with the condition. Indian patients develop AFib nearly a decade earlier than those in Western populations, at an average age of around 55 years, extending the long-term disease burden. Underlying AFib in India is detected at the time of stroke in 20–45% of cases. As a progressive condition, early intervention in AFib is critical to reducing stroke risk, particularly given that India accounted for 773,000 stroke deaths in 2021, or 10% of global stroke deaths. Catheter ablation is a minimally invasive procedure used to restore normal heart rhythm by treating areas responsible for abnormal electrical signals. PFA is a catheter ablation technique that uses short, high-voltage electrical pulses to target cardiac cells by creating pores in cell membranes, leading to cell death. It has the potential to offer safe, consistent, and efficient therapy for AFib treatment. The VARIPULSE™ Platform is the first PFA technology designed to streamline ablation and mapping through a single integrated workflow with the CARTO™ 3 System. This 3D electroanatomical cardiac mapping technology enables real-time visualization and supports precision, efficiency, reproducibility, and procedural accuracy for physicians treating patients with atrial fibrillation (AFib). It enables safe and efficient, patient-centric therapy with minimal to no fluoroscopy exposure and is compatible with deep and/or conscious sedation. ]]> https://biospectrumindia.com/news/93/27854/tata-elxsi-launches-material-intelligence-solution-vitel-for-medical-device-manufacturers.html https://biospectrumindia.com/news/93/27854/tata-elxsi-launches-material-intelligence-solution-vitel-for-medical-device-manufacturers.html Tue, 26 May 2026 16:45:39 +0530 Bengaluru-based Tata Elxsi, a global leader in design and technology services, has announced the launch of ViTel™, a Material Intelligence solution for Medical Device manufacturers, co-developed with Viridium AI, a material intelligence platform company. ViTel™ is being formally introduced at DeviceTalks Boston 2026 (on May 27 & 28), where Tata Elxsi is presenting its latest advances in AI-powered MedTech engineering and compliance. Medical device manufacturers are facing a new operating reality. Material decisions now affect margin, resilience, product velocity, and market access, yet critical product knowledge remains buried across BOMs, supplier documents, ERP and PLM systems, and expert teams. This makes every new regulation or customer requirement a costly manual exercise. ViTel™ addresses this by creating a reusable Material Intelligence layer across the enterprise, helping teams identify material and supplier dependencies, assess country-of-origin and sourcing exposure, evaluate alternatives, and understand where product or material risks affect cost, continuity, or market access. Powered by Viridium AI's Knowledge Cloud, Chemical Digital Twin, and science-constrained AI models, ViTel™ transforms scattered enterprise data into a living product-material knowledge graph connecting products, parts, materials, chemicals, suppliers, regulations, and evidence. ViTel™ draws on Tata Elxsi's three decades of Med-Tech engineering and regulatory expertise, knowledge that has been embedded into how the solution reasons about material risk, compliance, and sourcing decisions, not just how it is deployed. Tata Elxsi brings design-led and AI-first engineering, deep domain expertise, and access to global healthcare and medtech enterprises; Viridium AI brings platform and technology innovation. ViTel™ is co-developed through STEP UP, Tata Elxsi's co-innovation programme for high-potential deep-tech companies. ]]> https://biospectrumindia.com/news/93/27835/hcg-unveils-cancer-hospital-in-north-bengaluru-introducing-karnatakas-first-mr-linac.html https://biospectrumindia.com/news/93/27835/hcg-unveils-cancer-hospital-in-north-bengaluru-introducing-karnatakas-first-mr-linac.html Mon, 25 May 2026 18:54:10 +0530 HealthCare Global Enterprises Limited (HCG), India’s largest dedicated cancer hospital network, has announced the launch of its new comprehensive cancer hospital in Byatarayanapura (Hebbal), strengthening access to advanced oncology care in North Bengaluru. The new facility marks a major advancement in the region’s oncology landscape, bringing together clinical excellence, compassionate care and advanced technology to make world-class cancer treatment more accessible to people across Karnataka. Marking a significant milestone in precision oncology, the 110-bed facility introduces Karnataka’s first Elekta Unity MR-Linac, one of the world’s most advanced precision radiation therapy platforms. The technology combines high-quality MRI imaging with a linear accelerator to enable highly precise, adaptive cancer treatment. Designed as a full-spectrum oncology centre, the hospital brings together diagnosis, treatment, recovery support, and patient-centric care under one roof, making world-class cancer care more accessible to patients across North Bengaluru. Speaking on the launch, Dr B. S. Ajaikumar, Founder & Chairman of HealthCare Global Enterprises Limited (HCG), said: “Cancer care today has become increasingly data-driven, technology-oriented and focused on improving long-term outcomes. Our goal is not only to prevent recurrences, but also to make even advanced and metastatic cancers manageable through personalised, multidisciplinary care." The hospital is equipped with Accuray TomoTherapy with Radixact, further strengthening its radiation oncology capabilities, along with an 80-slice Digital PET-CT scanner for precise, high-resolution diagnostic imaging. In addition to advanced imaging and radiation therapy, HCG Hebbal features five robotic-assisted modular operation theatres, 19 chemotherapy daycare beds, 14 premium treatment bays, and a 15-bed ICU and HDU. The facility is also supported by a comprehensive range of diagnostic and clinical services, including endoscopy, bronchoscopy, ultrasound, X-ray, mammography, advanced laboratories, histopathology, frozen section services and blood storage. ]]> https://biospectrumindia.com/news/93/27825/indias-medtech-sector-to-move-from-import-dependence-to-4144-b-opportunity-by-2030-report.html https://biospectrumindia.com/news/93/27825/indias-medtech-sector-to-move-from-import-dependence-to-4144-b-opportunity-by-2030-report.html Fri, 15 May 2026 20:42:48 +0530 India’s medical technology (MedTech) sector is entering a more strategic phase, moving beyond a market-size narrative toward a competitiveness narrative built on capability, quality, and global readiness. This is the key headline from Poised for Takeoff: MedTech in India, a joint report by Boston Consulting Group (BCG), the Association of Indian Medical Device Industry (AiMeD), and the Kalam Institute of Health Technology (KIHT). According to the report, India’s MedTech market has reached approximately $16 billion and is growing at 13–15% annually, a pace that could scale the sector to $41–44 billion by 2030 and $ 83–89 billion by 2035. Domestic manufacturing’s share of local consumption has more than doubled from about 20% in 2022 to about 45% in 2025, growing at ~43% CAGR. Exports stand at approximately $4 billion today and could scale to $16–18 billion by 2035 as Indian-origin brands build credible quality systems and access regulated markets. Alongside ‘Make in India’, the report flags ‘Innovate in India’ as a powerful but currently underinvested second engine. India holds only ~3% of global MedTech patents, and Indian firms account for less than 1% of US FDA approvals between 2010 and 2025. Indian MedTech firms invest 2 - 4% of revenue on R&D, compared with 10–15% in the US and 15–20% in China. However, green shoots are visible: private equity and venture capital investment in Indian MedTech has scaled more than six-fold from $180 million in 2019 to $1.25 billion in 2025, and Indian challengers are emerging in high import-dependent segments such as helium-free MRI and soft-tissue surgical robotics. The report notes that the shift is being supported by a broader policy and capital environment, including the National Medical Devices Policy, a Rs 3,420 crore Production-Linked Incentive (PLI) scheme that has commissioned 24 projects across 57 products, four MedTech parks anchored by the Andhra Pradesh MedTech Zone (AMTZ), the launch of India’s first dedicated MedTech fund (MedArtha) by AMTZ in March 2026, and 100% FDI under the automatic route. Capital flows have also accelerated, with approximately Rs 10,940 crore deployed across 230+ private equity, venture capital, and corporate transactions in 2025. At the same time, the report cautions that India cannot scale on final assembly alone. A globally competitive MedTech ecosystem requires depth in components, medical-grade raw materials, testing, validation, sterilisation, clinical evidence, regulatory readiness, and post-market quality. Around 70–80% of high-value inputs, detectors, sensors, motors, printed circuit boards, specialty materials, and reagents, remain import-dependent, while inverted duty structures on critical inputs continue to undermine the viability of local manufacturing. MSMEs and growth-stage companies also face constraints around sequential approvals, certification costs, and access to scale capital.   This report was launched at the GMAAF MedTech Policy Mahotsav 2026 in Delhi, on 15 May, a forum that brought together industry leaders, policymakers, and experts to shape the future of MedTech. ]]> https://biospectrumindia.com/news/93/27815/even-hospital-partners-with-canara-surgicals-to-improve-minimally-invasive-surgeries-outcomes.html https://biospectrumindia.com/news/93/27815/even-hospital-partners-with-canara-surgicals-to-improve-minimally-invasive-surgeries-outcomes.html Thu, 14 May 2026 12:16:57 +0530 Even Hospital, a Bengaluru-based multi-speciality hospital, has collaborated with surgical-tech firm Canara Surgicals to introduce the latter’s laser technology-based medical devices facilitating minimally invasive surgeries. As a part of this long-term collaboration toward surgical equipment supply and deployment, Mumbai-based startup Canara Surgicals has deployed its medical-grade Angelas diode laser, calibrated at 1470 nm wavelength, at Even Hospital’s state-of-the-art facility located on Race Course Road, Bengaluru. The cutting-edge laser-tech device – which shall be used across multiple specialties/departments of Even Hospital, including vascular, interventional radiology, proctology, ENT, cosmetic, and gynaecology – enables a range of procedures such as endovenous ablation of varicose veins, haemorrhoidectomy (for treating piles), percutaneous laser disc decompression (PLDD) for spinal conditions, among other microsurgeries. Unlike traditional surgical methods that involved large incisions and longer recovery periods, modern procedures powered by laser technology and fibre-optics allow today’s surgeons to operate with greater precision and minimal tissue disruption. Laser-tech based minimally invasive surgeries are proven to not only reduce bleeding and post-operative pain, but also to minimise chances of recurrence. Canara Surgicals – which has obtained approval from the Central Drugs Standard Control Organization (CDSCO) for supplying its medical equipment across India – has been working closely with several reputed hospital chains of the country.  ]]> https://biospectrumindia.com/news/93/27813/wfns-partners-with-time-medical-ventures-to-drive-innovation-in-neurosurgery.html https://biospectrumindia.com/news/93/27813/wfns-partners-with-time-medical-ventures-to-drive-innovation-in-neurosurgery.html Wed, 13 May 2026 22:56:51 +0530 For the first time in its history, the World Federation of Neurosurgical Societies (WFNS) Innovation & Technology Committee has formally welcomed an industry partner into its innovation ecosystem, reflecting the growing importance of collaboration between neurosurgical leadership and advanced medical technology providers. The partnership aims to accelerate the development and dissemination of cutting-edge neurosurgical technologies, support global training and capacity-building initiatives, and facilitate meaningful collaboration between clinicians and industry innovators to improve patient outcomes worldwide. Chennai-based startup Time Medical International Ventures has been recognised for its contributions in advanced medical imaging and neurosurgical technologies, including single-room intraoperative MRI operation suites, Exoscope and visualisation technologies, and specialised MRI solutions for brain aneurysm and ICAD screening. The association is expected to create a strong platform for innovation-driven advancements in neurosurgery and neuroimaging. Commenting on the partnership, Prof. Dr Iype Cherian, Chairperson of the WFNS Innovation & Technology Committee, said, “This collaboration will help champion the development and global dissemination of cutting-edge neurosurgical solutions, facilitate knowledge exchange between leading neurosurgeons and industry experts, and support training and technology transfer initiatives in emerging markets. We believe this partnership will set a new benchmark for industry collaboration within global neurosurgical governance.”  Speaking on the association, Svetlana Rao, Director of Time Medical International Ventures said,“As a wholly owned subsidiary of Fischer Medical Ventures Limited, we remain committed to supporting transformative healthcare solutions that improve accessibility, precision, and patient outcomes across diverse healthcare systems.”   ]]> https://biospectrumindia.com/news/93/27792/american-medtech-firm-zimmer-biomet-opens-gcc-in-bengaluru.html https://biospectrumindia.com/news/93/27792/american-medtech-firm-zimmer-biomet-opens-gcc-in-bengaluru.html Mon, 11 May 2026 16:20:58 +0530 US-based Zimmer Biomet has opened its Global Capability Centre (GCC) in Bengaluru. This GCC will serve as a high-velocity hub for digital transformation, integrating the company’s nearly century-long heritage in musculoskeletal health with India’s digital engineering ecosystem.  By embedding its digital future within India’s premier talent ecosystem, the company is future-proofing its operations, ensuring it possesses the agility and technological prowess required to lead the next era of personalised, robotic-assisted healthcare. The GCC will focus on developing the next generation of patient-monitoring software; streamlining procurement and supply chain for the APAC market; and accelerating the development of AI-driven surgical platforms. The firm is aggressively pushing the boundaries of AI and robotics, highlighted by the regulatory clearance of ROSA® Knee with OptimiZe™, the most advanced upgrade to its flagship robotic system, and its comprehensive digital care platform, ZBEdge.   ]]> https://biospectrumindia.com/news/93/27793/icmr-transfers-three-indigenous-medical-technologies-to-industry.html https://biospectrumindia.com/news/93/27793/icmr-transfers-three-indigenous-medical-technologies-to-industry.html Mon, 11 May 2026 22:15:39 +0530 Indian Council of Medical Research (ICMR) participated in a special programme on the occasion of National Technology Day 2026, organised by BRIC- National Institute of Immunology (NII), New Delhi. The event was graced by the presence of Minister of State (Independent Charge) for Science and Technology, Dr Jitendra Singh; Prof. Ajay Kumar Sood, Office of the Principal Scientific Adviser (PSA); Dr Rajiv Bahl, Secretary, Ministry of Health and Family Welfare and Director General, ICMR, and other dignitaries. As part of its demonstration programme, ICMR showcased six high-impact indigenous technologies spanning the bio-pharma, health and bio-industrial and green chemical sectors. These included Covaxin, COVID Kavach ELISA kit, CRISPR-Cas based TB detection system, Nipah point-of-care assay, a diagnostic ELISA kit for dengue detection and a biolarvicide for mosquito control . In addition, an official compilation was released during the event that contains 25 new products developed by various ICMR institutes. A major attraction of the event was the transfer of three innovative technologies developed by ICMR, to industry partners. The first technique, titled 'Development of affordable PSP 94 ELISA for guiding biopsy decisions in patients with PSA less than 20 ng/ml', developed by National Institute for Research in Women's Health. The technology was licensed to KrishGen Labs. The second technology transfer included 'Factor VIII Inhibitors/ Coagulation Disorder Point-of-Care Diagnostic' developed by National Institute for Research on Blood and Immune Disorders (ICMR-NIRBID). The technology was licensed to Merrill Life Sciences. The third technique 'Single-tube multiplex real-time RT-PCR to detect dengue, chikungunya and Zika viruses', developed by National Institute of Virology, was licensed to Vanguard Life Sciences.   ]]> https://biospectrumindia.com/news/93/27769/government-institute-of-medical-sciences-launches-advanced-paediatric-orthopaedic-surgery-facilities-in-greater-noida.html https://biospectrumindia.com/news/93/27769/government-institute-of-medical-sciences-launches-advanced-paediatric-orthopaedic-surgery-facilities-in-greater-noida.html Thu, 07 May 2026 15:09:48 +0530 The Government Institute of Medical Sciences (GIMS), Greater Noida, with support from Healthium MedTech’s CSR initiative and implemented by Plan International India Chapter, is now fully equipped to undertake advanced paediatric orthopaedic surgeries. In a major boost to child healthcare, the institute can now treat conditions such as developmental dysplasia of the hip (DDH), clubfoot, limb deformities, fractures and complex bone disorders. With the installation of specialised equipment including the Midas Rex MR8 High Speed Electric Drill System, Paediatric Hip Plating Set, Paediatric and Small Bone Drill & Saw System, Paediatric Orthopaedic Instrument Set and a C-Arm Machine, GIMS is now ready to deliver precise, safe and age-appropriate surgical care for children. India faces a significant burden of paediatric orthopaedic conditions, with 1 to 2 percent of children born with disorders such as clubfoot, and many others developing deformities due to trauma, infections or untreated conditions. In states like Uttar Pradesh, limited access to specialised care often delays treatment, increasing the risk of complications, disability and higher costs. Addressing this gap, the strengthened infrastructure at GIMS is expected to benefit over 1,000 children annually, enabling timely interventions and reducing the need for referrals outside the region. Speaking at the launch, the Chief Guest, Dr G.N. Singh, Adviser to the Chief Minister, Uttar Pradesh said, “This initiative reflects our commitment to ensuring that every child, regardless of background, has access to quality and timely healthcare. Strengthening public health institutions through such partnerships is essential to building an inclusive and equitable healthcare system.” ]]> https://biospectrumindia.com/news/93/27770/germanys-ottobock-teams-up-with-celcius-logistics-to-build-prosthetics-warehouse-and-logistics-distribution-in-india.html https://biospectrumindia.com/news/93/27770/germanys-ottobock-teams-up-with-celcius-logistics-to-build-prosthetics-warehouse-and-logistics-distribution-in-india.html Thu, 07 May 2026 15:32:57 +0530 Celcius Logistics, a leading domestic 3PL logistics player providing end-to-end cold-chain solutions, has partnered with Ottobock India, the Indian arm of Germany’s Ottobock, to set up a dedicated prosthetics warehouse and logistics distribution hub in India. The company has also launched a tech enabled warehouse facility in Thane.  The facility will support the medical supply chain by reducing turnaround times and enabling nationwide access to prosthetic and assistive devices. Mumbai-based startup Celcius Logistics will leverage its network to manage the distribution of prosthetic limbs across India, enabling movement of products to clinics and partners in multiple regions. The 3,000 sq. ft. facility features ambient storage, 110 slotted angle racks with over 700 bin locations, and a 100 sq. ft. temperature-controlled area for sensitive medical materials. Designed to support efficient inventory management and faster order fulfilment, the facility operates through processes aligned with standard quality and handling protocols. The facility is equipped to manage over 2,000 SKUs and support seamless distribution across 24 clinics and more than 200 independent partners, including associations with the Government of India. Prosthetic manufacturing and distribution require controlled storage conditions to maintain product integrity, durability and performance. The inclusion of a dedicated temperature-controlled zone within the facility supports proper handling of sensitive components and ensures consistent quality, enabling reliable delivery of prosthetic solutions to patients. Celcius will manage end-to-end warehouse operations and transportation, leveraging its in-house WMS(warehouse management solutions) and TMS(Transport management solutions) for inbound, outbound, inventory management, and nationwide distribution. The facility is exclusively dedicated to Ottobock and is now operational, under a five-year contract. Looking ahead, the partners plan to expand the warehouse capacity by 25% within the next year, in line with growing demand and scale of operations. ]]> https://biospectrumindia.com/news/93/27754/digital-pet-ct-nuclear-medicine-department-opens-at-mahajan-imaging-labs-in-delhi.html https://biospectrumindia.com/news/93/27754/digital-pet-ct-nuclear-medicine-department-opens-at-mahajan-imaging-labs-in-delhi.html Mon, 04 May 2026 00:00:00 +0530 Former Indian cricket team captain Kapil Dev inaugurated the specialised Department of Digital PET-CT and Nuclear Medicine at Mahajan Imaging & Labs’ Pusa Road centre, marking an expansion of advanced diagnostic and therapy capabilities. With an increasing focus on early disease detection and precision diagnostics, the new department strengthens integrated diagnostics and advanced theranostics and treatment support across oncology, neurology, cardiology, and nephrology, among others.The department brings together advanced imaging and nuclear medicine technologies under one roof, including a digital PET-CT system and a gamma camera. It builds on the centre’s existing diagnostic capabilities at Pusa Road, which include high-end 3T MRI, 128-slice cardiac CT, along with ultrasound, mammography, X-ray, and CBCT services. With the addition of nuclear medicine and therapy support, the centre now offers a more comprehensive range of diagnostic and treatment-planning services within a single coordinated environment.The next-generation digital PET-CT system delivers high-resolution metabolic and anatomical imaging in a single scan, supporting the detection of small abnormalities with greater clarity. Its extended field of view enables complete organ coverage in a single pass, while the integrated CT component provides detailed anatomical context alongside metabolic insights. The system also reduces radiation exposure by up to 60 percent and enables faster scan times, improving both patient safety and efficiency.The high-end gamma camera further expands the centre’s capabilities in functional imaging and therapy support, allowing clinicians to assess organ function, evaluate cardiac activity, detect bone lesions, and support the management of conditions such as thyroid disorders and certain cancers through targeted radiation-based treatments.The development comes amid a growing need for early and accurate diagnosis of complex diseases, particularly cancer. In India, around 100 out of every 1 lakh people are diagnosed with cancer, and according to the Indian Council of Medical Research, more than 14 lakh new cases were estimated in 2023.PET-CT also plays a key role in radiation therapy planning by enabling accurate mapping of tumour volumes for precise targeting. It is used to monitor treatment effectiveness by distinguishing between active disease and post-treatment changes, allowing clinicians to adjust therapy as needed.  ]]> https://biospectrumindia.com/news/93/27734/essilor-stellest-becomes-the-only-us-fda-market-authorised-spectacle-lens-for-myopia-control-in-india.html https://biospectrumindia.com/news/93/27734/essilor-stellest-becomes-the-only-us-fda-market-authorised-spectacle-lens-for-myopia-control-in-india.html Mon, 27 Apr 2026 00:00:00 +0530 Late last year, EssilorLuxottica announced the US Food and Drug Administration (FDA) granted market authorisation for its Essilor® Stellest® lens using the De Novo pathway. This follows the product’s earlier recognition with the FDA granting designation as a Breakthrough Technology in 2021. The Essilor® Stellest® lens is the first and only US FDA market authorised spectacle lens to slow myopia progression in children. The effectiveness of the Essilor® Stellest® lens is evidenced by clinical data showing that the lens slowed down myopia progression by 71% on average over two years.  The sharp rise in myopia is a growing concern in India, with nearly 50% of urban children projected to be affected by 2050. With its legacy of clinical reliability, EssilorLuxottica aims to advance myopia care in India through FDA-approved innovations for slowing down of Myopia progression aligned with National Accreditation Board for Hospitals (NABH) & Healthcare Providers and global standards. By empowering doctors, parents, and institutions with internationally recognized, evidence-based myopia management, the goal is to transform the standard of care by making Essilor® Stellest® accessible to more children across India. As eye testing is not mandatory in India there are many children that go undetected or uncorrected and it’s important for parents to include eye testing as part of their routine back to school checks. EssilorLuxottica is prioritising regions with high myopia awareness and early adoption potential, including Metro cities and emerging hubs like Pune, Coimbatore, Ahmedabad, Kochi, and Chandigarh. The expansion will gradually extend to Tier-2 and Tier-3 cities through optical ophthalmologists, optometrists, and optical networks and professional education programmes.   ]]> https://biospectrumindia.com/news/93/27702/terumo-india-signs-mou-with-aig-hospitals-to-strengthen-interventional-radiology-training.html https://biospectrumindia.com/news/93/27702/terumo-india-signs-mou-with-aig-hospitals-to-strengthen-interventional-radiology-training.html Wed, 22 Apr 2026 00:00:00 +0530 In a significant step towards strengthening patient care in minimally invasive therapies, Terumo India, the Indian arm of global medical technology leader Terumo Corporation, has signed a Memorandum of Understanding (MoU) with Hyderabad-based AIG Hospitals to establish a Centre of Excellence for Interventional Radiology (IR) under its flagship ‘Elevate IR’ programme. This collaboration is designed with a clear patient-centric objective, i.e., to improve clinical outcomes, reduce procedural risks, and expand access to advanced, minimally invasive treatments for a wide range of conditions, from vascular diseases and cancers to life-threatening emergencies. As part of the initiative, AIG Hospitals will serve as the first training centre, offering a structured and immersive learning pathway for interventional radiologists. The programme integrates simulation-based training, expert-led sessions, and case-based discussions, supported by the Terumo India Skill Lab (TISL), an advanced training facility focused on enhancing real-world procedural skills. Speaking on the partnership, Shishir Agarwal, President and Managing Director, Terumo India, said, “Through this initiative, we aim to strengthen the Interventional Radiology ecosystem and enable young IRs to deliver better patient outcomes at scale.” Speaking on the occasion Dr. D Nageshwar Reddy, Chairman, AIG Hospitals said “India today stands at a critical intersection where the burden of chronic diseases is rising sharply, while the expectations from healthcare are shifting towards safer, faster, and more patient-friendly solutions. Interventional Radiology represents this shift, moving us away from invasive surgeries to precise, image-guided therapies that significantly improve recovery and quality of life." The programme leverages cutting-edge simulation tools, including liver flow models and Mentice Virtual Simulators, allowing practitioners to rehearse complex procedures in a risk-free environment before performing them on patients. Dedicated modules on vascular closure techniques further ensure safer post-procedural outcomes. Dr Jagadeesh R Singh, Director – Interventional Radiology, AIG Hospitals further added, “The Centre of Excellence aims to address this critical need by introducing a standardised training framework that bridges the gap between foundational knowledge and real-world clinical practice. Interventional Radiologists will gain proficiency in essential and advanced procedural areas such as vascular access, microcatheter navigation, and aorto-iliac interventions.” ]]> https://biospectrumindia.com/news/93/27699/cent-opens-clinical-prevention-centre-in-bengaluru-deepens-partnership-with-siemens-healthineers.html https://biospectrumindia.com/news/93/27699/cent-opens-clinical-prevention-centre-in-bengaluru-deepens-partnership-with-siemens-healthineers.html Tue, 21 Apr 2026 00:00:00 +0530 CENT, the early detection healthcare company founded by Shashank ND along with a team of clinical and operating leaders, has announced the opening of its first clinical prevention centre in Bengaluru.  Alongside the launch, the company announced a deepened strategic partnership with Siemens Healthineers to power the diagnostic and imaging infrastructure across its growing centre network. Spanning 7,000 square feet, the Bengaluru centre is India's most advanced clinical prevention facility, purpose-built from the ground up for a single objective: finding silent, life-threatening disease in people who feel healthy.  Unlike conventional diagnostic labs or hospital checkup wings that run dozens of unrelated tests on shared equipment, CENT's centre runs one standardised protocol, the CCNM Protocol (Cardiac, Cancer, Neurological, Metabolic), with the throughput, clinical rigour, and quality control of a single-purpose facility. The centre is also among the most advanced in India from an imaging standpoint. State-of-the-art Siemens Healthineers MRI, CT, and DEXA systems have been configured specifically for preventive use, with CENT and Siemens Healthineers jointly developing custom MRI protocols, deploying efficiency-enhancing software on Siemens Healthineers platforms, and pursuing joint research toward a new standard for preventive imaging.  The Bengaluru centre is the first physical node of a planned multi-city rollout, with Mumbai and Delhi-NCR to follow.      ]]> https://biospectrumindia.com/news/93/27670/global-surgical-institute-opens-in-bengaluru-to-support-evolving-surgical-education.html https://biospectrumindia.com/news/93/27670/global-surgical-institute-opens-in-bengaluru-to-support-evolving-surgical-education.html Wed, 15 Apr 2026 00:00:00 +0530 As healthcare systems worldwide continue to focus on improving patient safety, surgical precision and clinical outcomes there is a growing emphasis on strengthening how surgeons are trained. In this context, the launch of the Global Surgical Institute (GSI) in Bengaluru marks a significant step towards advancing surgical education through structured, simulation-led learning. India has long been recognized for its contribution to the global medical workforce with thousands of Indian trained doctors practicing internationally and the country continuing to be a preferred destination for medical value travel. Alongside this strong foundation there is an increasing opportunity to further enhance hands on surgical training in line with evolving global practices. Traditionally surgical education has followed an apprenticeship-based approach and often described as “see one, do one, teach one”. This model has played a vital role in developing generations of skilled surgeons. Today, simulation-based training is being increasingly integrated as a complementary method to further strengthen clinical preparedness in a safe and controlled environment. The Global Surgical Institute has been established as a multi-specialty training facility focused on skill development through simulation before real-world clinical exposure. The aim is to support surgeons in building both technical proficiency and confidence through a structured learning pathway. Commenting on the initiative Dr B S Ajaikumar, Chairman and CEO of Healthcare Global Enterprises “India has a strong legacy of medical excellence and as healthcare continues to evolve, so must our approach to training. Simulation-based learning offers an opportunity to enhance surgical preparedness by allowing clinicians to refine their skills in a structured environment. Initiatives like the Global Surgical Institute aim to complement existing training systems and contribute to improved patient care outcomes and training led by a distinguished faculty of highly accomplished surgeons." At the core of GSI’s approach is a progressive five-stage training pathway aligned with international practices:• Box trainers for foundational motor skills and hand-eye coordination• Virtual reality simulators to replicate complex surgical scenarios• Animal labs for tissue handling experience• Cadaver labs for anatomical realism• Supervised operating room exposure as the final stage This step-by-step progression is designed to support surgeons as they transition from simulated environments to clinical practice with greater confidence and competence. Globally there is a growing body of evidence supporting simulation-based training and indicating benefits such as improved efficiency, enhanced skill retention and reduced likelihood of intraoperative errors. As a result, many institutions are increasingly incorporating simulation into their teaching frameworks alongside traditional methods.   ]]> https://biospectrumindia.com/news/93/27649/success-for-medtech-startups-lies-at-the-intersection-of-innovation-regulation-market-strategy-and-human-behaviour-experts.html https://biospectrumindia.com/news/93/27649/success-for-medtech-startups-lies-at-the-intersection-of-innovation-regulation-market-strategy-and-human-behaviour-experts.html Mon, 13 Apr 2026 00:00:00 +0530 The panel discussion on “Capital, Regulatory & Go-To-Market,” held under the MedTech Scale-up Blueprint workshop by IKP Knowledge Park, evolved into a highly nuanced, ground-level conversation on what truly determines success or failure for MedTech startups. The session featured Naganand Doraswamy, Managing Director and Founder of Ideaspring Capital; Nidhi Mathur, Venture Partner at Axilor Ventures; Arjun Rao, General Partner at Speciale Invest; Karthik Venkataraman, regulatory and compliance expert formerly associated with TÜV SÜD and UL; Jai Ganesh, CEO of Dhariki Labs as panellists and Sridhar Ramanathan, Senior Vice President at IKP Knowledge Park and CEO of IKP EDEN as moderator. The session moved beyond theory into real-world execution challenges. A deeper layer of the discussion focused on how founders should think about “first traction.” While conventional wisdom often pushes startups toward securing early revenue, the panel clarified that in MedTech, not all traction is equal. Government partnerships, for instance, were reframed—not as immediate revenue drivers but as strategic enablers. They provide access to large patient pools, clinical environments, and real-world datasets. However, due to bureaucratic inertia and long sales cycles, relying on them for early cash flow can stall a startup’s momentum. Instead, founders were encouraged to adopt a dual-track strategy: use government or institutional collaborations for validation and credibility, while simultaneously building faster revenue pathways through private players. Another critical dimension explored was the paradox of large markets. As highlighted by Nidhi Mathur, markets like diabetes or cancer are attractive but brutally competitive. The panel stressed that entering such spaces requires more than incremental innovation—it demands clear technological defensibility. This includes strong patents, proprietary datasets, or unique delivery mechanisms. Without these, startups risk being overshadowed by global giants or fast followers. The conversation subtly underscored a key investor lens: “If this works, why won’t a large company replicate it tomorrow?” Founders must have a convincing answer. The panel also unpacked the India vs global market dilemma in greater depth. India was consistently described as a “living lab”—ideal for stress-testing products under diverse and cost-sensitive conditions. However, commercialization at scale often lies in international markets where pricing power, insurance systems, and healthcare spending are stronger. This creates an important strategic implication: startups must design not just for Indian constraints but for global regulatory pathways and customer expectations from day one. The ability to bridge this gap often determines whether a startup remains a niche player or evolves into a global company. On the regulatory front, Karthik Venkataraman provided a crucial mindset shift. Instead of viewing regulators as obstacles, founders should see them as partners in risk mitigation and patient safety. He emphasized the importance of defining a clear “intended use” early, as this becomes the foundation for regulatory classification, clinical validation, and market approval. A particularly important operational insight was the danger of “perfection paralysis”—where continuous feature additions delay product launch indefinitely. The recommendation was to launch with a well-defined baseline product and evolve through post-market iterations, balancing innovation with execution speed. From an investment perspective, Naganand Doreswamy offered a sharper lens on defensibility and founder mindset. He stressed that intellectual property is not just about filing patents but about ensuring that the core innovation cannot be easily bypassed. Equally important is the founder’s ability to remain adaptable. Startups operate in uncertain environments, and rigid adherence to initial assumptions can be detrimental. Investors, therefore, look for founders who combine conviction with flexibility—those who can pivot without losing sight of the core problem. Building on this, Arjun Rao highlighted a recurring gap among early-stage founders: lack of market intimacy. Many founders, especially from technical or academic backgrounds, focus heavily on the science while neglecting customer discovery. The panel emphasized that meaningful engagement with end-users—doctors, hospitals, patients—is non-negotiable. Insights from even a handful of real conversations can significantly refine product direction, pricing strategy, and go-to-market approach. Jai Ganesh reinforced the importance of problem clarity over solution rigidity. Investors are more willing to back founders who deeply understand the problem and are open to evolving their solution, rather than those fixated on a single approach. This ties into a broader theme of founder storytelling—the ability to clearly articulate why the problem matters, who it affects, and why the proposed approach is credible. Meanwhile, Sridhar Ramanathan brought in the uniquely Indian concept of “jugaad” (frugal innovation). He acknowledged its strength in enabling cost-effective solutions but cautioned against overextending it into areas where rigor is essential, such as regulatory compliance and clinical validation. The takeaway was that frugality should drive efficiency, not compromise quality. One of the most compelling insights from the discussion came through real anecdotes. A story shared about a founder who revisited investor feedback months later—with a refined approach and renewed clarity—highlighted the importance of resilience and iterative thinking. This demonstrated that what investors value is not just initial brilliance but the ability to learn, adapt, and persist. In conclusion, the panel painted a comprehensive picture of MedTech entrepreneurship as a multi-dimensional challenge—where success lies at the intersection of innovation, regulation, market strategy, and human behaviour. Founders must balance speed with compliance, ambition with realism, and conviction with adaptability. The final message resonated strongly: there is no single “correct” path, but those who remain flexible, deeply informed, and execution-focused are far more likely to navigate the complex journey from idea to impactful, scalable solution. ]]> https://biospectrumindia.com/news/93/27650/building-and-scaling-medtech-companies-requires-a-careful-balance-of-innovation-validation-and-execution-experts.html https://biospectrumindia.com/news/93/27650/building-and-scaling-medtech-companies-requires-a-careful-balance-of-innovation-validation-and-execution-experts.html Mon, 13 Apr 2026 00:00:00 +0530 The panel discussion on “Building & Scaling MedTech Companies”, held on April 1, 2026, in Bengaluru as part of the MedTech workshop titled “MedTech Scale-up Blueprint: A View from the Trenches” organised by IKP Knowledge Park, brought together a diverse group of founders and ecosystem leaders who shared nuanced, experience-driven insights into MedTech entrepreneurship, with a strong focus on founder journeys, go-to-market (GTM) strategies, and revenue generation. The session was moderated by Dr Priyankana Mukherjee, AVP & Head, BioNEST, IKP Knowledge Park, and featured an accomplished panel comprising Ravi Kiran Manapuram, Founder & Managing Director, MedevPlus; Chirag Shah, Co-Founder & CEO, Rymo; Varun AV, CTO & Co-Founder, Inito; Dr Shantanu Pathak, Founder, CareMother (Doto Health); and Dr Sanchita Chaudhary, Program Director – MedTech Acceleration, Blockchain for Impact (BFI). The discussion began with founders reflecting on their journeys, emphasising that impactful MedTech innovations are rooted in firsthand exposure to unmet clinical needs. Ravi Kiran Manapuram highlighted how his experience at Leica Microsystems revealed a gap in access to affordable ophthalmic technologies, inspiring him to build cost-effective solutions for wider adoption. Chirag Shah spoke about the limited accessibility of robotic rehabilitation systems, which led him to develop scalable physiotherapy technologies, while Varun AV shared how his stint at Siemens exposed the lack of decentralized diagnostics, leading to Inito’s home-based fertility monitoring platform. Dr. Shantanu Pathak brought in a public health perspective, focusing on maternal and neonatal care, where early monitoring can significantly improve outcomes. A major part of the discussion centred on GTM strategies and revenue generation, where the panellists candidly addressed the complexities of commercialising MedTech innovations. Chirag Shah emphasized that true market validation begins when customers are willing to pay, urging startups to prioritize early revenue even at the prototype stage. Varun AV elaborated on the limitations of traditional clinician-led distribution models, which are often slow and fragmented, and shared how Inito successfully pivoted to a direct-to-consumer approach using digital platforms, enabling faster adoption and continuous user feedback. He also cautioned against blindly replicating aggressive growth models like that of Flipkart, noting that such strategies require strong fundraising capabilities and must align with a startup’s inherent strengths. Dr Shantanu Pathak highlighted the importance of region-specific GTM strategies within India, pointing out that market dynamics differ significantly across geographies, and advised startups to begin with regions that offer quicker adoption before scaling further. From a revenue standpoint, the panel discussed hybrid models combining device sales with recurring income streams, institutional sales through hospitals and public health systems, and the growing relevance of D2C models in certain segments. They also acknowledged the critical role of grants and non-dilutive funding in sustaining MedTech startups through long development and regulatory cycles. Dr Sanchita Chaudhary provided a systemic perspective on common failure points, stressing that many startups begin with technology and attempt to retrofit it into healthcare settings, rather than starting with a clearly defined problem. She emphasised that clinical validation is essential for both adoption and revenue, as clinicians act as key gatekeepers, and highlighted the importance of designing solutions that integrate seamlessly into existing workflows without adding to the burden of healthcare providers. She also outlined the role of Blockchain for Impact as an ecosystem enabler, facilitating collaboration across stakeholders and supporting startups through structured programs such as NAMA, which provide funding, infrastructure, and regulatory guidance to de-risk innovation. The discussion also addressed operational realities such as supply chain dependencies on global components, regulatory complexities across markets, and the lingering impact of the COVID-19 pandemic, which, while disruptive, also accelerated innovation and adaptability. In conclusion, the panel underscored that building and scaling MedTech companies requires a careful balance of innovation, validation, and execution. Founders must ground their solutions in real clinical needs, adopt flexible and context-driven GTM strategies, and develop sustainable revenue models while navigating regulatory and operational challenges. The insights shared by the panellists collectively reinforced that success in MedTech is not defined by technology alone, but by the ability to align products with market realities, engage stakeholders effectively, and scale thoughtfully across diverse healthcare ecosystems. ]]> https://biospectrumindia.com/news/93/27647/smrsc-2026-announces-launch-of-breakthrough-defence-technology-ssi-vimana-and-project-operion.html https://biospectrumindia.com/news/93/27647/smrsc-2026-announces-launch-of-breakthrough-defence-technology-ssi-vimana-and-project-operion.html Sat, 11 Apr 2026 00:00:00 +0530 SS Innovations International, the maker of India’s first and only home-grown surgical robotic system, SSI Mantra, successfully hosted the Third Global SSI Multi-Specialty Robotic Surgery Conference (SMRSC) 2026 at Bharat Mandapam, Pragati Maidan, New Delhi, from 9th to 11th April. On the first day, the conference witnessed participation from over 1,500 doctors and 250+ leading experts from across the world, reinforcing its position as a premier platform for advancing robotic-assisted surgery and next-generation healthcare technologies. Building on the momentum of previous editions, SMRSC 2026 brought together global surgeons, healthcare leaders, researchers and innovators to explore the transformative potential of robotic surgery, artificial intelligence, telesurgery and mobile surgical platforms. The conference featured live telesurgeries, scientific sessions, immersive technology showcases and hands-on experiences, offering a comprehensive view of the rapidly evolving surgical landscape. Over the course of the three-day conference, a total of 15 live telesurgeries and 14 live surgeries will be performed using the Mantra-3 and MantrAsana systems, offering attendees a first-hand view of advanced robotic surgical capabilities in action. A defining highlight of SMRSC 2026 was the unveiling of two groundbreaking innovations that signal the next frontier in surgical mobility and accessibility. Taking centre stage, Project Vimana emerged as a game-changing advancement in battlefield and emergency medicine. Designed to deliver expert robotic surgical care directly to wounded soldiers in forward combat zones, the system is deployed via a heavy lift autonomous drone and lands near the casualty site. Equipped with dual 7-degree-of-freedom miniature robotic arms and advanced surgical instruments, Project Vimana enables trauma surgeons to perform life-saving procedures remotely through the SSI Mantra Surgeon Command Center. From haemorrhage control and chest decompression to shrapnel removal and wound repair, the system bridges the critical gap between injury and evacuation, bringing surgical precision to environments where immediate medical access is otherwise impossible. This innovation represents a paradigm shift in emergency response, transforming how critical care can be delivered in high-risk, time-sensitive scenarios. Complementing this vision, Project Operion showcased the future of surgical infrastructure through a fully mobile, platform agnostic operating room ecosystem. Built on a wheeled chassis with Overhead-Integrated Robotics and a Zero-Footprint Architecture, Operion eliminates conventional spatial constraints by suspending all surgical components from an integrated overhead system. This enables 360-degree clinician access, real-time reconfiguration, and seamless deployment across hospitals, remote locations, and disaster zones. With integrated telesurgery capabilities and low-latency connectivity, Operion allows expert surgeons to operate remotely, expanding access to advanced surgical care across geographies. From defence operations to humanitarian missions and rural healthcare delivery, Operion transforms the operating room into a deployable, mission-ready asset. Further strengthening the innovation momentum at SMRSC 2026, SS Innovations International unveiled a Single Arm Robotic Endoscopy and Ultrasound Assist Cart, representing a notable advancement in diagnostic and interventional robotics. Designed to provide stable, precise, and repeatable positioning of endoscopic and ultrasound instruments within clinical environments, the SSI Technologies Single Arm system brings robotic consistency to diagnostic workflows. Operating under direct clinician supervision, the robotic arm incorporates controlled speed, force limits, and predictable motion behaviour, ensuring safe interaction with both patients and operators. Its compatibility with standard hospital infrastructure and existing clinical workflows ensures seamless integration into established clinical settings. Equally transformative was the unveiling of SSI KAYA Humanoid Applications, which showcased SS Innovations International's bold foray into humanoid robotic platforms for real-world deployment across critical domains. Leveraging the advanced mobility, dexterity, and perception capabilities of humanoid systemsl, SSI KAYA is being trained and operationalised for high-impact applications spanning healthcare, defence, logistics, disaster response, and industrial settings.  Prataprao Jadhav, Minister of State (Independent Charge), Ministry of AYUSH and Ministry of Health & Family Welfare, Government of India, said, “India is fast emerging as a global hub for advanced medical technologies, and innovations showcased at SMRSC 2026 highlight the strength of our indigenous capabilities, with companies like SS Innovations International leading the way."    ]]> https://biospectrumindia.com/news/93/27624/gitam-and-bfi-ink-mou-to-establish-medtech-incubation-centre-in-visakhapatnam.html https://biospectrumindia.com/news/93/27624/gitam-and-bfi-ink-mou-to-establish-medtech-incubation-centre-in-visakhapatnam.html Tue, 07 Apr 2026 00:00:00 +0530 GITAM and Blockchain for Impact (BFI) have signed a Memorandum of Understanding (MoU) to establish a MedTech incubation centre at the GITAM Institute of Medical Sciences and Research (GIMSR) in Visakhapatnam. BFI will support the centre through a structured grant to build and operate it.India imports over 70% of its medical devices in key categories, while hospitals continue to generate clinical problems that rarely translate into usable technologies.The gap lies in how these problems move from identification to development and deployment. Clinical insight, engineering capability, and product development often operate separately, and most ideas do not move beyond early stages.GITAM’s multidisciplinary environment brings clinicians, researchers, and engineers into closer working coordination, with access to patients, diagnostics, and clinical data through GIMSR.The GITAM and Blockchain For Impact MedTech incubation centre will enable healthcare problems to be taken forward through design, prototyping, and clinical validation with clinician involvement, supported by infrastructure, mentorship, and access to clinical settings. The incubation centre aims to focus on non-invasive diagnostics and patient monitoring, where earlier detection can reduce time to diagnosis and lower the cost of care. The centre will support startups, students, residents, and faculty, and help develop, validate, and take solutions forward in India.GITAM is working towards strengthening India’s MedTech capability by supporting the development of medical technologies within the country, contributing to Make in India and Atmanirbhar Bharat. ]]> https://biospectrumindia.com/news/93/27616/aiims-partners-with-medisim-vr-to-drive-adoption-of-vr-skill-training-in-medical-education.html https://biospectrumindia.com/news/93/27616/aiims-partners-with-medisim-vr-to-drive-adoption-of-vr-skill-training-in-medical-education.html Mon, 06 Apr 2026 00:00:00 +0530 Chennai-based MediSim VR has announced its partnership with the All India Institute of Medical Sciences (AIIMS), New Delhi, to integrate its AI-enabled Virtual Reality (VR) solutions into medical and nursing education.  This collaboration represents a strategic milestone in advancing research on the integration of VR-based skill training within India’s medical education curriculum. As India’s leading academic and research home for medicine, AIIMS has consistently set the standards for excellence in healthcare education and training. Through this partnership, AIIMS and MediSim VR will jointly research and evaluate how VR can be embedded into the medical and nursing curriculum, studying its impact on skill development, standardisation, and long-term adoption. This collaborative effort reinforces AIIMS’ role as the benchmark institution for advancing new methods of medical learning in India. Dr M Srinivas, Director, AIIMS, New Delhi, said, speaking at the launch event stated, “If the country as a whole is to be in the best league, that has to extend to all spheres, including medical innovations, medical teaching, training and learning as well. VR-based simulation training allows for a learning environment where you are immersed and exposed to all things you will experience in a clinical setting. This collaboration enables us to further study how immersive technologies can contribute to skill development, assessment and training standardisation.” Dr Adith Chinnaswami, COO and co-founder of MediSim VR, added, “When AIIMS adopts a teaching tool, it sends a strong signal across the medical education ecosystem. This collaboration is centred around creating a framework where VR becomes part of standard training, and eventually, part of regulations." ]]> https://biospectrumindia.com/news/93/27607/zeiss-india-strengthens-portfolio-with-launch-of-clearmind-lenses.html https://biospectrumindia.com/news/93/27607/zeiss-india-strengthens-portfolio-with-launch-of-clearmind-lenses.html Thu, 02 Apr 2026 00:00:00 +0530 ZEISS, a pioneer of science in optics, has announced the launch its latest prescription lenses ZEISS ClearMind lenses in India. The all-day lenses addition to the lens portfolio delivers clear vision while reducing cognitive load due to blur for daily eyeglass wearers. For eye care professionals this offering elevates their practice with advanced lens technology that supports both visual performance and comfort. In today’s fast-paced world with countless visual stimuli to process, there is an increase in information overload where individuals may feel overwhelmed. With pre-existing conditions of blur on spectacle lenses, the ability to identify and interpret complex stimuli is compromised. ZEISS ClearMind lenses are built on a unique design that reduces and smooths optical errors, increasing the clear vision zones and reducing peripheral lens blur thus reducing cognitive load. Research conducted at the ZEISS Vision Science Lab (Tübingen University, Germany) established a direct connection between lens-induced blur and increased cognitive load. In consumer studies, 96% of wearers reported extremely clear vision when using ZEISS ClearMind lenses. 9 out of 10 wearers experienced reduced cognitive load compared to standard progressive lenses. Many wearers also reported an improvement in overall well-being while using the lenses.  By aligning lens clarity zones to natural eye-movement patterns, ZEISS NeurOptix technology aims to reduce the brain’s cognitive load, provide more relaxed, effortless vision, as well as improve comfort during long days of digital, visually busy and dynamic activity. ]]> https://biospectrumindia.com/news/93/27548/quality-care-india-signs-mou-with-intuitive-to-expand-robotic-assisted-surgery-in-tier-2-3-markets.html https://biospectrumindia.com/news/93/27548/quality-care-india-signs-mou-with-intuitive-to-expand-robotic-assisted-surgery-in-tier-2-3-markets.html Tue, 24 Mar 2026 00:00:00 +0530 Quality Care India Limited (QCIL), one of India’s leading healthcare platforms, has signed a Memorandum of Understanding (MoU) with Intuitive, a global technology leader in minimally invasive care and pioneer of robotic-assisted surgery (RAS), to scale robotic-assisted surgery across its multi-brand hospital network comprising CARE Hospitals, KIMSHEALTH and Evercare Hospitals through a phased multi-system installation plan.   The initiative will strengthen clinical capabilities while extending advanced minimally invasive care to patients in tier 2 and tier 3 markets. The expansion of robotic-assisted surgery aligns with QCIL’s broader strategy to strengthen advanced surgical infrastructure in emerging healthcare markets.   This collaboration will help scale its adoption across additional centres, strengthening clinical capacity and access to robotic-assisted surgery for patients across regions. The expanded deployment will support surgeons and care teams in delivering robotic-assisted procedures across specialties, including Thoracic, Transplant, urology, gynaecology, general surgery, and surgical oncology.   As part of the MoU, Intuitive will provide comprehensive technology training, customer service, and support to surgeons and care teams across QCIL’s network hospitals, strengthening programme adoption, procedural consistency, and scalable implementation across centres. The QCIL hospitals to have a faster recovery & precise surgery, thereby improving clinical outcomes.   There are currently over 200 da Vinci systems installed across India, with more than 1,500 surgeons trained in robotic-assisted surgery in specialties such as gynaecology, urology, general surgery, and oncology. Collectively, there have been more than 16.9 million da Vinci procedures performed globally to date, with more than 43,000 peer-reviewed scientific articles referencing da Vinci and related technologies. Intuitive has supported over 35 clinical studies in India, generating local evidence that supports structured and evidence-based program development across institutions. ]]> https://biospectrumindia.com/news/93/27551/andhra-pradesh-medtech-zone-and-medartha-capital-launch-indias-first-medtech-investment-platform.html https://biospectrumindia.com/news/93/27551/andhra-pradesh-medtech-zone-and-medartha-capital-launch-indias-first-medtech-investment-platform.html Tue, 24 Mar 2026 00:00:00 +0530 MedArtha Capital, in collaboration with Andhra Pradesh MedTech Zone Limited (AMTZ), has launched India’s first dedicated MedTech Capital fund, marking a significant step toward accelerating innovation, research, and manufacturing in India’s growing medical device ecosystem. The platform was unveiled by Union Minister for Commerce and Industry Piyush Goyal, who described the country’s MedTech sector as a “sunrise opportunity” driven by a strong talent pool and rising awareness around preventive healthcare.As global demand for advanced medical technologies continues to grow, initiatives like this are expected to strengthen India’s MedTech ecosystem, encourage innovation-driven startups, and support the development of globally competitive medical device manufacturers. Dr Jitendra Sharma, MD, Founder & CEO - Andhra Pradesh MedTech Zone Limited remarked, "India's strong engineering capabilities, clinical expertise, and cost-efficient manufacturing position the country to build globally significant medical device companies." Ganesh Sabat, Managing Partner at MedArtha Capital, highlighted that building globally competitive medical technology companies requires the right capital, deep domain expertise, and access to specialised manufacturing infrastructure, such as AMTZ, to support entrepreneurs in scaling innovation. ]]> https://biospectrumindia.com/news/93/27535/trivitron-introduces-app-for-radiation-protection-apparel-monitoring-in-india.html https://biospectrumindia.com/news/93/27535/trivitron-introduces-app-for-radiation-protection-apparel-monitoring-in-india.html Mon, 23 Mar 2026 00:00:00 +0530 Trivitron Healthcare, a global medtech organisation, has announced the launch of Kiran Smart Track, India’s first intelligent tracking application designed exclusively for radiation protection or X-Rays apparel. This marks a key advancement in strengthening safety, compliance, and operational efficiency across healthcare environments. Kiran Smart Track brings product insights to your fingertips with a simple QR code scan embedded on every radiation protection apparel. It offers a comprehensive, 360-degree view of each product, from manufacturing details and specifications to protection levels and shelf life, supporting precise usage and consistent regulatory compliance. With a clear focus on smarter tracking and operational efficiency, Kiran Smart Track brings together features such as instant quality checks, real-time shelf-life monitoring, and detailed product insights, all accessible through a single scan. The application enables users to verify product authenticity, identify aprons through unique codes, and access key specifications, including core material, protection levels (front and back), size, color, and quality and safety reports. Unique serial numbers further simplify warranty management and streamline inventory tracking. By enabling informed decision-making, ensuring safety compliance, and improving inventory control, the app enhances workflow efficiency across hospitals and diagnostic centers. It also introduces a digital-first, more structured, and transparent approach to managing radiation protection apparel in everyday clinical practice. ]]> https://biospectrumindia.com/news/93/27536/tracky-unveils-new-platform-to-track-patient-outcomes-for-glp-1-therapies.html https://biospectrumindia.com/news/93/27536/tracky-unveils-new-platform-to-track-patient-outcomes-for-glp-1-therapies.html Mon, 23 Mar 2026 00:00:00 +0530 DrStore Healthcare Services, a connected healthcare and medical device ecosystem company, through its smart medical devices and tech platform Tracky, has launched an integrated, real-time monitoring platform designed to track patient outcomes for GLP-1 therapies in India.   The platform brings together multiple health data streams into a unified system, enabling clinicians and pharmaceutical companies to monitor therapy effectiveness, improve patient management, and generate real-world evidence.   The rapid rise of GLP-1 therapies for diabetes and weight management is reshaping the treatment landscape in India and globally. However, as adoption accelerates, a critical gap is becoming increasingly evident, the lack of continuous, structured data to monitor patient outcomes and understand therapy effectiveness in real-world settings.   Addressing this gap, Tracky is pioneering an integrated, real-time monitoring platform designed to bring together multiple health data streams into a unified, continuous view of patient health. The platform integrates glucose data from continuous glucose monitoring (CGM), Body composition tracking, Food logs & calorie tracking, activity levels, and wearable inputs, enabling longitudinal tracking and deeper insights into patient progress.    Within the context of GLP-1 therapies, it supports real-time tracking of patient progress, enabling clinicians to make more informed decisions around dosage titration, identify and manage side effects early, and monitor adherence to therapy.   By correlating these parameters with lifestyle and behavioral data, the platform also helps in understanding the sustainability of outcomes, supporting a more structured and data-driven approach to weight management during and after GLP therapy.   The platform also addresses a growing concern around GLP-1 treatments, the sustainability of outcomes after therapy discontinuation. While these therapies have shown strong clinical results, maintaining weight loss and metabolic improvements post-treatment remains a challenge. By combining continuous monitoring with lifestyle-linked insights, Tracky aims to support a more sustainable and data-driven approach to weight management, both during and beyond the therapy cycle.   ]]> https://biospectrumindia.com/news/93/27517/terumotata-elxsi-offshore-development-centre-opens-in-pune.html https://biospectrumindia.com/news/93/27517/terumotata-elxsi-offshore-development-centre-opens-in-pune.html Thu, 19 Mar 2026 00:00:00 +0530 Tata Elxsi, a global leader in design and technology services, and Terumo Corporation, a global medical innovation company, have inaugurated the ‘Terumo–Tata Elxsi Offshore Development Centre’ in Pune. This dedicated centre will support the development of Terumo’s cardiac and vascular solutions, strengthening engineering and innovation capabilities while enabling continuous lifecycle support across international markets. The centre brings together multidisciplinary teams, with Tata Elxsi’s expertise in design, engineering, verification, regulatory compliance, and localisation, along with the thoughtful application of AI, GenAI, and digital capabilities in software engineering. This enables faster development and regional adaptation while addressing the growing demand for patient-centric medical devices with improved cost efficiency and product differentiation. The collaboration advances the reliability and performance of cardiac and vascular technologies, supporting their global availability and helping ensure they meet industry standards and the evolving needs of healthcare providers and patients. Fumihisa Hirose, Company President, Cardiac & Vascular Company Terumo Corporation, said, “This new Offshore Development Center strengthens our ability to innovate faster and deliver high-quality medical technologies across global markets. Tata Elxsi’s integrated design, engineering, and regulatory expertise will help us accelerate our global product roadmap while maintaining the highest standards of safety and compliance.” Sreevatsa Sahasranaman, Sr. Vice President & Head – Healthcare & Life Sciences, Tata Elxsi, said, “This Offshore Development Center represents a comprehensive long-term partnership model with Terumo Corporation to bring Tata Elxsi’s multi-disciplinary, cross-functional and deep domain expertise to drive innovation and cost efficiencies across Terumo’s Cardiovascular portfolio. We are committed to combining design, engineering, and regulatory capabilities, enhanced by the latest AI- and GenAI-powered technologies, to help Terumo bring next-gen medical technologies to global and emerging markets.” ]]> https://biospectrumindia.com/news/93/27459/alcon-launches-hydrus-microstent-for-long-term-glaucoma-management-in-india-.html https://biospectrumindia.com/news/93/27459/alcon-launches-hydrus-microstent-for-long-term-glaucoma-management-in-india-.html Tue, 10 Mar 2026 00:00:00 +0530 Alcon, the global leader in eye care, has announced the launch of Hydrus® Microstent in India. This minimally invasive glaucoma surgery (MIGS) device is designed to lower intraocular pressure (IOP) for patients with open-angle glaucoma in conjunction with cataract surgery. MIGS are a lower risk intervention for glaucoma patients, enabling physicians to lower IOP with a reduced risk of complications compared to incisional filtration surgeries while allowing for rapid visual recovery, Hydrus’ HORIZON trial is the first and only MIGS study to report 5-year clinical outcomes, with continuous follow up and 80% patient retention at year five. Hydrus is also recognised by leading medical bodies and evidence reviews including the European Glaucoma Society (EGS), Cochrane, and the American Academy of Ophthalmology (AAO) for the quality of its data. With over 200,000 implants worldwide, Hydrus Microstent is a proven solution for sustained IOP control. “In India, approximately 12 million people are affected by glaucoma, and the proportion of undiagnosed glaucoma is estimated at around 90%, underscoring the need for earlier detection and effective interventional treatment options2,3. At Alcon, we’re committed to bringing Hydrus to India to help glaucoma patients continue to see brilliantly. Hydrus’ unique Tri-Modal® mechanism of action enables its clinical effectiveness, and our high-quality, long-term data give surgeons the confidence to manage glaucoma both safely and effectively. This launch marks a significant milestone for the ophthalmic community and the many patients it serves,” said Amar Vyas, Country Head at Alcon India. ]]> https://biospectrumindia.com/news/93/27460/deloitte-india-unveils-firstofitskind-cyber-facility-to-safeguard-medtech-healthcare-ecosystems.html https://biospectrumindia.com/news/93/27460/deloitte-india-unveils-firstofitskind-cyber-facility-to-safeguard-medtech-healthcare-ecosystems.html Tue, 10 Mar 2026 00:00:00 +0530 Deloitte India has unveiled ConnectSafe™, the country’s first‑of‑its‑kind cyber‑security facility that moves the focus from data‑only protection to safeguarding human lives and critical infrastructure. Recent cybersecurity incidents reported globally highlight how vulnerabilities in connected operational systems can quickly escalate into large-scale disruption. India’s rapid transition towards connected ecosystems, across mobility, healthcare, manufacturing, energy, agriculture, digital and physical public infrastructure, significantly expands the cyber‑attack surface. The 4,500 sq ft. facility offers a live environment that simulates real‑world cyber‑threat scenarios across industries including automotive, MedTech, industrial and consumer ecosystems. It enables organisations to test, validate and strengthen security controls without disrupting live operations and directly address the hyper‑connected, systemic cyber risk they face. “As industries become increasingly connected, from smart factories and power systems to vehicles and medical devices, cyber threats are no longer limited to IT systems, they directly impact the operational backbone of our economy. Through ConnectSafe™, organisations can experience real-world threat scenarios, gain deeper visibility into emerging risks, and strengthen safeguards to protect critical infrastructure, operations, and innovation. In doing so, we are not only helping enterprises build trust and resilience but also positioning India as a leader in next-generation cyber defence”, said Romal Shetty, CEO, Deloitte South Asia.   ]]> https://biospectrumindia.com/news/93/27425/philips-and-actrec-tata-memorial-cancer-centre-join-hands-to-strengthen-early-cancer-detection-in-india.html https://biospectrumindia.com/news/93/27425/philips-and-actrec-tata-memorial-cancer-centre-join-hands-to-strengthen-early-cancer-detection-in-india.html Tue, 03 Mar 2026 00:00:00 +0530 Philips, a global leader in health technology, and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), a unit of Tata Memorial Centre, are advancing the future of cancer care in India by bringing next-generation Spectral CT imaging, reinforcing shared commitment to more precise diagnosis, enabling earlier disease detection, and improving clinical decision-making for patients with complex cancers. As India faces a growing burden of cancer and complex multi-system diseases, timely and accurate diagnosis has never been more critical. Diagnostic delays can contribute to avoidable patient harm, while repeat imaging may increase radiation exposure, patient anxiety, and treatment timelines — particularly in high-volume tertiary care centres. Philips Spectral CT 7500 enables clinicians to capture detailed spectral information during routine CT scans. This allows for deeper disease characterisation from a single scan, helping clinicians make earlier, more confident diagnostic decisions without increasing radiation dose. It provides richer insight from a single scan, reducing repeat imaging and enabling full body exams in approximately two seconds. Studies also show 36% fewer additional diagnostic procedures in complex cancer evaluations, directly reducing patient anxiety, radiation exposure and overall treatment delays.   The introduction of Spectral CT will support multiple clinical specialties including oncology, cardiology, neurology and emergency care, areas where rapid and confident assessment is critical to improving outcomes. ]]> https://biospectrumindia.com/features/93/27407/indiaeu-fta-redefining-the-pharma-growth-equation.html https://biospectrumindia.com/features/93/27407/indiaeu-fta-redefining-the-pharma-growth-equation.html Sun, 01 Mar 2026 00:00:00 +0530 India and the European Union (EU) have announced the conclusion of negotiations for a Free Trade Agreement (FTA), marking a milestone in one of India’s most strategic economic partnerships. Dubbed the ‘mother of all deals,’ the agreement is structured as a modern, rules-based trade framework designed to address current global trade challenges while enabling deeper market integration between the world’s fourth and second largest economies. The FTA unlocks access to the $572.3 billion EU pharmaceuticals and medical devices market, providing new opportunities for Indian manufacturers. The agreement is expected to support scaling of pharmaceutical production, employment generation, stronger MSME participation, and deeper integration into global supply chains. It reinforces India’s position as a major supplier of medicines and medical technologies. Key Highlights for Pharmaceuticals and Medical Devices Preferential market access to support growth in high-value segments Liberalised tariffs for key ‘Made in India’ medical devices Growth opportunities across inorganic and organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps, and detergents Capacity expansion and MSME cluster development Expansion across manufacturing hubs in Gujarat, Maharashtra, Karnataka, and Andhra Pradesh Strengthening of coastal export hubs to support export-led growth and employment The FTA is also expected to support Indian traditional medicine services. In EU Member States where regulations do not exist, AYUSH practitioners will be able to provide services based on qualifications obtained in India. The agreement provides certainty for establishment of AYUSH wellness centres and clinics and envisages greater exchange to facilitate trade in Indian traditional medicine services. India and the EU first initiated trade negotiations in 2007, but discussions stalled in 2013 over issues including patent protection, data security, and mobility of professionals. Negotiations were relaunched in 2022. In recent years, geopolitical pressures and the need to diversify export markets have accelerated the process, as both India and the EU seek to broaden trade partnerships, according to a World Economic Forum report. Industry Reacts Much of the industry has responded positively to the conclusion of the India–EU Free Trade Agreement, viewing it as a structural shift in trade and market access. “The conclusion of the India–EU Free Trade Agreement marks a watershed moment for India’s pharmaceutical exports and its long-term partnership with Europe—one of the world’s most regulation-intensive healthcare markets. For the pharmaceutical sector, the FTA delivers structural competitiveness. Near-zero tariff access significantly strengthens the position of Indian formulations, APIs, and value-added medicines in the EU, a development that is particularly consequential for India’s pharma MSMEs, many of whom possess strong quality capabilities but face cost and access barriers in highly regulated markets. Reduced tariffs and smoother market entry will directly enhance their ability to scale exports, invest in compliance, and integrate into European supply chains. The India–EU FTA is not a short-term export stimulus; it is a long-term competitiveness framework that empowers MSMEs and positions Indian pharma for resilient, quality-led growth,” said Namit Joshi, Chairman, Pharmaceutical Export Promotion Council of India (Pharmexcil). Hailing the developments Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA) said, “IPA welcomes the conclusion of the India–EU Free Trade Agreement, which marks an important milestone in strengthening bilateral trade. India and the European Union are long-standing and trusted partners in the pharmaceutical sector. Indian companies play a critical role in supplying quality-assured, affordable medicines to Europe. The expected removal of EU tariffs of up to 11 per cent on pharmaceuticals will enhance trade and support greater access to innovative medicines for Indian patients. The agreement reinforces the intellectual property framework under the TRIPS Agreement and the Doha Declaration. This will further strengthen trade opportunities and collaboration between India and the EU.” Industry experts have expressed similar views for the medical devices sector, noting that Indian healthcare delivery remains dependent on high-end medical, surgical, and diagnostic equipment imported from Europe. The elimination of tariffs under the India–EU trade agreement is expected to reduce input costs for hospitals and improve access to advanced technologies. “For the MedTech, medical devices, and diagnostics ecosystem, the FTA is particularly consequential—unlocking deeper market access, rationalised tariffs, and stronger regulatory cooperation between two of the world’s most innovation-driven healthcare markets. Importantly, reduced bilateral duties will make advanced medical equipment and devices more affordable in India while simultaneously catalysing local manufacturing scale and providing a strong export impetus for Indian-made medical devices and equipment into Europe. The agreement also enables regulatory convergence and predictability, a critical enabler for long-cycle MedTech investments and global quality certifications. By improving access to advanced diagnostics and precision technologies, it strengthens healthcare delivery outcomes while lowering system-wide costs. Beyond trade volumes, the agreement creates a platform for sustained investments, technology partnerships, and collaborative innovation, strengthening healthcare resilience across both economies,” said Dr GSK Velu, Chairman & Managing Director- Trivitron Healthcare, Neuberg Diagnostics and Maxivision Super Speciality Eye Hospitals. Experts also feel that the agreement has strategic importance in elevating India’s global manufacturing position. “The conclusion of the India–EU Free Trade Agreement is a consequential step in positioning India as a credible, long-term partner in global manufacturing and innovation. For the medical technology sector, the combination of tariff rationalisation and more predictable market access materially improves the competitiveness of Indian-manufactured devices in Europe, one of the world’s most regulated healthcare markets. Equally important, the agreement reinforces higher expectations around quality systems, regulatory discipline, and product performance, encouraging Indian MedTech companies to invest with a longer horizon in advanced manufacturing and R&D. In the context of evolving global healthcare supply chains, the FTA supports deeper integration of Indian manufacturers into European value chains and strengthens trust in India as a reliable source of critical medical technologies. This development aligns closely with the ‘Make in India for the World’ vision and creates a sustainable pathway for Indian MedTech companies to scale globally while contributing to a resilient, patient-centric healthcare ecosystem,” said Dr Shravan Subramanyam, Managing Director, BPL Medical Technologies. While challenges around regulation and execution remain, the India–EU FTA may well redefine the trajectory of India’s pharma and MedTech sectors in the years ahead. Ayesha Siddiqui ]]> https://biospectrumindia.com/news/93/27385/pulse-raises-4-m-to-build-full-stack-medical-equipment-manufacturing-brand.html https://biospectrumindia.com/news/93/27385/pulse-raises-4-m-to-build-full-stack-medical-equipment-manufacturing-brand.html Wed, 25 Feb 2026 00:00:00 +0530 Bengaluru-based startup Pulse has raised $4 million in seed round led by 3one4 Capital, with participation from Incubate Fund Asia & Stride Ventures, and angel investors including founders of Blackbuck and Agrizy to build a full-stack, asset-light medical equipment manufacturing brand that designs, sources and delivers affordable, globally compliant products at scale, with a focus on enabling Indian MSME manufacturers to compete with global incumbents. The company will use the funds to set up an R&D hub, accelerate product development, secure regulatory certifications, and build distribution across India. Founded in 2025 by Anshul Sharma and Nishant Goel, Pulse is headquartered in Bengaluru and currently operates with a 25-member team. The company focuses on low and mid-complexity medical equipment and consumables categories where India has strong manufacturing depth but remains highly import- dependent. Pulse’s long-term vision is to build a large horizontal OEM from India, serving multiple medical equipment categories for domestic and global markets. The newly raised capital will be deployed to set up a dedicated R&D hub, accelerate product development, secure regulatory certifications, and strengthen MSME manufacturing partners through quality and process upgrades. Pulse will also invest in building its distribution network across India and selectively in export markets. In its initial phase, Pulse is focused on serving mid-tier hospitals (50–200 beds) across India with reliable products in select categories such as critical care and renal care. The company plans to subsequently expand into larger hospitals and corporate hospital chains, while growing horizontally by adding more medical specialties and deepening product portfolios within each category. Exports are expected to become a meaningful part of the business over time. ]]> https://biospectrumindia.com/news/93/27392/aiims-patna-receives-funding-support-from-bfi-to-establish-medtech-incubation-centre.html https://biospectrumindia.com/news/93/27392/aiims-patna-receives-funding-support-from-bfi-to-establish-medtech-incubation-centre.html Wed, 25 Feb 2026 00:00:00 +0530 In a significant advancement for the medical innovation ecosystem in Eastern India, All India Institutes of Medical Sciences (AIIMS) Patna has received funding support for the establishment of a MedTech Incubation Centre. The grant has been awarded by BlockChain for Impact (BFI). The Letter of Intent was received by Dr Sanjay Pandey, Dean Research, AIIMS Patna; Dr Sudeep Kumar, Professor, Department of Orthopaedics, AIIMS Patna; and Dr Mousumi Saha, CEO, AIIMS Patna Incubation and Innovation Council.The project will be led by Dr Sudeep Kumar as the Principal Investigator. The MedTech Incubation Centre will be headed by Dr Mousumi Saha, who will lead the strategic vision, operations, and ecosystem development of the centre.This newly sanctioned MedTech Incubation Centre aims to strengthen the ecosystem for medical device innovation, translational research, and healthcare startups. The initiative is aligned with AIIMS Patna’s commitment to nurturing clinician-led innovation, supporting early-stage startups, and bridging the gap between clinical needs and technological solutions.AIIMS Patna has been steadily building a robust incubation ecosystem dedicated to empowering medical and healthcare innovators, startups, and entrepreneurs. The establishment of this centre will further enhance its capacity to provide mentorship, infrastructure, regulatory guidance and industry-academia collaboration. ]]> https://biospectrumindia.com/news/93/27373/larsen-toubro-group-inks-100-m-deal-with-european-medtech-firm.html https://biospectrumindia.com/news/93/27373/larsen-toubro-group-inks-100-m-deal-with-european-medtech-firm.html Mon, 23 Feb 2026 00:00:00 +0530 Mumbai-based LTM has announced a multi-year, $100 million strategic agreement with a MedTech company in Europe, a leading provider of innovative hearing solutions, to deliver product development and support across its flagship products. This agreement will span over seven years.   Towards this, LTM will leverage iNXT, its cross‑industry digital transformation and innovation platform designed to help enterprises manage the convergence of the physical and digital worlds. As part of this agreement, LTM will develop and support the MedTech’s primary hearing instrument brands and its private labels. This includes the MedTech’s core wearable devices, the fitting application used by hearing care professionals to configure hearing aids, and the mobile application for device control. Along with technological development and support, LTM will lead and navigate complex MedTech compliance & regulatory frameworks for the client. LTM, a Larsen & Toubro Group Company, is an AI-centric global technology services company and the Business Creativity partner to the world’s largest enterprises ]]> https://biospectrumindia.com/news/93/27356/philips-and-apollo-hospitals-collaborate-to-strengthen-stroke-and-structural-heart-disease-care-in-india.html https://biospectrumindia.com/news/93/27356/philips-and-apollo-hospitals-collaborate-to-strengthen-stroke-and-structural-heart-disease-care-in-india.html Thu, 19 Feb 2026 00:00:00 +0530 Philips and Apollo Hospitals have announced the signing of a non-exclusive Memorandum of Understanding (MoU) to explore potential initiatives to advance stroke care and structural heart disease management across India. Any specific initiatives will be subject to definitive agreements and required approvals. Under the MoU, the parties intend to strengthen technology-enabled care pathways informed by real-world clinical practice. By combining Philip’s advanced imaging and image-guided therapy capabilities with Apollo’s clinical expertise, the initiative intends to support integrated decision-making across diagnosis and intervention, particularly in complex, time-sensitive scenarios. The collaboration comes at a critical juncture for India’s healthcare system. India recorded over 1.25 million new stroke cases in 2021, nearly double the number reported in 1990, according to The Lancet Neurology, reflecting a sharp rise in both incidence and prevalence over the past three decades. This growing disease burden is mirrored in national mortality data, with cardiovascular diseases now the leading cause of death in India, accounting for nearly one‑third of all deaths, as per the Registrar General of India. These trends underscore the urgent need for integrated, technology-enabled approaches to diagnosis, intervention, and long-term care. Roy Jakobs, Chief Executive Officer, Royal Philips, said, “Healthcare systems in India are at a pivotal moment, with rising incidence of complex cardiovascular and neurological conditions placing increasing demands on clinicians. Through this collaboration with Apollo Hospitals, Philips aims to bring its global platforms in advanced imaging and image-guided therapies to help shape more resilient, data-driven care pathways supporting earlier intervention, greater precision, and sustainable improvements in patient outcomes at scale.” Dr Prathap C. Reddy, Founder and Chairman, Apollo Hospitals Group, said, "As India’s healthcare needs grow in complexity, the integration of advanced technology with clinical expertise is essential to deliver scalable, high-quality care. Our collaboration with Philips brings together Apollo’s legacy of clinical excellence with Philips’ AI-enabled advanced imaging solutions to further strengthen our stroke and structural heart disease pathways." The MoU focuses on two clinical areas: structural heart disease and stroke care. In structural heart disease, initiatives aim to improve procedural accuracy, optimise contrast usage, and strengthen real-time imaging guidance. For stroke care, the collaboration aim to accelerate imaging workflows and streamline patient pathways enabling intervention within the golden hour, reducing door-to-needle time, improving clinical efficiency, and supporting timely, consistent care when every minute matters.   ]]> https://biospectrumindia.com/news/93/27348/maverick-simulation-solutions-launches-siddh-indias-advanced-high-fidelity-critical-care-adult-patient-simulator.html https://biospectrumindia.com/news/93/27348/maverick-simulation-solutions-launches-siddh-indias-advanced-high-fidelity-critical-care-adult-patient-simulator.html Wed, 18 Feb 2026 00:00:00 +0530 Maverick Simulation Solutions, a leading manufacturer of advanced medical simulators, launched SIDDH at their corporate office in Dwarka, New Delhi. Developed and manufactured in India, SIDDH is a next-generation high-fidelity critical care adult patient simulator created to transform hands-on clinical training across medical colleges, teaching hospitals, and healthcare institutions. As a life-size, 65 kg full-body adult simulator, SIDDH is engineered to replicate real-world critical care scenarios with physiological accuracy. By integrating advanced lung simulation technology, AI-powered ultrasound capabilities, and real-time physiological response systems, SIDDH delivers a safe, immersive, and clinically realistic training environment. It enables doctors, nurses, paramedics, and medical students to practise complex procedures, manage emergencies, and make critical decisions with confidence before stepping into real patient settings. Speaking on the launch, Anuj Chahal, Founder of Maverick Simulation Solutions, said, “The global medical simulation industry is witnessing rapid growth as healthcare systems increasingly recognise the importance of safe, technology-driven training. In India, this need is even more urgent as the number of medical colleges and healthcare institutions continues to expand. However, access to high-fidelity simulators has traditionally depended on expensive imports. With SIDDH, we are proud to introduce a truly Make in India solution that matches global standards while being designed specifically for Indian healthcare realities.” SIDDH enables training across a wide range of critical care scenarios, including cardiac emergencies, respiratory distress, trauma, and complex airway management. It features realistic anatomy, advanced lung simulation, and real-time arterial blood gas feedback that dynamically responds to learner interventions. The platform also integrates an AI-powered ultrasound module with over 1,000 clinical cases, precise probe tracking, intelligent scoring, and adaptive guidance. Optional modules support communication training, structured assessments, team-based simulations, and cloud-based performance analytics for institutions.   ]]> https://biospectrumindia.com/news/93/27336/amtz-and-narayan-seva-sansthan-ink-5-year-pact-to-boost-affordable-indigenous-prosthetic-assistive-tech.html https://biospectrumindia.com/news/93/27336/amtz-and-narayan-seva-sansthan-ink-5-year-pact-to-boost-affordable-indigenous-prosthetic-assistive-tech.html Tue, 17 Feb 2026 00:00:00 +0530 In a landmark initiative to advance indigenous, affordable, and high-performance prosthetic, orthotic, and assistive technologies, AP Govt enterprise Andhra Pradesh MedTech Zone Limited (AMTZ), India’s premier medical technology park, has signed a five-year Memorandum of Understanding (MoU) with Narayan Seva Sansthan (NSS), a nationally recognised non-profit dedicated to improving the lives of persons with disabilities. The partnership aims to combine AMTZ’s state-of-the-art technology ecosystem, including R&D laboratories, prototyping, and manufacturing facilities, with NSS’s unmatched clinical expertise and rehabilitation experience. Together, the organisations will work to advance indigenous, cost-effective, and high-quality prostheic, orthotic, and assistive technologies, while supporting NSS’s Vision 2030 of delivering 1 lakh high-quality artificial limbs to beneficiaries nationwide. Geographically, 69.49% (1.86 crore) persons with disabilities live in rural India, highlighting the urgent requirement for affordable, accessible prosthetic and assistive technologies nationwide—aligning directly with the Vision 2030 goal of delivering 1 lakh high-quality artificial limbs to beneficiaries across the country. While a standard NSS limb currently costs around Rs 10,000, an advanced limb with a pneumatic knee joint for above knee prosthesis and carbon foot offering enhanced strength, balance, durability, and energy return costs Rs 41,000 due to reliance on imported components. Through this partnership and backward integration for indigenous manufacturing, the collaboration aims to reduce the cost of these advanced limbs to approximately Rs 10,000, without compromising quality or performance, marking a shift from basic limb provision to technology-enabled, performance-driven prosthetics. Under the MoU, AMTZ will provide technical and operational support, access to R&D and testing infrastructure, and assistance in joint research initiatives. NSS will lead clinical validation, rehabilitation protocols, and nationwide assistive device camps. Both parties will also jointly pursue grants, patents, and support programs from national and international funding bodies to accelerate innovation and expand access to high-quality medical devices for underserved communities. The collaboration encompasses a wide range of devices, including prosthetics such as powered, myoelectric, sports/recreational, and cosmetic restoration , ranging from partial foot to hip disarticulation. Orthotic solutions cover foot orthotics, diabetic foot management, off-loading shoes, modified insoles, and walking braces. The partnership also includes mobility and assistive aids such as walkers, crutches, canes, rollators, wheelchairs, standing frames, and twin devices, along with advanced hearing aids, representing a shift from basic limb provision to technology-enabled, performance-driven prosthetics.   ]]> https://biospectrumindia.com/news/93/27328/alkem-medtech-to-acquire-majority-stake-in-swiss-firm-occlutech-holding-for-rs-1074-cr.html https://biospectrumindia.com/news/93/27328/alkem-medtech-to-acquire-majority-stake-in-swiss-firm-occlutech-holding-for-rs-1074-cr.html Fri, 13 Feb 2026 00:00:00 +0530 Alkem MedTech, a wholly-owned medical devices subsidiary of Alkem Laboratories, has announced the execution of a binding offer for acquiring a majority stake in Occlutech Holding AG, a global medical devices company, headquartered in Switzerland, specialising in minimally invasive cardiac implants. Alkem MedTech intends to buy up to 55% stake in Occlutech for a consideration of EUR 99.4 million (Approx. Rs 1,074 crore), subject to statutory approvals. This acquisition represents a significant step in Alkem MedTech’s journey to build a global footprint and enables its entry into advanced cardiovascular devices. Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure. Occlutech is the second-largest company in Europe in the minimally invasive cardiac implants segment and the third-largest globally. It operates manufacturing and R&D facilities in Germany and Turkey, a global distribution hub in Sweden, and clinical operations in the US. In calendar year 2025, Occlutech recorded a revenue of EUR 49.4 million (unaudited), representing a 15.7% CAGR over the past three years. Occlutech derives about 85% of its revenue from Europe and the US.  The transaction remains subject to entering into definitive agreements, dompany’s conditions precedent to be fulfilled, authorisation by the statutory authority as part of the control of foreign investments in some of the geographies, as well as the absence of qualified material adverse events. The acquisition is expected to be completed by June 2026 after the regulatory approvals are obtained. ]]> https://biospectrumindia.com/news/93/27309/scottish-innovator-to-showcase-stroke-technology-through-uk-trade-mission-to-india-.html https://biospectrumindia.com/news/93/27309/scottish-innovator-to-showcase-stroke-technology-through-uk-trade-mission-to-india-.html Wed, 11 Feb 2026 00:00:00 +0530 An NHS spinout will be spotlighting its world-leading innovation in stroke treatment after being selected to showcase the breakthrough technology during a prestigious UK trade mission to India. Biopharmaceutical company Aurum Biosciences will be furthering its global growth ambitions when it joins a Department for Business and Trade (DBT) visit from 16-19 February, encouraging fresh international connections through events, round table meetings, and pitching opportunities. One focus of the trip will be the chance to engage global pharma companies and potential investors at the BioAsia 2026 Summit in Hyderabad, considered to be “Asia's foremost life sciences and healthcare event”. Aurum’s patented ABL-101 platform technology has the potential to dramatically change that for the overwhelming 90% of patients currently missing out during emergencies through its promise to help treat the stroke-related oxygen deprivation which can quickly cause brain damage. During Aurum’s visit to India – taking in Mumbai, Hyderabad, and Ahmedabad – the company aims to connect with partners who can help scale the company’s operations and further advance ABL-101. ABL-101, which is being manufactured in India, has undergone significant pre-clinical development and has completed early phase 1 and 2a human studies. Phase 2 trials in stroke and inflammation imaging are planned this year, underlining its huge promise. ]]> https://biospectrumindia.com/news/93/27274/oxymed-introduces-cure-and-inteli-5-lpm-setting-new-benchmarks-in-home-oxygen-therapy-in-india.html https://biospectrumindia.com/news/93/27274/oxymed-introduces-cure-and-inteli-5-lpm-setting-new-benchmarks-in-home-oxygen-therapy-in-india.html Tue, 03 Feb 2026 00:00:00 +0530 Oxymed, one of India’s leading home respiratory care companies, has announced the launch of two new 5 LPM home oxygen concentrators for the Indian market: Oxymed Cure and Oxymed Inteli 5 LPM. Together, these launches significantly strengthen Oxymed’s presence across both the affordable and premium segments of home oxygen therapy, reinforcing the company’s long-term vision of improving access, intelligence, and reliability in home respiratory care. The launches also mark a clear delivery on Oxymed’s public roadmap. At its India Dealer Meet last year, the company had outlined plans to introduce a more affordable 5 LPM concentrator alongside a technologically advanced, innovation-led model. The introduction of Cure and Inteli demonstrates Oxymed’s focus on measured, planned innovation, translating long-term commitments into market-ready products rather than reactive launches. Oxymed Inteli 5 LPM represents a major step forward in home oxygen therapy. It is India’s first home oxygen concentrator capable of automatically adjusting oxygen flow based on real-time patient SpO₂ levels. Paired with a Bluetooth-enabled pulse oximeter, the device continuously optimises oxygen delivery, shifting home therapy from fixed manual settings to intelligent, responsive care. Designed for comfort and efficiency, Inteli operates at under 30 dB, consumes close to 150 watts of power, and weighs approximately 12 kg, making it the lightest and quietest concentrator in its category. With premium lithium-based sieve beds and a best-in-class warranty of three years or 15,000 hours, Inteli is positioned as Oxymed’s most advanced offering, expected to be priced around Rs 45,000.   Oxymed was the first brand in India to introduce a built-in Oxygen Purity Analyzer in home oxygen concentrators and, with Inteli, is now the first to bring automatic oxygen flow adjustment based on patient SpO₂ levels to the Indian home-care market. Oxymed Cure expands access to reliable oxygen therapy in the affordable segment. Expected to be priced around Rs 32,000, Cure delivers medical-grade oxygen purity while retaining Oxymed’s three-year warranty and nationwide service support. ]]> https://biospectrumindia.com/news/93/27255/fujifilm-india-introduces-advanced-imaging-and-healthcare-it-solutions.html https://biospectrumindia.com/news/93/27255/fujifilm-india-introduces-advanced-imaging-and-healthcare-it-solutions.html Fri, 30 Jan 2026 00:00:00 +0530 Fujifilm India, a leader in advanced diagnostic imaging solutions, has announced the launch of four new diagnostic imaging and healthcare IT solutions at the Indian Radiological and Imaging Association (IRIA) 2026, underscoring its commitment to strengthening India’s diagnostic imaging ecosystem through advanced, clinically validated, and workflow-centric technologies that enable diagnostic confidence, operational efficiency, and broader access across diverse clinical environments.At the center of the showcase is FCT iStream, Fujifilm’s latest CT scan system, built on a “Less is More” design philosophy. FCT iStream combines high-definition imaging, dose optimization, and AI-enabled workflow automation powered by the Synergy-Drive workflow suite and REiLI Medical AI technologies. The CT scanner automates key steps across the imaging process, from patient positioning & scan planning to image reconstruction & seamless integration with SYNAPSE 3D Workstation for advanced visualization, helping radiology departments to manage rising patient volumes with greater efficiency and consistency.Complementing its CT offerings, Fujifilm India also highlighted its women’s health imaging portfolio, led by advanced full-field digital mammography systems, including AMULET SOPHINITY and AI Designed with a strong focus on patient comfort and diagnostic precision, these mammography machines support early breast cancer detection through high-resolution imaging, AI-assisted positioning, tomosynthesis, and contrast-enhanced mammography capabilities. The portfolio further includes digital radiography (X-ray) systems, such as the FDR Smart X Essential series, engineered for reliability, flexibility, and efficient workflows in high-throughput clinical environments. Designed for deployment across tertiary hospitals, diagnostic centres, and space-constrained facilities, these X-ray systems combine consistent image quality with space-efficient configurations and streamlined operations, supporting broader access to essential radiography services across urban and non-metro settings.Underpinning the imaging portfolio is Fujifilm’s healthcare IT ecosystem, including enterprise imaging and data management platforms such as HCIT Fenix, along with advanced visualisation solutions that enable seamless image access, interoperability, and clinical collaboration. By integrating imaging systems with intelligent software platforms, Fujifilm India aims to support end-to-end diagnostic workflows while enabling faster clinical decision-making and optimised clinical operations. ]]> https://biospectrumindia.com/news/93/27256/oxymed-unveils-new-5-lpm-oxygen-concentrator.html https://biospectrumindia.com/news/93/27256/oxymed-unveils-new-5-lpm-oxygen-concentrator.html Fri, 30 Jan 2026 00:00:00 +0530 Oxymed, one of India’s most trusted names in home oxygen concentrators, has announced the launch of Oxymed Cure, a new 5 LPM oxygen concentrator designed to make reliable oxygen therapy more affordable without compromising on medical or service standards. Oxymed has been a dominant force in the category for several years, with its flagship Oxymed Mini (5 LPM) emerging as one of the most successful oxygen concentrators in India and commanding over 50% market share in its segment. Headquartered in Bengaluru, Oxymed manufactures its products in India and has built a strong reputation for quality, transparency, and dependable after-sales support. With an expected end-user price of Rs 32,000–33,000, Oxymed Cure is positioned nearly 15% lower than the Oxymed Mini, which typically retails at Rs 39,000–40,000. Despite the lower price, Oxymed has retained its industry-leading 3-year warranty, a feature rarely seen in the affordable oxygen segment. The move reflects Oxymed’s understanding of India’s price-sensitive healthcare landscape, particularly for patients requiring long-term oxygen therapy. Oxymed Cure delivers medical-grade oxygen purity of 93% ±3%, in line with global standards. It features a built-in Oxygen Purity Analyzer (OPA) that allows users to monitor real-time oxygen purity, along with an integrated nebulizer for added clinical convenience. The concentrator also offers improved energy efficiency, consuming approximately 200 watts, significantly lower than earlier models, and does not require a stabiliser. Designed for home comfort, Oxymed Cure features a modern, premium design with a larger display, a sturdier build, and quieter operation at around 35 dB. Backed by Oxymed’s PAN-India service network, the launch positions Cure as a strong alternative to low-cost imported concentrators that often come with limited warranty and service support. ]]> https://biospectrumindia.com/news/93/27247/asi-telangana-partners-with-medtronic-to-train-young-surgeons.html https://biospectrumindia.com/news/93/27247/asi-telangana-partners-with-medtronic-to-train-young-surgeons.html Thu, 29 Jan 2026 00:00:00 +0530 Medtronic, a global leader in medical technology, has signed a Memorandum of Understanding (MoU) in India with the Telangana State Chapter of the Association of Surgeons of India (ASI) to train residents, post-graduates, and early career surgeons in open and laparoscopy procedures using new- age technologies via collaborative skill- building training programs. The collaboration aims to strengthen surgical capabilities by providing focused training in minimally invasive surgery, combining Medtronic’s technological expertise with ASI Telangana’s academic and clinical leadership. It will follow a blended learning format with interactive academic sessions and hands-on endo-trainer workshops to help participants gain practical exposure to laparoscopic techniques. The programme will be led by experienced surgical faculty from ASI and participating medical institutions, ensuring high-quality, structured learning tailored to the needs of early career surgeons. Commenting on the collaboration, Abhishek Bhargava, Senior Director, Medical Surgical, Medtronic India said, “Advancing surgical education is integral to improving patient outcomes. Our collaboration with ASI Telangana is a focused effort to build strong laparoscopic capabilities among the next generation through structured, hands-on training. By enabling access to the right skills and technologies early in their careers, the initiative supports surgical practices and contributes to a more resilient healthcare system." Dr B. Ramesh, Honorary Secretary, ASI Telangana Chapter said, “This programme helps bridge the gap between theoretical learning and real-world application by offering a structured environment to practice laparoscopic techniques and build essential hand–eye coordination. By combining our academic and clinical guidance with Medtronic’s expertise in surgical care and technology, this collaboration adds meaningful value and better prepares participants for independent surgical practice.”   ]]> https://biospectrumindia.com/news/93/27232/alicorn-medical-unveils-indigenously-manufactured-wound-healing-medical-device.html https://biospectrumindia.com/news/93/27232/alicorn-medical-unveils-indigenously-manufactured-wound-healing-medical-device.html Tue, 27 Jan 2026 00:00:00 +0530 As a significant milestone in the journey of Kerala-based Alicorn Medical, the company has announced the official launch of CholeDerm, India’s first indigenously manufactured extracellular matrix (ECM)-based Class D wound healing medical device, at Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST).This launch represents the successful translation of indigenous research into clinical reality, made possible through the unwavering support of DST, BIRAC, SCTIMST, and the collaborative spirit between scientists, policymakers, and industry. Dr Sanjay Behari, Director, SCTIMST, formally announced the product launch, and acknowledged Dr T V Anilkumar, the visionary scientist and father of CholeDerm (from decellularised pig gall bladder), whose pioneering research laid the foundation for this innovation. CholeDerm is a proud step towards Make in India and Atmanirbhar Bharat, delivering advanced wound care solutions that are clinically effective, affordable, and accessible. It is expected that with the introduction of CholeDerm to the Indian market, the treatment cost can be reduced from Rs 10,000 to Rs 2,000 making it more affordable to the common man. Moreover, the technology for recovering extracellular matrix from the gall bladder is not available to others and it gives a fair chance for competition in the international market. ]]> https://biospectrumindia.com/news/93/27226/cmc-vellore-launches-centre-for-excellence-in-neurotechnology-in-collaboration-with-vattikuti-foundation.html https://biospectrumindia.com/news/93/27226/cmc-vellore-launches-centre-for-excellence-in-neurotechnology-in-collaboration-with-vattikuti-foundation.html Sat, 24 Jan 2026 00:00:00 +0530 In a significant step towards strengthening India’s advanced neurological care and research ecosystem, the Vattikuti Foundation, in collaboration with Christian Medical College (CMC), Vellore, has launched the Centre of Advanced Neurotechnology at the CMC Vellore, Ranipet campus. The Centre marks the commissioning of an advanced MR guided Focused Ultrasound (MRgFUS) system, expanding to non-invasive treatment options for patients crippled with essential tremors and tremors in the patients suffering with Parkinson’s disease. The Vattikuti Foundation has donated an Insightec MR guided Focused Ultrasound system to CMC Vellore and will support the Centre’s long- term growth and sustenance for the initial years, including developing new technology, training surgeons through Vattikuti Fellowship programmes and implementing the best practices and research in identifying new surgical targets. MRgFUS uses real time MRI to precisely neuromodulate known surgical targets without the need for anesthesia, incisions, implants, blood loss, or prolonged recovery despite old age. It offers a lower risk therapeutic alternative for patients who continue to suffer as they do not want to undergo surgical risk and cannot afford it.  The launch addresses the growing burden of movement disorders in India, where an estimated four to ten million people are affected by tremors of different kinds and are dependent on medicines for the rest of their life.   Clinical focus at the Centre will initially include movement disorders such as Parkinson’s disease and essential tremors. While these represent current approved indications, experts noted that the technology holds wider promise for neurological care when supported by structured clinical research. The foundation launched a similar centre in 2025 at the All India Institute of Medical Sciences, New Delhi and hopes to synergise research efforts at both healthcare institutions in India. ]]> https://biospectrumindia.com/news/93/27217/qure-ai-secures-major-global-health-grant-to-build-ai-powered-point-of-care-ultrasound.html https://biospectrumindia.com/news/93/27217/qure-ai-secures-major-global-health-grant-to-build-ai-powered-point-of-care-ultrasound.html Thu, 22 Jan 2026 00:00:00 +0530 In an effort to advance health equity and reach the people that need help most, global digital health innovator Qure.ai has received a grant from the Gates Foundation. The multimillion-dollar grant will allow Mumbai-based startup Qure.ai to develop a large open-source multi-modal database to further advance future prevention and identification innovations. It will support WHO lung-health diagnostic pathways plus augment non-identifiable clinical history, medical images (Chest X-Ray, Thoracic Ultrasound, High Resolution CT), cough/lung recordings, and laboratory or biological markers to enable researchers and innovators around the world to develop, validate, and refine new AI models for the good of all. This grant will also allow Qure.ai to develop artificial intelligence (AI)-enabled point-of-care ultrasound algorithms as a ‘tool’ for the early detection of TB and pneumonia, two of the world’s deadliest infectious diseases in under-resourced regions. Both are curable if caught early yet TB deaths are approximately 1.23 million annually, pneumonia 2 million each year, 700,000 of which are children under five.  “This grant will allow us to build on the years of continuous innovation we have spearheaded in public health and our commitment to pushing the boundaries of what AI can do for global health. It brings together pneumonia, tuberculosis, and broader lung health priorities, with a focus on children in low and middle-income countries. A child dies of pneumonia every 43 seconds which is an unacceptable and an avoidable loss. It underscores the urgent need for better diagnostics and equitable access to care,” said Dr Justy Antony Chiramal, Project Lead and Clinical Director, Global Health Innovation at Qure.ai.   ]]> https://biospectrumindia.com/news/93/27200/max-institute-of-laparoscopic-robotic-bariatric-surgery-gi-surgery-signs-mou-with-intuitive-surgical-.html https://biospectrumindia.com/news/93/27200/max-institute-of-laparoscopic-robotic-bariatric-surgery-gi-surgery-signs-mou-with-intuitive-surgical-.html Tue, 20 Jan 2026 00:00:00 +0530 Max Institute of Laparoscopic, Robotic, Bariatric Surgery & GI Surgery has entered into a Memorandum of Understanding (MoU) with Intuitive Surgical, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. This collaboration will focus on strengthening surgeon capability, advancing structured training pathways, and supporting the adoption of robotic-assisted surgery across common and complex procedures, all with the goal of expanding access to robotic-assisted surgery to more patients across India. The MoU was signed by Dr Pradeep Chowbey, a world-renowned robotic surgeon and the Group Chairman of Max Institute of Laparoscopic, Robotic, Bariatric Surgery & GI Surgery; David J. Rosa, Chief Executive Officer of Intuitive and Rohitt Mahajan, Vice President and General Manager of Intuitive India. This MoU and subsequent collaboration brings together Intuitive’s global expertise in robotic-assisted surgery and Max Institute’s clinical leadership to establish structured outcome benchmarks for routine surgical procedures. By focusing on both complex and commonly performed surgeries, the initiative aims to demonstrate how robotics can enhance precision, standardisation, and efficiency across a broader range of procedures, supporting more consistent patient outcomes and greater patient access. The MoU formalises collaboration in clinical research, with Max surgeons participating in Intuitive-led studies for approved indications, and Intuitive supporting Max-led research across study design, analytics, and publication. The partnership also envisages a Centre of Excellence to build clinical and economic evidence for robotic-assisted surgery, supporting informed decision-making by hospitals and healthcare systems and, over time, helping insurance frameworks evolve to reduce financial barriers and enable broader patient access where clinically appropriate. ]]> https://biospectrumindia.com/news/93/27164/iit-m-inks-mou-with-bmec-imaging-to-establish-medical-design-and-imaging-lab.html https://biospectrumindia.com/news/93/27164/iit-m-inks-mou-with-bmec-imaging-to-establish-medical-design-and-imaging-lab.html Sat, 10 Jan 2026 00:00:00 +0530 The Department of Engineering Design, Indian Institute of Technology, Madras (IIT-M) has signed a Memorandum of Understanding (MoU) with BMEC Imaging, to establish the Medical Design and Imaging Laboratory, strengthening industry–academia collaboration in medical technology.The partnership will focus on joint research, product development and skill-building initiatives in medical imaging, oncology and allied healthcare technologies, addressing critical gaps in India’s MedTech ecosystem. It will further strengthen the Department’s B.Tech + M.Tech Dual Degree in Biomedical Design, along with MS (by Research) and doctoral programmes, by enabling students and researchers to work on real-world healthcare challenges.BMEC Imaging’s expertise in advanced imaging systems, combined with IIT Madras’ design-led, interdisciplinary approach, aims to deliver affordable, accessible healthcare innovations with global impact. ]]> https://biospectrumindia.com/features/93/27136/pre-budget-expectations-gst-simplifications-key-to-pharma-and-life-sciences-growth.html https://biospectrumindia.com/features/93/27136/pre-budget-expectations-gst-simplifications-key-to-pharma-and-life-sciences-growth.html Thu, 01 Jan 2026 00:00:00 +0530 The Budget 2025–26 had provided a significant boost to the sector. The Department of Health and Family Welfare received Rs 95,957.87 crore, while the Department of Health Research was allocated Rs 3,900.69 crore. Additionally, Rs 20,000 crore was earmarked for the Research, Development, and Innovation (RDI) initiative. The Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme also received Rs 2,300 crore to promote biomanufacturing, research, and entrepreneurship in novel drugs and medical devices. However, 2025 also brought global uncertainties, including geopolitical tensions and tariff-related pressures, particularly from the US. Against this backdrop, stakeholders are seeking policy stability, tax rationalisation, and regulatory reforms to help the sector remain competitive and resilient.   GST simplification and R&D incentives A recurring expectation across the life sciences ecosystem is simplification of the Goods and Services Tax (GST) regime, especially for pharmaceuticals and medical devices. The industry has long struggled with inverted duty structures, delayed refunds, and procedural complexities that strain working capital, particularly for MSMEs. Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA), emphasises that the Budget must provide a strategic thrust to help the industry achieve its long-term ambitions of reaching $120 billion by 2030 and $450 billion by 2047. “Increasing healthcare spending toward the National Health Policy target of 2.5 per cent of GDP by 2026–27 is critical. Restoring weighted tax deductions for R&D, rationalising inverted GST structures, simplifying compliance for physician samples, and strengthening incentives for biopharmaceutical manufacturing will help offset current external stresses,” he says. The reinstatement of higher weighted tax deductions under Section 35(2AB) for in-house R&D remains one of the industry’s strongest demands. According to BG Barve, Chairperson, Taxation Committee of Indian Drug Manufacturers’ Association (IDMA) and Joint Managing Director, Blue Cross Laboratories, such a move would directly encourage innovation, new drug development, and technology upgrades. He also highlights the need for simplification of TDS rates and thresholds to reduce disputes and improve cash flows, along with restoring the 15 per cent concessional corporate tax rate under Section 115BAB for new manufacturing units.   Customs, compliance, and MSME relief Beyond GST, the industry is seeking relief from long-standing customs and tax disputes. The IDMA has called for a Customs Amnesty Scheme, similar to Sabka Vishwas, to resolve legacy issues. Digitalisation of customs processes to reduce dependence on physical documentation and rationalisation of high import duties on certain medical devices (HSN 9018–9022) have also been proposed. Tax and compliance complexity disproportionately impacts MSMEs. Dr Ranjeet Mehta, CEO and Secretary General, PHD Chamber of Commerce and Industry, stresses that honest taxpayers should not lose Input Tax Credit due to supplier non-compliance. Allowing flexibility in invoice matching and ensuring recovery efforts first target defaulting suppliers would help build trust and improve ease of doing business.   Patient-centric and trust-based healthcare growth Industry bodies also expect the Budget to reinforce patient-centric healthcare delivery. Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI), notes that India stands at a pivotal moment to build a world-class life sciences ecosystem anchored in patient safety, quality, and equitable access. “A forward-looking Budget can catalyse trust-based partnerships between government, industry, and healthcare providers, ultimately improving patient outcomes through access to innovative therapies and stronger public health programmes,” he says.   Strengthening neurological and preventive care Public health priorities are also shaping budget expectations. Stroke remains one of the leading causes of death and disability in India, affecting an estimated 1.8 million people annually. The Indian Stroke Association (ISA) is urging the government to strengthen neurological care infrastructure by setting up more dedicated stroke units, improving ambulance response times, and training emergency teams. Dr Arvind Sharma, Stroke Specialist and Secretary, ISA, highlights the importance of expanding tele-neurology services to reach rural populations. He also calls for better insurance coverage for long-term neurological care, including physiotherapy, speech therapy, cognitive rehabilitation, and home-based support. Preventive healthcare and early diagnosis are gaining increasing attention across sectors. Stakeholders believe higher budgetary allocations for screening programmes, subsidised diagnostics, and annual health check-ups could significantly reduce long-term healthcare costs.   Healthcare investment and regional expansion Despite progress, India’s healthcare spending remains low compared to many developing nations. Several experts argue that combined central and state healthcare expenditure should rise to at least 5 per cent of GDP to build a robust and equitable system. Dr MI Sahadulla, National President, Association of Healthcare Providers – India (AHPI), advocates targeted tax incentives to encourage healthcare investments in underserved regions, particularly Tier II and Tier III cities. He also calls for enhanced support for oncology research, elderly care, and long-term treatment coverage under health insurance schemes.   Medical devices and diagnostics reforms The medical devices and diagnostics segments are seeking focused reforms to reduce import dependence and improve domestic competitiveness. The Association of Indian Medical Device Industry (AiMeD) has proposed pragmatic tariff rationalisation to encourage local value addition while safeguarding investments made by Indian manufacturers. Rajiv Nath, Forum Coordinator, AiMeD, suggests a calibrated tariff increase of 10–15 per cent, partially offset through a health cess, to generate funding for Ayushman Bharat without significantly burdening consumers. Imports currently dominate nearly two-thirds of India’s medical device market, a trend the industry wants to reverse. Similarly, the in-vitro diagnostics (IVD) sector has highlighted challenges such as inverted duty structures, limited export incentives, and high technology-transfer costs. Jatin Mahajan, President, Association of Diagnostics Manufacturers of India (ADMI), emphasises the need for sector-specific reforms, public–private R&D partnerships, and diagnostic hubs in Tier II and Tier III cities.   Regulatory streamlining and long-term reforms Several experts have also called for regulatory restructuring. Joydeep Ghosh, Partner and Life Sciences & Health Care Industry Leader, Deloitte India, recommends exploring a single regulatory authority for pharmaceuticals and medical devices to streamline approvals and boost investor confidence. He also supports introducing a clear policy on refurbished medical devices, with safeguards to ensure safety and efficacy. Looking ahead, stakeholders expect Budget 2026–27 to prioritise long-term reforms alongside immediate capacity building. Dr Milind Antani, Head, Pharmaceutical and Lifesciences Practice, Nishith Desai Associates, anticipates deeper support for health insurance penetration through reduced GST on premiums, higher tax-deduction limits, and expanded government-backed schemes. Budget 2026 is expected to boost pharmaceuticals through expanded PLI schemes, export incentives, and tariff support to strengthen supply chains and global competitiveness. “The sector is likely to be positioned as a key growth engine, with strong focus on R&D, innovation, and affordable care for NCDs,” says Bhanu Prakash Kalmath of Grant Thornton Bharat. “As we approach the 2026 Union Budget, the expectations are to provide necessary incentives and policy support to the pharmaceutical sector that transforms India’s role from a high-volume generics hub to a global innovation-led pharmaceutical powerhouse. Some of the enablers in this direction would be R&D incentives for innovation, expanded PLI coverage for APIs and advanced therapies, infrastructure development incentives to boost manufacturing competitiveness. Streamlining policy and regulatory pathways to align them with international standards would also accelerate cross-border investment and strategic M&A activity. A budget focussed on these themes will not only reinforce India’s position as the ‘pharmacy of the world’ but will help catalyse the next wave of growth and investment across the sector”, says Ravi Shah, Partner, Cyril Amarchand Mangaldas.   Conclusion The life sciences sector views Budget 2026–27 as a defining moment. Expectations range from GST simplification and R&D incentives to regulatory streamlining, tariff rationalisation, and stronger public health investment. With pharmaceuticals and healthcare emerging as key drivers of economic growth, innovation, and employment, a well-calibrated Budget can strengthen India’s global competitiveness while making healthcare more affordable and accessible for millions.   Sanjiv Dassanjiv.das@mmactiv.com ]]> https://biospectrumindia.com/news/93/27117/medtronic-launches-state-of-the-art-mobile-surgi-skill-lab.html https://biospectrumindia.com/news/93/27117/medtronic-launches-state-of-the-art-mobile-surgi-skill-lab.html Wed, 24 Dec 2025 00:00:00 +0530 Medtronic, a global leader in healthcare technology, has announced the launch of its pioneering Mobile Surgi-skill Lab, a state-of-the-art platform designed to equip healthcare professionals across India's underserved tier 2 cities with critical competencies in minimally invasive surgery (MIS). Medtronic Mobile Surgi-skill Lab represents a transformative approach to medical education, bringing world-class training directly to hospitals and clinics in cities where access to specialised surgical training has historically been limited. Equipped with cutting-edge simulation technology and hands-on learning modules, the surgical lab will serve as a Mobile center of excellence, enabling surgeons and healthcare professionals to develop and refine their minimally invasive surgical skills without disrupting their clinical responsibilities. "This initiative embodies our vision of equitable healthcare advancement across India," said Mandeep Singh Kumar, Managing Director & Vice President, Medtronic India, "By bringing surgical training to the doorstep of medical colleges in tier 2,3 cities, we're creating a far reaching influence  that elevates surgical standards, improves patient outcomes, and strengthens the entire healthcare ecosystem in underserved regions." The lab features state-of-the-art simulations equipped with realistic training models, video-assisted surgical instruments, and interactive learning platforms. The comprehensive curriculum covers fundamental and advanced MIS techniques, offering specialized training tracks tailored to the evolving needs of regional healthcare facilities. Each engagement includes hands-on practice sessions, mentorship from expert faculty, and post-training support to ensure sustained skill development. Access to specialised surgical training has long remained concentrated in metropolitan hubs, creating disparities in clinical capabilities across regions. The Mobile Surgi-skill Lab directly addresses this gap, ensuring that young surgeons and resident doctors in medical colleges in tier 2,3 cities can access the same quality training as their counterparts in larger centres. This democratisation of medical education is expected to significantly enhance surgical safety, reduce complication rates, and foster adoption of minimally invasive techniques across regional healthcare systems.  The organisation has already secured partnerships with leading healthcare institutions and regional medical associations to ensure the Mobile Surgi-skill Lab reaches the communities that need it most. The initial roadmap encompasses visits to 10 tier 2 cities over the next 12 months, with expansion planned based on feedback and demand. ]]> https://biospectrumindia.com/news/93/27093/sri-sathya-sai-institute-and-siemens-healthineers-enter-strategic-clinical-research-collaboration-to-strengthen-cardiac-care-delivery.html https://biospectrumindia.com/news/93/27093/sri-sathya-sai-institute-and-siemens-healthineers-enter-strategic-clinical-research-collaboration-to-strengthen-cardiac-care-delivery.html Fri, 19 Dec 2025 00:00:00 +0530 Sri Sathya Sai Institute of Higher Medical Sciences (SSSIHMS) and Siemens Healthineers have entered a strategic clinical research collaboration titled, ‘Collaborative Clinical Research in Echocardiography.’ It brings together SSSIHMS’s commitment to free medical care and the leadership of Siemens Healthineers in cutting-edge ultrasound and cardiovascular imaging. This effort will explore key research areas, which includes advancing 2D and 4D echocardiography capabilities, enhancing quantitative imaging and automated measurements, optimizing workflows and usability, and evaluating imaging performance across diverse patient groups to ensure consistent, high-quality diagnostic outcomes. The collaboration is designed to improve early detection and accurate assessment of cardiac diseases and supports the hospital’s mission to provide high-quality, compassionate healthcare free of cost. Dr DC Sundaresh, director of SSSIHMS said, “This collaboration aligns strongly with SSSIHMS’s mission of combining clinical excellence with compassionate service. By working closely with Siemens Healthineers on advanced echocardiographic research, we aim to generate meaningful clinical evidence that enhances early diagnosis, improves outcomes, and expands access to high-quality cardiac care for all, especially in resource-constrained settings.” Kalavathi GV, executive director (India) and head of global Development Center, Siemens Healthineers said, “Expanding access to care is central to our purpose. This clinical research will help understand the region-specific customer challenges and support in developing AI-powered solutions which will improve workflows and enable increased access to cardiac care.” This initiative builds on SSSIHMS’s long-standing association with Siemens Healthineers. The hospital has already integrated Siemens Healthineers technology to deliver advanced, high-precision cardiac and neurovascular interventions. ]]> https://biospectrumindia.com/news/93/27094/ss-innovations-files-us-fda-510k-for-homegrown-surgical-robot-ssii-mantra.html https://biospectrumindia.com/news/93/27094/ss-innovations-files-us-fda-510k-for-homegrown-surgical-robot-ssii-mantra.html Fri, 19 Dec 2025 00:00:00 +0530 Gurugram-based startup SS Innovations International, Inc. (SSII), India’s homegrown surgical robotics pioneer, has announced a landmark milestone with the submission of its 510(k) premarket notification to the US Food and Drug Administration (FDA) for the company’s next-generation SSi Mantra surgical robotic system. The submission covers multiple high-demand surgical specialties, including general, urological, colorectal, gynaecological, and cardiac procedures. The move marks one of the most significant global regulatory steps ever undertaken by an Indian developed surgical robotic platform, positioning India prominently in a sector long dominated by international players. Dr Sudhir Srivastava, Founder, Chairman, and CEO of SS Innovations, stated, “Submitting our 510(k) notification to the FDA is a defining moment, not only for SS Innovations, but for India’s emergence as a global leader in advanced medical technologies. The SSi Mantra is designed to be affordable, accessible, and technologically differentiated, and its proven performance across diverse geographies speaks for itself. We believe all hospitals, particularly those serving underserved communities, stand to benefit immensely from an option that is both world-class and cost-effective.” Following a pre submission meeting and detailed consultations with the FDA, the Company opted for the 510(k) pathway over a De Novo request, seeking to leverage the route’s potential speed and efficiency. The FDA’s target review timeline for 510(k) submissions is 90 days, though total review duration may vary. SS Innovations also continues to advance toward its European Union CE Marking, expected in the first half of 2026, further accelerating the global footprint of the Made-in-India platform. ]]> https://biospectrumindia.com/news/93/27076/maxivision-boosts-eye-care-technology-leadership-with-latest-widefield-retina-imaging.html https://biospectrumindia.com/news/93/27076/maxivision-boosts-eye-care-technology-leadership-with-latest-widefield-retina-imaging.html Wed, 17 Dec 2025 00:00:00 +0530 Maxivision Super Speciality Eye Hospitals has strengthened retinal diagnostics at its Somajiguda Centre of Excellence (Hyderabad) with the introduction of an advanced widefield fundus imaging system known as The Widefield Fundus Camera, which is significantly better than normal fundus cameras. The technology provides a much broader view of the retina, enabling clinicians to detect early lesions, degenerations, and vascular changes that conventional imaging often misses. The launch comes at a time when India is facing a growing burden of retinal and systemic health-linked eye diseases, including diabetic retinopathy, glaucoma, retinal tears, uveitis, and vascular occlusions, conditions that increasingly demand faster, wider, and more accurate imaging for timely intervention. The upgrade is particularly significant as 70–75% of patients in the retina department are diabetic and require regular screening for diabetic retinopathy, while 20–25% of high myopic patients need detailed peripheral evaluation and frequent monitoring. The system also supports undilated fundus examinations, allowing a fast-tracked OPD for patients with limited time due to professional or personal commitments. It produces high-quality DESC pictures, ensuring accurate documentation and continuity of care during follow-up visits.   The Somajiguda Centre of Excellence, Maxivision’s first and longest-standing facility, remains the organization’s core hub for innovation, clinical leadership, and complex case management. Equipped with high-end LASIK suites, modular OTs, paediatric OPDs, advanced surgical platforms, OCT, FFA, and optical biometry, the centre also anchors group-wide fellowship programs, community screenings, and multi-specialty training. With the addition of the widefield fundus imaging system, Somajiguda further strengthens its position as one of India’s premier centres for advanced retinal diagnostics, delivering sharper, wider, and more comprehensive imaging to support preventive, personalised, and precision-led eye care. ]]> https://biospectrumindia.com/news/93/27061/healthium-medtech-acquires-controlling-stake-in-paramount-surgimed.html https://biospectrumindia.com/news/93/27061/healthium-medtech-acquires-controlling-stake-in-paramount-surgimed.html Mon, 15 Dec 2025 00:00:00 +0530 Bengaluru-based Healthium Medtech is acquiring a controlling stake in Paramount Surgimed, one of India’s largest manufacturers and exporters of surgical blades, scalpels and dermal biopsy products. The non-surgical business of Paramount, including its lifestyle and hygiene business will be carved out prior to the transaction and retained with the Grover family. With this move, Healthium will expand its specialised presence in the surgical consumables segment, where Paramount’s blades and dermal biopsy categories represent a logical extension of its existing business line. This alignment creates a two-way synergy, allowing Healthium to broaden the range of solutions it offers while enabling both organisations to serve their respective customer bases with a more comprehensive product line. Paramount’s scaled manufacturing platform, coupled with its high-quality portfolio, offers a unique value proposition to customers globally. When combined with Healthium’s scale and market reach, this acquisition is expected to unlock opportunities for accelerated commercial expansion, shared R&D and development of differentiated, high-quality innovations. Paramount brings over three decades of specialised manufacturing expertise and has a global footprint built largely through exports, which account for more than 95% of its revenue. The company serves more than 300 OEM and branded customers across 100+ countries, supported by a complete suite of international product registrations, including EU MDR & USFDA. Paramount manufactures over 250 million devices annually making it one of the largest players in its space.  Shaily Grover, Managing Director of Paramount Surgimed said, "As we join forces, we will use the broader resources of a larger platform and an expanded portfolio to improve reliability and expand access across the markets we serve.”   ]]> https://biospectrumindia.com/news/93/27043/medi-mold-announces-rs-100-cr-investment-to-set-up-indias-first-3d-printed-ortho-implant-facility.html https://biospectrumindia.com/news/93/27043/medi-mold-announces-rs-100-cr-investment-to-set-up-indias-first-3d-printed-ortho-implant-facility.html Tue, 09 Dec 2025 00:00:00 +0530 Medi-Mold, a leading manufacturer of medical-grade molds and precision tooling based within the Andhra Pradesh MedTech Zone (AMTZ), has entered into a strategic partnership with OIC International (USA) and AddUp (France) to establish a state-of-the-art 3D printed orthopaedic implant manufacturing facility in Vizag. The Memorandum of Understanding (MoU) for this strategic collaboration was signed in New Delhi in the presence of Ajay Sood, Principal scientific adviser to the Government of India (PMO Office, New Delhi). The partnership brings together US-based OIC’s FDA-approved implant technology, French additive manufacturing systems, and India’s largest MedTech ecosystem (AMTZ). A dedicated manufacturing line will be set up within AMTZ to produce 3D-printed orthopaedic implants across trauma, spine, hip, and other segments. As part of the transaction, Medi-Mold has agreed to an investment outlay of over Rs 100 crore towards OIC International’s setup, India entry, manufacturing, and expansion plans. The capital will be deployed to set up and scale the 3D printed implants facility and localise production, thereby reducing India’s reliance on imports. It will also support the transfer of proprietary technology, patents, and manufacturing SOPs, and the development of a specialised workforce for advanced MedTech manufacturing. The facility will leverage AMTZ’s advanced testing labs, machining centres, and regulatory infrastructure to produce high-quality implants at globally competitive costs. Wodehouse Capital Advisors acted as the exclusive financial and India market entry advisor to OIC for this transaction. Sraboni Haralalka, Executive Director, Wodehouse Capital Advisors said, “This collaboration sets the stage for India to emerge as a global center for advanced orthopaedic implant manufacturing.” ]]> https://biospectrumindia.com/news/93/27031/mahe-dst-hub-to-accelerate-translational-research-and-medtech-development.html https://biospectrumindia.com/news/93/27031/mahe-dst-hub-to-accelerate-translational-research-and-medtech-development.html Sat, 06 Dec 2025 00:00:00 +0530 Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in collaboration with the Department of Science and Technology (DST), Government of India, has launched the Medical Instruments, Devices and Allied Services (MIDAS) DST–MAHE Hub at Manipal Campus, Karnataka. This is the first facility of its kind in a self-financed university. Inaugurating the DST-MAHE Hub in the MAHE Manipal campus, Dr Praveen Roy, Head of Scientific Divisions Technology, Translation, and Innovation (TTI) Division, Department of Science & Technology, Government of India, highlighted the critical importance of Translational innovation, which plays a critical role in strengthening India’s scientific ecosystem. He said, “We remain committed to supporting all activities of the MIDAS Hub. The DST–MAHE Hub is uniquely positioned, as MAHE’s multidisciplinary foundation enables seamless integration across diverse domains. This initiative represents a paradigm shift in our approach to research and innovation, and the Government of India will extend its full support to ensure its success.”  MAHE has launched the Advanced Certificate Programme in Medical Device Technology, Innovation and Leadership and released the MIDAS annual report. The Hub also introduced its industry–academia policy, service flyers, and signed multiple MoUs to foster long-term partnerships. Market-ready prototypes, including Laser Shoe, Mbilimeter, Armable Mini, WeCare, FluroAura, RevoCord, Wearable Electrolarynx, and Adrenaline Autoinjector—were showcased, reinforcing the Hub’s focus on impactful, deployable innovations. ]]> https://biospectrumindia.com/news/93/27026/medtronic-and-symbiosis-international-open-state-of-the-art-experience-centre-in-pune.html https://biospectrumindia.com/news/93/27026/medtronic-and-symbiosis-international-open-state-of-the-art-experience-centre-in-pune.html Thu, 04 Dec 2025 00:00:00 +0530 Symbiosis International (Deemed University), through its constituent institute, the Symbiosis Centre for Health Skills (SCHS), has entered a strategic collaboration with a global leader in healthcare technology Medtronic to establish the Symbiosis Medtronic Experience Centre, The TechKnow Verse, a pioneering training facility designed to advance healthcare education, training and practice in India. The Experience Centre in Pune represents India's first-of-its-kind integrated facility, bringing advanced surgical training and cadaver-based learning under one roof.  This state-of-the-art facility provides hands-on cadaver training using advanced Cranial, Spinal, and Orthopedic technologies including brain and spinal robotics, surgical navigation systems, and 3D imaging underscoring our commitment to experiential learning, innovation, and stronger academic–industry collaboration. The Experience Centre is designed as a continuous learning ecosystem that hopes to empower neurosurgeons, orthopedic, spine and ENT surgeons to learn essential skills through early exposure to experiential training. The Center aims to offer a platform to hone clinical techniques by practicing in real-world scenarios which will enable trainees to deliver quality patient care. Mandeep Singh Kumar, Managing Director & Vice President, Medtronic India, emphasised the shared vision behind the collaboration, "This collaboration underscores our shared commitment to advancing healthcare education and empowering clinicians with the latest healthcare technology and knowledge to address evolving clinical needs. At Medtronic, everything we do is guided by our mission to alleviate pain, restore health, and extend life. By elevating standards of care and improving patient outcomes, we continue to make that mission a reality." "This partnership is a tremendous opportunity for lifelong learning that will strengthen our healthcare professionals' clinical foundations," said Dr Rajiv Yeravdekar, Provost of the Faculty of Medical and Health Sciences at Symbiosis International University. "By providing access to advanced technologies and experiential training, we are directly contributing to improved patient outcomes and excellence in medical practice.". The Centre is expected to train super-specialists - neurosurgeons, spine surgeons, ortho surgeons & ENT surgeons, strengthening India’s healthcare workforce and contributing directly to improved patient success and serving as a hub for capacity-building, innovation and academic–industry collaboration. ]]> https://biospectrumindia.com/features/93/26994/trends-2026-rise-of-resilient-life-sciences-innovation-.html https://biospectrumindia.com/features/93/26994/trends-2026-rise-of-resilient-life-sciences-innovation-.html Sun, 30 Nov 2025 00:00:00 +0530 A major trend in 2025 was the rise of anti-obesity drugs. Mounjaro, in particular, saw rapid uptake and became the second-highest selling weight-loss drug in India within just six months. Another  highlight was the opening of several Centres of Excellence (CoE). Notably, Miltenyi Biotec inaugurated India’s first Cell and Gene Therapy (CGT) CoE in Hyderabad, reflecting the growing focus on advanced therapies.  Much like everything in life, artificial intelligence (AI) continued to deepen its presence across healthcare, transforming diagnostics, research, and drug development. Pharma and Biotech  Policy and Innovation Driving Advanced Therapies The Government of India has launched the ‘Promotion of Research and Innovation in Pharma MedTech sector (PRIP)’ scheme to promote innovation in India. The scheme has a total financial outlay of Rs 5000 crore, which includes Rs 700 crore to establish Centers of Excellence (CoEs) at seven National Institutes of Pharmaceutical Education & Research (NIPERs), and Rs 4200 crore to accelerate investments in the R&D ecosystem within the sector. The scheme has defined three priority areas for funding: new medicines, Complex generics and biosimilars and novel medical devices. “It will be interesting to see the impact this scheme will make in 2026 and beyond. Considering the immense potential for increase in innovation within Pharma/Medtech in India, the overall ecosystem will benefit from this scheme and promote innovation at both the industry and academic level. Considering India’s large population and specific healthcare needs, we can expect good innovation momentum in these areas moving forward.  Moreover, Indian pharma needs to transform from being a generics producer to an innovation producer for long term growth,” said Prashant Khadayate, Director – Lifesciences Consulting & Research, GlobalData. This policy-driven push is expected to accelerate biology-led innovation in 2026, with advanced therapeutic modalities driving the next wave of growth. Cell therapies, autologous, allogeneic, and in vivo, are expected to shift from niche applications to scalable platforms across oncology, immunology, and regenerative medicine. While India approved its first CAR-T therapy only last year, experts anticipate a steady rise in CGT approvals in the coming years.  “Upcoming year will be defined by acceleration in high-value generics, complex formulations, and biologics. India’s role as the leading global supplier of affordable medicines will deepen, but the next phase of growth clearly lies in complex Injectables, peptides, sustained-release products, specialty therapies, and biosimilars—segments that are seeing stronger regulatory acceptance and higher demand across developed and emerging markets. With global healthcare systems seeking cost-effective alternatives, compliance strength, quality maturity, and digital transparency will become decisive factors in winning international confidence,” said Bhavin Mehta, Vice Chairman of the Pharmaceutical Exports Promotion Council of India (Pharmexcil).    Expanding to other geographies  A parallel, equally powerful trend is the broad-based diversification of export geographies. To mitigate the impact of US tariffs, pharmaceutical companies are exploring expansion into other geographies. While the US will remain a key driver, momentum is now shifting toward Africa, Latin America, Southeast Asia, the Middle East, and China, supported by rising procurement volumes and deeper commercial linkages.  “Exporters are responding by expanding Active Pharmaceutical Ingredients (APIs) capacity, Contract Development and Manufacturing Organisation (CDMO) partnerships, and resilient supply-chain models, enabling stronger participation in global tenders and reducing vulnerability to single-market fluctuations. The scale of India’s domestic market further enhances this export competitiveness, strengthening the manufacturing base and enabling a wider, more agile product portfolio. Reinforcing these sectoral tailwinds is the strong policy and trade push from the Government which is proactively shaping a future-ready export ecosystem”, said Mehta. “Production-linked incentives (PLI) for APIs and formulations, new bulk drug and medical device parks, enhanced regulatory cooperation with partner countries, trade missions, and an active FTA pipeline are collectively expanding market access for Indian manufacturers. Initiatives around digital quality systems, track-and-trace compliance, logistics modernisation, and sustainability standards are also elevating our positioning as a dependable global supplier. These measures are creating an enabling environment for exporters to scale their global footprint and transition from being primarily volume-driven suppliers to becoming high-trust, innovation-aligned partners in the global pharmaceutical value chain”, added Mehta.    AI and Gen AI in Drug Discovery & Diagnostics Artificial intelligence including generative AI is revolutionising drug discovery by accelerating candidate analysis, predicting drug-body interactions, and enabling faster, cost-effective therapy development.  “AI also advances diagnostics, facilitating early disease detection and precision treatment tailoring. For instance, Qure.ai’s AI-driven medical imaging solutions enable early diagnosis of TB, lung cancer, and stroke. Concurrently, decentralised clinical trials leveraging remote monitoring and AI analytics are increasing patient-centricity, accessibility, and efficiency, thereby accelerating therapy approval processes. The healthcare industry is projected to face continued cost pressures driven by new medical technologies, cited as the top driver by 74 per cent of insurers globally, underscoring AI’s central role in innovation and cost management,” said Ajay Mahipal - Co-Founder and General Partner, HealthKois.   Rise of Preventive Interventions  Preventive healthcare is emerging as a key growth driver, reshaping patient care globally. “We are entering a pivotal moment, where innovation and patient expectations are converging to redefine the healthcare industry. The vaccines market, valued at over $78 billion in 2023 and projected to nearly double by 2032, is a clear indicator that preventive and accessible healthcare will drive global growth in the decade ahead,” observed Sarvesh Mutha, Managing Director, IntegriMedical.  Shakul Srivastava, Vice President, Indian Immunologicals Limited, echoing similar sentiments, said, “The key trends are shifting toward preventive interventions, driven by the latest biotech innovations and enhanced through smart use of digital technologies.”    MedTech  "India’s MedTech sector is poised for remarkable growth, projected to reach $50 billion by 2026. At Medtronic, we see this momentum transforming healthcare making it more personalised, predictive, and supportive for every patient. Innovations in AI, IoMT, and personalised therapies will enable clinicians to deliver virtual care, proactive interventions, and treatments tailored to individual needs. Rising chronic diseases and an ageing population (200M+ seniors by 2030) will increase demand for remote monitoring systems bringing healthcare closer to home. By combining compassionate care with leading-edge technology, the MedTech innovations will empower patients and clinicians to achieve better health outcomes, together,” said Mandeep Singh Kumar, Managing Director and Vice President, Medtronic India.  Sharing his views Mutha said “AI-driven diagnostics and decision support systems are transforming healthcare by enabling faster, more accurate clinical decisions through predictive analytics and digital monitoring tools, ultimately improving both care quality and operational efficiency. At the same time, needle-free and innovative drug delivery technologies are rapidly gaining traction across areas such as vaccines, IVF hormones, growth hormones, and pain management, offering greater patient comfort, reducing infection risks, and improving treatment adherence. Complementing these advancements, pharmaceutical companies are increasingly forming collaborative partnerships with MedTech innovators to enhance dosing accuracy, ensure treatment consistency, and deliver more patient-centered solutions, making healthcare safer, more effective, and more accessible.”      Clinical Trials  Rise in Early-Phase Trials The regulatory reforms introduced in 2025 are expected to act as a catalyst in 2026, driving a new wave of innovation-led clinical research in India. Experts note a growing interest in early-phase studies and multi-regional clinical trials, supported by increasing expertise in complex areas such as CGT and tri-specific antibodies, which are set to become a mainstay in the coming year. Digitisation of Clinical Trials  In 2026, India's life sciences sector is expected to significantly transform, driven by the increasing integration of technologies such as AI, wearables, and data analytics. In clinical trials, this will enhance participant access and accelerate study timelines, helping to position the country as a prominent global hub for clinical research.  “Foundational to this will be to tap into the country’s rapidly growing digital ecosystem. In particular, mobile-first approaches help bridge infrastructure gaps by allowing patients to engage with trials from their own devices, wherever they are. Tools like electronic clinical outcome assessment (eCOA) and eConsent will facilitate real-time data collection and ensure patients receive comprehensive trial information from their own devices, promoting inclusive participation, including in areas such as central nervous system (CNS) and rare diseases. These tools will also ultimately improve accessibility by making trial participation less disruptive to daily life, which will in turn improve patient retention and data quality,” said Santhosh A F, Vice President, Asia Pacific South & India, Medidata.  AI will also continue to be a game changer. Morgan Stanley estimates that AI could help bring 50 new treatments to market within a decade, cutting drug discovery timelines from years to months, and reducing development costs. Beyond discovery, AI-driven study feasibility will be critical in 2026 to help sponsors and CROs identify optimal, high-performing sites across the globe. This precision in planning will significantly support study conduct and reduce overall development costs. “In India, we expect to see AI playing a pivotal role in decentralised clinical trials (DCTs), improving oversight and treatment adherence through the processing of real-time information from wearables and digital health tools, and enabling remote patient monitoring and the creation of synthetic control arms,” said Santhosh.  He added, “To capitalise on these trends, India must address some existing challenges, including skill gaps and strengthen public trust in clinical research, particularly in tier-2 and tier-3 cities. It must also navigate regulatory and ethical considerations, while providing careful oversight over patient consent and data privacy to build trust.  Looking into 2026, the future of clinical trials in India is not just about technology; it is about making trials safer, more inclusive, and more efficient for all stakeholders.”   CDMOs Digital Transformation of CDMOsAs pharmaceutical operations grow more complex, the integration of technology into quality systems is setting a new benchmark. Paperless workflows, real-time monitoring, predictive analytics, and remote oversight are embedding compliance into daily execution. For Indian CDMOs, this shift is already underway. At Syngene, for example, these efforts are visible in the use of secure remote inspection technologies such as RealWear, digitised checklists, and electronic batch records. Together, they help sustain a state of continuous audit readiness. These digital initiatives are reinforced by a broader shift toward decentralised accountability, ensuring that quality is embedded across teams and processes rather than being managed in isolation. This evolution signals both progress and opportunity for Indian CDMOs. By combining a strong quality culture with digital tools, organisations can go beyond meeting today’s compliance requirements to proactively shaping tomorrow’s standards. Those that see quality not just as a safeguard but as a strategic advantage will build stronger partnerships, operate with greater efficiency, and secure a lasting place for India in the global pharmaceutical supply chain, as highlighted by Alok Mehrotra, Chief Quality Officer, Syngene International, in an earlier op-ed with BioSpectrum India. Rise of Gene Therapy specific CDMOs Following a highly volatile period of investment peaks between 2020 and 2022, the global Cell and Gene Therapy (CGT) sector, and its associated Contract Research, Development, and Manufacturing Organisations (CRDMOs), have entered a phase of turbulence, marked by significant consolidation. Despite recent heightened regulatory scrutiny across the US and European Union (EU) and a year of leadership shifts, a robust pipeline of CGT candidates, coupled with a highly selective yet recovering venture capital (VC) landscape, still indicates substantial potential for emerging Indian CGT CRDMOs. If Indian CRDMOs can swiftly establish specialised manufacturing capacity, maintain rigorous international quality standards, and secure strategic global alliances, 2026 is poised to confirm India's trajectory towards capturing a significant, high-value portion of the worldwide CGT development and manufacturing market. “While overall biopharma VC funding remains stable, the competitive CGT space is seeing capital deployed more selectively toward companies with a clear path to commercial scalability. This targeted investment drives predictable manufacturing demand, presenting a significant opportunity for Indian CDMOs to engage early with VC-backed biotech companies and offer essential services like process development, scale-up, and GMP capacity. With US and EU CGT approvals continuing to rise and therapies expanding from rare disorders to more prevalent conditions such as cancers, autoimmune, and neurological diseases, Indian CDMOs are well-positioned to capture upstream demand and support global clinical trials and manufacturing,” said Dr Raghu Malapaka, Chief Business Officer, Nucelion Therapeutics, a wholly owned subsidiary of Bharat Biotech International Ltd.    Healthcare  Accelerated Adoption of AI in India’s Public Health System Building on significant initiatives launched in 2025, India is set to expand the use of AI across its public health system in 2026. With All India Institute Of Medical Sciences (AIIMS) Delhi, Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh, and AIIMS Rishikesh designated as Centres of Excellence for AI, and solutions like Media Disease Surveillance, Clinical Decision Support Systems in eSanjeevani, and AI tools for TB screening and outcome prediction already deployed, 2026 is expected to see broader integration of AI for disease surveillance, early diagnosis, and improved treatment outcomes.  India’s inclusion in the HealthAI Global Regulatory Network positions the country as a global leader in responsible AI deployment, enabling the sharing of best practices and fostering safer, more effective healthcare applications. The year ahead is expected to see AI increasingly driving disease surveillance, early diagnosis, and improved treatment outcomes nationwide. Digital Health, Telemedicine, and Virtual Hospitals “The evolution from telemedicine to virtual hospitals is transforming healthcare delivery. Digital platforms incorporating AI-powered chatbots, such as Wysa for mental wellbeing, and remote monitoring tools, like Beato for diabetes management in India, are improving patient access and outcomes, especially in chronic disease management. Virtual hospitals, such as Saudi Arabia’s SEHA Virtual Hospital, which serves 400,000 patients annually across 130 centres, exemplify this shift, meeting the rising demand driven by aging populations and healthcare workforce shortages,” said Mahipal.  Expanding on this, Sagar Sen, Senior Vice President – Global Life Sciences and Strategic Alliances at Qure.AI, noted that by 2026 the true impact of digital health will emerge from deeper system integration. “In 2026, digital healthcare will create a more connected ecosystem where information flows seamlessly between patients and primary health systems. It will support earlier intervention through predictive technologies that identify risks before illness becomes severe. As adoption grows, digital tools will help India build a stronger and more resilient health system capable of responding quickly to emerging challenges. The transition will simplify clinical workflows, improve data movement across EMRs and lead to a more coordinated care experience. As outcome-driven digital tools gain wider acceptance, AI will become a central part of everyday care delivery, enabling earlier diagnosis, ultimately improving health outcomes at scale.”   Ayesha Siddiqui ]]> https://biospectrumindia.com/features/93/26995/how-indias-diabetes-crisis-is-driving-med-devices-market-.html https://biospectrumindia.com/features/93/26995/how-indias-diabetes-crisis-is-driving-med-devices-market-.html Sun, 30 Nov 2025 00:00:00 +0530 With diabetes seeing an uptick and India being the Diabetes Capital of the World, the diabetes care devices market is experiencing robust growth. A GlobalData analysis reveals that India accounted for around 20 per cent of the Asia-Pacific (APAC) diabetes care devices market in 2024, driven by a confluence of factors, including a rapidly escalating diabetic population, increased diagnosis, rising disposable incomes, and the adoption of advanced diabetes management technologies. According to Frost & Sullivan analysis, the Indian diabetes care devices market is currently estimated at $4.8 billion and will reach $7.7 billion in 2030 with a projected compounded annual growth rate (CAGR) of approximately 9 per cent for the projected period of 2026-2030. The digital health platforms segment reflects its high growth potential and encompasses a range of interconnected technologies, services, and applications. Its key components are mobile health (mHealth) apps for medication nudges and diet and exercise logs, teleconsultation and remote patient monitoring packages, predictive analytics for personalised medicine, and patient data management software. The segment will experience rapid adoption, driven by India's high smartphone penetration, the government's initiatives like the India AI mission, and growing Internet connectivity.   Key growth drivers Rising disease prevalence, increased health awareness, strategic partnerships in the private sector, technological advancements, insurance and corporate wellness inclusion, E-commerce and telehealth penetration. According to Frost and Sullivan, government initiatives such as Ayushman Bharat undertake population-based screening for non-communicable diseases like diabetes in individuals over 30 years of age by trained frontline workers, have helped the sector to flourish. Other growth factors are the Government e-Marketplace (GeM) procurement and the Production Linked Incentive (PLI) Scheme encourage local manufacturing and ensure the accessibility of the technologies to the masses. Recent Goods and Services Tax (GST) reforms reduce tax burdens on the value and supply chains for medical devices used in diabetes care in India, including glucometers and test strips, to 5 per cent from 12–18 per cent. The complete exemptions for diabetes devices and treatments under health insurance have made coverage more affordable and accessible for people managing chronic conditions like diabetes can also be attributed. Major Players With rising cases of diabetes patients, a more obese population, rapid urbanisation etc. are acting as a catalyst for the devices market, where players are making a beeline to launch products. Advancements in technology, like continuous glucose monitoring (CGM) to monitor glucose levels, have made diabetes management simpler. Despite the high prevalence, self-monitoring of blood glucose (SMBG) remains low due to pain and inconvenience, often resulting in poor glycemic control and increased complications. CGM addresses these barriers by offering painless, real-time, and connected glucose tracking. Evidence shows CGM improves HbA1c, reduces hypoglycemia, and increases time-in-range, enabling proactive and personalised care. Roche Diabetes Care is transforming traditional SMBG from a mere measurement into a meaningful, proactive management tool through its connected ecosystem. Its strategy centres on the seamless integration of its highly accurate Accu-Chek blood glucose meters with the user-centric mySugr app. This integration is innovative because it addresses the critical challenge of manual data logging and analysis, making diabetes management less burdensome.  The mySugr app automatically captures blood glucose readings via wireless transfer, ensuring consistent and accurate data without the need for manual transcription, which significantly helps in improving patient adherence to testing protocols. The app acts as a smart logbook, allowing patients to easily record key factors like meals, activity, and insulin doses alongside their readings. It then generates visual trends, daily averages, and an estimated A1c, providing actionable insights that are far more effective for therapy adjustments than simple paper records. By easily generating detailed, organised digital reports, the system enables a more productive and focused dialogue between the patient and their healthcare professional (HCP), leading to truly personalised and timely care decisions. Vaibhav Kohli, Head- Marketing, Access and Commercial Excellence, Roche Diagnostics India & Neighbouring Markets mentions, "We recognise that successfully deploying digital glucose monitoring solutions in India requires overcoming specific local challenges. We are focussed on bridging the digital literacy and infrastructure gap. We are committed to investing in educational programmes and user-friendly interfaces to simplify the digital experience and ensure that the benefits of connected SMBG are realised, even in regions with lower digital fluency. We want to build stronger partnerships with healthcare professionals and diabetes educators to provide the necessary support and coaching, ensuring that the technology translates into improved clinical behaviour and, ultimately, better glycemic control." We have another product called Tracky, a healthtech brand by DrStore Healthcare Services, which was launched recently, is positioned as India’s first Bluetooth-enabled CGM. The device, according to the company, is all set to transform diabetes care and preventive health management. Equipped with real-time Bluetooth connectivity, Tracky enables automatic syncing with the Tracky Health App every three minutes. It is a scan free solution that delivers instant glucose readings and customizable alerts for high or low levels to empower each user to take timely action without manual intervention. It enhances convenience, accuracy, and consistency to make it easier to manage diabetes on the go. We have another company called BeatO, which aims to positively impact the lives of over one crore Indians living with diabetes by 2026. BeatO's ecosystem includes its innovative app that works with smart glucometers to provide personalised care insights and 24x7 access to an experienced team of medical experts - top diabetologists, health coaches, and nutritionists. In addition to the local firms, multinationals such as Abbott, Eli Lilly too are active in this field. Abbott has launched FreeStyle Libre 2 Plus sensor, its latest addition to the FreeStyle Libre sensor portfolio. The innovative device offers automatic glucose readings every minute straight to one’s phone, empowering people with diabetes to manage their condition with confidence, precision, and ease. The device offers 14 days of continuous glucose monitoring via a small sensor worn on the upper arm. It provides a comprehensive glucose profile through easy scanning, eliminating routine finger pricks. Studies show that FreeStyle Libre technology can help reduce low blood sugar episodes by up to 43 per cent, a 0.9 per cent to 1.5 per cent drop in HbA1c levels, and even cut hospital visits by 66 per cent. Libre technology has been shown to reduce cardiovascular complication risk by 78 per cent in people with Type 1 diabetes post-severe hypoglycemia, and lower hospitalisation risk for stroke and diabetes-related complications by 44 per cent in insulin-treated Type 2 diabetes. Eli Lilly has launched Mounjaro KwikPen to advance care for adults with Type 2 diabetes and obesity in India. Mounjaro KwikPen is a multi-dose, single-patient-use prefilled pen. Each pen contains four fixed doses, administered once weekly. The pen will be available in six dose strengths: 2.5 mg (Rs 14,000), 5 mg (Rs 17,500), 7.5 mg (Rs 22,000), 10 mg (Rs 22,000), 12.5 mg (Rs 27,500), and 15 mg (Rs 27,500), allowing healthcare professionals to personalise treatment plans to better suit individual patient needs. Dexcom, an American healthcare company that develops, manufactures, produces and distributes a line of CGM systems for diabetes management, opened operation in India last year in Bangalore and provides the G6 CGM System that sends real-time glucose readings automatically to a compatible smart device or Dexcom receiver. It features a 10-day sensor that is easy to use. The device gives the freedom to manage your diabetes with zero fingersticks or calibrations. Incorporated in 2019 by second time entrepreneurs Mohit Kumar and Vatsal Singhal, Ultrahuman, a Bengaluru-based longevity and health-monitoring platform that designs, manufactures and sells the Ultrahuman Ring Air health tracker, Ultrahuman M1 CGM, pre-release Ultrahuman Home health monitor and related blood testing services like blood vision, provides M1, which has been developed in collaboration with top metabolic health experts and athletes to accurately measure the metabolic performance using glucose as a biomarker. It helps to track glucose trends in real-time with an app. Actofit, a wearable technology company from Mumbai that offers a range of health and fitness products, including smartwatches, smart scales, and a CGM system called Pro Plus, provides continuous glucose monitoring, streams the data to the Actofit Health App in real time. The glucose biosensor helps to unlock key recovery and performance nutrition insights. The app provides data-backed nutrition planning. Medtronics, a global leader in medical technology, services, and solutions launched MiniMed 780G system in India in 2022, a closed-loop insulin pump system for the treatment of Type 1 diabetes in people aged seven to 80 years. The system automates the delivery of both basal insulin and correction boluses every five minutes to help people with diabetes avoid highs and lows with greater ease.  Trivitron, a medical technology company from Chennai providing affordable healthcare solutions offers NANO H5, a fully automated High Performance Liquid Chromatography (HPLC) analyser. It is compact, uses Ion exchange liquid chromatography for quantitative determination of the glycated hemoglobin (HbA1c) in human whole blood. The NANO H110 is a compact, automated HPLC analyzer with Hb variant detection. Circa Validio Blood Glucose Monitoring System by Eris Lifesciences helps to monitor the blood glucose level. The system can store up to 300 test results and comes with a large display. Biorad Medisys, a Pune-based medical device manufacturing company with a focus on orthopedic, neurovascular, and endoscopic solutions, provides automated HPLC systems, the D-10, for high-performance liquid chromatography. The method separates and quantifies different forms of haemoglobin, including HbA1c, to help monitor blood sugar control over time. The company also offers a range of human whole blood-based controls, including Liquichek and Lyphochek. These are used to assess the precision of haemoglobin testing and ensure the accuracy and reliability of diabetes diagnostic results in clinical labs. Besides, it also offers InteliQ. Research work Sun Life Global Solutions (SLGS), the Global Capability Centre of Sun Life— one of the leading international insurance and asset management companies, has announced a groundbreaking research collaboration with the Indian Institute of Technology Madras (IIT Madras) with an aim to ease the burden of diabetes in India. The joint initiative is focussed on transforming early diagnosis and management of type 2 diabetes through the identification of Pancreastatin as a novel biomarker, along with genetic testing. The research, led by Dr Nitish R Mahapatra, Professor, Department of Biotechnology and BJM School of Biosciences at IIT Madras, aims to establish Pancreastatin as a reliable early indicator for pre-diabetes—a crucial step in preventing disease progression. The study will also investigate 10–12 genetic markers that may help predict diabetes risk years in advance, even in children.  A research team at the National Institute of Technology (NIT) Rourkela has developed a new artificial intelligence (AI)-driven approach to improve blood sugar predictions for people with diabetes. The research presents a machine-learning model that enhances the accuracy of blood glucose level prediction, helping individuals and healthcare providers make better and personalised treatment decisions.  Challenges Despite a good future, various challenges are plaguing the diabetes device care market. The first and foremost being the high cost and affordability issues. Devices like pumps, insulin pens are costly, resulting in many shying away from purchasing the products. Says Dr Vivek Iyer, Head, Medical Affairs, Abbott’s Diabetes Care Division for South Asia, “While awareness of diabetes is growing and technology is advancing rapidly, one of the key challenges is the perception that tools like CGMs are only relevant for people living with Type 1 diabetes. In reality, CGMs offer significant benefits for all individuals living with diabetes, including those with Type 2. The market remains largely treatment-centric, with medication at the forefront, while monitoring tools are still underutilised. CGMs like FreeStyle Libre empower users with real-time insights that drive meaningful behaviour changes — from dietary choices to physical activity — leading to small wins that improve long-term outcomes. The opportunity lies in shifting from reactive care to proactive management, where consistent management becomes a cornerstone of a healthy and full life.” In another scenario, the rural hinterlands of India have seen minimal penetration of medical devices. This may be due to a lack of proper information about the disease, resulting in low purchases. In some instances, primary healthcare centres lack the basic infrastructure for storing these high-end gadgets. Regulatory issues, data privacy etc. are some of the other challenges. While policy frameworks like the Digital Personal Data Protection Act (DAPA Act), enacted in 2023, mark an important step toward strengthening India’s data governance, the legislation still lacks clear provisions to address the privacy and cybersecurity complexities unique to medical devices. As connected diabetic care increasingly relies on continuous data transmission, from wearable sensors and glucometers to cloud- based analytics platforms, the risks of data breaches, unauthorised access, and algorithmic misuse remain. Swati Mishra, Research Analyst, TechVision, Frost & Sullivan, mentions, “India does not have a dedicated regulatory body or harmonised framework to oversee digital health devices’ cybersecurity compliance, interoperability, and data ownership norms. In the context of the diabetes device market, this gap becomes particularly critical. To ensure long-term trust and scalability, India needs cross-sectoral regulatory coordination between the Ministry of Electronics & IT (MeitY), the Central Drugs Standard Control Organisation (CDSCO), and the National Health Authority (NHA) to establish unified guidelines for data protection, device certification, and cyber resilience in healthcare Internet-of-Things (IoT) and wearable technologies. Only through such integrated oversight can India balance innovation with accountability, ensuring that its digital health revolution, led by connected diabetes care, remains inclusive and secure.” Outlook Through 2030, the market's trajectory will be shaped by rising awareness around early detection and self-management, technological advancements, including AI-powered glucose monitoring and mobile health platforms and shifts in consumer behaviour, with increasing adoption of home-based care and digital therapeutics.   Sanjiv Das sanjiv.das@mmactiv.com ]]> https://biospectrumindia.com/features/93/26996/converging-medtech-with-affordability-in-2026.html https://biospectrumindia.com/features/93/26996/converging-medtech-with-affordability-in-2026.html Sun, 30 Nov 2025 00:00:00 +0530 According to a report launched at the 17th CII Global MedTech Summit 2025, MedTech manufacturing can take the leap towards being a ~$30 billion sector by FY2030, reduce import dependency to less than 50 per cent and increase India’s share to 10–12 per cent in the global market. The report also highlights the need to build an accessible innovation ecosystem through partnerships with global hospitals helping accelerate clinical validation for Indian MedTech innovations; and to facilitate global companies to set-up ‘Co-innovation labs’ within MedTech parks in India to accelerate technology transfer, and deepen product R&D. In other words, local innovation can be fostered by promoting in-house capabilities, strengthening industry-academia collaboration and building infrastructure for low-cost prototyping and trials. The growth of the Indian MedTech sector was also well noticed during the 11th APACMed MedTech Forum, held in September 2025 in Delhi, which was convened outside Singapore for the first time, thereby signalling India’s emergence as a critical player in the global MedTech ecosystem. While multiple initiatives are being taken by the government and the industry to strengthen the domestic MedTech sector, the entrepreneurial ecosystem is taking the lead with bold innovations and new risks. As of 2025, India has an estimated 900 to 1,000 startups specifically focused on medical devices and MedTech hardware. However, when we look at the broader MedTech and health-tech landscape, which includes digital health, diagnostics, connected devices, and AI-driven healthcare solutions, the number increases significantly to around 3,000 to 6,000 active startups.   New Trend Setters Gurugram-based startup SS Innovations International launched the world's first tele surgeon console. This revolutionary innovation in robotic technology marks a defining moment in the evolution of surgical care, enabling expert surgeons to operate remotely through a compact, self-contained robotic system, designed and manufactured entirely in India for the world. Simultaneously, Bengaluru-based startup Articulus Surgical is emerging as a trailblazer in the field of soft tissue robotic surgery. One of the most anticipated developments from Articulus Surgical is PULSAR, a fully robotic system designed for multi-port minimally invasive surgeries, slated for launch in 2026. “Advanced healthcare should not be a privilege reserved for a select few. By engineering a system that enables last-mile connectivity, we must ensure that patients across diverse geographies can benefit from safer, more precise, and less invasive surgical care resulting in shorter hospital stays and quicker recoveries”, pointed out Saurya Mishra, Founder and CEO of Articulus Surgical. Within the surgery space, another Bengaluru-based startup is making noise. HRS Navigation has developed India’s first navigation system that integrates seamlessly with existing operating room infrastructure, to make advanced surgical navigation accessible to every hospital and surgeon. The startup has recently raised funding worth $5 million for its global expansion. On the diagnostics front, 2025 witnessed the launch of India's first microRNA-based blood test for breast cancer screening, developed by a Hyderabad-based startup PrecisionRNA Biotech (Prerna). This medtech innovation is well aligned with the 2024 Nobel Prize in Medicine recognising the discovery of microRNAs and their role in gene regulation, highlighting their significance in modern diagnostics. Further, Delhi-based startup Maverick Simulation Solutions is currently addressing a major challenge facing the medtech sector i.e. skilled workforce. The company is investing more than Rs 50 crore to advance medical training simulators with the integration of artificial intelligence (AI), augmented and virtual reality-based technologies. The company aims to expand its R&D capabilities to meet the growing demand for hands-on training in medical, nursing, and paramedical education. Anuj Chahal, Founder & CEO of Maverick Simulation Solutions said, “The medtech ecosystem in India still lacks enough localised R&D for training tools. By investing in indigenous innovation, we’re trying to fill that void by building an ecosystem where institutions, clinicians, and engineers co-create solutions suited for our healthcare landscape. Historically, medical simulation-based education has been concentrated in metropolitan teaching hospitals due to the high cost of imported systems. But that dynamic is shifting. The availability of locally manufactured simulators has made skill labs viable for smaller and mid-tier institutions.” Leveraging AI capabilities, Bengaluru-based startup Bayosthiti AI, in partnership with Narayana Health, is building India's first AI-powered heart disease predictor that is something to look forward to in 2026. While startups are working hard towards developing innovative medical solutions, a big support is also being provided by the bioincubators. Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) has launched the first cohort of the C-CAMP Healthium Innovations Programme for Surgical Interventions and Medical Technologies, to foster deep-science innovations in digitally enabled medical technologies that are affordable, scalable and clinically impactful. Dr Taslimarif Saiyed, CEO and Director, C-CAMP, said, “India’s medtech ecosystem is at a critical juncture where innovation must be paired with affordability and scalability. We need to enable startups not only with resources and mentorship, but also with an ecosystem that can help them transform their technologies into solutions that impact lives at scale.” Alongside these exciting innovations, we must keep a tab on the bottlenecks that might slowdown the leadership pace of our medtech entrepreneurial ecosystem in 2026 and beyond.  For instance, many startups underestimate the time and cost required to meet quality standards such as ISO 13485 and generate clinical evidence. This often slows commercialisation and increases capital needs. Also, since successful adoption depends heavily on clinician trust and training, startups need to design intuitive systems and invest in user training programmes to ensure smooth integration. However, on the brighter side, the funding environment is increasingly disciplined as investors are now focusing on startups that have validated their technology, proven outcomes, and strong intellectual property. According to Dr Vishal Gandhi, Founder & CEO, BIORx Venture Advisors, “India’s MedTech revolution is taking shape at the intersection of affordable engineering, clinical validation, and manufacturing readiness. The startups that bring these elements together will scale the fastest and redefine how healthcare is delivered across the country. From an investment perspective, we are seeing selective funding at the seed stage but continued interest from later-stage investors and strategic partners. Companies that can show clinical validation, scalable manufacturing, and sound economics are likely to grow quickly.”   Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/93/27009/elekta-introduces-advanced-ai-enabled-ct-linac-in-india.html https://biospectrumindia.com/news/93/27009/elekta-introduces-advanced-ai-enabled-ct-linac-in-india.html Fri, 28 Nov 2025 00:00:00 +0530 In a country with over 1.4 million cases reported annually, with most being reported at later stages, adaptive radiotherapy (ART) is a major benefit to India’s ever-growing cancer burden. ART not only has the possibility to improve survival rates, but it also will enhance the overall quality of life for patients. It has become a critical tool for cancer treatment and management as it allows real-time precision therapy - making personalized treatment a reality. To further strengthen India’s fight against cancer, Elekta, a global leader in precision radiation therapy is introducing Elekta Evo, an advanced artificial intelligence (AI)-enabled CT-Linac (linear accelerator). This launch will be held during the Association of Radiation Oncologists of India conference (AROICON) at Biswa Bangla Convention Centre, Kolkata, from November 28-30, 2025. ART is a cutting-edge treatment approach that helps personalize each radiotherapy session based on real-time changes in a tumour’s characteristics and location. It ensures that the radiation dose is accurately delivered to the tumour, elevating both efficacy and safety. This in turn, offers greater control to the clinician and reduces potential side effects for the patient. ART’s potential to improve outcomes and quality of life is especially relevant in India, where head and neck cancers account for nearly 30 percent of all cases, while breast and cervical cancers remain the most common among women, and prostate cancer is the third most common among men. ]]> https://biospectrumindia.com/news/93/26991/lords-mark-india-acquires-85-holding-of-renalyx-health-systems.html https://biospectrumindia.com/news/93/26991/lords-mark-india-acquires-85-holding-of-renalyx-health-systems.html Wed, 26 Nov 2025 00:00:00 +0530 In a strategic move to strengthen its presence in the medical diagnostics segment, recently listed Mumbai based Lords Mark India has acquired 85% holding in Bengaluru based Renalyx Health Systems. By March 2026, the acquisition will reach 92% holding. The company will continue to operate as an independent business unit of Lords Mark India. The acquired company, Renalyx Health Systems is the developer of Renalyx, the world’s first AI powered – Made in India sustained low efficiency dialysis machine (SLED).  The product represents a significant step toward India’s vision of becoming a global MedTech manufacturing hub. RxT 21, is an AI powered and IoT-enabled smart hemodialysis machine, offering remote monitoring, clinical connectivity, real-time data access, supports telenephrology platforms and enhances patient safety and quality of care. Features of the ISO and CE certified machine includes integration with DNP database for seamless dialysis centre operations and cloud based patient EMR management, one touch operation for streamlined dialysis sessions, SLED mode for intensive care environments, personalised dialysis prescriptions, Kt/V monitoring for dialysis adequacy and clearance validation, single needle dialysis support, Endotoxin removal filter for patient safety, advanced sodium and ultrafiltration profiling. The dialysis machine will be manufactured in collaboration with Bharat Electronics. Lords Mark recently received its manufacturing license on in September 2025.   ]]> https://biospectrumindia.com/news/93/26948/healthium-medtech-signs-mou-with-andhra-pradesh-economic-development-board.html https://biospectrumindia.com/news/93/26948/healthium-medtech-signs-mou-with-andhra-pradesh-economic-development-board.html Wed, 19 Nov 2025 00:00:00 +0530 Bengaluru-based Healthium Medtech, a global medtech company with a growing portfolio across surgical, post-surgical, advanced wound care, arthroscopy and infection prevention, has announced a Memorandum of Understanding (MoU) with the Andhra Pradesh Economic Development Board (APEDB). Under this MoU, Healthium will set up Healthium Medtech Unit 2 across 5 acres in Sri City Industrial Park, Sri City with a planned investment of Rs 150 crore, to be made in two phases. The new unit marks an expansion of Healthium Medtech’s existing presence in Sri City, where the company commenced operations in 2012 at the SEZ (Special Economic Zone) facility. The current unit manufactures sutures and meshes and the addition of Unit 2 consolidates the company’s foothold in a region that has matured into a competitive hub for medtech manufacturing. The proposed facility is expected to create 300 direct jobs within the factory premises by 2027, covering both payroll and contract roles. In addition, around 100 indirect opportunities are likely to be generated through supply chain activities, logistics, services and ancillary units. This development coincides with India’s medtech market trajectory toward $30 billion by 2030, highlighting the growing demand for advanced manufacturing capacity and a skilled workforce to sustain sectoral growth. By creating new jobs and adding to its production footprint, the project is positioned to strengthen local workforce participation and open up long term career pathways in the State. The new unit will expand Healthium Medtech’s production capabilities across the surgical, post-surgical and chronic care segments.  Healthium Medtech’s decision to expand is a significant step in strengthening Andhra Pradesh’s medical devices value chain. By bringing new investment, specialised skills and supporting industries to the region, the partnership is poised to deliver sustained economic impact and advance the State’s industrial development agenda.  ]]> https://biospectrumindia.com/news/93/26940/bpl-medical-technologies-partners-with-alpinion-to-introduce-x-cube-50-ultrasound-system-in-india.html https://biospectrumindia.com/news/93/26940/bpl-medical-technologies-partners-with-alpinion-to-introduce-x-cube-50-ultrasound-system-in-india.html Tue, 18 Nov 2025 00:00:00 +0530 Bengaluru-based BPL Medical Technologies has partnered with Korea's ALPINION Medical Systems to bring the X CUBE 50 from Korea to the Indian Market. This new-generation ultrasound imaging system sets higher standards for diagnostic precision and workflow efficiency in Indian healthcare settings. In routine diagnostic practice, clinicians often struggle with uneven image quality, repeated manual adjustments and fatigue from managing heavy patient loads, which can slow down procedures and affect the consistency of results. To overcome these limitations, the X CUBE 50 is built on ALPINION’s X+ Architecture. It brings together refined beamforming, high-sensitivity transducer technology, and advanced image optimization to deliver uniform, high-contrast images that support accurate and confident diagnoses across a range of clinical needs. By simplifying frequent tasks and minimizing operator effort, the system helps doctors work faster and more efficiently, even in demanding clinical settings. With the launch of the X CUBE 50, BPL Medical Technologies strengthens its commitment to providing advanced, reliable, and accessible diagnostic solutions that enhance clinical outcomes and support the evolving needs of healthcare professionals across India. Engineered for speed, comfort, and accuracy, the X CUBE 50 features a compact ergonomic design, a 21.5 inch Full HD monitor, and a 12.1 inch intuitive touchscreen for smooth operation and clear visibility from multiple angles. Intelligent workflow tools such as X+ Assistant, Power Preset, and Xpeed streamline routine scanning and reduce examination time, while automated measurements like Auto Biometry, Auto IMT, and Auto EF deliver consistent and reproducible results. This joint venture, utilizing an integrated imaging technology platform developed by ALPINION and supported by BPL's reliable network of services and local experience, introduces a highly customisable, high-quality, and affordable ultrasound solution for medical practitioners in India, thereby enhancing BPL's mission to deliver quality diagnostics and patient-based care.     ]]> https://biospectrumindia.com/news/93/26926/zydus-amplitude-receives-ce-mark-for-robotic-surgical-system-andy.html https://biospectrumindia.com/news/93/26926/zydus-amplitude-receives-ce-mark-for-robotic-surgical-system-andy.html Thu, 13 Nov 2025 00:00:00 +0530 Amplitude Surgical, a wholly owned subsidiary of Zydus MedTech France SAS, a wholly owned subsidiary of Ahmedabad-based Zydus Lifesciences, has announced that its proprietary robotic surgical system “Andy” has received CE mark approval. This confirms its compliance with European standards for safety, performance, and quality and is a milestone in orthopaedic innovation. ‘Andy’ is built with its proprietary navigation platform, Amplivision. The CE-marked solution integrates Amplitude’s navigation technology with robotic assistance, developed through a strategic collaboration with eCential Robotics. The Andy robotic surgical system marks a significant advancement in orthopaedic surgery. Conceived as a true surgical partner, Andy is a collaborative robot built on proprietary technology capable of performing bone resections with precision and reliability. This innovation empowers surgeons with greater confidence in the operating room and sets a new benchmark for robot-assisted procedures across Europe.  Earlier this year, Zydus MedtTech expanded its global presence with the strategic acquisition of Amplitude Surgical a European MedTech company specializing in high-quality lower-limb orthopaedic technologies.  ]]> https://biospectrumindia.com/news/93/26914/medtech-startup-hrs-navigation-raises-5-m-to-accelerate-product-innovation.html https://biospectrumindia.com/news/93/26914/medtech-startup-hrs-navigation-raises-5-m-to-accelerate-product-innovation.html Wed, 12 Nov 2025 00:00:00 +0530 HRS Navigation, a fast-growing Indian medtech startup, has raised $5 million in a Pre-Series A funding round backed by GVFL, Physis Capital, Sathguru Catalysers, India EXIM Bank and KITVEN. Funds raised will be used to accelerate product innovation, global market expansion, enabling HRS to scale manufacturing and advance next-generation navigation. “Our mission is to make advanced surgical navigation accessible to every hospital and surgeon, so that patients across India and beyond can benefit from precision surgery,” said Arpit Paliwal, Founder and Director of HRS Navigation. “With this investment, we are not only strengthening our ability to innovate and expand internationally but also showcasing India’s capability to develop world-class medtech solutions.” Founded by Arpit Paliwal and Shweta Paliwal, Bengaluru-based HRS Navigation has rapidly emerged as India’s leading surgical navigation companies in a segment traditionally dominated by global MedTech giants. The company designs and manufactures cutting-edge surgical navigation systems — truly Made in India made for the world — that empower surgeons to perform complex cranial, spine & ENT surgeries with world class precision and reliability. At the heart of its innovation is the easyNav™ platform, India’s first navigation system that integrates seamlessly with existing operating room infrastructure. By enabling hospitals to adopt advanced navigation technology, easyNav™ has made surgical navigation accessible for both smaller & bigger hospitals. The platform has supported over 20,000 surgeries, helping surgeons perform procedures with enhanced accuracy and confidence.   ]]> https://biospectrumindia.com/news/93/26892/ss-innovations-international-announces-launch-of-worlds-first-tele-surgeon-console.html https://biospectrumindia.com/news/93/26892/ss-innovations-international-announces-launch-of-worlds-first-tele-surgeon-console.html Thu, 06 Nov 2025 00:00:00 +0530 Gurugram-based startup SS Innovations International, Inc., a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, has once again redefined the boundaries of innovation with the unveiling of the world’s first Tele Surgeon Console (TSC), SSII MantrAsana. MantrAsana, the world’s first fully integrated, ergonomic and portable telesurgery console for remote precision operations is here to revolutionize the global robotics, beyond geographies. It demonstrates how surgical expertise can now be extended from the office of any expert surgeon to a smaller design of the Tele Surgeon Console (TSC) thereby not tying up the entire operating room to have access to the surgeon console to perform telesurgery. This revolutionary innovation in robotic technology marks a defining moment in the evolution of surgical care, enabling expert surgeons to operate remotely through a compact, self-contained robotic system, designed and manufactured entirely in India for the world. Speaking on the launch, Dr Sudhir Srivastava, Founder and Chairman, SS Innovations International, said, “With the Tele Surgeon Console, we are taking a monumental step toward making advanced surgical care accessible to everyone. Through MantrAsana, TSC we are showcasing how Indian innovation can transform healthcare delivery by bringing the surgeon’s expertise directly to the patient regardless of geography. The smaller size of the console will literally allow surgeons to perform telesurgery from their offices. So now, one does not need to tie up the operating room or the entire Mantra system to perform telesurgery. There is a huge advantage because of the console’s smaller footprint, being a self-contained chair wherein all electronics are inbuilt into the chair. The surgeon wears very light weight glasses with a magnified 3D view and uses magnetic sensor-based controls to control the movements of the robotic system remotely. This should be looked at as an advancement whereby these smaller telesurgery units can be placed anywhere to extend the expertise.”  MantrAsana, TSC is designed for efficiency, comfort, and connectivity. Its compact ergonomic footprint allows it to be installed in a surgeon’s office, enabling remote procedures without occupying an operating theatre. Surgeons experience seamless precision through an advanced headset offering magnified 3D HD visualization, while maintaining the same accuracy and outcomes as conventional robotic surgery. The MantrAsana, TSC also supports global collaboration, mentorship, and upskilling of surgical teams, aligning perfectly with SS Innovations International’s vision to democratize robotic surgery and expand access to advanced medical technologies. MantrAsana, TSC is expected to be commercially available by December 2025 in India and followed by global footprints.   ]]> https://biospectrumindia.com/news/93/26872/inviga-healthcare-fund-acquires-21-stake-in-forus-health.html https://biospectrumindia.com/news/93/26872/inviga-healthcare-fund-acquires-21-stake-in-forus-health.html Mon, 03 Nov 2025 00:00:00 +0530 Inviga Healthcare Fund (IHF), the private equity platform founded by Dr. B. S. Ajaikumar of HCG, has acquired a 21% stake in Bengaluru-based Forus Health, an ophthalmic diagnostics pioneer whose devices have screened over 22 million patients across 75+ countries. Forus Health’s comprehensive digital platform integrated with artificial intelligence (AI) for Ocular & Oculomics has helped deliver last mile comprehensive eye diagnostics to over 5M+ patients across the world. The secondary transaction signals Inviga’s intent to back world-class, AI-driven diagnostic solutions designed and built in India, and deployed globally at scale. This marks Inviga’s second major investment following its backing of Mynvax in 2024. Founded by Dr. B. S. Ajaikumar, a doctor-preneur and Chairman of HealthCare Global Enterprises (HCG), Inviga Healthcare Fund invests in high-impact healthcare ventures and champions Indian healthcare entrepreneurial talent. Its mission is to build sustainable, accessible, and outcome-driven healthcare platforms that blend clinical excellence with scalable innovation. Forus Health is founded by K. Chandrasekhar, an industry veteran with exceptional experience in health-tech & semiconductor industries. The company is best known worldwide for its 3nethra series of ophthalmic screening devices that have improved access to affordable eye care across the world. In 2025, Forus Health was listed among TIME Magazine’s World’s Top 400 HealthTech Companies for its significant impact on making vision care more widely accessible through technology. The Forus platform now offers an integrated digital solution for managing comprehensive eye health. Its latest product, 3nethra specto, is the world’s first wearable digital refractor controlled by a smartphone, enabling remote and tele-optometry services. The global burden of preventable blindness underscores the importance of scalable eye-care innovation. It is estimated that over 270 million Indians live with some form of visual impairment, a majority of which is preventable through early detection. With around 100 million diabetics, nearly one in five are at risk of diabetic retinopathy (DR), while 3.5 million preterm births annually place nearly 2 million infants at risk of retinopathy of prematurity (ROP)—both leading causes of avoidable blindness. Globally, over 2.2 billion people suffer from vision impairment or blindness, of which more than 1 billion cases are preventable or treatable. The challenge extends even to high-income countries, where aging populations and diabetes continue to drive incidence despite advanced health systems. Forus Health’s advancements have helped bridge these diagnostic gaps worldwide, improving access to affordable, portable, and early-stage eye screening solutions across both emerging and developed markets.   ]]> https://biospectrumindia.com/news/93/26842/philips-and-nicolab-collaborate-to-advance-stroke-care-in-india.html https://biospectrumindia.com/news/93/26842/philips-and-nicolab-collaborate-to-advance-stroke-care-in-india.html Tue, 28 Oct 2025 00:00:00 +0530 Dutch firm Philips, a global leader in health technology, is expanding its collaboration with Nicolab, The Netherlands-based company pioneering in artificial intelligence (AI)-powered stroke care, to advance stroke care in India. This expansion into India represents an important milestone in addressing one of the country’s most pressing healthcare challenges by combining Philips’ world-class imaging expertise with Nicolab’s advanced platform, StrokeViewer AI. With nearly 1.8 million new cases each year, stroke has become a leading cause of disability and mortality in India, creating an urgent need for models of care that deliver speed, precision and access. Timely diagnosis and intervention are critical, yet many patients continue to face delays in accessing specialist treatment. Through this collaboration, Philips and Nicolab aim to strengthen clinical workflows, support faster decision-making and improve access to life-saving stroke treatment. StrokeViewer, the first cloud-based solution in India to receive regulatory clearance for CT Perfusion (CTP) analysis provides instant AI-generated imaging results, centralised patient information and seamless communication between specialists. Integrated with Philips’ advanced image-guide therapy platform Azurion, the combined solution is designed to help clinicians deliver more efficient and effective stroke care. Azurion brings together real-time high-resolution imaging, advanced navigation tools, and seamless integration of advanced AI solutions such as Nicolab’s StrokeViewer to empower clinicians to act faster and more precisely. For example, physicians can review all relevant DICOM scans and AI results directly on Azurion, to determine eligibility for interventional treatment. The 3D planning view enables the interventional team to determine the best access route and viewing angles before the patient enters the interventional suite.  Nicolab’s StrokeViewer applies advanced AI to analyse multiple stroke imaging biomarkers, supporting faster and more confident diagnosis. Stroke teams can then collaborate seamlessly by securely sharing images and patient details through a DICOM viewer that is certified for diagnostic use on both mobile and desktop. This diagnostic-grade capability ensures that each patient gets the best possible chance of recovery – as every second matters. Philips is working closely with a global network of hospitals, research institutions, and technology partners such as Nicolab—alongside its strategic collaboration with the World Stroke Organization (WSO)—to advance the diagnosis and treatment of stroke. ]]> https://biospectrumindia.com/news/93/26832/anrf-in-collaboration-with-icmr-and-gates-foundation-launches-maha-medtech-mission.html https://biospectrumindia.com/news/93/26832/anrf-in-collaboration-with-icmr-and-gates-foundation-launches-maha-medtech-mission.html Sat, 25 Oct 2025 00:00:00 +0530 Anusandhan National Research Foundation (ANRF), in collaboration with the Indian Council of Medical Research (ICMR) and the Gates Foundation, has launched the Mission for Advancement in High-Impact Areas (MAHA)-Medical Technology (महा MedTech). This landmark initiative aims to accelerate innovation in India’s medical technology sector, reduce reliance on high-cost imports, and promote equitable access to affordable and high-quality medical technologies. The Mission will provide funding support to a wide range of entities including Academic and R&D institutions, Hospitals, Startups, MSMEs, MedTech industry and collaborations between entities. With milestone-linked funding of Rs 5–25 crore per project (and up to Rs 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market. Key objectives Drive public health impact by supporting technologies that address priority disease areas and expand access to safe, high-quality care; Ensure affordability and accessibility by supporting solutions that reduce costs; and Enhance self-reliance and competitiveness by catalyzing indigenous MedTech development, manufacturing, and industry–academia collaboration. Scope of the Mission The scheme will cover a broad spectrum of innovative medical devices and in-vitro diagnostics, including equipment and key subcomponents, implants, assistive and surgical devices, consumables, and software-based medical solutions. This may include (but is not limited to) advanced diagnostic imaging, minimally invasive technologies, point of care molecular diagnostics, AI/ML-enabled platforms, robotics and other emerging areas. The mission welcomes projects aligned with national health priorities such as tuberculosis, cancer, neonatal care, primary health care, etc. In addition to funding, the Mission will provide enabling support through national initiatives such as Patent Mitra (IP protection and technology transfer), MedTech Mitra (regulatory guidance and clearances), a Clinical Trial Network (for clinical validation and evidence generation), as well as mentorship from industry experts. The Mission will follow a two-stage application process: Concept Notes: Open from 15 September to 7 November 2025, to screen and prioritize projects. Applications will be accepted through the ANRF portal: www.anrfonline.in Full Proposals: The concept proposals that are shortlisted by the committee formed specifically for this purpose will be allowed to submit the full proposals. The window for submission will open in December 2025. ]]> https://biospectrumindia.com/news/93/26830/amtz-announces-new-initiatives-to-strengthen-medtech-innovation.html https://biospectrumindia.com/news/93/26830/amtz-announces-new-initiatives-to-strengthen-medtech-innovation.html Fri, 24 Oct 2025 00:00:00 +0530 Commemorating the birth anniversary of Dr A.P.J. Abdul Kalam, the Andhra Pradesh MedTech Zone (AMTZ) and its research arm, the Kalam Institute of Health Technology (KIHT), have undertaken two new pioneering initiatives that mark a significant stride in India’s MedTech innovation journey. SVL Bioscience, a startup within AMTZ, has inaugurated its state-of-the-art clean-room facility for the manufacturing of rapid diagnostic kits for dengue, with plans to expand production to cover a wider range of parameters — a move set to revolutionise affordable and rapid diagnostics in India. Additionally, AMTZ has initiated a Thermoforming Technology Centre, designed to provide large enclosures and custom components for medical device manufacturers, further strengthening India’s precision manufacturing ecosystem.   “We are in the process of enabling a MedTech Capital Fund to support growth-stage MedTech companies and take them towards IPO-readiness. In addition, AMTZ has acquired a World Trade Center (WTC) license, making it the only cluster in India — and the only one globally — to host both a WHO Collaborating Centre and a World Trade Center. This connects us to 392 WTCs across more than 100 countries, expanding India’s MedTech reach through global trade linkages. The aim is clear — to turn scientific success into commercial success,” said Dr Jitendra Sharma, Founder CEO and Managing Director, AMTZ, and Founder Executive Director of Kalam Institute. Since its inception in 2017, KIHT, an initiative of the Union Government’s Department of Biotechnology, has evolved into a national catalyst for indigenous R&D, evidence-based policy, and affordable innovation in healthcare technology. It has supported the development of over 100 medical technology products and continues to build a robust scientific and commercial ecosystem.   As the scientific ecosystem matures, KIHT and AMTZ are now deepening their focus on commercialization and scale-up. Around 160 companies currently operate within AMTZ, including nearly 30 foreign entities, making it one of the most vibrant and diversified MedTech manufacturing clusters in Asia. This synergy is yielding tangible global impact.   ]]> https://biospectrumindia.com/news/93/26824/remidio-secures-ce-marking-for-dual-offline-ophthalmic-ai-devices.html https://biospectrumindia.com/news/93/26824/remidio-secures-ce-marking-for-dual-offline-ophthalmic-ai-devices.html Thu, 23 Oct 2025 00:00:00 +0530 Remidio Innovative Solutions, a Bengaluru based med-tech innovator, has announced that its Medios HI Glaucoma AI and Medios HI DR AI have received CE Marking as Class II Software as a Medical Device (SaMD) under the EU Medical Device Regulation (MDR). The CE Approval marks a major milestone for Remidio, validating its  offline AI that can simultaneously detect diabetic retinopathy and glaucoma from a single retinal image. Delivering results in under 10 seconds without internet connectivity or cloud inferencing. With this achievement, Remidio strengthens its position as India’s only CDSCO-approved ophthalmic AI company and a leader in making advanced eye screening more accessible and affordable. As the burden grows, a shortage of specialists limits timely screening. For the first time, a powerful offline AI-based tool can help bridge this gap bringing early detection to the point of care and protecting millions from avoidable vision loss.   Remidio’s Medios HI Glaucoma AI goes beyond traditional screening methods. Instead of relying solely on the cup-to-disc ratio, it analyzes structural changes in the optic nerve head and retinal nerve fiber layer, similar to assessments done by specialists using high-end imaging tools. The AI also uses Class Activation Maps (CAMs) to highlight regions of interest, helping doctors quickly identify potential signs of glaucoma. To ensure its accuracy for global use, the AI was validated on over 100,000 real-world images, including data from diverse populations across India and Europe.   ]]> https://biospectrumindia.com/news/93/26820/icici-bank-pledges-rs-625-cr-to-set-up-radiation-therapy-facilities-at-tata-memorial-centre-navi-mumbai.html https://biospectrumindia.com/news/93/26820/icici-bank-pledges-rs-625-cr-to-set-up-radiation-therapy-facilities-at-tata-memorial-centre-navi-mumbai.html Sun, 19 Oct 2025 00:00:00 +0530 ICICI Bank, along with Tata Memorial Centre (TMC), has announced the commencement of construction of a new cancer care building at TMC’s Advanced Centre for Treatment, Research & Education in Cancer in Navi Mumbai, Maharashtra. Funded through the Bank’s CSR contribution of Rs 625 crore, the facility will be among India’s largest radiation therapy centres, equipped with cutting-edge cancer treatment technologies. This is part of the Bank’s larger commitment of Rs 1,800 crore to TMC for setting up of three state-of-the-art cancer care buildings, one each at Navi Mumbai in Maharashtra, Mullanpur (New Chandigarh) in Punjab and Visakhapatnam in Andhra Pradesh. The 11-storey building with a ground floor and two basements will span across 3.4 lakh square feet. It will house 12 state-of-the-art Linear Accelerators (LINACs), and other advanced cancer care equipment. LINACs deliver precise radiation to cancer cells thereby minimising damage to surrounding healthy tissues. The ‘ICICI Foundation Block for Radiation Oncology’ will serve 7,200 patients with radiation therapies annually, offering over two lakh radiation sessions to these patients. In addition, the block will provide OPD consultations and diagnostics to 25,000 new patients a year. It is expected to be completed by 2027. ICICI Foundation for Inclusive Growth, the CSR arm of ICICI Bank, will oversee its implementation.                                                                                                                       ]]> https://biospectrumindia.com/news/93/26821/biorad-medisys-accelerates-vascular-and-stroke-care-through-new-partnerships-and-technology.html https://biospectrumindia.com/news/93/26821/biorad-medisys-accelerates-vascular-and-stroke-care-through-new-partnerships-and-technology.html Sun, 19 Oct 2025 00:00:00 +0530 Pune-based Biorad Medisys has outlined a series of product development initiatives and investments in the neurovascular and peripheral vascular markets.  Biorad has invested in Frid Mind Technologies (FMT), a Belgium-based company founded by Noureddine Frid. FMT has developed a patented stroke-prevention product using advanced braiding technology. The technology has completed preclinical trials and two first-in-human cases with positive long-term follow-up.  In addition, Biorad has acquired 10 % stake in Motion Informatics (formerly Stroke Rehab), an Israel-based company specialising in stroke rehabilitation solutions. Motion Informatics manufactures and markets the US FDA-approved Stimel-03 device, which integrates NMES, FES, and Biofeedback technologies to support patient rehabilitation. Biorad also holds manufacturing and distribution rights for the device in select geographies, including India and the United States.  Commenting on these initiatives, Mr. J. M. Hegde, Managing Director, Biorad Medisys, said, “Our collaborations with FMT and Motion Informatics, together with our work in advanced braiding technologies, reflect our ongoing efforts in the field of vascular and stroke care.”  ]]> https://biospectrumindia.com/news/93/26809/healthium-medtech-strengthens-cardiac-care-portfolio-through-partnership-with-tisgenx.html https://biospectrumindia.com/news/93/26809/healthium-medtech-strengthens-cardiac-care-portfolio-through-partnership-with-tisgenx.html Wed, 15 Oct 2025 00:00:00 +0530 Bengaluru-based Healthium Medtech, a global medtech company with a growing portfolio across surgical, post-surgical, advanced wound care, arthroscopy and infection prevention, has announced an exclusive partnership with US-based Tisgenx, Inc., the world’s leading manufacturer of bovine pericardial tissue patches. These patches, widely used in valve repair, vessel reconstruction and other complex cardiovascular and soft tissue interventions, are now made available to Indian surgeons through this collaboration. Under this agreement, Healthium has secured exclusive multiple rights to distribute Tisgenx’s products in India. By expanding access to proven cardiac solutions, this partnership strengthens Healthium’s position in the cardiac care segment and reinforces its commitment to innovation-led, specialty-driven offerings. Known for their superior quality and reliability, the addition of Tisgenx’s pericardial tissue patches also aligns with Healthium’s focus on delivering high-performance, surgeon-centric innovations that simplify clinical decisions and support better healthcare outcomes. Anish Bafna, CEO & MD of Healthium Medtech, said that the collaboration enhances the company’s cardiac care offerings and reinforces its commitment to providing high-quality, best-in-class products that resonate well with Indian surgeons. “We are proud to bring Tisgenx’s globally respected pericardial tissue patches to India through this exclusive partnership. As a homegrown medtech company, we remain focused on providing solutions that address the evolving needs of Indian surgeons and support them in their effort to deliver the best care for their patients,” he commented. Kris Kupumbati, CEO & President of Tisgenx, Inc., noted that India is a strategic market for the company and expressed confidence in Healthium’s ability to deliver clinical value. "India represents one of the fastest-growing healthcare markets in the world and this exclusive partnership with Healthium allows us to play a meaningful role in advancing cardiac care here,” he said, adding, “Together, we are strengthening local access to global innovation and reinforcing our shared commitment to surgeon-centric, patient-first solutions." ]]> https://biospectrumindia.com/news/93/26792/cdsco-approves-xstep-device-for-treatment-of-paralysis-in-india.html https://biospectrumindia.com/news/93/26792/cdsco-approves-xstep-device-for-treatment-of-paralysis-in-india.html Fri, 10 Oct 2025 00:00:00 +0530 VIVATRONIX Tech and SpineX Inc. have announced that the Central Drugs Standard Control Organization (CDSCO) has approved xStep (powered by SpineX) for clinical and home use in India. The xStep device delivers painless, noninvasive electrical stimulation to the spinal cord—without the need for surgery—to help restore motor function, mobility, and independence in individuals living with paralysis. Formerly known as SCiP™ or SCONE™, the xStep technology has been recognised by the US Food and Drug Administration (FDA) as a Breakthrough Device for two distinct indications. It has demonstrated promising results in multiple global clinical trials, and SpineX continues to collaborate on investigator-initiated studies validating the safety, efficacy, and transformative potential of noninvasive spinal neuromodulation therapy. With CDSCO approval, SpineX Inc. and VIVATRONIX Tech are poised to expand access to advanced neurorehabilitation technology in India and worldwide—marking a major step toward transforming the standard of care for individuals living with paralysis. ]]> https://biospectrumindia.com/news/93/26791/motorica-launches-digital-prosthetics-programme-in-india-.html https://biospectrumindia.com/news/93/26791/motorica-launches-digital-prosthetics-programme-in-india-.html Thu, 09 Oct 2025 00:00:00 +0530 Motorica, a global medtech company specialising in assistive technologies and medical cybernetics, has officially launched its Digital Prosthetics Programme in India, marking a significant step toward transforming the production and accessibility of prosthetic solutions in the country. Through this initiative, Motorica leverages 3D scanning, digital modeling, and 3D printing to deliver highly customized mechanical prosthetic arms with unmatched speed and precision. By creating a digital 3D model of the user’s arm, the need for shipping physical molds is eliminated, significantly accelerating production. The final stages of design, printing, and assembly are completed at Motorica’s advanced manufacturing facility in Moscow, Russia ensuring consistent quality. This approach replaces traditional plaster molds with accurate digital data, allowing engineers to refine designs seamlessly using specialised software. Unlike conventional methods that require extensive manual adjustments, digital modeling minimises logistical delays while maintaining the highest standards of accuracy and flexibility. Motorica has already completed its first successful digital prosthetics cases in India, demonstrating the programme’s real-world impact. To capture the user’s hand geometry, the company utilised photogrammetry, a technique that reconstructs a 3D model from a series of photographs taken with a standard smartphone. This approach eliminates the need for costly scanning equipment, making the process more inclusive and accessible. In these initial cases, partner clinics in India provided photographs of the user’s limb, while Motorica’s engineering team generated the digital model and assembled the prosthesis in record time. ]]> https://biospectrumindia.com/news/93/26739/next-generation-leadless-pacemakers-revolutionising-treatment-of-abnormal-heart-rhythms.html https://biospectrumindia.com/news/93/26739/next-generation-leadless-pacemakers-revolutionising-treatment-of-abnormal-heart-rhythms.html Fri, 26 Sep 2025 00:00:00 +0530 As we celebrate World Heart Day on 29 September, we can't help noticing small devices powering the human heart to beat steadily. This next-gen cardiovascular technology, a leadless pacemaker, is designed to manage irregular heart rhythms or arrhythmias. Arrhythmias occur when the heart beats too fast, too slowly, or irregularly. If left untreated, they can lead to serious complications for patients, even becoming life-threatening. One common type is bradycardia, where the heart beats too slowly to meet the body’s needs.   “Leadless pacemakers have been developed to make both implantation and retrieval as smooth as possible for physicians, while offering meaningful improvements over existing technologies," said Ajay Singh Chauhan, General Manager for Cardiac Rhythm Management, Abbott in India, Southeast Asia, Hong Kong, Taiwan, and Korea. “This is really life-changing for patients, opening up new possibilities for managing their heart rhythm issues.”   Latest-generation leadless pacemakers help manage this condition effectively and efficiently. These pacemakers are miniaturised, minimally invasive and retrievable.   Breaking down what a ‘pacemaker’ means   A pacemaker is a medical device that helps regulate the heartbeat. Traditional pacemakers are implanted just beneath a person's skin near the collarbone and connected to the heart with wires (called leads). These wires deliver electrical signals to help the heart beat at a normal rate, relieving symptoms like chest pain, fatigue, palpitations, and discomfort.   While traditional pacemakers require a chest incision, leadless pacemakers are inserted into the heart using a catheter (tube). The new generation pacemakers are designed to provide electrical mapping prior to fixation thus empowering surgeons with a clear picture of the patient’s anatomy which enables them to implant the device with precision. During catheter insertion, the pacemaker is covered with a protective sleeve that makes navigation through blood vessels smoother and reduces the risk of injury.   Understanding the cutting-edge technology   While technology has made pacemakers smaller and sleeker, it has also helped address critical limitations of traditional systems such as elimination of chest pockets and wires, where infections, wire displacement and fractures can happen. These issues can lead to serious cardiac issues and often require surgical intervention. Newer advancements help overcome these pitfalls, as cardiovascular innovations have made cutting-edge leadless pacemakers possible.   “Every year, thousands of patients require pacemaker implantations. This surgery also involves some potential complications, or visible scarring,” said Dr Sanjeevkumar Kalkekar, MD (General Medicine), DNB (Cardiology), Interventional Cardiologist, Apollo Hospitals, CBD Belapur, Mumbai. “Leadless pacemakers represent a meaningful advancement in cardiac care. They’re minimally invasive, cosmetically invisible, and significantly reduce post-procedure complications.”   “This technology supports a more natural heartbeat, helping improve patient outcomes. It also, minimizes the chances of infection and lead-related issues, and reduces the need for reintervention. Designed for accurate placement and therapy flexibility, some leadless pacemakers offer customised solutions for each patient.”   Powered to be seamless   The biggest benefit is that the patients’ recovery time is reduced significantly. They can return home and resume their daily routine with fewer restrictions. The pacemaker becomes a part of the heart seamlessly as it leaves no visible signs like scars or bulge.   Dr Sanjeevkumar Kalkekar further explains, “The ability to implant a pacemaker via a minimally invasive procedure means shorter hospital stays and quicker recovery times for patients. In India, this technology is a breakthrough, especially in Tier 2 and Tier 3 cities where access to follow-up care can be limited. By removing some of the complexities of traditional systems, leadless pacemakers provide both safety and convenience, aligning perfectly with the evolving needs of our healthcare ecosystem.”   A new standard in heart care   What sets the leadless pacemaker apart is its ability to deliver safe and effective therapy while adapting to the changing needs of patients. As heart care evolves, this technology is setting a new standard – one that’s smarter, more seamless and built to keep pace with life itself. ]]> https://biospectrumindia.com/news/93/26733/nit-rourkela-develops-cost-effective-device-for-gait-profiling.html https://biospectrumindia.com/news/93/26733/nit-rourkela-develops-cost-effective-device-for-gait-profiling.html Thu, 25 Sep 2025 00:00:00 +0530 Researchers at the National Institute of Technology (NIT) Rourkela have uncovered new insights in developing low-cost indigenous force plate for measuring the multi-axial ground reaction forces (GRF). The GRF measured from the force plates will be useful to diagnose the abnormal gait patterns. This device will also be useful in sports academics, educational institutes, hospitals and rehabilitation centres in India as it is affordable compared to the existing foreign suppliers. The research team used the indigenously developed force plate along with the motion capture system to evaluate the heel pad stiffness in a non-invasive technique. By studying how the heel pad, the natural cushion of the foot, behaves in people with different body weights, the team has taken a step closer to developing better footwear and treatment strategies to reduce heel pain.  Speaking about the findings of the research, Prof. A. Thirugnanam, Department of Biotechnology and Medical Engineering said, “Most neuromuscular disorders will affect the gait pattern of an individual. Since, gait requires precise coordination of muscle strength and balance, disturbances in any of these can alter the walking pattern and the corresponding GRF. Some common neuromuscular diseases like myopathies, peripheral neuropathies, neuromuscular junction disorders, spasticity, ataxia, Parkinson’s disease, cerebral palsy, etc., can alter the GRF. These abnormalities in GRF can be diagnosed using the force plate. The device can also be used in designing orthotics, prosthetics, and insole design in the shoe manufacturing industry. The indigenous force plate designed and developed by our team can be supplied at a reasonable cost, making it affordable to all sports academies, healthcare sectors, and academic institutes across India.” Force plates are globally recognised as essential diagnostic tools for analysing human musculoskeletal health. Due to high costs and the lack of Indian manufacturers, its availability in India remains limited. The new device from NIT Rourkela can be supplied at one-fourth the price of international systems, making it an affordable alternative. The project received funding from the Department of Science and Technology (DST) under the Biomedical Device and Technology Development (BDTD) scheme. The industrial partner, N K Instruments, Kolkata, contributed to the fabrication. The innovation is being commercialised through the startup KineUtkal Private Limited, incubated at Foundation for Technology & Business Incubation (FTBI), NIT Rourkela.  ]]> https://biospectrumindia.com/news/93/26725/poly-medicure-announces-acquisition-of-citieffe-group-for-rs-324-cr.html https://biospectrumindia.com/news/93/26725/poly-medicure-announces-acquisition-of-citieffe-group-for-rs-324-cr.html Wed, 24 Sep 2025 00:00:00 +0530 Delhi-based medtech firm Poly Medicure has announced signing of definitive agreement to acquire 100% stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 Million). Citieffe is an Italy based manufacturer specialising in the orthopaedic trauma and extremities segment with a direct presence in Italy, USA, and Mexico, and distribution across 25+ countries. The company generated revenue of EUR 17.3 million and EBITDA of EUR 3.1 million in CY 2024, reflecting year-on-year growth of 15% and 14% respectively.  This strategic acquisition provides Poly Medicure with an entry point into the large global orthopaedics market, particularly in the trauma and extremities segment, which is the fastest growing and most resilient category within orthopaedics. Strategic rationale for acquisition provides platform for expanding into attractive orthopaedics segment specifically focused in the fastest-growing extremities sub-segment; platform to build a global orthopedic business. Commenting on the acquisition, Himanshu Baid, Managing Director, Poly Medicure Limited stated, "This acquisition marks another step in our journey to become a comprehensive healthcare solutions provider. Citieffe’s strong R&D capabilities and diverse trauma & extremity portfolio aligns with our mission to deliver innovative, patient-centric technologies. Together, we will be able to accelerate the expansion into orthopaedics adjacencies and expand reach to more patients globally. Citieffe has direct sales operations in the U.S., Italy, and Mexico providing us a deeper foothold in these key markets. We see synergies in combining Citieffe’s innovation pipeline with Polymed’s manufacturing scale and commercial reach—this is about creating long-term value for healthcare providers, patients, and our stakeholders."   ]]> https://biospectrumindia.com/news/93/26697/max-healthcare-partners-with-medtronic-to-launch-state-of-the-art-surgical-skill-lab-in-delhi.html https://biospectrumindia.com/news/93/26697/max-healthcare-partners-with-medtronic-to-launch-state-of-the-art-surgical-skill-lab-in-delhi.html Thu, 18 Sep 2025 00:00:00 +0530 Max Healthcare, one of the largest private sector healthcare services companies in India, and Medtronic, a global leader in healthcare technology, have announced the inauguration of the Max-Medtronic Skill Lab at Max Super Specialty Hospital, Saket, New Delhi. The facility is designed to advance training in minimally invasive surgical techniques and marks a significant step in their shared commitment to clinical excellence and education. This strategic collaboration aims to advance medical education and clinical training in laparoscopic and minimally invasive surgical techniques. In addition to training, Max-Medtronic Skill Lab will also prioritise educating patients and caregivers about the benefits of these advanced minimally invasive procedures, such as faster recovery, smaller incisions, reduced infection risk, and less tissue trauma compared to traditional surgeries. The lab will offer comprehensive, structured training modules for a wide range of medical professionals including surgeons, nurses, OT technicians, and paramedics, ranging from hands-on workshops to advanced upskilling sessions. Spearheaded by Max Healthcare’s experienced in-house faculty and facilitated by Medtronic, these programmes aim to provide a robust, practical, and impactful learning experience for all medical professionals. As part of this collaboration, both partners will also focus on regular upskilling programmes for paramedical staff, an often overlooked yet critical component of the surgical care team. The Max-Medtronic Skill Lab is set to become a benchmark in clinical education and innovation, aligning with the Government’s vision for a skilled and empowered healthcare workforce.    ]]> https://biospectrumindia.com/news/93/26690/11th-apacmed-medtech-forum-fuels-indias-rise-as-global-innovation-and-medtech-hub.html https://biospectrumindia.com/news/93/26690/11th-apacmed-medtech-forum-fuels-indias-rise-as-global-innovation-and-medtech-hub.html Tue, 16 Sep 2025 00:00:00 +0530 The 11th APACMed MedTech Forum (MTF), Asia’s most influential gathering of MedTech leaders, is being held on Sept 16 and 17, 2025 in New Delhi. Marking a defining moment for India’s healthcare and innovation landscape, it was organised by the Asia Pacific Medical Technology Association (APACMed). The two-day forum brought together over 500 participants, including senior government officials, global CEOs, regulators, and innovators, to position India as a global hub for MedTech innovation, manufacturing, and regulatory excellence. Themed “Swastha Bharat – A Healthier India, Together,” the event aligned with India’s vision of Viksit Bharat 2047 and Healthcare Vision 2030, the event marked the presence of the titans of the industry, as well as key legislators and policy makers of the country. The forum witnessed resolute participation from key government leaders, including JP Nadda, Union Minister of Health & Family Welfare; Anupriya Patel, Minister of State, Ministry of Health and Family Welfare and Ministry of Chemicals; Dr V K Paul - Member - Niti Aayog graded the inaugural session. Amit Agrawal, Secretary, Department of Pharmaceuticals; BVR Subramanyam - CEO Niti Aayog; Dr Rajiv Bahl, Secretary, Department of Health Research & DG, ICMR; Parvinder Maini, Scientific Secretary - PSA. Nadda remarked, “The MedTech sector is one of the key pillars of health transformation - whether through diagnostics, advanced devices, digital health or AI driven solutions - MedTech has the power to make healthcare more accessible, efficient and affordable for all citizens. The MedTech Forum 2025 is closely aligned with Prime Minister Narendra Modi's vision for Viksit Bharat 2047.” Global MedTech leaders, including Kevin Lobo (Chairman & CEO, Stryker), Gary S. Guthart (CEO, Intuitive Surgical), and Katarzyna Mazur-Hofsäß (CEO, Fresenius Medical Care), emphasised India’s strategic importance as a priority market for innovation and investment. Discussions explored India’s evolution from a cost-effective manufacturing hub to a global leader in high-value innovation, supported by its vibrant startup ecosystem, advanced R&D capabilities, and robust talent pool.  A key highlight was the Regulators Forum, which convened leaders from across the Asia Pacific to discuss how regulatory agility can drive innovation in emerging technologies like AI, digital health, and personalized medicine. Leadership dialogues also focused on India’s transition from import dependency to self-reliance, with discussions on scaling advanced manufacturing, fostering innovation, and ensuring equitable access to healthcare technologies. The forum underscored India’s ambition to achieve a $50 billion MedTech market by 2030, driven by initiatives like the National Medical Device Policy and Production Linked Incentive schemes. ]]> https://biospectrumindia.com/news/93/26684/bpl-medical-technologies-unveils-next-gen-ot-charting-software-to-enhance-surgical-workflows.html https://biospectrumindia.com/news/93/26684/bpl-medical-technologies-unveils-next-gen-ot-charting-software-to-enhance-surgical-workflows.html Mon, 15 Sep 2025 00:00:00 +0530 BPL Medical Technologies, India’s leading medical equipment brand with a 50-year-old legacy of the BPL Group, has announced the launch of its first OT charting software application called “BPL iCare OT” to enhance surgical workflows, efficiency, and safety in operating theatres. This next-gen digital OT software is set to transform surgical care by streamlining documentation, reducing manual intervention, and enabling data-driven decisions. BPL iCare OT marks a significant step in BPL Medical Technologies’ digital healthcare journey, bringing advanced technology to the core of surgical care. By integrating digital intelligence into the operation theatre, the solution enables seamless data management, supports clinical decision-making, and enhances efficiency for surgical teams. The platform integrates seamlessly with anaesthesia workstations and connected monitoring devices to digitally capture patient vitals, medications, fluids, and post-surgery notes. By automating these critical processes, BPL iCare OT ensures patient data is accurate, accessible, and reliable. Commenting on the same, Dr Shravan Subramanyam, Managing Director of BPL Medical Technologies, shared, “Managing operating rooms has always been a complex challenge, with clinicians balancing patient care alongside time-consuming manual documentation. With BPL iCare OT, we are addressing this challenge head-on. By digitizing workflow in an OT, the platform empowers clinicians to focus on patient care while hospitals operate more efficiently. This launch reflects our vision of creating a smarter, safer, and fully connected healthcare ecosystem." Automated report generation eases the administrative burden and allows hospitals to improve the patient care experience. With structured patient data storage and event tracking, BPL iCare OT ensures accuracy and accountability at every stage of care. The company also plans to further expand with digital solutions in radiology and ICU, enabling hospitals to improve patient management, access critical data seamlessly, and deliver higher-quality care across departments.   ]]> https://biospectrumindia.com/news/93/26676/medtronic-unveils-new-transcatheter-aortic-valve-evolut-fx-in-india.html https://biospectrumindia.com/news/93/26676/medtronic-unveils-new-transcatheter-aortic-valve-evolut-fx-in-india.html Sat, 13 Sep 2025 00:00:00 +0530 Medtronic, a global leader in healthcare technology, has launched its new transcatheter aortic valve, Evolut™ FX+, in India. The valve is designed to help improve treatment for patients with severe aortic stenosis, especially those who may need future coronary procedures. The Evolut FX+ TAVI system facilitates easier coronary access while maintaining the proven performance of the Evolut™ platform, based on CoreValve™ technology. It was approved by the Central Drugs Standard Control Organization (CDSCO) on June 10, 2025, paving the way for its launch in India. The main innovation of Evolut FX+ is its new frame with bigger windows to reduce frame interference while using guide catheters, especially during complex coronary procedures. The system continues to deliver the key advantages that clinicians have come to expect from previous Evolut valves. The system provides market leading valve performance including durable low gradients, which are important for long-term heart function. This makes it a strong alternative for patients at risk of coronary disease while supporting long-term treatment needs. The introduction of Evolut FX+ in India marks a significant advancement in transcatheter aortic valve therapy and reinforces Medtronic’s leadership in structural heart innovation. With enhanced coronary access and proven hemodynamic performance, the Evolut FX+ empowers physicians to deliver both immediate procedural success and sustained long-term care.  This milestone underscores Medtronic’s steadfast dedication to broadening access to advanced therapies and driving innovation in cardiovascular care and treatment across India.   ]]> https://biospectrumindia.com/news/93/26673/tata-elxsi-announces-opening-of-bayer-development-centre-in-radiology-in-pune.html https://biospectrumindia.com/news/93/26673/tata-elxsi-announces-opening-of-bayer-development-centre-in-radiology-in-pune.html Fri, 12 Sep 2025 00:00:00 +0530 Tata Elxsi, a global leader in design and technology services, has announced the inauguration of the ‘Bayer Development Centre in Radiology’ at Tata Elxsi, Pune, India. The centre is designed to co-develop with Bayer, a leader in key areas of Radiology, advanced radiology devices and technology that enable early and accurate diagnosis and treatment of critical illnesses, supporting Bayer’s global mission to bring innovative, safe, and compliant solutions to patients and clinical staff worldwide. This centre will provide a wide range of engineering for complex radiology devices, with an initial focus on Molecular Imaging. The facility’s integrated approach, which combines design, development, and validation, the centre will help accelerate time-to-market, enhance cost efficiency, and help deliver new technology to market fast, efficiently, and at an optimised cost, while meeting highest regulatory compliance standards. This collaboration leverages Tata Elxsi’s healthcare engineering expertise and the strength of the Tata and India ecosystems—enabling access to advanced labs, regulatory partnerships, and specialised technology talent. This creates a scalable foundation for innovation and strengthens Bayer’s ability to deliver radiology solutions across multiple geographies, including the US and EU. Dr Konstanze Diefenbach, Head of Research & Development, Radiology, Bayer, commented “Bayer is committed to innovative products and high-quality services in diagnostic imaging, and device innovation plays a critical role in delivering precision and safety in patient care. This new centre gives us direct access to specialised engineering capabilities through Tata Elxsi, enabling us to accelerate our pipeline of advanced radiology devices while maintaining the quality and reliability that healthcare providers expect from Bayer.” Sreevatsa Sahasranaman, Sr. Vice President & Head – Healthcare & Life Sciences, Tata Elxsi, said, “This centre is more than an engineering hub—it is where Bayer’s radiology vision meets Tata Elxsi’s design, AI/ML, and regulatory expertise. Our teams will work together to translate ideas into devices that address real-world diagnostic challenges, with the assurance of safety, compliance, and global scalability.” ]]> https://biospectrumindia.com/news/93/26651/edwards-lifesciences-launches-next-gen-transcatheter-heart-valve-platform-in-india.html https://biospectrumindia.com/news/93/26651/edwards-lifesciences-launches-next-gen-transcatheter-heart-valve-platform-in-india.html Fri, 05 Sep 2025 00:00:00 +0530 US-based Edwards Lifesciences, a global leader in structural heart innovations, has announced the launch of its next-generation transcatheter heart valve platform in India, marking a significant milestone in the treatment of aortic stenosis. This advanced therapy is designed to meet the needs of patients who are not candidates for open-heart surgery, offering a durable, minimally invasive solution that supports long-term health and quality of life. Aortic stenosis is a progressive, degenerative condition often linked to aging, caused by calcification of the aortic valve that restricts blood flow from the heart. Once symptoms appear, nearly 50% of patients face mortality within two years without timely intervention, underscoring the urgency of early diagnosis and treatment. According to the Global Burden of Disease study, in India, a large number of deaths are attributed to severe calcific non-rheumatic aortic stenosis. Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology that helps prevent calcium buildup on the valve leaflets, which is a primary cause of structural valve deterioration and the need for reintervention. The valve also features dry tissue storage, simplifying hospital workflows, and a taller, textured outer sealing skirt to reduce paravalvular leak. Parameswaran Nair, Country Leader of India and Southeast Asia at Edwards Lifesciences, commented, “At Edwards Lifesciences, we are deeply committed to pioneering innovations that redefine care for structural heart disease. By integrating minimally invasive techniques with exceptional durability, we are delivering therapies that meaningfully enhance survival and quality of life for patients with aortic stenosis in India. This milestone reflects our dedication to empowering clinicians, expanding access to care, and addressing the distinct needs of younger patients requiring lifelong treatment strategies.”   ]]> https://biospectrumindia.com/news/93/26632/admi-seeks-uniform-5-gst-rate-on-ivd-equipment-diagnostic-kits-and-reagents.html https://biospectrumindia.com/news/93/26632/admi-seeks-uniform-5-gst-rate-on-ivd-equipment-diagnostic-kits-and-reagents.html Tue, 02 Sep 2025 00:00:00 +0530 Guided by public health imperatives, industry viability, and policy consistency with the Government of India’s healthcare and manufacturing priorities, Association of Diagnostic Manufacturers of India (ADMI), a platform for the Indian In-Vitro Diagnostics (IVD) manufacturers has submitted a representation to Nirmala Sitharaman, Union Minister of Finance & Corporate Affairs and Chairperson, GST Council of India seeking a uniform 5% GST rate on both IVD equipment, diagnostic kits, and reagents. In a representation, ADMI observed that diagnostics form the first line of care—from common fevers to non-communicable diseases (NCDs). The current GST regime imposes 18% on equipment and 12% on reagents (with a few exceptions like CLIA at 5%). This differential tax structure increases testing costs and deters early diagnosis. Early detection significantly reduces the national healthcare burden, especially for diabetes, cardiovascular, and lifestyle-related diseases. Affordable diagnostics enable timely treatment and reduce long-term costs under public health programmes such as Ayushman Bharat. Health is not a luxury, but a necessity. Therefore, GST on diagnostics should remain minimal to ensure affordability and equitable access for every citizen. Rajat Kapoor, Assistant Director – Secretariat, ADMI, in submission to the Minister said that though IVD represents less than 2% of the total medical device market, it is critical to every clinical workflow. Currently, nearly 65% of IVD equipment and reagents are imported. A lower GST rate would encourage Make in India, reduce import dependence, and support the government’s self-reliance agenda. While the Production Linked Incentive (PLI) scheme aims to boost domestic IVD manufacturing, high GST rates undermine its impact by inflating final costs to healthcare providers and patients. Aligning GST reduction with the Prime Minister’s vision of “Atmanirbhar Bharat” will ensure both affordable healthcare for patients and enhanced competitiveness for Indian manufacturers. Rajat Kapoor further noted that medical appliances and implants already attract 5% GST. Extending the same parity to IVD products would align diagnostics with their essential healthcare utility. Imaging Diagnostics has already been proposed for 5% GST. Pathology Diagnostics, which serves a similar purpose of disease detection and monitoring, should also be included under the same 5% GST bracket. A uniform 5% GST rate would eliminate classification disputes, simplify compliance, and ease working capital strain for diagnostic laboratories, especially MSMEs and smaller healthcare providers. To ensure revenue neutrality, ADMI suggested couple of approach namely Health Cess on imports to provide a level playing field for domestic manufacturers and time-bound GST refund mechanism for input tax credits to ease liquidity constraints for industry, while maintaining revenue flow to the exchequer.   ]]> https://biospectrumindia.com/news/93/26593/terumo-india-launches-terufusion-advanced-infusion-systems.html https://biospectrumindia.com/news/93/26593/terumo-india-launches-terufusion-advanced-infusion-systems.html Tue, 26 Aug 2025 00:00:00 +0530 Terumo India, the Indian subsidiary of Japan's Terumo Corporation, a global leader in medical technology, has launched Terufusion™ Advanced Infusion Systems in India for the first time. This connected infusion system comprises a Smart Syringe Pump, Smart Infusion Pump (volumetric), and Pump Monitoring System software. Designed to enhance drug delivery accuracy, improve patient safety, and optimise clinical workflows, Terufusion™ Advanced Infusion Systems combine Terumo’s trusted global infusion technology with intelligent digital capabilities including remote monitoring, customisable dose modes, and an integrated drug library. As India’s critical care infrastructure evolves with over 95,000 ICU beds and increasing investment in high-dependency care, there is a growing demand for smarter, safer, and more efficient drug delivery systems. The Terufusion™ Advanced Infusion Systems are designed to address the everyday challenges faced by nursing staff by providing greater control, visibility, and confidence in drug delivery. This advanced technology streamlines critical care workflows, reduces manual errors, and simplifies pump management, enhancing workflow efficiency for nursing staff while supporting hospitals in their transition toward smarter, more transparent ICU operations. Terumo India is actively engaging with leading hospitals across the country to implement the Terufusion™ Advanced Infusion System capabilities in advanced critical care management. In the past two years, the company has brought to market several key innovations, including the TREO Abdominal Stent-Graft System, the Ultimaster Nagomi Drug-Eluting Stent, and more, demonstrating its continued focus on supporting clinicians with world-class, patient-centric solutions. ]]> https://biospectrumindia.com/news/93/26583/healthium-medtech-and-c-camp-launch-first-cohort-of-flagship-medtech-innovations-programme-.html https://biospectrumindia.com/news/93/26583/healthium-medtech-and-c-camp-launch-first-cohort-of-flagship-medtech-innovations-programme-.html Mon, 25 Aug 2025 00:00:00 +0530 Healthium Medtech and the Centre for Cellular and Molecular Platforms (C-CAMP) have recently launched the first cohort of the C-CAMP Healthium Innovations Programme for Surgical Interventions and Medical Technologies in Bengaluru. This programme is a part of the CSR initiative of Healthium Medtech. The partnership aims to foster deep-science innovations in digitally enabled medical technologies that are affordable, scalable and clinically impactful. In its first year, the initiative focuses on surgical interventions, an area undergoing rapid modernisation globally but still marked by limited access and affordability across large parts of India. Despite the increasing adoption of advanced surgical technologies in metropolitan hospitals, smaller healthcare systems in Tier 2 and Tier 3 cities often remain underserved. The high cost of imported solutions, along with infrastructure and training gaps, have made it difficult to scale access to modern surgical care. This program was created to address these challenges by nurturing India-led, frugal and scalable innovations that are tailored for local needs without compromising on quality or outcomes. The initiative brings together two organisations with complementary strengths. Healthium Medtech brings deep expertise in surgical and post-surgical technologies, supported by a diverse product portfolio and robust manufacturing capabilities. The company operates 6 facilities with global certifications and holds over 85 patents across India, the US and Europe. C-CAMP, an initiative supported by the Department of Biotechnology, Government of India, has built one of the country’s leading life sciences innovation ecosystems, having supported over 550 deep-tech start-ups across domains and connected with 3000 more. Together, the collaboration combines clinical insight, market access and ecosystem support to help early-stage ventures overcome critical barriers from research to commercialisation. Over the next nine months, the selected startups will receive structured mentorship and incubation support at C-CAMP and access to clinical and industry expertise to help advance their technologies toward market readiness and adoption.   ]]> https://biospectrumindia.com/news/93/26567/us-based-vyome-signs-mou-with-indias-leading-medical-device-innovation-studio-embryyo.html https://biospectrumindia.com/news/93/26567/us-based-vyome-signs-mou-with-indias-leading-medical-device-innovation-studio-embryyo.html Thu, 21 Aug 2025 00:00:00 +0530 Vyome Holdings, Inc., a US-based clinical-stage healthcare holding company, and Pune-based Embryyo Technologies have announced the signing of a Memorandum of Understanding (MoU) to jointly pursue the global artificial intelligence (AI)-enabled medical device market. This partnership will combine Vyome's healthcare industry experience and resources with Embryyo's medical technology capabilities to potentially productise and commercialise smart medical devices that can transform the standard-of-care in disease management and treatment. As part of this partnership, Vyome and Embryyo will host a global AI-enabled medical device innovation forum for companies along the US-India corridor. "We are currently developing a portfolio of transformative medical devices spanning interventional oncology, surgery, wearables, and drug delivery, and Vyome’s access to global capital markets and the US healthcare ecosystem will accelerate our mission to push the frontiers of medicine and elevate standards of care in healthcare globally,” said Nishant Kumar, Co-Founder and CEO of Embryyo Technologies. ]]> https://biospectrumindia.com/news/93/26572/alcon-india-launches-new-platforms-for-vitreoretinal-and-cataract-surgery.html https://biospectrumindia.com/news/93/26572/alcon-india-launches-new-platforms-for-vitreoretinal-and-cataract-surgery.html Thu, 21 Aug 2025 00:00:00 +0530 Alcon, the global leader in eye care, has announced the launch of the UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) in India. The new, versatile platform offers two configurations, a combined console (VCS) which is now available, and a standalone cataract system (CS), which will be commercially available in the coming months. This platform is designed to deliver superior efficiency for vitreoretinal and cataract surgery, while enabling exceptional outcomes for patients. The systems feature many first-to-market technologies designed to deliver transformative surgical innovation for cataract and vitreoretinal surgery, including UNITY 4D Phaco, HYPERVIT® 30K and the advanced UNITY Intelligent Fluidics system. With UNITY VCS/CS, surgeons can operate at more physiologic conditions without compromising efficiency. It is estimated that over 8 million cataract surgeries are performed annually in India, making it one of the highest volumes of cataract surgeries globally. The workload of surgeons is also very high with just one ophthalmologist for every 100,000 people. The combination vitreoretinal and cataract system intelligently transforms vitreoretinal and cataract surgery with first-to-market innovations. With the introduction of UNITY Intelligent Fluidics, a unique pressure and flow control technology with real-time sensing, surgeons can expect surgical stability and efficiency at each step of the procedure.   ]]> https://biospectrumindia.com/news/93/26496/shalby-multi-specialty-hospitals-performs-worlds-first-fully-autonomous-robotic-joint-replacement-surgery-.html https://biospectrumindia.com/news/93/26496/shalby-multi-specialty-hospitals-performs-worlds-first-fully-autonomous-robotic-joint-replacement-surgery-.html Thu, 07 Aug 2025 00:00:00 +0530 The Arthroplasty Team at Shalby Multi-Specialty Hospitals has achieved a historic medical milestone by successfully performing surgery using the world’s first fully autonomous robotic system for joint replacement. This revolutionary robotic technology, featuring the world’s only saw-based robotic arm with 7-axis movement, is designed to dramatically improve surgical accuracy, bone-cut precision, and enable minimally invasive procedures, resulting in faster recovery and improved patient outcomes. In a major global collaboration, the team of eminent surgeons from the United States, including the CEO of the company (Monogram Technologies) that developed this robotic system, specially flew in to perform this first-ever surgery using the technology. Their presence highlights the global significance of this achievement and Shalby’s role in pioneering next-generation medical care. ‘We are proud to be part of a pivotal moment in medical innovation. The reason our hospital was selected for this global clinical trial is the high surgical volume we manage and the need for precision in the Indian healthcare landscape. This new-generation robotic system offers unmatched accuracy, enhanced bone-cutting precision, and supports minimally invasive techniques. It’s a leap forward in joint replacement surgery, providing better outcomes, quicker recovery, and greater consistency. With over 20% of our surgeries already performed robotically, we believe this technology will shape the future of surgery in India.”— Dr Vikram Shah, CMD, Shalby Hospitals   ]]> https://biospectrumindia.com/news/93/26488/primelaze-introduces-german-q-switched-ndyag-technology-for-skin-treatment.html https://biospectrumindia.com/news/93/26488/primelaze-introduces-german-q-switched-ndyag-technology-for-skin-treatment.html Wed, 06 Aug 2025 00:00:00 +0530 Puducherry-based startup Primelaze collaborates with German dermatological laser pioneer Hypertech Laser Systems (HLS), introduces revolutionary BiAxis QS (Nano) & BiAxis Pico - Q-Switched Nd:YAG technology, a groundbreaking advancement in the field of aesthetic and medical dermatology.   This state-of-the-art laser system boasts novel features aimed at enhancing treatment efficacy and safety for dermatological applications.   Q-Switched Nd:YAG Technology is designed to cater to all skin types and allows for a comprehensive range of treatments. From addressing a variety of dermal and epidermal pigmentation lesions to the effective removal of multi-coloured tattoos, this system provides versatility like never before.   Dr Anurag Tiwari, a renowned dermatologist and laser expert, expressed his enthusiasm for this innovative technology, stating, "The introduction of the BiAxis QS (Nano) into our practices represents a significant leap forward in our ability to provide effective and safe treatments for our patients. This advanced laser system not only enhances treatment outcomes but also ensures a comfortable experience for clients."   Renowned German expert Dr Fedor Mayorov, PhD, who brings over 30 years of experience in medical laser systems development, emphasised the importance of high-performance technology stating, "The precision and efficacy of this laser system position it as a leader in the global market. Its adoption by dermatologists and plastic surgeons in over 50 countries is a testament to its success in delivering outstanding clinical results."   ]]> https://biospectrumindia.com/news/93/26478/robogynindia-2025-in-partnership-with-vattikuti-foundation-showcases-indias-leadership-in-robotic-gynaecologic-surgery.html https://biospectrumindia.com/news/93/26478/robogynindia-2025-in-partnership-with-vattikuti-foundation-showcases-indias-leadership-in-robotic-gynaecologic-surgery.html Mon, 04 Aug 2025 00:00:00 +0530 RoboGynIndia 2025, the flagship annual event of the Association of Gynaecological Robotic Surgeons of India (AGRS) held for the fourth year, concluded with high momentum and meaningful engagement at Mumbai. Held on August 2 & 3, the conference was themed “Robotic Surgery in Gynaecology—Redefining Boundaries” and brought together the country’s most prominent robotic gynaecologic surgeons and global experts for a two-day academic and clinical exchange. The event was held in association with the Vattikuti Foundation, a pioneering force behind the growth of robotic surgery in India. As part of its commitment to nurturing the next generation of robotic surgeons, the Foundation sponsored the  prestigious Vattikuti Scholar awards and honoured five winners for their outstanding surgical video presentations, each recipient earning a grant of $500 and the distinguished title of AGRS Vattikuti Scholar.  Speaking on the occasion, Dr. Mahendra Bhandari, CEO, Vattikuti Foundation, said, “RoboGynIndia 2025 has once again demonstrated the incredible depth of talent and innovation within India’s robotic surgical community. Our association with this platform reflects the Foundation’s commitment to nurturing the ecosystem, beginning with training the early pioneers in robotic gynaecology to now enabling the next generation of surgical leaders. Through initiatives like the AGRS Vattikuti Scholars and Champions Awards, we are proud to recognize emerging talent, foster innovation and drive the future of women’s healthcare.” Dr. Rooma Sinha, Founder & President of AGRS and a Senior Mentor at Vattikuti Foundation, added, “RoboGynIndia is not just a conference; it is a catalyst for change in the way we approach surgical care for women. Over last 3 years since it was registered at Hyderabad, Telangana, the  years, it has grown into a movement that celebrates innovation, fosters academic rigor and inspires a new generation of surgeons to think beyond boundaries. Our partnership with the Vattikuti Foundation has played an important role in this evolution. From mentoring early adopters to now empowering young clinical minds, the Foundation’s vision has always been aligned with advancing excellence and equity in robotic gynaecology. Together, we are shaping a future where precision surgery which has now become the standard, not the exception, in women’s healthcare.” The event concluded with a strong sense of purpose, highlighting India’s increasing leadership in robotic-assisted surgery and the role of global collaboration, technology and academic exchange in redefining the future of women’s health. ]]> https://biospectrumindia.com/features/93/26435/can-policy-reforms-investments-trigger-indias-medtech-makeover.html https://biospectrumindia.com/features/93/26435/can-policy-reforms-investments-trigger-indias-medtech-makeover.html Thu, 31 Jul 2025 00:00:00 +0530   India stands as the fourth-largest medical devices market in Asia, trailing only Japan, China, and South Korea, and is counted among the top 20 markets worldwide. The sector is broadly categorised into five key segments: electronic equipment (56 per cent), disposables and consumables (26.5 per cent), in-vitro diagnostics (8.1 per cent), implants (7.1 per cent), and surgical instruments (2.3 per cent). (Source: Invest India) Most domestic manufacturers are concentrated in the disposables and consumables segment, primarily serving local demand. In contrast, high-end categories such as electronic equipment remain dominated by multinational companies. The domestic industry comprises around 800 manufacturers, with production still focused on a limited set of product areas. In 2023–24, India’s medical device exports crossed $4 billion, which is an impressive number on its own, but compared to imports which stood at nearly double, at $8.1 billion, it highlights the country’s continued reliance on foreign medical technologies, with nearly 80 per cent of its medical device requirements still met through imports. To address this imbalance and expand domestic manufacturing capacity, the government has set a goal to reduce import dependence to below 50 per cent over the next five years and has announced a slew of initiatives, investments, and incentives.   Government Initiatives: Have they moved the needle? The government is pushing to transform the MedTech sector through policy reforms and targeted financial incentives, aiming to build self-reliance, drive innovation, and boost global competitiveness. This shift gained momentum in 2023 with the launch of the National Medical Devices Policy, which aims to position India as a global manufacturing and innovation hub. The policy sets ambitious goals: expanding India’s global market share in medical devices from less than 2 per cent to 10–12 per cent over the next 25 years, and growing the domestic market from $11 billion to $50 billion by 2030.  To complement manufacturing with innovation, the government launched the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme in August 2023. With a total budget of Rs 5,000 crore, Rs 4,250 crore of which is dedicated to building the R&D ecosystem. PRIP seeks to transform India into a global R&D hub for medical devices and pharmaceuticals. To guide implementation, an industry dialogue was held in Mumbai in March 2025, involving stakeholders such as the Indian Council of Medical Research (ICMR), the Council of Scientific & Industrial Research (CSIR), the National Institutes of Pharmaceutical Education and Research (NIPERs), regulatory bodies, and industry associations. The Expression of Interest (EoI) portal opened shortly thereafter, accepting proposals until April 7, 2025. In 2023, the government also launched MedTech Mitra, a strategic initiative designed to support MedTech startups and companies through clinical evaluation, regulatory facilitation, and new product adoption, providing end‑to‑end handholding from development to market entry. To boost local manufacturing, the government launched the Production Linked Incentive (PLI) Scheme for Medical Devices in 2020–21, with a financial outlay of Rs 3,420 crore and a timeline extending to 2027–28. The scheme offers 5 per cent incentives on incremental sales of domestically manufactured devices across four high-value categories: radiotherapy and imaging equipment, anaesthesia devices, cardio-respiratory and critical care equipment, and implants. So far, 19 greenfield projects have been commissioned, leading to the local production of 44 devices—including MRI machines, CT scanners, mammography systems, C-arms, and ultrasound machines—that were previously imported. As of September 2024, cumulative sales by participating companies have reached Rs 8,039.63 crore, including exports worth Rs 3,844.01 crore.  In 2024, the Government of India has launched a Rs 500 crore scheme to boost domestic medical device manufacturing through five targeted sub-schemes: Rs 110 crore for common infrastructure like R&D labs and testing centres; Rs 180 crore for 10–20 per cent capital subsidies to support local production of components; Rs 100 crore for capacity building through Master's programmes and vocational training; Rs 100 crore for clinical studies including animal trials, human trials, and diagnostic evaluations; and Rs 10 crore to support industry associations in promoting MedTech innovation. These efforts appear to be gaining traction. A key milestone was India’s entry into the International Medical Device Regulators Forum (IMDRF), signalling the country’s commitment to aligning with global quality and regulatory standards and paving the way for greater international collaboration. This growing credibility has been matched by rising investor interest. By August 2024, India’s MedTech sector had attracted over $1.2 billion in private equity and venture capital, the highest in five years. Foreign direct investment has also gained momentum. In just the first half of FY 2023–24, FDI stood at $425 million, reflecting growing confidence in the sector’s long-term potential. But the question is, have these initiatives truly moved the needle? Experts believe that while these are welcome developments, the on-ground reality is more nuanced.  “India's push for a self-sufficient medical device industry, through initiatives like PLI and medical device parks, has shown promise but delivered limited ground-level results so far, especially for domestic manufacturers in low-margin sectors where we are usually not competitive with China. While the PLI has spurred investment in certain high-end areas, its overall impact remains narrow, with very few projects sanctioned and disbursed,” said Rajiv Nath, Managing Director, Hindustan Syringes & Medical Devices Ltd & Forum Coordinator, Association of Indian Manufacturers of Medical Devices (AiMeD).  Similarly, the Marginal Investment Scheme, Clinical Performance Scheme, Common Infrastructure Scheme, and Skilling Scheme announced by the Department of Pharmaceuticals in November 2023 are yet to gain meaningful traction. “These schemes need faster implementation to improve manufacturers’ competitiveness. While policy intent is strong and some progress has been made, India’s MedTech sector needs more consistent execution, wider participation, and accelerated infrastructure development to truly unlock its global potential,” added Nath.  According to a white paper by AiMeD and Consocia Advisory, developing high-end medical equipment requires substantial investment in R&D, testing, and clinical validation. At present, Indian manufacturers face both financial and bureaucratic hurdles in these areas. Government schemes like the PLI programme exist, but smaller companies often struggle to access the benefits due to complex application procedures and delays in disbursement. There are also limited targeted research grants or tax incentives specifically designed for critical care devices. Without strong policy support for innovation, such as grants for designing next-generation ventilators or funding to upgrade manufacturing capabilities, domestic firms risk falling behind global competitors. While initiatives like the India AI Mission have received Rs 10,000 crore in structured government support, the MedTech sector’s PRIP scheme has been allocated only Rs 5,000 crore, which experts argue is disproportionately low given the sector’s potential and its critical role in healthcare innovation and national preparedness. Inside the MedTech Parks: Are they delivering? India is steadily building a network of medical device parks to support domestic manufacturing, R&D, and innovation in the MedTech sector. Under the Rs 400 crore ‘Promotion of Medical Devices Parks’ scheme (2020–2025), four states—Uttar Pradesh, Tamil Nadu, Madhya Pradesh, and Himachal Pradesh have received approvals of Rs 100 crore each. Separately, the Department of Pharmaceuticals has also supported a superconducting magnet testing facility at AMTZ, Andhra Pradesh, under a common facility scheme. The Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam, launched in 2016, is fully operational and hosts over 100 companies focused on R&D and manufacturing. Hyderabad’s Medical Devices Park, active since 2017, houses over 50 firms making devices ranging from imaging systems to ICU and home-use equipment. Other key parks are under development: Solan (Himachal Pradesh) is focusing on radiology and implants; Gautam Buddh Nagar (Uttar Pradesh) is attracting IVD and diagnostic manufacturers; and Kancheepuram (Tamil Nadu) has received 28 investment proposals to produce stents, implants, and diagnostics. Ujjain (Madhya Pradesh) is targeting high-risk devices, while MedSpark in Thiruvananthapuram (Kerala) is being developed as a hub for manufacturing, research, and training. New parks are also planned in Rajkot (Gujarat) and Panipat (Haryana), featuring proposed testing labs, centres of excellence, and R&D facilities. Together, these parks are expected to enhance India’s MedTech infrastructure, although several remain in various stages of development and await full operationalisation. “The medical device parks model, exemplified by AMTZ's success in Visakhapatnam, offers shared infrastructure and reduced capital costs but faces operational delays and inconsistent implementation across other states due to restrictive criteria and underdeveloped facilities. Improved execution and stronger coordination between central and state policies, using AMTZ as a benchmark, are needed,” said Nath.    Global giants and local players fuel MedTech manufacturing India’s ‘Make in India’ initiative in the MedTech sector has begun to show visible traction, with both multinational corporations and Indian companies scaling up their local manufacturing, R&D, and innovation capabilities. Several global players have expanded their operations in India, recognising its growing role in the global medical devices supply chain.  Medtronic, for instance, operates its largest R&D facility outside the United States in Hyderabad. The company has recently invested around Rs 3,000 crore to expand this facility further. The India innovation centres are not only engaged in traditional medical device development but are also focusing on building software capabilities for global product platforms. Similarly, Siemens Healthineers—one of the approved participants under India’s PLI scheme—has invested Rs 91.9 crore to manufacture CT and MRI systems at its Bengaluru plant. The company has also introduced the Multix Impact E digital radiography systems from this facility. Siemens’ mobile C-arm system, Cios Fit, is fully conceptualised, designed, and manufactured in India and is now exported to over 64 countries. Additionally, the company has received approval to manufacture RT-PCR kits for mpox detection at its Vadodara site. Philips Healthcare has also ramped up its ‘Make in India’ efforts. Over the past few years, the company has cumulatively invested around Rs 750 crore, including Rs 350 crore recently allocated to a new 300,000 sq ft R&D facility in Pune. This facility will focus on imaging and image-guided therapy technologies for global markets. The Pune centre already serves as a global hub for mobile surgery, exporting devices like the Zenition Mobile C-arm series to over 100 countries. In Bengaluru, Philips has invested an additional Rs 500 crore to establish its largest global innovation hub.  Philips has also launched the Affiniti ultrasound machines as part of its India-made portfolio. The India operation of Omron Healthcare, a japanese medtech company with $30 million in sales last year and growing at double digit has invested Rs 128 crore in its Chennai facility which is spread over 24000 square metres. The company will be rolling out about 1 million blood pressure monitors (BPM) per year from its Chennai facility with 'Made in India' log by December this year. The foundation for the facility was laid after signing the memorandum on the establishment of the factory on June 2, 2023 in the presence of M.K. Stalin, Chief Minister of the Tamil Nadu State Government. Wipro GE Healthcare is another major player deepening its India footprint. The company recently announced a strategic investment of over Rs 8,000 crore over the next five years to enhance manufacturing capacity and R&D. This investment supports supply chain resilience and strengthens the company’s role in both domestic and international markets. Products like the Made in India PET CT Discovery IQ are now exported to 15 countries. Other locally manufactured devices include the Revolution Aspire CT, Revolution ACT, and MR breast coils—all developed ‘In India for the World.’ The company currently operates four manufacturing plants in Bengaluru, all export-focused. The latest facility was set up in March 2022 with a Rs 100 crore investment under the PLI scheme. Spellman, the global leader in X-ray generator production, is set to establish its first-ever manufacturing facility in India at the AMTZ, a significant step in enhancing the country’s medical technology sector.  While multinational companies are deepening their footprint in India, local medical device manufacturers are also stepping up to reduce import dependence and drive indigenous innovation. Several Indian firms are now focusing on developing complex, high-end equipment that is traditionally imported. In 2024, Meril inaugurated new manufacturing facilities under the PLI scheme and signed an MoU with the Gujarat government to invest Rs 910 crore. The company has already invested over Rs 1,400 crore in the MedTech sector. This expansion is expected to create 5,000 jobs and reduce imports of critical devices. Efforts are also underway in the public sector and academia to accelerate the development of indigenous high-end technologies. The All India Institute of Medical Sciences (AIIMS), New Delhi, recently announced plans to install the country’s first indigenously developed 1.5 Tesla MRI machine by October 2025. The project is being executed in partnership with the Society for Applied Microwave Electronic Engineering and Research (SAMEER), an autonomous institution under the Ministry of Electronics and Information Technology.  IIT Kanpur is developing Hridayantra, India’s first indigenously designed left ventricular assist device (LVAD), aimed at helping patients with advanced heart failure. The implantable mechanical pump is expected to last 10–12 years and cost significantly less, Rs 10–15 lakh, compared to the global price of Rs 70–80 lakh. Bengaluru-based Voxelgrids Innovations, India’s first and only manufacturer of MRI scanners, has received regulatory approval and launched the country’s first indigenously developed Magnetic Resonance Imaging (MRI) scanner. SS Innovations, based in Gurugram, recently launched India’s first mobile tele-robotic surgery unit, SSI Mantra, marking a breakthrough in the country’s surgical capabilities. Innovation is also being backed by institutional support. The Technology Development Board (TDB), under the Department of Science and Technology (DST), has extended financial support to Mysuru-based S3V Vascular Technologies for its project on manufacturing mechanical thrombectomy kits for acute ischemic stroke treatment. This initiative positions S3V as the first Indian company to design and manufacture a full suite of neuro-intervention devices—including microcatheters, aspiration catheters, guidewires, and stent retriever systems- in a fully integrated upstream facility.   Filling the gaps All these initiatives and investments have propelled notable growth in India’s MedTech sector. However, structural challenges and limited policy support in key strategic areas continue to constrain the country’s global competitiveness.  “One challenge is the regulatory framework. Some stakeholders suggest the adoption of a separate decriminalised regulatory framework and an independent regulator for medical devices, like the Food Safety and Standards Authority of India (FSSAI) in the food sector. There are views that current regulations, which link medical devices closely with pharmaceuticals under a common Drug Law, may inhibit the independent implementation of Medical Device Rules. International guidance from the WHO and regulatory frameworks in markets such as the UK (Medicines and Healthcare products Regulatory Agency (MHRA), Canada (Health Canada), Singapore (Health Sciences Authority (HSA), and Malaysia’s Medical Devices Authority are often cited as references. The umbilical cord with pharma needs to be severed, as the bias of the drug rules at times overshadows the independent implementation of the Medical Device Rules. Medical devices, while classified as medical products, differ from medicines in that they are considered engineering goods. This distinction is like the way the Air Force, Navy, and Army each require unique treatment despite all being branches of the defence forces,” said Nath.  R&D in the sector is another area where India’s investment remains modest compared to global standards. While policies like the PRIP scheme and the creation of Centres of Excellence represent welcome positive developments, R&D activity tends to be fragmented and mainly led by the public sector. “In comparison, countries such as China have promoted integrated ecosystems with significant private-sector involvement and incentives for advanced medical device manufacturing,” said Nath.  Manufacturing output in India is largely focused on low-value consumables and in-vitro diagnostics, with less emphasis on high-technology electronic or implantable devices. This focus limits participation in high-tech international trade.  “Some manufacturers indicate that public procurement policies sometimes favour imported products by requiring overseas regulatory approvals, potentially limiting market access for Indian producers. The few units that bravely invested need nurturing but at times they face challenges in public procurement instead of getting preference and support in pruning the paradoxical enlargement of the GTE (Global Tender Exemption) list even for those medical equipment available since long and from more than one licensed manufacturer, but also in some public tenders continue to discriminate and disallow Indian manufacturers to participate in bidding process by seeking a mandatory qualifying criteria of overseas US FDA and CE approval instead of seeking a Central Drugs Standard Control Organisation (CDSCO) manufacturing license. Some Buyers' reasoning is to filter out low-priced but low-quality Indian goods, which, in many cases, are relabelled, repackaged, and shoddy Chinese goods. For this, some manufacturers seek an amendment of labelling requirements in the Indian MDR’17 for alignment with Department for Promotion of Industry and Internal Trade - Public Procurement Order (DPITT- PPO) and Department of Pharmaceuticals (DoP)’s guidance requirements and the label to clearly state if the Manufacturer is level 1, i.e. with over 50 per cent domestic content, or level 2, with over 20 per cent domestic content or simply a Repackaging or relabelling company. This distinction will help buyers give preference to higher value-added medical devices,” said Nath.  There is also discussion about the alignment of Indian certification standards, such as BIS-based CDSCO certification, with international regulatory benchmarks. The introduction of the QCI’s Indian Certification of Medical Devices (ICMED) 13485 Plus aims to provide Indian manufacturers with internationally recognised quality compliance credentials. Aligning these certifications with other international certifications, such as the MDSAP and CE, is considered a possible approach for enhancing market access via mutual recognition agreements in trade negotiations. “Some industry participants highlight the importance of a predictable nominal tariff policy to provide balanced protection for both domestic and foreign manufacturers, addressing Niti Aayog stated 15 per cent disability factors that affect the sector’s competitiveness,” said Nath. India currently holds a modest 1.5 per cent share of the global medical devices market. To claim a larger share, the country has laid out an ambitious vision backed by policies, incentives, and investments. But achieving the $50 billion target and becoming Atmanirbhar will depend on sustained execution, stronger ecosystem integration, and the ability to scale both innovation and manufacturing.   Ayesha Siddiqui   ]]> https://biospectrumindia.com/news/93/26454/fujifilm-india-unveils-endoveda-to-revolutionise-clinical-reporting-in-gastroenterology.html https://biospectrumindia.com/news/93/26454/fujifilm-india-unveils-endoveda-to-revolutionise-clinical-reporting-in-gastroenterology.html Tue, 29 Jul 2025 00:00:00 +0530 Fujifilm India, a global leader in healthcare technology, has unveiled its latest innovation in endoscopy reporting, ENDOVEDA, at the Endocon 2025 conference in Jaipur. Developed entirely in India, ENDOVEDA marks a significant leap forward in digital documentation for endoscopic procedures, designed to support clinicians with advanced reporting tools and intuitive workflow. ENDOVEDA offers a comprehensive suite of features for endoscopic reporting, including Full HD 4k and UHD 4K  image capture, intelligent image enhancement, and a user-friendly interface. It ensures seamless integration with hospital systems (PACS/HIS), robust data security, and flexible reporting options. Backed by dedicated local and remote support, ENDOVEDA streamlines workflows and enhances diagnostic precision for healthcare professionals. ENDOCON 2025 at Jaipur, a premier platform for knowledge exchange in gastroenterology, served as the ideal venue for the introduction of ENDOVEDA. The event brought together key opinion leaders, clinicians, and industry experts to discuss advancements in interventional techniques and medical technologies. Dheeraj Chaudhari, Head of Endoscopy Systems Division, Fujifilm India, added, “ENDOVEDA™ reflects our understanding of what modern-day endoscopists require, a solution that not only captures high-quality images but also simplifies the reporting journey. Developed in close consultation with medical professionals, it supports seamless integration, personalization, and precision, all within a single platform. We believe ENDOVEDA will become an essential component in the endoscopy workflow and help set new standards for digital documentation in India.”   ]]> https://biospectrumindia.com/news/93/26433/hybrid-endoscopic-microscopic-ent-skill-lab-opens-in-pune.html https://biospectrumindia.com/news/93/26433/hybrid-endoscopic-microscopic-ent-skill-lab-opens-in-pune.html Fri, 25 Jul 2025 00:00:00 +0530 A revolutionary leap in surgical education unfolded in Pune as Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pimpri, Pune inaugurated the world’s first Hybrid Endoscopic & Microscopic ENT Skill Lab – the EndoPlay Skill Lab – equipped with the US-patented EndoHold system for two-handed endoscopic surgery. This milestone was marked by the successful completion of the first-ever Hybrid Temporal Bone Dissection Workshop, training 20 select ENT surgeons and postgraduates from across India. The EndoPlay Skill Lab is a fully integrated cadaveric dissection unit that bridges the gap between traditional microscopy and modern two-handed endoscopic techniques. At its core lies the EndoHold system — a globally patented innovation developed by Dr Mubarak Muhamed Khan, Dr Sapna Parab and Dr Shirin Khan. The lab also houses over 15 additional surgical innovations from Dr Khan’s Creations, offering an unparalleled hands-on experience in otologic and neuro-otologic surgery. The EndoPlay Skill Lab will now serve as the dissection hub for the upcoming International ENT Conference – SEOCON 2025, scheduled from 11–14 September at Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pimpri, Pune. Surgeons from across the globe will have an opportunity to witness and experience this cutting-edge hybrid training ecosystem. As ENT surgery evolves into the era of minimal access and advanced reconstruction, the establishment of the EndoPlay Hybrid Skill Lab in Pune signals India’s leadership in training the next generation of otologic surgeons with precision, innovation and global standards. ]]> https://biospectrumindia.com/news/93/26404/adia-to-invest-usd-200-million-in-meril.html https://biospectrumindia.com/news/93/26404/adia-to-invest-usd-200-million-in-meril.html Sun, 20 Jul 2025 00:00:00 +0530 A wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) has entered into definitive agreements to invest USD 200 million for a 3% stake in Micro Life Sciences Private Limited (“Meril”), one of India’s leading medical devices companies. This investment values Meril at an enterprise value of USD 6.6 billion. The transaction is subject to regulatory approval by the Competition Commission of India (CCI). Post this investment, Meril will be backed by two globally recognized investors, ADIA and Warburg Pincus.   Founded by the Bilakhia Group, Meril is a global innovator in medical technology (MedTech), with a strong focus on clinically advanced solutions across multiple specialties — including Cardiovascular, Structural Heart, Orthopaedics, Endo-surgery, In-vitro Diagnostics and Surgical Robotics.   Headquartered in Vapi, India, Meril operates state-of-the-art, vertically integrated, and globally certified manufacturing and RCD facilities, across a 100 acre sustainable MedTech campus. The company employs more than 13,000 people, has 35+ global subsidiaries, and serves healthcare systems in 150+ countries. Meril is committed to becoming the world’s leading MedTech company, powered 100% by green energy, reinforcing its commitment to sustainable innovation.   With a robust in-house global RCD ecosystem and a portfolio of 200+ technology platforms, Meril continues to lead in global clinical research and education. Breakthrough innovations such as the Myval Transcatheter Heart Valve (THV) series, MyClip Transcatheter Edge-to-Edge Repair (TEER) system, and the MISSO Surgical Robotic System highlight Meril’s dedication to next-generation innovation. Through its 12+ global training academies, Meril empowers over 10,000 healthcare professionals annually.   Sanjeev Bhatt, Senior Vice President – Strategy, Meril said: “This investment by ADIA reinforces confidence in Meril’s long term vision and global ambitions. This investment will enable us to accelerate growth, attract world-class talent, and further strengthen our RCD and clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions.”     ]]> https://biospectrumindia.com/news/93/26406/mahajan-imaging-labs-dwarka-centre-installs-indias-first-ultra-fast-ai-powered-mri-scanner.html https://biospectrumindia.com/news/93/26406/mahajan-imaging-labs-dwarka-centre-installs-indias-first-ultra-fast-ai-powered-mri-scanner.html Sun, 20 Jul 2025 00:00:00 +0530 In a major step forward for diagnostic healthcare in India, Lieutenant Governor of Delhi Vinai Kumar Saxena inaugurated the new centre of Mahajan Imaging & Labs, in Dwarka. The event also marked the launch of India's first Ultra-Fast AI-powered MRI scanner, the “Excel 3T,” positioning Delhi at the forefront of medical innovation. Marking a significant expansion in Southwest Delhi, the new facility brings together multiple branches of advanced diagnostics—including imaging, laboratory medicine, and genetic testing—within easy reach for residents of Dwarka and nearby areas. Alongside this integrated approach, the centre also offers deep specialisation in key areas, especially cardiac imaging apart from neuroimaging, and musculoskeletal scans, addressing the growing demand for precision-led, organ-specific diagnostics. Thoughtfully designed with a patient-first approach, the space features locally sourced materials, ample natural light, and calming palettes that promote comfort and well-being. Its energy-efficient systems and water reuse mechanisms underscore a conscious approach to sustainable healthcare. Making its Indian debut at this facility, the Excel 3T MRI delivers up to 50% better signal-to-noise ratio, producing sharper, high-resolution images in less time. Cardiac MRI scans, for instance, have been reduced from more than an hour to just 30–40 minutes. Its advanced technologies, such as real-time motion correction, AI-driven reconstruction, and contactless respiratory tracking, help improve precision and make scans more tolerable for children, elderly patients, and those with claustrophobia. An immersive in-bore experience and smart automation further enhances comfort during procedures. The Dwarka centre, which offers advanced preventive health checks, also features a comprehensive range of advanced diagnostic technologies, including a 128-slice cardiac CT scanner, Full Field Digital mammography, 3D/4D Ultrasound with AI, Digital X-Ray, Dexa BMD, Echocardiography, Holter, and PFT systems. Many of these, such as the MRI, CT and ultrasound machines are AI-enabled—enhancing the speed, precision, and efficiency of diagnostics. ]]> https://biospectrumindia.com/news/93/26379/iit-delhi-inaugurates-state-of-the-art-mri-research-facility.html https://biospectrumindia.com/news/93/26379/iit-delhi-inaugurates-state-of-the-art-mri-research-facility.html Mon, 14 Jul 2025 00:00:00 +0530 The Indian Institute of Technology Delhi (IIT Delhi) has inaugurated a cutting-edge Magnetic Resonance Imaging (MRI) research facility, established under the Institute of Eminence (IoE) initiative. Prof. Rangan Banerjee, Director of IIT Delhi, formally inaugurated the facility. Equipped with a 1.5 Tesla clinical-grade MRI scanner, this facility is the first of its kind among leading engineering and technology institutions in India, dedicated exclusively to research and teaching. Unlike conventional MRI setups embedded within hospital ecosystems, this facility is designed to foster unrestricted innovation in medical imaging, particularly in Magnetic Resonance Imaging (MRI).     This facility will enable cutting-edge research in various areas across applications in MR imaging, including the development of new contrast agents, acquisition sequences, optimisation of imaging protocols, development of MR-compatible devices, and integration of artificial intelligence in image processing. This landmark achievement represents a major stride in India’s biomedical research capabilities and reaffirms IIT Delhi’s commitment to driving innovation in healthcare technology. Located within the Centre for Biomedical Engineering (CBME) at IIT Delhi, the facility will initially support research using phantoms and, with appropriate regulatory approvals, will extend to clinical studies involving volunteers. It will also serve as a hands-on training platform for students enrolled in IIT Delhi medical imaging courses, enhancing their practical exposure to advanced imaging technologies. ]]> https://biospectrumindia.com/news/93/26368/yashoda-medicity-and-intuitive-establish-indias-first-dual-bay-robotic-assisted-surgery-training-centre.html https://biospectrumindia.com/news/93/26368/yashoda-medicity-and-intuitive-establish-indias-first-dual-bay-robotic-assisted-surgery-training-centre.html Fri, 11 Jul 2025 00:00:00 +0530 Yashoda Medicity, a leading healthcare institution recognised for its excellence in patient care, has partnered with Intuitive, a global pioneer in minimally invasive care and robotic-assisted surgery, to establish an advanced robotic-assisted surgery (RAS) training centre at Yashoda Medicity, Indirapuram, Ghaziabad.  Harsh Malhotra, Union Minister of State in the Ministry of Corporate Affairs, Road Transport and Highways, inaugurated the training centre, in the presence of Sunil Sharma, Minister for IT and Electronics, Government of Uttar Pradesh. The training centre will equip surgeons and care teams with the skills to perform robotic-assisted surgery across specialities such as urology, gynaecology, general surgery, and more. Through this partnership, Yashoda Medicity, Indirapuram, Ghaziabad aims to accelerate the adoption of robotic-assisted surgery in India by offering advanced technology training and building a strong, future-ready surgical ecosystem nationwide. The dual-bay configuration is designed to significantly increase training capacity by enabling parallel sessions or advanced collaborative learning, making it possible to train more professionals efficiently while maintaining high standards of surgical technology training. The centre aims to offer an immersive training experience that supports standardised learning, consistent skill development across procedures, and hands-on practice. Dr P.N. Arora, Chairman and Managing Director of Yashoda Group of Hospitals, said, “Being among the first few hospitals in the country to establish a dual-bay robotic-assisted surgery training centre reflects our dedication to bringing global best practices to Indian healthcare. This centre will play a key role in training skilled surgeons and advancing surgical standards. We remain committed to building centres of excellence that drive progress and improve the future of patient care.”   ]]> https://biospectrumindia.com/news/93/26341/deeptek-ai-solution-gains-who-recommendation-in-global-fight-against-tb.html https://biospectrumindia.com/news/93/26341/deeptek-ai-solution-gains-who-recommendation-in-global-fight-against-tb.html Mon, 07 Jul 2025 00:00:00 +0530 Pune-based startup DeepTek, a leading medical imaging AI company, has received a significant recommendation from the World Health Organization (WHO) for its Chest X-ray AI solution for TB screening. In its latest policy guidance, WHO recommended the solution as meeting the performance standards for Computer-Aided Detection (CAD) softwareused in tuberculosis (TB) screening across both community and facility-based screeningsettings. This recommendation underscores the solution’s clinical reliability, global scalability, and real-world impact—making it one of the few AI tools globally validated for identifying presumptive TB cases rapidly and accurately, particularly in low-resource settings. In 2022, 10.6 million people were diagnosed with TB, with the highest burden seen in South-East Asia, Africa, and the Western Pacific. These regions often face a shortage of radiologists and fragmented screening systems, leading to delayed diagnosis and treatment. DeepTek’s Chest X-ray AI solution addresses this challenge head-on by delivering rapid analysis of chest X-rays in under a minute, even in remote areas without internet connectivity, making early intervention possible at scale. DeepTek’s Chest X-ray AI solution is certified by both the US FDA and EU CE MDR. Beyond detecting tuberculosis, it identifies over 21 other critical lung abnormalities—including nodules, masses, and pneumothorax—making it highly versatile for public health programs and routine lung screenings. A key differentiator of our solution is its ability to interpret pediatric chest X-rays for children aged four and above. DeepTek’s platform supports end-to-end patient management across the TB screening workflow. Digital X-ray machines are used to capture chest scans, which are analysed by DeepTek’s AI engine to generate TB risk predictions in under a minute. The system operates seamlessly even in offline settings, with data securely synced to the cloud once connectivity is restored.   ]]> https://biospectrumindia.com/news/93/26332/ssi-mantram-made-in-india-surgical-robot-yatra-kicks-off-india-tour.html https://biospectrumindia.com/news/93/26332/ssi-mantram-made-in-india-surgical-robot-yatra-kicks-off-india-tour.html Fri, 04 Jul 2025 00:00:00 +0530 SS Innovations, the maker of India’s first and only home-grown surgical robotic system, SSI Mantra, recently flagged off the SSI MantraM “Made in India” Surgical Robot Yatra from its headquarters in Gurugram. The roadshow was ceremoniously inaugurated by Rao Narbir Singh, Minister for Industries & Commerce, Government of Haryana. With the launch of the SSI MantraM Surgical Robot Yatra, India embarks on a transformative journey in healthcare, unveiling its first mobile robotic surgery training and demonstration unit. This innovative 'telesurgery-on-wheels' initiative brings cutting-edge surgical technology and skill-building opportunities directly to hospitals and healthcare professionals across the country. Developed indigenously, the unit is equipped to enable real-time collaboration and demonstrate the advanced features and capabilities of the SSI Mantra Surgical Robotic System. Through live simulations, interactive training modules, and guided demonstrations, it offers surgeons, medical students, and healthcare stakeholders a first-hand experience. This initiative marks a significant step toward increasing awareness and acceptance of robotic surgery in particularly by making cutting-edge surgical technologies more accessible to Tier 2 and Tier 3 cities. As part of its first leg through Rajasthan, the SSI MantraM Yatra has commenced on July 3 & 4 at SMS Medical College, Jaipur, featuring live demonstrations and interactive training sessions for both the medical fraternity. Later in the afternoon on July 4th , the MantraM will move to AIIMS Jodhpur, the yatra will participate in the RUFCON until July 6th. On the July 6th evening, proceed to Mathura Das Mathur Medical College for more sessions on July 7. The Rajasthan leg will conclude on July 8 with a final showcase at Jawaharlal Nehru Medical College, Ajmer, before returning to Gurugram.   Covering over 1,500 kilometres, the first leg of the Yatra will offer transformative training and learning opportunities to more than 500 doctors across Rajasthan, furthering SSI Innovations’ mission to democratize access to advanced surgical technologies in India. The total cost of SSI MantraM, including structural modifications, is approximately Rs 1.3 crore. However, this cost does not include the SSI Mantra Surgical Robotic System, whose price varies depending on features and robotic arm configurations.   ]]> https://biospectrumindia.com/news/93/26299/surgical-associations-urge-streamlined-insurance-implementation-for-robotic-assisted-surgery.html https://biospectrumindia.com/news/93/26299/surgical-associations-urge-streamlined-insurance-implementation-for-robotic-assisted-surgery.html Sat, 28 Jun 2025 00:00:00 +0530 Recognising the regulatory shift brought about by the Insurance Regulatory and Development Authority, IRDAI’s 2024 directive mandating coverage for robotic-assisted surgeries, key surgeon associations in India have stressed the need for uniform implementation across health insurance providers to ensure consistent patient access. “The healthcare industry in India has seen remarkable progress in recent years, and robotic technology has been central to this transformation in surgical care—not only by improving clinical outcomes but also by enhancing the overall patient experience during and after surgery,” said Dr Vivek Bindal, Chairman, Clinical Robotic Surgery Association (India Chapter). “Both emerging clinical evidence and real-world surgical experience indicate that robotic-assisted surgery is associated with lower recurrence rates, reduced need for blood transfusions, and a measurable decline in mortality.” With robotic-assisted surgery (RAS) now included under mandated health insurance coverage, many private insurers are gradually aligning with the directive. However, inconsistencies in claim approvals, sub-limits, and coverage caps across providers still hinder patient access. “As robotic-assisted surgery increasingly becomes standard in both public and private hospitals, it is important for insurance coverage and implementation to keep pace with clinical practice. The IRDAI mandate marked a pivotal shift in acknowledging the clinical value of robotic surgery. What we now need is consistent coverage inclusion in policy and implementation across providers and insurers alike,” Dr. Bindal added.  Even with mandated insurance coverage in place, robotic-assisted surgery often encounters uneven implementation on the ground. This disconnect has shifted the financial burden onto patients, who are frequently forced to weigh the clinical benefits of RAS against the risk of high out-of-pocket expenses. Nevertheless, clinicians continue to see growing demand for robotic procedures, driven by greater awareness and patient preference. “Despite knowing that the insurance might not cover the expense, a lot of patients choose robotic-assisted surgery over traditional laparoscopic or open surgery, even for benign conditions considering the benefits the surgical procedure offers. This reflects the high satisfaction and positive outcomes that patients experience with the robotic approach,” said Dr Randeep Wadhawan, President, Obesity and Metabolic Surgery Society of India.  “Collaboration among healthcare providers, insurers, and policymakers is crucial to making robotic-assisted surgery more accessible to a wider population,” Dr Wadhawan added. ]]> https://biospectrumindia.com/news/93/26269/kayas-artiqa-offers-non-invasive-breakthrough-in-tackling-obesity-and-body-contouring.html https://biospectrumindia.com/news/93/26269/kayas-artiqa-offers-non-invasive-breakthrough-in-tackling-obesity-and-body-contouring.html Thu, 19 Jun 2025 00:00:00 +0530 Kaya, India’s leading dermatology and aesthetic care brand, has launched Artiqa, a next-generation aesthetic device from Italy designed to help tackle stubborn fat and body contouring challenges.   By combining thermal hot and cold therapy with Electro Muscle Stimulation (EMS), Artiqa offers a safe and effective way to reduce inches, tone muscles, and rejuvenate skin—all without pain, needles, or downtime. It’s a breakthrough solution for those looking to manage weight, shape, and skin health—naturally and non-invasively.   As more Indians look for beauty treatments that are effective yet gentle, Artiqa brings an advanced solution backed by medical-grade safety and clinical precision. Whether it is firming up the skin, reducing cellulite, toning muscles, or speeding up postpartum recovery, Artiqa provides visible improvement without surgery or downtime.   The CE-certified device (Class IIb) uses smart temperature sensors to ensure comfort and safety during each session. It also improves lymphatic drainage, boosts collagen production, and helps with cryofacials, making it ideal for fitness lovers, new mothers, and anyone wanting natural-looking, anti-aging results.   With Artiqa, Kaya is raising the bar in non-invasive aesthetic care and bringing international technology to Indian clinics, while ensuring the highest standards of comfort, safety, and results.       ]]> https://biospectrumindia.com/news/93/26260/virohan-partners-with-orange-health-labs-to-place-skilled-medical-laboratory-technologists.html https://biospectrumindia.com/news/93/26260/virohan-partners-with-orange-health-labs-to-place-skilled-medical-laboratory-technologists.html Wed, 18 Jun 2025 00:00:00 +0530 With India’s medical diagnostics market projected to grow significantly and reach $44.87 billion by 2030, Gurugram-based startup Virohan, a leading institute for healthcare education, has partnered with Bengaluru-based Orange Health Labs to offer Medical Laboratory Technology (MLT) students internships and job opportunities across 76 cities, including major hubs like Mumbai, Delhi NCR, and Bengaluru. Orange Health Labs, launched in 2020, is a leading diagnostics provider in India, offering fast, at-home medical testing with 60-minute sample collection and reports delivered within six hours. Its mission is to make high-quality diagnostics accessible and convenient. By revolutionizing the industry with its on-demand, at-home testing model and partnering with over 1,000 clinics, Orange Health is committed to making healthcare more efficient and patient-centric. The company currently hires around 300 MLT professionals annually, with demand expected to grow to 1,000 professionals per year over the next five years as it expands its reach. Virohan equips future Medical Laboratory Technologists with comprehensive education and training in clinical pathology, hematology, immunology, serology, and many more. The curriculum includes subjects such as biochemistry, histopathology, and cytopathology, along with advanced skills in blood banking and laboratory management. By combining classroom education with hands-on diagnostic practice, Virohan aims to bridge the gap between education and employment—producing work-ready talent for India’s rapidly evolving healthcare ecosystem. While technology and AI have enhanced the efficiency of the entire ecosystem, a pressing concern remains: the growing shortage of skilled frontline workers like phlebotomists. As traditional diagnostic collection centers phase out, the demand for MLT professionals is set to rise sharply, particularly in urban areas, yet India’s skilling ecosystem remains unprepared. According to GlobeNewswire, the country’s diagnostics sector is projected to triple by 2030, but a significant talent gap threatens to hinder this growth. ]]> https://biospectrumindia.com/news/93/26248/aster-institute-of-advanced-orthopedics-robotic-surgery-opens-in-bengaluru.html https://biospectrumindia.com/news/93/26248/aster-institute-of-advanced-orthopedics-robotic-surgery-opens-in-bengaluru.html Mon, 16 Jun 2025 00:00:00 +0530 Bengaluru-based Aster RV Hospital has recently launched their world class Aster Institute of Advanced Orthopedics & Robotic Surgery (AIAORS).  The institute leverages cutting edge robotic technology, along with world class specialists to perform minimally invasive and accurate orthopedic procedures. The institute was inaugurated by CP Yogeshwar - MLA & MP Shayam Shetty, President, RV Trustees. The launch event saw more than 250 people attend. The department is headed by Dr JV Srinivas, Lead & Senior Consultant, Orthopedic & Joint Surgery, Aster RV Hospital and can perform many complex orthopedic surgeries, using their state-of-the-art Cori Surgical System. The robotic system helps with knee replacements, hip replacements and revision knee replacement surgeries as well. The institute provides treatments for people with knee degradations, hip injuries, foot and ankle injuries, sports injuries, spine surgeries, advanced orthopedic procedures like GFC/PRP and stem cell therapy, pediatric orthopedics and Robotic Knee Replacement Surgery for accurate positioning of implants. The institute also provides services such as trauma / fracture surgeries and management of open fractures, Joint Replacement surgeries of knee and hip (TKR and THR), Ortho Onco Surgery, Hand Surgery Limb Reconstruction Surgery, Keyhole surgeries such as Arthroscopic Ligament Reconstruction (ACL, PCL and Multi-ligament), meniscus and chondral surgeries, A fusion of joints (Arthrodesis), Polytrauma Management, Complex pelvic and acetabular fracture, and Pediatric orthopaedic surgeries for clubfoot, congenital hip dysplasia, bone and joint infection management. ]]> https://biospectrumindia.com/news/93/26231/renalyx-launches-worlds-first-indigenous-ai-based-smart-hemodialysis-machine.html https://biospectrumindia.com/news/93/26231/renalyx-launches-worlds-first-indigenous-ai-based-smart-hemodialysis-machine.html Wed, 11 Jun 2025 00:00:00 +0530 Bengaluru-based Renalyx Health Systems has launched RENALYX – RxT 21, world's first fully indigenous, artificial intelligence (AI) and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility.   Price starting at Rs 6.7 lakh - significantly lower than the imported machines - RENALYX – RxT 21 will make dialysis affordable and accessible to a larger population and bridge the demand-supply gap in the renal care across semi-urban and rural regions.   Completely designed and manufactured in India, RENALYX – RxT 21 leverages latest technologies including cloud-based telenephrology platforms to offer safety and quality care to kidney patients, end-stage renal disease (ESRD) patients especially those with cardiovascular, pulmonary and acute kidney injury-related issues.   RENALYX – RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification.   Renalyx has plans to invest Rs 800 crore in the next four years to build the manufacturing capacity of 5,000 machines by FY25-26 and will develop additional capacity of 1500 machines by FY27-28. The company also have plans to manufacture consumables indigenously. The company has manufacturing facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra to support its scale-up plans and meet the growing demand.   The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. Renalyx also has plans to go public within the next three years.   With initial deployments of the machine planned in Maharashtra and Karnataka, Renalyx will go for rapid pan-India distribution of RENALYX – RxT 21 with its partners as well as exports to other countries. The company has successfully penetrated international markets, securing orders from South Africa, the USA, and Europe.   The Indian CDSCO approval of the machine is in its final stages and is expected by July 2025, while the US FDA approval process is underway and anticipated by March 2026.   Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres and hospitals to make renal care available to a large number of people.    The company, in collaboration with its partner, will set up franchise centres across India and in international markets.   In addition, Renalyx has awarded manufacturing license to Bharat Electronics Ltd. (BEL) to produce 6,000 RENALYX – RxT 17 in the next three years. RENALYX – RxT 17 is a previously launched dialysis machine by Renalyx which comes with standard features and facilities.  ]]> https://biospectrumindia.com/news/93/26217/stryker-launches-advanced-icu-air-mattress-apaiser-x1-designed-for-indian-market.html https://biospectrumindia.com/news/93/26217/stryker-launches-advanced-icu-air-mattress-apaiser-x1-designed-for-indian-market.html Mon, 09 Jun 2025 00:00:00 +0530 Stryker, one of the world’s leading medical technology companies, has announced the launch of its advanced ICU air mattress, APAISER X1, at ANEiCON 2025, the annual conference of the Association of Nurse Executives (ANEi) India, held in Kochi. Tailored specifically for the Indian market, the APAISER X1 seamlessly integrates with Stryker’s SmartMedic platform; and is designed to enhance patient comfort, reduce the risk of pressure injuries and improve caregiver efficiency in critical care settings. Key features include independent low-air loss technology, a 3-in-1 TrueCare alternating pressure system, and three customizable care modes: Alternate, Static, and Constant Low Pressure. Other notable features include auto fowler detection, a quiet pump for noise-sensitive environments, and a transportation cap that preserves mattress pressure for extended periods without power, ensuring continuity of care during patient transfers or power outages. Arvind Srinivas, Business Unit Director, Medical, said, "The increasing need for better patient outcomes and stronger caregiver support demands innovations that combine advanced technology with solutions tailored to local challenges. APAISER X1 is a proud ‘Customised for India’ innovation, crafted to enhance patient comfort and assist nurses in critical care. We look forward to collaborating with healthcare professionals to elevate ICU care across the country." With the launch of APAISER X1, Stryker reinforces its focus on developing meaningful innovations that address unmet clinical needs and empower caregivers with technology-driven solutions. ]]> https://biospectrumindia.com/news/93/26209/tracky-launches-indias-first-bluetooth-connected-continuous-glucose-monitor.html https://biospectrumindia.com/news/93/26209/tracky-launches-indias-first-bluetooth-connected-continuous-glucose-monitor.html Thu, 05 Jun 2025 00:00:00 +0530 To tackle one of the country’s most pressing health challenges, Thane-based startup Tracky, an innovative healthtech brand by DrStore Healthcare Services, has officially launched its flagship product - India’s first Bluetooth-enabled Continuous Glucose Monitor (CGM). With this revolutionary device, Tracky is all set to transform diabetes care and preventive health management across the country. This addition comes as a vital addition to the company's vision of creating a holistic smart medical devices ecosystem.   The state-of-the-art device embeds modern sensor technology with a bluetooth-enabled transmitter and a mobile app. Ultimately, it emerges as a future-ready solution for glucose monitoring and management for the Indian populace while also focusing on innovation, affordability and accessibility.  Traditional CGM systems in India remain limited by outdated NFC technology, high sensor costs and inconvenient user experiences. Being recognised as a preventive healthtech player, Tracky changes that narrative by offering real-time, scan-free glucose monitoring at a significantly more accessible price point which brings global innovation within reach of the Indian consumer. Equipped with real-time Bluetooth Connectivity, Tracky enables automatic syncing with the Tracky Health App every three minutes. It is a scan free solution that delivers instant glucose readings and customisable alerts for high or low levels to empower each user to take a timely action without manual intervention. It enhances convenience, accuracy and consistency to make it easier to manage diabetes on the go.  Additionally, Tracky has designed its Health app on both Android and iOS to offer a complete lifestyle tracking experience. It allows users to log food, medication and physical activity to create a holistic view of their health. The company is planning to integrate AI-enabled features to provide personalised insights, predictive alerts and trend based analytics.  The Tracky CGM welcome kit is priced at an introductory offer of Rs 5,999 which comes with a sensor and a transmitter which is the reusable and rechargeable bluetooth unit. From the second use onward, users only need to purchase the sensor, which costs Rs 3,899 as the same transmitter can be reused for up to 2 years.   ]]> https://biospectrumindia.com/news/93/26186/multi-institutional-study-highlights-role-of-robotic-assisted-surgery-in-reshaping-gynaecological-care-in-india.html https://biospectrumindia.com/news/93/26186/multi-institutional-study-highlights-role-of-robotic-assisted-surgery-in-reshaping-gynaecological-care-in-india.html Thu, 29 May 2025 00:00:00 +0530 As India observes Women’s Health Month in May, a study conducted across five tertiary care hospitals by analysing the data of surgeries performed using the da Vinci technology over a decade is shedding light on how robotic-assisted surgery (RAS) is steadily transforming gynaecological care across the country. The study documents a significant rise in the use of robotic surgery for both benign and malignant conditions and is significant for its implications on access, recovery, and surgical outcomes for women. The multi-institutional study—‘Trends in Gynecological Robotic Surgery in India: A Real-World Scenario’—analysed data from ten years across five hospitals: Apollo Health City (Hyderabad), PGIMER (Chandigarh), Manipal Hospital (Bengaluru), Narayana Health (Bengaluru), and Tata Memorial Hospital (Mumbai). Notably, over 70% of robotic gynaecological procedures took place in the final five years, indicating a strong upward trajectory. “Women’s Health Month is a time to reflect on how surgical technology innovations like the da Vinci robotic technology are enhancing healthcare outcomes for women,” said Dr Rooma Sinha, Honorary Professor and Chief Gynaecologist at Apollo Health City, Hyderabad, one of the surgeons who oversaw the study. “Robotic-assisted surgery is increasingly being used to manage benign gynaecological conditions such as fibroids and endometriosis, offering enhanced precision and improved outcomes across a wide range of cases.” Many studies across the globe show reduced blood loss and faster recovery times for robotic-assisted surgery compared to other modalities. The patients in this study similarly experienced minimal blood loss and faster recovery times. Dr Sinha, who is also the Founder-President of Association of Gynecological Robotic Surgeons, noted that “Even in cases involving large fibroids or endometriosis, we were able to keep blood loss low, recovery times short, and port-site pain/discomfort minimal. That matters a lot in a country like India, where patients often travel long distances for care and want to return home quickly.”  The study found that fibroids were the most common benign indication for robotic surgery, followed by endometriosis, adenomyosis, vault prolapse, and ovarian cysts. These conditions often require careful dissection and suturing, particularly when fertility preservation is important. While more public and private insurers are beginning to include robotic-assisted surgery (RAS) in their coverage, the study highlights that there is still room to improve affordability and access. To optimise value and accessibility, surgeons are refining techniques—using fewer robotic arms and incorporating multifunctional instruments—to reduce costs while still delivering high-quality care and better patient outcomes. “Given the clear benefits demonstrated in studies like this, there is a strong case for insurance payers to further expand coverage for robotic-assisted surgery. Broader, streamlined reimbursement support can help ensure more women across India have access to advanced surgical options,” Dr Saha added. ]]> https://biospectrumindia.com/news/93/26165/aerolase-brings-breakthrough-laser-technology-to-india-for-transforming-future-of-aesthetic-care.html https://biospectrumindia.com/news/93/26165/aerolase-brings-breakthrough-laser-technology-to-india-for-transforming-future-of-aesthetic-care.html Mon, 26 May 2025 00:00:00 +0530 US-based Aerolase, a global pioneer in aesthetic laser technology, marks its entry into India with its award-winning flagship products, Neo Elite and Era Elite—optimised to address key Indian skin concerns such as pigmentation, acne, and rejuvenation. With an established international presence in markets like the US, UK, and Canada, Aerolase brings its clinically proven, high-performance laser systems to India's rapidly evolving aesthetic sector. The brand’s groundbreaking technology delivers safer, comfortable, and pain-free treatments with zero downtime, perfectly suited to the lifestyle of India’s busy, urban consumers. With its new office in Bengaluru, Aerolase is strategically positioned to provide dedicated support, training, and customer care, ensuring seamless integration into India’s vibrant aesthetic community. India’s dermatology and aesthetic market is among the fastest-growing globally, projected to grow at a CAGR of 10.11% from 2025 to 2032. Aerolase’s entry is perfectly timed to meet India’s rising demand, fueled by increasing disposable incomes, rapid urbanization, and heightened awareness of advanced skincare treatments. Pavel Efremkin, CEO, Aerolase said, “India’s vibrant demographics, escalating awareness and investment in skin health, and thriving medical tourism landscape make it a pivotal hub for cutting-edge aesthetic care. With an accelerating demand for safer, precise, and downtime-free procedures, Aerolase’s FDA-approved technologies are uniquely positioned to empower Indian clinics and dermatologists to deliver world-class treatments tailored specifically for Indian skin." Madhusudan HK, Country Head, Aerolase India, added, “While India’s aesthetic dermatology space is rapidly expanding, there remains a significant gap in access to advanced laser solutions that are truly effective, safer, and inclusive of all skin types. Aerolase aims to bridge this gap by offering highly personalized, zero-downtime treatments that are ideal for Indian skin concerns — from pigmentation to acne and rejuvenation. We are also laying the foundation to collaborate with reputed homegrown clinics and brands to scale our presence responsibly and sustainably.”   ]]> https://biospectrumindia.com/news/93/26154/mahe-and-bpl-medical-technologies-forge-strategic-partnership-to-advance-medical-device-innovation.html https://biospectrumindia.com/news/93/26154/mahe-and-bpl-medical-technologies-forge-strategic-partnership-to-advance-medical-device-innovation.html Sat, 24 May 2025 00:00:00 +0530 Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University, and BPL Medical Technologies Private Limited have signed a landmark Memorandum of Understanding (MoU) to foster industry-academia collaboration, drive innovation in medical devices, and equip future healthcare professionals with hands-on experience. The partnership, signed under MAHE's "Year of Excellence in Industry-Academia Collaboration” initiative, aims to combine academic research with industry expertise to develop clinically validated, cost-effective medical devices for both Indian and global markets. The partnership aims to promote academic research cooperation, joint educational activities, exchange of scholars, and shared internship opportunities. Both institutions will collaborate to develop clinically validated, cost-effective medical devices tailored for emerging markets, with a focus on the ‘Make in India’ vision. “This collaboration represents a significant step towards bridging the gap between academia and industry,” said Dr H S Ballal, Pro Chancellor, MAHE. "By combining our research capabilities with BPL's industrial expertise, we can develop healthcare solutions that are not only innovative but also affordable for rural populations," he added. Emphasizing the broader vision Lt Gen (Dr) Venkatesh, Vice Chancellor, remarked, “Our institutions share a common vision of advancing healthcare technology. This partnership will provide our students and researchers with valuable real-world exposure while contributing to meaningful healthcare innovations." ]]> https://biospectrumindia.com/news/93/26141/indias-orthopaedic-and-cardiac-implant-sector-to-touch-5-b-by-fy28-report.html https://biospectrumindia.com/news/93/26141/indias-orthopaedic-and-cardiac-implant-sector-to-touch-5-b-by-fy28-report.html Wed, 21 May 2025 00:00:00 +0530 According to CareEdge Ratings, India’s orthopaedic and cardiac implant sector, including exports, which stood at ~$2.4 to $2.7 billion in FY24, is expected to reach ~$4.5 to $5 billion by FY28, driven by strong domestic demand and gradually growing export presence. Foreign MNCs, with their long track record of safety and efficacy, have built trust among medical practitioners, which has led to their dominance in the Indian market. However, Indian implant manufacturers are making rapid strides in the domestic market and are gradually expanding their presence in the export market. CareEdge Ratings cited that with only 7.5% customs duty on the import of most coronary and orthopaedic implant products, any potential trade deal with the US resulting in tariff reduction is not likely to materially change the market dynamics for domestic manufacturers. However, material changes in non-tariff barriers, such as the relaxation of price caps, can significantly alter the competitive landscape for domestic manufacturers compared to MNCs. The prices of knee implants are capped at approximately ~Rs 32,000 to ~ Rs 83,000, depending on the type and material used. Drug-eluting stents are capped at ~Rs 38,000, while bare metal stents have a ceiling price of ~Rs 10,500. ]]> https://biospectrumindia.com/news/93/26112/nit-rourkela-designs-breakthrough-ecg-lead-system-for-enhanced-diagnosis-of-atrial-arrhythmias.html https://biospectrumindia.com/news/93/26112/nit-rourkela-designs-breakthrough-ecg-lead-system-for-enhanced-diagnosis-of-atrial-arrhythmias.html Thu, 15 May 2025 00:00:00 +0530 Researchers at National Institute of Technology (NIT) Rourkela, Odisha, have developed an effective upgrade to Electrocardiography (ECG), one of the most commonly used techniques to monitor heart activity. This new system helps in easily detecting subtle electrical signals from the upper chambers of the heart, which are often too indistinct to be seen clearly in regular ECGs. These signals play a key role in identifying abnormal heart rhythms that can lead to serious conditions such as atrial fibrillation which can further lead to stroke. Irregular heart rhythms, or arrhythmias, are responsible for a large number of cardiac-related deaths around the world. Irregular heart rhythm in the heart’s upper chambers, known as atrial arrhythmias, are among the most common, especially in patients who have been hospitalised. Identifying these arrhythmias in early state can help doctors begin timely treatment and prevent complications. Detecting atrial arrhythmias can sometimes be difficult, particularly in busy clinical settings or with low-cost monitoring equipment. To address this challenge, NIT Rourkela research team has designed a novel lead placement system called the Atrial Lead System (ALS). In an ECG, leads refer to specific patterns of electrical measurement created by placing electrodes on different parts of the body. Lead placement involves positioning these electrodes to capture clear signals from the heart. The ALS uses a modified arrangement to improve how electrical activity from the atria is recorded. By strengthening these signals, especially the P-wave, the system helps improve the accuracy of arrhythmia detection, both by doctors and by computer-based diagnostic tools. One of the most promising aspects of this work is that it requires no change to the ECG machine itself. The innovation lies entirely in the way the leads are placed, which means the upgrade can be easily adopted in both public and private healthcare settings without additional cost. The research team has also filed a patent application for the Atrial Lead System. The project has received financial backing from the Anusandhan National Research Foundation (ANRF), Government of India. This collaborative achievement by NIT Rourkela, MIOT International, Chennai, and Jaiprakash Hospital, Rourkela, represents the impactful synergy between academic research and clinical practice, paving the way for significant advancements in cardiac diagnostics and patient care across India and beyond. ]]> https://biospectrumindia.com/news/93/26106/abbott-introduces-tactiflex-sensor-enabled-ablation-catheter-in-india.html https://biospectrumindia.com/news/93/26106/abbott-introduces-tactiflex-sensor-enabled-ablation-catheter-in-india.html Wed, 14 May 2025 00:00:00 +0530 Abbott, the global healthcare company, has announced the launch of the TactiFlex Sensor Enabled Ablation Catheter, the world’s first ablation catheter with a flexible tip and contact force technology.   The heart uses its own electrical system to start up every beat. But if that system breaks down, and the heart beats in an irregular way, that’s arrhythmia. The most common type of irregular heartbeat is called atrial fibrillation, or AFib, for short. It’s caused by electrical impulses that misfire, causing the top chambers, or atria, to quiver or flutter.    Cardiac ablation is a minimally invasive procedure in which a physician accesses the heart through a blood vessel. A catheter (a long, steerable tube) enters the vessel and is placed in the heart where diagnostic devices will be used to determine the area of the heart that needs to be treated. The physician will use the catheter to apply energy to the targeted heart tissue to create small scars. These block the faulty electrical signals that cause the irregular heartbeat. TactiFlex is a catheter used to perform ablation procedures that treat AFib. This device results in reduced procedure times and better safety as compared to the company’s previous generation catheters.   “For those suffering from AFib, daily tasks can be challenging due to dizziness, chest pain and heart palpitations. If left untreated, AFib can also lead to a stroke, making it critical to address the issue as early as possible,” said Henry Cheng, General Manager, Asia and Director Strategy, Asia Pacific for Abbott’s Electrophysiology business. “This device helps doctors restore normal heart rhythms by guiding electrical currents back to their proper pathways.”   “When used with the EnSite X EP System, doctors can accurately map and identify areas of the heart that need treatment, ensuring precise results and better patient outcomes. Unlike other catheters, the TactiFlex catheter uses a tip design with a laser-cut pattern that flexes when in contact with the heart wall. This helps direct fluid to the treated tissue and allows for more accurate positioning of the catheter – providing up to two-times higher stability in a beating heart – for consistent therapy delivery,” said Rahul Sharma, Country Manager for Abbott’s Electrophysiology business in India.   ]]> https://biospectrumindia.com/news/93/26092/johnson-johnson-medtech-partners-with-qure-ai-to-boost-early-detection-of-lung-cancer-in-india.html https://biospectrumindia.com/news/93/26092/johnson-johnson-medtech-partners-with-qure-ai-to-boost-early-detection-of-lung-cancer-in-india.html Thu, 08 May 2025 00:00:00 +0530 Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has onboarded Qure.ai, a global leader in artificial intelligence (AI) for healthcare, as a strategic partner with Johnson & Johnson Private Limited, a Johnson & Johnson company, to enhance early detection of lung cancer in India. This collaboration brings together cutting-edge AI and medical technology, helping identify lung cancer at its most treatable stage.This initiative is part of Project BreatheEZ, a broader strategic collaboration between Qure.ai and Johnson & Johnson MedTech, and designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across leading hospitals in India. These clinics will act as integrated screening hubs, optimizing early detection, triaging, and follow-up care for lung cancer patients. As part of this collaboration, Qure.ai’s AI technology will be deployed across 10 hub medical centres in India, with an additional 20 supporting spoke sites. The first such clinic has been launched in Thangam Cancer Centre in Namakkal, Tamil Nadu.In India, one in nine persons is likely to be diagnosed with cancer in their lifetime. It is an increasing health concern, and the projected cancer burden is expected to rise from 26.7 million DALYs (Disability-Adjusted Life Years) in 2021 to 29.8 million in 2025.By harnessing of artificial intelligence in the modalities of X-Ray & CT scans, Johnson & Johnson MedTech India & Qure.ai are enabling the detection of potential lung nodules that might otherwise be missed. This happens through flagging risky nodules in X-Rays and CT Scans that can potentially turn out to be malignant. It also introduces the concept of structured IPN clinics where there is a proactive impetus towards incidental screening of early-stage lung cancer. This partnership embodies Johnson & Johnson MedTech’s commitment to enhancing early lung cancer detection, ultimately transforming the standard of lung cancer care.Anuj Virmani, Managing Director, India, Johnson & Johnson MedTech, said, “Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment."  ]]> https://biospectrumindia.com/news/93/26075/yashoda-medicity-introduces-indias-first-elekta-unity-mr-linac-with-integrated-cmm.html https://biospectrumindia.com/news/93/26075/yashoda-medicity-introduces-indias-first-elekta-unity-mr-linac-with-integrated-cmm.html Mon, 05 May 2025 00:00:00 +0530 Ghaziabad-based Yashoda Medicity has introduced the Elekta Unity MR Linac, an advanced radiation therapy system combining Magnetic Resonance Imaging (MRI) with a Linear Accelerator (LINAC) and Integrated CMM for the first time in India.This marks the first installation in India with advanced integrated CMM (Comprehensive Motion Management). The Elekta Unity MR Linac features a high-resolution 1.5 T MRI, which allows for real-time imaging during radiation therapy. This capability enables doctors to visualize tumors and surrounding healthy tissues with exceptional clarity and adapt treatment plans based on daily anatomical changes. The result is improved targeting accuracy, reduced damage to healthy organs, and enhanced treatment outcomes for patients. Unlike traditional CBCT systems, Elekta Unity’s MRI offers superior soft-tissue contrast, improving tumor visualization. It also supports hypo fractionated treatments, delivering higher doses in fewer sessions, which optimizes patient convenience and clinical resources. It allows sub-millimetric accuracy and is particularly effective for treating tiny tumours, lymph nodes, and oligometastatic lesions. Additionally, remote access allows clinicians to review and approve treatment plans from any location, improving workflow efficiency. The system also paves the way for Biology-Guided Radiotherapy (BgRT), an emerging approach using biological markers like gene expression or hypoxia levels to further personalize radiation therapy. ]]> https://biospectrumindia.com/news/93/26068/ss-innovations-international-makes-historic-nasdaq-debut.html https://biospectrumindia.com/news/93/26068/ss-innovations-international-makes-historic-nasdaq-debut.html Fri, 02 May 2025 00:00:00 +0530 In a defining leap for Indian medical technology on the global stage, Gurugram-based startup SS Innovations International (SSII), the makers of the indigenous SSI Mantra surgical robotic system, has been listed on NASDAQ, in the US. SS Innovations International reported impressive financial growth for the year ending December 31, 2024, with revenues reaching $20.6 million - a 3.5-fold increase from the previous year’s revenue of $5.9 million. Gross margins also showed significant improvement, rising to 40.9% from 12.3% in 2023, highlighting the company’s robust financial performance and expanding market presence. Furthermore, SS Innovations International has made remarkable progress with its clinically validated and patented SSI Mantra Surgical Robotic System, which has been installed in 80 hospitals across 75 locations in India, as well as expanding its footprint in countries including Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka, and Ukraine. The SSI Mantra Surgical Robotic System is transforming access to advanced robotic surgery, offering a cost-effective solution to a broader patient population. With plans to expand into Europe and the United States, SSII is positioning itself as a global leader in the field of medical robotics, further solidifying India’s role in advancing healthcare technology worldwide. Dr Sudhir Srivastava, Founder, Chairman, and CEO, SSII, said, “The timing of our uplisting coincides with our global expansion beyond India into multiple countries worldwide. We are pursuing the EU CE Mark and US FDA approval for our SSI Mantra surgical robotic system, which we expect to receive in late 2025 and early 2026, respectively. We believe that this uplisting to NASDAQ will enhance market awareness of our growth story, improve transparency, expand our potential investor base, and ultimately increase share liquidity, all while showcasing India’s innovation on the global stage.”  With over 3,700 surgeries performed using the SSI Mantra, including more than 200 robotic cardiac procedures, the system has demonstrated an impeccable safety record, with zero reported device-related mortality, injuries, or complications. Furthermore, SS Innovations became the first and only company in India to receive regulatory approval from the Central Drugs Standard Control Organization (CDSCO) for telesurgery and tele-proctoring procedures, marking a significant milestone in the company’s global expansion strategy. ]]> https://biospectrumindia.com/news/93/26071/intuitive-and-hssc-come-together-to-strengthen-indias-healthcare-workforce.html https://biospectrumindia.com/news/93/26071/intuitive-and-hssc-come-together-to-strengthen-indias-healthcare-workforce.html Fri, 02 May 2025 00:00:00 +0530 Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, is working with the Healthcare Sector Skill Council (HSSC),  a recognised body under the Ministry of Skill Development & Entrepreneurship (MSDE), to support the government’s efforts in skilling emergency healthcare professionals to meet the growing demand for qualified personnel. “By combining advanced robotic-assisted technologies with HSSC’s expertise in skill development, we aim to empower healthcare professionals across India with critical skills and expertise required to transform patient care,” said Rohitt Mahajan,  Vice President and General Manager, Intuitive India. Through this initiative, HSSC and Intuitive contribute to training healthcare professionals in critical skills associated with emergency medical responses. More than 200 candidates in Delhi and Jharkhand are undergoing a structured training programme as Emergency Medical Technician (EMT). As crucial frontline responders, EMTs play a vital role in delivering timely medical care during emergency situations. The programme is designed to enhance their employability and provide career opportunities in the healthcare sector. This initiative aligns with the broader vision of empowering youth with industry-relevant skills and supporting the development of a skilled workforce. This initiative aligns with the objectives of the Skill India initiative, which was launched to bridge the gap between industry demands and workforce capabilities through structured skill development programs. Commenting on the objective of the initiative, Ashish Jain, CEO, HSSC said, “By working alongside industry leaders like Intuitive, we are committed to building a robust, sustainable, and industry-aligned skilling ecosystem for the healthcare sector. HSSC aims to bridge the demand-supply gap by equipping professionals with specialized skills, hands-on experience, and industry-relevant knowledge." ]]> https://biospectrumindia.com/news/93/26057/maharashtra-governor-inaugurates-revamped-aditya-jyot-eye-hospital-in-mumbai.html https://biospectrumindia.com/news/93/26057/maharashtra-governor-inaugurates-revamped-aditya-jyot-eye-hospital-in-mumbai.html Tue, 29 Apr 2025 00:00:00 +0530 Maharashtra Governor C.P. Radhakrishnan inaugurated the newly revamped Aditya Jyot Eye Hospital in Wadala, Mumbai. A unit of Dr Agarwals Eye Hospital, the revamped 9,000 sq. ft. facility marks a major step forward in the group’s mission to offer advanced and accessible eye care across Maharashtra. The hospital has been transformed into a state-of-the-art facility, equipped with a modular operating theatre, a world-class laser refractive operation theatre, a modern optical retail and diagnostic display unit, and a fully stocked in-house pharmacy. Designed to deliver a seamless and all-inclusive eye care experience, the centre now offers a comprehensive range of ophthalmic services under one roof, including advanced treatments in Cataract, Retina, Cornea, LASIK, Glaucoma, Uveitis, Squint, Pediatric Ophthalmology, Neuro-Ophthalmology, and Oculoplasty. The hospital is equipped with cutting-edge ophthalmic technology to support high-precision diagnosis and treatment. Key systems include the Alcon Constellation surgical unit and the 3D ARTEVO microscope for advanced retinal and cataract procedures, the WAVE LIGHT EX500 for high-speed LASIK, and laser platforms such as the ZEISS Green Laser and YAG Laser for retinal and posterior capsulotomy treatments. Diagnostic and imaging capabilities are powered by the NIDEK Mirante, ZEISS OCT 5000, Pentacam, ZEISS IOL Master, and B-scan, while clinical examinations are enhanced with tools like the indirect ophthalmoscope and applanation tonometer—ensuring comprehensive, world-class eye care under one roof. Dr Agarwals Eye Hospital currently operates over 230 hospitals across 10 countries, including 18 in Mumbai and 30 across Maharashtra. The group serves more than 2 million patients annually and performs over 200,000 surgeries globally. Moving forward, it remains committed to expanding its presence by adding more facilities in both Maharashtra and Mumbai to further enhance access to quality eye care. As part of its ongoing efforts to promote eye health, the hospital is offering free eye check-ups for senior citizens aged 50 and above, available until May 31. ]]> https://biospectrumindia.com/news/93/25989/spark-radiology-unveils-new-platform-in-india-to-transform-radiology-reporting-with-ai.html https://biospectrumindia.com/news/93/25989/spark-radiology-unveils-new-platform-in-india-to-transform-radiology-reporting-with-ai.html Tue, 15 Apr 2025 00:00:00 +0530 Bengaluru-based SPARK Radiology, an innovator in medical imaging solutions, has announced the India launch of SPARK.ai, a powerful new technology platform built to transform how radiologists manage their daily reporting workflows. In a healthcare environment where radiologists are under increasing pressure, SPARK.ai introduces a reimagined approach to workflow design, reducing manual overhead, enabling faster report turnaround, and helping radiologists focus on what truly matters: delivering accurate and timely diagnoses. India currently has approximately 20,000 radiologists serving a population of over 1.4 billion, resulting in a significant gap between diagnostic demand and available expertise. For every 100 scans performed daily, there’s only one radiologist available to interpret them. SPARK.ai has been developed to address this gap by automating routine documentation tasks, simplifying case management, thus allowing radiologists to focus on making the diagnosis instead of the report. The platform has been thoughtfully built to integrate seamlessly into existing systems, allowing radiologists to work more fluidly. It bridges the gap between existing processes and an entirely new way of reporting that enables the radiologist to seamlessly share any key findings they observe in a study, automatically generate a final report, and enable a quick review, approval, and distribution process. This new workflow creates the conditions for more consistent, high-quality reporting, supporting improved diagnosis without burdening the practitioner. As AI-driven solutions like SPARK.ai reshape radiology, they pave the way for healthcare professionals to provide timely and precise care in a landscape where demand far outpaces supply. ]]> https://biospectrumindia.com/news/93/25981/india-inks-mous-with-dubai-to-advance-academic-and-research-collaboration.html https://biospectrumindia.com/news/93/25981/india-inks-mous-with-dubai-to-advance-academic-and-research-collaboration.html Mon, 14 Apr 2025 00:00:00 +0530 Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, and Minister of Defence of the UAE; and Piyush Goyal, India’s Minister of Commerce and Industry, witnessed the signing of eight Memorandums of Understanding (MoUs) aimed at deepening collaboration across key sectors including infrastructure, healthcare, higher education, maritime services, logistics, and private sector engagement. The MoUs were inked during a special event organised by Dubai Chambers in Mumbai. The signing ceremony formed part of Sheikh Hamdan bin Mohammed’s official visit to India. In a series of agreements that underscore the vital role of business communities in advancing collaboration and mutual growth, Dubai Chambers signed three Memorandums of Understanding (MoUs) with the Confederation of Indian Industry (CII), the Federation of Indian Chambers of Commerce and Industry (FICCI), and the IMC Chamber of Commerce and Industry. In another agreement that furthers a common commitment to delivering inclusive healthcare, Dubai Health signed an MoU to establish the UAE-India Friendship Hospital (UIFH), a new not-for-profit initiative aimed at providing inclusive and accessible healthcare, in Dubai.  Another agreement was formalised between the Dubai Medical University (DMU) and the All India Institute of Medical Sciences (AIIMS), the country’s top-ranked medical institute. The cooperation  agreement aims to strengthen academic and research collaboration by promoting direct cooperation between faculty, administrative staff, departments, and research centres of both institutions.Key areas of collaboration include student and staff exchange programmes, joint research in priority fields such as infectious diseases, metabolic disorders, and climate change, and the development of global health initiatives. The agreement also provides a framework for the exchange of academic materials and research publications. The agreement also covers cooperation with AIIMS in areas related to AI research, development, and digital transformation in medical education and healthcare. ]]> https://biospectrumindia.com/news/93/25978/omron-partners-with-tricog-to-launch-ai-based-cardiac-care-platform.html https://biospectrumindia.com/news/93/25978/omron-partners-with-tricog-to-launch-ai-based-cardiac-care-platform.html Fri, 11 Apr 2025 00:00:00 +0530 Omron Healthcare, the leading player in the home monitoring health solutions space, has announced its next initiative with Tricog Health, a renowned company in the medtech space addressing cardiovascular conditions. Omron and Tricog joined hands in 2023 to announce foray into remote home heart monitoring and management segment. This collaboration involves launching and deploying “KeeboHealth”, a connected and artificial intelligence (AI)-based cardiac care solution aimed at improving heart failure management through remote monitoring and personalised care solutions. Striving to empower doctors and patients, KeeboHealth is a sophisticated platform integrating state-of-the-art AI-based medical technology with data analytics, leveraging home ECG monitoring to enhance the ability of healthcare providers to manage patient care efficiently. Besides the digital ecosystem, it offers a range of Omron products- particularly home ECG monitors along with Blood Pressure Monitors and Weighing Scales - to help cardiac care patients enhance monitoring and in turn receive more effective & timely treatment strategies from their doctors. As OMRON and KeeboHealth prepare to introduce this transformative solution to the market by early April 2025, the healthcare industry can expect a paradigm shift in the way patient care is delivered and managed in the remote cardiac care segment. ]]> https://biospectrumindia.com/news/93/25949/lords-mark-industries-goes-global-with-1m-medtech-order-in-us.html https://biospectrumindia.com/news/93/25949/lords-mark-industries-goes-global-with-1m-medtech-order-in-us.html Mon, 07 Apr 2025 00:00:00 +0530 Lords Mark Industries Limited, a distinguished company known for its diverse portfolio, through its subsidiary Lord’s Mark Global LLC, has made a strategic entry into the United States (US) market by securing its first major order valued at approximately $1 million. This milestone marks a significant step in the company’s global expansion, reinforcing India’s ‘Made in India’ initiative with cutting-edge MedTech innovations. The order includes Contactless Remote Patient Monitoring (RPM) and artificial intelligence (AI)-based Early Warning Systems (EWS), state-of-the-art healthcare solutions developed and manufactured in India by Lord’s Mark Industries. These advanced systems provide real-time patient monitoring, predictive analytics, and seamless Electronic Health Record (EHR) integration, offering a revolutionary approach to patient care. Commenting on the development, Sachidanand Upadhyay, Managing Director, Lord’s Mark Industries Ltd., said, “This entry into the US market is a testament to our commitment to innovation and excellence. Our AI-powered and contactless monitoring solutions align with the future of global healthcare, and we are proud to represent Indian technological capabilities on the world stage.” The company continues to expand its healthcare footprint with ISO 13485:2016, HIPAA, and IEC 60601-1/1-2 compliant products, ensuring global standards in safety and efficacy. This breakthrough in the US market signifies a new era of Indian medtech exports, driving innovation and accessibility in healthcare worldwide. Lord’s Mark Industries operates through key subsidiaries, including LordsMed, Lord’s Mark Insurance Broking Limited, Lord’s Mark Biotech, Lords Mark Microbiotech, and Lords Automative Private Limited, along with verticals in renewable energy products and paper. ]]> https://biospectrumindia.com/news/93/25937/alcon-introduces-indias-first-fully-personalised-laser-assisted-in-situ-keratomileusis-treatment.html https://biospectrumindia.com/news/93/25937/alcon-introduces-indias-first-fully-personalised-laser-assisted-in-situ-keratomileusis-treatment.html Fri, 04 Apr 2025 00:00:00 +0530 Alcon, the global leader in eye care, has announced the launch of wavelight plus, India’s first fully personalised Laser-Assisted In Situ Keratomileusis (LASIK) treatment. Alcon is a leader in refractive vision correction and its next-generation wavelight plus technology introduces a new era of precision in refractive surgery, with unprecedented levels of personalisation offering patients outstanding visual outcomes with minimal risk and excellent predictability. Wavelight plus has received Central Drugs Standard Control Organisation (CDSCO) India approval, CE Mark and recently received US Food and Drug Administration (FDA) approval. Myopia is the most common refractive error, and globally, more than 30% of the population currently suffers from myopia. This number is expected to grow to nearly 50% by 2050. In India, cases of refractive errors are steadily increasing because of factors like increased screen time, reduced outdoor activities and lifestyle changes. Unlike conventional Lasik treatment, wavelight plus uses Ray Tracing Technology to create a Digital Eye Twin, a highly detailed 3D model of each patient’s eye. This allows surgeons to simulate, test and optimise a fully customised treatment plan before surgery, ensuring a high level of accuracy and personalised vision correction. By considering the complete optical system rather than just the cornea, this innovation enhances surgical precision, safety and visual outcomes, often enabling patients to achieve vision beyond 20/20. Wavelight plus was first launched in China. It is available in several markets in Europe, Asia, and has recently received approval in the US. ]]> https://biospectrumindia.com/news/93/25881/remidio-invests-in-uks-occuity-to-enhance-eye-healthcare.html https://biospectrumindia.com/news/93/25881/remidio-invests-in-uks-occuity-to-enhance-eye-healthcare.html Tue, 25 Mar 2025 00:00:00 +0530 In a move set to redefine non-invasive disease detection, Bengaluru-based Remidio, a global leader in artificial intelligence (AI)-powered ophthalmic solutions, has made a strategic investment in Occuity, a pioneering UK-based developer of handheld, optical screening and monitoring devices that are non-contact and require no consumables. Remidio and Occuity’s partnership will begin with the integration of technologies to co-develop a comprehensive myopia screening solution, addressing India’s growing myopia epidemic. By 2050, nearly 48% of urban children are expected to be affected, with 20% experiencing rapid progression and around 4% facing complications that could lead to permanent vision loss. A key part of this solution is the introduction of India’s first-of-its-kind handheld, non-invasive, and highly accurate axial length measurement device for myopia detection and monitoring. This innovation eliminates the need for complex and expensive eye exams, making early diagnosis more accessible—particularly for children. This collaboration will also introduce a novel non-contact, handheld device for accurately assessing corneal thickness—critical for managing glaucoma patients and evaluating suitability for interventions such as LASIK. This innovation will enhance Remidio’s widely used Comprehensive Eye Clinic in a Bag, further extending access to comprehensive eye disease screening. Leveraging Remidio’s expertise in AI-powered diagnostics and scalable manufacturing, this collaboration will accelerate the development and deployment of Occuity’s non-contact, handheld screening solutions globally. This includes the Occuity Indigo, an optical glucose meter designed to measure glucose levels through a simple eye scan, eliminating the need for painful finger-prick tests currently endured by over 100 million diabetes patients in India. This will further strengthen Remidio’s leadership in AI-driven detection of chronic eye diseases like Diabetic Retinopathy, Glaucoma and Macular Degeneration.   ]]> https://biospectrumindia.com/news/93/25867/entod-pharma-and-infigo-eyecare-hospitals-join-hands-to-revolutionise-under-eye-aesthetics.html https://biospectrumindia.com/news/93/25867/entod-pharma-and-infigo-eyecare-hospitals-join-hands-to-revolutionise-under-eye-aesthetics.html Fri, 21 Mar 2025 00:00:00 +0530 Entod Pharmaceuticals has announced a strategic collaboration with Infigo Eyecare Hospital, Mumbai, to introduce advanced treatment options for under-eye dark circles and other ocular aesthetic concerns. This partnership aims to address an often-overlooked aspect of dermatological and ophthalmic care, periorbital health, by integrating progressive innovations into clinical practice. The skin around the eyes is thinner, more sensitive, and prone to issues like pigmentation, fine lines, and puffiness, yet conventional skincare solutions often fail to deliver precise and lasting results. Current treatments frequently rely on temporary solutions such as topical creams that offer limited absorption and performance. There is a strong need for breakthroughs in this space to invent specialised, scientifically backed solutions that attend the root causes of periorbital concerns rather than providing superficial improvements. Nanotechnology has transformed dermatology, boosting treatment efficacy for various skin conditions. It enables deeper penetration of active ingredients, augments bioavailability, and provides sustained release mechanisms, making treatments more impactful. Periorbital hyperpigmentation (POH) affects a significant portion of the population, with prevalence rates reaching up to 30% in India, particularly in individuals with darker skin tones. Genetic predisposition, lifestyle habits, and environmental factors contribute to the condition, often causing distress, particularly among women. Infigo Eyecare Hospital, known for its expertise in ophthalmic care, will integrate these developments into its clinical offerings. The collaboration will provide patients access to state-of-the-art treatment protocols designed to mend under-eye pigmentation, reduce puffiness, and promote overall under eye skin health. Beyond Mumbai, Entod and InfigoEyecare Hospital plan to expand these specialised treatment options to other cities, making modern under-eye care accessible to a wider population.    ]]> https://biospectrumindia.com/news/93/25851/irish-minister-inaugurates-new-aerogen-office-in-new-delhi-.html https://biospectrumindia.com/news/93/25851/irish-minister-inaugurates-new-aerogen-office-in-new-delhi-.html Wed, 19 Mar 2025 00:00:00 +0530 Aerogen, the Ireland-based global leader in acute-care aerosol drug delivery, has announced the opening of its India headquarters in the National Capital Territory of Delhi.  The new office was officially inaugurated by Ireland’s Minister for Higher Education, Research, and Innovation, James Lawless, during his visit to India on the occasion of Ireland’s National Day – St. Patrick’s Day, on March 17. This strategic expansion underscores Aerogen’s commitment to supporting India’s growing healthcare sector by improving access to cutting-edge aerosol drug delivery solutions. With over 55 million people in India suffering from chronic obstructive pulmonary disease (COPD) and a significant burden of respiratory diseases, Aerogen’s innovative vibrating mesh nebuliser technology is set to play a transformative role in enhancing patient outcomes. Already the standard of care in Europe and the USA, Aerogen’s drug delivery system is now poised to support Indian healthcare providers in delivering high-quality respiratory care. The opening of the India headquarters represents a major investment in the APAC region and reinforces Aerogen’s long-term vision for India. The new office in New Delhi will serve as the operational hub for a growing team of experts, including a country director, marketing professionals, commercial sales specialists, and clinical experts. Starting with 14 team members, Aerogen plans to expand to 30 employees over the next five years to support its growth and market penetration. Designed to foster innovation and collaboration, the India headquarters features state-of-the-art meeting rooms, private offices, a reception area, a library, a gym and yoga space, a recreation zone, and a landscaped lawn, providing a dynamic and inspiring workspace for the team. Aerogen’s India expansion is a reflection of the robust economic ties between Ireland and India. The company’s global growth has been supported by Enterprise Ireland, the Irish government agency that helps Irish businesses scale internationally. Aerogen’s presence in India is set to drive investment in research, partnerships, and training programmes to ensure the widespread adoption of its advanced aerosol drug delivery technology. By collaborating with leading clinicians, hospitals, and channel partners across India and Sri Lanka, Aerogen is positioned to revolutionize respiratory care, ultimately improving patient outcomes and strengthening the country’s healthcare infrastructure.   ]]> https://biospectrumindia.com/news/93/25814/zydus-to-acquire-majority-stake-in-france-based-amplitude-surgical-for-256-8-m.html https://biospectrumindia.com/news/93/25814/zydus-to-acquire-majority-stake-in-france-based-amplitude-surgical-for-256-8-m.html Tue, 11 Mar 2025 00:00:00 +0530 Ahmedabad-based Zydus Lifesciences has entered into exclusive negotiations to purchase from PAI Partners and Amplitude Surgical’s management, as well as two minority shareholders, 85.6% of the share capital of Amplitude Surgical, at a price of €6.25 per Amplitude Surgical share. The acquisition price represents a 80.6% premium over the last closing price as on 10/03/2025 and premia of 88.2% and 92.2% over the 3-month and 6-month volume-weighted average price of Amplitude Surgical respectively. Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies. The company provides numerous value-added innovations to best meet the needs of patients, surgeons and healthcare facilities. This includes the design and development of knee and hip prostheses, which are implanted in place of damaged or worn-out joints. Supported by PAI Partners, through its Mid-Market Fund, Amplitude Surgical has experienced significant growth over the last four years, driven by new product development, international growth, investments in manufacturing capabilities and R&D. In fiscal year ended June 30, 2024, Amplitude Surgical generated sales of €106 million and EBITDA of €27.1 million on a consolidated basis under IFRS. For the 6 months ended December 31, 2024, Amplitude Surgical’s consolidated sales amounted to €51.5 million (a growth of 5% Y-o-Y at current exchange rates) with an EBITDA margin of approximately 25.4% (unaudited figures). Zydus MedTech is focusing on high quality products and solutions for patients with cutting-edge research and innovation around design and engineering. The focus will also be on state-of-the-art manufacturing capabilities that will enable high quality solutions supported by a specialist team. The business currently markets interventional cardiology products.   ]]> https://biospectrumindia.com/news/93/25807/ss-innovations-unveils-indias-first-mobile-tele-robotic-surgery-unit.html https://biospectrumindia.com/news/93/25807/ss-innovations-unveils-indias-first-mobile-tele-robotic-surgery-unit.html Mon, 10 Mar 2025 00:00:00 +0530 SS Innovations, the maker of India’s first and only home-grown surgical robotic system, SSI Mantra, has unveiled the SSI Mantra Tele-Sync Mobile Unit, well known as SSI MantraM– India’s first-of-its-kind mobile tele-robotic surgery unit. This revolutionary unit, designed as 'telesurgery on wheels', brings advanced surgical care closer to patients. It enables real-time collaboration for surgeons to perform or guide procedures remotely with minimal latency. Built on a BharatBenz 1824 chassis, SSI MantraM has a gross vehicle weight rating of 18,500 kg(18.5 Tons) and measures 11.9 meters in length, 2.59 meters in width, and 3.49 meters in height. The total cost of SSI MantraM including structural modifications, is approximately Rs 1.3 crores. However, this cost excludes the SSI Mantra Surgical Robotic System, whose price varies based on features and robotic arm configurations. Designed to serve underserved regions, SSI MantraM is equipped with backup power systems, including onboard 5 kVA generators and external power compatibility, ensuring uninterrupted telesurgery capabilities even in remote locations. Its 380-litre fuel tank allows for extensive travel, making it well-suited for rural and remote transportation. With high-speed telecommunication systems and ongoing R&D into satellite connectivity, the unit has the potential to enable remote telerobotic surgeries in even the most inaccessible areas. SSI has designed SSI MantraM with a special entrance and ramp for safe robotic system movement, reinforced locking mechanisms to minimize vibrations, and actuator-based carts to maintain calibration. The actuator-based design ensures the patient-side carts remain firmly in place, preserving the delicate calibration and integrity of the robotic arms. To optimise space, the unit features an extendible cabin, providing ample room for medical staff to perform or assist in telesurgical procedures. Additionally, multiple entry and exit points (one at the rear and two on the side panels) enhance the efficient movement of personnel and equipment. For safety and focus during procedures, a separate driver’s cabin isolates the operating and patient area from the driving compartment, ensuring an uninterrupted surgical environment. ]]> https://biospectrumindia.com/news/93/25801/pm-inaugurates-namo-hospital-in-silvassa-witnesses-indias-first-ai-powered-knee-replacement-robot-misso.html https://biospectrumindia.com/news/93/25801/pm-inaugurates-namo-hospital-in-silvassa-witnesses-indias-first-ai-powered-knee-replacement-robot-misso.html Fri, 07 Mar 2025 00:00:00 +0530 Prime Minister (PM) Narendra Modi inaugurated the first phase of the 450-bedded Namo Hospital in Silvassa, Dadra and Nagar Haveli. The Rs 460 crore facility is a state-of-the-art healthcare institution, designed to provide advanced medical services to the region. The Prime Minister also launched multiple public welfare projects worth over Rs 2,500 crore, including new hospitals, schools, and critical infrastructure initiatives aimed at enhancing public services and healthcare accessibility. During his visit, PM Modi reviewed the 3D model of the upcoming hospital, appreciating its modern medical infrastructure. A significant highlight of the event was the demonstration of Misso, India’s first indigenously developed AI-powered robotic system for knee replacement surgery, presented by Meril’s CEO, MVivek Shah. This cutting-edge technology is poised to revolutionise orthopaedic surgeries in India, offering greater precision and improved patient outcomes. The Prime Minister expressed keen interest in the innovation and technological advancements driving India’s healthcare sector. He emphasised the importance of indigenous medical technology in making high-quality healthcare more accessible. The launch of Namo Hospital marks a crucial step in strengthening India’s medical ecosystem and reaffirms the country’s commitment to world-class healthcare infrastructure. ]]> https://biospectrumindia.com/news/93/25781/wipro-ge-healthcare-launches-ai-enabled-made-in-india-ultrasound-system-versana-premier-r3.html https://biospectrumindia.com/news/93/25781/wipro-ge-healthcare-launches-ai-enabled-made-in-india-ultrasound-system-versana-premier-r3.html Tue, 04 Mar 2025 00:00:00 +0530 Wipro GE Healthcare has announced the launch of the Versana Premier R3, an advanced artificial intelligence (AI)-enabled ultrasound system designed to enhance clinical efficiency and accuracy, streamline workflows, and improve patient outcomes. Catapulting Government’s ‘Make in India’ vision, the state-of-the-art ultrasound system will be manufactured at Wipro GE Healthcare’s PLI factory in Bengaluru. An extension of the Versana ultrasound range, Versana Premier R3 integrates artificial intelligence and offers automation and AI-enabled productivity tools to improve workflow and clinical features designed to enhance clinical efficiency and accuracy. The advanced ultrasound system aims to help clinicians deliver more personalised, ubiquitous, and preventive care. Addressing the skill gap, the system will optimize dynamic tissue imaging, assist with volume calculations, and streamline workflows. Its self-learning onboarding tool will empower the clinicians to enhance their skills and adapt to new workflows.  A recent report by PwC indicates that 57% of healthcare providers in India are using AI, significantly higher than the adoption rates globally. As India embraces the potential of artificial intelligence in healthcare, Versana Premier R3 represents a significant leap in diagnostic capabilities. The product’s cutting-edge ‘VisionBoost architecture’ and 8-million-channel digital processing deliver exceptional image clarity. With compatibility for 23 different probes, the system offers dynamic organ scanning. Wipro GE Healthcare has been pioneering ‘Make in India – for India and the world’ for decades. Other Made in India products from the company’s PLI factory include the Revolution Aspire CT system and Optima IGS320 AI-enabled Cath Lab, among others. Earlier this year, Wipro GE Healthcare also announced an investment of over Rs 8000 crore in manufacturing output & local R&D over the next 5 years. ]]> https://biospectrumindia.com/views/93/25765/there-is-limited-investment-in-the-area-of-infection-control-in-indian-hospital-settings.html https://biospectrumindia.com/views/93/25765/there-is-limited-investment-in-the-area-of-infection-control-in-indian-hospital-settings.html Sat, 01 Mar 2025 00:00:00 +0530 What are some of the new technologies being introduced by Getinge, to make surgeries smarter and safer for Indian patients? Philippe Rocher: The transformation of Operating Rooms (ORs) has already started to support the development of new surgical techniques such as minimally invasive surgery, guided surgery or robotic surgery that are safer for patients. These techniques require the integration of new equipment inside the OR. We also see an increasing demand for providing the surgical team with comprehensive patient information in a seamless and consolidated manner. Rooms with high technology density must be designed intelligently to respond to these changing trends. Within our portfolio, we offer complete turnkey solutions to our customers using the IN2 Modular System combined with our medical equipment such as anaesthesia machines, operating tables, ceiling pendants and surgical lights. We have recently introduced the Maquet Corin, a next-generation premium operating table with intuitive user controls, patient recognition, and a unique colour-coding system; and the Maquet Ezea surgical light, which offers user-friendly simplicity and robust reliability for a wide range of surgical applications. These products are innovative and comply with the latest and most stringent international quality standards. We have also recently launched Torin, an OR management software that is using artificial intelligence to improve OR scheduling. It helps in better planning surgeries by managing resources, accurately predicting the duration of interventions, and notifying all relevant stakeholders in real-time. This ensures efficient scheduling, minimises wait time, and maximises operating room utilisation; ultimately improving patient care and safety.    How does Getinge plans to further strengthen its presence in the Indian market? Are you looking for partnerships with more hospitals? Aruna Nayak: India is today in the top 12 of our leading markets in terms of net sales. It has been a high-growth market, and we have observed significant advancements in healthcare infrastructure. The government’s focus through initiatives like Ayushman Bharat and its goal of establishing an All India Institute of Medical Sciences (AIIMS) in every state is creating substantial opportunities.  We are very excited about the rapidly growing healthcare infrastructure in India, particularly driven by the government’s efforts. This will help India catch up to global norms on average bed capacity. We have worked with about 10,000 hospitals and clinics in tier I and tier II cities to create world-class infrastructure.  Another major trend is the increasing adoption of digital solutions, essential not only to address cost pressures but also to manage the shortage of trained clinical staff. Our digital health solutions and modular operating room enable hospitals to optimise workflows, including patient management, hospital operations, and central sterile service department (CSSD) workflows. This allows healthcare providers to get more out of their existing infrastructure. Additionally, our Innovation Center in Bengaluru has recently supported the development of software called Twin View. It replicates the interface of our ventilator screen and allows clinicians to monitor parameters remotely, even outside the ICU. This software not only supports better patient monitoring but also acts as a valuable training tool for clinicians to be more efficient. We find clinicians in India are highly supportive and eager to adopt newer technologies. For example, we have introduced advanced technologies like Fluoptics, NAVA, advanced hemodynamic monitoring, which address key challenges in the patient treatments and helps in decision making and improving clinical outcomes.  Right next to our Mumbai Experience Center, we have a dedicated training room where we will conduct sessions for healthcare professionals on cardiovascular and critical care. We also have an Experience Center in Chennai where we organise numerous training sessions. We also offer hands-on training for the technicians and clinicians directly in their hospitals. For government hospitals, we typically conduct on-site training sessions. We have organised programmes at AIIMS, R&R (rest and recuperation) and other prominent government hospitals. In India, we have around 250 employees, a combination of sales and service teams. We have one of the largest service teams based throughout India, with coverage across the country. Our sales team operates nationwide, primarily covering metro cities and tier-1 cities. We work with about 150 distributors who help cover the entire country.    What is the company’s current share within the Indian market? Aruna Nayak: We have a 90 per cent market share for Endoscopic Vessel Harvesting (EVH), 85 per cent for Extra Corporeal Membrane Oxygenation (ECMO), 70 per cent for Intra-aortic Balloon Counterpulsation and 30 per cent for Advanced Ventilation in India. We have a very broad portfolio across Critical Care, Cardiovascular Surgical Workplaces, Infection Control, and Life Sciences. We have a large portfolio, and we face competition from around 5 to 10 major manufacturers, but the competition overlaps in specific areas only. We provide equipment used in the research and production of sterile injectables including biosimilars and vaccines. Specifically, we supply GMP sterilisers, GMP washers, sterile transfer equipment, isolators, and bioreactors. We work with leading sterile manufacturers in India, both in the biologics and small molecules sectors, particularly for injectables.   What are some of the challenges within the healthcare settings that Getinge is addressing through its innovative products? Philippe Rocher: Getinge is a leading player in Infection Control worldwide. In India, however, the focus and the budget allocated to central sterile service departments (CSSD) are currently limited. While we would be happy to equip more hospitals, there has been limited investment in this area so far. That said, we are committed to expanding our presence and have developed more affordable products for the mid-segment to help address this issue. Our offering includes a large range of washers, sterilisers and consumables designed to improve hospital standards and reduce cross-contamination. Our washer and steriliser systems are user-friendly, featuring two doors: one for the loading and one for the unloading. The dirty instruments enter through the loading door and undergo the washing cycle, and the clean instruments exit through the other door, creating a single flow to avoid cross-contamination. After washing, the instruments are moved to the steriliser, where they pass through a similar process. This design ensures that no instrument skips any step in the cycle. We have designed these systems to be foolproof and guarantee the complete cycle of washing and sterilisation is followed. Given that India is such a vast country, another big challenge that we face is geographical coverage. But there is a strong motivation among many clinicians in India to adopt newer technology. This is very encouraging for us. We have a portfolio of innovative products, and our focus is on continuing to provide the necessary training to ensure that they can be used safely and effectively on patients.   Abhitash Singh abhitash.singh@agrospectrumindia.com ]]> https://biospectrumindia.com/news/93/25775/tamil-nadu-approves-primary-hemostatic-agent-seraseal-under-nk-48-cmchis-scheme.html https://biospectrumindia.com/news/93/25775/tamil-nadu-approves-primary-hemostatic-agent-seraseal-under-nk-48-cmchis-scheme.html Fri, 28 Feb 2025 00:00:00 +0530 SeraSeal, the world’s first and only primary hemostatic agent, has been approved for use in trauma and emergency bleed management under the Nammai Kaakkum 48 (NK-48) scheme of the Chief Minister’s Comprehensive Health Insurance Scheme (CMCHiS) in Tamil Nadu. This milestone approval will strengthen emergency care across 702 empanelled state hospitals, covering a wide range of specialties including neuro, ENT, spine, cardiac, vascular, liver, kidney transplant, and orthopaedic surgeries. The NK-48 scheme, a crucial component of the Innuyir Kappom Thittam (IKT), provides cashless treatment for road accident victims within the first 48 hours. The initiative aims to reduce mortality rates and improve trauma care efficiency by ensuring access to immediate medical intervention. SeraSeal, developed by US-based Wortham Labs, is a groundbreaking primary hemostatic agent engineered to stop bleeding on contact, making it a game-changer in emergency and surgical applications. Formulated with agar and bovine factor proteins (IIa, VIIa, IXa, and Xa), it acts as a catalyst in the clot formation process, delivering superior efficiency in controlling both arterial and venous hemorrhages. Unlike conventional hemostatic agents, SeraSeal is effective across all coagulopathies, including those induced by anticoagulant drugs and platelet inhibitors. ]]> https://biospectrumindia.com/news/93/25749/vydehi-institute-of-medical-sciences-and-research-centre-and-intuitive-collaborate-to-expand-access-to-robotic-assisted-surgery.html https://biospectrumindia.com/news/93/25749/vydehi-institute-of-medical-sciences-and-research-centre-and-intuitive-collaborate-to-expand-access-to-robotic-assisted-surgery.html Thu, 27 Feb 2025 00:00:00 +0530 Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, a leading institution in multi-specialty tertiary care, has joined hands with Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), to introduce resident surgeons to robotic-assisted surgical technology through the Intuitive Robotic Onboarding Programme and Education (I-ROPE). This initiative marks the introduction of I-ROPE in a private hospital in India, providing surgical oncology postgraduate trainees with exposure to robotic-assisted surgery and its clinical applications.   The I-ROPE programme is designed to introduce early-career surgeons to robotic-assisted surgery through structured sessions that cover the technology, its applications across various surgical disciplines, and its potential role in modern clinical practice. At Vydehi Institute of Medical Sciences and Research Centre, the programme is being conducted using the state-of-the-art da Vinci surgical system, providing residents hands-on familiarity with one of the most advanced robotic-assisted surgical platforms available today. Despite the increasing adoption of robotic-assisted surgery worldwide, exposure to this technology remains limited within traditional surgical training programs in India. This collaboration between Intuitive and Vydehi Institute of Medical Sciences and Research Centre aims to bridge this gap by integrating robotic-assisted surgery into early-stage surgical exposure, to help prepare future surgeons for evolving medical practices.  Intuitive has been expanding access to robotic-assisted surgery in India through the successful implementation of the I-ROPE programme across leading government medical institutions. These include AIIMS Delhi, Kidwai Memorial Institute of Oncology, Bengaluru, AIIMS Bhubaneswar, Dr. Ram Manohar Lohia Hospital in Delhi, and Armed Forces Medical College in Pune.     ]]> https://biospectrumindia.com/news/93/25734/zimmer-biomet-launches-tekcem-antibiotic-bone-cements-in-india.html https://biospectrumindia.com/news/93/25734/zimmer-biomet-launches-tekcem-antibiotic-bone-cements-in-india.html Tue, 25 Feb 2025 00:00:00 +0530 American medical device company Zimmer Biomet Holdings, Inc. has announced the launch of Tekcem 1G and Tekcem 3G antibiotic bone cements in India.   TEKCEM G bone cements are indicated for the fixation of prosthesis to living bone in arthroplasty procedures or joint reconstruction following trauma, in primary and revision surgeries. Tekcem offers several key advantages, including the incorporation of gentamicin (1G) for superior bacterial defense, ensuring better efficiency against infections. Its formulation boasts lower monomer release, reducing toxicity and shrinkage, while promoting improved implant fixation and minimising the risk of monomer shock.   Gentamicin is a highly hydrophilic, bactericidal, broad-spectrum antibiotic used for the treatment of various Gram-positive and Gram-negative infections including pathogenic species of: Escherichia, Enterobacter, Klebsiella, Salmonella, Serratia, Shigella, Staphylococcus aureus, some Proteus and Pseudomonas aeruginosa.   Additionally, with the lowest exothermicity of 68.9°C, Tekcem reduces the risk of necrosis. Tekcem 1G’s high viscosity makes it particularly ideal for knee arthroplasties. Certified under the European MDR (Medical Device Regulation), Tekcem sets a new standard in bone cement technology. ]]> https://biospectrumindia.com/news/93/25726/meril-unveils-new-surgical-products-for-cardiovascular-portfolio.html https://biospectrumindia.com/news/93/25726/meril-unveils-new-surgical-products-for-cardiovascular-portfolio.html Mon, 24 Feb 2025 00:00:00 +0530 Meril, a Vapi-based company in medical devices and technology, has launched its latest range of surgical products portfolio for cardiovascular procedures, reinforcing its commitment to innovation and clinical excellence. The new product line aims to provide advanced solutions that enhance surgical precision and patient safety. The Dafodil Neo Pericardial Bioprosthesis is a biomechanically engineered valve with enhanced implantability, optimised hemodynamics, and advanced tissue matching, offering a unique solution for both aortic and mitral valve replacement. The MILTONIA Bi-Leaflet Mechanical Heart Valve features durable Pyrolytic Carbon with Silicon alloying for thromboresistance and wear resistance, an open pivot design for passive washing, and a titanium-reinforced sewing cuff for precise implantation in aortic and mitral positions. Further, Filaprop is a blue polypropylene suture designed for high visibility during stitching, minimizing memory effect for smoother application; and Mericron XL is a braided polyester suture featuring oval-shaped pledgets to reduce tissue damage, ensuring enhanced tissue protection. Meristeel is another new product, which is a stainless-steel monofilament suture available in various sizes, offering strength and reliability for different surgical needs. Meril has also launched advanced cardiac suture needles namely Hemovas Needles (Specially designed to minimise blood loss during blood vessel extraction, enhancing surgical precision); V-Black Needles (Equipped with tissue and plexiglass penetrators, offering precise tissue penetration and reduced trauma); and C2 Calcified Coronary Needles that are engineered for improved penetration in calcified vessels, minimizing tissue damage and ensuring optimal results during coronary procedures.     ]]> https://biospectrumindia.com/news/93/25674/neurasim-qwr-revolutionise-amblyopia-with-indias-first-ai-powered-immersive-vr-therapy.html https://biospectrumindia.com/news/93/25674/neurasim-qwr-revolutionise-amblyopia-with-indias-first-ai-powered-immersive-vr-therapy.html Thu, 13 Feb 2025 00:00:00 +0530 Bengaluru-based heath-tech startup NeuraSim Health, in collaboration with QWR - Fabless OEM XR Hardware manufacturer, is transforming the future of eye care with BeeVee, India’s first artificial intelligence (AI)-powered VR wearable for amblyopia treatment. Recently featured on Shark Tank India, this revolutionary digital therapeutic is clinically proven to deliver mild to severe recovery in just 1-3 months, offering a groundbreaking, non-invasive alternative to traditional vision therapy. After extensive market testing, BeeVee is now officially launching home therapy in the Indian market to make it accessible. Amblyopia, or lazy eye, is a rare eye condition which is estimated to jump 175.2 million by 2030 worldwide, making it the most common cause of childhood vision impairment. Traditional treatments like eye patching are slow, uncomfortable, and often ineffective due to poor compliance. BeeVee transforms this approach with AI-driven VR therapy, using adaptive exercises to retrain the brain and improve vision faster, more effectively, and with greater engagement. Recognising the need for greater accessibility and comfort for patients, the brand will also offer at-home therapy sessions across India. Looking ahead, NeuraSim and QWR are pushing the boundaries of medical XR, developing breakthrough solutions that extend far beyond amblyopia treatment. Their pipeline includes Neurametry, an AI-driven eye-tracking system for early detection of glaucoma and neuro-diseases; NeuraSport XR, a cutting-edge performance-enhancing tool for elite athletes that combines eye-tracking with cognitive training; and NeuroXR, an advanced EEG and XR-based platform for neurodegenerative screening and therapy, enabling early diagnosis and better patient outcomes. ]]> https://biospectrumindia.com/news/93/25648/alkem-labs-announces-strategic-acquisitions-in-skincare-and-medical-devices-sector.html https://biospectrumindia.com/news/93/25648/alkem-labs-announces-strategic-acquisitions-in-skincare-and-medical-devices-sector.html Fri, 07 Feb 2025 00:00:00 +0530 Mumbai-based Alkem Laboratories, a leading Indian pharmaceutical company, has announced two strategic acquisitions to further cement its position in the domestic market. Alkem has signed a binding term sheet to acquire 100% stake of Adroit Biomed, a pharmaceutical company with focus on skincare segment, for around Rs 140 crore. Also, Alkem’s subsidiary Alkem MedTech has signed a binding offer to acquire 100% stake of Bombay Ortho Industries, a manufacturer of orthopaedic implants, for around Rs 147 crore. B.N. Singh, Chairman, Alkem, said, “The acquisition of Adroit will enable Alkem to diversify its portfolio, enhance market penetration and strengthen presence in the growing segments of dermatology and cosmetology. Also, our investment in Bombay Ortho is in line with our strategy for Medtech in India.” Sandeep Singh, Managing Director, Alkem, said, “Medtech is a fast-growing space in India and the patient need for quality products is high. Through our acquisitions in the medical devices segment, we aim to meet the growing demand for implants in India.” Adroit has a differentiated dermatology portfolio with the key brands being Glutone, SkinFay, Racine and FortiSil. Adroit had a revenue of Rs 53.55 crore in the financial year ended March 2024.  Alkem intends to complete the acquisition of Adroit by April 1, 2025 and the acquisition of Bombay Ortho by June 30, 2025, subject to customary closing conditions. ]]> https://biospectrumindia.com/news/93/25636/braintap-unveils-cutting-edge-brain-fitness-technology-in-india.html https://biospectrumindia.com/news/93/25636/braintap-unveils-cutting-edge-brain-fitness-technology-in-india.html Wed, 05 Feb 2025 00:00:00 +0530 BrainTap, a pioneering Brain Fitness company, recently unveiled its state-of-the-art innovation to boost mental clarity, alleviate stress, and elevate overall well-being in India, at T Hub, Hyderabad. The revolutionary device was officially launched by Chief Guests Dr Nawab Mir Nasir Ali Khan, Consulate of Republic of Kazakhstan; Dr Patrick Porter, Founder & Co-CEO, BrainTap USA; Cynthia Porter, Co-Founder, CMO, (Brain Tap) USA; Vishal Baijal, Board of Director, (Brain Tap) USA; Dr Francisco Cidral, Chief Science Officer, (Brain Tap) USA; Chhayal Baijal, COO, Nirvana Neuro (Brain Tap) India; Harshil Maun, Business Development Head, (Brain Tap) India. Attendees witnessed the technology in action through an immersive live demo. After years of research, BrainTap has crafted an innovative tool that helps the brain reorganise and build new neural pathways for a more balanced and empowered life. Backed by clinical studies and trusted by thousands of healthcare providers, BrainTap technology has demonstrated significant benefits. “BrainTap seamlessly integrates ancient Indian wellness practices with modern neuroscience. Inspired by Dhyana (meditation), Nada Yoga (sound healing), and Trataka (light therapy), BrainTap uses binaural beats, guided visualisation, and photonic stimulation to activate the brain’s natural healing states. Just as Ayurveda balances mind-body energy, BrainTap harmonises brainwave activity—bridging timeless Vedic wisdom with cutting-edge technology for holistic wellness”, said Vishal Baijal. Despite its importance, mental health remains one of the most neglected aspects of healthcare. BrainTap aims to change that by providing a science-backed, at-home solution to improve focus, enhance willpower, promote sound sleep, reduce stress and anxiety and prevent burnout.     ]]> https://biospectrumindia.com/news/93/25633/boat-joins-hands-with-antara-senior-care-to-provide-innovative-technology-solutions-for-elders.html https://biospectrumindia.com/news/93/25633/boat-joins-hands-with-antara-senior-care-to-provide-innovative-technology-solutions-for-elders.html Tue, 04 Feb 2025 00:00:00 +0530 boAt, India's leading audio and wearable tech brand, has announced its partnership with Antara Senior Care, a holistic senior care eco-system and part of the $5 Billion Max Group, to redefine senior care through innovative, customised technology solutions. The partnership aims to leverage boAt’s cutting-edge wearable and audio technology expertise along with Antara’s deep understanding of senior care needs. Together, the two brands are set to transform senior care by co-creating innovative, customised devices designed to enhance the health, safety, and overall quality of life for senior citizens. The partnership was formally signed off by Sameer Mehta, Co-Founder & CEO of boAt, and Ishaan Khanna, CEO of Antara Assisted Care Services. Antara’s AGEasy platform is committed to enriching the quality of life for seniors by addressing common health challenges such as joint pain, respiratory rehabilitation, and fall-risk management. The platform combines product innovation, expert assistance, and easy-to-use technology to help seniors manage chronic conditions effectively. As part of this collaboration, boAt will design and manufacture a series of advanced tech solutions specifically tailored for seniors. The devices will address key challenges faced by the elderly, incorporating cutting-edge technology to improve their well-being. These include built-in fall detection and alerts, emergency response, SOS alerts, location tracking thus enabling quick assistance during emergencies. There will also be real-time health tracking for vital signs such as heart rate, SpO2, and sleep patterns, alongside remote monitoring capabilities that allow family members and caretakers to stay connected and informed. Additionally, the devices will feature advanced solutions that cater to seniors with hearing challenges, offering superior comfort and accessibility.    ]]> https://biospectrumindia.com/news/93/25612/qr678-partners-with-spectra-medical-to-expand-access-nationwide.html https://biospectrumindia.com/news/93/25612/qr678-partners-with-spectra-medical-to-expand-access-nationwide.html Sat, 01 Feb 2025 00:00:00 +0530 QR678, a pioneering company dedicated to revolutionising hair science through clinical research and innovative solutions, has partnered with Spectra Medical, a leading distributor of high-quality aesthetic equipment and products. The collaboration aims to make cutting-edge, non-invasive hair restoration solutions of QR678 widely accessible across India addressing the growing demand for advanced, patient-friendly treatments. Spectra Medical’s expertise in distributing high-quality medical equipment and products from some of the world’s leading manufacturers makes it an ideal partner to bring QR678’s solutions to a broader audience. Known for its commitment to innovation and quality, the company has played a vital role in equipping healthcare providers with state-of-the-art equipment that improves patient outcomes.   QR678 has emerged as a pioneering innovation in the field of hair regrowth therapy. Developed after years of rigorous research, this regulatory-approved treatment utilises biomimetic polypeptides to stimulate hair follicles, effectively halting hair loss while promoting the density and thickness of existing hair. As a non-surgical solution, QR678 offers patients a safe and effective alternative to traditional procedures. The partnership underscores the shared vision of QR678 and Spectra Medical to bridge gaps in accessibility to advanced hair restoration treatments, leveraging innovation to drive impactful results. ]]> https://biospectrumindia.com/news/93/25613/india-to-expand-global-medtech-share-to-10-12-by-2030.html https://biospectrumindia.com/news/93/25613/india-to-expand-global-medtech-share-to-10-12-by-2030.html Sat, 01 Feb 2025 00:00:00 +0530 MedTekon 2025, the flagship event of the Medical Technology Association of India (MTaI), recently convened policymakers, global dignitaries, investors, and healthcare leaders at Taj Palace, New Delhi. Focused on Investments, Reforms, and Synergies, the event set the agenda for policy acceleration, investment growth, and technological advancements in India’s MedTech sector. The event was graced by Chief Guest MAnupriya Patel, Union Minister of State for Health & Family Welfare and Chemicals & Fertilizers, and Guest of Honour Dr V. K. Paul, Member, NITI Aayog, who underscored the critical role of medical technology in shaping India’s healthcare future. While addressing the gathering, Anupriya Patel said, “It is an honour to inaugurate MedTekon 2025, a key platform uniting industry leaders, policymakers, and healthcare stakeholders to shape the future of India’s MedTech sector. With the industry poised to double its market size to $30 billion by 2030 and expand its global share from 1.65% to 10-12%, India is rapidly emerging as a MedTech powerhouse. Our exports reached $3.8 billion last year, reflecting the sector’s growing manufacturing strength and global competitiveness. As we drive this momentum forward, collaborative efforts in innovation, investment, and policy reforms will be crucial to positioning India as a leader in affordable, high-quality medical technology.” In his remarks during the session on Catalysing Foreign & Domestic Investments in MedTech, Dr. V. K. Paul, Member, Niti Aayog said, “India’s 4,000+ health-tech startups need greater investment, regulatory support, and structured incubation to scale globally. Additionally, harmonising regulatory standards with global benchmarks is vital for investor confidence and sector growth. By focusing on innovation, investment, and policy stability, we can cement India’s role as a leader in affordable, high-quality medical technology." Pavan Choudary, Chairman, MTaI, emphasised the need for investment-friendly policies, regulatory coherence, and a robust MedTech infrastructure to support India’s growing healthcare needs. ble for de-humanization and a lot of stress, Mr. Choudary disagreed and highlighted, “The rise of communities like Hikikomori (term used in Japan) for those who prefer technology-driven interactions over human engagement as human interactions can lead to some level of stress and distress. Machines don’t judge and don’t tire and therefore are preferred by the many millions of hikikomories in the world today, whose number is soaring.”   A major focus area during the event was catalysing foreign and domestic investments, where stakeholders explored India’s potential as a global MedTech manufacturing and R&D hub. In the discussion on hospital technology integration, experts delved into the impact of AI, robotics, and digital health solutions on improving patient outcomes. Another key session on reimbursement policies examined the case to design health insurance for emerging needs. The regulatory panel addressed harmonising standards, reducing non-tariff barriers, and other aspects regarding regulatory and ease of doing business. The final session highlighted ethical marketing practices in MedTech and the need for skill development programmes to create a future-ready workforce capable of leveraging next-generation medical innovations. ]]> https://biospectrumindia.com/features/93/25593/when-can-india-become-a-global-gateway-for-the-medtech-industry.html https://biospectrumindia.com/features/93/25593/when-can-india-become-a-global-gateway-for-the-medtech-industry.html Fri, 31 Jan 2025 00:00:00 +0530 The Indian medtech market, valued at $12 billion in 2023-24, is projected to reach $50 billion by 2030, with India's global market share set to grow from 1.65 per cent to 10-12 per cent over the next 25 years. Further, Indian medtech exports reached $3.8 billion in 2023-24, with the US as the primary market. Although India is still import dependent in the medtech sector, the growing number of startups in this space are moving the tailwinds in a global direction. Over the past few years, medtech startups have emerged as trailblazers, using innovation to bridge gaps, solve pressing challenges, and unlocking new possibilities in healthcare. This growth is particularly crucial in India, where healthcare challenges include vast geographical disparities, increasing disease burdens, and affordability constraints.   For example, artificial intelligence (AI)-driven diagnostic solutions are helping healthcare providers detect diseases at earlier stages, while wearable devices are empowering individuals to monitor their health in real time. As a result, Indian medtech startups are actively integrating digital solutions such as AI, IoT, and cloud computing to democratise healthcare with portable devices, remote monitoring and screening tools. Taking a few examples, BrainSight AI, a Bengaluru-based deep-tech neuroscience startup, is revolutionising the diagnosis and treatment of complex brain disorders through its technology platform, VoxelBox. Likewise, another Bengaluru-based startup 4baseCare is using advanced genomics and digital health technology to offer cutting-edge precision oncology solutions. The developer of the country’s first indigenous surgical robotic technology, Gurugram-based startup SS Innovations, the visionary force behind Made-in-India SSI Mantra Surgical Robotic System, has recently achieved a historic feat in Indian medical science by becoming the first and only company in India to receive Central Drugs Standard Control Organization (CDSCO) approval for Telesurgery and Teleproctoring, signifying a monumental leap in surgical robotics. Medprime Technologies, a Thane-based medical device company focused on developing cutting-edge healthcare solutions in diagnostics, has announced the launch of Micalys, first-of-its-kind innovative AI-integrated digital microscopy platform that is set to revolutionise digital pathology in India.  “As of 2024, the number of medtech startups has surpassed 10,000, with an impressive annual growth rate of over 15-20 per cent. This expansion is a testament to the sector's ability to address critical healthcare challenges through innovative solutions, including AI, IoT, and nanotechnology integration. Government programmes such as Startup India and Make in India have been instrumental in fostering this growth, encouraging entrepreneurs to focus on affordable, high-quality medical devices”, said Dr Vishal Gandhi, Chief Executive Officer, BioRx Venture Advisors. The Health Ministry, in early November last year, announced the launch of a scheme to strengthen the medical device industry. With an outlay of Rs 500 crore, this scheme is a comprehensive one which targets critical areas of the medical device industry, covering manufacturing of key components and accessories, skill development, support for clinical studies, development of common infrastructure and industry promotion. At present, this scheme is providing regulatory support for 6 technology-based startups funded by Pfizer INDovation Programme. These include- Aarca Research (diagnosing Peripheral Artery Disease), Babycue (POC device for childhood diarrhoea), Biolockey Healthworks (at-home test for cervical cancer), Brela Innovations (breast pads for women for early detection of breast cancer), RNT Health Insights (AI-assisted early gastric cancer detection software) and Utopic Tech (POC test for kidney health). "The government has approved these startups for assistance under the research linked incentive scheme, and also approved their products for support for pre-clinical and clinical studies. We hope to see these innovations entering the market in the next 2-3 years", said Dr Arunish Chawla, the then Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India while announcing the assistance.  Out of these startups, Chandigarh-based startup RNT Health Insights is gaining global attention as it received second US FDA breakthrough device designation for oesophageal cancer detection tool in January this year. The startup has previously received US FDA breakthrough device designation for its early gastric cancer detection tool. Touching global heights Besides RNT Health Insights, there are numerous medtech startups in India that are developing technology integrated products and launching them in the global market. Mumbai-based Qure.ai is transforming radiology with AI-powered medical imaging, providing faster and more accurate diagnoses. Recently it has achieved a major milestone with the 510(k) US FDA clearance for its latest AI-powered chest CT solution – qCT LN Quant. Designed to assist radiologists and pulmonologists, this advanced solution analyses lung nodules on non-contrast chest CT scans and tracks volumetric growth for precise progression monitoring. In addition, the startup has also received breakthrough device designation from the US FDA Center for Devices and Radiological Health (CDRH) for its AI-powered Tuberculosis (TB) solution, qSpot-TB. Citing another example, Pune-based startup DeepTek's US FDA-approved platform, Augmento Enterprise, has been chosen as the national radiology AI platform, contributing to improved productivity and quality of care across public hospitals in Singapore. Then there is SigTuple, a Bengaluru-based medtech startup that develops Artificial Intelligence (AI) powered digital microscopy solutions. The startup’s path-breaking device AI100 with Shonit (Peripheral blood smear application) has received US FDA 510(k) clearance. This is the first integrated hardware and AI medical device, and the first product in AI assisted digital microscopy from India to obtain the coveted clearance and one of the handful of companies in the world to obtain it.  While the innovation level is touching the sky for our medtech entrepreneurs, these global approvals are making it easier for the products to reach different parts of the world. Simply because developing products as per globally accepted standards ensures smooth export and helps overcome technical or qualitative differences across regions and countries. In this context, Gaurav Agarwal, Managing Director, Innvolution Healthcare is of the opinion, “Any startup with an eye on the future must have global regulatory approvals in its design phase. Today over a dozen Indian medtech companies have strong international presence. I believe in the next 20 years India will corner a large chunk of medtech exports as well. With a favourable investment, regulatory and policy environment, there is an unprecedented surge in medtech startups in the country.” Sharing her perspective, Gauri Navalkar Godse, Director and CEO- India, UE LifeSciences said, “Indian medtech startups aren't waiting for global nods before making waves. They're leveraging India's unique strengths i.e. a massive, diverse population of over 1.4 billion, a burgeoning digital landscape with over 900 million internet users expected by 2025, and supportive government initiatives like Startup India and Make in India, to build innovative solutions first for the Indian market. This approach allows them to rapidly iterate, gather crucial real-world data from this vast user base, and scale quickly, all while directly addressing pressing local healthcare needs.” One of the very earlier players in the medtech startup space, UE LifeSciences received US FDA approval many years ago to launch iBreastExam - a handheld, mobile connected and completely wireless device which can detect tumour tissues as small as 3-5 mm while emitting no harmful radiation. For 2025, UE LifeSciences is poised to launch not one, but two groundbreaking solutions. In the first half of the year, the company is unveiling a novel triple cancer screening solution, offering early detection capabilities, and by year's end, the company will empower individuals with an at-home breast cancer screening solution. Currently, Bengaluru-based startup Niramai has partnered with Goa-based company MolBio Diagnostics to accelerate the adoption of Niramai's AI-based non-invasive breast cancer screening solution in developing countries around the world. “Niramai is the first Indian company to get an US FDA clearance for a medical device used for women’s health. We have also received European CE approval for our Thermalytix Solution. While it is a great learning experience to go through the very rigorous US regulatory process, we have also observed that globally approved products get easily accepted in India. This strengthens the trust factor for an Indian innovation, which can otherwise take time to establish its presence in the market”, said Dr Geetha Manjunath, CEO and Founder of Niramai. Dr Geetha further adds, “As India’s healthcare ecosystem embraces digital transformation, startups are pioneering groundbreaking solutions. But there are challenges that persist for medtech startups in India, especially in terms of funding, investments and getting good collaborative opportunities with bigger medtech players.”   Still a lot more to be done Both established entities and burgeoning startups in the Indian medtech sector are introducing innovative products that cater to local demands while aligning with international advancements. Moving forward, a great strategy would be needed for the established players to collaborate with the startups for expediting the path from ideation to market introduction. “There is a need to connect hospitals, medtech companies, and startups, supporting critical stages such as multi-centric trials, regulatory compliance, securing scale-up funding, and facilitating product launches. For instance, KIIT TBI envisions establishing a Technology Development & Deployment Hub for molecular diagnostics, encompassing translational research, product development, validation, regulatory compliance, and skill development. A significant milestone is the creation of the Centre of Innovation in Molecular Diagnostics, a convergence platform for academia, startups, and industries. This centre, supported by Thermo Fisher Scientific, offers industry-aligned training to biotech scholars while driving product innovation in molecular diagnostics”, said Dr Mrutyunjay Suar, Chief Executive Officer, KIIT-Technology Business Incubator (TBI). Reflecting upon the current funding and investment opportunities in store for the medtech startups, Dr Vishal Gandhi adds, “The funding landscape for medtech startups in India has transformed significantly. Between January and November 2024 alone, venture capital investments across sectors reached $16.77 billion, with medtech being a key beneficiary. This represents a 14.1 per cent increase in value and a 21.8 per cent rise in deal count compared to the same period in 2023.” He also mentions that over the past five years, investments in medtech startups have surged, with significant interest in diagnostics, AI-driven healthcare solutions, and telemedicine platforms. Another important factor that is ensuring success of many medtech innovations in India lately is the presence of cross-functional leadership teams, where one founder can focus on the science and technology, while the other can take the commercialisation aspect forward. As the sector matures, the focus will likely expand to include more advanced technologies, global collaborations, and regulatory harmonisation to unlock its full potential. India's journey to becoming a global healthcare hub is well underway, and the medtech startup ecosystem stands at the forefront of this evolution.   Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/93/25607/iit-guwahati-and-miraclus-orthotech-join-forces-to-drive-breakthroughs-in-orthopaedic-technology.html https://biospectrumindia.com/news/93/25607/iit-guwahati-and-miraclus-orthotech-join-forces-to-drive-breakthroughs-in-orthopaedic-technology.html Wed, 29 Jan 2025 00:00:00 +0530 Indian Institute of Technology Guwahati (IIT-G) has signed a Memorandum of Understanding (MoU) with Miraclus Orthotech, a leading orthopedic implant manufacturer, to collaborate on innovative research, development, and testing of advanced orthopedic implants and instruments.  This partnership marks a significant milestone in advancing biomedical engineering by combining IIT Guwahati's expertise in cutting-edge research with Miraclus Orthotech's industry leadership. Together, they aim to address critical challenges in the medical device sector and deliver high-quality, efficient solutions to improve patient care. The partnership will focus on four key areas: Research and Development: Joint efforts to design next-generation orthopedic implants and instruments. Product Testing and Validation: Leveraging IIT Guwahati's state-of-the-art facilities to ensure products meet global quality standards. Skill Development: Conducting workshops, training programs, and knowledge-sharing sessions to provide students and researchers with practical exposure to medical device technology. Intellectual Property Creation: Co-developing patents and publishing research outcomes to advance the field. As the next step, IIT Guwahati jointly with Miraclus plans to establish a facility equipped with advanced prototyping and testing tools for orthopedic implants and instruments. This facility will serve as a hub for interdisciplinary research, bringing together experts from biomedical engineering, materials science, and clinical practice. Additionally, the partnership will initiate industry-academia exchange programmes, allowing researchers and students to work closely with industry professionals to bridge the gap between theoretical research and practical implementation. A roadmap for regulatory approvals and commercialisation will also be developed to accelerate the transition of innovative medical devices from the lab to the market. ]]> https://biospectrumindia.com/news/93/25601/abbott-introduces-next-generation-of-heart-valve-technology-designed-to-treat-aortic-stenosis-in-india.html https://biospectrumindia.com/news/93/25601/abbott-introduces-next-generation-of-heart-valve-technology-designed-to-treat-aortic-stenosis-in-india.html Tue, 28 Jan 2025 00:00:00 +0530 Abbott, the global healthcare company, has announced the launch of Navitor Vision in India for the treatment of patients with symptomatic severe aortic stenosis who are at high or extreme surgical risk. The device is the latest iteration of the company’s Navitor transcatheter aortic valve implantation/replacement (TAVI/TAVR) system. The Navitor platform, known for its stable delivery, remarkable performance, and future readiness, has been enhanced with three large Vision markers for improved visibility and easier valve deployment during a TAVI/TAVR procedure. These markers help interventionists implant the device more accurately, while making the TAVI valve easier to see during the procedure. Aortic stenosis is one of the most common and life-threatening heart valve diseases. Prior to TAVI, the standard of care for severe aortic stenosis was surgical aortic valve replacement, but not all patients were candidates for open-heart surgery. Neeraj Singh, country manager for Abbott’s structural heart business in India said, “For some people, open-heart surgery is considered a high-risk procedure due to the potential complications stemming from age, frailty or having multiple other diseases or conditions. TAVI serves as a less invasive alternative to surgical aortic valve replacement and can reduce symptoms and improve the life expectancy of patients with this condition. Abbott’s Navitor Vision valve is an important addition to our range of treatments for structural heart issues, particularly for heart valve disease and offers hope to people who may not have other treatment choices.” The Navitor Vision valve comes in different sizes to fit heart openings (annulus) ranging from 19 mm to 27 mm and thereby fits almost all patients in need of TAVI. The device also has a dynamic sealing cuff that reduces the leaking of blood back to the heart. Navitor is implanted with Abbott's FlexNav delivery system, which offers a slim design, allowing treatment of people with vessels as small as 5.0 mm. The FlexNav catheter can accommodate different aortic anatomies for stable, predictable and accurate valve delivery and placement. ]]> https://biospectrumindia.com/news/93/25603/intuitive-appoints-new-vice-president-and-general-manager-in-india.html https://biospectrumindia.com/news/93/25603/intuitive-appoints-new-vice-president-and-general-manager-in-india.html Tue, 28 Jan 2025 00:00:00 +0530 Medtech firm Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, has announced its appointment of Rohitt Mahajan as vice president and general manager for India. Mahajan will lead the company's business strategy and operations. "India is poised to be a global leader in minimally invasive care. The combination of innovative surgeons, patient-focused hospitals, and forward-thinking policymakers committed to delivering exceptional care makes India incredibly dynamic and important for Intuitive,” said Intuitive Senior Vice President and President, Asia Pacific, Glenn Vavoso. “Rohitt Mahajan brings deep healthcare experience from India and across Asia, which will enable Intuitive to build stronger partnerships with healthcare providers and positively impact patient care in India.” Mahajan brings more than 17 years of diverse experience in sales, marketing, strategy, and operations in the healthcare, consumer durables, and IT sectors. Since joining Intuitive in 2018, he has held key leadership roles, including area sales director for India and director of commercial operations for Asia, where he contributed to the expansion of Intuitive’s commercial operations capabilities and range of global offerings across India and broader Asia region including China, Japan, South Korea, and Taiwan. Intuitive began direct operations in India in 2018 and has focused on advancing minimally invasive care across the country through the adoption of its robotic-assisted surgical systems. The company has invested $6 million to establish four training centres across India, including at AIIMS New Delhi. Today, there are more than 180 da Vinci surgical programmes across India, with more than 1 lakh procedures performed by more than 850 da Vinci trained surgeons. To support its expanding operations, Intuitive recently opened a global capability centre (GCC) in Bengaluru. ]]> https://biospectrumindia.com/news/93/25599/royal-philips-launches-ai-enabled-ct-5300-at-asian-oceanian-congress-of-radiology-in-chennai.html https://biospectrumindia.com/news/93/25599/royal-philips-launches-ai-enabled-ct-5300-at-asian-oceanian-congress-of-radiology-in-chennai.html Mon, 27 Jan 2025 00:00:00 +0530 Royal Philips, a global leader in health technology, has launched the artificial intelligence (AI) enabled CT 5300 at the 23rd Asian Oceanian Congress of Radiology (AOCR) 2025. Philips CT 5300 system, equipped with advanced AI capabilities, is designed for diagnosis, interventional procedures and screening. The flexible X-ray CT system increases diagnostic confidence, streamlines workflow efficiency, and maximises system up-time, helping to improve patient outcomes and department productivity. With cutting-edge AI features like AI reconstruction, AI cardiac motion correction & AI smart workflows, CT 5300 is designed to enhance diagnostic accuracy coupled with high speed.  Philips also celebrated the installation of 1500+ Helium Free 1.5T wide Bore (70 cm) MRI systems worldwide. The revolutionary MRI with BlueSeal magnet technology is the industry's first wide bore 1.5T fully sealed magnet, which relieves healthcare providers from helium-related complications and unpredictability. BlueSeal magnet requires only 0.5% of helium compared to a conventional MRI system. Based on a decade of innovation, Philips BlueSeal is a fully sealed magnet designed to simplify MRI installations, reduce lengthy and costly disruptions in MRI services, and help healthcare departments transition to sustainable helium-free operations. This revolutionary magnet operates with only seven liters of liquid helium and is fully sealed – freeing up the minds of healthcare providers from potential helium complications. With BlueSeal magnet, Philips aims to help MRI facilities overcome potential helium-related issues of classic magnet design and eliminate the radiology department's dependency on scarce helium supply.    ]]> https://biospectrumindia.com/news/93/25559/medtech-manufacturers-hail-cdsco-move-on-stopping-import-of-used-medical-devices.html https://biospectrumindia.com/news/93/25559/medtech-manufacturers-hail-cdsco-move-on-stopping-import-of-used-medical-devices.html Fri, 17 Jan 2025 00:00:00 +0530 Medical device manufacturers have hailed the clarification by the Central Drugs Standard Control Organization (CDSCO) that current law does not provide for granting of licenses for import of refurbished devices. Pointing out that the healthcare security of the country is already compromised with about 70% of the current medical device requirements being met through imports, the Association of Indian Medical Device Industry (AiMeD) said that ongoing import of used medical devices without any regulatory controls had further jeopardized it as nearly 60% of the Rs 40,000 Cr of imports of medical electronic equipment were estimated to be of preowned equipment being dumped into India. That is one of the main reasons why domestic manufacturers have been seeking regulations of this sector to enable a level playing field. All medical devices had come under regulations in Feb 2020 and a transition time had been provided thereafter for importers and manufacturers to get licensed under Medical Devices Rules of D&C Act. “A stop to import of refurbished medical equipment is a true policy intervention that will guard the domestic industry against dumping of equipment with uncertain quality and will also help the patients in receiving appropriate medical care thereby bringing the best value of cost for them and for the payers, including insurance agencies. This is a welcome and much awaited long due intervention”, said Dr Jitendra Sharma, Managing Director, AMTZ, Visakhapatnam. At a time when the domestic industry is already grappling with issues like negligible import tariff of 0 to 7.5% on medical devices in India, allowing import of refurbished devices had further acted as a deterrent to the entrepreneurial spirits of the domestic manufacturing industry making India severely imports dependent, pointed out Rajiv Nath, Forum Co-Ordinator, AiMeD.   “We welcome MNCs to invest in India and make high technology equipment and make these affordable to the Indian patients as is being done in Mobile phones and the automobile sector. A healthy competition is welcome,” said Nath. “There is a Policy review of the need for imports underway and we have sought related regulations for refurbished or remanufactured Indigenous medical equipment that has lived beyond the extended warranty terms, with adequate and additional patient safety safeguards  to bring in the necessary discipline “ and Mr. Nath hoped that the guidelines issued by the Ministry will be in consonance with the National Medical Devices Policy 2023  to make India a leading hub of manufacturing of medical devices globally. Confusion arose after a notification by the Ministry of Environment, Forest, and Climate Change (MoEFCC) allowed the import of certain second-hand medical devices and equipment in India. Nath has pointed out that while (MoEFCC) may be right in addressing the concerns regarding e-waste management, other regulators like CDSCO must diligently carry out their duties in addressing the high-risk patient safety concerns. He also highlighted the fact that, many-at-times, the import of new medical devices is resulting in end-users paying 10-30 times of the import landing price of the devices because of absence of trade margin rationalization measures. This is where the Ministry of Health, Dept. of Pharma, together with the Ministry of Finance, must play its part in regulating the MRP of the devices in a rational manner so that ethical manufacturers and marketers as well as consumers gain. India’s import bill for medical devices is going up every year, with a 13% jump in 2023-24 alone. India currently imports a staggering Rs 69,000 crore worth of devices. “The circular issued by CDSCO regarding refurbished medical devices imported into India has shown Modi 3.0 is awake and ready to listen to a common consumer. Now our next logical step should be to recall all such illegally imported medical devices from every corner of the country and destroy them in the interest of 'Patient Safety', said Prof Bejon Kumar Misra, Founder of Patient Safety and Access Initiative of India Foundation. As per industry insiders a lot of domestic businessmen have become pseudo manufacturers and importers because of the meager import duties and genuine manufacturers are being pushed out of the business due to prevalent nonconductive duty structures presently. AiMeD has demanded the import duties to be in the range of 10-15% for medical devices to provide a level playing field to the domestic manufacturers. “We applaud the CDSCO in removing the confusing signals we had been getting as on one side we had been supported by GoI excellent PLI scheme to manufacture high end Cath labs & imaging equipment in India but were despondent when we had to compete against low-priced second-hand imports. The Medical Device rules do need a provision for extra safeguards needed for refurbishing or re-manufacturing of equipment beyond extended warranty period and the existing informal sectors that had been repairing and refurbishing imported pre-owned equipment can now use their skills to do so for the indigenously produced equipment. With a growing market expected from a stable and competitive domestic manufacturing, this sector will also have ample opportunities to grow as a support to the healthcare industry, explained Gaurav Aggarwal, Managing Director, Innvolution Healthcare.   ]]> https://biospectrumindia.com/news/93/25543/stryker-launches-insignia-hip-stem-for-total-hip-and-hemiarthroplasty-procedures-in-india.html https://biospectrumindia.com/news/93/25543/stryker-launches-insignia-hip-stem-for-total-hip-and-hemiarthroplasty-procedures-in-india.html Mon, 13 Jan 2025 00:00:00 +0530 Stryker, a global leader in medical technologies, has announced the launch of its Insignia Hip Stem in India. Insignia is engineered to optimise patient fit and enable surgeon ease of implantation for total hip and hemiarthroplasty procedures. It is compatible with Stryker’s Mako SmartRobotics utilising Total Hip 4.1 software, which allows surgeons to use data from a 3D CT-based plan to capture each patient's unique anatomy. Stryker utilised its proprietary Orthopaedics Modeling and Analytics (SOMA) database to analyse information from more than 1,300 patient CT images and develop a device that accurately replicates patient biomechanics for complete hip replacement procedures. SOMA allowed Stryker to design and test unique implant features to allow for an enhanced implant fit across various femoral morphologies. Insignia offers a unique Tri-Stage Broach, Stryker’s patent-pending and first instrument designed with SOMA technology. This unique broach features three different tooth geometries, as well as unique size-specific collar lengths and market-leading range of femoral offsets designed to provide enhanced fit and function across a broad range of femoral morphology. Further, Insignia's low-profile shoulder, short stem lengths and distal relief are engineered for ease of lateralization and insertion. Aman Rishi, Vice President and General Manager, Stryker in India said, “With its compatibility with Mako SmartRobotics and design based on SOMA technology, Insignia delivers a truly personalized approach to hip replacement through patient-specific fit, function and flexibility, allowing surgeons to improve patient outcomes.” Stryker will be holding demonstrations in upcoming national conferences and events in India to showcase Insignia. ]]> https://biospectrumindia.com/news/93/25541/aig-hospitals-set-to-invest-rs-800-cr-to-revolutionise-cancer-treatment.html https://biospectrumindia.com/news/93/25541/aig-hospitals-set-to-invest-rs-800-cr-to-revolutionise-cancer-treatment.html Sat, 11 Jan 2025 00:00:00 +0530 The Board of AIG Hospitals has approved the acquisition of Proton Beam Therapy system. Consequently, AIG Hospitals has entered into an agreement to acquire state-of-the-art Proteus ONE Proton Therapy System including DynamicARC from IBA, a Belgium-based supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. With this new delivery technique called DynamicARC proton therapy, the system will be the first-of-its-kind installation in South-East Asia. This strategic acquisition marks a significant milestone in AIG Hospitals' commitment to delivering the most advanced, effective, and accessible cancer care to patients in India. Proton Beam Therapy is a highly precise form of radiation therapy that targets tumours with exceptional accuracy, substantially minimising damage to surrounding healthy tissues. This technology is a gamechanger in treating complex cancers, particularly in children and adults with tumors located near critical organs. Dr D Nageshwar Reddy, Chairman of AIG Hospitals said that “The Proteus ONE Proton Therapy System will be part of our new 300-bedded dedicated Oncology Centre coming up within the existing Gachibowli campus, enabling comprehensive cancer care comparable to the best in the world.” AIG Hospitals will invest Rs 800 crore in this new Oncology Centre, making it only the Third Proton Therapy Centre in the country and the first one in twin Telugu states of Telangana and Andhra Pradesh.       ]]> https://biospectrumindia.com/news/93/25530/tata-capital-healthcare-fund-ii-leads-20-m-investment-in-harsoria-healthcare.html https://biospectrumindia.com/news/93/25530/tata-capital-healthcare-fund-ii-leads-20-m-investment-in-harsoria-healthcare.html Thu, 09 Jan 2025 00:00:00 +0530 Tata Capital Healthcare Fund II (TCHF II), the healthcare focused private equity fund of Tata Capital, has led a $20 million investment in Harsoria Healthcare, a Gurugram-based manufacturer of single-use medical devices in the country, for an undisclosed equity stake. The funding round also saw participation from marquee investors, including Utpal Sheth, Ashish Kacholia and associates, and the LNB Group. Harsoria Healthcare plans to utilise the capital to expand manufacturing capacities, enhance R&D efforts, and drive business development. The Indian medical devices industry is the 4th largest in Asia and ranks among the top 20 globally. It is projected to grow at a CAGR of 13% over the next five years, reaching an estimated value of $22 billion. Within the medical consumables segment, Indian companies have historically excelled at low value, commoditized product categories but they are now shifting focus towards high-value segments. Candle Partners acted as the exclusive financial advisor to Harsoria Healthcare and its shareholders on this transaction. Speaking on the partnership, Visalakshi Chandramouli, Managing Partner at Tata Capital Healthcare Fund II said, “Under the leadership of first-generation entrepreneurs Neeraj and Nitin Gupta, the company has thrived over two decades by focusing on product innovation and manufacturing high-quality medical consumables. Harsoria exemplifies the ethos of ‘Make in India for the World,’ with its products achieving success in markets like the US and Western Europe. We believe in the company’s potential and look forward to being a part of its growth journey.” Neeraj Gupta, Managing Director, Harsoria Healthcare said, “We look forward with great excitement to accelerating our growth trajectory, while remaining committed to developing high-quality, innovative and cost-effective medical devices for global and Indian healthcare providers.”   ]]> https://biospectrumindia.com/news/93/25517/zoplar-secures-3-4-m-to-revolutionise-medical-equipment-accessibility.html https://biospectrumindia.com/news/93/25517/zoplar-secures-3-4-m-to-revolutionise-medical-equipment-accessibility.html Tue, 07 Jan 2025 00:00:00 +0530 Gurugram-based startup Zoplar, an innovative platform dedicated to enhancing the medical equipment procurement process for small and medium-sized hospitals in India, has successfully raised $3.4 million in a Series A funding round led by Blume Ventures. The round also saw participation from Beenext, Saison Capital, Atrium Angels, Finfirst, and LogX. In total, the company has raised $5.1 million in funding with contributions from Titan Capital, Stride Ventures and Panthera Peak. With the newly raised funding, Zoplar plans to strengthen its operational capabilities by focusing on backward integration in the supply chain and developing a robust service engineering team. This will enable the company to deliver best-in-class after-sales service while leveraging technology to enhance efficiency. Since its inception, Zoplar has gained significant momentum in the market, partnering with approximately 300 hospitals, including prominent nephrology chains. The company boasts a 40% rate of repeat customers, underscoring the demand for quality medical equipment in the sector. ]]> https://biospectrumindia.com/views/93/25495/indias-transformative-leap-in-medtech.html https://biospectrumindia.com/views/93/25495/indias-transformative-leap-in-medtech.html Tue, 31 Dec 2024 00:00:00 +0530 AI-driven Diagnostics The application of artificial intelligence (AI) in healthcare has moved beyond experimentation to become a cornerstone of modern diagnostics. Globally, AI has proven its potential to detect diseases with unparalleled precision. For example, in the US, AI-driven systems have achieved an impressive 95 per cent accuracy in early cancer detection, demonstrating its ability to significantly reduce diagnostic errors. In India, startups are using AI to address complex health challenges like Niramai uses AI for pain-free breast cancer screening and Qure.ai developed a deep learning algorithm to interpret radiology scans in just a few seconds. Ireland, known for its advanced medtech research, has also been pioneering AI applications in diagnostics. One notable example is Ireland's Health Innovation Hub, which facilitates collaborations between healthcare providers and AI startups to develop cutting-edge diagnostic tools. Drawing from such practices, India could foster partnerships between academia, startups, incubators and healthcare institutions to bridge gaps in diagnostic accessibility, particularly in rural regions.   Enhancing healthcare accessibility with POCT  Point-of-care testing (POCT) could make healthcare accessible across India, including rural India.  According to Statista reports it is transforming the way diagnostics are conducted by enabling real-time, accurate testing at or near the patient’s location. Innovations in biosensing, microfluidics, and paper-based diagnostics are enhancing affordability and diagnostic precision, while improving healthcare delivery, especially in rural settings. Indian companies like Agappe, Cipla Diagnostics, Mylab, and TransAsia Biomedicals have products in use in the market, and they continue to innovate.  We see the widespread adoption of POCT is helping address infectious diseases like tuberculosis and dengue, and this is just the beginning.   As per Grand View Research Data, the Indian diagnostics market was valued at about $13 billion in 2023 and is expected to grow twice its current size by 2028, while the global market size of this industry was valued at $44.24 billion in 2023, and it is projected to grow at a CAGR of 6.1 per cent from 2024 to 2030. We see the impact of the deployment of POCT in developed countries too. For example, in the UK, the National Health Service (NHS) has effectively used POCT to diagnose conditions such as sepsis quickly, often saving lives in critical situations.  Ireland’s medtech industry, which accounts for 8 per cent of its GDP, has excelled in producing compact, portable POCT devices designed for global markets. Companies like Randox and Abbott Diagnostics Ireland have contributed significantly to revolutionising how care is delivered in emergency and rural settings.   Indispensable Wearables  Wearable devices continue to evolve from the time they were used as fitness gadgets. Wearables are essential tools for monitoring and managing health. Today’s sophisticated devices track metrics like heart rate, glucose levels, and blood pressure and are becoming indispensable for managing chronic conditions and promoting preventive care.  Increasing use of wearable devices offers an incredible opportunity to improve individual and population-level health outcomes. Wearable technology when properly integrated into healthcare systems where data is interoperable and shared, rather than siloed, can play a key role in understanding the key factors which affect health at a population level and can deliver actionable insights to improve health and well-being. Ireland has a national health strategy that is focused on delivering the right care, in the right place, at the right time. Data, analytics, AI and wearable technology are supporting the realisation of this strategy, although there are several challenges to overcome.   India has also witnessed the rise of affordable wearables developed by startups like GOQii and BeatO. These devices are integrated into digital health ecosystems, allowing patients to take greater control of their health while enabling physicians to provide more informed, timely care.   New era of Precision Medicine The study of genomics is shaping the future of healthcare by enabling treatments tailored to an individual’s genetic makeup. Precision medicine, driven by genomic insights, has shown promise in effectively treating complex diseases while minimising side effects. The Genomic Medicine Ireland initiative is driving forward advancements in personalised medicine in Ireland. This initiative aims to collect and analyse genetic data to improve disease diagnosis and treatment on a global scale. In India, genomic research is beginning to address diseases such as cancer and rare genetic disorders. With similar initiatives tailored to its population diversity, India could not only expand its genomic capabilities but also contribute to global research.  We see the emergence of Indian companies operating in this field, including Yoda Diagnostics.  The global precision medicine market is expected to grow from $80 billion in 2022 to $168 billion by 2028, indicating a 13.3 per cent CAGR. In India, the adoption of precision medicine is still in its nascent stages although it is gaining momentum and significant growth is predicted in the coming years. This will be spurred by increasing private sector investments in R&D and the rising incidence of chronic diseases.    Sustainability through Medtech Innovation  The medtech industry is aligning its practices with global sustainability goals. Ireland, a country committed to sustainable development, has made significant strides in adopting green manufacturing practices within its medtech sector. Companies like Medtronic and Stryker are setting benchmarks in reducing carbon footprints and incorporating renewable energy into their operations. In India, while sustainability in healthcare is still at a nascent stage, medtech companies are beginning to explore environmentally friendly solutions. While India’s medtech and diagnostics sector is growing rapidly, there is much to learn from global leaders. Ireland’s ability to foster collaborations between government, academia, and industry has been instrumental in its rise as a medtech hub. Similarly, the US invests 3.1 per cent of its GDP in R&D, fostering a culture of continuous innovation, while the UK’s focus on training and upskilling healthcare professionals ensures the seamless adoption of new technologies.   India’s Opportunities and Inspirations For India, increasing investment in R&D, fostering public-private partnerships, and developing a skilled workforce will be critical in sustaining growth and innovation. Adopting global best practices while tailoring them to India’s unique healthcare challenges could accelerate progress across the medtech ecosystem, which is on the cusp of significant transformation. With a unique blend of local innovation and global inspiration, the country is well-positioned to accelerate redefining healthcare delivery in 2025. By focusing on technology, accessibility, and sustainability, India can address its healthcare challenges while setting a global benchmark for emerging economies. Collaboration among stakeholders, increased investment in innovation, and a commitment to equitable healthcare will be essential. As India picks up best practices from countries that have seen success in this area, it has the potential to not only transform its medtech landscape but also ensure a healthier, more sustainable future for its 1.4 billion citizens.   Tanaz Buhariwalla, Director - South Asia, IDA Ireland ]]> https://biospectrumindia.com/news/93/25485/smt-launches-hydra-tavi-system-in-russia.html https://biospectrumindia.com/news/93/25485/smt-launches-hydra-tavi-system-in-russia.html Mon, 23 Dec 2024 00:00:00 +0530 Mumbai-based SMT (Sahajanand Medical Technologies), a global leader in innovative cardiovascular solutions, has announced the launch of its Hydra Transcatheter Aortic Valve Implantation (TAVI) system in Russia. Hydra introduces a highly refined approach to managing severe aortic stenosis, providing physicians with a dependable and innovative option for high-risk patients who are not candidates for open-heart surgery. TAVI procedures are increasingly gaining traction in Russia as an effective, minimally invasive solution for severe aortic stenosis. Hydra has been designed to meet the unique clinical needs of this growing patient population, reflecting SMT’s ongoing commitment to advancing healthcare through technology. “Russia’s medical community has shown significant interest in adopting TAVI technologies, and Hydra is a meaningful addition to the solutions available for treating complex cases,” said Sergey Antonov, Head of Commercial Operations for Russia. “Our entry into the market reinforces SMT’s dedication to supporting physicians with devices that combine precision, flexibility, and reliability.” Hydra enters the Russian market at a pivotal time, with TAVI gaining widespread recognition for its ability to address complex cardiac cases. SMT’s presence in Russia, established through its successful Supraflex Cruz drug-eluting stent system, now expands to structural heart disease solutions with Hydra.  ]]> https://biospectrumindia.com/news/93/25474/bd-and-babson-diagnostics-launch-innovative-fingertip-blood-testing-technology.html https://biospectrumindia.com/news/93/25474/bd-and-babson-diagnostics-launch-innovative-fingertip-blood-testing-technology.html Wed, 18 Dec 2024 00:00:00 +0530 BD (Becton, Dickinson and Company), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, have announced an expansion of fingertip blood collection and testing technologies for use by US health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings. This innovative blood testing process integrates BD's MiniDraw Capillary Blood Collection System with Babson's BetterWay technologies to enable test results from as few as six drops of capillary blood collected from a patient's finger. With this less-invasive alternative to venipuncture blood draws, samples can be collected and prepared by any trained healthcare worker, including those without prior phlebotomy experience. With 70% of clinical decisions informed by diagnostic results, blood tests are a routine part of care to help clinicians diagnose, monitor and treat patients. This novel capillary solution enables care providers to improve access to blood testing in underserved locations that do not have phlebotomy capabilities, while lowering common barriers to testing such as fear of needles and logistical challenges. The commercial partnership is an expansion of BD and Babson's collaboration to advance capillary blood testing, which started in 2016 and has since evolved into a strategic partnership. ]]> https://biospectrumindia.com/news/93/25438/indias-first-cdsco-certified-robotic-system-for-telesurgery-by-ss-innovations-to-lead-the-way.html https://biospectrumindia.com/news/93/25438/indias-first-cdsco-certified-robotic-system-for-telesurgery-by-ss-innovations-to-lead-the-way.html Wed, 11 Dec 2024 00:00:00 +0530 The developer of the country’s first indigenous surgical robotic technology, SS Innovations, the visionary force behind Made-in-India SSI Mantra Surgical Robotic System, has achieved a historic feat in Indian medical science by becoming the first and only company in India to receive Central Drugs Standard Control Organization (CDSCO) regulatory approval for Telesurgery and Teleproctoring, signifying a monumental leap in surgical robotics. This landmark achievement positions SSI Mantra as the first surgical robotic system in India authorised to perform these advanced capabilities. It paves the way for SS Innovations' commitment to advancing surgical technology, making cutting-edge procedures more accessible, and reinforcing the position of India as a global leader in healthcare innovation. Telesurgery, first envisioned in the 1980s for use in space and on remote battlefields, faced significant challenges due to the technological limitations and lack of bandwidth available at the time. Today, with advancements in both technology and connectivity, SSI has turned this vision into reality with its groundbreaking SSI Mantra Surgical Robotic System. By enabling Telesurgery and Teleproctoring, the system aims to decentralise and democratise access to surgical expertise, addressing critical gaps in healthcare, particularly in remote areas, where access to specialized medical care has often been a challenge. This historic achievement marks a significant step forward in India’s healthcare landscape, with SSI leading the charge in revolutionising surgical care through cutting-edge technology. The approval of Telesurgery and Teleproctoring capabilities for SSI Mantra Surgical Robotic Systems not only underscores the company’s commitment to innovation but also opens up new possibilities for accessible, high-quality healthcare across India and beyond.   ]]> https://biospectrumindia.com/news/93/25449/medtech-firm-getinge-opens-new-experience-centre-in-mumbai.html https://biospectrumindia.com/news/93/25449/medtech-firm-getinge-opens-new-experience-centre-in-mumbai.html Wed, 11 Dec 2024 00:00:00 +0530 Getinge, a global medtech company, has announced the opening of its new Experience Centre in Mumbai. Executives from Getinge with leaders from healthcare and government unveiled the Experience Centre, designed to recreate hospital and other healthcare settings including operating rooms and intensive care units.  The launch event was attended by Sven Östberg, the Consul General of Sweden in Mumbai, who highlighted the significance of this milestone in Getinge's commitment to the Indian healthcare market. The Experience Centre showcases Getinge's innovative solutions, including the Getinge IN2 OR Modular Room System, designed to meet the evolving needs of modern surgery. The system is engineered to offer flexibility, efficiency, and highly customisable options, addressing the key challenges faced by traditional operating theaters. "This centre will offer healthcare professionals an interactive, hands-on experience with our solutions, demonstrating how they can improve efficiency and elevate the patient experience," says Philippe Rocher, President South Asia Pacific. Aruna Nayak, Managing Director, India, adds "The opening of our Experience Center in Mumbai is a significant step in our mission to bring world-class healthcare solutions closer to India’s growing medical needs. With our modular OR system and other advanced technologies, we are confident that healthcare facilities across the country will be able to achieve greater efficiency, sustainability, and quality of patient care. We are excited to support the healthcare sector as it adapts to the needs of modern surgery and rapidly evolving technology." The centre will play a crucial role in helping hospitals and healthcare providers adopt advanced solutions that enhance patient care, improve operational efficiency, and promote sustainability.     ]]> https://biospectrumindia.com/news/93/25391/bureau-of-indian-standards-to-prioritise-development-of-standards-for-214-critical-medical-devices.html https://biospectrumindia.com/news/93/25391/bureau-of-indian-standards-to-prioritise-development-of-standards-for-214-critical-medical-devices.html Tue, 26 Nov 2024 00:00:00 +0530 The Bureau of Indian Standards (BIS), India’s National Standards Body is addressing growing need for reliable and affordable medical assistive technology. The Bureau is developing standards for innovative products such as therapeutic footwear, portable ramps, braille displays, and fall detectors, which support individuals with disabilities and enhance their quality of life. In line with the National Medical Device Policy, 2023, BIS is prioritising standards development for 214 critical medical devices. These have been identified in consultation with the Department of Pharmaceuticals (DoP). It includes septal closure devices, plasma sterilisers, and phototherapy machines. The initiative is set for phased completion by December 2025. The Bureau is also driving improvements in healthcare quality, safety, and reliability by developing robust medical device and service standards. By aligning with the Medical Devices Rules, 2017, and the National Medical Device Policy, 2023, BIS is proving to be instrumental in establishing a robust regulatory framework that prioritizes public safety while fostering innovation. BIS has published over 1,700 standards for the medical sector, covering specialities such as cardiology, neurology, orthopaedics, ophthalmology, and more. Of these, around 1,200 standards specifically focus on medical devices critical to healthcare, including: Life-saving devices: Cardiac pacemakers, heart valves, ventilators, and haemodialysis machines. Advanced diagnostic tools: X-ray machines, CT scanners, MRI systems, and blood glucose monitors. Assistive technology: Hearing aids, wheelchairs, Jaipur Foot, and tactile pathways for visually impaired individuals. ]]> https://biospectrumindia.com/news/93/25380/aiims-new-delhi-iit-d-and-ucl-announce-trilateral-partnership-to-scale-up-medtech-innovation.html https://biospectrumindia.com/news/93/25380/aiims-new-delhi-iit-d-and-ucl-announce-trilateral-partnership-to-scale-up-medtech-innovation.html Sun, 24 Nov 2024 00:00:00 +0530 The All India Institute of Medical Sciences (AIIMS), New Delhi and the Indian Institute of Technology Delhi (IIT-D) have launched a ground-breaking new collaboration with University College London (UCL) to co-create pioneering solutions in the field of medical technology. For the first time, the three institutions will join forces to draw on their complementary areas of expertise to develop new technologies that help tackle some of today's biggest health challenges The partnership, which will seek to leverage industry connections across all three institutions, will pave the way for devising multidisciplinary technology and innovation focused solutions across healthcare. Together, the universities aim to advance the field of medical technology in cutting-edge areas such as detection, diagnostics and imaging; devices and implants; assistive technologies; digital health; artificial intelligence, machine learning and quantum; surgical and treatment interventions and sensing technologies. The partnership will be underpinned by development of staff and student exchange, joint research programmes, collaborative degrees, workshops and conferences, and joint publications.     UCL has had longstanding bilateral partnerships with both AIIMS and IIT Delhi and this is the first time the three institutions will collectively work together across disciplines. ]]> https://biospectrumindia.com/news/93/25378/jipmer-puducherry-comes-up-with-an-innovative-surgical-technique-for-pancreatic-cancer.html https://biospectrumindia.com/news/93/25378/jipmer-puducherry-comes-up-with-an-innovative-surgical-technique-for-pancreatic-cancer.html Thu, 21 Nov 2024 00:00:00 +0530 Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER Puducherry has announced a breakthrough in pancreatic cancer treatment with the development of a novel robotic-assisted surgery technique. Conceptualised by Dr Kalayarasan, a leading robotic surgeon, this pioneering approach has set a new benchmark in precision, reducing complications and improving recovery for patients battling one of the deadliest forms of cancer. This cutting-edge technique leverages the advanced da Vinci robotic system to perform the intricate pancreaticoduodenectomy (PD) procedure with unparalleled accuracy. A key innovation lies in the precise and systematic vascular control technique, which minimises blood loss and enhances the chances of complete tumour removal (R0 resection). By carefully identifying and controlling key vessels – such as the pancreatoduodenal arteries (inferior and superior) and pancreatic veins (posterior, anterior, superior, and inferior), this technique ensures safe vascular management, reducing the risk of complications like bleeding, which is a common challenge in pancreatic surgery. This meticulous approach involves a detailed sequence of vessel control, starting with the gastrocolic trunk and progressing to the remaining pancreatoduodenal vessels. The systematic control of these critical vessels, in contrast to blind dissection, significantly reduces the likelihood of haemorrhage, a frequent issue in traditional procedures. Additionally, the technique improves oncological outcomes by ensuring an R0 resection, where the tumour is completely removed with clear margins. One of the most important margins to address during the procedure is the superior mesenteric artery margin. If not carefully approached, this margin can become positive, leading to recurrence. However, following this method ensures a close and precise resection, thereby improving oncological control and patient outcomes. The innovation not only enhances the safety of the procedure but also plays a pivotal role in preventing recurrence and improving long-term survival rates for patients undergoing pancreatic surgery. Recently, a 58-year-old patient with advanced pancreatic cancer and a history of chronic pancreatitis underwent the procedure at JIPMER. The surgery achieved a complete tumour resection, enabling the patient to return home within just five days. Early initiation of adjuvant chemotherapy was possible due to the patient’s rapid recovery, showcasing the immense potential of this advanced technology. Over 100 pancreatic cancer surgeries have been successfully performed using this technique.   ]]> https://biospectrumindia.com/news/93/25369/surya-eye-hospital-unveils-western-indias-first-oculus-myopia-master-tool-for-early-detection.html https://biospectrumindia.com/news/93/25369/surya-eye-hospital-unveils-western-indias-first-oculus-myopia-master-tool-for-early-detection.html Tue, 19 Nov 2024 00:00:00 +0530 Mumbai-based Surya Eye Hospital, a leading eye care centre in India, has launched Western India's first Oculus Myopia Master, an advanced diagnostic tool from Germany designed to track and manage myopia progression in children. Myopia Master uses a contactless, painless approach to measure critical eye parameters such as axial length, keratometry, and refraction, allowing for accurate monitoring and personalised treatment plans. The Myopia Master has been developed in collaboration with OCULUS GmbH, Germany, and Brien Holden Vision Institute (BHVI) in Australia and empowers doctors to offer more precise diagnoses and treatment plans. By measuring key parameters of eye health and utilizing a unique artificial intelligence (AI)-based model for data analysis, the Myopia Master ensures personalised, effective care for every child, setting a new standard in myopia management. By 2030, 40% of Indian children will need spectacles due to myopia, reflecting a significant rise in this eye condition. Globally, one in three children is already affected, with myopia prevalence tripling to 36% between 1990 and 2023, highlighting its growing public health impact. Asia is projected to be most affected, with nearly 69% of the population at risk of moderate myopia by 2050. Dr Vinod Goyal, Senior Ophthalmologist and Director at Surya Hospital said, "Myopia is a pressing global health issue that requires proactive intervention. Through initiatives like the launch of the Myopia Master, we aim to provide comprehensive, preventive care that improves outcomes for children affected by myopia. We aim to detect and manage this condition early, giving every child a chance at clear, healthy vision." Dr Jay Goyal, LASIK and Retina Specialist and Director of Surya Eye Hospital, added, "By providing a more accurate diagnosis and customised care plan, we can significantly reduce children's dependency on glasses and minimize long-term risks, such as retinal detachment and glaucoma. With projections indicating that 40% of Indian children will be affected by myopia by 2030, Surya Eye Hospital's efforts are geared towards providing timely, comprehensive care and preventive solutions."   ]]> https://biospectrumindia.com/news/93/25362/apollo-radiology-international-strengthens-global-teleradiology-footprint-with-acquisition-of-inhealth-uks-reporting-division.html https://biospectrumindia.com/news/93/25362/apollo-radiology-international-strengthens-global-teleradiology-footprint-with-acquisition-of-inhealth-uks-reporting-division.html Mon, 18 Nov 2024 00:00:00 +0530 Apollo Radiology International (ARI), a unit of Apollo Hospitals Group and a premier global teleradiology provider, has announce acquisition of the radiology reporting wing of InHealth Group, the UK’s largest specialist provider of diagnostic and healthcare solutions. This acquisition solidifies ARI's commitment to addressing the critical shortage of radiologists worldwide, enhancing access to quality diagnostic services across the UK and globally. ARI is projected report over two million scans annually, covering 24 countries and continuing to serve 200+ healthcare organizations. This collaboration marks a seamless fusion of InHealth’s expertise in providing radiology reporting to the UK’s NHS and ARI’s global reach, technical excellence, and AI-powered solutions. Together, ARI and InHealth aim to extend reporting services across a wider network of NHS-partners in the UK, addressing critical gaps in radiology staffing and providing patients with accurate, timely diagnoses. This acquisition also extends ARI’s current commitment to the UK health sector. As a global exam delivery partner of The Royal College of Radiologists and a recruitment partner of NHS England, ARI has been supporting the NHS through academic and training initiatives and radiologist recruitment programs for over eight years. Through this partnership with InHealth, ARI reinforces its dedication to training, accrediting, and providing essential diagnostic support to the NHS and beyond.   ]]> https://biospectrumindia.com/news/93/25349/philips-india-introduces-new-azurion-interventional-imaging-system.html https://biospectrumindia.com/news/93/25349/philips-india-introduces-new-azurion-interventional-imaging-system.html Wed, 13 Nov 2024 00:00:00 +0530 Philips India, a leader in health technology and innovation, has introduced the new Azurion to specialist interventionalist across cardiology, neurology, vascular as well as surgery in India. Designed to streamline neurovascular procedures and help care teams make the right decisions faster, treat more patients, and achieve better outcomes, the new interventional system features enhanced C-arm rotation and angulation (imaging angles). It also provides parking facilities that allow rapid transitioning between 2D to 3D imaging, comprehensive table-side control that eliminates the need to leave the sterile field, automatic beam rotation to obtain correctly oriented images for every angulation and rotation, and a new head immobiliser to support enhanced stroke care.  Additionally, Philips is maximising the uptime of its angio suite solutions by using AI and machine learning to monitor system performance through the new remote connection services of the Philips Service Hub. These services communicate, monitor, and proactively respond to potential service issues in advance so that pre-emptive action can be taken. The new Azurion, set-up at Philips Innovation Campus, Bengaluru - the company’s largest innovation hub globally - was showcased to 80 interventionalists from across India.  The new Azurion system brings state-of-the art imaging capabilities and flexible ergonomic gantry positioning to optimize clinician workflow, ensuring faster and more precise treatment for the patients. This focus on enhanced imaging and efficiency reflects Philips’ commitment to improving patient outcomes in India. By allowing interventionalists to treat more patients, more efficiently, with potentially better outcomes, the new Azurion enhances both the staff and patient experience and contributes to lower cost of care.     ]]> https://biospectrumindia.com/news/93/25338/iit-ropar-designs-patented-mechanical-knee-rehab-device.html https://biospectrumindia.com/news/93/25338/iit-ropar-designs-patented-mechanical-knee-rehab-device.html Mon, 11 Nov 2024 00:00:00 +0530 In a significant breakthrough for post-surgical knee rehabilitation, researchers at the Indian Institute of Technology (IIT) Ropar have unveiled an innovative solution to make continuous passive motion (CPM) therapy more accessible and affordable. The team at IIT Ropar has developed a Completely Mechanical Passive Motion Machine for Knee Rehabilitation that has been awarded a patent. Unlike traditional motorised CPM machines, which are expensive and depend on electricity, the newly developed device is entirely mechanical. It utilises a piston and pulley system, which stores air as the user pulls a handle, enabling smooth and controlled motion to aid in knee rehabilitation. This simple yet effective design eliminates the need for electricity, batteries, or motors, making it both lightweight and portable. The mechanical CPM machine offers a promising alternative to costly electric machines that are often out of reach for many patients, especially in rural areas with unreliable electricity supply. By reducing the reliance on electricity, it makes continuous passive motion therapy feasible even in off-grid locations. Additionally, its portability allows for patients to use it in the comfort of their homes, reducing the need for prolonged hospital stays and rehabilitation visits. “This device has the potential to revolutionise knee rehabilitation in India, where access to advanced medical technology can be limited, particularly in rural areas,” said Dr Abhishek Tiwari, the lead researcher, along with his team comprising Suraj Bhan Mundotiya and Dr Samir C. Roy. “It’s designed to be a low-cost, sustainable solution that not only aids in recovery but also helps reduce the environmental impact associated with motorised devices”, he added. ]]> https://biospectrumindia.com/news/93/25334/govt-launches-scheme-for-strengthening-medical-device-industry.html https://biospectrumindia.com/news/93/25334/govt-launches-scheme-for-strengthening-medical-device-industry.html Sat, 09 Nov 2024 00:00:00 +0530 To provide a big boost to the medical devices industry, the Union Minister of Chemicals & Fertilizers and Health & Family Welfare, Jagat Prakash Nadda, has launched the Scheme for Strengthening the Medical Device Industry. Anupriya Patel, Union Minister of State for Chemicals and Fertilizers and Health & Family Welfare and Arunish Chawla, Secretary, Department of Pharmaceuticals along with officials of the department and representatives of industry were also present on the occasion. The scheme is a comprehensive one which targets critical areas of the medical device industry, covering manufacturing of key components and accessories, skill development, support for clinical studies, development of common infrastructure and industry promotion. The new scheme has a total outlay of Rs 500 crore. It consists of five sub-schemes which are as follows- Common Facilities for Medical Devices Clusters (Rs 110 crore); Marginal Investment Scheme for Reducing Import Dependence (Rs 180 crore); Capacity Building and Skill Development for Medical Devices (Rs 100 crore); Medical Device Clinical Studies Support Scheme (Rs 100 crore); and Medical Device Promotion Scheme (Rs 10 crore). Union Minister for Chemicals and Fertilizers appealed to the industry to make good use of the scheme and assured the industry of all help from the government stating that the Department is there to provide all support. Pavan Choudary, Chairman, Medical Technology Association of India (MTaI) said, "The scheme, launched after comprehensive research that included two groundbreaking stackathons, serves as a fine example of an evidence-based stimulation package. The efforts helped in identifying key areas where the industry needs support. This is where the scheme derives its focus on five critical aspects: manufacturing of essential components and accessories, skill development, support for clinical studies, development of shared infrastructure, and industry promotion." ]]> https://biospectrumindia.com/news/93/25323/mechanical-thrombectomy-treatment-is-cost-effective-for-patients-with-stroke-medtronic-study.html https://biospectrumindia.com/news/93/25323/mechanical-thrombectomy-treatment-is-cost-effective-for-patients-with-stroke-medtronic-study.html Wed, 06 Nov 2024 00:00:00 +0530 Medtronic, a global leader in healthcare technology, has unveiled results from the Prospective Registry for Assessment of Acute Ischemic Stroke Patients Treated with stroke Devices in India (PRAAN) at the World Stroke Congress 2024, held in Abu Dhabi.   PRAAN is India’s first industry-sponsored dedicated registry on mechanical thrombectomy, collecting real-world data on the use of stroke devices in patients with acute ischemic stroke (AIS) caused by large vessel occlusion.   The multi-centre study evaluates the clinical outcomes associated with market-released stroke devices of Medtronic for AIS patients with large vessel occlusion condition.   The PRAAN registry enrolled 200 patients over 24 months, across 14 centres, and demonstrated that mechanical thrombectomy is a safe, effective, as well as cost-effective treatment for AIS in India.   The data from the PRAAN study demonstrated high rates of positive functional outcomes and procedural success of mechanical thrombectomy with a low mortality rate in AIS patients. Additionally, the health economic analysis revealed that mechanical thrombectomy (MT) alone or in combination with intravenous tissue plasminogen activator (IV-tPA) appears to be cost-effective compared to IV-tPA treatment alone.   Discussing the PRAAN registry, Mandeep Singh Kumar, Vice President and Managing Director, Medtronic India, said, “Stroke is the fourth leading cause of death in India, making it one of the top non-communicable diseases in the country. PRAAN is a first-of-its kind multi-centric prospective stroke clinical registry in India that tracks and reports on mechanical thrombectomy. We are confident that the data and outcomes from the study will help ignite critical discourse to raise awareness about the dangers of stroke and available treatment pathways and will empower healthcare professionals and policy makers alike in providing the right resources and guidance for the Indian public.”   ]]> https://biospectrumindia.com/news/93/25316/pm-virtually-inaugurates-merils-advanced-medtech-manufacturing-facility-in-gujarat-under-pli-scheme.html https://biospectrumindia.com/news/93/25316/pm-virtually-inaugurates-merils-advanced-medtech-manufacturing-facility-in-gujarat-under-pli-scheme.html Fri, 01 Nov 2024 00:00:00 +0530 Meril, one of India’s leading global medtech company, celebrated a significant milestone as Prime Minister Narendra Modi virtually inaugurated its state-of-the-art manufacturing facilities under the Production Linked Incentive (PLI) scheme. Gujarat’s Chief Minister, Bhupendrabhai Patel was present in Vapi at the Meril headquarters during the inauguration. At the 2024 Vibrant Gujarat summit, Meril signed a Memorandum of Understanding (MoU) with the Gujarat government, committing Rs 910 crore in new investments in the medical devices sector. To date, Meril has invested over Rs 1,400 crore, highlighting its commitment to India’s medtech ecosystem. This investment is expected to create 5,000 jobs and significantly reduce imports of critical medical devices. “This new facility embodies Meril’s commitment to innovation and quality, enabling us to deliver advanced healthcare solutions globally across 150 countries. With 12 Meril Academies in India and abroad, we are equally dedicated to education and training, empowering healthcare professionals worldwide” said Vivek Shah, CEO, Meril. Under the PLI scheme, four of Meril’s group companies operating in Structural Heart, Vascular Interventions, Orthopaedics, and Endo Surgery are included, supporting the production of essential devices domestically. Founded in 2007, Meril operates across five key segments: Cardiovascular, Orthopaedics, Endo Surgery, Surgical Robotics, and Diagnostics. With over 10,000 employees and operations in 150+ countries, Meril has established direct subsidiaries in 31 countries.   ]]> https://biospectrumindia.com/views/93/25310/how-ai-is-propelling-radiology-medical-imaging-capabilities.html https://biospectrumindia.com/views/93/25310/how-ai-is-propelling-radiology-medical-imaging-capabilities.html Thu, 31 Oct 2024 00:00:00 +0530 In India, there is only one radiologist for every one lakh patients, which translates to one radiologist for every 100 scans performed each day. There is a severe shortage of radiologists in tier 2 and 3 cities as well. As the number of scans keeps rising and new high-resolution imaging technologies enter the market, it has become highly imperative to develop faster analytical techniques to assist pathologists and radiologists.     Demand- Supply mismatch for radiologists    Enter AI, ML Artificial intelligence (AI), using machine learning (ML) and deep learning (DL) algorithms has provided interventions in this direction. Machine learning and deep learning algorithms have been used for the past decade to interpret and analyse medical images and aid radiologists and pathologists in screening and diagnosis. Today AI has extended its capability to the entire radiology world, which includes digitising the devices, aiding in diagnosis and finally collating all the data and information into a digital assistant. Image analysis can be broken down into computer-aided detection, diagnosis, and image segmentation. Computer-aided detection and diagnosis involves the use of AI algorithms to analyse medical images and detect abnormalities and diseases.    On the other hand, image segmentation uses AI algorithms to identify and label various parts of a medical image as organs, blood vessels, or tumours. This can help radiologists locate abnormalities and design surgeries more accurately. For example, around 3.5 billion chest X-rays are performed annually worldwide, which require timely and accurate interpretation. AI solutions categorise X-rays based on suspicions of diseases which can be prioritised by radiologists for faster diagnoses boosting efficiency by 30-50 per cent. On the digital assistant front, traditional Picture Archiving and Communication Systems (PACS) are used for managing the medical images. However, the growing volume of these images is a huge challenge. Novel AI platforms are aiding PACS by optimising radiology workflows. These platforms use cutting-edge AI and enhance reporting and overall productivity. Some of these platforms act as a virtual assistant, intelligently prioritising worklists and efficiently sorting the scans. They highlight important cases and catch hold of abnormalities with precision by carefully scrutinising each image. Further, they also offer click-generated reports, saving radiologists’ time, and fostering seamless collaboration between technicians, radiologists, and referring physicians.    Major Pros & Cons Machine learning has in many cases, been shown to perform on par with medical experts. However, despite the high promise and comparisons with benchmark data, conversion into clinical data and problem-solving has been lacking. A recent review of 62 AI models developed to detect COVID-19 using X-ray and CT images showed that none could be translated into clinical use due to methodological flaws. The “non-explainability”, or the inability of the algorithm to explain the diagnosis through evidence, discourages and deters clinicians from adopting AI systems.  Secondly, there are challenges in data availability and collection. Medical datasets are typically small in size, on the order of hundreds or thousands. These datasets come with inherent biases, around various demographics, spectrum of patients and symptoms, which also feed into the algorithms. The test data must be an actual representation of the actual population, rather than being a subset of the training dataset, the latter being the prevailing practice. In medical imaging, dataset bias has been demonstrated in chest X-rays, retinal imaging, brain imaging, histopathology, or dermatology. Sometimes images capture medical interventions as well, which create unnecessary errors during the analysis. Finally, labelling-related errors also exist which need to be avoided. Generating high-quality data sets for very specific use cases and collecting these data sets without any biases will go a long way in improving the clinical outcomes of the use of machine learning in medical diagnosis. In March 2024, Google partnered with Apollo Radiology International to advance the use of AI in healthcare. The Google Health AI team has been working on various disease conditions such as tuberculosis, and breast and lung cancer and through this partnership, Apollo Radiology will provide them access to high-quality medical data.   Startup Pioneers and Future Prospects  In India, startups such as Niramai, Qure.ai, and Sigtuple were the first set of companies focused on using machine learning for disease diagnosis and reporting. These startups have deployed their solutions pan-India, and they collect more real-world unbiased data and constantly improve their algorithms. Sigtuple has raised more than $40 million during its journey in digitising the pathology and radiology labs and claims to have a portfolio of 21 granted patents. Qure.ai raised a $40 million round in 2022 to scale its medical imaging diagnostics AI services globally. Niramai received the US FDA approval for its breast cancer screening system SMILE-100 in 2022 and boasts a portfolio of more than 25 patents. Some new-generation startups are also using Gen AI to generate synthetic medical images that resemble real patient data, to aid the training and validation of machine-learning models. Gen AI solutions are also automating the radiology report generation, thereby reducing the burden on radiologists and creating a fast and seamless experience for patients.  The advancements in Gen AI and machine learning to understand complex medical images and provide precise diagnoses in the fastest time possible will shape the future of radiology across the world.   Suraj Nair, Lead, TechSprouts, Ankur Capital ]]> https://biospectrumindia.com/news/93/25293/industry-leaders-call-for-pms-intervention-in-long-lasting-issue-of-allowing-imports-of-refurbished-medical-devices.html https://biospectrumindia.com/news/93/25293/industry-leaders-call-for-pms-intervention-in-long-lasting-issue-of-allowing-imports-of-refurbished-medical-devices.html Sun, 27 Oct 2024 00:00:00 +0530 The PHD Chamber of Commerce and Industry (PHDCCI) and the Association of Indian Medical Devices (AiMed), in alliance with the Manufacturers of Imaging, Therapy and Radiology Devices Association (MITRA), the Association of Diagnostic Manufacturers of India (ADMI), and key stakeholders from the MedTech industry, recently held a press meet at PHD House to discuss serious concerns regarding recent Office Memorandums issued by the Ministry of Environment, Forest, and Climate Change (MoEFCC), the Directorate General of Health Services (DGHS), and the Ministry of Health & Family Welfare (MoHFW). These memorandums permit the import of refurbished and pre-owned medical devices, despite similar devices being manufactured in India. Industry leaders believe this poses a significant threat to India’s self-reliance in medical device manufacturing, undermining the nation’s efforts under the Prime Minister's vision of 'Make in India' and 'Aatmanirbhar Bharat' initiatives. This development is seen as a major setback for domestic manufacturing capabilities and India’s push toward self-sufficiency. Additionally, concerns have been raised about potential risks to patient safety, as refurbished devices may not meet the rigorous quality standards of newly manufactured equipment, further intensifying the issue.   Refurbished devices, which undergo repairs and cosmetic updates, cannot replicate the functionality and reliability of new equipment. New medical devices maintain optimal performance throughout their lifecycle, typically lasting around ten years, while refurbished options may show diminished functionality due to prior use. Additionally, refurbished devices often lack the latest technological advancements and come with lower warranties, inadequate service support, and higher failure rates, all of which can impact the quality of treatment and surgical outcomes.   In light of these issues, industry leaders collectively urged the Prime Minister to address the current challenges and order an immediate ban on the import of refurbished devices that are manufactured locally. They emphasised the importance of aligning policies with national manufacturing initiatives to support domestic manufacturers and reduce reliance on imports. Furthermore, they called for enhanced post-market surveillance to monitor the safety and effectiveness of all medical devices used in India, ensuring that patient safety remains a top priority. ]]> https://biospectrumindia.com/news/93/25239/drger-india-launches-babyroo-tn300-to-assist-in-postnatal-care.html https://biospectrumindia.com/news/93/25239/drger-india-launches-babyroo-tn300-to-assist-in-postnatal-care.html Tue, 08 Oct 2024 00:00:00 +0530 Dräger India has announced the launch of the BabyRoo TN 300 open warmer, with state-of-the-art thermoregulation capabilities as well as advanced integrated technologies to support emergency resuscitation and family- centered care. The BabyRoo TN300 is the ideal assistant in postnatal care, ensuring newborns receive the best possible start in life. From delivery room to the neonatal intensive care unit and through the final discharge, the BabyRoo TN300 is scalable to use in a variety of hospital environments along the patient pathway. Key features of BabyRoo TN300 include Lung-protective respiratory support in the first few minutes after birth; Efficient workflows with ergonomic workplace options; and Family-friendly design to support parental involvement. In the first crucial minutes after birth, for newborns who require respiratory support, the resuscitation module of the BabyRoo with an optional AutoBreath function automatically maintains all preset ventilation parameters, such as the fraction of inspired oxygen (FiO2), airflow, pressure, breathing frequency, and positive end-expiratory pressure (PEEP). Further the AutoBreath decreases the workload for the caregiver by automatically delivering breaths at a set rate, giving staff more time for other important tasks. Close body contact and the early involvement of parents in the care process play an important role in ensuring the best possible development for newborns. The open warmer goes beyond merely supporting workflows, it actively promotes parental involvement in the care process. To encourage bonding between infants and parents at an early stage, the BabyRoo offers a family-friendly design and an easy-to-reach bed area. It also offers a kangaroo mode that reduces disruptive alarms during skin-to-skin contact, allowing parents to bond with their newborns in developmentally supportive environment. “At Draeger, we believe that every newborn deserves the best start in life, regardless of the circumstances of their birth. The introduction of BabyRoo TN300 reinforces our commitment to providing advanced thermoregulation and developmental care. By fostering a closer bond between infants and their parents, we are setting new standards in creating a nurturing environment”, said Shalin Patel, Managing Director of Draeger India Group. “The device is a major leap forward in shaping the future of neonatal care, where both technology and compassion are at the forefront”, added Shalin. The BabyRoo device is designed for offer flexibility in labor and delivery rooms and neonatal intensive care units (NICUs) alike. “The BabyRoo TN300 depending on the need can be transformed into a comprehensive neonatal intensive care workstation. Whether through extended monitoring or integration of additional therapy devices such as the Dräger Babylog neonatal ventilator, or the Dräger BiliLux phototherapy light for the treatment of jaundice, BabyRoo offers a flexible and robust platform for newborn care,” said Dhritimay Dhar, Head- Sales and Marketing, Medical Business. The BabyRoo offers versatile respiratory support, from simple oxygen delivery to fully automated resuscitation with suction, ensuring comprehensive care in the delivery room. Its intuitive user interface and specialised modes streamline workflows, aiding in the stabilisation of newborns both in delivery and NICU settings. To optimise resuscitation settings, the BabyRoo provides SpO2 and pulse rate measurements, along with practical features such as height adjustment, a built-in scale and an optional pass-through X-ray tray, that enables caregivers to spend less time interacting with the device and devote more time focusing on infant care. ]]> https://biospectrumindia.com/news/93/25225/hyderabads-kims-hospitals-signs-mou-with-intuitive-to-launch-25-new-robotic-surgery-programmes.html https://biospectrumindia.com/news/93/25225/hyderabads-kims-hospitals-signs-mou-with-intuitive-to-launch-25-new-robotic-surgery-programmes.html Thu, 03 Oct 2024 00:00:00 +0530 Krishna Institute of Medical Sciences (KIMS) Hospitals, one of India’s leading corporate healthcare groups, has signed a Memorandum of Understanding (MoU) with Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS). The Robotic Surgery Centre of Excellence will be based out of KIMS-PES Hospital, Bengaluru and will provide training for all Robotic Surgeries across specialities to all KIMS branches in India. This collaboration will establish 25 robotic surgery programmes featuring da Vinci robotic-assisted surgical systems in Maharashtra, Karnataka, Andhra Pradesh, and Telangana, with a focus on expanding access to advanced minimally invasive surgical care in tier 2 and tier 3 cities. The da Vinci systems will be deployed in key locations, including Nagpur, Nashik, and Thane in Maharashtra; Bengaluru in Karnataka; and Secunderabad, Begumpet, Kondapur, and Gachibowli in Telangana. In Andhra Pradesh, the da Vinci systems will be located in cities including Visakhapatnam, Srikakulam, Rajahmundry, Ongole, Kurnool, Nellore, and Anantapur and in Kerala at Kannur. There are currently over 170 da Vinci systems installed across India, with more than 850 surgeons trained in robotic-assisted surgery in specialties such as gynecology, urology, general surgery, and oncology. Collectively, there have been more than 14 million da Vinci procedures performed globally to date, with more than more than 38000 scientific articles referencing Intuitive’s technologies underscoring the safety, efficacy, and benefits of surgery performed with the da Vinci system, including fewer complications and conversions, and faster patient recovery. As part of this collaboration, Intuitive India will provide comprehensive technology training, customer service and support to surgeons and care teams associated with KIMS Hospitals.   ]]> https://biospectrumindia.com/news/93/25198/surgical-robotics-pioneer-intuitive-opens-global-capability-centre-in-bengaluru.html https://biospectrumindia.com/news/93/25198/surgical-robotics-pioneer-intuitive-opens-global-capability-centre-in-bengaluru.html Thu, 26 Sep 2024 00:00:00 +0530 US-based Intuitive, a global technology leader in minimally invasive care and the pioneer in robotic-assisted surgery (RAS), has announced the opening of its Global Capability Centre (GCC) in Bengaluru. The new centre will drive innovation and enable the enhancement of operational efficiency across the global organisation. Gary S. Guthart, Intuitive CEO and Dr Sharanprakash Rudrappa Patil, Minister for Medical Education, Skill Development, Entrepreneurship and Livelihood, Government of Karnataka inaugurated the centre at its location at the Embassy Golf Links. The GCC will serve as one of Intuitive’s core global hubs for functions including IT support, enterprise analytics, software quality, human resource management system (HRMS) and post-market surveillance, all of which strengthen the safety, performance and reliability of Intuitive’s systems and technologies. The GCC will be an important contributor to Intuitive’s operations, reflecting the company’s dedication to innovation, quality, and excellence. While inaugurating the centre, Dr Sharanprakash Rudrappa Patil said, "This Global Capability Centre will play a crucial role in training more doctors, a field where India has immense potential and already produces some of the finest medical professionals globally. With further collaboration, including public-private partnerships, we can expand these advancements to even the most remote areas. The government looks forward to working with medical technology leaders like Intuitive to bring modern healthcare technology to every corner of Karnataka." Announcing the opening of the GCC in Bengaluru, Gary S Guthart, CEO of Intuitive said, “This Global Capability Centre will play an important role in helping us to advance minimally invasive healthcare technology, and the ecosystem of services, support and insight that ensure its successful use and adoption.” Intuitive expects to have more than 250 full-time positions at the GCC, including functions that will add value to the overall product lifecycle, including product upgrades, quality improvement, and customer service. This expansion aligns with Intuitive’s commitment to fostering a dynamic and inclusive workplace culture, and the team at GCC will embody Intuitive’s core values of integrity, transparency, and flexibility.   ]]> https://biospectrumindia.com/news/93/25180/exclude-medical-devices-from-the-list-of-india-eu-free-trade-agreement-fta-items-aimed.html https://biospectrumindia.com/news/93/25180/exclude-medical-devices-from-the-list-of-india-eu-free-trade-agreement-fta-items-aimed.html Wed, 25 Sep 2024 00:00:00 +0530 In view of the steep growth in imports of medical devices from Europe and other countries into India, the domestic manufacturers of these devices have demanded the exclusion of medical equipment and consumables from the list of EU Free Trade Agreement (FTA) items. Amidst the ongoing India-EU FTA talks, in a letter written to the Commerce Ministry, the Association of Indian Medical Device Industry (AiMeD) has highlighted that the imports of these items in India has grown at a staggering rate of 68% in the last four years, making India dependent on imports to the tune of 70% currently. At a time when India’s existing import duty on medical devices is already very low (0.0%-7.5%), bolstering imports further by including these medical items in the EU-FTA list would not only jeopardise the medical security of India but also prove to be highly detrimental to the domestic manufacturing industry, according to Rajiv Nath, Forum Coordinator, AiMeD. Whenever India has signed any FTA with another country, the imports of medical devices into India have only grown. India signed the Japan-India Comprehensive Economic Partnership Agreement (JICEPA) but the imports of medical equipment from Japan has risen from Rs 1826 crore in FY20 to Rs 3085 crore in FY24, a jump of 19%. Similarly, India inked India–Singapore Comprehensive Economic Cooperation Agreement (ISCECA) but the imports from Singapore have jumped from Rs 4294 crore in FY20 to Rs 6779 crore in FY24. Germany and Netherlands, both EU countries, are already among the top five exporters of medical devices into India. “EU has many non-tariff barriers for Indian imports into any EU nation. We need a Tit-for-Tat policy from India’s side. Indian manufacturers require CE Certification to sell to EU nations which is not only an expensive affair but also leads to a lot of time wasted in getting the certification - approximately 2 years. EU nations get our factories inspected rigorously before buying from here. We need a similar policy from India where-inspection of EU factories and verification of compliance to Indian Medical Device Rules (MDR) and also of Domestic Content in EU factories is done by Indian regulators,” said Nath in AiMeD’s letter to the Commerce Ministry. AiMeD has also highlighted that the regulatory system for medical devices in the EU permits organisations to label themselves as a 'Legal Manufacturer' even if they are not making the product themselves. This was done to allow EU regulators to make Market Authorisation Holder to be responsible and accountable from the patient safety perspective but this facility has been abused and lead to pseudo manufacturing to thrive in EU as Country of Origin is not insisted upon on the labeling of medical devices in Europe & UK, unlike the case of USA & India, which seek labeling of ‘Country of Origin’ on medical items. There’s a huge risk of 3rd country exports to be routed via EU to India under this legal manufacturing route whereby a marketing company can pass itself off as a legal manufacturer. The Indian medical device manufacturing industry has been given assurance in past for UK-India FTA that ‘Legal Manufacturer’ labeled packages will not enjoy ‘ZERO Duty’ FTA benefits if the manufacturer/ exporter is not an actual manufacturer and not able to prove that he assembles and manufacture the medical device in the UK with at least 40% value addition. AiMeD has sought to know how this assurance will be enforced. “When there is inspection is done by Bureau of Indian Standards (BIS) for items like steel and plastics when imports are involved, then why not make it mandatory for factories if Medical Devices in foreign countries to be inspected by BIS and CDSCO in case of medical devices which are far more crucial than simple plastic items,” said Nath. China, Singapore, Malaysia, Japan, South Korea, Thailand, Argentina, Vietnam, Indonesia, Philippines, New Zealand, etc. have gained much more than India after FTAs were signed by Indians with them. ]]> https://biospectrumindia.com/news/93/25193/dr-devi-shetty-unveils-first-of-its-kind-robotic-cardiac-coe-in-bengaluru.html https://biospectrumindia.com/news/93/25193/dr-devi-shetty-unveils-first-of-its-kind-robotic-cardiac-coe-in-bengaluru.html Wed, 25 Sep 2024 00:00:00 +0530 Dr Devi Shetty, Chairman and Executive Director of Narayana Health, unveiled first-of-its-kind robotic cardiac centre of excellence (CoE) in an event held at Mazumdar Shaw Medical Centre, Narayana Health City, Bengaluru. This is a significant step in making one of the advanced surgical technologies, robotic-assisted surgery, accessible to cardiac patients from across India. This centre recently became the fastest in the country and the second fastest in the world to successfully perform 100 robotic-assisted cardiac surgeries, by completing it in 147 days. Commenting on this occasion, Dr Devi Shetty, Chairman and Executive Director – Narayana Health, said, “We believe that the utilisation of technology in the field of surgery is an important goal in advancing science. We have introduced robotic-assisted surgery at multiple Narayana Hospitals across the country and we are one of the hospitals to train most number of surgeons in robotic-assisted surgery in India. With cardiac diseases becoming one of the fastest-growing healthcare problems globally, now we have taken a step in the right direction to consolidate the best available surgical robotics technology. This exclusive robotic cardiac centre of excellence is equipped with one of the most advanced 4th generation robotic-assisted surgery systems, da Vinci to help address the growing disease burden in India through timely treatment interventions using the latest in advanced technologies. This will allow patients nationwide to get the best cardiac surgical treatment.” In comparison to traditional open-heart surgery, which involves opening up the chest by splitting the breastplate, the da Vinci's innovative technology allows for complex cardiovascular surgeries to be performed through smaller incisions and precise motion control. For instance, in procedures like Mitral Valve Repair, Mitral Valve Replacement and Atrial Septal Defect (ASD) surgery, the surgeon doesn’t have to cut the patient's ribs or make an incision between the ribs, to perform the surgery.    ]]> https://biospectrumindia.com/news/93/25166/kriya-medical-technologies-introduces-automated-system-to-deliver-blood-collection-tubes.html https://biospectrumindia.com/news/93/25166/kriya-medical-technologies-introduces-automated-system-to-deliver-blood-collection-tubes.html Fri, 20 Sep 2024 00:00:00 +0530 Kriya Medical Technologies, a Chennai-based medical devices company, has introduced the ICHOR Medical Molding System, a fully automated, state-of-the-art system designed to deliver 250 million units of blood collection tubes annually. The machinery was unveiled by Thiru. DR. T.R.B. Rajaa, Minister for Industries, Investment Promotions and Commerce, Government of Tamil Nadu, at KRIYA Medical’s manufacturing facility at Oragadam Industrial Corridor in Chennai.  The ICHOR System is a state-of-the-art, fully integrated high-speed manufacturing system for Evacuated Blood Collection Tubes. With a production capacity of 7 lakh tubes per day, amounting to 250 million tubes annually, this advanced system will play a key role in localising production of blood collection tubes. This initiative places India on the global stage as a high-tech manufacturing hub, positioning the country to export these products to key markets such as the United States, Canada, and Japan.  The ICHOR system operates 24/7 with full automation and remote monitoring capabilities from Canada, Japan, and Luxembourg. Developed through a global partnership, Kriya Medical Technologies was responsible for the product design and quality standards, while Husky managed the automation and equipment design.  ]]> https://biospectrumindia.com/news/93/25164/french-healthcare-meets-indian-ecosystem-at-indo-french-healthcare-conference.html https://biospectrumindia.com/news/93/25164/french-healthcare-meets-indian-ecosystem-at-indo-french-healthcare-conference.html Wed, 18 Sep 2024 00:00:00 +0530 Business France India hosted the 2024 edition of the Indo-French Healthcare Conference, a landmark event highlighting the expertise and scope of the French and the Indian healthcare sectors, on 17th September 2024, at the Embassy of France in India. Organised in partnership with the French Institute in India (IFI) and Medical Technology Association of India (MTaI) as knowledge partner, this conference was inaugurated by the Ambassador of France to India, Thierry Mathou along with Dr Vinod K. Paul, member of NITI Aayog, as esteemed chief guest of the event. Dr Vinod K. Paul highlighted the importance of the Indo-French partnership in healthcare and potential ways of collaboration.   This event saw the participation of about 85 attendees and had the support of the Indo-French Chamber of Commerce & Industry (IFCCI), CEFIPRA, Invest India, the French Healthcare association and APHP. The Indo-French Healthcare Conference, which brought together healthcare professionals, medical experts and industry leaders from both France and India, aimed to create dialogues and foster collaborations between leading healthcare companies of the two countries. This conference included diverse topics of discussion ranging from new age technologies to medical research and development as well as opportunities for the growing Indian healthcare industry and areas of cooperation in this field between the two nations. CEOs of medical devices companies, Indian hospitals, prominent researchers’ practitioners from France and India gathered and discussed topics such as Emerging healthcare opportunities in India; New areas for healthcare R&D between France and India; Innovations in pharma and biotech- Manufacturing and Retail; and How global MedTech companies and hospitals are transforming healthcare innovation & skill development in India. Participating companies seeking to enter the Indian market included 2PS, Inlog S.A.S, Dagard, and F2D Medical. The event also saw the participation of prominent French subsidiaries in India namely Peters Surgical, Vygon, BioMérieux, Air Liquide Medical Systems, and Eradicus.    ]]> https://biospectrumindia.com/news/93/25128/atal-innovation-mission-niti-aayog-hosts-20th-medtech-mitra-technical-advisory-meeting.html https://biospectrumindia.com/news/93/25128/atal-innovation-mission-niti-aayog-hosts-20th-medtech-mitra-technical-advisory-meeting.html Tue, 10 Sep 2024 00:00:00 +0530 Atal Innovation Mission (AIM), NITI Aayog recently hosted the 20th Technical Advisory Committee (TAC) meeting of the MedTech Mitra initiative. Launched on December 25, 2023, jointly by Indian Council of Medical Research (ICMR) and Central Drugs Standard Control Organization (CDSCO) under the guidance of NITI Aayog, the MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions by providing crucial support for clinical evaluation, regulatory facilitation, and the uptake of new products. Since its launch, the MedTech Mitra portal has received an overwhelming response from innovators across the country. In order to address the queries received on the portal and to provide strategic holistic handholding support to MedTech innovators, twenty Technical Advisory Committee (TAC) meetings of ‘MedTech Mitra’  have been held at ICMR-Hqrs, CDSCO and NITI Aayog wherein, innovators were invited by ICMR-Medical Device and Diagnostics Mission Secretariat (MDMS) to make presentation before senior officials from the MedTech Mitra knowledge partner organisations including CDSCO, AIM-NITI Aayog, Bureau of Indian Standards (BIS), ICMR-Indian Clinical Trial & Education Network (INTENT), Kalam Institute of Health & Technology, (KIHT)/ Andhra Pradesh MedTech Zone (AMTZ), DHR-Health Technology Assessment in India (HTAIn), DHR-Centre for Guidelines, National Health Systems Resource Centre (NHSRC), Government e-Marketplace (GeM) and Atomic Energy Regulatory Board (AERB) & ICMR-MDMS. To streamline the process, operational Standing Operating Procedures (SOPs) have been established to define stakeholder roles and responsibilities.  The meeting was followed by the launch of AIM’s 6th edition of ‘Innovations for You’ coffee table book. The book highlights 50 pioneering entrepreneurs incubated under the various Atal Incubation Centres spread across the country, who are driving change through their contributions in Life Sciences and Biotechnology. Within this sector, the publication delineates innovations into subcategories—Diagnostics, Therapeutics, Bioengineering, and Drug Discovery. The publication is intended to highlight the stories of these innovations and underscore the vast applications and impact for society at large. Intended to both guide and inspire upcoming startups, the book also underscores the pivotal role of AIM-supported incubators in fostering innovation and research within these domains. ]]> https://biospectrumindia.com/news/93/25106/pristyn-care-partners-with-curemyknee-to-establish-coe-for-joint-replacement-surgeries.html https://biospectrumindia.com/news/93/25106/pristyn-care-partners-with-curemyknee-to-establish-coe-for-joint-replacement-surgeries.html Wed, 04 Sep 2024 00:00:00 +0530 Pristyn Care, a leading healthcare provider specialising in advanced secondary care surgeries, is establishing a Centre for Excellence (CoE) in Joint Replacement Surgeries with Cure My Knee. This integration marks a significant milestone in delivering top-notch orthopaedic care, starting from Delhi NCR and extending across India. The Centre for Excellence will be dedicated to providing the highest quality services for patients requiring joint replacement surgeries. It will leverage the combined clinical expertise of Pristyn Care and Dr Das (Founder of Cure My Knee). The initiative aims to enhance patient outcomes through advanced surgical techniques, state-of-the-art technology, and a patient-centric approach. As per recent market surveys, the rate of joint replacement surgeries in India has steadily increased each year. For instance, knee arthroplasty procedures were estimated to be about 2,00,000 in 2020 whereas hip arthroplasties are projected to grow at the fastest pace globally.  With the current demographic trend in India being that of a bell-curve population distribution where there will be more people in their 50s and 60s over the next decade, a significant number of people will need joint replacement surgeries than what it is today.     ]]> https://biospectrumindia.com/news/93/25091/multispecialty-hospital-shalby-announces-strategic-clinical-trial-agreement-with-monogram-technologies.html https://biospectrumindia.com/news/93/25091/multispecialty-hospital-shalby-announces-strategic-clinical-trial-agreement-with-monogram-technologies.html Mon, 02 Sep 2024 00:00:00 +0530 Shalby Limited, a leading multispecialty hospital in India, has announced a strategic partnership with US-based startup Monogram Technologies Inc., an artificial intelligence (AI)-driven robotics company specialising in orthopedic surgery. This collaboration will focus on conducting a multicenter clinical trial in India to demonstrate the safety and effectiveness of Monogram's mBȏs TKA System, a precision robotic surgical system designed for knee replacements. Monogram's mBôs precision robotic surgical system is designed to autonomously execute optimised paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced better-fitting bone sparing knee replacements. The company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored. Under the agreement, Shalby will enroll up to patients at various sites in India for surgeons to evaluate the safety and effectiveness of the mBȏs TKA System with the Consensus CKS implant, which is substantially equivalent to the Monogram mPress implants for regulatory purposes. Monogram received comments on the Clinical Investigational Plan during its February 2024 Pre submission Communications with the FDA and has incorporated feedback. Notably, the strategic Clinical Trial Agreement contemplates the post-trial transfer of a robot to the hospital system under certain conditions following the trial as the companies contemplate further collaboration.  Monogram plans to leverage the clinical data from the US study for post-launch marketing and to support international clearance and commercialisation.  ]]> https://biospectrumindia.com/news/93/25060/reprosci-strengthens-focus-on-medical-simulation-with-upcoming-event-in-bengaluru.html https://biospectrumindia.com/news/93/25060/reprosci-strengthens-focus-on-medical-simulation-with-upcoming-event-in-bengaluru.html Mon, 26 Aug 2024 00:00:00 +0530 ‘Driving Outcomes in the Health Sector with Emerging Tech’ is one of the most sought-after event being organised by Reprosci Biosciences (dedicated to revolutionising the field of reproductive medicine), in collaboration with NASSCOM and Karnataka government, to be held on 29 August in Bengaluru. The global healthcare system faces a critical shortage of skilled medical professionals. This shortage is a major obstacle to achieving universal healthcare access. Inadequate training, difficulties in recruitment and retention, and suboptimal performance contribute to this crisis. Bengaluru-based startup Reprosci is addressing this challenge with an innovative solution. Its advanced medical education platform provides a comprehensive training experience, combining cutting edge technology with real world simulations. Simulation technology enhances medical product demos, improving decision-making among healthcare professionals. It integrates Virtual Reality (VR) walkthroughs and Augmented Reality (AR) overlays, offering practical insights into product use. This upcoming event by Reprosci offers a unique opportunity to explore how emerging technologies can revolutionise healthcare training and marketing. Don’t miss this chance to see the latest advancements in action! Registration Link: https://forms.gle/LkRbGHLmZUdHJQda8 ]]> https://biospectrumindia.com/news/93/25014/sree-chitra-tirunal-institute-for-medical-science-and-technology-signs-mou-with-who.html https://biospectrumindia.com/news/93/25014/sree-chitra-tirunal-institute-for-medical-science-and-technology-signs-mou-with-who.html Fri, 09 Aug 2024 00:00:00 +0530 Sree Chitra Tirunal Institute for Medical Science and Technology (SCTIMST) has signed a Memorandum of Understanding with the World Health Organisation (WHO). It allows SCTIMST and Department of Science and Technology to enter into a partnership with global entrepreneurs, licensing the technologies and creating revenue generation through royalty. Union Minister Dr Jitendra Singh hails WHO on signing MoU with India for production of medical devices at the ceremony to formally announce the agreement at INSA, New Delhi. The Science and Technology Minister highlighted our world class facilities related to the development of technologies like in-vitro testing, genomics, precision medicine and vaccine production and added that technology developed by SCTIMST is a part of the rapidly expanding ecosystem of medical diagnostics. Dr Jitendra Singh expressed his confidence on the collaboration with WHO, which will result in more technology development as well as innovations and foster international partnerships to strengthen our medical, diagnostic, and therapeutic infrastructure and stay ahead in combating global diseases and future pandemics. ]]> https://biospectrumindia.com/news/93/24999/getinge-launches-operating-room-table-and-surgical-light-for-medtech-market-in-india.html https://biospectrumindia.com/news/93/24999/getinge-launches-operating-room-table-and-surgical-light-for-medtech-market-in-india.html Tue, 06 Aug 2024 00:00:00 +0530 In an effort to enhance efficiency and safety in surgical departments, Swedish medtech firm Getinge has introduced Maquet Corin, a state-of-the-art operating room (OR) table, and Maquet Ezea, an easy to use surgical light. These new products are designed to simplify daily operations for medical professionals while prioritising user-friendly features and advanced safety measures. Maquet Corin, the OR table from Getinge, offers an intuitive and simple interface that aims to streamline workflow and enhance teamwork among surgical staff.  On the other hand, Maquet Ezea addresses the need of operating room staff, with a focus on durability and user-friendliness. It is built to last and align with evolving risk management standards. Its versatility and simplicity makes it an essential tool for healthcare professionals working in surgical settings. Maquet Corin is also the very first connected operating table as it provides biomed and service technicians, with the possibility to easily access a wide range of service data and usage statistics, making sure the table is always ready to perform for a surgery. Aruna Nayak, Managing Director at Getinge India, commented on the launch, "The launch of Maquet Corin and Maquet Ezea represents a significant milestone for Getinge India. These products are a testament to our unwavering commitment to delivering advanced medical technology that meets the highest standards of quality and safety. We are excited to bring these innovations to the Indian market, where they will undoubtedly enhance the capabilities of our healthcare professionals and improve patient outcomes." ]]> https://biospectrumindia.com/news/93/25000/apollo-cancer-centre-launches-cyberknifes7-fim-robotic-radio-surgery-system-with-an-academia.html https://biospectrumindia.com/news/93/25000/apollo-cancer-centre-launches-cyberknifes7-fim-robotic-radio-surgery-system-with-an-academia.html Mon, 05 Aug 2024 11:00:00 +0530 The CyberKnife S7 FIM System is a non-invasive treatment for cancerous and non-cancerous tumors and other conditions where radiation therapy is indicated. It is used to treat conditions throughout the body including brain, lung, spine, prostate and abdominal cancers, and may be an alternative to surgery for patients who have inoperable or surgically complex tumors. Patients previously treated with radiation, who have metastatic lesions or with recurrent cancers, can also benefit from CyberKnife treatment. The CyberKnife System is the only radiation delivery system that features a radiation delivery device, called a linear accelerator, directly mounted on a robot to deliver the high-energy X-rays or photons used in radiation therapy. It uses real-time image guidance and a robot to deliver doses from thousands of beam angles, setting a new standard for delivery precision anywhere in the body. Mr. Dinesh Gundu Rao, State Minister for Health and Family Welfare, Govt. Of Karnataka, said, “It is equally commendable by Apollo Cancer Centers to introduce the CK Academia thereby benefitting a larger ecosystem of cancer warriors. We are indeed proud that both the latest technology and the future practitioners/adopters of this technology, will originate from our state.” Dr Sridhar PS,  Dr Vinay Ural , Dr Vikram Maiya, radiation oncologists, stated “The CyberKnife S7 FIM System redefines the future of radiation therapy, combining speed, precision and Synchrony AI-driven, real-time target tracking with dynamic delivery to deliver precise hypo fractionated SRS/SBRT treatments for a wider range of indications which include benign brain tumors, brain metastases, select medically refractory functional indications: trigeminal neuralgias, cluster headaches, tremors, lesional epilepsy & select extra cranial inoperable cancers of lung,  pancreas, liver, prostate, recurrent Head and neck cancers and metastatic directed therapy to oligomets.”   ]]> https://biospectrumindia.com/news/93/24992/skanray-partners-with-tata-elxsi-to-advance-surgical-imaging-and-healthcare-innovation.html https://biospectrumindia.com/news/93/24992/skanray-partners-with-tata-elxsi-to-advance-surgical-imaging-and-healthcare-innovation.html Mon, 05 Aug 2024 00:00:00 +0530 Skanray, a Mysuru-based medtech R&D and manufacturing company specialising in diagnostic imaging, critical care and surgery/OT solutions, has chosen Tata Elxsi as a strategic partner for advanced surgical imaging core technology and software platform development. This collaboration aims to revolutionise diagnosis and treatment by leveraging cutting-edge technology modules, making them predictable, accurate, and consistent. Skanray is actively pursuing a long-term strategy to expand its portfolio by including new device families and modalities. This initiative aims to build a suite of reusable modules and components for medical devices, alongside the development of an advanced analytics cloud platform. Bengaluru-headquartered Tata Elxsi will lead a software platform-led approach to diagnostics that will support all imaging, critical care and surgical systems from the Skanray family, ensuring interoperability, compatibility and multi-modal functionality. This platform will also incorporate the latest technologies and process efficiencies from AI and GenAI. Combining Skanray's expertise in medical devices, core component technology, systems and applications with Tata Elxsi's domain experience in medical imaging, software platform development, digital capabilities in cloud, AI and analytics, and ready-to-use solution accelerators provides Skanray an opportunity to redefine the landscape of medical technology, with advanced, modular, and yet affordable diagnostics systems.   ]]> https://biospectrumindia.com/views/93/24974/innovation-and-future-trends-in-magnetic-resonance-imaging.html https://biospectrumindia.com/views/93/24974/innovation-and-future-trends-in-magnetic-resonance-imaging.html Wed, 31 Jul 2024 00:00:00 +0530 Clinical MRI systems have continually improved over the years since their commercial introduction in the 1980s, although MRI research was conducted even before that time.. Today, MRI technology stands as the gold standard for medical imaging of  soft tissuesextensively used for diagnosing and treating various health conditions. Innovations and advancements in MRI technology are expected to continue to evolve, with advancements such as faster scanning, higher resolution of images, increased accessibility, and enhanced patient experiences. The medical imaging market is constantly evolving. MRI systems market is projected to surpass $6.6 billion by 2028 driven by technological advancements and growing healthcare not just  in Asia Pacific, but,across the world Let’s look at some of the biggest medical imaging technology trends shaping the industry.   Advancement in MRI Systems Remarkable progress has been made in MRI technology with the introduction of Sealed Super Conducting MagnetTechnology, a groundbreaking shift away from relying on liquid helium. -. Operating an MRI machine involves advanced magnet technology utilizing superconductors. To maintain the magnet's superconductivity, sophisticated cryogenic physics is employed to keep the magnet at an extremely low temperature of -269 degrees celsius. Traditionally, reaching this temperature required a substantial amount of liquid helium, typically between 1000-2000 liters per MRI system. However, Sealed Technology offers a sustainable and cost-effective solution by drastically reducing helium consumption to just 7 liters per system. By reducing the need for the limited resource of liquid helium, Sealed Technology not only decreases overall costs for users but also demonstrates a dedication to environmental sustainability within the realm of medical imaging. AI is already making waves in the MRI world, assisting vendors in enhancing patient comfort and enabling better diagnosis. In the realm of MRI technology, the integration of artificial intelligence (AI) is poised to usher in a transformative era. AI's expanding role encompasses three key areas within MR imaging: AI for improving Patient Comfort and Workflow AI for improving Diagnostic Image Quality and Speed of Image Acquisition, and AI for reducing system downtime by predicting failures of components much earlier Going beyond just enhancing images, AI brings the potential for automated reporting and predictive maintenance, which can streamline diagnostics and minimize system downtime. Through the utilization of AI algorithms, radiologists are empowered to not only analyze images more confidently but also enjoy the perks of automated report creation, ultimately optimizing operational efficiency. Moreover, AI's predictive capabilities hold the promise of anticipating system malfunctions, facilitating proactive maintenance, and reducing interruptions to patient care. This multifaceted impact highlights AI's pivotal role in elevating patient outcomes, diagnostic accuracy, and operational effectiveness in the field of MRI technology, representing a significant leap forward in medical imaging advancements.   Emerging Trends: What Does the Future Hold for MRI? MR entering screening space: The field of MRI technology is experiencing a major transition, expanding its traditional roles in diagnosis and treatment to encompass screening and other areas. This evolution positions MRI to play an even more significant role in the future. By utilizing MRI technology for preventive screenings, healthcare providers can identify issues at an earlier stage and provide more effective treatment options. This shift towards proactive screening with MRI may ultimately lead to improved health outcomes and reduced healthcare costs in the long run. For example, researchers have used MRI technology to identify changes in brain activity that may indicate the development of certain health disorders. Additionally, MRI scans can help monitor the progression of chronic conditions and guide treatment plans for better patient outcomes. As MRI technology continues to advance, its integration into screening programs holds the potential to revolutionize healthcare delivery, enabling proactive interventions and fostering a culture of preventive health management. MR in treatment space: The integration of MRI technology into the treatment space highlights MRI's emerging role in not only identifying anomalies but also actively participating in their treatment. The integration of MRI with  radiation therapy devices, as well as focused ultrasound devices, cryoablation devices, etc., are also emerging trends for faster and easier treatment of cancer that enables precise targeting and treatment. By leveraging the MRI's imaging capabilities, clinicians can deliver radiation therapy with unparalleled accuracy, minimizing damage and enhancing treatment efficacy while reducing the risk of adverse side effects for patients. This integration of MRI technology into treatment protocols represents a significant leap forward in healthcare, promising improved patient outcomes and advancing the possibilities for personalized, targeted therapies in the fight against disease. Enhancing Patient Experience In the realm of medical imaging, the role of AI in reshaping the patient journey during MRI examinations is gaining attention. Specifically, in situations like cardiac imaging, where patients might face challenges with certain diagnostic procedures, AI stands out as a hopeful remedy. By utilizing AI algorithms to track heart and breathing patterns minus the requirement for additional gear such as ECG leads, patients can experience MRI scans with enhanced ease. This advancement not only tackles patient unease but also supports the broader aim of elevating the overall MRI exam  By seamlessly incorporating AI technology, MRI practices can evolve to prioritize patient needs, nurturing a positive atmosphere for healthcare provision. This progress highlights the significant influence of AI in healthcare, where ensuring patient comfort and contentment plays a pivotal role in striving for better medical results. The field of medical imaging is undergoing a revolution due to the advancements in MRI technology and the incorporation of AI-driven solutions. These breakthroughs not only improve diagnostic precision and operational efficiency but also emphasize patient well-being and satisfaction. As AI continues to play a growing role and with ongoing technological progress such as helium-free procedures, the future of MRI holds the potential for increased effectiveness, precision, and availability. This translates to enhanced patient care and better healthcare results overall.   Sathish Kumar Balakrishnan, Vice President, Global MR R&D Leader, Philips Innovation Campus, Bengaluru ]]> https://biospectrumindia.com/news/93/24965/stryker-unveils-multigen-2-radiofrequency-generator-in-india-for-chronic-joint-pain-management.html https://biospectrumindia.com/news/93/24965/stryker-unveils-multigen-2-radiofrequency-generator-in-india-for-chronic-joint-pain-management.html Tue, 30 Jul 2024 00:00:00 +0530 Stryker, one of the world’s leading medical technologies companies, has announced the launch of MultiGen 2 Radiofrequency (RF) Generator at the Interventional Radiofrequency Pain Conference in Delhi. This technology provides physicians with the efficiency, control and reliability they need when performing RF ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain. With a prevalence rate of 19.3%, over 180 million Indians suffer from chronic pain. Facet joint pain is a well-recognized source of pain in patients with persistent back pain. Multiple clinical studies show that for majority of patients, RF ablation significantly reduces pain severity and frequency for one year. “MultiGen 2 is the next generation of radiofrequency ablation that provides physicians with control and customisation to perform chronic pain management procedures with confidence”, said Aman Rishi, VP and GM – India for Stryker. “With MultiGen 2, radiofrequency ablation becomes more efficient and reliable than ever before, providing lasting relief to millions of people living with facet joint pain.” Engineered with double the industry standard for power, the MultiGen 2 Generator achieves target temperature faster, with fewer errors, for increased reliability and efficiency. Physicians can start a procedure with the push of a single button, create strip lesions without removing electrodes and resolve errors without stopping the procedure, maximising time and schedules. ]]> https://biospectrumindia.com/news/93/24959/medtronic-and-swizton-medcare-collaborate-to-establish-first-vein-clinic.html https://biospectrumindia.com/news/93/24959/medtronic-and-swizton-medcare-collaborate-to-establish-first-vein-clinic.html Mon, 29 Jul 2024 00:00:00 +0530 India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc, and Swizton Medcare (an initiative of 98 Farenheit Pvt. Ltd. subsidiaries), have joined hands to inaugurate vein clinics, aiming to offer advanced varicose vein treatments in partnership with leading hospitals. The signing ceremony for this milestone collaboration took place at Aveksha Hospital in Singapura, Bengaluru. It also happens to be this partnership's first vein clinic.  It is estimated that about 20% of all adults will get varicose veins at some point in their lives. Recognising the pressing need for accessible and effective treatments, Medtronic and Swizton Medcare are committed to democratising healthcare by making specialised vein treatments available to a wider population. Under this partnership, Medtronic will provide innovative varicose vein treatment solutions, along with training and education for healthcare professionals and patient education and awareness initiatives, to enhance patient outcomes. Swizton Medcare will leverage its expertise in healthcare services to deliver varicose vein-related therapies, ensuring holistic patient care and promoting awareness among the public about treatment modalities. This partnership will empower individuals seeking relief from varicose veins. Equipped with advanced treatments such as adhesive treatment and radiofrequency ablation (RFA) from Medtronic, as well as sclerotherapy, the clinic is poised to deliver comprehensive care at an affordable cost. Present at the inauguration were Mandeep Singh, Managing Director and Vice President, Medtronic India, Dr Tahsin Neduvanchery and Dr Rahul Deep from Swizton Medcare.   Image caption- From L to R- Dr Tahsin Neduvanchery, a renowned expert from Swizton Medcare and Mandeep Singh, Managing Director and Vice President, Medtronic India ]]> https://biospectrumindia.com/news/93/24932/worlds-first-international-conference-on-paediatric-heart-valve-repairs.html https://biospectrumindia.com/news/93/24932/worlds-first-international-conference-on-paediatric-heart-valve-repairs.html Mon, 22 Jul 2024 00:00:00 +0530 Sri Madhusudan Sai Institute of Medical Sciences and Research (SMSIMSR), in collaboration with the Paediatric Cardiac Society of India (PCSI) and the Indian Association of Cardiovascular and Thoracic Surgeons (IACTS), successfully hosted the World’s 1st International Conference on Paediatric Heart Valve Repairs on 19 and 20 July 2024. This one-of-its-kind two-day hybrid event brought together 100+ doctors from across the world to Ataee Shaw Lecture Hall, Sathya Sai Grama, Muddenahalli, Karnataka, to address the congenital defects in cardiac valves and setting a new standard in paediatric cardiac care. Under the visionary leadership of Professor Dr A Kalangos as the Organising Chairman and Dr C S Hiremath as the Organising Secretary, the event provided a valuable platform for cardiothoracic surgeons, cardiologists, imaging specialists, and healthcare professionals to share knowledge, facilitate hands-on training through wet lab sessions and collaborate on reducing the global burden of paediatric heart valve diseases. The conference focussed on the anatomical understanding, diagnosis, and imaging of both surgical and non-surgical management techniques for paediatric heart valves. It emphasised detailed discussions on mitral, aortic, tricuspid, pulmonary, and common AV valve repairs in children. Additionally, the event included a hands-on wet lab workshop showcasing advanced valve repair techniques, extending to discussing innovative solutions to solve challenging cases, emerging technologies, and long-term outcomes in paediatric valve surgery. This Conference represented a significant step in advancing medical education and research in the field of paediatric cardiac care bringing together the best doctors in the field, globally. ]]> https://biospectrumindia.com/news/93/24929/deep-tech-vc-unicorn-india-ventures-announces-partial-exit-from-medtech-startup-sascan-with-6x-returns.html https://biospectrumindia.com/news/93/24929/deep-tech-vc-unicorn-india-ventures-announces-partial-exit-from-medtech-startup-sascan-with-6x-returns.html Sun, 21 Jul 2024 00:00:00 +0530 Unicorn India Ventures (UIV), a deep tech focused fund house, which is currently raising its third fund of Rs 1,000 crore, has announced a partial exit from neo diagnostics startup Sascan Meditech. UIV had invested Rs 2 crore spread across 2 rounds. The first investment was made in 2020.  The partial exit from Sascan has generated 6X returns for the Fund as UIV continues to hold a substantial stake in the company. Thiruvananthapuram-based Sascan Meditech is an emerging healthcare innovation company founded in 2015 by Dr Subhash Narayanan, a laser scientist with interest in the development of Biophotonics products. The primary objective of the company is to develop affordable healthcare products and solutions for cancer care based on Biophotonics and allied technologies. The focus is to make these products available through sustainable business models and create impact among the population at the base of the pyramid. Sascan has two distinct products: OralScan (the first multimodal image capturing device that uses multi-spectral imaging technology at its core for non-invasive and real-time screening of oral cancer and biopsy guidance) and  CerviScan (a  product developed to replace the conventional digital colposcopy). Unicorn India Ventures has invested in the company in 2020 and was the first only institutional investor. The Fund invested in Sascan again in 2021.    ]]> https://biospectrumindia.com/news/93/24903/noccarc-v730i-icu-ventilator-receives-bis-certification.html https://biospectrumindia.com/news/93/24903/noccarc-v730i-icu-ventilator-receives-bis-certification.html Mon, 15 Jul 2024 00:00:00 +0530 Noccarc, a Pune-based medical technology company, has recently received the prestigious Bureau of Indian Standards (BIS) Certification IS 13450: Part 2: SEC 12:2023 for its Made-in-India ICU Ventilator Noccarc V730i. This All India First License is a monumental achievement for Noccarc and marks a significant advancement for the critical medical devices industry in India. The BIS certification is a mark of excellence, highlighting the Noccarc V730i’s superior quality and performance. It demonstrates the company’s dedication to meeting the highest standards in medical technology and delivering world-class medical devices developed and manufactured in India. This accomplishment positions Noccarc at par with imported products conforming to US FDA and CE certifications. This is especially significant given that over 80% of medical devices in India are typically imported. The V730i has garnered endorsements from prominent medical institutions such as Apollo Hyderabad, Royal Care Coimbatore, AIIMS Bhopal, Ruby Hall Clinic, Pune, etc. These endorsements further validate the V730i’s reliability and effectiveness in critical care settings. Earlier this year, Noccarc also obtained the CDSCO Manufacturing License, which is now mandatory to manufacture ventilators in India. The Noccarc V730i features both invasive and non-invasive ventilation modes, expansion modules such as EtCO2, Mesh nebulizer with inspiratory sync, and revolutionary remote monitoring capabilities via mobile phones, making critical care seamless and efficient. ]]> https://biospectrumindia.com/news/93/24899/medisim-vr-launches-chennais-first-virtual-reality-based-coe-for-medical-training.html https://biospectrumindia.com/news/93/24899/medisim-vr-launches-chennais-first-virtual-reality-based-coe-for-medical-training.html Sun, 14 Jul 2024 00:00:00 +0530 MediSim VR has announced the establishment of Chennai's first Center of Excellence (CoE) virtual reality (VR) lab at Sri Ramachandra Institute of Higher Education and Research (SRIHER). This state-of-the-art facility offers access to immersive and interactive VR- training for medical students across the nation. Since its inception, MediSim VR has benefited over 4,000 students, providing unparalleled access to immersive, hands-on medical training. The innovative VR technology employed in the lab offers realistic medical scenario simulations in a safe and controlled environment to prepare upcoming medical professionals with procedural competency, skills, and the confidence needed to care for their patients. MediSim VR uses Virtual Reality to bridge the gap between theoretical understanding and practical application to ensure that students are well-prepared for real-world medical situations. This Center of Excellence at SRIHER redefines medical education by incorporating VR-based learning, empowering students from across the state and all over the country to perfect their skills and improve patient outcomes. ]]> https://biospectrumindia.com/news/93/24889/medtronic-inaugurates-global-it-centre-in-hyderabad-with-60-m-investment.html https://biospectrumindia.com/news/93/24889/medtronic-inaugurates-global-it-centre-in-hyderabad-with-60-m-investment.html Thu, 11 Jul 2024 00:00:00 +0530 Medtronic, the global leader in medical technology, has inaugurated its new Global IT (GIT) Centre at Medtronic Engineering & Innovation Centre (MEIC), Hyderabad in the presence of Minister for IT, Industries and Commerce, Government of Telangana, D Sridhar Babu and US Consul General, Jennifer Larson, along with senior leaders from Medtronic including Rashmi Kumar, SVP and CIO Global, Medtronic, and Divya Prakash Joshi, Vice President & Site Leader of MEIC. Global IT Centre is Medtronic’s first large-scale IT centre outside of US. The company will be investing $60 million which will support in creating 300 new job opportunities over the next 3-5 years. GIT will focus on cutting-edge technologies such as Cloud Engineering, Data Platforms, Digital Health applications, Hyper automation, and AI/ML. The talent competencies include Cloud & DevOps, Advanced Analytics & Visualization, Integration & Middleware, Full Stack Engineering, Robotic Process Automation, Process & Data Mining, Agile Program Management, Process Excellence & Business Analysis, along with IT Security & Compliance. Through these competencies, the new GIT centre will boost productivity, manage risks, and drive growth in healthcare technology.  Speaking at the inauguration event, Minister for IT, Industries and Commerce, Government of Telangana, D Sridhar Babu said, “I had the pleasure of inaugurating MEIC’s expanded R&D facility in February this year and during this time, I discussed about various other opportunities. In about 5 months, we are here to launch Medtronic’s new global IT Center. Reputed firms like Medtronic choosing to double down on their existing investments in Telangana underscores the vibrant innovation ecosystem that is being nurtured here."   ]]> https://biospectrumindia.com/news/93/24881/horiba-invests-rs-200-cr-to-open-medical-equipment-and-consumables-manufacturing-facility-in-nagpur.html https://biospectrumindia.com/news/93/24881/horiba-invests-rs-200-cr-to-open-medical-equipment-and-consumables-manufacturing-facility-in-nagpur.html Mon, 08 Jul 2024 00:00:00 +0530 Horiba India, a group company of Kyoto based Japanese leader in analytical equipment and measurement solutions for the three megatrend fields of Energy & Environment, Bio & Healthcare, and Materials & Semiconductor, which are essential to our lives, has inaugurated its state-of-the-art medical equipment and consumables manufacturing facility in Butibori, Nagpur. The facility is in line with the vision of Atmanirbhar Bharat and Make in India for the World and will be one of India's largest medical equipment and consumables (reagents) manufacturing unit. With an investment of approximately Rs 200 crore, in a phased manner, the Nagpur facility is poised to serve over 30,000 diagnostic labs and hospitals across India and represents Horiba's third significant investment in India, reinforcing its commitment to generating employment opportunities in tier-2 cities. Global business revenue of Horiba Ltd is $2.3 billion. The inaugural event, themed "Celebrating HONMAMON," was graced by Union Minister Nitin Gadkari; Deputy Chief Minister of Maharashtra Devendra Fadnavis; Atsushi Horiba, Chairman and Group CEO, Horiba Ltd.; Dr Jai Hakhu, Board of Director, Horiba, Ltd., Japan and Chairman, Horiba India and Dr Rajeev Gautam, Corporate Officer, Horiba, Ltd., Japan and President, Horiba India.  This state-of-the-art manufacturing facility, covering 50,000 square meters, includes a medical equipment production unit for blood diagnostics, clinical chemistry equipment, and medical consumables (reagents). The Nagpur facility also houses the Horiba India Technical Institute, offering biomedical learning programmes through a partnership with Nagpur University, and the Horiba Experience Zone, which showcases the full range of Horiba healthcare equipment. Additionally, the facility features an international training centre and a central warehouse. The facility currently has 100 employees and is expected to increase to almost double in the next 5 years. ]]> https://biospectrumindia.com/news/93/24857/camouflaging-as-a-dead-enzyme-vegfr1-holds-key-to-medical-solutions-for-colon-and-renal-cancers.html https://biospectrumindia.com/news/93/24857/camouflaging-as-a-dead-enzyme-vegfr1-holds-key-to-medical-solutions-for-colon-and-renal-cancers.html Wed, 03 Jul 2024 00:00:00 +0530 Researchers have decoded the molecular mechanism in which a cell surface receptor belonging to the family of enzymes that bind growth factors, regulate cell differentiation, proliferation, survival, metabolism, and migration, prevents cancers. This enzyme called VEGFR1 withholds self-expression (autoinhibited) in the absence of a ligand—for example hormones. The research can show the way for developing medical solutions for colon and renal cancers by using molecules that preferentially stabilises the inactive state of VEGFR1. Cell surface receptors like Receptor Tyrosine Kinases (RTK) are crucial for converting extracellular signals (from chemical cues like growth factors, generally referred to as ligands) to tightly regulated cellular response. Ligand binding to extracellular receptors activates intracellular coupled enzymes (tyrosine kinases). The activated enzyme, in turn, adds phosphate group to several tyrosine molecules that function as an adaptor for assembling a signalling complex. The formation of the signalling complex regulates diverse cellular functions like cell growth, development, and host immune response. Spontaneous activation of RTKs, in the absence of ligands, is often linked to multiple human pathologies like cancers, diabetes, and autoimmune disorders. Researchers are exploring how a cell maintains an autoinhibited state of the enzyme and why such autoinhibition is breached during the progression of human pathology. Researchers at the Indian Institute of Science Education and Research (IISER), Kolkata, investigated one such RTK called Vascular Endothelial Growth Factor Receptor (VEGFR). The VEGFR family of receptors is the key regulator of the process of generating new blood vessels.  This process is essential for functions like embryonic development, wound healing, tissue regeneration, and tumor formation. Various malignant and non-malignant diseases can be treated by targeting VEGFRs. The researchers were intrigued by the fact that two members of family VEGFR 1 and VEGFR 2 behaved quite differently. While VEGFR 2, the primary receptor regulating process of formation of new blood vessels, could be spontaneously activated, without its ligand, the other member of the family VEGFR 1 cannot be spontaneously activated even when overexpressed in cells. It camouflages as a dead enzyme VEGFR1 and binds with ten-fold higher affinity to its ligand VEGF-A than VEGFR2. This ligand binding induces a transient kinase (speeding up chemical reactions in the body by an enzyme) activation. Probing into why one member of the family is so spontaneously activated and the other autoinhibited, Dr Rahul Das and his team from IISER Kolkata found that a unique ionic latch, present only in VEGFR1, keeps kinase autoinhibited in the basal state. The ionic latch hooks the juxtamembrane segment onto the kinase domain and stabilizes the autoinhibited conformation of VEGFR1. Exploring the mechanism of the autoinhibited state of VEGFR 1 the researchers proposed a crucial role for cellular tyrosine phosphatase in modulating VEGFR1 activity. The research carried out at the Analytical Biology Facility at IISER Kolkata with its DST-FIST supported ITC and stopped-flow fluorimeter, highlighted the therapeutic potential of phosphatase modulators in regulating VEGFR1-mediated pathological formation of new blood vessels (angiogenesis) which takes place in cancer. This discovery published in the journal Nature Communication may open new avenues for developing therapeutic interventions against pathological conditions due to the spontaneous activation of VEGFR signalling. The small molecules targeting the autoinhibited state will have a higher potential for treating cancers like human colorectal carcinoma and renal cancer, where VEGFR1 is overexpressed. ]]> https://biospectrumindia.com/news/93/24843/medisim-vr-unveils-indias-first-vr-skill-training-lab-for-nursing-at-kd-hospital-ahmedabad.html https://biospectrumindia.com/news/93/24843/medisim-vr-unveils-indias-first-vr-skill-training-lab-for-nursing-at-kd-hospital-ahmedabad.html Tue, 02 Jul 2024 00:00:00 +0530 MediSim VR has announced the establishment of Gujarat's first VR (virtual reality) Skill Training Lab at KD Hospital, inaugurated by the Rushikesh Patel, Health & Family Welfare Minister, Gujarat. This state-of-the-art VR skill training lab at KD Hospital is designed to provide immersive and highly realistic medical scenario simulations, enabling nursing students and healthcare professionals to practice essential medical procedures and develop critical clinical skills in a safe, controlled environment. Additionally, the lab is equipped with MediSim VR’s ergonomically designed and patented automated VR stations. This innovative technology ensures a high standard of training and helps bridge the gap between theoretical knowledge and practical application. As a Center of Excellence (CoE), the lab will not only benefit students and healthcare professionals from KD Hospital, but will also extend its advanced training facilities to other nursing colleges across Gujarat, fostering a comprehensive improvement in healthcare education throughout the state.   ]]> https://biospectrumindia.com/features/93/24823/meditech-stackathon-2024-to-drive-explosive-growth.html https://biospectrumindia.com/features/93/24823/meditech-stackathon-2024-to-drive-explosive-growth.html Sun, 30 Jun 2024 00:00:00 +0530 India’s medtech sector has shown a promising growth trajectory over the past decade. It is a fast-growing industry today, holding strong potential for technological innovations and making unique industrial transformative strides. Being the world’s second most populous country with a rising number of diseases, effective healthcare delivery to improve health outcomes is important. While India hosts an impactful healthcare professionals’ ecosystem and is home to an excellent pharmaceutical domain, there is a wide gap in healthcare delivery to patients. The development and incorporation of medical devices and technology in healthcare can be a key factor in bridging this gap. In the past few years, new dedicated policies and initiatives have been introduced to boost the growth and development of India’s medtech sector. Some of the significant ones from the recent past include the National Medical Devices Policy from April 2023, the Production Linked Incentive (PLI) Scheme for medical devices, under which new medical device manufacturing parks will be developed to foster indigenous manufacturing of medical devices; and, in August 2022, the Department of Pharmaceuticals reconstituted the National Medical Devices Promotion Council (NMDPC) under the Chairmanship of the Secretary of the Department of Pharmaceuticals. Continuing the momentum and supporting this niche space, the Meditech Stackathon initiative launched on May 7, 2024 by the Department of Pharmaceuticals (DoP) in collaboration with the Confederation of Indian Industry (CII) is an important one. During the launch of the Meditech Stackathon, Dr Arunish Chawla, Secretary of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers emphasised the importance of policymakers and industry coming together to draw up a sturdy policy stack for the growth of the medical devices industry in the country. The Meditech Stackathon is ‘designed to catalyse transformative change within India's burgeoning medtech sector by undertaking a comprehensive value chain analysis of select medical devices’. It will serve as a platform to bring together policymakers, industry players, healthcare professionals, and experts to strategise the growth of India’s medical devices sector.   Prospects and obstacles The World Health Organisation (WHO) defines a medical device as ‘any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article, intended by the manufacturer to be used, alone or in combination for a medical purpose.’ Such a multi-faceted industry spanning several segments, the medtech sector can present its fair share of challenges and opportunities. Streamlining industry operations and establishing strong market growth could enable better accessibility of quality healthcare and affordability to a larger proportion of India’s population. Medical technology innovation can be a significant tool to make this possible by lowering the cost of the product or delivery. The key focus of the Stackathon will be to identify critical challenges and opportunities and carry out a comprehensive value chain analysis of the various segments of the MedTech industry. In addition, the Stackathon initiative will also focus on targets of reducing import dependence and building a strong and self-sufficient domestic manufacturing of medical devices. Dr Arunish Chawla, during the launch of Meditech Stackathon, highlighted the critical need to focus on quality to ensure that India becomes globally competitive. Through the Stackathon, Dr Chawla said, the participants will delve into the complexities of different product segments within the medical devices industry to gain insights into their unique challenges and opportunities, analyse and map value chains across various segments of the medical devices industry to identify key stakeholders, processes, and dependencies, identify critical issues hindering the development of the medical devices industry, such as import dependence, regulatory hurdles, and technological gaps. Regulatory landscape Focusing on the quality of medical devices and related regulatory frameworks will be instrumental in increasing the market penetration and trust factor at the consumer end for indigenously manufactured medical devices and equipment. Gauging the ground reality through primary and secondary healthcare providers, and driving effective and continuous dialogue between the key stakeholders – from doctors to industry leaders and policymakers – would be crucial in ensuring the highest quality and safety standards are met in the medical devices sector. Initiatives like Meditech Stackathon could help streamline regulatory policies and quality standards and provide a simultaneous boost to domestic production of innovative medical devices; a factor that can prove crucial for the holistic growth of India’s medtech sector. This is especially important in view of reports around India being at the receiving end of refurbished medical devices and equipment. According to recent reports, the Patient Safety and Access Initiative of India Foundation (PSAIIF) has filed a writ petition, in the nature of a Public Interest Litigation (PIL). The PIL arises from concerns regarding the laxity in the regulatory framework concerning the quality, safety and efficacy assessment of second-hand or used medical devices, which are compromising the standard of health services in the country. The cause of action also arises in view of refurbished medical devices posing an inherent safety risk to the life of the general public at large. Some of the overseas multinational companies are importing refurbished/ reconditioned medical devices, such as robotic surgical systems. The cause of action in the nature of a PIL inter alia also arises from the risks associated with India being made a dumping ground for such pre-used/refurbished/reconditioned medical devices. A wholly indigenously operating medtech company, Gurgram-based SS Innovations has been developing cutting-edge, first-in-India robotic surgical systems, with a dedicated goal of making advanced robotic surgeries cost-effective and accessible to a global population. SS Innovations is also driving innovations in Telesurgery. Dr Sudhri Srivastava, Founder and CEO of SS Innovations shared his views on how the Meditech Stackathon can address issues of domestic manufacturers and increase the overall trust in Indian brands in the medtech sector. “The whole initiative of ‘Make in India’ must become a reality. We continue to import a majority of devices, nearly 80 per cent. Refurbished devices and equipment are imported. Government should take actions in the direction of discouraging imports in general, especially in reducing imports of refurbished equipment.” Stressing the fact that India not having the kind of technology yet increases dependence on this kind of import, Dr Srivastava added, “The only way to address these issues is to build the technologies in India by fostering innovations. Innovations take time and money and boosting investments in the sector will be the key to encouraging advanced medical technologies in India. He added that the government’s help to the medtech sector in this regard would also be needed to reduce the duty on some imported devices to make affordable healthcare delivery accessible to a larger percentage of our population. He also emphasised that there is a huge need for the right kind of governmental support to build an enabling and holistic infrastructure in the medtech sector to achieve a collective goal of equitable healthcare, especially in rural areas. Speaking about how initiatives like Meditech Stackathon can help address such issues, Prof Dr Somashekhar SP, Chairman – Medical Advisory Board, Aster DM Healthcare (GCC & India) and Board of Director, SS Innovations International shared that the right laws are in place to prevent import of refurbished and outdated devices, but their implementation is the main problem. He also added that there is a bias among healthcare professionals in using indigenous medical devices even now. Further elaborating on the ‘Make in India’ initiative, he opined that India is a leader in technological advancements, and domestic manufacturing of advanced, technology-heavy medical devices needs to be boosted. Sharing his views Pavan Choudary, Chairman, Medical Technology Association of India (MTaI) said, “As we navigate the evolving landscape of medtech in India, harmonising Indian regulations and standards with global best practices will be the keystone which will not only attract international investment in the sector but will also enable Indian manufacturers to get greater acceptability of their products in global markets, furthering the ‘Make in India’ objective of the government and keeping India aligned to global supply chains. We feel that domestic and international trends will together help carve out key policy recommendations that will be instrumental in furthering the medtech industry in India.” ‘Make in India’ ventures Aligning to initiatives such as ‘Atmanirbhar Bharat’ and ‘Make in India’, supported by the government’s schemes such as the Production Linked Incentive (PLI), global medtech leading companies have taken strides in advancing their footprints in India aligning with the direction of domestic manufacturing and overall indigenous advancements in medical technology in India. Dublin headquartered medtech leader, Medtronic, has significant operations in India, including manufacturing facilities. Over the past few years, Medtronic has introduced plans for advancing medical technology in the Indian market. In 2020, the company opened a Medtronic Engineering & Innovation Center (MEIC) in Hyderabad to support their global operations; and in May 2023, Medtronic announced an investment of approximately Rs 3,000 crore ($362.8 million) to expand the MEIC centre in India. The MEIC is Medtronic’s largest R&D centre outside the USA. Additionally, in 2023, Medtronic announced a partnership with Qure.ai to integrate artificial intelligence (AI) for advanced stroke management in India. In 2021, Medtronic India introduced a surgical robotics experience centre in Gurugram to help clinicians with robotic-assisted surgery technology In 2022, Wipro GE Healthcare, announced the launch of its new manufacturing facility in Bengaluru, under the Indian government’s PLI Scheme. The new facility was launched to further boost local manufacturing of medical devices in India. The company has invested around Rs 100 crore in this facility. Wipro GE Healthcare has also launched its next-generation Revolution Aspire CT (Computed Tomography) scanner in 2022, an advanced imaging solution designed and manufactured end-to-end in India. With the government emphasising early diagnosis of Non-Communicable Diseases (NCDs) and self-reliance, through ‘Ayushman Bharat’, there is an increased demand for advanced medical devices. The Revolution Aspire CT aims to address this need and enable access to quality medical equipment across India, including tier 2 and tier 3 cities. Commenting on this development of end-to-end manufacturing in India, Dr Devi Shetty, Founder and Chairman of Narayana Health said, “Access to healthcare has been deeply asymmetric in India and innovative medical technology products will help bridge this gap. We are witnessing this change with cutting-edge, locally manufactured, and affordable products such as the Revolution Aspire CT scanner helping democratise the market, taking quality healthcare to tier 2 cities and beyond. It is critical for all health centres, big and small, to have access to quality diagnosis.” Additionally, earlier this year Wipro GE Healthcare strides towards further strengthening a ‘Make in India’ initiative. The company signed an MoU with IISc, Bengaluru to advance medtech innovation from India – ‘for India and the world’. The company also announced an investment of over Rs 8000 crore in manufacturing output and local R&D over the next five years. In 2020, Siemens Healthineers announced an investment of $179.7 million for five years till 2025 to establish an innovation hub in Bengaluru. The innovation hub will focus on the design and development of entry-level products. Expanding its manufacturing footprint in India, it has launched a new production line of Computed Tomography scanners approved under the Government of India’s PLI scheme. Additionally, the company also inaugurated an MRI facility at Bengaluru, under the Government of India’s PLI scheme. In 2022, Stryker inaugurated a neurovascular research lab at Stryker’s Global Technology Centre (SGTC) in Gurugram to develop innovative solutions for brain stroke. Expressing his views on how the Meditech Stackathon initiative is poised to boost the medtech industry, Falgun Jani, Business Head – India, Freudenberg Medical said, “Meditech Stackathon is a much needed and timely initiative that will definitely help to propel the growth of India’s medtech industry. Thoughtful selection of 8 chosen medical device segments will encourage more collaborative activities amongst various stakeholders that are involved either directly or indirectly with these segments. Such initiatives will help foster domestic manufacturing, reducing import dependence, and positioning India as a frontrunner in the global medtech arena. Some of the important aspects are the analysis of import-export dynamics & supply chain of these devices, the formation and implementation of industry-friendly policies, and streamlining of the regulatory framework. Through close collaboration and concerted efforts, the initiative aims to address critical challenges, stimulate innovation, and unlock the full potential of India’s medtech industry.”   A robust domestic market Increasing penetration of medical technology into the Indian healthcare ecosystem to grow the medtech market can be a key factor in the overall development of this fast-growing sector. Frugal innovations across the value chain in areas of product development, technology, marketing, business modelling, service delivery, etc. to increase market penetration and drive the growth of the indigenous market. Given that the Stackathon initiative is designed to drive transformative change in India’s growing medtech sector, catering to the needs of domestic businesses to boost market growth will be a crucial factor. Speaking about factors that can help to create and drive strong market demand for innovative medical devices within India, Amit Gandhi, Founder & CEO of Insight Tribe, said that government initiatives like incentivising domestic manufacturing can help in creating a more robust ecosystem for innovative devices and potentially lower costs for consumers. In line with this crucial factor, he added, “Innovation tailored to Indian needs by developing cost-effective, yet high-quality, medical devices suitable for the Indian market will be crucial for wider adoption. A focus on innovation in devices for the prevention, diagnosis, and management of India’s specific disease burdens/health conditions, will be a particularly attractive factor. Also, encouraging the use of locally sourced materials and components can further reduce manufacturing costs and create a more sustainable supply chain.” “Growing public awareness about health issues and preventive care will create a market for innovative devices for early detection and treatment. An untapped rural market, where expanding healthcare access to rural areas, presents a significant opportunity for affordable and portable medical devices”, said Amit Gandhi. He further added that a rising disposable income, increased insurance penetration, and increased health awareness; in addition to important government initiatives are some factors that can accelerate a strong market demand for innovative medical devices within India. He said, “As insurance coverage expands, patients become more open to considering advanced medical procedures that were previously cost-prohibitive. Some insurance plans cover the cost of certain medical devices, such as pacemakers or insulin pumps. This makes these devices more accessible to patients, further stimulating the medtech market.” Harmonious to this, leveraging on the opportunities presented by the development and streamlining of a holistic infrastructure needed for boosting India’s medtech sector growth can also aid in driving the sector’s growth and expansion. Sharing his views on how the Meditech Stackathon initiative is poised to boost the medtech industry, Dr Rajiv Chhibber, Vice President External Affairs, Sahajanand Medical Technologies said, “The Meditech Stackathon is a much-needed step as India becomes a net exporter in the long run, and also significantly reduces import dependency on high-end medical devices. The fact that Dr Arusnish Chawla emphasised the necessity of anchoring the policy stack on a solid foundation, encompassing precise economic classifications such as HSN and NIC Codes, meticulous assessment of tariffs and taxes at each stage of the value chain gives an impetus to manufacturers and helps them to overcome obstacles within the medtech domain including the need for standard harmonisation, supply chain, raw material and even post-market surveillance and streamlining the regulatory landscape so that better and ease of doing business can be enhanced, side by side, making India a net exporter in earmarked devices.” Further adding on what needs to be priority areas of focus for the With optimal support and participation from all stakeholders, initiatives like Meditech Stackathon are set to make this a reality in the coming years, as India continues to grow its global standing as a leading country in Science and Healthcare innovations and technology. Meditech Stackathon, Dr Chhibber said that the industry had highlighted the imperative of identifying and mitigating policy arbitrage, spanning price, quality, taxation, incentive structures, and regulatory frameworks that need to be relooked at when discussing Ease of Doing Business. “From the industry we requested the DoP to organise segment-wise workshops to build on the Stackathon findings, bridge the gaps and strengthen the value chain analysis to decide on the production-linked and research-linked incentive schemes, which will give a major boost to domestic manufacturing in India, making us more Atmanirbhar, and joining forces with the Government of India towards a Viksit Bharat”, added Dr Chhibber. All in all, India’s medtech sector is a fast-growing industry poised to achieve exponential progress. Several policies and initiatives are in place or expected to be introduced, and key stakeholders at all levels of the medtech sector seem to be carrying the torch forward to see India through to the pinnacle of a global medtech hub. The government’s help through initiatives like the Meditech Stackathon and a robust policy and regulatory framework will be instrumental in orchestrating this progress. A growing medtech sector fuelled by innovations and collaborations could bridge the gaps between critical healthcare delivery, including accessibility and affordability, in India. It remains to be seen how this eventuates.   Shivani Thakar shivani.thakar@biospectrumindia.com ]]> https://biospectrumindia.com/news/93/24787/hrs-navigation-announces-aggressive-hiring-plans-for-rd-and-clinical-support-teams.html https://biospectrumindia.com/news/93/24787/hrs-navigation-announces-aggressive-hiring-plans-for-rd-and-clinical-support-teams.html Tue, 18 Jun 2024 00:00:00 +0530 HRS Navigation, a series A-funded, Bengaluru-based health tech startup pioneering 'Made in India' medical navigation systems, has announced plans to expand its workforce to 30% - 40% this year from its current 90-member-strong team, focusing on its R&D (Research and Development) and Clinical Support teams. The startup plans on underscoring its strategic growth and long-term success. This expansion will help bolster the company's capabilities and ensure it meets market demands.Tailored strategically, HRS Navigation’s hiring initiatives will involve recruiting college graduates and training them extensively, bringing fresh perspectives and cultivating future leaders familiar with the company culture. Additionally, experienced professionals in R&D and Clinical Support are being sought to bring established knowledge and proven expertise. This blend of new talent and seasoned professionals will create well-rounded teams ready to propel the company forward.The expansion of its R&D and Clinical Support teams is expected to enhance HRS Navigation's products and services significantly. By leveraging top-tier talent and cutting-edge technology, the company aims to make precision technology accessible and affordable worldwide, ultimately improving patient outcomes and transforming lives.The company is currently seeking individuals skilled in C++ programming and emerging technologies like AI, ML, and computer vision to drive innovation. To facilitate a smooth transition for new team members, a comprehensive induction programme and ongoing support from department heads will also be provided. ]]> https://biospectrumindia.com/news/93/24748/bcs-to-expand-manufacturing-of-cyclotrons-for-research-radioisotope-production-theranostics-in-india-europe-usa.html https://biospectrumindia.com/news/93/24748/bcs-to-expand-manufacturing-of-cyclotrons-for-research-radioisotope-production-theranostics-in-india-europe-usa.html Tue, 11 Jun 2024 00:00:00 +0530 Best Cyclotron Systems (BCS), a TeamBest Global Company (TBG) in the US, plans to expand its manufacturing operations in India, Europe, and the USA to produce hundreds of cyclotrons annually. Within two years, BCS and TBG will have access to high-energy/high-current 70 MeV and 30 MeV proton beams, as well as 35 MeV alpha, deuteron, and proton multi-particle cyclotrons, and several low-energy proton cyclotrons for research, radioisotope production, and theranostics. In 2024, BCS plans to ship between 10-15 cyclotrons for global customers. BCS is capable of and has demonstrated that it can manufacture low-energy cyclotrons with as high as 1000 micro amp current for proton beams. BCS and TBG companies plan to produce the following cyclotrons and ion rapid cycling medical synchrotrons (iRCMS) for research, radioisotope production, theranostics, and for radiation therapy using proton beams from 70 MeV to 250 MeV variable energy and heavy ion therapy up to 400 MeV for Carbon: (1) 7.5 MeV, proton beam, B100, self-shielded cyclotron, (2) 9.5 MeV cyclotron, BG-95 for proton beam, self-shielded, (3) 11 MeV, self-shielded, proton beam cyclotron, (4) 15 MeV, high current up to 1000 micro amp current proton beam cyclotron, and (5) 25 MeV proton beam 1000 plus micro amp current cyclotron, 35 MeV adp, and 70 MeV adp alpha deuteron and proton beam cyclotron with 1000 plus micro amp for proton beam and 500 plus micro amp current for deuteron beam and 100 plus micro amp for alpha beam. ]]> https://biospectrumindia.com/news/93/24737/canon-eyes-strengthening-industrial-and-medical-business-in-india.html https://biospectrumindia.com/news/93/24737/canon-eyes-strengthening-industrial-and-medical-business-in-india.html Fri, 07 Jun 2024 00:00:00 +0530 Highlighting India's crucial role in its global growth strategy, Japanese company Canon hasannounced its outlined plans for strengthening its core business segments of imaging, printing, and surveillance, along with growing presence in the Semiconductor, Flat Panel Display business and the medical industry. Reaffirming the brand's commitment to India, these announcements were made during Canon's strategy meet in Mumbai, attended by key global leadership. With respect to healthcare, Canon has a comprehensive portfolio of advanced medical products and solutions from diagnostic imaging systems and healthcare IT solutions. With India as a key market, Canon further focuses on bolstering the rapidly growing medical business. The brand has established a strong footprint in the digital imaging industry, as an end-to-end solutions provider, having diversified into new markets, broadening its product range and asserting its leadership across customer segments. Koh Yamada, President, Canon Medical Systems India said, "Canon Medical Systems India is a subsidiary of Canon Medical Systems Corporation in Japan. Canon Medical Systems has a comprehensive portfolio of advanced medical imaging from diagnostic and interventional imaging systems to healthcare IT solutions for the wider healthcare enterprise. Recognized as a world leader in innovation, Canon Medical Systems continues to develop breakthrough technology and applications including using AI, to support diagnostic imaging and therapeutic needs, all while optimising patient outcomes. We understand that more and more people are suffering from non-communicable, life-style diseases such as cardiovascular diseases, cancer, and diabetes, and hope that our unique technologies can contribute and help medical professionals better deal with them. In India, Canon Medical Systems aim to provide our customers with higher quality services as a priority."   ]]> https://biospectrumindia.com/news/93/24704/bsv-and-fogsi-partner-to-bring-indias-first-colposcopy-workshop-to-tier-2-cities.html https://biospectrumindia.com/news/93/24704/bsv-and-fogsi-partner-to-bring-indias-first-colposcopy-workshop-to-tier-2-cities.html Sat, 01 Jun 2024 00:00:00 +0530 Bharat Serums and Vaccines Limited (BSV), Mumbai-vased biopharmaceutical company, has partnered with the Public Awareness Committee, Federation of Obstetric and Gynaecological Societies of India (FOGSI) to increase awareness and access of colposcopy, a diagnostic method that allows for detailed examination of the cervix, vagina, and vulva, in the early detection of precancerous changes and cervical cancer.  The first colposcopy workshop was conducted by renowned and acclaimed faculty Dr Priya Ganeshkumar at the New Ramakrishna Sevasadan Hospital, Siliguri. The workshop, which is the first-ever attempt in a Tier 2 city aimed to enhance awareness among several gynaecologists and specialists on the importance of colposcopy in the early detection and accurate diagnosis of cervical cancer. Speaking on the initiative, Dr Priyankur Roy, Chairperson, Public Awareness Committee, FOGSI, said, “Ranked as the second most frequent cancer among women in India between15 and 44 years of age, cervical cancer remains a significant public health concern in India.  Current estimates indicate that every year 123907 women are diagnosed with cervical cancer and 77348 die from the disease. One of the most effective tools in the fight against cervical cancer is the colposcopy procedure."  Alok Khettry, COO, India Business, BSV, said, “India is taking bold steps towards eradicating cervical cancer with a range of preventive measures.  As a dedicated women’s health company, we are committed to spearheading initiatives that raise awareness and widen access to preventive care, promoting the health and well-being of women.  Our role as a leading biopharma company driven by research, goes beyond treatment. We aim to educate our stakeholders through continued scientific knowledge-sharing, even while we are not present in the management or treatment of such diseases." Colposcopy enables healthcare providers to identify abnormal cervical cells early, often before they develop into cancer. When a Pap smear test indicates abnormal results, colposcopy provides a more accurate follow-up examination. It allows for biopsies of any suspicious areas, ensuring that any abnormal cells are detected and treated promptly. ]]> https://biospectrumindia.com/news/93/24700/armed-forces-medical-services-iit-h-ink-mou-for-collaborative-research-and-training.html https://biospectrumindia.com/news/93/24700/armed-forces-medical-services-iit-h-ink-mou-for-collaborative-research-and-training.html Fri, 31 May 2024 00:00:00 +0530 Armed Forces Medical Services (AFMS) have signed a Memorandum of Understanding (MoU) with the Indian Institute of Technology Hyderabad (IIT-H) to collaborate on research and training. The MoU was signed by Director General of Armed Forces Medical Services Lt Gen Daljit Singh, and Director of IIT Hyderabad Prof B S Murty. The MoU aims to foster innovation and research in developing novel medical devices and addressing health issues specific to soldiers serving in varied terrains. IIT Hyderabad, with its departments of Biotechnology, Biomedical Engineering, and Bioinformatics, will provide the necessary technical expertise to tackle the diverse medical challenges faced by the Armed Forces. Key areas of collaboration discussed include drone-based patient transport, telemedicine innovations, the application of Artificial Intelligence in the medical field, and advancements in nanotechnology. Additionally, the MoU will facilitate student exchange programs, short-term courses for undergraduates, and faculty exchange initiatives. Lt Gen Daljit Singh emphasised the AFMS’s commitment to delivering comprehensive medical care to soldiers, both in peripheral and tertiary care settings. He highlighted that partnering with an institute like IIT Hyderabad, known for its cutting-edge technology, represents a significant step towards enhancing research and training, ultimately improving the quality of life for soldiers and their families.   ]]> https://biospectrumindia.com/news/93/24671/medtech-firm-stryker-opens-customer-experience-centre-in-gurugram.html https://biospectrumindia.com/news/93/24671/medtech-firm-stryker-opens-customer-experience-centre-in-gurugram.html Tue, 28 May 2024 00:00:00 +0530 Stryker, a global leader in medical technologies, has announced the opening of its Customer Experience Centre housed at Stryker’s Global Technology Centre (SGTC) in Gurugram. This state-of-the-art centre is designed to demonstrate Stryker’s industry-leading portfolio of medical equipment and offer an interactive environment for customers to experience Stryker’s emerging technologies. This centre will provide a seamless and effortless customer experience in showing Stryker’s products and how they address caregivers’ current challenges.  The centre will showcase ICU beds, emergency transport ambulance cots, surgeon stools and automated external defibrillators (AEDs), and other medical products. It will enable healthcare professionals to experience firsthand the capabilities of Stryker's quality offerings through personalised demonstrations and provide valuable feedback to Stryker’s R&D team. Aman Rishi, vice president and general manager of Stryker in India said, “I am excited about our new Customer Experience Centre as it showcases our acute care and emergency care products that enable an effective care environment and deliver value across the continuum-of-care, helping ensure safety, efficiency and improved outcomes for caregivers and patients. This experience centre also signifies Stryker's commitment to advancing collaboration, innovation and patient care in the Indian healthcare landscape.”    ]]> https://biospectrumindia.com/news/93/24648/tdk-corp-partners-with-iit-madras-to-support-diagnostic-medtech-startups.html https://biospectrumindia.com/news/93/24648/tdk-corp-partners-with-iit-madras-to-support-diagnostic-medtech-startups.html Tue, 21 May 2024 00:00:00 +0530 TDK Corporation, a Japan-based leader in electronic solutions for the smart society, is partnering with the Gopalakrishnan-Deshpande Center for Innovation & Entrepreneurship (GDC) at the Indian Institute of Technology (IIT) Madras to launch ‘TIIC Accelerator Program 2024’. The programme aims to foster innovation in the healthcare technology and diagnostics sector arising from Indian STEM university researchers and startups. Through this collaboration, TDK Corporation aims to harness India's deep talent pool and creativity to propel breakthroughs in diagnostics, medical devices, and related areas. The programme will provide targeted support, mentorship, and partnership and investment opportunities to catalyse the growth of promising healthcare technology ventures. By combining TDK's extensive experience in the technology industry with GDC’s experience in commercialisation of research and fostering entrepreneurship, the ‘TIIC Accelerator Program 2024’ aims to make a significant impact on the healthcare technology startup ecosystem in India. The programme seeks participation of startups from multiple segments of the healthcare technologies and diagnostics sector, including diagnostic labs/services; diagnostic devices (excluding implants); consumables; advanced materials for medical diagnostics and equipment; equipment-related services; wearables; analytics; 3D printing; robotics; AR/VR etc. It starts with a Call for Applications in June 2024 from which highly promising startups/teams will be selected. Thereafter, GDC will host an in-person workshop of the selected teams/startups at the IIT Madras campus. Following this, the teams will undergo an intensive 6–8-week boot camp focussing on customer discovery. In the next phase, a set of shortlisted teams will participate in a Business Mentorship programme, which will help them get investment-ready and prepare them for their pitch to TDK to secure investments or explore other potential collaborations. ]]> https://biospectrumindia.com/news/93/24606/omron-healthcare-collaborates-with-alivecor-to-improve-heart-healthcare-in-india.html https://biospectrumindia.com/news/93/24606/omron-healthcare-collaborates-with-alivecor-to-improve-heart-healthcare-in-india.html Thu, 09 May 2024 00:00:00 +0530 Omron Healthcare India, the Indian arm of the Japanese global leader in medical equipment for home health monitoring and treatment, has announced its collaboration with AliveCor India, the Indian subsidiary of the global leader in USFDA-cleared, CE marked and CDSCO approved personal electrocardiogram (ECG) technology. With this partnership, Omron Healthcare India now offers artificial intelligence (AI)-based handheld ECG technology besides being a top blood pressure monitor player in India. This collaboration, marking a significant milestone in Omron’s "Going for Zero" vision to enhance cardiovascular health awareness and prevent incidents, brings forth devices including the first home BPM+ECG Monitoring FDA cleared Device (blood pressure monitor with AliveCor ECG capability in a single device) for early CVD (CardioVascular Disease) detection and management and AliveCor's FDA-cleared world’s most clinically-validated and pocket-sized personal ECGs. These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more. Afib disrupts the normal heartbeat and causes small & irregular vibrations in the heart, leading to the collection of blood inside. This can create a clot in the heart, which can travel to the brain, and cause a stroke. “Stroke risk is 3.4 times higher with hypertension, but it is 5 times higher with Afib and so if people frequently have Afib, they may face a stroke shortly. This signifies that monitoring both ECG and blood pressure at home and keeping the doctor informed is crucial for the early management of cardiovascular and cerebrovascular health conditions like stroke,” says Tetsuya Yamada, Managing Director, Omron Healthcare India.   ]]> https://biospectrumindia.com/news/93/24594/kkr-buys-healthium-medtech-from-apax-funds.html https://biospectrumindia.com/news/93/24594/kkr-buys-healthium-medtech-from-apax-funds.html Tue, 07 May 2024 00:00:00 +0530 KKR, a leading global investment firm, has announced the signing of definitive agreements under which funds managed by KKR will acquire Bengaluru-based Healthium Medtech, a leading Indian medical devices company, from an affiliate of Funds advised by Apax Partners LLP, a leading global private equity advisory firm. The acquisition will be made by a special purpose vehicle owned by KKR-managed funds which will acquire a controlling interest in Healthium group, including Healthium. Founded in India in 1992, Healthium is a medical devices company that develops, manufactures and sells a broad range of surgical products globally. Its comprehensive, high-quality portfolio caters to a wide spectrum of surgeons’ needs, offering wound closure, arthroscopy, and advanced wound closure products. The Apax Funds acquired Healthium in 2018 and transformed the company from a domestic suture player into a global medical devices leader. With the support of the Apax Funds, the company bolstered its management team to add deep industry experience with the appointment of Anish Bafna as CEO and Vishal Maheshwari as CFO, positioning Healthium for growth. Healthium strengthened its existing portfolio of wound closure devices and consumables and invested in new franchises such as arthroscopy and advanced wound care through in-house R&D and M&A. During this period, Healthium expanded its presence from 50 countries to more than 90 today. KKR makes its investment from its Asian Fund IV. Healthium marks KKR’s latest investment in the healthcare sector in India and Asia Pacific. ]]> https://biospectrumindia.com/news/93/24582/smt-and-heartx-forge-transformative-partnership-in-cardiovascular-space.html https://biospectrumindia.com/news/93/24582/smt-and-heartx-forge-transformative-partnership-in-cardiovascular-space.html Fri, 03 May 2024 00:00:00 +0530 Surat-based medical device company SMT (Sahajanand Medical Technologies), has announced a strategic partnership with HeartX, a pioneering medtech company focused on research and development. Through this collaboration, SMT gains an innovative product line in the Congenital Heart Defect space. This collaboration not only broadens SMT's advanced product offerings within the Congenital Heart Defect space but also marks a significant stride toward revolutionising healthcare on a global scale. HeartX's portfolio includes advanced products like the JOVE VB Stent for Sinus Venous ASD, JOVE Versatile ASD (VASO), Fenestrated VASO and JOVE PFO, with ongoing developments in PDA and VSD closures as well as advanced visualisation systems for structural interventions. The collaboration between SMT and HeartX aims to address gaps in current medical procedures by prioritizing simplicity, efficiency, and cost reduction. By leveraging SMT's global reach and regulatory expertise, HeartX's innovative products will be made more accessible to patients worldwide. SMT’s CEO Ganesh Sabat further claims, “This strategic partnership greatly expands SMT’s portfolio of medical solutions in the Congenital heart space. This is a part of our growth strategy and is also in line with our ‘Pledge to save millions’ philosophy.” Adding more on the partnership, the CEO of HeartX, Cheran Uthirapathi says, “This partnership is aimed at leveraging the core competencies of both HeartX and SMT to deliver innovative solutions that address unmet clinical needs. I firmly believe that this strategic collaboration will accelerate the process of taking HeartX’s Congenital heart portfolio from India to the world.” ]]> https://biospectrumindia.com/news/93/24566/paras-health-expands-footprint-in-delhi-ncr-with-new-medical-technologies.html https://biospectrumindia.com/news/93/24566/paras-health-expands-footprint-in-delhi-ncr-with-new-medical-technologies.html Mon, 29 Apr 2024 00:00:00 +0530 Paras Healthcare, a corporate hospital chain which launched its first hospital in Gurugram in 2006, is expanding its healthcare services in Delhi-NCR with the forthcoming 300-bed hospital in Gurugram. The hospital chain will double the number of beds in Gurugram to 600 beds approximately, expanding its presence in the National capital region (NCR) to 2 hospitals.  With this addition, the total number of hospitals under Paras Health will be 9, covering North India, Bihar and Jharkhand. The new hospital will be situated in Gurugram sector 63-A and is expected to be completed in 2026. This marks another significant milestone in the hospital's journey towards expanding its healthcare offerings.  The second hospital is focusing to expand their Organ Transplant programmes by including Lung and Liver transplants. They are already catering to the Kidney and Bone Marrow transplant programmes. Furthermore, the facility will be equipped with advanced medical technology such as Robotic and Navigation systems while catering to both international and domestic patients. The new hospital will offer healthcare services in Oncology, Gastroenterology, Neuro Sciences, Cardiac Sciences, and Orthopedics to the patients.  ]]> https://biospectrumindia.com/news/93/24548/german-medtech-firm-joimax-obtains-registration-for-all-products-in-india.html https://biospectrumindia.com/news/93/24548/german-medtech-firm-joimax-obtains-registration-for-all-products-in-india.html Fri, 26 Apr 2024 00:00:00 +0530 Germany based joimax, the market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, has announced the full registration of all its products for India, one of the fastest growing endoscopic spine surgery markets worldwide. The Indian registration includes all joimax Class II and III, as well as Class I instruments, which were approved in 2023. Now, the Indian health community has access to all the latest spinal endoscopic technologies invented, developed and manufactured by joimax. “Earlier this year, joimax received its CE MDR approvals, granted by TÜV-South, an important step for marketing our existing products under the new European regulation, which opened a backlog of products to India,” states joimax Founder and CEO Wolfgang Ries. “We’re already active in more than 60 countries. These partners are eager to launch the newest joimax treatment technologies.” ]]> https://biospectrumindia.com/news/93/24532/iit-jodhpur-aiims-jodhpur-collaborate-and-create-groundbreaking-medical-technologies.html https://biospectrumindia.com/news/93/24532/iit-jodhpur-aiims-jodhpur-collaborate-and-create-groundbreaking-medical-technologies.html Tue, 23 Apr 2024 00:00:00 +0530 Indian Institute of Technology (IIT) Jodhpur and  All India Institutes of Medical Sciences (AIIMS) Jodhpur have created a robust multidisciplinary framework to spawn deep-tech innovation-based healthcare products. In order to achieve India’s Vision Viksit Bharat@2047 goals with ‘health’ at its centre, the two institutes have developed a pipeline of prototypes of novel medical technologies, developed out of joint academic programmes in medtech, which is training future of medtech entrepreneurs. Explaining the salient features of this collaboration, Prof. Santanu Chaudhary, Director, IIT Jodhpur said, “Indian patients receive medical technologies that were created for the developed world and are now adapted for local needs. This method of introducing novel medical technologies in India needs significant improvement as it cannot capture the diverse needs of Indian patients. This collaboration is a step in that direction to bring about solutions to cater to Indian needs. This first-of-its-kind joint degree programme offered by IIT Jodhpur and AIIMS Jodhpur lets students identify needs from real-life problems and create deep-tech solutions.” IIT and AIIMS Jodhpur offer joint programmes in medical technologies to students from engineering, medicine, nursing, bioengineering and allied fields. Students from these diverse backgrounds are mentored through three phases of this academic programme: Identify, Invent, and Implement. In the last phase of implementation, the students earn Biodesign fellowships, Prayas grants, and startup seed support to build small enterprises.  Both institutes have created an ecosystem of innovation and have also incentivised it to promote the conversion of deep-tech research into products and technologies.  Some of the startups and technologies that spun out of the joint medtech programme have created futuristic technologies in the areas of novel syringe design, digitally designing maxillofacial prosthetics, device to correct nasal septal defect without surgery, 3D cell models for precision oncology, non-animal disease models for drugs/formulation testing, nanosensor technologies for early disease diagnosis. ]]> https://biospectrumindia.com/views/93/24525/medical-cobotics-centre-is-developing-indigenous-cobots-to-enhance-healthcare-services-in-india.html https://biospectrumindia.com/views/93/24525/medical-cobotics-centre-is-developing-indigenous-cobots-to-enhance-healthcare-services-in-india.html Mon, 22 Apr 2024 09:00:00 +0530   Please give a brief on MCC, its vision and mission. The Medical Cobotics Centre (MCC) located at Indraprastha Institute of Information Technology (IIIT), Okhla, New Delhi, has been set up as a joint initiative of IHFC (Technology Innovation Hub of IIT Delhi) and iHub Anubhuti (Technology Innovation Hub of IIIT Delhi), under the NM-ICPS mission of Department of Science and Technology (DST), Government of India. This facility is envisaged as one of its kind Centre of Excellence (COE) in the field of Healthcare, Medical Cobotics and AI in India. The centre has been set up to create an ecosystem for Skill Development, R&D and Start-ups in the field of Medtech devices and equipment. This Facility aims at bridging the gap between the medical & engineering fields by providing a common platform for collaboration on training, research, new product development and commercialisation. The stated objectives of the Medical Cobotics Centre (MCC) include: To provide long-term sustainable indigenous solutions to the country in medical systems and technologies.  To remain connected with medical industry to cater to their demands at every stage. To create a widespread network of stakeholders like facilities created by other hospitals and Govt. Institutions like ICMR etc. MCC is a 10,000 square feet facility in the heart of Delhi with the following facilities: - Space for trainings, workshops & meetings - Human Patient Simulator (HPS) for simulation-based trainings in healthcare. - Innovation and Research facility to help Academic institutes & researchers in technology & medicine. - Incubation centre for startups for better and affordable Product design.  - Medical Devices Test centre and AR/ VR facility.  - Display Centre of Prototypes, conceptualized by Students and Researchers. - High Performance Computing Facility & data centre. MCC is also partnering for creating a better ecosystem around with entities like: - Industry including Medtech, Pharma, Digital health. - Ecosystem partners – Healthcare service providers, hospitals, diagnostics centres. - Researchers, Academicians, Product developers.  - Incubators, Accelerators, Financial, Regulatory and design consultants.   What are the unique challenges faced by the Indian healthcare system that the Medical Cobotics Centre aims to address through its innovations? Could you provide specific examples of cobot-driven solutions tailored to India's needs? Most of the innovation, research and new business ideas in healthcare happen in silos. Various stakeholders in the ecosystem – healthcare providers, technologists and researchers, industry, medical and technology academia, start-ups – do not interact with each other. This poses significant challenges to the innovation ecosystem like: - Lack of lab to market commercially viable product-oriented research. - Product creation happens in silos.  - Lack of problem-oriented approach. - Poor product market fit for innovative products. - Difficulty in getting regulatory and compliance related approvals. - Difficult to scale up health tech products created by startups. These are some of the challenges that we are trying to solve for at MCC.  An example of a homegrown innovation includes a telerobotic Ultrasound System, developed by Prof. S.K. Saha and Prof. Chetan Arora from IIT Delhi and Dr Chandrashekhara from AIIMS, New Delhi. This system has been designed for use in future pandemics where contact between healthcare providers and infected patients is to be avoided. Moreover, IHFC is funding various R&D projects in the area of rehabilitation robotics and prosthetic devices at premium institutes across the country to deliver low-cost healthcare solutions for the Indian disabled population.    What initiatives has the Centre undertaken to build a skilled workforce capable of developing, deploying, and maintaining medical cobot technologies in India? Are there any specific programs or collaborations addressing this area? IHFC is conducting simulation-based trainings and workshops to address this concern by partnering with Vidyanta and AIIMS. Since it has recently started, our endeavour is to keep this MCC dedicated 365 days in a year for such trainings. Other threads are included medical start-up incubation and collaborations with relevant govt. and non-govt. medical entities such.   In the next 2-3 years, what do you see as the most promising areas for medical cobot development in India? Where do you see the Centre making the greatest contributions? The Centre is already making headway in conducting training for healthcare professionals using simulators. IHFC has also spearheaded multiple R & D projects in rehabilitation. Both IHFC and its collaborator i-Hub Anubhuti are supporting lots of start-ups in the field of applying AI in healthcare. The future could see more diversification of MCC activities into multiple domains.    What are the primary regulatory, infrastructural, or adoption barriers the Centre foresees in the widespread use of medical cobots in India? How is the Centre working to proactively address these challenges? These are the challenges:  Regulatory Challenges: Introducing new medical technologies involves navigating regulatory approval processes such as ISO 14971. Streamlining these processes for emerging technologies like medical cobots is essential to ensure timely deployment. Infrastructure: Widespread adoption of medical cobots requires robust technological infrastructure, including high-speed internet connectivity, to support remote monitoring, data exchange, and teleoperation. Proper training facilities and educational programs for healthcare professionals are necessary to ensure they can effectively use and integrate medical cobots into their practice. Adoption Issues:  The use of medical cobots involves the collection and exchange of sensitive patient data. Establishing robust data security and privacy measures is critical to gain trust and ensure compliance with regulations. Efforts to make these technologies more affordable and accessible could drive adoption. Cultural attitudes towards technology in healthcare may differ, and public perception can influence the acceptance of medical cobots. Educating the public about the benefits and safety of these technologies is essential for widespread adoption.  Developing a legal framework that addresses liability issues associated with the use of medical cobots is crucial. This includes determining responsibility in case of errors or malfunctions and defining insurance policies to cover potential risks. Addressing ethical considerations related to patient autonomy, informed consent, and the responsible use of artificial intelligence in healthcare is essential for gaining public and professional trust. Lack of awareness and education among healthcare providers, administrators, and the general public about the capabilities and benefits of medical cobots can hinder widespread adoption. The Medical Cobotics Centre is trying to overcome these barriers by collaborating with regulatory bodies, industry stakeholders, healthcare professionals, and policymakers to create an environment which in inclusive and conducive to the successful integration of medical cobots into the Indian healthcare system. Barriers to training are that today it is not compulsory for medical students and doctors to dedicate certain number of hours for the simulation-based trainings. Presence of affordable simulators in India is also a challenge. Hence, we want startups to make indigenous simulators for nurses, paramedical staff, police, and other departments as well.   Anusha Ashwin ]]> https://biospectrumindia.com/news/93/24530/indian-embassy-in-moscow-bats-for-tapping-potential-of-indo-russian-medical-device-industry.html https://biospectrumindia.com/news/93/24530/indian-embassy-in-moscow-bats-for-tapping-potential-of-indo-russian-medical-device-industry.html Mon, 22 Apr 2024 00:00:00 +0530 Given the enormous opportunities in the medical device industry for multifaceted bilateral engagements, experts from India and Russia have vouched for faster efforts to give a boost to collaborations to make the most of emerging opportunities in the areas of manufacturing and marketing lifesaving medical equipment and devices. Association of Indian Medical Device Industry (AiMeD) and Centre for the Development of Russia Strategic Partnership (DRISP) had signed a Memorandum of Understanding (MoU) last year and are now moving ahead towards strengthening the bilateral relations through their collaborative efforts. “The support extended by Indian Embassy in Moscow in our collective efforts to mutually cash in on emerging opportunities in medical device industry will go a long way in giving a further fillip to bilateral trade ties between two nations,” said Rajiv Nath, Forum Coordinator, AiMeD. Nath informed that experts from India and Russia at a recently held webinar rightly stressed the need for a dynamic and multifaceted economic engagement, guided by shared interests and a commitment to further deepen bilateral cooperation and the two organisations will contribute in their own humble manner in line with that objective. The online event was attended by over 70 Indian manufacturers and exporters alongside some key Russian investors. Rohit Neema, Second Secretary, Indian Embassy in Moscow, promised his support for facilitating trade and cooperation in the medical device sector between India and Russia, recognising the sector's potential for economic growth and job creation.  Denis Stepanov, General Director of CES Spine Medics, Russia, highlighted the potential for Indian medical device manufacturers entering Russia. He said that there are opportunities in the market, such as the interest from manufacturers and the need for high-tech and high-quality medical products. He also addressed the challenges, including the registration process, competition from Chinese and Turkish manufacturers, and the need for international collaboration. Ashish Rangra from Invest India made a detailed presentation on the Indian medical devices sector, covering its current valuation, projected growth, key segments, import dependency, and the government’s initiatives and incentives. He also discussed the upcoming manufacturing infrastructure, including the introduction of four new parks and success stories of companies investing in India.   ]]> https://biospectrumindia.com/interviews/93/24522/india-will-witness-a-rising-demand-for-surgical-navigation-systems-in-the-next-5-years.html https://biospectrumindia.com/interviews/93/24522/india-will-witness-a-rising-demand-for-surgical-navigation-systems-in-the-next-5-years.html Sat, 20 Apr 2024 00:00:00 +0530 Can you share a brief on Cartosense’s technology and products? Cartosense develops technology and products for making surgical interventions more targeted and precise using data. We are soon launching the C75 Surgical Navigation System, a breakthrough in single camera optical navigation. At the heart of the product is a real-time tracking system which uses a single optical sensor to track specialized instruments with infrared emitters. Navigation software takes the patient’s radiological images, such as CT, MR, as input, and overlays real-time information such as tracked instrument positions and trajectories on to the images, which helps the surgeon make accurate decisions intraoperatively. Our innovative single camera optical system tracks instruments at superior accuracies in working volumes that are much larger than the current state of art. And due to the advantage of requiring a single viewpoint for tracking instruments, it opens up valuable new workflows and brings a paradigm shift to the reliability of existing workflows in the operation theatre.  Cartosense is one of the handful of companies globally and the only company in India to have developed the complete navigation stack, including optical tracking technology. Our accuracies are tested in compliance with the ASTM F2554 standard and benchmarked against the best in the current state of art. Given the growing interest in image-guided surgical navigation systems, how does Cartosense envision the potential integration of such technologies in cobot solutions within the Indian medical field? When any invasive surgery is performed, you want it to be as targeted as possible while ensuring positive patient outcomes. There are 4 steps to achieving this: knowing how you want to operate, quantifying the plan, accurate execution, and post-operatively quantifying the outcome. Surgical Navigation started out in neurosurgery as a means to quantify the plan and provide real-time information for accurate execution. However, under the umbrella of digital surgery, it is now playing an increasing role in all of the four areas and has expanded to many more clinical specialties.  Navigation technologies are the backbone of digital surgery because the tracking system component generates information that is complementary to radiological imaging, and the software component is a hub for integrating that information along with radiological images with a variety of tools such as imaging equipment, robotic solutions and advanced visualization displays. Together these technologies enhance the surgeon’s awareness and increase the accuracy of specific actions. Cartosense is laser focused on building very strong foundation technologies so that products built over these can continue to deliver effective patient care over years and decades to come. Robotic solutions in particular augment the surgeon’s motor skills guiding instruments and implants to more controlled positions. Robots do and will continue to work in lockstep with the surgeon, so that the surgeon is always the approving authority. This is due to the fundamental nature of risk and liability in medical treatment, and therefore surgical robots are almost always cobots. In the Indian market, the adoption of these technologies by surgeons and hospitals is on an increasing trend in the last 5 years and will continue to rise faster in the near future. Early adopters might receive great bundling deals from multinational multi-product companies, and their purchases can often be marketing expenses. However, only products that are truly beneficial and practical can succeed over a longer period of time.   As a startup focused on medical robotics, how do you view the importance of collaboration between established players like hospitals and emerging companies like yours in driving the adoption of medical cobots in India? What is your vision for Cartosense's role in this ecosystem? There is an emerging consensus that medical device innovation developed out of India and other emerging countries with relatively cost-efficient healthcare systems has the potential to do a lot of good world-over, by making good quality healthcare accessible globally. There is widespread recognition even in developed economies where the costs of healthcare are ballooning, that medical device innovation needs to be cost-effective.  Cost-effective doesn’t necessarily mean lower cost, but rather higher quality innovation which is mindful of unit economics of the healthcare system. This is vitally important for innovation in the space of digital surgery and cobots because these are expensive capital equipment. The utility and effectiveness of the solution depends entirely on whether it can continue to provide value to the surgeon and the hospital over a long horizon of 8-10 years, rather than being an attractive marketing tool, which has to be decommissioned after a couple of years due to the impracticality of using it or its unaffordable unit economics (examples of such products are quite prevalent in the market). India can play a pioneering role in this regard. Our high-quality and relatively cost-efficient healthcare system can be aligned to become an effective vehicle for nurturing locally developed high-quality innovation and present it as a proven solution to the world.  This of course requires a strategic priority from financers, regulators, surgeons and hospitals for identification, adoption, and promotion of genuine high-quality innovation. The government already recognizes its role in financing such innovation because focus on such sectors needs to be strategic before it can become capitalistic.  Cartosense has been the beneficiary of grants and schemes administered by BIRAC, MeitY and C-CAMP. With increased strategic participation from private capital, regulators, surgeons and hospitals, India can become a hub for quality medical device innovation.   Anusha Ashwin ]]> https://biospectrumindia.com/news/93/24498/iit-m-launches-indias-first-mobile-medical-devices-calibration-facility.html https://biospectrumindia.com/news/93/24498/iit-m-launches-indias-first-mobile-medical-devices-calibration-facility.html Mon, 15 Apr 2024 00:00:00 +0530 The Indian Institute of Technology Madras (IIT-M) has launched India’s first ‘medical devices calibration facility on wheels’. This has been developed by IIT-M under its ‘Anaivarukkum IITM’ (IIT-M for all) Initiatives. Prof. V. Kamakoti, Director, IIT-M launched this facility at the campus in the presence of Prof. R. Sarathi, Dean (Planning), Prof. M. Anbarasu (Head, CEC), Prof. S. Ramakrishnan, faculty and students. Highlighting the importance of this initiative, Prof. V. Kamakoti, Director, IIT Madras, “Proper Diagnosis and treatment are extremely important and for that the medical devices need to be calibrated accurately and frequently. With escalating cost for calibration this effort not only reduces the cost of calibration but also the transportation cost and time required. This is a progressive step towards affordable, scalable, quality health care for all.” Maintenance and quality assurance of life-saving medical devices are of paramount importance for healthcare delivery. Calibration is crucial as it ensures the accuracy of medical instruments for precise disease diagnosis and effectiveness. This facility is first-of-its-kind in India and is geared towards providing an affordable quality calibration facility and enabling accurate disease diagnosis and treatment. This mobile facility will ensure pervasive quality healthcare irrespective of geographical locations across the country. This will help to test and maintain medical devices that are used in wide range of hospitals including those in villages at their doorsteps. This initiative boosts the United National Sustainable Development Goal 3, which calls for Health and well-being for all. The infrastructure available in this mobile unit include state-of-the-art equipment to test the safety of medical devices and their functionalities as per international standards. ]]> https://biospectrumindia.com/news/93/24479/secretary-dop-expounds-concept-of-proximate-advantage-at-mtai-fraternity-meeting.html https://biospectrumindia.com/news/93/24479/secretary-dop-expounds-concept-of-proximate-advantage-at-mtai-fraternity-meeting.html Mon, 08 Apr 2024 00:00:00 +0530 Medical Technology Association of India (MTaI), which represents leading research-based medical technology companies with a large footprint in manufacturing and training in India, recently organised a high–level meeting with government stakeholders, and MediTech industry captains in New Delhi. The event was graced by Dr Arunish Chawla, Secretary, Department of Pharmaceuticals (DoP), and MAseem Sahu, Deputy Drugs Controller, the Central Drugs Standard Control Organization (CDSCO). The event revolved around India's prospects and obstacles within the MediTech domain including tariff and non-tariff barriers, price control, procurement challenges, the need for standard harmonization, and streamlining the regulatory landscape. Alongside this, various strategic inputs also were discussed aiming to encourage investments in India's healthcare sector. Speaking during the event, Pavan Choudary, Chairman, MTaI stated, “The government and its offices like the Department of Pharmaceuticals, CDSCO deserve our appreciation for creating policies that have enabled the upward growth trajectory of India’s medical device sector in recent years. The last marker of this ascent is the record breaking FDI in the sector in 2023. The continued learning of the intricacies of this sector will be key to achieving the goal of making India a MediTech hub”. Addressing the gathering, Dr Arunish Chawla, Secretary, DoP said, “Most MediTech hubs around the world specialise in a few segments that they robustly export. Therefore, for the growth of the Meditech sector in India, we must initially focus on areas where the country already has some underlying strengths, like Medical Textiles, Consumables, Software, Artificial Intelligence, etc. Growth budding from areas close to our strengths is proximate growth. And this I call the ‘Proximate Advantage’ which we should leverage to begin with.” “To take a comprehensive view, we have been collating the metadata and will organize the first of its kind, think tank event for the MediTech sector called the ‘India MediStack’ in Delhi NCR. This will be a very important congregation of MediTech experts which will raise the caliber of dialogue in this space”, he added.   ]]> https://biospectrumindia.com/news/93/24425/wipro-ge-healthcare-to-invest-rs-8000-cr-in-manufacturing-output-local-rd-over-next-5-yrs-in-india.html https://biospectrumindia.com/news/93/24425/wipro-ge-healthcare-to-invest-rs-8000-cr-in-manufacturing-output-local-rd-over-next-5-yrs-in-india.html Tue, 26 Mar 2024 00:00:00 +0530 Wipro GE Healthcare has announced an investment of over Rs 8000 crore in manufacturing output & local R&D over next 5 years. This strategic investment bolsters Wipro GE Healthcare’s local manufacturing footprint to address the growing domestic and international market and will build supply chain resiliency for the organisation.  As a part of this investment, the Wipro GE Healthcare ‘Made in India’ PET CT Discovery IQ will be exported to 15 countries. Additionally, the ‘Made in India’ Revolution Aspire CT, Revolution ACT and MR breast coils will be manufactured ‘In India for the World’.  Over the decades, the organisation has fostered a strong local supplier ecosystem of medtech component manufacturing, covering capabilities like plastics, EMS, machining, castings, 3D printing, contributing $1 million supplier labour hours. The investment will include creation of additional 400,000 labour hours. Currently, the organisation has four manufacturing plants in Bengaluru. All four manufacturing plants are export plants, the latest one established in March 2022 with an investment of a little over Rs 100 crore under the Indian government’s PLI Scheme.   ]]> https://biospectrumindia.com/news/93/24414/medtech-solutions-take-centre-stage-as-winners-of-qualcomm-design-in-india-challenge-2023.html https://biospectrumindia.com/news/93/24414/medtech-solutions-take-centre-stage-as-winners-of-qualcomm-design-in-india-challenge-2023.html Thu, 21 Mar 2024 00:00:00 +0530 Qualcomm Incorporated has announced the winners of the eighth edition of Qualcomm Design in India Challenge, India’s longest-running hardware startup incubation programme, launched in collaboration with Nasscom and Startup India. 3 winners were chosen from the 12 finalists through a meticulous evaluation by a jury comprising leaders and experts from within and outside Qualcomm. Ayati Devices, who has developed a laser-based medical imaging device for real-time microcirculation visualisation and quantification, emerged as the challenge winner receiving a Rs 50 Lakh grant award Rymo Technologies, with its computer vision and AI/ML technology to integrate with physical rehabilitation solution took the 1st runner up spot receiving a Rs 30 Lakh grant award SIAMAF Healthcare, with its AI/ML enabled MafPro device platform, an ultrasensitive hand-held magnetic probe system for detecting cancer staging, localisation and margins, bagged the 2nd runner up spot receiving a Rs 20 Lakh grant award The eighth edition of Qualcomm Design in India Challenge witnessed a total of 155 applications out of which 12 startups were shortlisted to the 2023 cohort, with solutions catering to use cases across areas such as medtech, robotics, automotive, AR/VR, AI/ML, and IoT, Through the programme, each finalist received a grant of up to Rs 3.2 lakh along with business mentorship and access to dedicated engineering support and the well-equipped, state of the art Qualcomm Innovation Lab to help them build out their prototypes for various commercial use cases and applications.  The finalists also qualified to receive incentives for patent-filing, opportunities to participate in Qualcomm hosted or sponsored events and business development opportunities from Qualcomm Technologies’ global sales and business teams.   ]]> https://biospectrumindia.com/news/93/24373/medical-aesthetics-brand-beagle-lasers-aims-to-expand-in-50-cities.html https://biospectrumindia.com/news/93/24373/medical-aesthetics-brand-beagle-lasers-aims-to-expand-in-50-cities.html Wed, 13 Mar 2024 00:00:00 +0530 Surat-based medical aesthetics company Beagle Lasers has announced its expansion plans across 50+ cities, significantly increasing its footprint from 17 cities presently served. This expansion primarily targets tier 2 and 3 cities like Srinagar, Tamil Nadu, Karnataka, and Orissa to name a few. With this expansion, Beagle Lasers' aims to enhance accessibility to medical equipment and technologies for doctors, hospitals, and healthcare providers nationwide. As part of this expansion, Beagle Lasers will be investing between Rs 10 to 15 crore in infrastructure development, including the establishment of new factories and production facilities. This investment will further solidify the company's commitment to scaling its operations and meeting the growing demand for advanced medical equipment and technologies across the country. This in turn will create employment opportunities for 5000 people in the country. With a vision to enhance the medical aesthetic device landscape, Beagle Lasers aims to bridge the gap between manufacturers and end-users by providing a comprehensive range of high-quality laser products and devices such as Dhanush, Nakul etc.  They currently have stores in Delhi, Gujarat, Madhya Pradesh, Haryana, Chattisgarh etc. This expansion initiative is poised to bring innovative solutions closer to medical practitioners and healthcare institutions, ensuring they have access to the latest advancements in medical technology. Beagle Lasers has also recently obtained a manufacturing license, enhancing its capabilities to produce and distribute innovative medical devices. ]]> https://biospectrumindia.com/news/93/24300/us-based-modmed-opens-global-capability-centre-in-hyderabad.html https://biospectrumindia.com/news/93/24300/us-based-modmed-opens-global-capability-centre-in-hyderabad.html Fri, 01 Mar 2024 00:00:00 +0530 ModMed, a US-based company that develops all-in-one cloud solutions for multiple medical specialties, has announced the launch of its first Global Capability Center (GCC) in Hyderabad, India. Located in a new facility in HITEC City, the GCC reflects ModMed's commitment to fostering innovation and harnessing the abundant tech talent in Hyderabad, one of India's fastest-growing GCC hubs. The state-of-the-art facility is spread across approx. 20,000 square feet. ModMed aims to grow from its current strength of 100 employees to 200 by the end of this year and is actively recruiting across a range of positions in engineering, product development and support. With more than 1,700 employees globally, including doctors, ModMed powers a medical specialty-specific cloud platform for allergy, dermatology, gastroenterology, OBGYN, ophthalmology, orthopaedics, otolaryngology, pain management, plastic surgery, podiatry and urology practices, as well as ambulatory surgery centers.  With ModMed’s specialty-specific electronic health records (EHRs), practice management, revenue cycle management and analytics tools, as well as products for patient engagement, payment processing and marketing, the company is trusted by over 35,000 providers to help drive clinical and operational success.  ]]> https://biospectrumindia.com/news/93/24295/garware-fulflex-india-acquires-avcor-health-care-products-to-strengthen-medtech-portfolio.html https://biospectrumindia.com/news/93/24295/garware-fulflex-india-acquires-avcor-health-care-products-to-strengthen-medtech-portfolio.html Thu, 29 Feb 2024 00:00:00 +0530 Garware Fulflex India has announced the acquisition of Avcor Healthcare Products Inc., a prominent US-based developer, manufacturer, and marketer of premium compression dressings, thermal compression & cohesive compression bandages, tourniquet straps, and I.V. aids for both institutional and consumer/retail healthcare markets. As part of the asset purchase agreement, Garware Fulflex integrated Avcor Healthcare Products into its global portfolio, serving both existing and new customers with a wider range of medical consumable products. Garware Fulflex is a distinguished industry leader in thin gauge polymers, serving a wide array of sectors including medical, sports and rehabilitation, PPE, textile, and others.  Founded in 1984, Avcor has built a reputation for excellence with its patented elastic bandages, including the widely recognized Honeycomb X-TEN bandage known for its superior performance and reliability.  ]]> https://biospectrumindia.com/news/93/24298/medtronic-announces-expansion-of-engineering-innovation-center-in-hyderabad.html https://biospectrumindia.com/news/93/24298/medtronic-announces-expansion-of-engineering-innovation-center-in-hyderabad.html Thu, 29 Feb 2024 00:00:00 +0530 Medtronic, the global leader in medical technology, has inaugurated its newly expanded state-of-the-art Medtronic Engineering and Innovation Center (MEIC) in Hyderabad. The center was inaugurated by D. Sridhar Babu, Minister of IT, Industries & Commerce, Govt. of Telangana, along with Geoff Martha, Chairman and CEO, Medtronic in the presence of Guest of Honor, Jennifer Larson, US Consul General. The R&D center’s expansion strategically aligns with Medtronic’s objective to expand its global R&D footprint and invest in the local innovation ecosystem. The expansion is part of the investment of approximately Rs 3000 crore (more than $350 milliion) announced by Medtronic over a five-year period to scale up and expand the R&D facility and to employ 1500 people in future. MEIC is also Medtronic’s largest R&D center outside the US. At 250,000 sq. ft. of total space, MEIC is going to focus on collaborative innovation, training and education, immersive experiences from the expanded space, all aimed towards shaping the future of healthcare technology. The new space will house a Digital Therapy & Innovation Lab, Connected Care Lab, Platform & Tech Lab, Systems Engineering Lab, Software Lab, as well as new workstations and wellness amenities for employees. With 900+ engineers, MEIC is home to some of the best STEM talent bringing in diverse perspectives, and ambition to engineer the extraordinary.  ]]> https://biospectrumindia.com/news/93/24282/medtech-firm-stryker-expands-prototype-and-testing-facility-in-india.html https://biospectrumindia.com/news/93/24282/medtech-firm-stryker-expands-prototype-and-testing-facility-in-india.html Wed, 28 Feb 2024 00:00:00 +0530 Stryker, a global leader in medical technologies, has officially expanded its prototype and testing facility in India, marking significant growth of its R&D footprint in the country. This advanced 55,600-square-foot facility integrates cutting-edge infrastructure, enhanced microbiology capabilities, and a talented team to drive innovation and ensure product quality across its medical technology portfolio. “Investing in innovation from India is a focus area for Stryker," said Ram Rangarajan, Vice President of Stryker Global Technology Center, India. "This new lab represents our commitment to developing medical technologies that improve patient outcomes and comply with the highest regulatory standards." Stryker's new facility is dedicated to the rigorous life cycle testing of medical devices. The new lab boasts several key features: Prototyping and product assurance hub: Equipped with state-of-the-art infrastructure for plastic 3D printing, metal machining, and a diverse range of testing capabilities, the lab supports prototyping and product assurance across Stryker's entire product portfolio. Expanded microbiology competency: The lab strengthens Stryker's ability to conduct comprehensive microbiological testing, ensuring the safety and efficacy of its medical technologies. Talented team of engineers and microbiologists:  Highly skilled engineers and microbiologists will use the advanced equipment and expertise to develop innovative solutions that positively impact patients around the world.   ]]> https://biospectrumindia.com/news/93/24252/smartcardia-collaborates-with-kokilaben-dhirubhai-ambani-hospital-to-enhance-cardiac-arrhythmia-care.html https://biospectrumindia.com/news/93/24252/smartcardia-collaborates-with-kokilaben-dhirubhai-ambani-hospital-to-enhance-cardiac-arrhythmia-care.html Mon, 26 Feb 2024 00:00:00 +0530 SmartCardia, a renowned leader in the field of cardiac monitoring solutions, has announced an exciting partnership with Kokilaben Dhirubhai Ambani Hospital (KDAH), Mumbai to revolutionise patient care for individuals with cardiac arrhythmia, a condition when the heartbeat is irregular due to a problem with the heart’s electrical signals. This collaboration will create a more accurate and efficient monitoring system, enabling early detection and improved patient outcomes. The announcement was made at a special session for healthcare professions on the “Role of AI in Cardiology and Healthcare” held at Kokilaben Hospital. One of the key highlights of this collaboration is the introduction of the SmartCardia 7L patch, which allows for the detection of severe cardiac arrhythmia conditions earlier than ever before due to its real-time transmission of ECG and multiple vitals. This breakthrough technology provides doctors with immediate access to data, and auto alerts on cloud, enabling them to make more informed clinical decisions. With early detection, physicians can now devise tailored treatment plans, leading to more successful outcomes and increased patient satisfaction. SmartCardia leverages cutting-edge developments in AI to design systems that can identify cardiac events swiftly and accurately. This integration of AI technology enhances patient care by providing real-time updates to physicians and nurses, allowing them to proactively respond to any cardiac episodes, thereby reducing response times and improving patient outcomes.    Image caption- From Left- Dr Sunil Wani; Dr Venkant D Nagarjan, Head of Heart Rhythm & Cardiac Device; Dr Jag Singh, MD, Professor of Medicines at Harvard Medicine School, Boston, USA; Dr Santosh Shetty, Executive & CEO, KDAH; Dr Vidhyadhar Lad Head Cardiac Surgeon, KDAH   ]]> https://biospectrumindia.com/news/93/24209/stanford-biodesign-innovators-garage-programme-picks-iit-mandis-innovation-syncubator.html https://biospectrumindia.com/news/93/24209/stanford-biodesign-innovators-garage-programme-picks-iit-mandis-innovation-syncubator.html Tue, 13 Feb 2024 00:00:00 +0530 SynCubator, a neonatal incubator developed by Dr Gajendra Singh, Assistant Professor, Dr Satvasheel Ramesh Powar, Associate Professor, at the School of Mechanical and Materials Engineering, Indian Institute of Technology (IIT) Mandi, and Keshav Verma, BTech 3rd Year, Mechanical Engineering has been selected for the prestigious ‘Stanford Biodesign Innovators Garage’ programme. Designed as a multifunctional neonatal incubator, SynCubator offers a unique solution to the challenges faced in transporting and providing critical care to newborns. Unlike traditional incubators, the developed device doubles as both a standalone warmer and an incubator, adaptable to the specific needs of each infant. During the innovators’ discussions with the Centre of Innovation at the Government Institute of Medical Sciences in Noida regarding the medical dimensions of the SynCubator, an opportunity emerged to participate in a prestigious programme. Upon presenting the proposal to the Stanford Biodesign Team, the team’s innovative approach to improving access to healthcare in remote regions resonated with them. With India grappling with high neonatal mortality rates and a significant number of preterm births, SynCubator will play a pivotal role in improving healthcare outcomes. By leveraging Artificial Intelligence and Machine Learning technologies in the future, the core design team aims to further enhance SynCubator's capabilities, enabling predictive healthcare interventions and timely treatments.   ]]> https://biospectrumindia.com/news/93/24205/us-based-starkey-launches-genesis-ai-hearing-aids-in-india.html https://biospectrumindia.com/news/93/24205/us-based-starkey-launches-genesis-ai-hearing-aids-in-india.html Mon, 12 Feb 2024 00:00:00 +0530 Starkey, a global leader in hearing technology, has announced the launch of its revolutionary Genesis AI hearing aids in India. With a deep commitment to improving hearing health and overall well-being, Starkey continues its legacy of innovation by introducing cutting-edge solutions tailored to address the rising prevalence of hearing loss in India. India faces a significant challenge, with hearing loss affecting millions of individuals across all age groups. According to the World Health Organisation, approximately 63 million people in India suffer from significant auditory impairment, highlighting the urgent need for effective solutions and interventions. Moreover, with India's ageing population projected to double by 2050 surpassing the number of children, the prevalence of hearing impairment is expected to rise, underscoring the importance of proactive measures to address this pressing health issue. Launching the revolutionary Genesis AI in India, Brandon Sawalich, President and CEO of Starkey said, “The new technology is already changing lives in the US, Canada, Europe, Australia, and New Zealand and now, we are very excited about its launch in India.” The key features of Genesis AI include an Advanced Starkey Neuro Sound Processor, a long-lasting rechargeable battery, health tracking sensors, enhanced sound processing with Edge Mode+, ergonomic design, and comfortable fit.   Image caption- Brandon Sawalich, President and CEO (Centre) and Dr Achin Bhowmik, Chief Technology Officer & EVP of Engineering of Starkey (Right) along with Starkey India MD Akhil Chauhan   ]]> https://biospectrumindia.com/news/93/24186/amrita-hospital-faridabad-partners-with-iit-h-for-innovative-cancer-treatment-technology.html https://biospectrumindia.com/news/93/24186/amrita-hospital-faridabad-partners-with-iit-h-for-innovative-cancer-treatment-technology.html Sat, 10 Feb 2024 00:00:00 +0530 Amrita Hospital in Faridabad has embarked on a groundbreaking collaboration with the Indian Institute of Technology Hyderabad (IIT-H), Eranki Labs, and Amrita Centre for Advanced Robotics to develop state-of-the-art technology in radiation therapy for cancer treatment. Dr Bhaskar Viswanathan, Head of the Department of Radiation Oncology at Amrita Hospital, Faridabad, has been awarded a research grant to spearhead the development of an indigenous robotic ultrasound system for tumour motion and radiation hyperthermia. This technology aims to revolutionise cancer treatment by providing non-invasive, precise, and effective therapies. The collaboration aims to leverage robotic ultrasound systems to track tumour movement in real-time, ensuring accurate radiation therapy delivery while minimising damage to surrounding healthy tissue. Dr Avinash Eranki, Assistant Professor at the Department of Biomedical Engineering at IIT-H and CEO of Eranki Labs, underscored the importance of precise energy delivery in cancer treatment. He emphasised the interdisciplinary nature of the collaboration, combining expertise from medical and engineering domains to advance technology in cancer care. The project, funded by the Indian Council of Medical Research (ICMR), is expected to be completed in three years.  The partnership between Amrita Hospital, IIT-H, and Eranki Labs signifies a significant step forward in cancer treatment technology, promising improved outcomes for patients battling this debilitating disease. ]]> https://biospectrumindia.com/news/93/24130/medtech-diagnostic-sectors-require-budget-2024-25-to-pay-attention-on-indigenous-production-skill-development.html https://biospectrumindia.com/news/93/24130/medtech-diagnostic-sectors-require-budget-2024-25-to-pay-attention-on-indigenous-production-skill-development.html Mon, 29 Jan 2024 00:00:00 +0530 Empowering the medtech and healthcare industry as a cornerstone of the Indian economy requires a dynamic shift towards Atmanirbhar Bharat and innovation. The diagnostic and medical devices industry players lay down their expectations from Union Budget 2024-25. “It is heartening to see that the government has placed affordability as one of its top priorities. However, the customs duties and taxes levied on medical devices in India are one of the highest in the world and highest among the neighbouring countries which directly impacts patient affordability; this is therefore contradictory to what the government is trying to achieve. As per government data, more than 80% of critical medical devices are imported into India to meet the rising demand for quality healthcare. We hope that as the preparation for the Union Budget 2024 gets underway, a correction on the tariff rates is urgently being considered”, said Pavan Choudary, Chairman, Medical Technology Association of India (MTaI). "In the upcoming budget, the government could further support the medtech sector by reducing import duties and lowering GST on locally procured raw materials, particularly for critical medical devices such as stents, heart valves, knee and hip implants. Incorporating advanced treatment methods like TAVI/TAVR into the Ayushman Bharat – Pradhan Mantri Jan Aarogya Yojana (AB-PMJAY) insurance scheme, and encouraging private health insurance companies to follow suit, can significantly enhance healthcare access for economically weaker sections",Vivek Shah, Chief Executive Officer, Meril voiced his opinion. Sharing his perspective, Mandeep Singh Kumar, Vice President and Country General Manager, Intuitive India said, “With the need for adoption of modern technology in various aspects of healthcare, accessibility to advanced surgical technologies like robotic-assisted surgery (RAS) must be a continued focus in this year’s union budget. Streamlined approval processes for high-tech devices across various ministries, coupled with a fair and predictable policy regime, would accelerate patient access to life-saving technologies and improve clinical outcomes. A reduction in the high customs duties for medical devices will enable the industry to expand its distribution in India and help the industry grow to its potential. Abolishing the 5% health cess ad valorem tax on imported medical devices is imperative to help the country gain better access to advanced technologies in healthcare.” “Through preferential treatment for homegrown companies in tender allocation and increased customs duties on readily available equipment, the nation can create the groundwork for a thriving ecosystem supporting the growth of local manufacturers. Furthermore, continued funding along with comprehensive technological and manpower-related assistance from the administration will establish a welcoming environment for Indian startups to flourish, leading to unprecedented technological advancements within the borders and beyond”, Chander Shekhar Sibal, Sr. Vice President & HOD, Healthcare Business, Fujifilm India further added. Giving an overview on behalf of the diagnostic industry, Chandra Ganjoo, Group Chief Executive Officer, Trivitron Healthcare said, “The industry advocates for a comprehensive strategy: incentivising R&D and indigenous production, streamlining regulatory processes for faster product approvals, and enhancing infrastructure and skills. Tax incentives for investment in advanced technology, streamlining bureaucratic procedures, and fostering industry-academia collaboration can stimulate domestic manufacturing. This approach should align with global standards and ensure a stable regulatory environment to attract investments.” Laying emphasis on the diagnosis of rare diseases,  Surajit Chakrabartty, Chief Financial Officer, MedGenome said, “We would urge the Government of India to lead awareness campaigns that can educate and build trust around the effectiveness and benefits of genetic testing in identifying and managing the genetic diseases. Making prenatal genetic testing accessible across all socioeconomic backgrounds coupled with nationwide awareness campaigns on rare diseases, will empower early interventions. For further progress and building a robust genomics infrastructure, increased investment in research is crucial along with establishing strict regulatory guidelines and ethical frameworks which address aspects like partnerships, data storage, usage protocols, consumer protection, de-identification methods, potential discoveries, and outcome distribution." "With the growing burden of non-communicable diseases (NCDs) and infectious diseases, we underscore the importance of comprehensive screening and diagnostics programmes, along with expanded skilling courses for healthcare professionals to attract and enhance talent in the advanced diagnostic field”, said Gaurav Srivastava, Co-Founder & Chief Operating Officer, HaystackAnalytics. Adding another perspective, Sandeep Gulati, General Manager, South Asia, ResMed said, “Considering the dynamic healthcare landscape, there is potential for medical equipment and home healthcare using telemonitoring to be covered under insurance. We also encourage the inclusion of sleep-related disorders such as Obstructive Sleep Apnea (OSA) to the classification of Noncommunicable illnesses (NCDs). Additionally, there is a need to incorporate sleep testing in the category of diagnostics under National Diagnostics Essential List.” Summing it up, Jatin Mahajan, Secretary, Association of Diagnostic Manufacturers of India (ADMI) said, "Even though the government has created a policy for purchase preference for Made in India products, unfortunately, this policy has not worked. In most government purchases, there is no preference for 'Made in India' as the state governments are not implementing this policy effectively. This policy is either ignored or side-lined." "The government must work with the industry to identify the specific need-gap for timely addressal of the issue. Industry-academia linkages should be strengthened, and more professional courses that fully cater to the industry's skill requirements and ensure higher employment for the trained personnel need to be introduced", Mahajan concluded.   ]]> https://biospectrumindia.com/news/93/24105/iisc-signs-mou-with-wipro-ge-healthcare-to-advance-medtech-innovation-from-india.html https://biospectrumindia.com/news/93/24105/iisc-signs-mou-with-wipro-ge-healthcare-to-advance-medtech-innovation-from-india.html Tue, 23 Jan 2024 00:00:00 +0530 Wipro GE Healthcare has signed a Memorandum of Understanding (MoU) with the Indian Institute of Science (IISc), Bengaluru, for a pioneering alliance to advance healthcare innovation, research, and technology development in India. This collaboration aims to take a comprehensive approach in solving the care gap by addressing the full lifecycle that includes co-developing solutions, validating the technologies, and manufacturing them locally to bring them to the market. With the impending commencement of the Bagchi-Parthasarathy Hospital & IISc Medical School, this strategic collaboration will enable translation of technologies from bench to bedside.  The collaboration will entail co-development initiatives in the areas of basic and applied science, systems engineering, product & software development, consultancy, joint IP & publications, academic studies, internships, fellowships, and training. IISc and GE HealthCare will constitute a joint working committee, comprising representatives from both sides, for research around product and solution development. Govindan Rangarajan, Director, Indian Institute of Science (IISc), said, “The collaboration will emphasise combining science and engineering with translational & clinical research to epitomise “bench-to-bedside” innovation. GE HealthCare is the right partner for us in this initiative, given their leadership and strong footprint in India for R&D and manufacturing." Chaitanya Sarawate, Managing Director, Wipro GE Healthcare and President & CEO, GE HealthCare South Asia, said, “This is a strategic collaboration that combines the strengths, capabilities, and local infrastructure of both entities. Our aim together is to invest in technologies of the future that can revolutionize the care paradigm – with more precise, connected, and compassionate care to patients in India and worldwide.” ]]> https://biospectrumindia.com/news/93/24093/apollo-cancer-centre-launches-indias-1st-ai-precision-oncology-centre.html https://biospectrumindia.com/news/93/24093/apollo-cancer-centre-launches-indias-1st-ai-precision-oncology-centre.html Sat, 20 Jan 2024 00:00:00 +0530 In a significant move that will substantially enhance the quality of oncology care, Apollo Cancer Centre (ACC), Bengaluru, has launched India’s first artificial intelligence (AI)-Precision Oncology Centre (POC). The Centre will help the oncologists, patients and care givers to arrive at the best possible results in a time bound manner, using the enormous possibilities offered by AI. The POC with its comprehensive and specialised medical services ensures accurate diagnosis, real-time insights, cancer risk assessment, treatment protocol and continuum of care, thus providing cutting-edge services in oncology care not seen in India earlier. The AI-POC is designed to be patient-centric, in the most personalised manner. It identifies eligible patients for targeted therapy and immunotherapy, as part of the diagnosis and treatment planning. With the help of conversational AI, it educates the patients and family on diagnosis, treatment FAQs and connections to support groups. The facility was inaugurated by Dinesh Gundu Rao, State Minister for Health & Family Welfare, Karnataka in the presence of Suneeta Reddy, Managing Director at Apollo Hospitals Enterprise; Dr Vijay Agarwal, Lead & Senior Consultant – Medical Oncology, Apollo Cancer Centre (ACC); and Dr Vishwanath S, Senior Consultant, ACC, Bangalore.   Dr Vijay Agarwal, Lead & Senior Consultant – Medical Oncology, ACC, Bengaluru, said, “The Centre will support new patient identification through auto-alerts to operational teams that identify eligible patients for PoCs. Patient SOS auto-alerts to operational teams on deteriorating patient outcomes for intervention and clinical escalation form another key feature.”      ]]> https://biospectrumindia.com/news/93/23996/government-unveils-medtech-mitra-platform-to-empower-innovators-and-advance-healthcare-solutions.html https://biospectrumindia.com/news/93/23996/government-unveils-medtech-mitra-platform-to-empower-innovators-and-advance-healthcare-solutions.html Tue, 26 Dec 2023 00:00:00 +0530 “MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge, logic etc. and help them in getting regulatory approval.” This was stated by Dr Mansukh Mandaviya, Union Minister of Health and Family Welfare and Chemicals & Fertilizers as he virtually launched 'MedTech Mitra': A Strategic Initiative to Empower MedTech Innovators and Advance Healthcare Solutions, in the presence of Prof. S.P. Singh Bhagel, Union Minister of State for Health and Family Welfare who virtually joined and Dr V.K Paul, Member Health, Niti Aayog. The event was attended by Dr Rajiv Bahl, Secretary, DHR and Director General, ICMR; Dr Suchita Markan Sc-E, Mission In-charge, Medical Device and Diagnostics Mission Secretariat (MDMS), ICMR; Dr Taruna Madan Sc-G, Head (Development Research), ICMR; Dr Rajeev Singh Raghuvanshi Drugs Controller General of India, CDSCO; Manisha Saxena Sr DDG(A), ICMR and senior government officials.  Highlighting the challenges facing the innovators in bringing innovations to light, Dr V.K Paul underscored the role of MedTech Mitra in handholding the innovators for clinical evaluations and regulatory compliance, emphasising that “MedTech Mitra will empower emerging startups and ensure ease of innovation, ease of doing research and development, ease of rendering service in building an Atmanirbhar Bharat.” He further added, “in harboring collaboration amongst all stakeholders, it will effectively break silos, catalysing growth and independence in this sector.”  ]]> https://biospectrumindia.com/news/93/23982/impelsys-announces-launch-of-advanced-medical-device-testing-lab-in-mangalore.html https://biospectrumindia.com/news/93/23982/impelsys-announces-launch-of-advanced-medical-device-testing-lab-in-mangalore.html Wed, 20 Dec 2023 00:00:00 +0530 Impelsys, a leading global technology company, has announced the launch of an advanced medical device testing lab in Mangalore. As a provider of cutting-edge technologies to the healthcare industry, this testing facility adds to its wide array of solutions and services, which include data and analytics, artificial intelligence (AI)-powered platforms and solutions, cloud services, and learning solutions. Vincent Emerald, Global Head & Director of QA – Impelsys, said, "Our goal with this facility is to accelerate transformation in healthcare, which will help hospitals and wellness centres offer safe and secure care to patients. It will also help medical device original equipment manufactureres (OEMs) bring their products to the market faster." With technology becoming a key differentiator in providing quality healthcare, the medical device testing facility is designed to make diagnostics and patient care safer. Impelsys offers comprehensive Quality Engineering services leveraging the latest automation tools covering functional and non-functional testing. ]]> https://biospectrumindia.com/news/93/23970/mtai-unveils-indias-historic-464-m-medtech-fdi-leap.html https://biospectrumindia.com/news/93/23970/mtai-unveils-indias-historic-464-m-medtech-fdi-leap.html Sat, 16 Dec 2023 00:00:00 +0530 India has witnessed a record-breaking surge of $464 million in foreign investments in MedTech in the first 3 quarters, said the Medical Technology Association of India (MTaI), which represents leading research-based medical technology companies with a large footprint in manufacturing and training in India.  Elaborating on the record FDI in MedTech, Pavan Choudary, Chairman, MTaI said, “The MedTech sector has seen a significant increase in FDI, already clocking 464 million dollars in the first three quarters of 2023. This shows the high potential of this sector and global investors’ recognition of the same. The government’s focus on increasing the ease of doing business in the country, the creation of a globally harmonised regulatory regime for the medical device sector, and initiatives like the National Medical Device Policy (NMDP) 2023 and PRIP scheme have been welcomed by the industry as reflected by the growing confidence of investors. Notably, this surge also indicates a shift in global dynamics, with Western nations, including Japan, increasingly favouring India as their preferred destination for friend-shoring activities.” The MedTech FDI inflow for the first quarter of this year (Jan-March 2023) was around $39 miilion which rose to $301 million in the second quarter (April-June 2023). For the third quarter (July- September 2023), the figures were $124 million with a cumulative total inflow of $464 million for the period of January-September 2023.  ]]> https://biospectrumindia.com/news/93/23955/tv-sd-invests-15-m-in-lab-training-centre-for-medical-devices-in-bengaluru.html https://biospectrumindia.com/news/93/23955/tv-sd-invests-15-m-in-lab-training-centre-for-medical-devices-in-bengaluru.html Thu, 14 Dec 2023 00:00:00 +0530 TÜV SÜD, a leading certification, testing, auditing, inspection and training company and the wholly-owned subsidiary of the TÜV SÜD Group, Germany, has inaugurated its new state-of-the-art facility 'TÜV SÜD Bengaluru Campus' for testing and certifying electrical and electronic products and medical devices to national and international standards in Bengaluru. 'TÜV SÜD Bengaluru Campus' was inaugurated at the hands of, Guest of Honour Friedrich Birgelen, Deputy Consul General, German Consulate General, Bengaluru; Dr Johannes Bussmann, TÜV SÜD CEO & Chairman of the Board of Management and the TÜV SÜD Global leadership team. The event was attended by over 100 key stakeholders from India's Electrical & Electronics, MedTech and other allied industries. The 'TÜV SÜD Bengaluru Campus' spans across 3 acres and comprises 70,000 sq. feet in Phase 1. It is designed by and utilises latest technology and building materials to be energy efficient, sustainable and has incorporated workspace design to enhance employee collaboration and wellbeing. This new integrated office, training centre and laboratory with an investment of EUR 15 million is in KIADB Hitech Defence and Aerospace Park, Devanahalli, Bengaluru and is TÜV SÜD's second lab facility in Bengaluru. The first one being the Food Analytical, Chemical & Microbiology laboratory in Peenya Industrial Estate. 'TÜV SÜD Bengaluru Campus' will provide testing facility for luminaries, home appliances, IT equipment, telecommunications equipment, automotive electronics, industrial electronics, machinery equipment, active medical devices, in vitro diagnostic devices, non-active medical devices and other electric components. ]]> https://biospectrumindia.com/news/93/23914/harmonising-indian-regulations-with-global-best-practices-to-propel-indias-medtech-sector.html https://biospectrumindia.com/news/93/23914/harmonising-indian-regulations-with-global-best-practices-to-propel-indias-medtech-sector.html Fri, 08 Dec 2023 00:00:00 +0530 The Medical Technology Association of India (MTaI), which represents leading research-based medical technology companies with a large footprint in manufacturing and training in India, recently hosted a high–level meeting with international delegates, government stakeholders, and MedTech industry captains at Shangri-La, New Delhi.  The event was graced by Aseem Sahu, Deputy Drugs Controller, Central Drugs Standard Control Organisation (CDSCO), and Abby Pratt, Senior Vice President, Advanced Medical Technology Association (AdvaMed). The discussion revolved around opportunities and current challenges within the MedTech domain including tariff and non-tariff barriers, friend-shoring opportunities, and streamlining of the regulations. Several strategic discussions also took place aiming to promote India as an attractive destination for investments from global as well as domestic players. During the event, the Deputy Drugs Controller stated that quality and patient safety are at the centre of any policy or related decisions that the government makes and is already working towards global harmonisation of standards, capacity building, and promoting innovation in MedTech space. Speaking at the event, Pavan Choudary, Chairman, MTaI stated, “We feel that domestic and international currents will together help carve out key policy recommendations which will be instrumental in furthering the MedTech industry in India." Adding to Choudary’s views, Abby Pratt, Senior Vice President, AdvaMed stated, “I really appreciate for this vital dialogue on the importance of harmonized regulations and global consensus standards. It is also reassuring to see the inclusive approach of the government to consult with industry on policy matters and regulations and offering association's cooperation to the government. The government-industry discourse underscores India's intent and its potential to emerge as a key player in the global MedTech arena."   Image caption- L-R- Sanjeev Sawhney, Managing Director, Medskin Suwelack; Abby Pratt, Senior Vice President, AdvaMed; Pavan Choudary, Chairman, MTaI; Aseem Sahu, Deputy Drugs Controller, CDSCO; Sanjay Bhutani, Managing Director, Bausch & Lomb India; and Nitesh Piplani, CEO, Steris India   ]]> https://biospectrumindia.com/news/93/23930/telerad-group-unveils-ai-based-solution-for-enhanced-pulmonary-embolism-detection-in-radiology.html https://biospectrumindia.com/news/93/23930/telerad-group-unveils-ai-based-solution-for-enhanced-pulmonary-embolism-detection-in-radiology.html Mon, 04 Dec 2023 00:00:00 +0530 Telerad Group, a leading global provider of remote radiology services, has unveiled a breakthrough artificial intelligence (AI)-based solution to assist radiologists around the world in their workflow and to improve accuracy and efficiency of Pulmonary Embolism detection. Pulmonary embolism (PE) is a grave medical condition that affects millions of people globally, occurring when a blood clot obstructs the arteries in the lungs, potentially leading to life-threatening consequences. The technology was launched at the Radiological Society of North America (RSNA), held from November 26-29, 2023. The revolutionary Pulmonary Embolism Assist (PE Assist) promises to reshape the global landscape of medical diagnostics used in the analysis of chest and thoraco-abdominal Computed Tomography angiography. PE Assist is designed to assist radiologists in flagging and communicating suspected positive findings of chest CT angiograms for pulmonary embolism, thus enabling quicker intervention and potentially saving lives. PE Assist utilises state-of-the-art artificial intelligence algorithms to analyze medical images, classify thrombus into four subclasses, and provide critical information about the presence or absence of right heart strain.  ]]> https://biospectrumindia.com/news/93/23891/indias-first-ircad-centre-to-establish-surgical-training-in-collaboration-with-saims-in-indore.html https://biospectrumindia.com/news/93/23891/indias-first-ircad-centre-to-establish-surgical-training-in-collaboration-with-saims-in-indore.html Mon, 27 Nov 2023 00:00:00 +0530 IRCAD India, a mirror institute of IRCAD France (Strasbourg), was inaugurated on November 24th in collaboration with Sri Aurobindo Institute of Medical Sciences (SAIMS) in Indore. This marks the establishment of the first Indian centre of excellence solely devoted to training and research & development in the realm of minimally invasive surgery. It adds to the existing Six IRCAD mirror institutes worldwide. IRCAD India is poised to become one of the world's largest animal and cadaver labs in the SAARC region, boasting 42 state-of-the-art stations equipped with robotics, 3D, and 4K technology. This cutting-edge facility will serve as a global hub, providing advanced training to surgeons from around the world in the latest surgical techniques. Dr Mohit Bhandari a renowned Indian bariatric surgeon globally known for his work in Bariatric and robot-assisted surgery will lead the centre as the President of IRCAD India. Speaking on IRCAD India’s vision Dr. Mohit Bhandari, President IRCAD India said, "Both the institutions will be able to share their expertise in the field of Artificial Intelligence (AI) and Augmented Reality (AR). Apart from this, surgical training of IRCAD will also be given in SAIMS, which will directly benefit the doctors and surgeons of Indore and entire India including SAARC countries. This collaboration anticipates the establishment of at least 20 new startups in India dedicated to producing medical devices for research and development." The signing ceremony for the joint venture witnessed the presence of Prof. Jacques Marescaux, the President of IRCAD Global, who expressed his admiration for the exceptional infrastructure and facilities at SAIMS.  Under the distinguished chairmanship of Dr Mohit Bhandari, the IRCAD India board features eminent individuals such as Dr Vinod Bhandari, Chairman IRCAD India, and Dr Mahak Bhandari, Vice President IRCAD India. IRCAD India is slated to commence operations in 2024. ]]> https://biospectrumindia.com/news/93/23874/act-for-health-collaborates-with-global-health-labs-to-support-indias-medtech-innovation.html https://biospectrumindia.com/news/93/23874/act-for-health-collaborates-with-global-health-labs-to-support-indias-medtech-innovation.html Thu, 23 Nov 2023 00:00:00 +0530 ACT, an Indian venture philanthropy organisation, and Global Health Labs, Inc. (GH Labs), an international non-profit funded by Gates Ventures, have announced their collaboration to jointly identify Indian digital and medical technology innovators and support development and scale of their digital health and medical technology innovations within India’s public healthcare system, with a view to positively impact the access to quality and affordable healthcare for underserved populations.  Inadequate infrastructure and a shortage of healthcare professionals in low-resourced areas in India are significant barriers to access to quality and affordable healthcare. The bold aim of this collaboration is to enable cutting-edge healthcare technology to traverse the divide and improve the quality of care across primary healthcare settings. Says Krisha Mathur, Director – ACT For Health, “Our collaboration with GH Labs will focus on bringing innovative health-tech solutions to the last mile, where they have the highest potential for impacting the underserved. The goal is to make a meaningful impact on the public healthcare system, in a way that bridges the accessibility to affordability gap on quality healthcare for Bharat.” ACT For Health and GH Labs will leverage their collective expertise and resources to offer technology assistance, conduct evaluations in public health settings, and explore pathways for scaling Indian health-tech innovations. The ultimate goal is to make a meaningful impact in communities where access to quality healthcare is a critical challenge. ]]> https://biospectrumindia.com/news/93/23856/lt-collaborates-with-nvidia-to-unveil-gen-ai-and-advanced-software-defined-architecture-for-medical-devices.html https://biospectrumindia.com/news/93/23856/lt-collaborates-with-nvidia-to-unveil-gen-ai-and-advanced-software-defined-architecture-for-medical-devices.html Mon, 20 Nov 2023 00:00:00 +0530 L&T Technology Services, a listed subsidiary of Larsen & Toubro, has announced a collaboration with NVIDIA to develop software-defined architectures for medical devices focused on endoscopy, which will enhance the image quality and scalability of products. This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components. The architecture is a scalable platform that supports multiple applications, providing a real-time decision-making tool for the medical fraternity. Developed from the ground up, the architecture boasts an image processing pipeline for noise reduction, edge and contrast enhancement, texture and color enhancement, and speckle correction. What sets it apart is its inclusion of artificial intelligence (AI)/ machine learning (ML) models developed for the detection, identification, and classification of polyps - abnormal growths often found during colonoscopies. The solution further impresses with its user-friendly interface and seamless integration of the image processing pipeline for visualization. It promises low-latency data transfer, superior image processing without performance bottlenecks, and scalability. The collaboration leverages the NVIDIA  Holoscan and NVIDIA IGX Orin platforms, featuring ultra-low latency in data transfer, superior image processing, and scalability to support multiple AI-enabled applications. This helps ensure enhanced visualization for image processing and AI-based decision-making support, such as for polyp detection and classification.   ]]> https://biospectrumindia.com/news/93/23850/mtai-advocates-for-integration-of-life-saving-medical-devices-for-spectators-during-cricket-matches.html https://biospectrumindia.com/news/93/23850/mtai-advocates-for-integration-of-life-saving-medical-devices-for-spectators-during-cricket-matches.html Fri, 17 Nov 2023 00:00:00 +0530 In a path-breaking move to prioritise spectator well-being at cricket matches, the Medical Technology Association of India (MTaI), which represents leading research-based medical technology companies with a large footprint in manufacturing and training in India, recently wrote a persuasive letter to both the International Cricket Council (ICC) and the Board of Control for Cricket in India (BCCI) advocating for the integration of life-saving medical devices near spectators as a safety measure. A report by Harvard Business School has indicated that the adrenaline rush, stress levels, and emotional fluctuations experienced by spectators at live sports matches can significantly increase the risk of cardiovascular events, brain strokes, etc. In their findings, they underscore the importance of timely access to life-saving medical interventions, such as defibrillators and ECG monitoring, as critical components of spectator safety protocols. The proposed integration includes advanced medical monitoring systems, emergency response equipment, and other cutting-edge technologies that can significantly enhance the ability to respond promptly to any health-related incidents in the crowd. Pavan Choudary, Chairman, Medical Technology Association of India said, “We propose that the cricketing landscape be made safe with the integration of state-of-the-art medical devices strategically placed within the spectator areas, creating a safety net that aligns seamlessly with the thrill of the game." Adding to Choudary's views, Dr O.P. Yadava, CEO & Chief Cardiac Surgeon, National Heart Institute & Director, All India Heart Foundation said, "The escalating prevalence of cardiac arrests among India's young population necessitates the integration of life-saving medical devices near spectators during live sporting events." Dr Ratna Devi, Director, Patient Academy for Innovation and Research & Chairwoman, ISPOR Patient Council stated, “This move could establish a new standard for public health at sporting events, setting an example for global best practices in ensuring the safety and well-being of diverse audiences."  ]]> https://biospectrumindia.com/news/93/23827/dr-d-y-patil-medical-college-launches-cochlear-implant-programme-for-children.html https://biospectrumindia.com/news/93/23827/dr-d-y-patil-medical-college-launches-cochlear-implant-programme-for-children.html Thu, 09 Nov 2023 00:00:00 +0530 In a groundbreaking move towards inclusivity and healthcare excellence, Dr. D. Y. Patil Medical College, Hospital & Research Centre has announced a significant milestone. Under the support of the Rashtriya Bal Swasthya Karyakram (RBSK) scheme, the institution recently launched a cochlear implant programme for deaf-mute children. Cochlear implant surgery is a medical procedure that can significantly enhance the quality of life for children with hearing disabilities. The first cochlear implant surgery took place on November 5, 2023, under the mentorship of Prof. Dr Hetal Marfatia, HOD, Dept of ENT, KEM Mumbai. Dr Vinod Shinde, a distinguished Professor in the Department of Otorhinolaryngology at Dr. D. Y. Patil Medical College, Hospital & Research Centre and Dr Mubarak Khan, an Adjunct Professor at the same department, provided invaluable assistance.  Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune is one of Maharashtra’s leading multi-specialty hospitals with various Centres of Excellence. The hospital is spread over 8,27,702 sq. ft. and is well-equipped with state-of-the-art healthcare infrastructure and life-saving latest medical technology. With 2000+ beds dedicated to different Specialties and ]]> https://biospectrumindia.com/news/93/23815/keralas-first-advanced-centre-for-neuro-endoscopy-surgeries-opens-at-amrita-hospital.html https://biospectrumindia.com/news/93/23815/keralas-first-advanced-centre-for-neuro-endoscopy-surgeries-opens-at-amrita-hospital.html Tue, 07 Nov 2023 00:00:00 +0530 Amrita Hospital, Kochi has launched Kerala's first Centre for Neuro Endoscopy, known as the Amrita Centre for Neuro Endoscopy (ACNE) for patients suffering from neurological and neurosurgical conditions. The centre brings together a dedicated team of experts from various specialties, including skull base endoscopy, cranial endoscopy, spine endoscopy, robotic endoscopy, and paediatric endoscopy, to provide comprehensive care in the field of endoscopic neurosurgery. The centre's specialisation within each division ensures highly targeted and effective treatments, promising the best possible outcomes for patients. The establishment of the Amrita Centre for Neuro Endoscopy (ACNE) marks a significant milestone in healthcare. It is the first Neuro-Endoscopy Centre in Kerala to provide comprehensive diagnostic and treatment services and aims to become a leading source for these services. The hospital aims to revolutionise deformative surgery by introducing advanced neuro endoscopy techniques, providing patients with improved, less invasive treatment options. This approach enhances patient outcomes, accelerates recovery, and minimizes risks, elevating specialized medical care. The collaboration between the Department of Neurosurgery, ENT, and Head and Neck Department has set an exemplary standard of care for brain and head and neck disorders treated through endoscopy. Amrita Hospital in Kochi is one of the few hospitals in India that has established a dedicated centre for Neuro and Endoscopy surgeries. ]]> https://biospectrumindia.com/news/93/23804/medtech-startup-instashield-signs-mou-with-montgomery-county-for-us-expansion.html https://biospectrumindia.com/news/93/23804/medtech-startup-instashield-signs-mou-with-montgomery-county-for-us-expansion.html Mon, 06 Nov 2023 00:00:00 +0530 Instashield, a medical device technology startup in Hyderabad, has signed a Memorandum of Understanding (MoU) with Montgomery County, Maryland, USA. This significant agreement was made possible with the support of the US India SME Council during the Economic Development Trade Mission to India. The mission, led by Marc Elrich, County Executive of Montgomery, MD, and Elisha, CEO of the US India SME Council, involved more than 25 business and government leaders from the United States. The MoU signing took place at the US India SME Council Annual 2023 Incredible Inc 50 event in Hyderabad.  Instashield's revolutionary medical device technology is designed to disable a wide range of viruses and fungi. This innovative device has received validation from the Centre for Cellular and Molecular Biology (CCMB), Government of India, and is the world's first of its kind to effectively neutralise various viruses. Instashield emits hypercharge high-velocity electrons that strategically target the s-protein of the corona family of viruses, significantly reducing infectivity and curbing air and surface-borne transmission. The device generates an electron cloud across enclosed spaces, providing coverage over vast areas, starting from 5,000 square feet, and activates within just 18 minutes. This patented technology is certified by accredited labs and ensures safety for both human occupants and the environment. The startup has already made a successful entry into the Indian market in 2021 through various channels, including distributors, institutions, hospitals, pharmacies, and online platforms like Amazon. In recognition of its ground-breaking innovation, Instashield was awarded as the fast-growing Medical Device Technology company during the event.  ]]> https://biospectrumindia.com/news/93/23783/aimed-drisp-join-hands-to-promote-medical-device-industry-in-india-and-russia.html https://biospectrumindia.com/news/93/23783/aimed-drisp-join-hands-to-promote-medical-device-industry-in-india-and-russia.html Wed, 01 Nov 2023 00:00:00 +0530 In a significant move aimed at giving a further boost to robust and long-standing trade relationship between India and Russia, Association of Indian Medical Device Industry (AiMeD) and Centre for the Development of Russia Strategic Partnership (DRISP) have joined hands for taking the medical device industry in two countries to greater heights of growth. “The Memorandum of Understanding (MoU) signed between DRISP and AiMeD assumes significance as the leaders of India and Russia have outlined their aim of achieving a $30 billion mark in mutual trade by 2025, thus continuing with a dynamic and multifaceted economic engagement, guided by shared interests and a commitment to further deepen bilateral cooperation and our two organisations will contribute in our own humble manner in line with that objective,” said Rajiv Nath, Forum Coordinator, AiMeD. The MoU assumes significance as India is fast emerging as a key supplier of medicines, car and machine parts, textiles and clothing, and food products to Russia. According to St Petersburg International Economic Forum (SPIEF), India-Russia trade hit a record $39.8 billion in 2022–23.  Talking about the MoU, Prasun Prakash, Public Affairs Director, DRISP, said that AiMeD and DRISP Russia would exchange information on economic and commercial matters, that is, trade, investment and technology transfer opportunities as well as trends. “AiMeD will provide free online access to its web based services, except for those sectors, which are priced, for all users,” he said.  According to Nath, AiMeD and DRIPS Russia would cooperate in supporting workshops, courses, conferences, and trade fairs organised in both the countries based on sectors and topics of mutual interest, and facilitate networking among the companies of both the countries through their established mechanisms. AiMeD will offer a business-to-business matchmaking bridge role with regard to the promotion of technology and investment tie-ups to companies based in Russia on a cost basis. Similarly, DRISP Russia will assist AiMeD members in their business endeavours.   ]]> https://biospectrumindia.com/views/93/23754/future-of-medical-refrigeration-looks-promising.html https://biospectrumindia.com/views/93/23754/future-of-medical-refrigeration-looks-promising.html Tue, 31 Oct 2023 00:00:00 +0530 The exceptional growth in the healthcare industry today is driven by several factors such as a surge in chronic illnesses, the government’s initiatives to improve healthcare infrastructure, and increased investments in the sector. Consequently, the medical refrigeration device market in India has also seen commensurate growth in recent years. With the ever-growing demand for healthcare services and the need for proper storage and transport of medicines, vaccines, and blood products, the market for medical refrigerators has also expanded rapidly. Growth The market for medical refrigeration devices in India is growing for several reasons. There is a rise in the number of clinics and hospitals, along with a growing population, resulting in a boost in the demand for these devices to store blood, medications, vaccines, and other essential medical supplies. It has increased the need for refrigeration devices with cutting-edge temperature-control capabilities. Technical advancements in the medical industry have made these devices more refined, efficient, and more appealing to buyers. As a result, India is presently experiencing rapid growth in the medical refrigeration market.In addition, the number of medical and pharmaceutical products that require precise temperature conditions is increasing significantly especially in fields such as oncology. Research published by Benzinga has shown that India’s medical refrigeration device market has been growing at an average rate of 8.5 per cent. In 2017, the revenue for medical refrigeration devices in India was nearly $10.4 million. Medical refrigerators play a critical role in preserving the integrity of temperature-sensitive medical resources. However, they come with their own set of challenges.   Challenges The Medical cold chain industry in India suffered from high capital costs, outdated technology, opaque networks, lack of skilled resources, poor reverse logistics, and extensive complexity. Some of the major challenges that we face in the medical refrigeration industry are: Lack of Awareness:There is a general lack of awareness regarding the importance of maintaining the intended temperature of medicines, drugs, vaccines, and other biologics. Especially during transportation resulting in the spoilage of critical and expensive medical resources. There is also a general attitude where people mistakenly think that a domestic household refrigerator can do the work of a medical refrigerator. Temperature Precision: Maintaining precise temperatures required for various medical products, such as vaccines, blood samples, and medications, can be challenging due to fluctuations. Energy-efficient and Sustainable systems: Medical refrigeration devices can be energy-intensive, leading to high operational costs and environmental concerns especially ones that use non-green refrigerants. Regulatory Compliance: The healthcare industry is subject to stringent regulations related to medical refrigeration to ensure patient safety. Compliance can be complex and demanding. Despite that in India there are many gaps in the policies and guidelines that allow substandard local players to operate in the market.   Overcoming challenges This growth is predominantly attributed to the growing adoption of energy-efficient and precise cooling strategies within the biomedical refrigerators and freezers industry. However, addressing the various challenges in this field requires a multifaceted approach. Awareness and training programmes are the need of the hour to ensure the best practices are followed during storage and transportation of valuable medical samples and resources. Advanced control tech minimises fluctuations to maintain precise temperatures, ensuring safe medical storage. Energy efficiency is crucial, encouraging eco-friendly refrigerants in cost-effective devices, reducing costs, and aiding conservation. Meeting regulatory compliance is vital. Streamlined processes, simplified requirements, and strict adherence are essential for product safety. Raising awareness about low-temperature importance is key.   Government’s initiatives The government's initiatives and policies profoundly influence the accessibility and affordability of healthcare services for individuals and communities. By implementing initiatives that prioritise healthcare innovation and research, the government can foster a conducive environment for advancements in medical technology and treatments. Temperature Control Protocols: In India, regulations ensure that these temperature-sensitive products are stored and transported at the optimum temperatures to maintain their efficacy and safety. However, these regulations have room for improvement to make them more robust and effective. These include setting clear standards for temperature control, monitoring, and compliance to prevent product spoilage or degradation. Investments to Strengthen Medical Cold-Chain Infrastructure: Investments are needed to strengthen the Cold-Chain infrastructure to ensure medical products remain safe and effective. These include upgrading storage and transportation facilities, adopting advanced temperature monitoring and control technologies, and providing training for healthcare personnel involved in handling these products. These investments are crucial to guarantee the integrity of medical supplies and contribute to better healthcare services in India. These regulations and investments can help drive positive change in the healthcare market and improve the overall quality of healthcare services.   Environmental considerations Do you know these medical refrigeration machines can greatly impact the environment? They consume a lot of energy and sometimes refrigerants that are not so friendly to the planet. Medical refrigeration has a substantial environmental footprint, primarily due to energy consumption and the use of harmful refrigerants. However, the healthcare industry is actively pursuing eco-friendly alternatives like hydrofluoroolefins (HFOs) and natural refrigerants such as CO2 and hydrocarbons. These choices emit fewer greenhouse gasses, promoting environmental sustainability. Technological advancements, including efficient compressors and insulation materials, contribute to energy savings in refrigeration. Moreover, solar-powered refrigeration solutions, like those offered by B-Medical Systems, are emerging as eco-friendly alternatives, especially in hot climates and remote areas with inconsistent power supply. These systems benefit the environment and reduce operational costs for healthcare facilities.   Outlook Recent advancements in medical refrigeration technology are transforming healthcare. IoT sensors have become increasingly common in cold-chain equipment. These are small devices embedded in cold-chain equipment such as refrigerators, freezers, and shipping containers. These sensors can measure temperature, humidity, and other environmental conditions and transmit that data to a central system. Our investments and collaborative efforts aim to raise the bar for temperature control standards, ensuring the safety and efficacy of medical supplies and vaccines nationwide. Moreover, artificial intelligence algorithms analyse data from refrigeration units, detecting potential issues in real-time for proactive maintenance and preventing spoilage. These advancements also enable predictive analytics, optimise inventory management, and ensure timely restocking of essential supplies. Due to these developments, the future of medical refrigeration looks extremely promising.   Jesal Doshi, Director, Board of Medical Technology Association of India (MTaI) ]]> https://biospectrumindia.com/news/93/23730/ge-healthcare-and-novo-nordisk-to-advance-novel-treatment-for-t2d-and-obesity-with-ultrasound.html https://biospectrumindia.com/news/93/23730/ge-healthcare-and-novo-nordisk-to-advance-novel-treatment-for-t2d-and-obesity-with-ultrasound.html Thu, 19 Oct 2023 00:00:00 +0530 US-based medtech firm GE HealthCare has announced a collaboration with Danish multinational pharma company Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound (PFUS). This is a novel technology that has potential to specifically regulate metabolic function in the body using ultrasound that may support the treatment of chronic diseases such as type 2 diabetes and obesity. PFUS is a non-invasive type of bioelectronic medicine that uses ultrasound to activate the nervous system to stimulate a response that may be able to treat disease. Pre-clinical proof of concept and initial early-stage clinical research suggests that it may impact glucose metabolism in people with diabetes via personalised ultrasound stimulation of nerve pathways. If validated with further clinical evidence, PFUS could represent a non-pharmacologic approach to normalize blood glucose levels in people with type 2 diabetes. The existing technology was developed by a team of scientists at GE HealthCare’s HealthCare Technology and Innovation Center, formerly part of the GE Research Center. As part of the collaboration, GE HealthCare and Novo Nordisk will contribute their respective expertise in ultrasound medical technology and metabolic disease treatment and management as both parties work together to develop a PFUS solution to improve patient care, building upon the extensive foundational research done to date by the GE HealthCare team. ]]> https://biospectrumindia.com/news/93/23693/govt-launches-global-health-innovation-fellowship-to-promote-medtech-sector.html https://biospectrumindia.com/news/93/23693/govt-launches-global-health-innovation-fellowship-to-promote-medtech-sector.html Sat, 14 Oct 2023 00:00:00 +0530 Union Minister for Science and Technology, Dr Jitendra Singh presided over the launch of the DBT and World Intellectual Property Organization (WIPO) supported Global Health Innovation Fellowship to promote medtech startups and innovators among youth. The Minister informed that the Department of Biotechnology (DBT) and WIPO fellowships will be implemented in the DBT Bio-design centres at IIT Delhi and AIIMS, New Delhi; IIT-B and Hinduja and Nanavati Hospital, Mumbai. Lauding the efforts of the DBT and WIPO, Dr Jitendra Singh remarked, “This is a flagship partnership and must be strengthened to enable India attain global leadership in innovation and startup promotion”. WIPO has initiated a formal collaboration with the DBT to support four WIPO-supported Fellows to participate in the DBT Bio-design Programme. The partners received 157 applications from young professionals across the world including low- and middle-income countries. DBT has scaled up Biodesign programme by twinning over 20 medical and technical institutions across the country and World Intellectual Property Organization (WIPO) has recognised this program for support under their Global Health challenges initiative. Dr Rajesh S. Gokhale, Secretary, Department of Biotechnology, Government of India said “This partnership will enable us to co-develop national, regional and global institutional capacities of innovators across regions to collaboratively address global health challenges, including by promoting Global South-South cooperation”. ]]> https://biospectrumindia.com/news/93/23652/medical-cobotics-centre-opens-in-delhi-to-foster-innovation-in-healthcare.html https://biospectrumindia.com/news/93/23652/medical-cobotics-centre-opens-in-delhi-to-foster-innovation-in-healthcare.html Sat, 23 Sep 2023 00:00:00 +0530 iHub Anubhuti-IIITD Foundation (Technology Innovation Hub of IIIT-Delhi) and iHub Foundation for Cobotics (IHFC, Technology Innovation Hub of IIT Delhi) recently inaugurated their joint medical facility, ‘MCC-Medical Cobotics Centre’ on the Indraprastha Institute of Information Technology (IIIT) Delhi campus. Dr Akhilesh Gupta, Secretary, Science and Engineering Research Board (SERB) and Sr. Advisor, Department of Science and Technology (DST), Government of India, was the chief guest on this occasion. The DST has funded this joint facility to be operated by iHub Anubhuti and IHFC under the National Mission on Interdisciplinary Cyber-Physical Systems (NMICPS). The Medical Cobotics Centre is aimed at being India’s first state-of-the-art technology-enabled medical simulation and training facility for doctors, paramedics, technicians, engineers, biomedical researchers, and entrepreneurs. The Centre is also equipped to offer hands-on simulation training to the medical fraternity across the country. The training programmes, ranging from basics to advanced, will be designed in consultation with leading doctors and experts, mainly drawn from the All India Institute of Medical Sciences (AIIMS). The Centre will also act as a test bed for many young startups in the medical field that are developing innovations in medical technology in digital medical healthcare and healthcare using AR/VR, AI, cobotics, robotics, cognitive sciences, and such. The MCC has launched its first 'Call for Proposal' for young startups, with funding up to Rs 1 crore available in digital healthcare and medical healthcare using the above application areas. ]]> https://biospectrumindia.com/news/93/23600/amwc-india-2023-defines-roadmap-shaping-indias-aesthetic-medicine-industry-with-projected-13-cagr.html https://biospectrumindia.com/news/93/23600/amwc-india-2023-defines-roadmap-shaping-indias-aesthetic-medicine-industry-with-projected-13-cagr.html Sat, 16 Sep 2023 00:00:00 +0530 The Aesthetic and Anti-Ageing Medicine World Congress (AMWC) India 2023, the inaugural Indian edition of the globally renowned AMWC event series, made its debut recently in Mumbai. This annual groundbreaking event, organised by Informa Markets in India, is reshaping India's Aesthetic Medicine Industry in the coming years.  Fostering knowledge exchange, networking, innovation adoption, and industry growth while ensuring safe and high-quality patient care, AMWC India is playing a crucial role in advancing the aesthetics and anti-ageing medicine industry in India. The inaugural ceremony of the debut show was marked by the presence of international and domestic experts, including Dr Woffles Wu (Singapore), Dr Chytra Anand (India), Dr Jamuna Pai (India), Dr Anjali Mukherji, Dr Gopinath Shenoy, Mandira Bedi, Dr Ryan Fernando, Yasmin Karachiwala along with Yogesh Mudras, Managing Director, Informa Markets in India and Rahul Deshpande, Sr Group Director, Informa Markets in India. AMWC India is an extension of the globally renowned Aesthetic & Anti-Ageing Medicine World Congress (AMWC) that originated in Monaco in 2003.  Key exhibitors such as Allergan Healthcare, Aakaar Medical Technologies, BNC Global, ExoCoBio,  Benev Eunsung Global, Dermakor, A.Menarini India, BTL Aesthetics, Spectra Medicals, Leader Healthcare India and many more made their presence felt amidst the attendees, including aesthetic practitioners, dermatologists and plastic surgeons.  Emphasising on India’s evolving medical aesthetics landscape Dr Chytra Anand, Founder of Kosmoderma & SkinQ Dermacare and President of the Indian Academy of Aesthetic Doctors said “The Indian Medical Aesthetic Devices Market is expected to reach $2.67 billion by 2028, with a CAGR of 13.28%. This growth is driven by factors like increasing obesity prevalence, which is projected to reach over 16% by 2040, leading to a surge in demand for body sculpting and cellulite treatment procedures. Furthermore, the India Anti-Ageing market is set to grow at a CAGR of 9% from 2023 to 2028.” The conference programme and live streaming sessions, crafted by experts spanning diverse aesthetic and anti-ageing domains, covered a wide spectrum of topics on its opening day. These encompassed sessions such as 'Injecting Confidence: Exploring the Latest Innovations & Techniques in Aesthetic Injectables'; 'Unmasking the Science of Pigmentation: Investigating the Latest Breakthroughs in Treatment & Management’, to name a few.   ]]> https://biospectrumindia.com/features/93/23592/advanced-robotic-technology-revolutionising-healthcare-in-unprecedented-ways.html https://biospectrumindia.com/features/93/23592/advanced-robotic-technology-revolutionising-healthcare-in-unprecedented-ways.html Thu, 14 Sep 2023 00:00:00 +0530 It is 10 in the morning, and the Operating Room (OR) at Max Hospital, Saket is abuzz with surgeons' chit-chat. The patients are being wheeled into the ORs on the second floor of the gastro-intestinal and general surgery department. Three patients are to undergo surgeries – two for removal of the gall bladder and one for hernia repair.  One of them is in his forties. He had been admitted for severe abdominal pain caused by gallstones blocking his bile duct. Dr Pradeep Chowbey, a renowned gastric surgeon, and chairman, Max Institute of Laparoscopic, Endoscopic & Bariatric Surgery, was at the console of the Versius, a next-generation surgical robotic system developed by CMR Surgical, a Cambridge-based company. The 70-year-old doctor’s team had already inserted the surgical arms of the Versius into the patient's body through three small incisions.    Dr Chowbey could see a three-dimensional image of the gallbladder and its surroundings on the large screen attached to the console. His wrists firmly rested on the console, providing adequate support to his elbows, as he navigated the complex procedure. The gallbladder is nestled within fat deposits, with two major blood vessels tangled around it. He enlarged the area he needed to operate on, and with fine precision, untangled and clipped the blood vessels. Then, without making any extra incisions or touching the patient's liver, which was adjacent to the gallbladder, he excised the gallbladder and removed the gallstones protruding from the bile duct. In a mere 10 minutes, Dr Chowbey completed the procedure with unmatched precision.  "That's the beauty of robots. They provide me with an entire 3D view of the organ, allowing me to operate without causing any damage to the surrounding tissue. This not only ensures a quicker recovery for the patient but also results in significantly less pain compared to conventional and laparoscopic surgery." said Dr Chowbey (seen in the image below) as he moved to the next OR for his second surgery of the morning.      His technician folded the console and wheeled it into the next OR. "See, it's portable, allowing us to reduce the time spent preparing the OR after we wheel out the previous patient after surgery. By the time I finish one surgery, my team in the operating room is already preparing the next patient. We use the device so efficiently that its cost to the patient is almost the same as that of laparoscopic surgery."  Advanced robotic technology is revolutionising healthcare in unprecedented ways, constantly evolving to meet the increasing demands of the medical field. These robots are not only reducing risks in complex surgeries but also helping patients in their rehabilitation, dispensing medications, and even preventing fall when patients are alone. This technology is gaining popularity among thousands of medical professionals across India, including those in Tier-2 and Tier-3 cities.  According to a report by BIS Research, a technology research and advisory firm, the Indian surgical robotics market is expected to experience significant growth, with an estimated compound annual growth rate (CAGR) of 20% between 2017 and 2025. This growth is projected to result in a market value of $350 million, a substantial increase from the $64.9 million in 2016.  The first surgical robot, Da Vinci , made by California-based company Intuitive, arrived  at Apollo Hospital, Delhi  in 2002. However, the adoption of robotic surgeries in private hospitals in the National Capital Region (NCR) can be traced back to 2015-2016. In 2018, the number of robotic surgeries across various specialities such as urology, general surgery, gynecology, and pediatrics saw an increase of around 50% compared to 2016. The adoption of robotic technology picked up across India post-Covid.  Mandeep Singh Kumar, Vice President and country GM, Intuitive Surgicals (as seen in the image below) says, “The robotic-assisted surgery (RAS) market is rapidly expanding in India. The growth is driven by an increased interest among surgeons to adopt technology to deliver improved clinical and patient outcomes.”        While hospital networks and teaching institutions in larger cities  led the early adoption of RAS, now,  he says, there is growing adoption across wide range of customers across all geographies, including large hospital networks, government tertiary care and teaching institutions, independent private hospitals, and state government hospitals. “India has over 800 robotic-assisted trained surgeons working across 125 plus  da Vinci surgical programs focused on wide ranging specialties,” he adds.   A typical robot employed in abdominal surgeries features four arms. While three are dedicated to holding various surgical instruments, the fourth is equipped with a 3D camera. The three instrument-holding arms  are controlled by a computer and mimic the precise movements of the surgeon, who operates the system from a nearby console. The surgeon can closely monitor and control the surgical procedure on a high-definition 3D screen connected to the robotic system. This screen offers a detailed view of the organ being operated on.  CMR Surgical launched its next-generation Versius in India in 2019. In just two years, the company has successfully deployed its robotic systems in 38 hospitals across India and has trained over 300 surgeons in robotic surgery.   “Indian hospitals, including those located in Tier-2 and Tier-3 cities such as Lucknow, Nagpur, Ghaziabad, and Faridabad, have enthusiastically adopted this technology. Surgeons are happy because these advanced machines allow them to perform complex surgeries with greater ease and precision” says Pradeep Singh, Commercial Head  for CMR Surgical in South Asia.  What is making robotic surgery so popular among surgeons is the fact that robotics has significantly reduced human labour and increased efficiency. "Robotic-assisted surgeries allow surgeons to perform more procedures in a shorter amount of time, increasing the capacity of healthcare facilities to serve more patients," says Dr Chowbey.  Patients also benefit as  surgical robots enable minimally invasive procedures, resulting in shorter hospital stays, reduced recovery times, and lower healthcare costs. Some healthcare centres are also using robots for tasks like drug dispensing, laboratory analysis, and sterilization.  The ability to operate in difficult-to-reach areas in the human body is another advantage. "We have used it for spine surgery for three years, a procedure where it is difficult to reach certain areas of the spine. Spine surgeries require extreme precision as the spine is surrounded by blood vessels and nerves. When we feed the patient's CT scan into the robotic system, using AI, the robot skilfully navigates the intricate spinal regions with utmost safety, reducing tissue trauma and leading to quicker recovery," explains Dr Rajesh Malhotra, a noted orthopaedic and spine surgeon at Apollo hospital, Delhi.    “It provides a sense of relaxation to the surgeon by alleviating both physical and mental strain. It's like a periscope. Just as one can see outside from a submarine using a periscope, robotics allows you to see areas behind the organ, significantly improving our reach and access during surgery” says Dr Malhotra.  Robotics also provides a personalised fit for joint replacements, minimising errors significantly. Dr Malhotra explains, "In hip and knee replacements, there can be a margin of error of up to 3 degrees, but with a robot, we can virtually eliminate these outliers.  There are two types of robotic systems—automatic and semi-automatic. In automatic robots, you feed the data, and the robot handles the entire process. In semi-automatic ones, the robot positions itself, but the actual surgical cut is made by the surgeon. It is like flying a plane in autopilot mode. So, the planning is done by the surgeon, but the execution is by the robot", says Dr Malhotra. “This technology allows for precise and tailored joint replacements, enhancing patient outcomes.”     Robotics in orthopedic surgery are fast gaining popularity  Cuvis joint robotic system, for example,  has been deployed in 62 hospitals across India. Apart from allowing surgeons to study the multi-dimensional image of the bone and tissue, its AI algorithms help position its arms. “It handles 90-95 per cent of the surgical work autonomously, always seeking validation from the surgeons before executing each step. This cutting-edge technology costs approximately Rs 5 crore", says Navish Bagla of Meril, which markets Cuvis joint robotic system, a South Korean brand, in India.  So, can robots replace human intervention in surgeries in the coming years? "The technology should never be our master,” says Dr Malhotra. “Even with automatic robots, the surgeon's role in planning and decision-making constitutes a significant 90 per cent of the surgical process. Robotic technology is a valuable tool that enhances precision in procedures like fixing osteoporotic fractures, trauma cases, and knee and hip implants. It should only be a supportive element to human expertise and judgment in healthcare”.  Agrees Dr Yash Gulati, advisor,  Orthopedics, Apollo Group (as seen in the image below), who has been using Mako Stryker, a semi-automatic robot for knee and hip replacement surgeries for the past couple of months. “It ensures that the amount of bone that needs to be removed is much less, the soft tissue handling is better, and the alignment of the implant is near perfect when compared to a traditional surgery,” he says.          Statistically, orthopaedic implants are successful in 85 percent of cases, he explains, which is considered a good success rate. “But our aim is to achieve 100 per cent success rate. Some patients experience niggling pain or discomfort even after a successful surgery. The longevity of an implant depends on how accurately it is fitted in the body and how closely it replicates the original tissue,” he says, adding , “All human beings are different, and similarly, the anatomy of the knee and hip of all individuals is different. What we have been doing conventionally is taking an average size and positioning and making the implants accordingly. With robots, we do a CT scan to  determine the exact size and angle for implant placement. This allows us to  pinpoint the patient’s original axis, and the implant can be precisely tailored to mimic it. The result is a near-perfect alignment”, says Dr Gulati.   Robots, says Dr Prasoon Kamra, Director, Department of Orthopedics, Sarvesh Hospital, Hissar, (as seen in the image below) have changed his perception of a successful surgery. “It has been only a couple of months since I started performing surgeries using robotic technology. I have done hundreds of successful surgeries and my patients have been highly satisfied with the outcomes, but  I believe that robotic surgical system has further improved the precision, with significantly better  surgical outcomes,” says Dr Kamra.      However, there is one major concern with the use of robotics in surgeries—the high cost of surgery for patients. The robotic solutions are expensive and the cost is indirectly passed on to the patients. A basic robotic system for abdominal procedures, including those in gastro-intestinal, gynaecology, urology, and others, costs between Rs 10 crore and Rs 15 crore, and annual maintenance can be around Rs 4.5 lahk. The high cost makes the technology unaffordable for many smaller surgery centres and public healthcare facilities.  “The only way to bring down the cost of robotic surgeries is to use these machines for as many surgeries as possible. When more surgeries are conducted, the cost per surgery automatically comes down," explains Dr Kamra. “The good thing is most patients know the advantages of robotic surgery and are comfortable spending a little extra for the safety it offers. As a result, now the difference between laparoscopic surgery and robotic surgery is less than 20 percent.”  Besides, the robotic companies are making flexible robots which allows hospitals and surgeons to buy robots according to their specific needs. For example, made-in-India Mantra robots by SS Innovations,  feature 5 arms, each mounted on a separate cart. “Most surgeons typically require three to four arms, which brings down the cost for them. Besides, we offer hospitals easy payment plans, allowing them to maximize the benefits of robotic solutions without imposing excessive financial burdens on their patients,” says Dr Sudhir Srivastava, founder of SS Innovations (as seen in the image below).        Experts express optimism about the future of surgical robotics in India. Dr Seema Grover, chief, physiotherapy and rehabilitation, at Apollo Hospitals in Delhi, says robotics holds a lot of  potential in the rehabilitation of stroke-affected patients. “ The process of rehabilitating a paralyzed patient often involves creating alternative neural pathways in the brain using brain plasticity. Robotics in physiotherapy plays a pivotal role in facilitating this recovery journey,” she says.      So, how does it work?    Dr Grover explains that the brain relies on receiving stimuli for its proper function. In cases where nerve cells have died or are in a state of spasm, as is often the case with paralyzed patients, the brain doesn't receive the necessary stimuli. "Repetitive movement of a body part may eventually generate alternate pathways to communicate with the brain. However, achieving this level of movement manually is not possible. Robots play a crucial role in facilitating this process. Moreover, they also help in repositioning bed-ridden patients,"  says Dr Grover.  Dr Ashish Dutta, a professor in the Department of Mechanical Engineering at IIT Kanpur, is the innovator behind a ground-breaking wearable exoskeletal robot, which operates in tandem with a brain-computer interface, marking a significant advancement in the field of robotics and assistive technology.  The patient wears the exoskeleton on the affected hand, observes the movement on a computer screen and tries to mimic it using the robot. Physiotherapy, he explains, is the primary method for restoring movement in a stroke patient. Stroke can affect the part of the brain that controls movement in a specific part of the body. Through physiotherapy, continuous stimuli are sent to the brain , prompting it make alternate pathways for communication between the brain and the affected limb.  “But it is crucial that these movements are performed with conscious effort. If the patient is distracted or engaged in other activities, the effectiveness of these movements may be diminished.  With our rehabilitative robot, the patient has to focus on the computer screen and mimic the movement. During our clinical trials in India and the UK, we have seen a 100 per cent recovery in patients who previously showed no recovery with manual physiotherapy,” says Prof Dutta. The device is set to undergo further clinical trials involving a larger patient population before it is introduced to the market.   “The entire solution, which costs only about Rs 2.5 lakh, could be a game changer for stroke patients across the world,” says Dutta. “There are many other robotic solutions being developed across Indian engineering colleges for various other health conditions. Soon we are going to see a revolution in healthcare robotics.”  A range of robotic solutions are being developed and tested in diagnostics and imaging-- for biopsies, endoscopy, ultrasounds, etc.   Several robotic solutions are currently under development and undergoing testing in the field of diagnostics and imaging, spanning a range of medical procedures, including biopsies, endoscopy, ultrasounds, and more.   “The future of robotic surgery systems holds the potential for surgeons to perform procedures on patients in a separate sterile environment without any direct human contact or interference,” says Dr Srivastava. “Mixed reality, the convergence of virtual reality and robotics, enabling surgeons to perform surgeries while simultaneously viewing the patient's anatomy and scans, is not far."  Dr Mahendra Bhandari, director of Robotic Surgery Research at Henry Ford Health System in Michigan, USA, and CEO of the Vattikuti Foundation, a non-profit organisation dedicated to advancing robotic surgery in India, believes that robotics in healthcare will experience significant growth. This growth, he points out,  will be driven by several factors, including the availability of a variety of surgical robots from multiple vendors, an increasing number of trained doctors, and the commitment of both government and corporate hospitals to invest in surgical robots.   “Surgical robots are now being used in newer medical specialities like joint replacement and coronary artery bypass grafting. With the availability of robots from at least half a dozen manufacturers the cost of surgeries is bound to go down,” he says.    Agrees Dr Vivek Bindal, who started Indian chapter of Clinical Robotic Surgery Association, the USA in 2019, “New training facilities are coming up to provide robotic surgery skills to hundreds of surgeons. This training will enable these surgeons to deliver better outcomes to patients, ultimately increasing access to high-quality medical care and reducing costs,” he says.      Click here for an exclusive conversation with Dr Sudhir Srivastava, founder of SS Innovations    Gunjan Sharma    gunjan.sharma@mmactiv.com ]]> https://biospectrumindia.com/news/93/23564/pune-based-startup-alveofit-receives-us-fda-clearance-for-alveoair-spirometer.html https://biospectrumindia.com/news/93/23564/pune-based-startup-alveofit-receives-us-fda-clearance-for-alveoair-spirometer.html Thu, 07 Sep 2023 00:00:00 +0530 Alveofit (Roundworks Technologies Private Limited), a Pune-based startup, has announced that its groundbreaking product, alveoair spirometer, has earned US FDA clearance for distribution in the United States. Specialising in digital therapeutics for respiratory care, the company is committed to delivering affordable and interoperable lung health solutions. Alveoair offers real-time, valuable insights to healthcare professionals, enabling timely interventions in respiratory care. This US FDA approval, coupled with strategic partnerships like the one with AstraZeneca, positions alveofit for broader international expansion, particularly in the US and emerging economies.  Since achieving Central Drugs Standard Control Organisation (CDSCO) certification in India in June 2022, alveoair has been adopted by over 400 healthcare facilities across India. Partnerships with organisations like India Sweden Innovation Centre (ISIHC), NASSCOM COE, PATH, Forge Innovation & Ventures, and DST have helped positively impact the lives of thousands of patients. Furthermore, Alveofit collaborates with prominent academic institutions such as AIIMS Delhi for clinical research and has formed an alliance with Tatvacare to extend digital respiratory care solutions to patients' homes. Earlier this year, to cater to the growing US market, Alveofit inaugurated its office in New York. ]]> https://biospectrumindia.com/features/93/23509/will-3d-bioprinting-turn-disruptor-in-healthcare.html https://biospectrumindia.com/features/93/23509/will-3d-bioprinting-turn-disruptor-in-healthcare.html Fri, 01 Sep 2023 00:00:00 +0530 3D bioprinting has been in focus these days with healthcare professionals, researchers taking interest on how the technology can impact the overall healthcare scenario. It is an application of additive manufacturing techniques to live cells, growth factors and/or biomaterials to fabricate biomedical parts, to mimic natural tissue characteristics. 3D bioprinting covers a broad range of bioprinting techniques and biomaterials. Currently, bioprinting can be used to print tissue and organ models to help research drugs and potential treatments. According to various bioprinting market reports, the global 3D bioprinting market is currently valued at $1.3 billion as of 2022 and is projected to reach $3.3 billion by 2027. And there is a huge demand seen in the pharmaceutical and cosmetology industries. The technology is being used to create living tissues such as blood vessels, bones, hearts, skin etc. It is anticipated that 3D bioprinting is likely to revolutionise the healthcare space in two main ways. Firstly by creating organ models which can be used for preclinical testing of drugs and other interventional molecules. Secondly by creating organ scaffolds that can be used for clinical transplantation. Additionally, 3D bioprinting is a step towards personalised medicine because, unlike conventional organ transplantation, the 3D printed tissue substitutes can be customised for the individual case.   Role of academics and research activities The concept of 3D is slowly gaining momentum in India and most of the current efforts in the country are being pursued in academic and research labs such as the Indian Institute of Science (IISc), Indian Institutes of Technology (IITs), National Institutes of Technology (NITs), Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) and other universities such as Shanmugha Arts, Science, Technology & Research Academy (SASTRA), Vellore Institute of Technology (VIT), etc. These efforts are still in the research stage. A major boost to the 3D bioprinting technology ushered in when CELLINK, a global leader in developing 3D bioprinters and IISc partnered to establish a Centre of Excellence (CoE) for 3D bioprinting in Bengaluru. The CoE, the first-of-its-kind in the sub-continent, will be housed in the Centre for BioSystems Science and Engineering (BSSE) at IISc. The CoE will provide access to 3D bioprinting systems, enabling researchers to accelerate their work across critical applications with the ultimate goal of improving health outcomes. The new CoE will house several state-of-the-art 3D bioprinters from CELLINK and will serve as a hub for several research initiatives and training activities within this emerging and exciting technology. IISc and CELLINK will work together to conduct workshops aimed at providing researchers within the institute, and elsewhere, the skills necessary to utilise 3D bioprinting within their work and reap the benefits of 3D cell culture. The two groups will undertake and advise on research projects across multiple applications spanning the fields of tissue engineering, drug discovery, material science and regenerative/personalised medicine. The CoE will have a keen focus on work around the heart, bone, cartilage and cancer. Apart from this, IISc has taken initiatives when it comes to innovation in 3D bioprinting. The institute has taken efforts to regenerate tissues using 3D bioprinting, particularly, for bone, cartilage and skin tissues. Another area of work undertaken is to create tissue models such as breast cancer and fibrotic lung tissue models. These models, which hold promise as alternatives to animal models, can help the biotech and biopharma industries in testing the efficacy and toxicity of drugs. There are efforts to prepare deployable medical devices. Through a combination of smart choice of materials and design, it is possible to fabricate shape-changing 3D printed parts widely, a theme of technology called 4D printing. These 4D printed parts can facilitate minimally invasive surgery and reduce the complexity of surgeries. Kaushik Chatterjee, Professor, Department of Materials Engineering, Indian Institute of Science, mentions, “As a new technology, there is limited penetration in the country. Many researchers are unaware of how this technology can help their work. The centre has started conducting workshops and will continue to conduct them for researchers from academia and industry. Many new technologies are being introduced in the market. We can look forward to many developments with respect to new printing technology and also their applications in medicine. In terms of technology development in the country, there are other companies in India that are working to launch 3D bioprinters or have recently launched.”   Making inroads in medicine Hospitals and startups are taking baby steps to make 3D printing a reality in the country. The team at Raegene Biosciences lead by Dr Subrahmaniyam Vangala, Founder & CEO and Dr Uday Saxena, Co-Founder & Chief Ideator have developed several first-in-class models - the 3D bioprinted human vascular lung model which mimics some features relevant to human COVID and not seen in animal models of this disease. In total, to date, four such models have been developed. The startup is currently looking to offer these tools to others to foster drug discovery and will also use these for launch of products. It is open to developing any model that its collaborators would need and is useful in drug discovery and development. Hyderabad-based L V Prasad Eye Institute is working on 3D bioprinting of corneas, in collaboration with Indian Institute of Technology (IIT) Hyderabad, and Centre For Cellular And Molecular Biology (CCMB). According to Sayan Basu, Network Director, L V Prasad Eye Institute, “corneal diseases are a major cause of blindness worldwide and particularly in the developing world. The shortage of donor tissues is also most acute in these geographies. With 3D bioprinted corneas we hope to bridge the gap in demand and supply, provide personalised solutions for individual patients, and new innovations in corneal surgery through refractive lenticules and biological contact lenses. Our focus is not just on the material or the product, but also on the method of delivery/application and the cost.” Apart from this, Amrita Hospital, Kochi has developed a first-of-its-kind Extended Reality (XR) Supported ecosystem in healthcare which leverages augmented reality (AR), virtual reality (VR), and mixed reality (MR) technologies to significantly enhance capabilities in patient care, medical training, and research. The integration of this advanced technology in clinical practice marks a major milestone in the healthcare industry of India, according to experts. The hospital’s paediatric cardiac unit has been utilising 3D printing and extended reality (AR/VR) technologies for the clinical benefit of patients. These state-of-the-art 3D+ technologies enable doctors to create precise replicas of real or actual heart or any organ, facilitating in-depth study and preparation before actual surgery. The hospital houses India's first "point of care" medical 3D printing and virtual reality laboratory. Says Dr Mahesh Kappanayil, Professor, Paediatric Cardiologist and Lead at 3D Labs, Amrita Hospital, Kochi, “We have handled numerous rare and unique cases using the 3D imaging system. Many of the cases we have undertaken have been either first in the world or in India. Despite the advanced nature of the technology, only a handful of centres worldwide have adopted it on a large scale. We are now able to treat patients who have been rejected by other hospitals due to doctors' constraints to understand the structural complexities of organs and plan the surgeries effectively. The process involves converting a patient's real CT scan into a digital 3D file, allowing doctors to examine each case in three dimensions using 3D printing technology or AR/VR.” Australia-based biotech company Inventia Life Science has announced a new distribution agreement with Mumbai-based Biotron Healthcare, for Inventia Life Science’s flagship RASTRUM platform to enter the Indian market. The RASTRUM platform helps researchers accelerate the quest to investigate and cure debilitating diseases such as cancer, neurodegenerative and fibrotic diseases. RASTRUM is designed specifically for cell biology and is a world-first technology. The platform is highly automated which creates complex, miniaturised 3D cell cultures quickly by printing hydrogels and cells in a highly controlled way. Bengaluru-based startup Avay Biosciences has launched ‘Mito Plus,’ an indigenous state-of-the-art 3D bioprinter that can print human tissues. The first prototype of Mito Plus was installed at IISc. Mito Plus can be used for pharmaceutical drug discovery and drug testing applications, It can also be used in cancer biology and cosmetology applications. Avay Biosciences has developed the bio printers in-house with around 70 per cent of manufacturing undertaken in Chennai and Bengaluru.   Safety & Efficacy One of the major challenges is to source the right material followed by to procure the right combination of strength and other tissue properties. Another challenge is to develop a tissue substitute that has the right physical and structural properties, is easy to handle, can be transported over long distances, is bio integrable, and most importantly is affordable. A key challenge to adopting these technologies in the clinic is to establish the efficacy and safety of the technologies for tissue regeneration through animal and, eventually, human trials. As a new and disruptive technology, the regulatory process also needs to be updated to enable translation. Also with any emerging technology, 3D bioprinting raises ethical and regulatory questions. Issues such as patient safety, quality control, intellectual property rights, and the equitable distribution of bioprinted products need to be carefully addressed.   Increased acceptance & adoption Dr Uday Saxena, Co-founder & Chief Ideator, Raegene Biosciences, is upbeat and thinks that every major city will potentially have 3D bioprinting clusters very shortly. He adds, “The uptick in the use of 3D bioprinting is tremendous and the Indian government agency Department of Biotechnology/ Biotechnology Industry Research Assistance Council (BIRAC) has recently launched a grant dedicated to alternate tools such as 3D bioprinting, which shows the need and excitement of this type of technologies.” According to Dr Ajay Kaul, Chairman-Cardiac Science, Fortis Noida, India would need to develop robust regulations and guidelines to ensure the responsible and ethical use of this technology. While 3D bioprinting has the potential to make a significant impact on healthcare in India, it's important to note that the technology is still evolving and faces several challenges. The scalability, long-term viability, and regulatory framework are among the key factors that will determine the extent of its impact. However, with ongoing research and development, 3D bioprinting could play a transformative role in improving healthcare outcomes and driving innovation in India. The strong existing R&D community base and massive scope of 3D bioprinting in medical services will drive demand for 3D bioprinting, thus reducing the time and cost of bioconvergence R&D, leading to bringing the innovation early. Though only a handful of centres worldwide have adopted 3D bioprinting on a large scale, a lot of research needs to be undertaken to make its impact being felt on the healthcare sector. As 3D bioprinting technology advances and becomes more accessible, it has the potential to lower the costs associated with organ transplantation and prosthetics. This affordability factor can be particularly beneficial in a country like India, where a large population lacks access to expensive medical treatments.   Sanjiv Das sanjiv.das@mmactiv.com ]]> https://biospectrumindia.com/features/93/23512/indigenous-medtech-innovations-drive-cardiac-care.html https://biospectrumindia.com/features/93/23512/indigenous-medtech-innovations-drive-cardiac-care.html Fri, 01 Sep 2023 00:00:00 +0530 Medical technology in cardiac care is gaining traction in the Indian healthcare space. The benefits of robotic-assisted diagnostics and surgical procedures are being delivered to patients with positive results. It may be noted that 85 per cent of deaths result from a heart attack or a stroke and going by the alarming statistics, the need of the hour is intervention at a lightning pace, early identification and rapid preventive measures to avert mortality, something that precision devices are adept at doing. The day is not far when AI and machine learning-based tools and next-generation biomimetic implants will be indigenously developed and curated in India.   AI in cardiac diagnosis With Artificial Intelligence (AI), a paradigm shift has been observed in cardiac diagnosis and delivering precise and timely care to those with cardiovascular disorders. For instance, AI-based applications have enhanced the understanding of various types of heart failures and congenital heart diseases. These, in turn, have led to newer treatment strategies for different types of cardiovascular diseases. In addition, AI can  accurately predict cardiovascular outcomes, non-invasive diagnosis of coronary artery disease and outcomes for heart failure patients.  The World Health Organisation's data indicate that cardiovascular diseases claim around 17.9 million people each year, translating to 31 per cent of all fatalities, globally.   Indigenous players Indian companies and startups have been manufacturing medtech tools for cardiac care. Gurugram-based med tech startup SS Innovations manufactures the first and only Made-in-India surgical robot, which can be utilised for all major surgical specialities including cardiac. In 2021, the startup launched the first fully Made in India surgical robot SSI Mantra, a technologically advanced surgical robotic system that has more and better features and applications than existing systems.  Recently, the company acquired a controlling interest in Avra Medical Robotics, a Nasdaq-listed company in the US. SS Innovations International announced the successful completion of two cardiac surgical procedures utilising the company’s SSI Mantra surgical robotic system. The startup received its first international order unit that has been delivered to and will be installed in Aster Hospital, in Dubai, UAE. Dr Sudhir Srivastava, CEO, Chairman and Founder, SS Innovations along with Dr Nitin Rajput, Senior Consultant Cardiac Surgery recently conducted two adult coronary artery bypass procedures at Narayana Hrudayalaya Institute of Cardiac Sciences in Bengaluru, Karnataka. Dr Srivastava has completed more than 1,400 robotic cardiothoracic surgical procedures, including 750 beating heart endoscopic coronary artery bypass (TECAB) cases. In May 2023, Dr Srivastava performed an additional robotic cardiac surgery using the SSi Mantra Surgical Robotic System at Continental Hospitals, Hyderabad. Says Dr Srivastava, “We are committed to improving access for patients and optimising surgical outcomes with our accessible and cost-effective surgical system, the SSI Mantra. We believe there is an enormous opportunity to address the significant unmet need for safe, timely, and affordable cardiac surgical care in India and around the world.”  Meril, aVapi (Gujarat)–based medtech company, has a rich R&D portfolio and drives innovation across diverse business verticals. In interventional cardiology, the company is working towards calcium management in Percutaneous Coronary Intervention (PCI) procedures. Similarly, it is also focusing on structural heart interventions in left atrial appendage closure, mitral valve repairs and replacements.  Meril Vascular Intervention has developed new concepts in engineering employing novel designs with a cleverly iterated diverse portfolio including devices ranging from drug-eluting stents, bioresorbable scaffolds, balloon catheters, peripheral vascular and transcatheter aortic valves replacement systems (TAVR). Sanjeev Bhatt, Senior Vice President, Meril says, “India has come a long way in terms of indigenously developing technologies for diseases related to the heart and human vasculature, which are at present very high amongst our Indian population. India is developing the latest generation technologies which are either at par or even better than their western counterparts. The burden of cardiovascular and structural heart diseases is very high and until 10 years ago India was dependent on the import of medical devices. But today, we can proudly say India has indigenously developed technology such as transcatheter heart valves, manufactured by Meril which are not only responding to some of the unmet clinical needs but are also supplied globally to developed and emerging markets worldwide benefitting a large number of patients.” Ghaziabad-based Innvolution, a group focussed on interventional cardiology with a comprehensive portfolio of imaging and consumable products, raised growth capital from OrbiMed, a global healthcare-focused investment firm. The funds will be used to ramp up the R&D efforts, develop new products, and expand into international markets. Mumbai-based Sahajanand Medical Technologies (SMT), developer and manufacturer of minimally invasive cardiovascular devices including coronary, structural heart and closure devices products was recently selected as the exclusive distributor of US-based Penumbra’s peripheral and coronary vascular thrombectomy technologies in select domestic geographies in India. Bengaluru-based startup Heartnet India has announced the launch of its groundbreaking telecardiology product, Asaan - an IoT-based solution, aimed at transforming the landscape of cardiac healthcare in India. It empowers physicians to do cardiac health checks at their clinics with the help of technology and specialist advice. Asaan is set to bridge the gap between urban and rural areas, ensuring access to top-tier cardiac care at affordable costs. The initiative, slated to start in August 2023 from Karnataka, Maharashtra and West Bengal, has taken a pioneering step by integrating telecardiology into its services. Asaan will also empower cardiologists to monitor their patient's health in real-time, facilitating prompt recommendations for medications or lifestyle changes without the need for in-person office visits.   Noteworthy initiatives Kauvery Heart Institute recently unveiled comprehensive cardiovascular healthcare at Kauvery Hospital, Radial Road, Chennai. The hospital has established the Centre for CHIP PCI and Mechanical Circulatory Support System (Impella, ECMO) for treating advanced coronary artery disease with heart failure/shock. Dr Ankur Phatarpekar, Interventional Cardiologist and Director at Symbiosis Speciality Hospital Mumbai announced the integration of the latest Optical Coherence Tomography system (OCT), Optis Mobile Next, with Ultreon technology at the Symbiosis Speciality Hospital. The hospital has become one of the first healthcare facilities in India to equip itself with this state-of-the-art imaging system, revolutionising the diagnosis and treatment of heart disease.  In the north eastern region of the country, a research team from the Indian Institute of Technology Guwahati (IIT-G) has developed a ‘Recombinant Protein Toolbox’ consisting of six special proteins, which can be used to convert healthy skin cells or any somatic cells from an adult human body into heart cells, specifically cardiomyocytes. The heart cells created using this tool box can have the same function as the original heart cells and can be used to regenerate damaged heart tissues. Importantly, this toolbox can facilitate the generation of autologous heart cells in a lab. The team has collaborated with Dr Vishwas Kaveeshwar from the Central Research Laboratory at SDM College of Medical Sciences and Hospital in Dharwad, Karnataka, to validate the biological activity of the recombinant fusion proteins. In addition to the active participation of private players, the public sector too is making efforts in cardiac care. The Government of Karnataka has launched STEMI programme in partnership with Tricog Health, a Bengaluru-based health AI company, to set up an end-to-end system of care for heart attacks. The aim is to enable rapid diagnosis of heart disease in all taluka and district health facilities in Karnataka along with timely treatment.  Apart from this, Lupin Digital Health (LDH) recently announced the launch of Lyfe Digital Heart Failure Clinic in India. The Lyfe Digital Heart Failure (HF) Clinic has been developed to address the growing burden on healthcare infrastructure due to increasing heart failure instances in India. It combines in-clinic consultation with at-home patient monitoring and care. A team of experts, including paramedics, nurses, cardiotherapists, health coaches and care managers, work together with the treating cardiologist to deliver improved patient health outcomes. The system is equipped with advanced technology, providing doctors with real-time updates and patients with personalised care pathways, emergency services and educational resources. Also, Lupin Digital Health and the American College of Cardiology (ACC) have announced a collaboration to deliver in-home cardiovascular care with Digital Therapeutics (DTx) in India. This collaboration aims to accelerate the application and adoption of DTx in Cardiology in India. Lupin Digital Health’s DTx platform, Lyfe, also aims to give patients and their healthcare providers tools to manage heart diseases at home and help to ensure patients stay healthy after hospital discharge and reduce rehospitalisation. As part of this collaboration, Lupin Digital Health will leverage ACC’s CardioSmart platform, guidelines, and workbooks to guide healthcare professionals and caregivers. These tools will be accessible to doctors, patients, and caregivers through Lupin Digital Health’s Lyfe app and website. Besides, Portea, AliveCor and NanoHealth - companies in healthcare technology and services - announced their collaborative initiative, HeartSmart, the cardiac care service at home. It is specifically designed to provide comprehensive and holistic care for high-risk cardiac patients. HeartSmart integrates smart devices, advanced software applications, and personalised services to enhance the well-being and cardiac health of individuals at home. HeartSmart offers a wide range of tools and services to empower patients with high-risk cardiac conditions, providing them with the confidence and support needed to manage their health effectively. The key components of HeartSmart include AliveCor's KardiaMobile 6L device, NanoHealth's comprehensive and integrated technology platform, and Portea's exemplary healthcare services.   Changing healthcare landscape  With the government approving the National Medical Devices Policy, in 2023, things are looking positive for the Indian manufacturers of cardiac care devices. Indian cardiac device manufacturers need government support to enhance their manufacturing capabilities and later import the products. Right policy decisions like the approval of the policy are the right step in the direction. However, one move by the FICCI’s Medical Devices Division didn’t go down well among the med devices players. Gaurav Agarwal, Managing Director, Innvolution Healthcare mentioned, “The utilisation of refurbished equipment under the guise of C-arms and advanced X-ray systems for performing catheterisation procedures is both misleading and potentially hazardous. Against the need for 500 Cath Labs a year to serve the Indian population, Indian Manufacturers can manufacture more than 600 indigenised Cath Labs which play a critical role in diagnosing and treating cardiovascular diseases, and these facilities must meet the highest standards of quality, reliability, and patient safety." He added, "By importing refurbished equipment, we miss the opportunity to nurture a robust ecosystem of innovation, research, and development in the medical technology sector.” The future of medical device technologies developed in India is promising as the innovation engine in India has triggered new developments. The global healthcare landscape is changing rapidly, developed nations are facing healthcare budget limitations and require next-generation technologies which are scientifically and clinically proven. Moreover, emerging markets also deserve the latest technologies at an affordable price point.   Sanjiv Das (sanjiv.das@mmactiv.com)   ]]> https://biospectrumindia.com/news/93/23472/india-medtech-expo-2023-showcases-indigenous-technologies-on-global-stage.html https://biospectrumindia.com/news/93/23472/india-medtech-expo-2023-showcases-indigenous-technologies-on-global-stage.html Sun, 20 Aug 2023 00:00:00 +0530 The India MedTech Expo 2023 was held from 17th to 19th August, 2023 at Gandhinagar, Gujarat. In the exhibition, huge range of medical equipment ranging from the state-of-the-art imaging systems to precision surgical instruments, from wearable health monitors to artificial intelligence (AI)-driven diagnostic tools, were on display. Various sessions were held on themes relevant to the medical devices sector during the course of three day Expo. The Expo witnessed large participation from global and Indian companies including MSMEs, startups, academic and research institutions, state governments, Central and state procurement agencies, regulatory agencies etc.  More than 4000 meetings were held in first two days and more than 10,000+ visitors visited India Medtech Expo 2023.There was participation from 225 companies - Indian (Including MSMEs) and Foreign companies operating in India, 80 Startups, 7 States - Madhya Pradesh, Tamil Nadu, Uttar Pradesh, Himachal Pradesh, Rajasthan, Andhra Pradesh and Gujarat.  Rushikesh Ganeshbhai Patel, Health Minister, Government of Gujarat stated that there is huge talent in the country and several technological innovations are taking place in the medical devices sector. Gujarat is a leading state in both pharma and medical devices sectors in the country and the Government of Gujarat is committed to build an ecosystem providing requisite infrastructure to young entrepreneurs, who are waiting for appropriate opportunity. An Open House session chaired by Dr Rajeev Raghuvanshi, Drugs Controller General of India was held with participation of MedTech Regulators and the Industry players. Key gaps and challenges faced by the medical device manufacturers were discussed along with their potential solutions. Dr Rajeev Raghuvanshi said that there is a huge opportunity in medical devices sector to grow and replace imports with indigenisation, particularly if we are able to produce good quality products. ]]> https://biospectrumindia.com/news/93/23473/experts-dive-into-future-trends-for-geriatric-home-based-healthcare-at-india-medtech-expo-2023.html https://biospectrumindia.com/news/93/23473/experts-dive-into-future-trends-for-geriatric-home-based-healthcare-at-india-medtech-expo-2023.html Sun, 20 Aug 2023 00:00:00 +0530 The India Medtech Expo 2023, held from 17th to 19th August, 2023 at Gandhinagar, Gujarat, moved the needle on its second day through the thought-provoking session on ‘Future Trends in MedTech for Geriatric & Home-based Care’. The session on elder care which was chaired by Dr Vinod Kumar Paul, Member, NITI Aayog and moderated by Pavan Choudary, Chairman, Medical Technology Association of India (MTaI) trained the spotlight on MedTech’s crucial role in enabling care for seniors. Pavan Choudary said, “The increasing healthcare and caregiving costs are making elders an expensive burden. Many caregiving children fall in the ‘sandwich generation’, with parents to care for on one side and their own children to care for on the other, added Choudary.”  Dr Vinod Kumar Paul, during the panel discussion, stated, “The ageing demographic presents both a societal and governmental obligation to address the needs of the elderly population. A landmark study recently revealed that 43% of the elderly population would require one or more assisted medical device in the coming future. At present, the disability rate among individuals aged 60 and above surpasses 10%, emphasising the significance of comprehensive support mechanisms. Within this context, there exists a promising trajectory for the advancement of assisted medical devices tailored to senior living. He also stressed that the industry should through its efforts address the specific needs of elderly women in India as well.” The panel sought the government’s help on resolving GST anomalies, non-coverage under Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (ABPMJAY) and other government schemes. It also explained that the draft Uniform Code for Medical Device Marketing Practices (UCMDMP) was put together meticulously by Department of Pharmaceuticals (DoP) after thorough stakeholder consultations with industry, patient groups, healthcare practitioners, etc.  ]]> https://biospectrumindia.com/news/93/23452/stryker-supports-punjab-to-help-develop-medical-manpower.html https://biospectrumindia.com/news/93/23452/stryker-supports-punjab-to-help-develop-medical-manpower.html Thu, 10 Aug 2023 00:00:00 +0530 Setting a stage for a dynamic collaboration that promises to drive positive change in the healthcare landscape as desired by Chief Minister Bhagwant Mann, Department of Medical Education & Research, Punjab and Consocia Advisory/Stryker India have signed a Memorandum of Understanding (MoU) under the leadership of Punjab Medical Education & Research Minister Dr Balbir Singh. Dr Balbir Singh said that this partnership is a significant step towards fostering innovation and advancement, which aims to leverage the unique strengths and expertise to tackle challenges, seize opportunities, and create meaningful impact, on patient care and research especially in the field of stroke and brain attacks, initially in the Government Medical Colleges in the state. “This MoU will help in the development of medical manpower with quality education in the field of medicine and preparation of specialist and super specialist doctors in the state and to promote research activities in the Medical Colleges of Punjab State,” he said. The Health Minister said that the state is committed to identifying, developing and propagating the best medical innovations for the treatment of stroke in the state, with the latest intervention that is mechanical thrombectomy as an alternative to the first line of action other than conventional treatments for stroke. Meanwhile, both parties have agreed on the mutual consent to establish an awareness and capacity-building programme to train medical practitioners, doctors and interventionists. This partnership also underscores the state government's resolve to provide better and more affordable healthcare in the community. ]]> https://biospectrumindia.com/news/93/23455/7-states-to-showcase-manufacturing-investment-potential-at-indias-first-ever-medtech-expo.html https://biospectrumindia.com/news/93/23455/7-states-to-showcase-manufacturing-investment-potential-at-indias-first-ever-medtech-expo.html Thu, 10 Aug 2023 00:00:00 +0530 Addressing the Curtain Raiser of ‘India MedTech Expo 2023’, scheduled to be held in Gandhinagar, Gujarat from 17th to 19th August 2023, Dr Mansukh Mandaviya, Union Minister for Health & Family Welfare and Chemicals & Fertilizers, Government of India said that India is set to emerge as the global manufacturing hub for medical devices through a holistic development of healthcare, pharmaceuticals and medical devices sectors. The market size of Indian medical devices sector is likely to reach $ 50 billion in coming years from current $ 11 billion. He further emphasised that in order to make healthcare affordable, the government is targeting to increase the share of generic medicines to 50-60 per cent from current level of 14 per cent alongside localisation of medical devices. To unleash the potential of the sector and brain-storm the path ahead, the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India is hosting the pioneering ‘India MedTech Expo’ with central theme ‘India: The Next MedTech Global Hub’ Future of Devices, Diagnostics and Digital’, which is being organised alongside G20 Health Ministers’ Conference. The Federation of Indian Chambers of Commerce & Industry (FICCI) is the industry partner for the Expo. The Expo will have various pavilions, including Future Pavilion, R&D Pavilion, Start-up Pavilion, State Pavilion, Regulators Pavilion and Make in India Showcase. More than 400 exhibitors including 150 plus MSMEs, 150+ Domestic and International Manufacturers, Start-ups, Regulatory agencies, State Governments and Central Departments will participate in it. As many as 7 States - Madhya Pradesh, Tamil Nadu, Uttar Pradesh, Himachal Pradesh, Rajasthan, Andhra Pradesh and Gujarat are setting up pavilions during the expo. Also, a total of 231 foreign buyers from 50 countries primarily from 5 major regions Africa, ASEAN, CIS, Middle East and Oceania will participate in the international buyer-seller meet. ]]> https://biospectrumindia.com/news/93/23430/yashoda-medicity-and-drger-india-to-bring-cutting-edge-medical-gas-management-system-in-india.html https://biospectrumindia.com/news/93/23430/yashoda-medicity-and-drger-india-to-bring-cutting-edge-medical-gas-management-system-in-india.html Thu, 03 Aug 2023 00:00:00 +0530 Yashoda Medicity, the upcoming healthcare facility by Yashoda Foundations in Indirapuram, is collaborating with Dräger India, a renowned global medical and safety technology solutions provider. Yashoda Medicity is the new addition to the renowned healthcare institution Yashoda Super Speciality Hospital, well acknowledged for its exceptional patient care and facilities.  Together, Yashoda Medicity and Dräger are embarking on a groundbreaking initiative to establish one of the largest modular Intensive Care Unit (ICU) setup in South Asia. The focus of this project is to prioritise infection prevention control, patient and staff safety, and enhanced hospital efficiency, while ensuring adaptability to respond to the ever-evolving needs of the hospital.  The upcoming Yashoda Medcity project in Indirapuram, Ghaziabad, spans across 8 acres of land and will house a state-of-the-art 250-bedded modular ICU. This landmark infrastructure project will significantly strengthen the healthcare sector in Delhi NCR, Uttar Pradesh, and neighbouring states of India. The construction of the medical gas management system and the modular ICU setup is already underway and is expected to be completed within the next few months. Once operational, the facility will significantly enhance the critical care capabilities of Yashoda Medicity, providing patients with access to state-of-the-art medical care in a cutting-edge environment. ]]> https://biospectrumindia.com/views/93/23409/a-dispute-between-industry-governments-opinion-on-medtech-sector.html https://biospectrumindia.com/views/93/23409/a-dispute-between-industry-governments-opinion-on-medtech-sector.html Mon, 31 Jul 2023 00:00:00 +0530 A concern has been recently raised by the Association of Indian Medical Device Industry (AiMeD) based on an interministry policy issue for permitting import of pre-owned medical devices, which appears to be in direct conflict with Prime Minister (PM)'s Make in India agenda. “The decision to permit the import of pre-owned medical devices is in contravention to India’s recently launched National Medical Device Policy-2023 that seeks to make our country not only Atma Nirbhar in medical devices but also the global leader. The Office Memorandum (dated 19th June) is a regressive step that has confused the investors who have been putting up manufacturing capacity in the last few years in response to Prime Minister Narendra Modi’s call for self-reliance”, said Rajiv Nath, Forum Coordinator, AiMeD. Cautioning against the policy of allowing free imports of old, used and discarded medical equipment from other countries, Suresh Vazirani, Chairman, Transasia Bio-Medicals said, “The use of old, discarded medical equipment can not only be dangerous for the lives of our fellow Indians but it will destroy our PM Modi's dream of making India Atma Nirbhar in medical technology.” Based on these concerns, Federation of Indian Chambers of Commerce & Industry (FICCI) has responded that the imported refurbished equipment should be of very high quality providing precise diagnosis and treatment at affordable costs in India. On the other hand, the government is all set to highlight the capabilities of the Indian Medical Devices Sector under the G-20 Indian Presidency, with the first ever expo being spearheaded by the Government in association with Indian medical devices industry, the three-day India MedTech Expo (IMTE)-2023 being held in Gandhi Nagar, alongside the G-20 Health Ministers meeting in August 2023, for showcasing the capabilities of Indian Medical Devices Industry and to create opportunities to network and explore collaborations both for the sector’s growth in India and its potential contribution globally. Department of Pharmaceuticals is planning to organise a large-scale first-time National Level Expo on Medical Devices sector for three days (18-20 August 2023), at Helipad Exhibition Centre, Gandhi Nagar, Gujarat, with FICCI playing the role of industry partner for this event. With such conflicts in sight, is PM’s ‘Make in India’ dream being bulldozed or is the government in the process of making right policy decisions for the country's best interests?   ]]> https://biospectrumindia.com/news/93/23386/nesa-medtech-gets-us-fda-clearance-for-fibroid-mapping-reviewer-application.html https://biospectrumindia.com/news/93/23386/nesa-medtech-gets-us-fda-clearance-for-fibroid-mapping-reviewer-application.html Mon, 24 Jul 2023 00:00:00 +0530 Nesa Medtech, a Bengaluru-based startup, has received 510(k) clearance from the US Food and Drug Administration (FDA) for the company's Fibroid Mapping Reviewer Application (FMRA). The technology is intended for use by physicians to generate a 3D model of the uterus from ultrasound images to assist in the accurate diagnosis and planning of interventional procedures for patients with uterine fibroids. "While uterine fibroids are extremely common, for some patients they can be extremely painful and require intervention," commented John Petrozza, MD, Department of Obstetrics and Gynecology at Massachusetts General Hospital and Co-Director of the Integrated Fibroid Program. "Nesa's FMRA technology allows physicians to determine fibroid location and dimensions, critical details for effective minimally invasive image guided treatment planning." Uterine fibroids, also known as leiomyomas, impact one in four women. While these growths are non-cancerous, they can significantly impact a patient's quality of life, causing excessive menstrual bleeding, pelvic pain, and infertility. Unfortunately, medication is effective only for a small percentage of patients, leaving many to require open surgery or minimally invasive procedures. Fibroid size and location are key considerations as physicians select the appropriate surgical approach for each case. "Receiving FDA clearance is a significant milestone and a proud moment for the company," said Sreekar Kothamachu, CEO of Nesa Medtech.  ]]> https://biospectrumindia.com/views/93/23373/unrivalled-precision-of-12-lead-ecg.html https://biospectrumindia.com/views/93/23373/unrivalled-precision-of-12-lead-ecg.html Fri, 21 Jul 2023 00:00:00 +0530 The mortality rate related to Cardiovascular Diseases (CVD) is unfortunately very high. CVD refers to conditions that affect the heart and blood vessels, such as heart attacks and strokes. Additionally, lack of awareness about the importance of a healthy lifestyle and delayed medical intervention can contribute to the gravity of the situation. It is crucial for individuals to understand the significance of timely and accurate diagnosis. When a healthcare condition is detected early and accurately with a 12 Lead ECG, or Electrocardiogram it allows for swift intervention and appropriate treatment. Studies published in medical journals, as well as the consensus of cardiologists and medical societies, consider the 12-Lead ECG as the standard tool due to its higher sensitivity and specificity. This means that it is more capable of identifying heart abnormalities, leading to more accurate diagnoses and appropriate treatment plans for patients.   From Labs to Hands: Rise of Portable ECG devices The global market for portable ECG devices has witnessed significant advancements over the years, with various innovative products leading the way. The initial breakthrough came with the introduction of the single-lead ECG patch, providing a portable solution for heart monitoring. However, the challenge of continuous monitoring with Single Lead ECG patch persisted. Even the integration of single lead ECG devices into smartwatches was initially considered a mere gimmick rather than a serious medical tool. Overcoming the challenge of continuous monitoring and the limitations of single lead and six lead portable ECG devices, the industry experienced a revolution with the development of a 12-lead touch-based ECG device. The market for portable 12 Lead ECG devices continues to expand as these technological advancements improve the effectiveness, accessibility, and convenience of monitoring heart health on the go.   Difference Between 12 Lead ECG, 6 Lead ECG and Single Lead ECG When comparing the interpretation of the graph obtained from a Single Lead ECG and a 12-Lead ECG, there are notable differences in the areas of the graph that can be seen. The level of detail measurements of intervals, segments, and amplitudes on the ECG graph empowers healthcare professionals to detect abnormalities that may indicate myocardial infarction, ventricular hypertrophy, electrolyte imbalances, myocardial ischemia, and other critical cardiac conditions. The 12-lead ECG serves as a vital tool in making accurate diagnoses, leading to appropriate treatment strategies. 12 lead can detect ST elevation and depression which corresponds to MI, Hyper-acute T Wave, Ischemia, while Single lead cannot detect ST elevation or depression because readings from minimum 2 precordial leads are required to confirm Myocardial Infraction.   What You need to Know while choosing ECG In the dynamic world of cardiac diagnostics, the 12-lead ECG shines as the pinnacle of accuracy and comprehensive assessment. Its complete limb lead configuration, precise measurements, and ability to differentiate between cardiac conditions make it an indispensable tool in the hands of healthcare professionals. As individuals, we must make informed decisions and prioritise the use of 12-lead ECG devices for prevention and monitoring purposes. Let us move beyond superficial trends and embrace the true essence of care and concern for our own and our loved ones' heart health, extending our dedication beyond special occasions to the regular days that truly matter.   Ojasvi Nirav, Senior Cardiac Analyst, Agatsa Software   ]]> https://biospectrumindia.com/news/93/23350/pluss-advanced-technologies-enhances-availability-of-neonatal-cooling-device-miracradle.html https://biospectrumindia.com/news/93/23350/pluss-advanced-technologies-enhances-availability-of-neonatal-cooling-device-miracradle.html Mon, 17 Jul 2023 00:00:00 +0530 UK-based The Rodnight Partnership has announced a partnership with Gurugram-based Pluss Advanced Technologies, to enhance availability of 'MiraCradle', a unique neonatal cooling device in the Middle East, Africa and South East Asia markets. MiraCradle is the world's first non-electronic, portable device based on Phase Change Materials (PCMs), developed in partnership with Christian Medical College, Vellore. The MiraCradle neonatal cooler is an affordable passive cooling device that uses advanced phase change material (PCM) technology to induce therapeutic hypothermia among newborns suffering from birth asphyxia. MiraCradle can bring the much-needed hypothermic therapy to neonates through affordable passive cooling at a fraction of the price as compared to alternate active cooling methods. "Our partnership with The Rodnight Partnership will further drive the market penetration of the life-saving technology of this product throughout Africa, the Middle East, and Southeast Asia. Their knowledge of the neonatal market and the relevant channels will allow us to vastly increase the speed with which we can serve these markets with high need potential," said Udit Mangal, Vice President & Business Head-Lifesciences, Pluss Advanced Technologies.   ]]> https://biospectrumindia.com/news/93/23327/sir-hn-reliance-foundation-hospital-introduces-ground-breaking-technology-to-revolutionise-cancer-treatment-in-india.html https://biospectrumindia.com/news/93/23327/sir-hn-reliance-foundation-hospital-introduces-ground-breaking-technology-to-revolutionise-cancer-treatment-in-india.html Tue, 11 Jul 2023 00:00:00 +0530 Sir HN Reliance Foundation Hospital introduces India’s first Ethos Linear Accelerator in combination with Surface Guided Radiotherapy, a ground-breaking innovation in cancer care. ETHOS enables a patient-centric approach by providing personalised treatment plans based on each person's unique anatomy and changes in the tumour on daily basis. This ability to adapt and adjust the treatment plan throughout the course of therapy ensures precise targeting of the tumour and minimizes radiation exposure to healthy tissues. The technology also adapts to changes in the tumour shape, position, and size during treatment. By accurately tracking and adjusting the treatment beam in real-time, ETHOS maximises the radiation dose to the tumour while minimizing damage to surrounding healthy tissues. This ensures optimal treatment, improved outcomes, and reduced side effects. Sharing his thought Dr Prasad Dandekar, Head of Radiation Oncology said, “Ethos is an Artificial Intelligence based Precision Radiotherapy treatment machine, that will lead to improving cancer outcomes in patients and reduced side effects for the treatment of any kind of cancer."  With the Varian Ethos platform doctors can now efficiently plan & administer the adaptive treatment in just a 15min time slot with the Adaptive Intelligence feature.   ]]> https://biospectrumindia.com/news/93/23275/translumina-strengthens-technology-portfolio-with-acquisition-of-blue-medical-devices-in-netherlands.html https://biospectrumindia.com/news/93/23275/translumina-strengthens-technology-portfolio-with-acquisition-of-blue-medical-devices-in-netherlands.html Fri, 30 Jun 2023 00:00:00 +0530 New Delhi-based medtech firm Translumina, a global leader in interventional cardiovascular medical devices with manufacturing presence in Germany and India, has announced the acquisition of Blue Medical Devices, a Wellinq group company, based out of Helmond, Netherlands. The company incorporated in 2013 produces an innovative basket of balloon catheters including Drug Coated Balloons (DCB) and other speciality balloons for complex coronary interventions. Notably, Blue Medical DCB catheters, Protégé NC and Protégé SC, significantly overcome the limitations of current DCB technologies and offers high efficacy and safety. The EU-MDR approved DCB catheters have a unique offering of a non-compliant and a semi compliant version. The technology involves a patented drug application technology that prevents any drug loss during the advancement of the device to the lesion resulting in high concentration of the drug at the targeted site. Drug Eluting Balloons are now being considered a treatment of choice for in-stent restenosis, smaller vessels, bifurcations and multivessel disease. The current estimates project DCB market to be almost 30% of the global drug eluting stents (DES) market in the next 5 years. The acquisition shall also enable Translumina to use the patented Drug application technology of Blue Medical in other product lines in peripheral and neurovascular interventions complimenting its leadership in unique and innovative dug coating recipes. ]]> https://biospectrumindia.com/news/93/23238/fujifilm-india-redefines-healthcare-with-new-service-and-support-app.html https://biospectrumindia.com/news/93/23238/fujifilm-india-redefines-healthcare-with-new-service-and-support-app.html Tue, 20 Jun 2023 00:00:00 +0530 Fujifilm India, the Indian arm of Japanese medtech firm Fujifilm, is emerging as a comprehensive healthcare solution provider with their state-of-the-art mobile application ‘FUJIFILM Connect’. It is the one-stop solution for healthcare professionals to manage the service and support for their medical diagnostic devices with real-time push notifications to keep the users updated. Through ‘FUJIFILM Connect’, the company has provided a single platform to healthcare providers where creating and tracking service requests is now a convenient process with efficient technical support in just one tap. In addition to raising service request tickets for already purchased Fujifilm medical devices, users can explore new products as well. The app is available on both the apple store and google play store. The key features of ‘FUJIFILM Connect’ include easy service request submission, timely & efficient technical support, access to a comprehensive service history along with features to track the status of all service requests, view maintenance records and monitor device performance. Moreover, this app aids remarkable customer support services through 24x7 call logging process and real time contract status visibility. The app comprises various categories of Fujifilm medical products like FDR & Mammography scanners, X-ray imaging devices, and MRI & CT scanners among other healthcare products. It benefits healthcare professionals in numerous ways including one-tap product description access, elimination of call logging and toll-free number for assistance. Besides, the app facilitates users with real-time contract status visibility and aids in transparency and helps to maintain time-to-time services of medical products. The app will also encompass a range of Endoscopy products in the future.   ]]> https://biospectrumindia.com/news/93/23186/medtech-firm-translumina-bolsters-german-presence-with-acquisition-of-lamed-gmbh.html https://biospectrumindia.com/news/93/23186/medtech-firm-translumina-bolsters-german-presence-with-acquisition-of-lamed-gmbh.html Wed, 07 Jun 2023 00:00:00 +0530 New Delhi-based Translumina, a global leader in interventional cardiovascular medical devices with manufacturing presence in Germany and India, has announced the acquisition of Munich-based Lamed GmbH. With this acquisition, Translumina has taken a step further towards its stated goal of providing a comprehensive cardiovascular portfolio at scale across key markets globally. Established in 1989, Lamed is a leading market access platform of vascular and cardiovascular products. It covers 1,000+ hospitals through its GPO network in Germany, which is the largest interventional cardiology market in Europe; the company exclusively distributes a portfolio of differentiated products for a marquee international supplier base. Lamed's seasoned senior management team brings 30+ years of experience and deeply entrenched ecosystem relationships. Translumina intends to leverage the platform to introduce a basket of owned and partnered products in the German market. "This acquisition is of strategic importance and gives us significant access in vascular and cardiovascular markets in Germany, which is one of the largest in Europe. The synergy of our unique technologies and market penetration of Lamed shall create a formidable business opportunity for us," said Gurmit Singh Chugh who along with Punita Sharma founded Translumina in 2010. ]]> https://biospectrumindia.com/news/93/23179/omron-healthcare-to-launch-manufacturing-facility-in-chennai.html https://biospectrumindia.com/news/93/23179/omron-healthcare-to-launch-manufacturing-facility-in-chennai.html Mon, 05 Jun 2023 00:00:00 +0530 Japanese firm Omron Healthcare has announced a plan to establish a manufacturing factory at ORIGINS by Mahindra, Chennai, in Tamil Nadu. The factory will begin manufacturing blood pressure monitors in March 2025. Prior to this, the company signed a memorandum on the establishment of the factory in the presence of M.K. Stalin, Chief Minister of the Tamil Nadu State Government. In India, an average GDP annual growth rate is expected to be around 6% until 2030 and the population is expected to reach 1.66 billion in 2050. Owing to the accelerating economic growth and acute population growth, India has now seen a rise in the number of lifestyle disease patients. Among these types of diseases, hypertension is one of the most common causes of cerebro-cardiovascular diseases such as stroke and heart failure. Regular blood pressure monitoring at home is considered to be essential in hypertensive management. However, the penetration rate of blood pressure monitors in India remains low at around 2%. The establishment of the manufacturing factory and the steady distribution structure are the company's efforts to deliver blood pressure monitors to as many people as possible. ]]> https://biospectrumindia.com/news/93/23113/8th-edition-of-international-conference-on-india-pharma-india-medical-device-2023-to-open-in-delhi.html https://biospectrumindia.com/news/93/23113/8th-edition-of-international-conference-on-india-pharma-india-medical-device-2023-to-open-in-delhi.html Sat, 20 May 2023 00:00:00 +0530 The Union Minister for Chemicals and Fertilizers Dr Mansukh Mandaviya will inaugurate the 8th edition of the International Conference on 'India Pharma & India Medical Device 2023' organised by the Department of Pharmaceuticals in association with Federation of Indian Chambers of Commerce and Industry (FICCI) from May 26 - 27, 2022 in New Delhi.  As part of the conference, Dr Mandaviya will launch the National Medical Devices Policy, 2023, as well as the Export Promotion Council for Medical Devices.  The Union Minister will also launch a new scheme named ‘Assistance for Medical Devices clusters for Common Facilities (AMD-CF') with the objective to strengthen or establish common infrastructure facilities in the medical devices clusters and also to strengthen or establish testing facilities for medical devices. The annual flagship conference will be conducted over two days – 26th May 2023 dedicated for India Medical Device sector on the theme "Sustainable MedTech 5.0: Scaling and Innovating Indian MedTech," and 27th May 2023 dedicated for the Pharmaceutical sector on the theme "Indian pharma industry: Delivering Value through Innovation. Over 100 CEOs of the pharmaceutical and medical device industries will participate in several thematic sessions during the two days, bringing participation from all over the world to the event. More than 700 participants from the pharma and medical devices sectors are expected to attend the two-day conference.   ]]> https://biospectrumindia.com/news/93/23102/medtronic-invests-rs-3000-cr-to-expand-engineering-innovation-centre-in-hyderabad.html https://biospectrumindia.com/news/93/23102/medtronic-invests-rs-3000-cr-to-expand-engineering-innovation-centre-in-hyderabad.html Thu, 18 May 2023 00:00:00 +0530 In a significant move towards the growth of the healthcare technology sector in India, Ireland-headquartered Medtronic plc, the global leader in healthcare technology, has announced an investment of  approximately Rs 3000 Cr (more than $350 million) to expand the Medtronic Engineering & Innovation Center (MEIC) in Hyderabad. MEIC is Medtronic’s largest research and development (R&D) centre outside of the US. The investment is a part of Medtronic’s overall global R&D led innovation and growth strategy.  Medtronic supports the Govt. of Telangana’s efforts to position Hyderabad as a global hub for healthcare technology research and innovation.  This investment builds on the initial investment of $160 million in MEIC that was announced back in 2020 and expands the company’s footprint in India. MEIC currently employs 800+ people, primarily engineers, and is expected to grow to 1500+ over the next 5-year period with the investment announced now. With this expansion, MEIC aims to leverage the sizeable pool of diverse and skilled talent in India involving engineering, mobile apps, application and desktop software, cloud / web apps, data engineering, embedded software, product security, and cyber-product security. The investment will support in key healthcare technology areas like robotics, imaging and navigation, surgical technologies, and implantable technologies.     Image caption- Mani Prakash, VP Entreprise R&D Medtronic; Divya Prakash Joshi, Site Leader, MEIC at medtronic; Mike Marinaro Global Head Surgical Robotic Technology, Medtronic; Minister KTR Rama Rao, Govt. of Telangana ]]> https://biospectrumindia.com/news/93/23094/health-minister-invites-japanese-medical-companies-for-opportunities-to-make-in-india.html https://biospectrumindia.com/news/93/23094/health-minister-invites-japanese-medical-companies-for-opportunities-to-make-in-india.html Tue, 16 May 2023 00:00:00 +0530 “The medical devices sector is an essential and integral constituent of India’s healthcare sector. The sector’s contribution became even more prominent as India supported the domestic and global battle against COVID-19 pandemic through large scale production of medical devices & diagnostic kits.” This was stated by Dr Mansukh Mandaviya, Union Minister of Health and Family Welfare, Government of India, during his interaction with representatives of Japanese Medical Devices Companies, in Tokyo recently. He has invited Japanese Medical Devices companies to take advantage of the opportunities to “Make in India”,  “Innovate in India”, and “Discover in India”. “To invite investors from across the world, India is allowing 100% FDI under the automatic route for both Greenfield & Brownfield setups. To boost domestic manufacturing, the government launched the Production Linked Incentive Schemes for medical devices with financial incentives worth $400 million. To support our investor community, government has also approved the establishment of 4 Medical Devices Parks in the states. These Parks will significantly reduce manufacturing cost, optimise resources, build on economies of scale, and provide easy access to standard testing and infrastructure facilities", said the Minister. Dr Mandaviya also informed that in order to facilitate orderly growth of the medical devices sector and to meet the public health objectives of access, affordability, quality and innovation, India recently approved its first National Medical Devices Policy. ]]> https://biospectrumindia.com/news/93/23074/medikabazaar-partners-with-amtz-to-build-fulfillment-centre-in-vizag.html https://biospectrumindia.com/news/93/23074/medikabazaar-partners-with-amtz-to-build-fulfillment-centre-in-vizag.html Thu, 11 May 2023 00:00:00 +0530 Mumbai-based startup Medikabazaar has joined hands with Andhra Pradesh Med Tech Zone (AMTZ) to set up an 8000 sq ft fulfillment centre within their premises. The centre will cater exclusively to the manufacturing units within the MedTech zone, providing better reach, availability, and faster delivery of healthcare products manufactured at AMTZ. Medikabazaar's robust supply chain and health-tech platform will enable the fulfillment centre to streamline the distribution of medical equipment and supplies manufactured at AMTZ. This partnership will help both companies expand their reach and further strengthen the healthcare infrastructure of the region. This partnership between Medikabazaar and AMTZ is a significant step towards creating a more robust healthcare infrastructure in the region. It will undoubtedly help bridge the gap between manufacturers and end-users of medical equipment and supplies, ultimately benefiting patients and healthcare professionals alike. ]]> https://biospectrumindia.com/news/93/23059/aster-medcity-launches-advanced-heart-valve-centre.html https://biospectrumindia.com/news/93/23059/aster-medcity-launches-advanced-heart-valve-centre.html Mon, 08 May 2023 00:00:00 +0530 Aster Medcity has launched a specialised department named ‘Aster Advanced Heart Valve Centre’ under Aster Cardiac Sciences. The unique department focuses on the diagnosis and treatment of valvular heart disease and offers a comprehensive range of services, including medication, minimally invasive procedures, and surgical procedures such as valve repair or replacement. Dr Azad Moopen , Chairman & Managing Director of Aster DM Healthcare launched ‘Aster Advanced Heart Valve Centre’ in an event held in Kochi. The centre comprises a Heart Valve Clinic, collaborative services such as Heart Failure Clinic, and non-cardiology support from Vascular and General Surgery, Neurology, Nephrology, Infection Control, Stroke and Elderly care, and Psychiatric care. The centre also has a multidisciplinary Heart Team that specialises in valve disease diagnosis and management. Complex cases are discussed in the heart team to ensure the most scientific treatment.  “The centre is equipped with state-of-the-art imaging facilities, including the Vivid E95 echocardiographic machine with 3D transesophageal echo and intracardiac echo (ICE), which help in the evaluation and fine-tuning of procedures. The complex interventions are performed in a "Hybrid Cath Lab," which can also act as a surgical theatre if needed. Mechanical circulatory support systems like ECMO are also used for appropriate cases”, said Dr Anil Kumar R, Senior Consultant Cardiologist, Aster Medcity.    ]]> https://biospectrumindia.com/news/93/23058/diplomats-france-germany-canada-uk-explore-medtech-business-prospects-in-india.html https://biospectrumindia.com/news/93/23058/diplomats-france-germany-canada-uk-explore-medtech-business-prospects-in-india.html Sat, 06 May 2023 00:00:00 +0530 Medical Technology Association of India (MTaI) which represents leading research-based medical technology companies with significant investments in Manufacturing, R&D, and Healthcare worker training in India, recently hosted a high-level roundtable in New Delhi with medtech industry captains and international diplomats from various Embassies. With the theme “Capitalising opportunities for Global MedTech companies in India”, the roundtable included Dr Stephan Hesselmann, Minister Councillor, Embassy of Germany; Eric Fajole, Trade Commissioner, Embassy of France; Prashanth Nair, Managing Director, High Commission of Canada and one representative from the British High Commission. Pavan Choudary, Chairman, MTaI said, “India is a natural ally for the Western countries including Japan, and is emerging as one of the most attractive destinations for foreign players looking to invest in the healthcare space. The opportunities for global MedTech players to collaborate lie in R&D, Healthcare worker skilling, harnessing India as the China+1 destination in Asia in Manufacturing, Conducting Clinical Trials, and striking Academic partnerships.” Adding further to the roundtable discussion, Dr Stephan Hesselmann, Minister Councillor, Embassy of Germany added, “Germany is one of India's largest trading partners in the European Union, and India is one of Germany's most important economic partners in Asia. More than 2000 German companies have remarkable investments in India with sectors ranging from automotive, engineering, chemicals, pharmaceuticals, and MedTech." Eric Fajole, Trade Commissioner, Embassy of France said, “France and India have a long-standing history of business ties, which has been strengthened by growing economic and strategic cooperation in recent years. The two countries have established strong trade relations across several sectors, including aerospace, defense, energy, information technology, and healthcare. French companies have been investing in India for several decades, and today, France is one of the top ten investors in India. Similarly, India has become an important market for French companies, with several major French multinationals having a significant presence in the country.” According to Sanjay Bhutani, Managing Director, Bausch & Lomb, “With the increasing demand for medical devices and technology in India, global MedTech companies have an opportunity to develop products and solutions that cater to the specific needs of the Indian market.”   ]]> https://biospectrumindia.com/news/93/23047/aiims-and-medtronic-partner-to-open-new-surgical-robotics-training-centre-in-new-delhi.html https://biospectrumindia.com/news/93/23047/aiims-and-medtronic-partner-to-open-new-surgical-robotics-training-centre-in-new-delhi.html Wed, 03 May 2023 00:00:00 +0530 All India Institute of Medical Sciences (AIIMS) New Delhi and India Medtronic, a wholly owned subsidiary of Ireland-based Medtronic plc, has announced the opening of a state-of-the-art surgical robotics training centre at AIIMS, New Delhi. The centre will provide surgeons with best-in-class training in robotic-assisted surgery. It is the first such centre at AIIMS utilising Medtronic’s Hugo robotic-assisted surgery (RAS) system, which was first introduced in India in September 2021. RAS is an emerging medical technology that can help standardise surgical procedures and enable surgeons in performing complex surgeries. The training centre will offer a broad spectrum of training to enhance the knowledge and skill set in RAS, ranging from basic skills training to procedural training to more advanced and specialized areas in soft-tissue surgery. The training will help impart procedural knowledge skills using surgical robotics among surgeons, fellows, and residents from across the country.The Hugo robotic-assisted surgery (RAS) system is not cleared or approved in all markets. Regulatory requirements of individual countries and regions will determine approval, clearance, or market availability. In the US, the Hugo RAS system is an investigational device not for sale. “Medtronic’s partnership with AIIMS is a cornerstone of our commitment to make the benefits of RAS available to more patients in India. Together, we will make training and education on the latest technology more accessible and enhance the skill sets of both current and the next generation of surgeons,” said Michael Blackwell, Vice President & Managing Director, Medtronic India. ]]> https://biospectrumindia.com/news/93/23006/medtech-firm-murata-vios-to-double-headcount-in-next-five-years-in-india.html https://biospectrumindia.com/news/93/23006/medtech-firm-murata-vios-to-double-headcount-in-next-five-years-in-india.html Wed, 26 Apr 2023 00:00:00 +0530 Murata Vios, one of leading manufacturers of Remote Monitoring Devices, with operations in India and the US, has in place a strategic and a well-researched plan to enter the different market segments of the healthcare industry in India. Speaking to BioSpectrum, Amit Patel, Co-Founder and CEO, Murata Vios, who was recently on his first visit to India after COVID-19 outbreak, said, "the company plans to cater to the specific needs of the healthcare industry in India and establish a trustworthy name in the medical device fraternity. For this, we will double our headcount in the next five years.” With a mission to reduce healthcare facilitation costs, deliver greater clinician productivity, increase operational efficiency, and improve patient outcomes, the company has reached out to 15 hospital partners spread across Tier 1 cities and few Tier II cities such as Bangalore, Mangalore, Hyderabad, Mysore, Pune, Delhi etc. The company is also planning to expand its operations to the Middle East, Europe and Japan in the next 12-18 months. Murata Vios is working on formalities of introducing the range of devices/ technologies it has to fulfil the stringent regulatory requirements in the developed markets such as Japan and Europe. “I feel in the next 12-18 months our devices will be made available in Japan, Europe and the Middle East.” Murata Vios today specialises in medical-grade IoT sensors and remote monitoring services for clients such as hospitals, medical and surgical units, step-down units, specialty care units, long-term acute care hospitals, skilled nursing facilities, and ambulatory surgery centres. ]]> https://biospectrumindia.com/news/93/23002/scientists-in-guwahati-develop-new-device-for-wearable-sensors-and-point-of-care-testing-.html https://biospectrumindia.com/news/93/23002/scientists-in-guwahati-develop-new-device-for-wearable-sensors-and-point-of-care-testing-.html Tue, 25 Apr 2023 00:00:00 +0530 A new flexible bio-electronic uric acid detecting device has been fabricated by the researchers from the Institute of Advanced Study in Science and Technology (IASST), Guwahati that can be used for various applications such as wearable sensors and point-of-care diagnostics. Uric acid is one of the most important antioxidants that maintain blood pressure stability and reduce oxidative stress in living beings. However, the fluctuation of uric acid levels due to the lack of balancing between the production and excretion causes several diseases like hyperuricemia, which in turn may lead to gout disease, type 2 diabetes, increase risk of cardiovascular diseases, Lesch–Nyhan syndrome, hypertension, and renal disorders. The fabricated device shows reversibility in interaction with the uric acid, which repeatedly enables the use of the device for sensing experiments. It outperforms all currently available ones in terms of effectiveness and cost because it doesn't need any enzymes. The response of the fabricated device was investigated with real samples like human blood serum and artificial urine. The device thus developed is simple, portable, cost-effective, and easy to fabricate for detecting uric acid with a limit of about 0.809 µM. ]]> https://biospectrumindia.com/news/93/22992/first-time-national-level-expo-on-medical-devices-sector-taking-place-in-gujarat.html https://biospectrumindia.com/news/93/22992/first-time-national-level-expo-on-medical-devices-sector-taking-place-in-gujarat.html Mon, 24 Apr 2023 00:00:00 +0530 To highlight the capabilities of Indian Medical Devices Sector under the G-20 Indian Presidency, the first ever expo being spearheaded by the Government in association with Indian medical devices industry, the three-day India MedTech Expo (IMTE)-2023 will be held in Gandhi Nagar, alongside the G-20 Health Ministers meeting in August 2023, for showcasing the capabilities of Indian Medical Devices Industry and to create opportunities to network and explore collaborations both for the sector’s growth in India and its potential contribution globally. Department of Pharmaceuticals is planning to organise a large-scale first-time National Level Expo on Medical Devices sector for three days (18-20 August 2023), at Helipad Exhibition Centre, Gandhi Nagar, Gujarat. The G-20 Health Ministers meeting is scheduled at Gandhi Nagar from 17-19 August 2023. India MedTech Expo, rescheduled to be held in January 2023, received tremendous response from the MedTech Industry and with the plan to host the same in August 2023 in alignment with the G-20 Health Ministers meeting, will give the much needed boost to this Sunrise Sector, which the Department of Pharmaceuticals is supporting through various initiatives such as PLI scheme, Medical Devices Park Scheme, etc. About 150+ startups, more than 275 Indian and International Medical Device companies and MSME units, and about 50 Research Institutions will be participating in the Expo. About 200 foreign buyers will be hosted for B2B engagement.   ]]> https://biospectrumindia.com/news/93/22981/mtai-invites-diplomats-from-various-countries-to-discuss-opportunities-for-global-players-in-india.html https://biospectrumindia.com/news/93/22981/mtai-invites-diplomats-from-various-countries-to-discuss-opportunities-for-global-players-in-india.html Thu, 20 Apr 2023 00:00:00 +0530 Medical Technology Association of India (MTaI) which represents leading research-based medical technology companies with significant investments in Manufacturing, R&D, and Healthcare worker training in India, is coming up with their first meeting for this financial year and a day-long event to discuss the opportunities & challenges for the MedTech industry in India.   The event will take place on 5th May 2023 at J W Marriott, Aerocity, New Delhi. The event will also include a high-level roundtable with the theme “Capitalising opportunities for Global MedTech companies in India” where diplomats from countries like the United States, United Kingdom, France, Germany, Japan, Denmark, Netherlands, Sweden, etc. are likely to participate.   Speaking about the event, Pavan Choudary, Chairman, MTaI said, “The growing hospital capacity and the Govt. of India’s Emphasis on this sector is making India a favourite spot for the MedTech Industry. Additionally, India also provides a China +1 alternative for global investors as it shares a similar market, political systems, and a history of peace with the West and Japan. We feel that domestic and international currents will together help carve out key policy recommendations and initiatives which will be instrumental in furthering the MedTech industry in India. ” ]]> https://biospectrumindia.com/news/93/22966/omron-healthcare-enters-at-home-heart-monitoring-management-segment.html https://biospectrumindia.com/news/93/22966/omron-healthcare-enters-at-home-heart-monitoring-management-segment.html Tue, 18 Apr 2023 00:00:00 +0530 Omron Healthcare India has announced its foray into remote home heart monitoring and management segment via collaboration with Bengaluru-based firm Tricog. The endeavour aims to further improve the country’s cardiovascular disease management ecosystem with the launch of TriCare, a remote patient management platform combining the synergies of Omron’s connected monitoring devices and Tricog’s artificial intelligence (AI)-based health data analytical capabilities. The collaboration aims to deliver technology that enables monitoring of heart conditions at home, and AI that enables timely interventions to focus on urgent & unmet needs that lead to excess mortality and morbidity. This includes scenarios of delayed detection of symptoms and diseases (for secondary healthcare level segment patients) that might cause cardiovascular events like heart failure amongst hypertensive patients. Regular measurement of symptoms, vital parameters and an electrocardiogram (ECG) at home can prevent cardiovascular events however it is challenging owing to varied factors like shortage of ECG measurement devices at hospitals & clinics, irregular availability of cardiologists to interpret the clinical data and the need for more accurate & easy-to-use home monitoring devices.   Image caption- Katsuyuki Yamamoto, Manager New Business & Marketing, OMRON Healthcare India with Dr Charit Bhograj, Founder and CEO, Tricog Health ]]> https://biospectrumindia.com/news/93/22962/manipal-hospitals-enhances-use-of-high-end-minimally-invasive-procedures.html https://biospectrumindia.com/news/93/22962/manipal-hospitals-enhances-use-of-high-end-minimally-invasive-procedures.html Mon, 17 Apr 2023 00:00:00 +0530 Bengaluru-based Manipal Hospitals has announced the partnership with an established hospital campus, Queen Elizabeth University Hospital (QEUH) in Glasgow, Scotland.  This initiative will provide more academic opportunities for interventional radiologists from Manipal Hospitals which will help them learn advanced techniques and high-end procedures. Similarly, trainees from QEUH, Glasgow, will be able to spend time learning the new techniques adopted by the doctors in Manipal Hospitals. With this strategic partnership, Manipal Hospitals and QEUH will create new avenues for academic collaboration, innovation, and excellence in Interventional Radiology, benefiting patients and healthcare professionals alike. Interventional Radiology (IR) is a rapidly growing medical specialty that treats complex diseases, such as uterine fibroids, enlarged prostate, dialysis access, thyroid nodules, hemoptysis (coughing up blood), varicose veins in the legs, liver and kidney cancers, pelvic congestion syndrome, through minimally-invasive methods. This initiative can be a stepping stone to the highest possible quality care and advancement in the treatment methods for patients in India. ]]> https://biospectrumindia.com/features/93/22918/who-put-the-brakes-on-med-devices-sector-growth.html https://biospectrumindia.com/features/93/22918/who-put-the-brakes-on-med-devices-sector-growth.html Tue, 11 Apr 2023 00:00:00 +0530 According to statistica.com, India’s medical devices segment is projected to touch $5.99 billion in 2023 and the market volume of the cardiology devices segment, the largest segment in the medical devices sector, is projected at $0.85 billion. The revenue is expected to show an annual growth rate (CAGR 2023-2027) of 8.35 per cent, resulting in a market volume of $8.26 billion by 2027. The government has set up a Medical Device Park Scheme with a total financial outlay of Rs 400 crore to establish common facilities across several states. The government has also provided various incentives, such as tax exemptions and subsidies, to promote the growth of the medtech sector. Additionally, the government is also making concerted and coordinated efforts on R&D and innovation in the pharma medtech sector to indiscriminately develop cutting-edge products and technologies. Medical device imports continued to grow at an alarming level by 41 per cent in FY22, on account of low duties and convenience to import. While initiatives like Make in India and Atmanirbhar Bharat Abhiyaan have given a much-needed thrust to the manufacturing of medical devices in the country, schemes like the Production Linked Incentive (PLI) Scheme and promotion of Medical Device Parks still need a boost for promoting domestic manufacturing of medical devices. Prime Minister Narendra Modi, during a recently held webinar on ‘Health and Medical Research’, said that several new schemes have been launched in the last few years given the possibilities in the pharma and medical device sector. More than Rs 30,000 crore have been invested in schemes like PLI whether it is the bulk drug park or developing the medical device park systems. The PM further mentioned that this market is going to touch Rs 4 lakh crore in the next two to three years. Work has begun to acquire skilled manpower for future medical technology, high-end manufacturing and research initiatives. Biomedical engineering or similar courses will also be introduced for training in the manufacturing of medical equipment, in IITs and other institutions. Himachal Pradesh recently signed 17 Memoranda of Understanding (MoU) amounting to Rs 2,110 crore at the pharma-expo in Mumbai. Himachal Pradesh showcased the pharma ecosystem of the state to invite potential pharma device players for investments in the upcoming Medical Devices Park in the state. The state has a 300-acre medical devices park in Nalagarh. According to the state government, it will provide liberal incentives and highly subsidised utility rates for manufacturers in medical devices parks.   The growth story In March 2022, Wipro GE Healthcare announced a new 35,000 sq ft medical device manufacturing factory in Bengaluru. It will manufacture CT, ultrasound imaging devices, cath lab equipment, patient monitoring solutions, ECG machines and ventilators. In April of the same year, Siemens Healthineers started its new computed tomography scanners manufacturing facility in Bengaluru.  Apart from this, the government-sanctioned four medical device parks (in Madhya Pradesh, Tamil Nadu, Himachal Pradesh, and Uttar Pradesh) of about 1,326 acres and will also provide a maximum grant-in-aid of Rs 400 crore (Rs 100 per park) or 70 per cent of the common infrastructure cost, whichever is less. AMTZ in Andhra Pradesh supplied 1 million RT-PCR kits per day at the peak of the pandemic. Transasia Diagnostic Pvt Ltd (TDPL) launched the first-in-India Transasia-Erba Monkeypox RT-PCR kit in August 2022, and the company can manufacture more than 200 million Monkeypox RT-PCR kits per month. Sahajanand Medical Technologies (SMT) has set up Asia's largest stent manufacturing and R&D facility at Hyderabad Medical Devices Park. The facility aims to manufacture more than one million stents and two million balloon catheters.  However, there seems to be some mismatch between what the government is promoting and what the industry is demanding.   Unheard voices of the industry  Several associations that represent the medtech sector in India, such as the Association of Indian Medical Device Industry (AIMED) and the Medical Technology Association of India (MTaI), have been actively engaging with the government to address issues faced by the sector. While it may be beneficial for these associations to come together to form a larger lobby, it is important to recognise that each association has its own unique goals and objectives. Pavan Choudary, Chairman, MTaI says, “Several of the trade associations already have or claim to have a large number of members, therefore it is not a matter of forming a larger group. Rather, compelling arguments and actual investments should tilt the scale in favour of the side which has them. As far as we know, the biggest investments in the sector, whether in manufacturing or R&D, come from global investors. These remarkable contributions, which are spread across the country, have been instrumental in the growth of the medtech industry.” MTaI members have 12 state-of-the-art manufacturing units and eight research and development centres with footprints in states like Maharashtra, Haryana, Telangana, Tamil Nadu, Himachal, Gujarat, Karnataka, and Punjab. MTaI member companies also train more than two lakh healthcare workers annually. According to Jatin Mahajan, Secretary, Association of Diagnostic Manufacturers of India (ADMI) and MD, J Mitra & Company,  “There is absolute unity in diversity. There are numerous associations within the overall ambit of medtech and they represent the unique subsets within it. Naturally, for all associations, it is paramount to first address their members' problems and primary needs before looking at other associations’ issues or needs. The individual associations continue to make representations and recommendations to the Centre, seeking redressal. A primary problem for one segment may be secondary for another and non-existent for the third. The associations continue to join hands and make collective representations for common issues.”   AiMeD is an umbrella association of Indian Manufacturers of Medical Devices and is quite vocal for the causes of the med devices sector. Alongside AiMeD there are associations like the All India Syringe & Needle Manufacturers Association (AISNMA), the association for needle manufacturers, a manufacturing association for surgical dressings, the manufacturing association for surgical blades, Preventive Wear Manufacturers Association of India (PWMAI) that takes care of PPE coveralls and gowns, masks etc.  Says Rajiv Nath, Forum Coordinator, AiMeD, “We have a common agenda and we commonly seek these points and the smaller regional associations operate specific associations that look at AiMeD to lead the way and for wider leadership. Unfortunately, other associations like FICCI, CII, are dominated by overseas manufacturers having offices in India who, in many cases, don't even have a factory in the country but claim to be the voice of the industry. Unless they produce in India, they cannot feel the pains of manufacturers in India.” According to Dr Sanjeev Relan, Chairman, Preventive Wear Manufacturers Association of India (PWMAI), the industry is gearing up for compliance with medical device reporting (MDR), which will help Indian manufacturers go global as MDR will give a boost to manufacturing of quality products which are at par with global standards. He further mentions, “There are a few hurdles like coordination gap between Central and State Regulators, unavailability of complete ecosystem which includes testing labs and skilled manpower, willingness from industry to upgrade due to lack of capital. I believe if the above hurdles are taken care of, India can soon be a manufacturing hub for medical devices.”   Does the Govt favour Imported Products?  The government has come up with multiple initiatives and policies to promote India's medical device sector. A wide range of medical devices, from consumables to implantable medical devices that were not produced in India a decade ago, are now indigenously manufactured. However, a large number of devices and diagnostic equipment are still imported. Having said so, there is a need for the government to take some urgent steps to address the industry's pain points. As we are aware that clubbing medtech with drugs and cosmetics within the regulatory structure has created a lot of grey areas, although there is nothing common between them. According to Aravind Viswanathan, CEO, Transasia Bio-Medicals, “Even though the government has created a policy for purchase preference for Made in India products, unfortunately, this policy has not worked. In 95 per cent of government purchases, there is no preference given to 'Made in India' as the state governments are not implementing this policy”. It is exactly not clear on why the government is shying away from buying India-made products where data suggests that more imports are happening. One of the major reasons may be due to low quality products as compared to globally produced devices. It may be also due to lack of skilled manpower and high cost of equipment.   Focus on Innovation & Quality  The domestic manufacturing unit needs a big boost from the government. An urgent need to offer technologically advanced products that are customised for the Indian market is the need of the hour to improve the quality of products manufactured locally. Manufacturers need to ensure that the products are available to Indian patients at affordable rates. An increase in domestic manufacturing capacity and competitiveness would help the country don a new identity of ‘Making in India for the World’. This will also help India's exports grow at a record pace. Sachidanand Upadhyay, MD & CEO, Lord’s Mark Industries (LordMed, healthcare division of Lord’s Mark Industries) says, “The government exhorted the health sector to improve and upgrade manufacturing with the use of technology to reduce dependence on the large imports that India makes. Indian manufacturers can focus on innovation, R&D and quality to compete with imported medical devices.” The government should further promote medtech parks with specific ecosystems, benefits and sops. There should be easy access to standard testing and infrastructure facilities through the creation of world-class common infrastructure facilities for increased competitiveness. This will result in a significant reduction in the cost of production of medical devices leading to better availability and affordability of medical devices in the domestic market. Ganesh Sabat, CEO, SMT mentions, “As we envision to become a global hub by 2047, I would request the government to seize this opportunity to expand and accept R&D in the medtech sector done by local players, hence playing a pivotal role to revive the image of the domestic industry, who get intimidated by demands of US FDA/CE certifications.  With innovation in this sector happening rapidly, R&D incentives need to be re-looked at in addition encouraging procurement of innovative devices in central and state government purchase programmes, tax exemptions in medical devices parks where shared infrastructure to support medtech innovation such as shared raw material supplier base, testing services, among others are available. Besides, government and private companies should collaborate and make an effort to manufacture products of all ranges. Key education institutes like IITs should be enabled to use their might and research to ensure a futuristic focus on medical research, collaborative research and R&D to develop state-of-the-art medical technology, which is core to enhanced care delivery. The road to success is not easy and several challenges need to be taken into account. One of the major challenges is the lack of monitoring of unscrupulous Chinese devices that are marketed as Made in India products, impacting Indian manufacturers and patients alike. Ease of doing business by providing access to infrastructure, balanced policies and the right training to young people are some of the measures that need to be taken into account before the medical devices sector can see the day of light in the long run and make India proud. Associations need to work together for the betterment of the industry. While the government may not have provided as much relief as some may have hoped for, it is important to acknowledge the progress that has been made in recent years. However, several policy changes are required to further accelerate the Medtech sector’s growth. Incentivising R&D should become a norm and a robust industry-academia collaboration model will give the sector the much-needed boost.   Sanjiv Das (sanjiv.das@mmactiv.com)  ]]> https://biospectrumindia.com/news/93/22906/wadhwani-institute-deploys-ai-solution-for-tb-treatment-at-govt-health-facilities-in-haryana.html https://biospectrumindia.com/news/93/22906/wadhwani-institute-deploys-ai-solution-for-tb-treatment-at-govt-health-facilities-in-haryana.html Thu, 06 Apr 2023 00:00:00 +0530 Wadhwani Institute for Artificial Intelligence (Wadhwani AI) has announced the deployment of an AI solution to predict the risk of loss to follow-up (LFU) and mortality among tuberculosis (TB) patients when they start TB treatment from government-run health facilities in Haryana. The National TB Elimination Programme (NTEP) staff will provide intensive care to the AI predicted high-risk patients during six to twelve months of treatment. The AI solution, titled Comprehensive Loss to Follow-Up And Mortality Prediction (CLAMP-TB), was developed by Wadhwani AI under the USAID-supported TRACE-TB Project. CLAMP-TB will be used by NTEP staff across Haryana. Leading up to the launch of the study, Wadhwani AI conducted training sessions for NTEP staff in Gurugram, Bhiwani, Ambala, and Rohtak districts, to facilitate the usage of CLAMP-TB at approximately 157 government health facilities across the state of Haryana. The District TB Officers, data entry operators, Senior Treatment Supervisors, and TB Health Visitors will use this AI solution to predict and initiate targeted TB treatments for almost 12,000 high-risk patients in the next 15 to 18 months.   ]]> https://biospectrumindia.com/news/93/22895/medtronic-and-qure-ai-to-advance-stroke-management-using-ai-in-india.html https://biospectrumindia.com/news/93/22895/medtronic-and-qure-ai-to-advance-stroke-management-using-ai-in-india.html Tue, 04 Apr 2023 00:00:00 +0530 India Medtronic, a wholly owned subsidiary of Ireland-headquartered Medtronic plc, has announced a partnership with Mumbai-based startup Qure.ai to integrate artificial intelligence (AI) for advanced stroke management in India. The partnership combines Medtronic's leadership in neurosciences with Qure’s AI enabled innovations. The collaboration aims to provide AI solutions to comprehensive stroke centers as well as primary stroke centers and establish a hub-and-spoke network which is connected via technology. This network will aid in faster identification, decision making and triaging of stroke patients, thus potentially facilitating better patient outcomes. Qure’s comprehensive set of solutions, qER and the Qure app, are specifically designed to assist clinicians in streamlining the stroke care pathway for patients. qER provides a speedy reading and interpretation of head CT scans along with other vital parameters. All the information is captured in the Qure app which is a platform for communication and brings together multidisciplinary teams from different hospitals. The turnaround time of reading and diagnosing head CT appears to have reduced from ~65 mins to~2 mins using qER as per public records. ]]> https://biospectrumindia.com/news/93/22852/penumbra-picks-smt-as-exclusive-distributor-for-thrombectomy-technologies-in-india.html https://biospectrumindia.com/news/93/22852/penumbra-picks-smt-as-exclusive-distributor-for-thrombectomy-technologies-in-india.html Mon, 27 Mar 2023 00:00:00 +0530 Mumbai-based Sahajanand Medical Technologies (SMT) has been selected as the exclusive distributor of US-based Penumbra’s peripheral and coronary vascular thrombectomy technologies in select domestic geographies in India. Under the terms of the agreement, SMT will provide healthcare providers with Penumbra’s latest Indigo System portfolio, including CAT RX, which recently received India CDSCO (Central Drug Standard Control Organization) approval, and Lightning technologies, upon regulatory approval, to address conditions such as coronary thrombosis, venous thrombosis, arterial thrombosis and pulmonary embolism.  Penumbra’s Indigo System portfolio is designed for single session blood clot removal in peripheral arterial and venous systems, including the treatment of pulmonary embolism, and now with Lightning Aspiration Tubing, is the first and only computer-aided mechanical aspiration technology that can differentiate between clot and blood, which is designed to minimise blood loss. Additionally, Penumbra’s Indigo System CAT RX is designed for safe and efficient blood clot removal from the coronary and peripheral vasculature. ]]> https://biospectrumindia.com/news/93/22749/younger-generation-propels-15-cagr-of-indian-medical-devices-industry-.html https://biospectrumindia.com/news/93/22749/younger-generation-propels-15-cagr-of-indian-medical-devices-industry-.html Mon, 06 Mar 2023 00:00:00 +0530 The medical devices industry is growing at a CAGR of 10 to 15 per cent with the rise in awareness about preventive home healthcare and rising income levels in the younger generation. Yet, relatively untapped in the rural markets, the younger generation in urban areas is now investing in devices that help them track vital signs such as blood pressure, heart rate and blood oxygen levels. Moreover, the rise in the number of cases of cardiac arrests amongst the younger population has been an alarming factor for youngsters to consider monitoring their health periodically and keeping these devices handy. The medical technology devices industry is worth approximately six billion dollars  in India. It is a relatively nascent industry with low penetration which will increase over the years, according to experts. There is a huge shift in the age group of consumers buying health monitoring devices, with 58 per cent  of their buyers being younger audiences between the age group of 25 to 45 years. Interestingly, the age group of consumers purchasing medical devices has shifted from primarily seniors to a much younger demographic. According to Rajnikant Shah, Chairman of Medtech Life, a leading manufacturer of homecare electromedical devices in India, “The space has seen a steep rise in competition post pandemic. However, there has also been a rise in the awareness of these products thereby increasing the market size. There are many Indian importer brands and a couple of MNCs.” Talking about the challenges, he added, “We manufacture the products in our factory while many competitors just import from China which increases dependency on them. More investment in manufacturing in India will help make our country a manufacturing hub of the world.” “The analysis of buyers’ data over the last six months indicates that post COVID-19, consumers are opting for at-home monitoring solutions as a precautionary measure.The market for health monitoring devices is expected to grow substantially in the coming years, with innovations in technology making these devices more accessible and user-friendly for consumers of all ages”, concluded Rajnikant Shah.   Bhagwati Prasad ]]> https://biospectrumindia.com/news/93/22727/lifesigns-partners-with-kerala-based-amala-hospital-to-launch-smart-ward-technology.html https://biospectrumindia.com/news/93/22727/lifesigns-partners-with-kerala-based-amala-hospital-to-launch-smart-ward-technology.html Wed, 01 Mar 2023 00:00:00 +0530 Amala Hospital, a leading multi-disciplinary chain of hospitals based in Kerala, has launched a new and innovative smart ward with wearable wireless technology. This smart ward, the first in Kerala, is equipped with advanced technology that provides continuous patient monitoring and aims to improve patient outcomes and reduce the risk of medical errors. The hospital chain has partnered with Chennai based health-tech startup, LifeSigns to implement their iMS technology across cardiology and medicine departments at its hospital based in Thrissur, Kerala. One of the key features of the smart ward is its wireless patient monitoring system, with early warning scores which allows for real-time monitoring of vital signs and other important health indicators. This technology eliminates the need for traditional wired monitoring systems, which can be cumbersome and uncomfortable for patients, and provides a more efficient and effective way to monitor patient health. In addition to the wireless monitoring system, the smart ward is also equipped with monitors at nursing station, and patient information systems for the hospital, all of which work together to improve patient care and streamline the healthcare process.   ]]> https://biospectrumindia.com/news/93/22646/medical-grade-smartwatch-cardiacsense-receives-approval-from-us-fda-cdsco.html https://biospectrumindia.com/news/93/22646/medical-grade-smartwatch-cardiacsense-receives-approval-from-us-fda-cdsco.html Thu, 16 Feb 2023 00:00:00 +0530 Medtech solutions provider Xplore Health, with presence in Pune, Mumbai, Delhi and Bengaluru, has received approval from the Central Drug Standard Control Organisation (CDSCO) for its aspirational medical watch CardiacSense. The approval came ahead of its commercial launch in collaboration with Israeli medtech company CardiacSense Ltd. The product has already been approved by US Food and Drug Administration (FDA) and is the only medical watch to demonstrate accuracies higher than FDA set thresholds, making it one of the only approved medical watch. With its approval from CDSCO, the CardiacSense will be available in the Indian markets as well.  CardiacSense technology is designed to ensure that one is able to continuosly monitor their vital signs and whenever there is a notification raised by watch for increased or decreased heart rates or for arrhythmias, the watch prompts the user to take an ECG and share it instanly with the doctor for immediate advise. It is one such device that will enable doctors and hospitals to monitor patients 24/7 who have recently undergone major surgeries or those suffering from chronic heart disease or organ failure.   Having received approval from India, CardiacSense is now available in over 40 countries, including the US, all European countries, Australia, New Zealand, and many other South American countries. ]]> https://biospectrumindia.com/news/93/22638/industry-seeks-establishment-of-medical-devices-consortium-from-government.html https://biospectrumindia.com/news/93/22638/industry-seeks-establishment-of-medical-devices-consortium-from-government.html Wed, 15 Feb 2023 00:00:00 +0530 At the recently held International Health Dialogue, convened by Apollo Hospitals in New Delhi, a panel of biomedical experts deliberated upon the exisiting gap between academia and industry within the medical devices sector in India. It is but evident that academia and industry must unite to be able to offer indigenous medical devices and reduce the country's dependency on imports. But numerous challenges are still looming which need urgent attention. From the academic perspective, Prof Rohit Srivastava, Department of Biosciences and Bioengineering, Indian Institute of Technology (IIT) Bombay said, "We want large healthcare companies coming to IIT campuses, giving us problems, and seeking solutions. Once a product is ready, we as academicians find it difficult to get access to large patient samples, as medical devices need clinical validation." In sync with this thought, Prof Amit Mehndiratta, Centre for Biomedical Engineering, IIT Delhi said, "Many startups are emerging from IITs but they face challenges while scaling-up. We want industry to come to us at early stage of the product development, so that pivotal studies should be done with the industry." Dr Rajeev Gautam, President, Horiba India emphasised on the need to manufacture medical devices in India. "There is a suggestion to the government that a medical device consortium should be set up. At present, there is no platform in India where industry and academia can meet up and update each other about their recent work. This would in turn help fill the gap between industry and academia", he said. The experts further discussed about the increasing interaction between the doctors and academicians, to better understand the need of developing new medical devices for a number of health conditions. As a result of which, a number of doctors are now opting for a PhD in biomedical engineering in our country. " Biomedical engineering is no longer just a subject, it has become a standalone division", said Prof Mehndiratta. Prof Renu John, Biomedical Engineering Department, IIT Hyderabad further indicated for industry's support in manufacturing new devices with the academic sector, in line with the existing regulatory framework.   Image caption- L-R- Prof Amit Mehndiratta (IIT Delhi); Prof Rohit Srivastava (IIT Bombay); Dr Rajeev Gautam (Horiba); and Prof Renu John (IIT Hyderabad)   ]]> https://biospectrumindia.com/features/93/22541/leveraging-early-cancer-detection-tech-.html https://biospectrumindia.com/features/93/22541/leveraging-early-cancer-detection-tech-.html Sat, 04 Feb 2023 00:00:00 +0530 Cancer is associated with stigma, fear and anxiety. Apart from a cancer patient who has to undergo a host of tests and treatments like chemotherapy and radiation, the relatives accompanying the patients also suffer mental agony. India has a huge burden of cancer and according to Indian Council for Medical Research (ICMR) estimates on the ‘Burden of Cancers in India’, seven cancers accounted for more than 40 per cent of the total disease burden: lung (10.6 per cent), breast (10.5 per cent), oesophagus (5.8 per cent), mouth (5.7 per cent), stomach (5.2 per cent), liver (4.6 per cent) and cervix uteri (4.3 per cent). As per biomedcentral.com, the highest incidences of cancer are in the North (2,408 patients per 100,000) followed by the North East (2,177 per 100,000). Incidences of cancer are going to show an upward trend with lung and breast cancer being common among males and females and it is a worrying sign.  Cancers of the oral cavity and lungs in males and cervix and breast in females account for over 50 per cent of all cancer deaths in India. As a large proportion of cancers are diagnosed at the advanced stage, it leads to poorer survival, drainage of economic resources, along with loss of socio-economic productivity. Cancer prevention and early detection remain critical goals worldwide.  According to Keith T Flaherty, Director of Clinical Research, Massachusetts General Hospital Cancer Center, new methods that can be taken into primary care and remote care environments are not yet on the market, but are rapidly progressing in clinical validation studies. The biggest area of investment of development has been in blood-based methods for detecting DNA shed by cancer cells.  He goes on to add, “The ability of these methods to detect smaller and smaller quantities of circulating tumour DNA, now make it feasible to detect a single copy of tumour DNA in a 10 ml tube of blood, which is the needed level  to detect cancers at an early stage. Those tests also incorporate techniques for determining the 'cell of origin' in a way that suggests the cancer type that is developing. This is an important feature and it remains to be determined as to whether these tests will be equally useful across the spectrum of common cancers.”   Early screening The key to preventing cancer is early screening. Screening helps to locate early signs of cancer or precancerous conditions. This leads to the treatment being more likely to be successful and the chances of survival are much better. New technology developments such as Artificial Intelligence (AI), liquid biopsies, genome editing, telehealth, robotics and gene therapies amongst others are powering better diagnosis and helping accelerate progress against cancer. While global cancer incidence is on the rise, rapidly increasing medical evidence coupled with numerous innovations in cancer diagnosis and treatment is improving how cancer is getting identified. Liquid biopsy is the analysis of tumours using biomarkers circulating in fluids such as blood for early detection of cancer. Multi-cancer early detection (MCED) test is now available that offers the detection of the presence of multiple different types of cancers using a simple blood sample. It is an Next Generation Sequencing (NGS)-based test that uses AI algorithms to analyse methylation patterns of cell-free DNA (cfDNA) in blood.  AI-based algorithms are also available for screening cervical PAP smears to facilitate early detection of cervical cancer with higher accuracy. Theranostic markers are offered to the oncologists to guide targeted therapies and immunotherapy of their patients. A fully automated genomics laboratory for advanced molecular and genetic testing of cancers helps in detecting cancer. Real-time PCR, digital PCR, MLPA, Fragment Analysis, Sanger Sequencing, Pyrosequencing and Next Generation Sequencing are some of the methods being adopted in early cancer detection.  For breast cancer, self-examination, yearly mammography above the age of 40 years and targeted biopsies can detect a large proportion of cancers in the early stage. For cervical cancers, yearly PAP smear and human papillomavirus (HPV) testing followed by cervical biopsies for high-risk cases are helpful. Monitoring serum PSA levels can help triage men in need of early biopsy to detect prostate cancer. For oral cavity cancers, early consultation for non-healing ulcers, white patches, growth etc. will detect oral cancers early. Other forms to screen cancer are advanced immunohistochemical markers on biopsy or excision specimens which serve as surrogates for molecular testing, as well as molecular testing by fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-generation sequencing (NGS) are modalities we offer. These tests help to treat physicians in making informed decisions for patients to avail precision and targeted medicine.  However, Dr Jay Mehta, President & Head, Neuberg Oncopath mentions, “We are somewhere between developed and developing countries in the sense that we don't have as many extensive screening programmes as needed for a population our size, however, we have progressed in terms of increased awareness among common people, offering affordable screening tests so the people can access healthcare earlier than they would have.”   Breakthrough technologies Experts at the Imperial College London have recently developed a surgical knife capable of identifying tumours that can detect endometrial cancer within seconds. The surgical knife could aid the treatment strategies for cancer by enhancing the diagnosis time and giving the go-ahead for treatment. Dubbed Rapid Evaporative Ionisation Mass Spectrometry (REIMS), the surgical intelligent knife (iKnife) can rapidly identify human tissues in real time and is a form of ambient mass spectrometry. The intelligent surgical knife can locate the presence of endometrial cancer using standard electrosurgical methods. It is known to identify different tissue types, including lung, colon and liver. Innovation-driven company PredOmix with its cost-effective cancer detection blood test called OncoVeryx-F is capable of detecting early-stage cancers in women with 98 per cent accuracy. Backed by metabolomics-based technology, the new age innovation enables the screening for early-stage cancers. Designed for women, the screening tool accurately diagnoses cancer before tumour development begins with high specificity. Says Dr Kanury VS Rao, Co-Founder & CSO, PredOmix, “While global cancer incidence is on the rise, rapidly increasing medical evidence coupled with numerous innovations in cancer diagnosis and treatment is improving how we identify, perceive, comprehend, and treat cancer. What once seemed impossible in the field of cancer research is now a reality. Accelerating progress against this disease may be possible if these technologies are further investigated and used.” The current cancer screening solutions at Datar Cancer Genetics are CE accredited, with the US Food and Drug Administration (FDA) having granted 'Breakthrough Device Designation' for the early-stage breast and prostate cancer detection tests. Says Dr Vineet Datta, Executive Director, Datar Cancer Genetics, “Genetic research over the past few years has rapidly increased the incorporation of such solutions in clinical practice. With the benefits of genetic testing getting increasingly established, efforts must be made to increase access to genomic services for all who can benefit. India is at the cusp of a revolution in biotech innovation, and genetic tests offer diverse purposes, including screening and diagnosis of genetic disorders, prediction of drug responses and identifying therapies that provide personalised cancer care.” Apart from this, Virtual Tumour Board’s (VTB) National Cancer Grid (NCG) initiative aims to provide standardised care to individuals across the country. Different centres from across India join this virtual tumour board to discuss the management of oncology cases. Mention can be made of Karkinos Healthcare which aims to significantly enhance access to cancer care services by creating a technology-enabled data-driven platform and distributed cancer care model (DCCM), wherein the knowledge architecture is centralised and the delivery systems are democratised and distributed. The DCCM encompasses a ‘hub-and-spoke and further spoke’ hospital infrastructure on the back of robust technology and clinical decision support systems.     Dr Moni Abraham K, Co-Founder, Medical Director and CEO, Karkinos Kerala mentions, “We have a technology platform where a patient can assess whether there is an elevated risk of particular cancer or not. When somebody is diagnosed or suspected as a highly elevated risk, we need to send them to what we call a community cancer centre. We aim to significantly enhance access to cancer care services by creating a technology-enabled data-driven platform and DCCM, wherein the knowledge architecture is centralised, and the delivery systems are democratised and distributed. The DCCM encompasses a ‘hub-and-spoke and further spoke’ hospital infrastructure on the back of robust technology and clinical decision support systems.” Bengaluru-based Mestastop has created three proprietary platforms, both in vitro and in vivo, along with patient tumour translational validation, to unravel the complexity of metastasis drug discovery and early predictive diagnostics. These platforms are ready to be used for novel drug discovery, drug repurposing and profiling current anti-cancer leads or candidates for their anti-metastatic effect. About 9.6 million people died of cancer globally in the year 2016 and 90 per cent of those deaths were due to metastasis, i.e. spreading of the primary tumour to other parts of the body. Mestastop is not into the early detection of cancer but in the early detection of the metastatic probability of cancer, i.e., of solid tumours. According to Mestastop, a minimum of 10^9 (^ refers to the power of) cancer cells are needed to be recognised by a PET scan, and 10^5 cells are required to be detected by liquid biopsy. PET scan is the gold standard, as a liquid biopsy can still have false negatives. This means that even if one has 90,000 cancer cells in the body, the person will be clinically undetected. This highlights the importance of increasing the sensitivity of detection, or in other words, early detection, even when the cancer is small. Arnab Roy Chowdhury, Founder, Mestastop Solutions opines, “90 per cent of cancer deaths are due to metastasis, and once the tumour metastasises, i.e., spreads, there is almost no curative treatment. Clinicians use the node status of primary tumour patients to understand their metastatic probability, but it has a lot of variations and could be better. METSCAN can take a primary patient tumour and then predict its metastatic probability, thereby empowering clinicians in their decision-making ability.” Medical diagnostics company Harae Dx Corp has developed a next-generation automated multi-cancer early detection system to revolutionise current methods of cancer screening with liquid biopsies. The non-invasive portable rapid cancer diagnostic system can offer reliable test results in as little as 30 minutes. The system is based on a multi-application platform using a proprietary lab-on-a-disc centrifugal microfluidic technology. Says Dr Nitin Malekar, Director, Harae Dx Corp, “The primary goal of the screening programme is to detect cancer at an early stage, especially when an individual is asymptomatic and may have a family history. If detected early, the cure rates are better and the treatment is also not expensive, thus helping doctors and patients to accomplish the best results. Additionally, it reduces the morbidity, mortality and disease burden in the society at large.” Apollo Hospitals Navi Mumbai recently launched Apollo Genomics Institutes to provide comprehensive care to patients and families with genetic disorders. Genomic medicine is a new medical discipline that deals with genetic disorders and helps in the diagnosis and treatment of rare and inherited diseases. This move is likely to help in the early detection of cancer. Genetic research over the past few years has rapidly increased the incorporation of such solutions in clinical practice. With the benefits of genetic testing getting increasingly established, efforts must be made to increase access to genomic services for all who can benefit. India is at the cusp of a revolution in biotech innovation, and genetic tests offer diverse purposes, including screening and diagnosis of genetic disorders, prediction of drug responses and identifying therapies that provide personalised cancer care. Referring to enhancing survival rates, Manikandan Bala, Managing Director, India & SA, Senior Vice President, Direct Sales Strategies &, TIMEA & Asia Pacific, Elekta says, “Cancer survival increases with early detection. Unfortunately, when cancer is diagnosed, about 50 per cent of cases are already at advanced stages. Early intervention is made possible by early diagnosis of cancer or precancerous changes.” Elekta has launched innovative cancer treatment solutions. One such solution for radiation therapy is Elekta Harmony, a state of the art linear accelerator. It was unveiled on World Cancer Day. This technology is critical for curative cancer treatments. All the above technologies, among others, are likely to become game changers in early cancer detection and will indeed bring hope to the medical fraternity and patients. However, there remains a host of challenges while going in for early detection of cancer.       Underutilised facilities  General awareness about cancer including its risk factors and early symptoms is relatively low in India. Fewer people seem to be concerned about developing cancer in their lifetime in India compared to the global average. The natural outcome is that fewer people go in for screening tests like pap smears, and mammography as a routine practice.  Dr Rajiv Tangri, Technical Director of Histopathology and Cytopathology, Dr Lal PathLabs opines, “Despite the availability of cancer screening programmes and excellent clinical diagnostic facilities in India, the services are mostly under-utilised. Major challenges that we face in our war against cancer include – a low level of awareness amongst the general public about cancer, late detection of cancer, poor access to specialised cancer care especially in rural and remote parts of the country and high cost of treatment.” Almost 75-80 per cent of patients have advanced disease (Stage 3-4) at the time of diagnosis. This is mostly due to the late diagnosis which in turn is due to a low level of awareness in the population and among community physicians, lack of screening programmes, lack of diagnostic facilities locally and the requirement to travel long distances to reach a major tertiary cancer centre, financial constraints and stigma associated with the diagnosis. The situation is even worse in rural areas which constitute almost 70 per cent of the total population. This is further compounded by factors like limited finances, language and cultural differences etc. A large proportion of cancers are diagnosed at an advanced stage which leads to poorer survival, drainage of economic resources, along with loss of socio-economic productivity. Cancer prevention and early detection remain critical goals worldwide. India is still lagging in terms of the sensitivity and efficiency of liquid biopsy. However, on the brighter side, image-based detection, e.g., lung cancer has improved due to artificial intelligence.   The way forward Government bodies should evaluate the performance of the innovations to traditional techniques in mass screening programmes, following which certain tests/technologies can be incorporated into routine screening guidelines.  Dissecting the economics of cancer screening is key to ensuring the equitable distribution of resources and appropriate interventions to improve cancer outcomes via early detection. Early diagnosis can reduce the cost of treatment, with estimated cost-savings in the disease course to be two to four times less than those diagnosed at later stages, including the adverse financial impact on the patient and their family. Early diagnosis of key individual risk factors is crucial for improved prevention of serious illness. The cancer burden will continue to increase over the next 15-20 years, with much of this increase seen in parts of the world where the health systems are already struggling. The proportion of patients receiving genetic tests will only increase as more data points enumerate the benefits of such solutions. However, additional factors like regular cancer screening, healthy eating, vaccination, and avoiding tobacco and alcohol consumption remain critical strategies for not just preventing cancer, but also reducing the detrimental effects of cancer. The Government of India has taken proactive steps over the past decade in the prevention and early detection of cancer and has launched various schemes to strengthen cancer control activities. Expanding the ambit of the National Cancer Registry could halt morbidity and mortality rate.  As Dr Sundeep Jain, Founder GI & HPB Surgeon Abdominal Cancer Foundation, Jaipur, rightly points out, “While India has recently established the National Cancer Grid to promote the use of digital technologies and tools to improve cancer care across the country, the increased fund allocation would facilitate in tracking the clinical care and outcomes of a large sample space of the defined patient population. The data from the registry can also help device public health interventions to create awareness about prevention and early detection of these cancers.”  Cancer cannot be treated by building cancer centres alone. Currently, one in eight of us will develop cancer in our lifetime and the numbers are only going to increase. As with most health related dictums, everyone must adopt a ‘Forewarned is forearmed’ outlook to put a stop to cancer.   Sanjiv Das sanjiv.das@mmactiv.com ]]> https://biospectrumindia.com/news/93/22500/fujifilms-state-of-the-art-nura-health-screening-centre-opens-in-mumbai.html https://biospectrumindia.com/news/93/22500/fujifilms-state-of-the-art-nura-health-screening-centre-opens-in-mumbai.html Wed, 18 Jan 2023 00:00:00 +0530 Fujifilm India has announced the inauguration of its flagship health screening centre NURA which focuses on early detection of cancer and other lifestyle diseases. NURA is a collaboration between Fujifilm India and Dr Kutty's Healthcare. Fujifilm opened its first NURA health screening centre in Bengaluru, followed by Gurugram and now Mumbai, to launch its health screening service business in India. The NURA centre is equipped with Fujifilm’s various medical devices capable of providing high-definition images including CT scan and mammography system. The medical IT systems of NURA centres are based on artificial intelligence (AI) technology that are designed to support doctors, to carry out screening and tests for cancer and lifestyle diseases. Considering the needs of the financial capital of India that is driven by speed, efficiency, and accuracy, NURA centres accomplish the procedure of complete body screening in 120 minutes followed by a meeting with specialist doctor who explains the results of the screening.  Located at Worli in Mumbai, NURA health screening centre will tap into insights gained through health screening services. For example, users will be able to check screening results any time on their smartphones. There will also be a workflow that uses a wrist band with a QR code to manage the progress of each visitor to shorten waiting time for individual tests. Fujifilm’s health screening service business in India became recognized under the Supply Chain Resilience Projects in the Indo-Pacific region promoted by the Japanese Ministry of Economy, Trade and Industry, receiving high acclaim as an initiative that uses digital technology to contribute to solving social issues in emerging economies. The project involves building data coordination infrastructure based on blockchain technology to verify an AI-based mechanism for analysing screening data collected from the three NURA centres to provide feedback to NURA users.     ]]> https://biospectrumindia.com/news/93/22477/theranica-and-dr-reddys-bring-nerivio-to-millions-of-people-with-migraine-in-india.html https://biospectrumindia.com/news/93/22477/theranica-and-dr-reddys-bring-nerivio-to-millions-of-people-with-migraine-in-india.html Fri, 13 Jan 2023 00:00:00 +0530 Theranica, a prescribed digital therapeutics company based in Israel developing advanced neuromodulation devices for migraine and other pain conditions, has announced a strategic license and supply agreement with Hyderabad-based Dr. Reddy's Laboratories, for the exclusive marketing and distribution of FDA-approved Nerivio in India, subject to completion of the regulatory approval process in India. Under the terms of the agreement, Dr. Reddy's will be responsible for the regulatory approval of Nerivio in India, after which it will exclusively market Nerivio in India, manufactured and supplied by Theranica. The agreement includes licensing fees for exclusive rights to market Nerivio in India. While the agreement applies only to India, the companies will continue discussions about expanding to additional territories outside the United States and China. Nerivio is the first US FDA-cleared, prescribed, digitally connected, drug-free wearable device for the acute treatment of episodic and chronic migraine in individuals age 12 and older. Worn on the upper arm, Nerivio utilises remote electrical neuromodulation (REN) to trigger an endogenous descending pain inhibition mechanism known as conditioned pain modulation (CPM), which aborts or alleviates migraine headache and associated migraine symptoms. Clinical studies have shown Nerivio to be as effective as standard of care pharmacological options for acute migraine treatment. The company recently published topline results of a pivotal trial demonstrating the efficacy and safety of Nerivio for the preventive treatment of migraine, an indication currently under FDA review.   ]]> https://biospectrumindia.com/news/93/22437/teleflex-introduces-urolift-system-in-india-for-benign-prostatic-hyperplasia-treatment.html https://biospectrumindia.com/news/93/22437/teleflex-introduces-urolift-system-in-india-for-benign-prostatic-hyperplasia-treatment.html Tue, 03 Jan 2023 00:00:00 +0530 Teleflex Incorporated, based in the US, has announced the commercial launch of the UroLift System in India for treating benign prostatic hyperplasia (BPH), or enlarged prostate.  BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity,  depression, interrupted sleep, and decreased quality of life. The UroLift System is a minimally invasive approach to treating BPH that can be performed as a same-day outpatient procedure. The UroLift System provides rapid symptom relief for men with BPH and allows a quick recovery time for patients.  Arun Kaushik, Managing Director, South Asia,  Teleflex said, “This technology offers clinical benefits in the minimally invasive treatment of BPH and offers physicians more options in how they treat their patients." BPH cases with the  UroLift system have been performed in Max Super Specialty Hospital (Saket), Medanta The Medicity (Gurugram), Manipal Hospital (HAL  Road, Bengaluru,) and CURI Hospital (Chennai).   The UroLift System is a minimally invasive treatment for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50  years and above in India. In India, a  prostatic urethral lift like UroLift is an optional therapy and shall be offered as an alternative to patients presenting with moderate-to-severe LUTS who failed to respond to medical management and who are not tolerant or compliant to medical management. ]]> https://biospectrumindia.com/news/93/22331/healthium-sells-clinisupplies-divesting-continence-care-product-portfolio.html https://biospectrumindia.com/news/93/22331/healthium-sells-clinisupplies-divesting-continence-care-product-portfolio.html Tue, 06 Dec 2022 00:00:00 +0530 Bengaluru-based Healthium Medtech has entered into a definitive agreement to sell its UK-based subsidiary, Clinisupplies to KKR, which is investing through its KKR Health Care Strategic Growth Fund II. The company will re-invest the proceeds from the transaction to strengthen its portfolio in advanced surgery, wound care, orthopaedics, and post-surgical care through organic and inorganic routes. Based in Watford, UK, Clinisupplies was acquired by Healthium in 2016. The company has a strong portfolio of products in continence care and partners with the NHS to supply quality and cost-effective continence care products. The move marks Healthium&rsquo;s strategic decision to focus on innovation and expansion in areas that the organisation sees as its own core growth areas. Healthium will continue to remain in the UK through its surgical consumables portfolio. Healthium Medtech has a diverse portfolio of medical devices and consumables, which includes surgical sutures, needles, a patented arthroscopy portfolio, patented wound care portfolio, hernia meshes, haemostats, ligation clips, surgical staplers and other wound closure devices. Currently, the company has eight manufacturing facilities across India, and holds 64 patents across US, Europe and India (including pending applications).     ]]> https://biospectrumindia.com/news/93/22265/swedish-medtech-firm-c-rad-sets-up-india-experience-centre-for-precision-radiotherapy.html https://biospectrumindia.com/news/93/22265/swedish-medtech-firm-c-rad-sets-up-india-experience-centre-for-precision-radiotherapy.html Fri, 18 Nov 2022 00:00:00 +0530 Swedish medtech company C-RAD, the global leader in surface guided radiation therapy (SGRT) solutions, has established its first-ever Experience Centre in India at Faridabad in Delhi-NCR. Set up as a joint project with its India partner Marrsis Disha, the facility will train and upskill clinical professionals in precision radiotherapy. It will offer first-hand experience of C-RAD’s SGRT technologies and hands-on opportunities to explore how these can impact outcomes in cancer patients undergoing radiation therapy. SGRT is a tattoo-free alternative for patients who require radiation therapy. The technology uses advanced 3D camera technology to track and monitor patient movements during set-up and treatment. Said Rohan Mehtani, CEO, Marrsis Disha, who are C-RAD India partners and host for the Experience Centre: “Collaborating with C-RAD as their educational partners, we want to use this Experience Centre as a platform to promote cutting-edge technologies like SGRT. There is a huge unmet demand of radiation therapy equipment in India and not every patient is able to get treatment in time." The Experience Centre is equipped with C-RAD Catalyst+ HD system with complete software suite, including modules for respiratory gating, patient setup and positioning, and motion monitoring. It demonstrates accurate patient setup prior to the treatment and continuous monitoring of patient during a treatment fraction. The technology provides accuracy and safety for the patient to support high precision treatment techniques as well as efficiency in a complex treatment workflow.   ]]> https://biospectrumindia.com/news/93/22254/pharmaceuticals-medical-devices-converge-at-chitra-institute-in-thiruvananthapuram.html https://biospectrumindia.com/news/93/22254/pharmaceuticals-medical-devices-converge-at-chitra-institute-in-thiruvananthapuram.html Tue, 15 Nov 2022 00:00:00 +0530 Union Minister for Science and Technology Dr Jitendra Singh said that India is among the top five countries in the world manufacturing life-saving high risk medical devices but the cost of our devices is about one-third of those manufactured by the other four countries. Addressing the faculty and students after inaugurating Combined Devices Block at Chitra Triunal Institute of Medical Science and Technology in Thiruvananthapuram, Dr Jitendra Singh said that technologies developed by the institute like the artificial heart valve, hydrocephalus shunt, oxygenator and drug eluting intra uterine device are being manufactured in three to four countries like USA, Japan, Brazil and China. Dr Jitendra Singh said that the Combined Devices Block at Chitra Institute is a perfect example of convergence of pharmaceuticals and medical devices, and this must be institutionalised. He was happy to note that the institute is in the process of setting up a medical device park, MedSpark, as a joint initiative with the Kerala State Industrial Development Corporation, Government of Kerala. He said, new initiatives in the combination devices will definitely help the institute to take up a more significant role in supporting the Indian Medical Device Industry for strengthening its indigenous capability. ]]> https://biospectrumindia.com/news/93/22235/xplore-health-technologies-launches-smart-respiratory-training-device-airofit-pro-in-india.html https://biospectrumindia.com/news/93/22235/xplore-health-technologies-launches-smart-respiratory-training-device-airofit-pro-in-india.html Fri, 11 Nov 2022 00:00:00 +0530 Pune-based Xplore Health Technologies has come up with a first-of-its-kind respiratory muscle training (RMT) device called Airofit PRO in collaboration with Airofit, Denmark. Lying at the intersection of advanced medtech and modern respiratory medicine, it is the world’s first personal data-driven smart respiratory training system. Possessing the ability to pair with a smartphone, Airofit PRO can truly personalise the breathing training experience for anyone making their respiratory muscles stronger, faster, and more efficient. Importantly, the device can train both inspiratory and expiratory muscles, another unique feature. Essentially, the device works by subjecting the diaphragm and other breathing muscles to resistance training, an exercise involving resistance wheels providing adjustable but restricted airflow to the individual. To explain, since the resistance causes fatigue in breathing muscles, it gets compensated by muscle tissue growth thereby making respiratory muscles more robust allowing longer and deeper breathing.    Offering 17 unique breathing sessions, the device has a real-time live guidance platform that guides a person through all exercises and sessions while tracking his progress derived from real-time data. Moreover, going beyond simple respiratory muscle training, the device also addresses other related aspects of breathing such as Respiratory strength, Vital capacity, Anaerobic threshold, and relaxation.     ]]> https://biospectrumindia.com/news/93/22194/medtronic-launches-new-tool-for-diagnostic-and-operative-hysteroscopy-in-india.html https://biospectrumindia.com/news/93/22194/medtronic-launches-new-tool-for-diagnostic-and-operative-hysteroscopy-in-india.html Tue, 01 Nov 2022 00:00:00 +0530 India Medtronic, a wholly owned subsidiary of Medtronic plc, has announced the launch of the TruClear system, a mechanical hysteroscopic tissue removal system used for the safe and effective treatment of intra uterine abnormalities (IUA). Some of the commonly seen IUA includes fibroids, polyps, retained products of conception, adhesions, malignancies, or hyperplasia. One of the symptoms of IUA is abnormal uterine bleeding (AUB) which is reported to occur in 9-14% women between menarche and menopause. The prevalence varies in each country. In India, the reported prevalence of AUB is around 17.9%.  “TruClear system is a new addition to our GYN and women’s health portfolio and by introducing innovations like these we’re bringing choice, control and confidence to women’s healthcare in India. The system is built to facilitate a less invasive and effective way of treating intra uterine pathologies, giving patients the choice to retain the organ and go back to routine faster. Its precision and enhanced visibility provides gynecologists much needed comfort and helps avoid complications, yielding better patient outcomes,” said Abhishek Bhargava, director, Surgical, Patient Monitoring, Respiratory Interventions & ENT, Medtronic India. TruClear is a next-generation device that provides practitioners with a clear operative field and patients with gentle mechanical resection during procedure to help efficiently execute a hysteroscopy. Unlike other intrauterine abnormality treatment options that use a high-frequency electric current, the TruClear system uses a simple mechanical approach to remove intrauterine tissue. Therefore, there is no scarring of the uterine lining from thermal energy or electrical energy, thus providing more hope of preserving the uterus for the future. ]]> https://biospectrumindia.com/news/93/22186/south-asias-first-most-advanced-model-of-cath-lab-opens-in-mumbai.html https://biospectrumindia.com/news/93/22186/south-asias-first-most-advanced-model-of-cath-lab-opens-in-mumbai.html Fri, 28 Oct 2022 00:00:00 +0530 DY Patil Medical College, Hospital & Research Centre, one of Mumbai’s most renowned healthcare facilities, has launched Navi Mumbai’s first ever IGS 6 - AutoRIght Advanced Bi-Plane Cath Lab that combines the latest advancements in Cath lab Technology with Artificial Intelligence (AI).  This state-of-art facility was inaugurated by Dr Mansukh Laxmanbhai Mandaviya, Minister of Health and Family Welfare and Chemicals and Fertilizers, Government of India. This is South Asia’s first state-of-the-art, most advanced model of Cath Lab and the IGS 6 from Wipro GE Healthcare is the first AutoRight enabled Cath Lab in India.  Till now more than 25,000 cardiac interventions have been done by Cardiology Department of the hospital. This new addition is designed to especially be beneficial to cardiac patients. Some of the other benefits of this Bi-plane AI enabled Cath lab are faster interventions for faster recovery; high-definition 3D imaging for treatment accuracy; AI enabled dose optimisation for patient safety; and augmented reality (AR) enabled/intuitive clinical tools for improved outcomes.  ]]> https://biospectrumindia.com/news/93/21962/padma-shri-awardee-dr-sandra-desasouza-launches-book-on-cochlear-implants.html https://biospectrumindia.com/news/93/21962/padma-shri-awardee-dr-sandra-desasouza-launches-book-on-cochlear-implants.html Thu, 15 Sep 2022 00:00:00 +0530 Padma Shri winner, ENT Head, Neck, and Cochlear implant surgeon, Dr Sandra DeSaSouza’s new book ‘Cochlear Implants: New and Future Directions’ is a compelling testimony about the benefits of cochlear implantation and its life-changing capabilities. With the book, she hopes to continue to positively influence the lives of thousands of hearing impaired by encouraging them to take advantage of the amazing advancements in modern medicine and technology. Published by Springer Nature, ‘Cochlear Implants: New and Future Directions’ is available on Kindle and will be available in hard copy soon. As the name suggests, the book traces the journey of cochlear implants, right since the time when the first implant was conceived around 50 years ago to today, when modern cochlear implants are smaller and provide far better hearing and speech discrimination with the evolution of technology. She became the first Indian doctor to perform cochlear implant surgery in 1987, at a cochlear implant workshop organised at Jaslok Hospital. Over the years, her funding programme to offer surgery to underprivileged children has changed around 2,800 lives, and in 2020, she won the Padma Shri for her efforts.   ]]> https://biospectrumindia.com/news/93/21954/reconstituted-national-medical-device-promotion-council-holds-first-meeting.html https://biospectrumindia.com/news/93/21954/reconstituted-national-medical-device-promotion-council-holds-first-meeting.html Wed, 14 Sep 2022 22:20:00 +0530 The reconstituted National Medical Device Promotion Council (NMDPC) under the Department of Pharmaceuticals, in its first meeting held at Dr Ambedkar International Centre in New Delhi, was updated on the steps taken up by the Central Drugs Standards and Control Organisation (CDSCO) and the State Licensing Authorities (SLAs) for the smooth transition to licensing of Class A and B Medical Devices w.e.f October 1, 2022.   The council under the chair of the Secretary, Department of Pharmaceuticals has members from stakeholder departments/organisations, functions of which have a bearing on the growth of the sector and has representation from several medical device industry associations, representing the sector in India. The NMDPC deliberated on the important issues of the medtech industry.    At the outset, the Department of Pharmaceuticals presented the latest status of the various initiatives taken by the Department for the sector to the Council such as 100 per cent FDI in the medtech sector on the automatic route, PLI scheme for medical devices, medical devices parks in four states, assistance for common infrastructure facility of superconducting magnetic coil testing facility, etc. The department is also engaging the medical devices industries for arriving at a consensus on the industry issues by forming standing forums and by organising regulatory round tables.    Department of Health and Family Welfare updated the preparedness for transition to licensing of Class-A and Class-B medical devices, w.e.f October 1, 2022, under Medical Devices Rules 2017.    Another important issue deliberated was to reduce the regulatory burden of labelling requirements of Medical Devices. The council, after deliberating the issues with the industry associations, suggested to the Health Regulator to move forward to harmonise the provisions of labelling of Medical Devices under the Legal Metrology (Packaged Commodity) Rules, 2011 into Medical Device Rules, 2017, for the licensed medical devices.            ]]> https://biospectrumindia.com/news/93/21835/c-camp-signs-mou-with-aster-hospitals-to-boost-clinical-participation-in-biomed-tech-developments.html https://biospectrumindia.com/news/93/21835/c-camp-signs-mou-with-aster-hospitals-to-boost-clinical-participation-in-biomed-tech-developments.html Mon, 22 Aug 2022 15:45:00 +0530 Centre for Cellular and Molecular Platforms (C-CAMP) has joined hands with Aster Hospitals Bangalore, to kick off a joint innovation development programme, C-CAMP Aster Clinical Innovation Hub. The agreement was signed at C-CAMP by Dr Taslimarif Saiyed, CEO and Director, C-CAMP and Dr Shugota Chakrabarti, Chief of Medical Services, Aster Hospitals, Bangalore.The MoU envisages a bridge between clinicians, healthcare practitioners and innovators for joint ideation and problem solving through product development, validation, mentorship, and capacity building. The agreement has identified the following areas of cooperation: Antimicrobial resistance (AMR) for greater exchange on key topics such as Infection Prevention and Control, Stewardship etc, clinical validation of emerging technologies for improved problem identification and solution and clinical and medical mentorship for C-CAMP startups and SMEs and knowledge building through joint scientific programmes. Of these, AMR is a priority although the MoU is open to other areas of mutual interest. ]]> https://biospectrumindia.com/news/93/21823/trivitron-healthcare-opens-rd-centre-at-amtz-campus-vishakhapatnam.html https://biospectrumindia.com/news/93/21823/trivitron-healthcare-opens-rd-centre-at-amtz-campus-vishakhapatnam.html Fri, 19 Aug 2022 15:10:00 +0530 Trivitron Healthcare has launched a centre of excellence with state-of-the-art R&D and manufacturing facilities at AMTZ Campus, Vishakhapatnam. The launch ceremony was attended by Prof Ajay Kumar Sood, Principal Scientific Advisor to the Government of India and Prof (Dr) Balram Bhargava, Former Director General, Indian Council of Medical Research.   Dr GSK Velu, Chairman & Managing Director, Trivitron Healthcare said: "This centre will implement research and innovation in the field of Metabolomics, Genomics, Newborn Screening, and Molecular Diagnostics and bring out cost-effective and affordable medical technology products and services." The centre includes an Advanced Genomics and Molecular diagnostics facility for developing kits and reagents for Next Generation Sequencing (NGS) and Oligonucleotide synthesis (synthesis of customized primers and Taq Man Chemistry dual labelled probes), Protein Chemistry (design and expression of different recombinant enzymes and proteins), Cell culture and analytical lab. The company plans to manufacture all the raw materials and components of molecular diagnostics, NBS, and NGS in-house following advanced protocols and research approaches. The new centre of Trivitron will have provision to manufacture 300 million RT-PCR tests and over 70 million tests of Rapid Card/POCT per annum. Additionally, more than 100 million tests can be manufactured for Genomics, ELISA, CLIA, NBS and other diagnostics kits.     ]]> https://biospectrumindia.com/news/93/21538/medisim-vr-unveils-vr-lab-in-puducherry-based-medical-college.html https://biospectrumindia.com/news/93/21538/medisim-vr-unveils-vr-lab-in-puducherry-based-medical-college.html Thu, 30 Jun 2022 16:35:00 +0530 MediSim VR, a med-tech company working in the field of healthcare simulation, has set up India’s first fully automated Virtual Reality (VR) lab in the Puducherry Institute of Medical Sciences (PIMS) for MBBS students to enhance their key medical skills and train them for the future. MediSim VR recently closed a pre-series A round of funding. The company was also backed by funds from IIT Madras & Dept. of Science & Technology (DST) for R&D.   Supported by AI-powered technical advancement, the medical field is expected to undergo radical transformation with benefits like expert medical advisory, digital diagnosis, wearable health monitors, and digital simulations. MediSim develops virtual reality platforms designed to make comprehensive medical training accessible and affordable across the world.    Dr Adith Chinnaswami, Co-Founder, MediSim VR, said, “With this product, our plans are directed toward the pre-final and final years of the MBBS degree. We also want to unveil new content for nursing and allied health professionals and are looking to partner with the right firm. We aim to expand to not just the medical fraternity but the entire healthcare fraternity. And of course, both regional and global expansion is next on the radar.”     ]]>